

Toxicological Profile for Lead

Draft for Public Comment

May 2019



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

This information is distributed solely for the purpose of pre dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, intermediate, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine the levels of exposure that present a significant risk to human health due to acute, intermediate, and chronic duration exposures; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. ATSDR plans to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Electronic comments may be submitted via: www.regulations.gov. Follow the on-line instructions for submitting comments.

Written comments may also be sent to: Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences
Environmental Toxicology Branch
1600 Clifton Road, N.E.
Mail Stop S102-1
Atlanta, Georgia 30329-4027

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breysse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

VERSION HISTORY

Date	Description
May 2019	Draft for public comment toxicological profile released
August 2007	Final toxicological profile released
April 1993	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Henry Abadin, M.S.P.H. (Lead)
Jessilynn Taylor, M.S., CDR USPHS
Melanie Buser, M.P.H.
Franco Scinicariello, M.D., M.P.H.
Jennifer Przybyla, Ph.D.

Julie M. Klotzbach, Ph.D.
Gary L. Diamond, Ph.D.
Lara L. Chappell, Ph.D.
Laura A. McIlroy, B.A.

ATSDR, Division of Toxicology and Human Health
Sciences, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Health and Safety (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Division of Community Health Investigations; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; Occupational Safety and Health Administration (OSHA); Department of Defense (DoD); EPA; NIOSH.

PEER REVIEWERS

1. Howard Hu, M.D., M.P.H., Sc.D., Department of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, Michigan
2. Anthony Knafla, M.Sc., DABT, P. Biol., Founder/Senior Scientist & Manager, Equilibrium Environmental Inc., Calgary, Canada
3. Nelly Mañay, Ph.D., Professor, Department of Toxicology and Environmental Hygiene, Faculty of Chemistry, University of the Republic of Uruguay, Montevideo, Uruguay

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS	vi
CONTENTS.....	vii
LIST OF FIGURES	x
LIST OF TABLES.....	xi
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES.....	1
1.2 SUMMARY OF HEALTH EFFECTS	2
1.3 MINIMAL RISK LEVELS (MRLs).....	9
CHAPTER 2. HEALTH EFFECTS.....	10
2.1 INTRODUCTION	10
2.2 ACUTE LEAD TOXICITY.....	18
2.3 DEATH.....	19
2.4 BODY WEIGHT	28
2.5 RESPIRATORY	33
2.6 CARDIOVASCULAR.....	38
2.7 GASTROINTESTINAL	72
2.8 HEMATOLOGICAL.....	75
2.9 MUSCULOSKELETAL.....	85
2.10 HEPATIC.....	92
2.11 RENAL	96
2.12 DERMAL.....	110
2.13 OCULAR.....	111
2.14 ENDOCRINE	111
2.15 IMMUNOLOGICAL.....	115
2.16 NEUROLOGICAL	126
2.17 REPRODUCTIVE.....	181
2.18 DEVELOPMENTAL.....	199
2.19 CANCER	221
2.20 GENOTOXICITY.....	230
2.21 GENERAL CELLULAR MECHANISMS OF ACTION	236
2.21.1 Perturbation of Ion Homeostasis	236
2.21.2 Protein Binding/Sequestration.....	244
2.21.3 Oxidative Stress.....	245
2.21.4 Inflammation	247
2.21.5 Epigenetic Effects.....	249
2.21.6 Apoptosis.....	249
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS	251
3.1 TOXICOKINETICS	251
3.1.1 Absorption.....	252
3.1.2 Distribution.....	263
3.1.3 Metabolism.....	272
3.1.4 Excretion	273

3.1.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	276
3.1.5.1	O'Flaherty Model	278
3.1.5.2	EPA IEUBK Model	281
3.1.5.3	Leggett Model.....	286
3.1.5.4	EPA All Ages Lead Model (AALM).....	290
3.1.5.5	Model Comparisons.....	292
3.1.5.6	Slope Factor Models	294
3.2	CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	295
3.3	BIOMARKERS OF EXPOSURE AND EFFECT.....	300
3.3.1	Biomarkers of Exposure.....	301
3.3.2	Biomarkers of Effect	309
3.4	INTERACTIONS WITH OTHER CHEMICALS.....	312
3.5	METHODS FOR REDUCING TOXIC EFFECTS	313
3.5.1	Reducing Absorption Following Exposure	314
3.5.2	Reducing Body Burden	316
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION		319
4.1	CHEMICAL IDENTITY	319
4.2	PHYSICAL AND CHEMICAL PROPERTIES	322
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE		329
5.1	OVERVIEW	329
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL.....	332
5.2.1	Production	332
5.2.2	Import/Export	340
5.2.3	Use.....	340
5.2.4	Disposal.....	342
5.3	RELEASES TO THE ENVIRONMENT	343
5.3.1	Air.....	345
5.3.2	Water	351
5.3.3	Soil	353
5.3.4	Paint.....	354
5.4	ENVIRONMENTAL FATE.....	356
5.4.1	Transport and Partitioning.....	356
5.4.2	Transformation and Degradation.....	363
5.5	LEVELS IN THE ENVIRONMENT	367
5.5.1	Air.....	369
5.5.2	Water	372
5.5.3	Sediment and Soil.....	375
5.5.4	Paint.....	377
5.5.5	Other Media.....	377
5.6	GENERAL POPULATION EXPOSURE	385
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	401
CHAPTER 6. ADEQUACY OF THE DATABASE.....		402
6.1	Information on Health Effects	402
6.2	Identification of Data Needs	403
6.3	Ongoing Studies.....	407
CHAPTER 7. REGULATIONS AND GUIDELINES		409

CHAPTER 8. REFERENCES	415
APPENDIX A. ATSDR MINIMAL RISK LEVEL WORKSHEETS	A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR LEAD.....	B-1
APPENDIX C. INGESTION OF LEAD DEBRIS	C-1
APPENDIX D. QUICK REFERENCE FOR HEALTH CARE PROVIDERS	D-1
APPENDIX E. GLOSSARY	E-1
APPENDIX F. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	F-1

LIST OF FIGURES

2-1. Overview of the Number of Studies Examining Associations Between PbB and Health Effects.....	17
2-2. Change in the Systolic Pressure Associated with a Doubling of the Blood Lead Concentration (PbB).....	45
2-3. Change in the Diastolic Pressure Associated with a Doubling of the Blood Lead Concentration (PbB).....	46
2-4. Pb Interactions in the Heme Synthesis Pathway.....	83
2-5. Multiorgan Impact of Reduction of Heme Body Pool by Lead.....	84
2-6. Immunological Pathways by which Pb Exposure Potentially may Increase Risk of Immune-Related Diseases	126
2-7. Relationship Between Blood Lead Concentration (PbB) and Birth Weight at PbB ≤ 10 $\mu\text{g}/\text{dL}$	209
3-1. Compartments and Pathways of Lead (Pb) Exchange in the O’Flaherty Model.....	279
3-2. Structure of the IEUBK Model for Lead (Pb) in Children	282
3-3. Compartments and Pathways of Lead (Pb) Exchange in the Leggett Model	287
3-4. Blood Lead Concentrations (PbBs) in Children Predicted by the IEUBK, Leggett, and O’Flaherty Models and AALM	293
3-5. Blood Lead Concentrations (PbBs) in Adults Predicted by the Leggett and O’Flaherty Models and AALM.....	294
5-1. Number of NPL Sites with Lead Contamination.....	329
5-2. Number of NPL Sites with Lead Compound Contamination	330
5-3. Annual Maximum 3-Month Average Representing the National Trend	370

LIST OF TABLES

2-1. Summary of Epidemiological Studies Evaluating Death	22
2-2. Summary of Epidemiological Studies Evaluating Effects on Body Weight at Mean Blood Lead Concentrations (PbB) ≤ 10 $\mu\text{g/dL}$	30
2-3. Effects on Body Weight Associated with Mean Blood Lead Concentrations (PbBs) ≤ 10 μg	33
2-4. Overview of Respiratory Effects in Adults and Children Chronically Exposed to Lead (Pb)	35
2-5. Summary of Epidemiological Studies Evaluating Respiratory Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	36
2-6. Overview of Cardiovascular Effects in Adults and Children Associated with Chronic Exposure to Lead (Pb)	40
2-7. Characteristics of the Study Population in Meta-Analyses of Effects of Lead (Pb) on Blood Pressure.....	42
2-8. Summary of Epidemiological Studies Evaluating Effects on Blood Pressure at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	48
2-9. Summary of Epidemiological Studies Evaluating Atherosclerosis at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	62
2-10. Summary of Epidemiological Studies Evaluating Heart Disease at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	64
2-11. Summary of Epidemiological Studies Evaluating Mortality due to Cardiovascular Disease at Mean Blood Lead Concentrations (PbB) ≤ 10 $\mu\text{g/dL}$	66
2-12. Associations Between Bone Pb and Blood Pressure Outcomes	68
2-13. Associations Between Bone Pb and Cardiac Function, Disease, and Mortality.....	70
2-14. Summary of Studies Evaluating Gastrointestinal Symptoms Associated with Chronic Exposure to Lead (Pb)	73
2-15. Overview of Hematological Effects Associated with Chronic Exposure to Lead (Pb).....	77
2-16. Summary of Epidemiological Studies Evaluating Hematological Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	80
2-17. Overview of Musculoskeletal Effects Associated with Chronic Exposure to Lead (Pb)	87
2-18. Summary of Epidemiological Studies Evaluating Musculoskeletal Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	88
2-19. Summary of Epidemiological Studies Evaluating Hepatic Effects Associated with Blood Lead Concentration (PbB).....	94

2-20. Effects on Liver Function Tests Associated with Chronic Exposure to Lead (Pb)	96
2-21. Overview of Renal Effect Associated with Chronic Exposure to Lead (Pb).....	99
2-22. Summary of Epidemiological Studies Evaluating Renal Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	101
2-23. Associations Between Bone Pb and Renal Function.....	109
2-24. Overview of Endocrine Effects Associated with Chronic Exposure to Lead (Pb)	113
2-25. Effects on Thyroid Hormones Associated with Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	113
2-26. Overview of Immunological Effects Associated with Chronic Exposure to Lead (Pb)	117
2-27. Summary of Epidemiological Studies Evaluating Immunological Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	120
2-28. Overview of Neurological Effects in Children Associated with Chronic Exposure to Lead (Pb)..	130
2-29. Overview of Neurological Effects in Adults Associated with Chronic Exposure to Lead (Pb).....	132
2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	135
2-31. Associations Between Bone Pb and Neurological Outcomes in Children	159
2-32. Summary of Epidemiology Studies Evaluating Neurodevelopmental Effects in Adults at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	162
2-33. Associations Between Bone Pb and Neurological Outcomes in Adults.....	173
2-34. Overview of Effects on the Male Reproductive System Associated with Chronic Exposure to Lead (Pb)	184
2-35. Effects on Reproductive Hormones Associated with Chronic Exposure to Lead (Pb) in Males....	185
2-36. Summary of Epidemiological Studies Evaluating Effects on the Male Reproductive System at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	187
2-37. Overview of Effects on the Female Reproductive System and Pregnancy Outcomes Associated with Chronic Exposure to Lead (Pb)	192
2-38. Summary of Epidemiological Studies Evaluating Effects on the Female Reproductive System at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	193
2-39. Overview of Developmental Effects Associated with Chronic Exposure to Lead (Pb)	201
2-40. Effects on Birth Outcomes at Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	202

2-41. Summary of Epidemiological Studies Evaluating Birth Outcomes Effects of Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	203
2-42. Overview of Decreased Anthropometric Measures in Children at Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	211
2-43. Summary of Epidemiological Studies Evaluating Anthropometric Measurements in Infants and Children with Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	212
2-44. Summary of Epidemiological Studies Evaluating the Onset of Puberty at Children with Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	217
2-45. Associations Between Maternal Bone Pb and Birth Outcome and Postnatal Growth.....	220
2-46. Summary of Epidemiological Studies Evaluating Cancer Endpoints and Blood Lead Concentration (PbB).....	224
2-47. Overview of Epidemiology Studies Evaluating Genotoxicity Associated with Chronic Exposure to Lead (Pb)	232
2-48. Results of Genotoxicity Studies at Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$	234
2-49. Effects of Lead (Pb) on Function of Various Proteins.....	239
3-1. Ranking of Relative Bioavailability of Lead (Pb) Mineral Phases in Soil	260
3-2. Comparison of Slope Factors in Selected Slope Factor Models.....	295
3-3. Influence of Other Metals and Metalloids on Lead (Pb) Toxicity.....	312
3-4. Recommended Actions Based on Child Blood Lead Level (PbB).....	315
3-5. Recommended Actions for Workers Based on Blood Lead Level (PbB)	316
4-1. Chemical Identity of Lead and Compounds	319
4-2. Physical and Chemical Properties of Lead and Compounds	324
5-1. Current U.S. Manufacturers of Lead Metal and Selected Lead Compounds.....	333
5-2. U.S. Lead Production 2010–2013.....	335
5-3. Facilities that Produce, Process, or Use Lead.....	336
5-4. Facilities that Produce, Process, or Use Lead Compounds.....	338
5-5. Current and Former Uses of Selected Lead Compounds.....	341
5-6. Releases to the Environment from Facilities that Produce, Process, or Use Lead	345
5-7. Releases to the Environment from Facilities that Produce, Process, or Use Lead Compounds	347

5-8. Historic Levels of Lead Emissions to the Atmosphere in the United States (in Thousand Metric Tons).....	350
5-9. U.S. Surface Water Discharges of Lead and Lead Compounds (Pounds/Year).....	352
5-10. Canada Surface Water Discharges of Lead and Lead Compounds (Tonnes).....	352
5-11. Lowest Limit of Detection Based on Standards	368
5-12. Lead Levels in Water, Soil, and Air of National Priorities List (NPL) Sites	369
5-13. Summary Data for Lead Monitors Across the United States, 2008–2010 ($\mu\text{g}/\text{m}^3$)	370
5-14. Percentile Distribution of Mean Lead (TSP) Concentrations ($\mu\text{g}/\text{m}^3$) Measured in Ambient Air at Locations Across the United States	371
5-15. Lead Levels in Foods Commonly Eaten by Toddlers and Infants.....	378
5-16. Selected Mean Lead Concentrations in Food from the FDA Total Diet Study	379
5-17. Estimated Median and Maximum Lead Exposures	381
5-18. Lead Content in Ayurvedic Medications and Other Health Remedies.....	382
5-19. Lowest Limit of Detection Based on Standards	385
5-20. Geometric Mean Blood Lead Levels ($\mu\text{g}/\text{dL}$) and the 95 th Percentile Confidence Interval, by Race/Ethnicity, Sex, and Age for the Years for 2011–2016.....	388
5-21. Geometric Mean Urine Lead Levels ($\mu\text{g}/\text{dL}$) and the 95 th Percentile Confidence Interval, by Race/Ethnicity, Sex, and Age	390
5-22. Industries by Sector with Most Workers having Blood Lead Concentrations (PbBs) ≥ 25 $\mu\text{g}/\text{dL}$, 2010–2016	391
5-23. Number and Rate per 100,000 Children Aged <5 Years with Blood Lead Levels 5–9 $\mu\text{g}/\text{dL}$ in the Childhood Blood Lead Surveillance System, United States, 2010–2014.....	392
5-24. Geometric Mean Urine Lead Levels ($\mu\text{g}/\text{dL}$) and the 95 th Percentile Confidence Interval by Smoking Status.....	393
5-25. Measurements of Lead in Indoor Dust in the United States from 2006 to 2011	396
6-1. Ongoing Studies on Lead (Pb).....	407
7-1. Regulations and Guidelines Applicable to Lead (Pb).....	409

CHAPTER 1. RELEVANCE TO PUBLIC HEALTH

1.1 OVERVIEW AND U.S. EXPOSURES

Lead (Pb) is an element that is found in concentrated and easily accessible Pb ore deposits that are widely distributed throughout the world. A major source of Pb in the U.S. environment has historically been anthropogenic emissions to the atmosphere from combustion of leaded gasoline, which was phased out of use after 1973 and then banned in 1995 (with the exception of fuels for piston-driven aircraft) (EPA 1996a). Lead continued to be used as an anti-knock agent in National Association for Stock Car Auto Racing (NASCAR) fuels until it was phased out beginning in 2008. Deteriorating Pb-based paints from weathered surfaces (which produce highly concentrated Pb debris and dusts) in older housing stock (pre-1978) continues to be a source of childhood Pb poisoning in the United States (CDC 1991, 2012d). The combination of corrosive water and Pb pipes or Pb-soldered joints in either the distribution system or individual houses can create localized zones of high Pb water concentrations (EPA 1989d, 2007a; Hanna-Attisha et al. 2016). Other anthropogenic sources of Pb have included mining and smelting of ore; manufacture of and use of Pb-containing products (e.g., Pb-based paints, pigments, and glazes; electrical shielding; plumbing; storage batteries; solder; and welding fluxes); manufacture and application of Pb-containing pesticides; combustion of coal and oil; and waste incineration.

Pb does not degrade in the environment, although it can exist in various chemical forms. Particulate matter contaminated with Pb can be transported through air, water, and soil. In general, atmospheric deposition is the largest source of Pb found in soils not impacted by other local non-air sources (e.g., dust from deteriorating leaded paint). Pb is transferred continuously between air, water, and soil by natural chemical and physical processes such as weathering, runoff, precipitation, dry deposition of dust, and stream/river flow; however, soil and sediments appear to be important sinks for Pb. Pb adsorbs strongly to most soils, which limits the rate of leaching. Soil acidity (pH) and composition are the most important factors affecting solubility, mobility, and phytoavailability of Pb in soil. Other conditions that increase Pb mobility in soil are reducing conditions and high chloride content.

The general population may be exposed to Pb in ambient air, foods, drinking water, soil, and dust. Pb has also been found in a variety of other consumer products including storage batteries, solders, pottery glazes, leaded crystal glassware, cosmetics, hair dyes, jewelry, gun shot and ammunition, relic fishing sinkers, tire weights, and imported children's toys, traditional or folk remedies, and candy/food packaging. For adults, exposure to levels of Pb beyond background is usually associated with occupational exposures. For children, exposure to high levels of Pb is associated with living in areas

1. RELEVANCE TO PUBLIC HEALTH

contaminated by Pb (e.g., soil or indoor dust in older homes with Pb-based paint). The primary source of Pb exposure to children is from surface dusts (on the ground or entrained) that contain Pb from a variety of sources including deteriorated Pb-based paint (CDC 2009; Lanphear et al. 1998a; Succop et al. 1998). Environmental Pb is particularly accessible to children because of their more intensive hand-to-mouth activity and the proximity of the child breathing zone to Pb entrained from surface dusts. Because Pb is transported from soil very slowly, historic sources of deposition of Pb to soil continue to contribute to current exposures (Laidlaw and Filipelli 2008; Laidlaw et al. 2012). Based on a multimedia Pb exposure modeling analysis for children 1–5 years old at upper percentiles of blood Pb (PbB) levels in the U.S. population, soil and dust ingestion are dominant exposure pathways, but for lower percentiles, other age groups (e.g., younger children), or specific local U.S. locations, the main exposure source/pathway could be different (Zartarian et al. 2017).

PbB has been used as a biomarker of Pb exposure, and periodic surveys of PbB of the U.S. population are conducted by the Centers for Disease Control and Prevention (CDC). Based on data from the National Health and Nutrition Examination Survey (NHANES) (2015–2016, CDC 2018a), the geometric mean PbB in a representative sample of U.S. adults, ≥ 20 years old, was 0.920 $\mu\text{g}/\text{dL}$ (95% confidence interval [CI] 0.862, 0.982). The geometric mean blood PbB of a representative sample of U.S. children, 1–5 years old, was 0.758 $\mu\text{g}/\text{dL}$ (95% CI 0.675, 0.850). PbBs in the U.S. have decreased considerably in the last several decades as a result of removal of Pb from gasoline and restrictions placed on the use of Pb in residential paints (Brody et al. 1994; CDC 2011, 2018a; Pirkle et al. 1994, 1998; Schwartz and Pitcher 1989).

Seasonal variations in blood lead concentration (PbB) levels in children have been observed, with a general trend of increasing PbB during late summer and early fall (Gulson et al. 2008; Johnson and Bretsch 2002; Laidlaw et al. 2005). Seasonal patterns in behavior (e.g., outdoor activities) and weather that promotes re-entrainment and transport of dust Pb (humidity and wind velocity) may contribute to the observed seasonal patterns in PbB (Laidlaw et al. 2005, 2012) and provide additional evidence for surface dusts being a major contributor to child Pb exposure and PbB.

1.2 SUMMARY OF HEALTH EFFECTS

The toxicity of Pb to humans has been known for over 2,000 years, and is not disputed. Early epidemiological studies focused on overt toxicity associated with high occupational exposures. However, during the past few decades, there has been a growing awareness that low-level environmental exposure

1. RELEVANCE TO PUBLIC HEALTH

resulting in PbB <10 µg/dL is associated with adverse effects, particularly in children. Currently, it is accepted that adverse effects occur at PbB <5 µg/dL and for the most studied endpoints (neurological, renal, cardiovascular, hematological, immunological, reproductive, and developmental), effects occur at the lowest PbBs studied (≤5 µg/dL). CDC (2018b) states that “no safe blood lead level in children has been identified.” As a result, U.S. public health policy has changed to focus on lowering PbB levels to well below 10 µg/dL. CDC considers PbB to be elevated in children when it exceeds a reference value defined as the 97.5th percentile for the U.S. population. The current CDC reference value, based on data from NHANES 2007–2009 and 2009–2010, is 5 µg/dL. Therefore, the primary objective of current research is on health effects associated with PbB ≤5 µg/dL.

The literature evaluating the health effects of Pb is enormous, and includes an extensive database in humans, including children and infants. Information on health effects reviewed below is taken from epidemiological studies that identify the major lines of evidence regarding health effects in humans. Although the literature on adverse effects of Pb in laboratory animals also is extensive, due to the large number of available epidemiological studies, results of animal studies were not considered for the identification of health effects associated with Pb. This potentially leaves out discussion of effects that may have been observed in animal models that have not been studied in humans and that may be future targets of human epidemiology and clinical toxicology studies. Animal studies were included in discussion of mechanisms of toxicity of Pb and toxicokinetics.

To quantify exposure, epidemiological studies on the toxicity of Pb rely on internal exposure metrics, rather than measurements of external exposures (e.g., concentration of Pb in water or air) or ingested dose. The most common internal dose metric for Pb is the concentration of Pb in blood (PbB, typically expressed in terms of µg/dL). Blood Pb concentration reflects both ongoing exposure and Pb stores in bone, which can be transferred to blood. Because of the relatively rapid elimination of Pb from blood compared to bone, blood Pb will reflect mainly the exposure history of the previous few months and not necessarily the larger burden of Pb in bone (see Section 3.1). As a result, a single PbB measurement may not be a reliable metric for Pb body burden or cumulative exposure. Longitudinal measurements of PbB can be used to construct a cumulative blood Pb index (CBLI), which may be a better reflection of exposure history; however, the CBLI will not capture shorter-term variation in exposure that may occur between measurements. Direct, noninvasive measurements of bone Pb concentrations have been used as a metric of long-term exposure on the basis that most of the absorbed Pb retained in the body will reside in bone (see Section 3.1). The health effects of Pb are the same, regardless of the route of exposure (e.g., inhalation or ingestion). Given that exposure is quantified by internal exposure metrics (e.g., PbB, bone

1. RELEVANCE TO PUBLIC HEALTH

Pb), epidemiological studies do not attempt to define the route of exposure. Environmental exposure to Pb occurs continuously over a lifetime and Pb is retained in the body for decades. Because internal dose metrics cannot define the complete history of exposure, the exposure duration and timing that correlates most strongly with the observed health effect are typically unknown or highly uncertain.

Adverse health effects of Pb have been observed in every organ system. This is because the mechanisms that induce toxicity are common to all cell types and because Pb is widely distributed throughout the body. Health effects of Pb have been observed in all organ systems over a wide PbB range (≤ 5 – >50 $\mu\text{g}/\text{dL}$). Exposure thresholds for effects on specific organ systems have not been identified (i.e., no safe level has been identified). Cognitive deficits in children occurring at the lowest PbB concentrations (≤ 5 $\mu\text{g}/\text{dL}$) are the best substantiated effects. However, data for some organ systems results are inconsistent, and insufficient data are available to provide information on dose-response relationships. It is also important to note that effects observed in adults, especially older adults, may be due to higher environmental or occupational exposures in the past; therefore, exposure history is an important consideration in epidemiological studies on the health effects of Pb.

The most extensively studied health outcomes, as described below, are neurological, renal, cardiovascular, hematological, immunological, reproductive, and developmental effects. Neurological effects of Pb are of greatest concern because effects are observed in infants and children and may result in life-long decrements in neurological function. Infants are born with a Pb burden derived from maternal transfer *in utero* and subsequently can continue to absorb maternal Pb from ingestion of breast milk. Children are also more vulnerable because of behaviors that increase ingestion of Pb surface dusts (e.g., hand-to-mouth activity) and because gastrointestinal absorption of ingested Pb is higher in children compared to adults, possibly due to a combination of physiological differences and differences in diet and nutrition. The following briefly summarizes health effects of chronic exposure to Pb observed in humans. More detailed information, including reference citations, is provided in Chapter 2.

Neurological Effects in Children. Numerous prospective and large cross-section studies in children provide consistent evidence of decrements in neurological function, including decrements in cognitive function (learning and memory), altered behavior and mood (attention, hyperactivity, impulsivity, irritability, delinquency), and altered neuromotor and neurosensory function (visual-motor integration, dexterity, postural sway, changes in hearing and visual thresholds). These effects have been associated with a PbB range from ≤ 5 to >50 $\mu\text{g}/\text{dL}$, with numerous studies providing evidence for effects at PbB ≤ 5 $\mu\text{g}/\text{dL}$. Taken together, studies support the concept that Pb affects cognitive function in

1. RELEVANCE TO PUBLIC HEALTH

children prenatally and/or environmentally exposed to low levels of Pb. No threshold for these effects has been identified (i.e., no safe level has been identified). Decrements in cognitive function increase with PbB, and several PbB-effect models predict that larger decrements in cognitive function would occur when PbB increases from 1 to 10 $\mu\text{g/dL}$, compared to when PbB increases from levels $>10 \mu\text{g/dL}$. Supra-linear dose-response relationships for neurological outcomes are discussed in greater detail in Section 2.16 (Neurological). At higher PbB ($>30 \mu\text{g/dL}$), other neurotoxic effects have been observed, including alterations in nerve function (decrements in fine and gross motor skills, peripheral neuropathy) and encephalopathy.

Neurological Effects in Adults. Epidemiological studies in adults demonstrate decrements in neurological function associated with PbB. All of the cognitive and neurobehavioral effects of Pb observed in children also have been observed in adults associated with PbB ranging from ≤ 10 to $>50 \mu\text{g/dL}$, with evidence of effects occurring at PbB $\leq 5 \mu\text{g/dL}$. At higher PbB ($>30 \mu\text{g/dL}$), other observed neurotoxic effects include peripheral neuropathy, psychiatric symptoms (depression, panic disorders, anxiety, hostility, confusion, anger, and schizophrenia), and changes in regional brain volumes and neurochemistry. It is not clear if cognitive decrements are related to exposures that occurred during adulthood or during periods of nervous system development (e.g., prenatal and childhood exposures) or if effects are due to cumulative exposure. Results of a few studies that have followed children to early adulthood show an association between child PbB and behavioral and neuroanatomical changes in adults, suggesting a possible impact of exposures on childhood to adult outcomes.

Renal Effects. Adverse renal effects of Pb are well-established in numerous epidemiological studies. Studies show consistent evidence of renal damage and reduced renal function associated with a wide range of PbB (≤ 10 – $50 \mu\text{g/dL}$), with several studies providing evidence for effects at PbB $\leq 5 \mu\text{g/dL}$. Deficits in renal function include enzymuria, proteinuria, impaired transport of organic anions and glucose, and depressed glomerular filtration rate (GFR). At higher PbB ($>30 \mu\text{g/dL}$), Pb-induced nephrotoxicity is characterized by proximal tubular nephropathy, glomerular sclerosis, interstitial fibrosis, and tubular necrosis. Note that Pb-induced decrements in renal function can lead to higher Pb body burden due to decreased excretion of Pb (i.e., reverse causality). In addition, other causes of decreased renal function could result in an increased body burden of Pb.

Cardiovascular Effects. A large number of epidemiological studies in adults show adverse cardiovascular effects associated with a PbB range from ≤ 5 to $>50 \mu\text{g/dL}$. Effects on blood pressure is the most-studied cardiovascular outcome, with studies showing increased systolic and diastolic blood

1. RELEVANCE TO PUBLIC HEALTH

pressure, with some evidence of effects occurring at $PbB \leq 5 \mu\text{g/dL}$. A few studies show increased blood pressure in children and pregnant women. Nawrot et al. (2002) estimated that with doubling of PbB (for example, from 5 to 10 $\mu\text{g/dL}$), systolic and diastolic blood pressure would increase by 1 and 0.6 millimeters of mercury, respectively. Other cardiovascular effects include increased risk of hypertension and heart disease, atherosclerosis, altered cardiac conduction, cardiac disease, and increased mortality due to cardiovascular disease. A recent study concluded that low-level environmental Pb exposure is an important risk factor for cardiovascular disease mortality (Lanphear et al. 2018).

Hematological Effects. The toxicity of Pb to the hematological system of humans has been established in numerous studies in adults and children. Exposure to Pb causes dose-dependent decreases in heme synthesis through inhibition of the enzyme delta-aminolevulinic acid dehydratase (δ -ALAD). At $PbB \leq 10 \mu\text{g/dL}$, decreased blood hemoglobin is observed; however, it should be noted that the magnitude of this decrease is typically small and may not represent a biologically significant change. As PbB increases, further decreases in blood hemoglobin and loss of erythrocytes due to a Pb -induced increased membrane fragility results in the development of anemia (NAS 2013). Other effects of Pb on the hematological system include decreased activity of other erythrocyte enzymes (pyrimidine 5'-nucleotidase or red blood cell membrane $\text{Ca}^{2+}/\text{Mg}^{2+}\text{ATPase}$) and altered levels of plasma erythropoietin (a hormone that stimulates red blood cell formation); however, fewer studies on these endpoints have been published and study results are mixed.

Immunological Effects. Epidemiological studies provide evidence that Pb exposure can perturb the immune systems of children and adults. Evidence for this derives from changes in various indicators of humoral and cell-mediated immunity in association with increasing PbB . Effects have been observed in populations that had average $PbB < 10 \mu\text{g/dL}$. These effects are consistent with more extensive studies conducted in animal models and isolated immune cells that have shown that Pb can perturb the humoral and cell-mediated immune systems, leading to sensitization, autoimmunity, and inflammation (EPA 2014c; NAS 2013).

Reproductive Effects in Males. Health effects of Pb on the male reproductive system have been evaluated in numerous epidemiological studies. Effects include damage to sperm (decreased sperm count, concentration, motility, and viability, and increased immature sperm concentration and percentage of morphologically abnormal sperm), possible alterations in serum levels of reproductive hormones (testosterone, estradiol, luteinizing hormone [LH], and follicle-stimulating hormone [FSH]), decreased fertility, and histopathological changes to the testes. Severity of these effects increases with PbB . Studies

1. RELEVANCE TO PUBLIC HEALTH

conducted in populations with mean PbB ≤ 10 $\mu\text{g/dL}$ provide evidence of damage to sperm, although effects are more consistently observed at PbB > 10 $\mu\text{g/dL}$. Regarding effects on serum levels of reproductive hormones, results of available studies for PbB ranging from ≤ 10 to > 50 $\mu\text{g/dL}$ are inconsistent; thus, Pb-induced effects on circulating reproductive hormones are not firmly established. At higher PbB (> 10 $\mu\text{g/dL}$), a few studies provide evidence of more severe effects, including decreased fertility and histopathological damage to testes.

Reproductive Effects in Females. Compared to studies of male reproductive effects, the epidemiologic literature database for effects of Pb on the female reproductive system is smaller, with most epidemiological studies conducted in populations with mean PbB ≤ 10 $\mu\text{g/dL}$. Studies provide some evidence of alterations in serum reproductive hormone levels (estradiol, LH, and FSH), decreased fertility, increased spontaneous abortion, increased preterm birth, and decreased age at onset of menopause. However, results are inconsistent, with several studies reporting no association between PbB and female reproductive effects.

Developmental Effects (Excluding Neurodevelopmental). Numerous epidemiological studies have evaluated developmental outcomes, with most studies conducted in populations with maternal and/or umbilical cord PbB ≤ 10 $\mu\text{g/dL}$. Some studies provide evidence of decreased birth size (weight, length, head circumference), decreased child growth (weight, height, head circumference, trunk length, leg length, arm length, body mass index [BMI]), and delayed onset of puberty in males and females. Although it is difficult to assess dose-dependence for developmental effects within the relatively narrow range of PbB (≤ 10 $\mu\text{g/dL}$) in most studies, dose-related decreases in birth weight have been observed in populations with PbB ≤ 10 $\mu\text{g/dL}$. Although studies provide evidence of associations between PbB and developmental outcomes, results are inconsistent and several studies, including prospective studies, show no associations with non-neurodevelopmental outcomes.

Other Health Effects Associated with Pb. In addition to the effects summarized above, health effects to other organ systems have been reported. The epidemiological databases for these effects are much less extensive than for the effects reviewed above. Effects described below occur over a wide range of PbBs, including PbB ≤ 10 $\mu\text{g/dL}$. However, results are inconsistent and insufficient data are available to provide information on dose-response relationships.

1. RELEVANCE TO PUBLIC HEALTH

- **Respiratory Effects.** Associations have been observed between PbB and decreased lung function, increased bronchial hyperreactivity, symptoms of respiratory disease, and increased risk of respiratory diseases (e.g., asthma and obstructive lung disease).
- **Endocrine Effects (Excluding Reproductive Hormones).** Studies in adults, adolescents, and children show effects on thyroid function, cortisol levels, vitamin D levels, and serum levels of growth factors. Effects on thyroid function are the most studied effect, although results do not demonstrate a consistent pattern of effect.
- **Hepatic Effects.** Most studies were conducted in workers with PbB >10 µg/dL. Several studies show altered plasma levels of liver enzymes, although no consistent pattern of effects has been observed. Liver enlargement and increased gall bladder wall thickness have been associated with PbB.
- **Musculoskeletal Effects.** Studies provide evidence of bone loss, increased markers of bone metabolism/turn over, and adverse periodontal and dental effects (periodontal bone loss, tooth loss, periodontal disease, dental caries) in adults and children.
- **Gastrointestinal Effects.** Gastrointestinal colic is a predominant clinical symptom of Pb poisoning. Epidemiological studies provide evidence of gastrointestinal symptoms (abdominal colic/pain, nausea, vomiting, diarrhea, and/or constipation) associated with PbB ranging from 8 µg/dL to approximately 100 µg/dL.
- **Body Weight Effects.** A few studies evaluating effects of PbB ≤10 µg/dL on body weight provide some evidence of decreased body weight in children and adults, although inconsistent results have been reported.
- **Ocular Effects (Excluding Neurological Effects).** Limited data provide some evidence that exposure to Pb is associated with macular degeneration in adults and increased risk of cataracts.

Cancer. Numerous epidemiological studies have evaluated associations between Pb exposure and cancer. Although studies provide limited evidence of carcinogenicity of Pb in humans, results are inconsistent, with several negative studies, and interpretation of data may be limited due to confounding factors (e.g., smoking status, family history of cancer, co-exposure to other carcinogens). At PbB ≤10 µg/dL, increased risks were reported for all cancers and lung cancer. At PbB >10 µg/dL, increased risks were observed for all cancer, respiratory tract cancer, stomach cancer, intestinal cancer, cancer of the larynx, and glioma.

The Department of Health and Human Services classified Pb and Pb compounds as reasonably anticipated to be human carcinogens (NTP 2016). In 1988, EPA classified Pb as a probable human carcinogen based

1. RELEVANCE TO PUBLIC HEALTH

on sufficient evidence in animals; evidence in humans was considered inadequate (IRIS 2004). The International Agency for Research on Cancer (IARC) has classified inorganic Pb compounds as probably carcinogenic to humans (Group 2A) based on sufficient evidence in animals and limited evidence in humans; evidence for organic Pb compounds was considered to be inadequate in humans and animals (IARC 2006).

1.3 MINIMAL RISK LEVELS (MRLs)

As reviewed in Section 1.2, epidemiological studies have evaluated the health effects of Pb in all organ systems. For the most studied endpoints (neurological, renal, cardiovascular, hematological, immunological, reproductive, and developmental), effects occur at the lowest PbBs studied ($\leq 5 \mu\text{g/dL}$). Because the lowest PbBs are associated with serious adverse effects (e.g., declining cognitive function in children), MRLs for Pb have not been derived.

CHAPTER 2. HEALTH EFFECTS

2.1 INTRODUCTION

The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and other interested individuals and groups with an overall perspective on the toxicology of lead (Pb). It contains descriptions and evaluations of epidemiological investigations and provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.

A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.

To help public health professionals and others identify potential health effects in persons with elevated PbB, the information in this section is organized by health effect.

As discussed in Appendix B, a literature search was conducted to identify relevant studies examining health effect endpoints. Figure 2-1 provides an overview of the database of epidemiology studies included in this chapter of the profile.

Since development of the 2007 Toxicological Profile on Lead (ATSDR 2007), results of numerous epidemiological studies have prompted growing attention to the adverse health effects of Pb exposures that result in blood Pb concentrations (PbB) of <10 $\mu\text{g}/\text{dL}$ (EPA 2014c). Awareness of the potential adverse consequences of such exposures has led to changes in U.S. public health policy, with a focus on lowering PbB levels to well below 10 $\mu\text{g}/\text{dL}$ (CDC 2012d; EPA 2016b). In 2012, CDC established a PbB reference value for lead, replacing the 10 $\mu\text{g}/\text{dL}$ level of concern. The reference value is based on the 97.5th percentile of the PbB distribution among children 1–5 years of age in the United States, using data generated by NHANES (CDC 2012d). At that time, the PbB reference was approximately 5 $\mu\text{g}/\text{dL}$ (NHANES 2011–2012) (CDC 2018a). The reference value would be updated every 4 years using the two most recent NHANES surveys and would be used in recommendations for follow-up evaluations and identification of high-risk childhood populations (CDC 2012d). It is likely that PbB values among children will continue to decline; therefore, the primary focus of this toxicological profile is on health effects associated with low Pb exposure (i.e., those observed at $\text{PbB} \leq 5$ $\mu\text{g}/\text{dL}$). Detailed information on effects at $\text{PbB} \leq 10$ $\mu\text{g}/\text{dL}$ is also presented to examine potential exposure-response relationships. Information on health effects observed at higher PbB levels (>10 $\mu\text{g}/\text{dL}$) is also included to provide a comprehensive overview of the adverse effects of Pb.

2. HEALTH EFFECTS

Literature Search Strategy. The literature on health effects of Pb in humans is enormous, with countless epidemiological studies in workers and the general population, including children. Due to the extent of the Pb database in humans, it is impossible to cite all, or even most, of the studies on health effects of Pb; thus, this profile does not attempt to provide a comprehensive review of all literature; instead, the profile summarizes the major lines of epidemiological evidence regarding health effects in humans. Although the literature database on adverse effects of Pb in laboratory animals is also extensive, given the large number of studies available in humans, animal studies are not included in this toxicological profile. For a recent review of studies in animal models, the reader should consult the EPA's Integrated Science Assessment for Lead (EPA 2014c).

The following were used as primary sources to identify literature on health effects of Pb:

- The previous Toxicological Profile for Lead (ATSDR 2007) was used to identify literature published through 2007.
- The EPA (2014c) Integrated Science Assessment for Lead was used to identify literature published from 2006 to 2013.
- Literature searches were conducted from 2013 to 2016 to identify studies published after EPA (2014c).

In addition, recent reviews by NTP (2012) and NAS (2013) were consulted. As anticipated, the literature search revealed an extensive epidemiological database of literature published since 2013. To narrow the evaluation to those studies of greatest utility identifying health effects of low exposures to Pb exposure, a series of inclusion criteria were defined; only studies meeting the criteria were considered for inclusion in the toxicological profile. These criteria are described further in Appendix B. Data from selected studies were tabulated and discussed in subsequent sections of this chapter.

Duration of Exposure. Typically, toxicological profiles organize the discussion of health effects according to exposure duration categories. However, this is not a particularly informative approach to the discussion of Pb epidemiology. The epidemiologic study of Pb toxicity in human populations has relied on internal dose metrics (PbB, bone Pb) for evaluating associations between health outcomes. These metrics are considered to represent relatively recent exposure history, in the case of PbB, and longer-term cumulative exposure, in the case of CBLI or bone Pb. However, neither metric offers a confident estimate of exposure duration or of changes in lead exposure over time (including peak exposure periods that may have occurred in the past), and, in general, the complete exposure history is not known. Health

2. HEALTH EFFECTS

outcomes associated with acute exposures is available from clinical case studies of Pb poisoning (see Section 2.2). However, even in these cases, the exposure duration that preceded the identification of the case is rarely known with certainty.

Routes of Exposure. For the general population, exposure to Pb occurs primarily via the oral route, with some contribution from the inhalation route, whereas inhalation exposures can be more important in occupational settings, depending on particle size. In addition, occupational exposure to organic Pb compounds may involve dermal absorption as a significant exposure route. This profile does not attempt to separate health effects by route of exposure. As noted previously, epidemiology studies have relied on internal dose metrics (PbB, bone Pb), which reflect Pb body burden (to varying degrees), irrespective of the route of exposure. The primary systemic toxic effects of Pb are the same regardless of the route of entry into the body,

Exposure Metric. To quantify exposure in humans, data are expressed in terms of absorbed Pb, and not in terms of external exposure levels (e.g., concentration in water) or dose (e.g., mg/kg/day). The most common metric of absorbed dose for Pb is the concentration of lead in blood (PbB), although other measures of exposure (e.g., concentration of Pb in bone, hair, teeth, or urine) are used; however, measurements of Pb in urine, teeth, and hair are not as reliable as measurements in blood or bone. PbB mainly reflects exposure history of the previous few months and does not necessarily reflect the larger burden and much slower elimination kinetics of Pb in bone (see Section 3.1). Pb in bone is considered a biomarker of cumulative or long-term exposure because Pb accumulates in bone over the lifetime and most of the Pb body burden resides in bone. Most of the body burden of Pb (the total amount of Pb in the body) is distributed to the bone, with approximately 94 and 76% of the body burden found in bone in adults and children, respectively. The remainder is distributed to blood and soft tissues. However, the concentration of Pb in blood can vary considerably with age and physiology/lifestage (e.g., pregnancy, lactation, menopause). For this reason, measurement of Pb in bone has seen wider application in epidemiological studies of adults in which measures of cumulative lifetime exposures are of interest. However, bone Pb measurements require specialized radiologic equipment (e.g., K-shell x-ray fluorescence; XRF) and, as a result, are used less commonly than PbB in human epidemiology. Since most of the epidemiology has relied on PbB as the dose metric, this profile has focused on describing dose-response relationships based on PbB to facilitate comparisons across studies and endpoints. This approach also aligns with public health practices, which rely on PbB for evaluating elevated exposures to Pb (CDC 2012d; EPA 2016b). However, it is recognized that some health outcomes may be correlated with cumulative exposure, in which case, bone Pb may be a better dose metric than PbB. For these

2. HEALTH EFFECTS

outcomes, short-term variation in PbB may contribute to exposure classification error (i.e., the same PbB could be observed in individuals who have different bone Pb). The exposure history of the subjects may also be an important factor in determining associations observed between outcomes and blood or bone Pb. Some studies of historically exposed occupational populations (e.g., former workers) have found stronger associations between bone Pb and health outcomes than with PbB, while some studies of concurrently exposed populations have found stronger associations with PbB (Shih et al. 2007).

Confounding Factors and Effect Modifiers. Bias can occur in epidemiological studies when the background risk of the outcome being measured is not the same in the exposed and reference groups. Confounders are variables that affect the measured outcome and are also associated with the Pb exposure metric (e.g., PbB, bone Pb). For example, Pb body burden increases with age; therefore, age can be a confounding factor if it is also a risk factor for the outcome (e.g., renal or cardiovascular disease). Not adjusting for confounders may attenuate or strengthen the apparent associations between Pb exposure and the outcome, depending on whether it is a negative or positive confounding variable. Effect modifiers are variables that affect the measured outcome independently of the Pb exposure metric. For example, renal disease from any cause can affect blood pressure and, thereby, could interact with Pb to change blood pressure. Effect modifiers can also be confounders, if they are associated with the Pb exposure metric (e.g., socio-economic status [SES] and cognitive development). Failure to account for important effect modifiers can result in underestimation or overestimation of the apparent strength of the association, depending on the direction of the effect of the modifying variable. Confounding factors and effect modifiers are discussed in greater detail in sections that describe specific categories of health effects.

Overview of Health Effects of Pb. The health effects of Pb are diverse, and exposure to Pb is associated with toxicity to every organ system. This is not surprising because the mechanisms of action associated with Pb-induced toxicity, including perturbations of ion homeostasis and transport, protein binding, oxidative stress, and inflammation, are common to all cell types. In addition, Pb is widely distributed throughout the body, and has been measured in all tissues evaluated (see Section 3.1.2). For all organ systems, toxicity has been observed at PbB ≤ 10 $\mu\text{g}/\text{dL}$. Neurological effects of Pb are of greatest concern because effects are observed in infants and children; furthermore, these effects may result in life-long decrements in neurological function. Children are also more vulnerable because of behaviors that increase ingestion of Pb surface dusts (e.g., hand-to-mouth activity) and because gastrointestinal absorption of ingested Pb is higher in children compared to adults, possibly due to a combination of physiological differences and differences in diet and nutrition. The weight-of-evidence for all adverse

2. HEALTH EFFECTS

health effects is strongly supported by studies in animal models and *in vitro* systems; see EPA (2014c) for a review of this literature.

Effects observed in association with PbB are briefly described below. Note that for some of the effects listed below, study results are not consistent, which limits interpretation of observations; this is reviewed in more detail in subsequent sections for each organ system in Chapter 2. The most extensive epidemiological databases examining Pb are for neurological, renal, cardiovascular, hematological, immunological, reproductive, and developmental effects.

- **Neurological Effects:**
 - **Children.** Decreased cognitive function; altered mood and behaviors that may contribute to learning deficits, altered neuromotor and neurosensory function, peripheral neuropathy, and encephalopathy.
 - **Adults.** Decreased cognitive function including attention, memory, and learning; altered neuromotor and neurosensory function; altered mood and behavior; and decreased peripheral nerve conduction velocity.

- **Renal Effects.** Decreased GFR, proteinuria, enzymuria, impaired tubular transport, and histopathological damage.

- **Cardiovascular Effects.** Increased systolic and diastolic blood pressure, increased risk of hypertension, atherosclerosis, altered cardiac conduction, increased risk of heart disease, and increased mortality due to cardiovascular disease.

- **Hematological Effects.** Inhibition of δ -ALAD leading to decreased blood hemoglobin and anemia, decreased activity of other erythrocyte enzymes, and altered plasma erythropoietin (EPO) levels.

- **Immunological Effects.** Perturbation of humoral and cell-mediated immune systems, decreased resistance to disease, sensitization, autoimmunity, and inflammation.

2. HEALTH EFFECTS

- **Reproductive Effects:**
 - **Males.** Effects on sperm, alterations in semen quality, decreased fertility, histopathological damage to the testes, and possible altered serum concentrations of reproductive hormones.
 - **Females.** Possible alterations in serum concentrations of reproductive hormones, decreased fertility, spontaneous abortion, preterm birth, and decreased age at the onset of menopause.

- **Developmental Effects.** Decreased birth weight and size, decreased anthropometric measures in children, and delayed onset of puberty in males and females.

Other health outcomes associated with PbB include the following:

- **Respiratory Effects.** Decreased lung function, increased bronchial hyperreactivity, increased risk of asthma, and obstructive lung disease.

- **Hepatic Effects.** Possible increases in plasma liver enzymes and cholesterol, enlarged liver, and increased thickness of gall bladder wall.

- **Endocrine Effects.** Possible alterations in serum of thyroid hormones, altered cortisol responses, alteration in serum growth factors, and decreased serum vitamin D levels.

- **Gastrointestinal Effects.** Abdominal pain/colic, nausea, vomiting, and diarrhea and/or constipation.

- **Musculoskeletal Effects.** Bone loss, osteoporosis, dental caries, tooth loss, and periodontitis.

- **Ocular Effects.** Possible macular degeneration and cataracts.

- **Cancer.** Increased risk of cancer, including all cancers, cancer of the respiratory tract, intestinal tract, and larynx, and glioma.

2. HEALTH EFFECTS

Many specific health effect endpoints have been evaluated in numerous studies. To provide the reader with a weight-of-evidence for these endpoints, the profile indicates if results are consistent and corroborated in numerous studies or if results are inconsistent (or mixed).


Figure 2-1 shows the numbers of epidemiological studies included in this chapter of the toxicological profile, based on health outcome studied. The number of studies evaluating effects at PbB ≤ 10 $\mu\text{g/dL}$ also is indicated. The PbB ≤ 10 $\mu\text{g/dL}$ was selected to evaluate effects at the lowest PbB (e.g., ≤ 5 $\mu\text{g/dL}$) and to evaluate potential exposure-response relationships for PbB ≤ 10 $\mu\text{g/dL}$. As noted above, due to the enormous number of epidemiological studies published, the profile does not attempt to provide a comprehensive review of all literature. Therefore, this figure should not be interpreted as depicting all epidemiological studies that have been published on Pb toxicity.

2. HEALTH EFFECTS

Figure 2-1. Overview of the Number of Studies Examining Associations Between PbB and Health Effects^a

Most studies examined the potential cardiovascular, renal, and neurological effects of lead

A subset of studies evaluating health effects for **PbB ≤10 µg/dL** compared to **all PbB studies** (counts represent studies examining endpoint)



^aIncludes studies discussed in Chapter 2. A total of 540 epidemiological studies (including those finding no effect) have examined toxicity; some studies examined multiple endpoints.

2. HEALTH EFFECTS

2.2 ACUTE LEAD TOXICITY

Overview. No controlled studies in humans have evaluated the acute toxicity of Pb (acute Pb poisoning). Available information is anecdotal, obtained from numerous case reports. Thus, data are not sufficient to establish a dose-response relationship for acute toxicity relative to PbB. Acute Pb toxicity is characterized by symptoms of abdominal pain/colic, vomiting, constipation, peripheral neuropathy, and cerebral edema and encephalopathy, which can lead to seizures, coma, and death. Children are more susceptible than adults to acute Pb poisoning. Additional information on toxicity of ingested Pb debris (e.g., Pb shot) is provided in Appendix C.

Rather than reviewing numerous case reports, the information presented below was taken from the following reviews: Beers et al. (1999); Chisolm (1977); Klaassen (2001); Landrigan (1995); NAS (1972a); Needleman (2004); and Skerfving and Bergdahl (2015). Citations are only specifically noted below if quantitative information is discussed.

Confounding Factors, Effect Modifiers, and Uncertainties. There are several uncertainties from case reports on acute toxicity of Pb. Therefore, it is difficult to establish dose-response relationships for acute toxicity relative to PbB. Uncertainties include:

- Baseline PbB data are rarely available.
- There is a lack of quantitative data on the dose of Pb ingested.
- No information on the fractional absorption of ingested Pb.
- Time from ingestion of Pb to development of symptoms of acute Pb toxicity is often unknown.
- Time from ingestion of Pb to first clinical evaluation and PbB assessment is often unknown.
- Gastrointestinal symptoms and general malaise are typically the first symptoms of acute Pb toxicity to appear; these general symptoms are often attributed to other causes, leading to an initial misdiagnosis or delay in diagnosis.
- Data to develop PbB time-concentration curves are incomplete.
- Numerous factors may contribute to individual susceptibility to acute Pb exposure, including age, intercurrent illness, underlying developmental issues, dietary and nutritional status, concurrent medication use, and exposure to other chemicals.

Clinical Presentation of Acute Pb Toxicity. The onset of acute toxicity is rapid, usually occurring within 1–5 days of exposure. The main organ systems involved are the gastrointestinal, hematological, and

2. HEALTH EFFECTS

neurological systems. Signs and symptoms increase in severity with increasing PbB, ranging from mild to severe. Gastrointestinal effects include abdominal colic/pain, nausea, vomiting, diarrhea, and constipation. Massive loss of gastrointestinal fluids can lead to dehydration. Hematological effects include decreased hemoglobin synthesis, anemia, and acute hemolytic crisis characterized by anemia and hemoglobinuria. Numerous neurological symptoms are associated with acute Pb toxicity, including headache, hyperirritability, decreased activity, paresthesia, muscle pain and weakness, ataxic gait, decreased consciousness, cerebral edema leading to seizures and coma, encephalopathy, and death. Other reported symptoms include astringency of the mouth, metallic taste in the mouth, and thirst.

Susceptibility of Children. Children are more susceptible than adults to Pb poisoning because the fractional absorption of ingested Pb is higher than in adults and the developing central nervous system is more vulnerable to toxicity compared to a fully developed nervous system (Needleman 2004). In addition to being more sensitive than adults, acute toxicity in children may have long-lasting effects. For example, children who recover from acute encephalopathy can have long-term decreases in cognitive abilities, attention deficits, and impaired behavior. Children are also susceptible due to increased exposure.

Dose-Response Relationship for Acute Toxicity Relative to PbB. As noted above, data from case reports are not sufficient to establish a dose-response relationship for acute toxicity relative to PbB. Some general observations can be made from available reports; however, dose-response relationships are highly uncertain and may not apply to individuals acutely exposed to Pb. At PbB <30 µg/dL, signs and symptoms of acute toxicity typically are not observed. This should not be interpreted to mean that no Pb-induced adverse effects (e.g., decreased hemoglobin synthesis) occur at PbB <30 µg/dL, but that symptoms causing individuals to seek medical intervention (e.g., abdominal colic and vomiting) typically are not observed at PbB <30 µg/dL. As PbBs increase to >30 µg/dL, signs and symptoms of gastrointestinal and neurological toxicity are observed, with severity increasing with PbB. Pb-induced encephalopathy has been reported at PbB <100 µg/dL, but is more commonly associated with PbB >100 µg/dL (NAS 1972b). In a review of 96 cases of death due to acute Pb poisoning in children, death occurred at PbB >100 µg/dL (NAS 1972b).

2.3 DEATH

Overview. Numerous epidemiological studies have investigated associations between Pb exposure and death. Studies include exposure of workers and general populations, and report a wide range of PbB levels. In the general population, studies have shown significant associations between PbB and mortality

2. HEALTH EFFECTS

due to disease of blood and blood-forming organs. In occupationally exposed individuals, mortality due to infection, endocrine diseases, and digestive diseases were associated with PbB in male workers, but not female workers, while mortality due to respiratory disease was associated with PbB in a cohort of male workers. In addition, studies of the general population and Pb occupations show an association between PbB and cumulative “all-cause” mortality (including cancer). However, results are inconsistent and interpretation may be limited due to confounding factors. Studies assessing associations between PbB and mortality due to cardiovascular diseases and cancer are discussed in Sections 2.5 and 2.19, respectively, and are not reviewed here.

The following causes of death have been associated with PbB:

- $\leq 10 \mu\text{g/dL}$:
 - Increased risk of death from all causes (including cancer and cardiovascular disease); evaluated in a few studies with generally consistent results.
- $> 10 \mu\text{g/dL}$:
 - Increased risk of death from all causes (including cancer and cardiovascular disease); evaluated in several studies with positive associations in some studies.
 - Increased risk of death from chronic or unspecific nephritis or non-malignant kidney disease; evaluated in several studies with positive associations in some studies.
 - Increase risk of death from infection; demonstrated in one study.
 - Increased risk of death from endocrine disease; demonstrated in one study.
 - Increased risk of death from digestive disease; evaluated in several studies with positive associations in some studies.
 - Increased risk of death from diseases of the blood and blood forming organs; demonstrated in one study.
 - Increased risk of death from respiratory diseases (emphysema, pneumonia, and other respiratory diseases); evaluated in several studies with positive associations in some studies.

Confounding Factors and Effect Modifiers. Numerous factors can influence results of epidemiological studies evaluating associations between Pb exposure and mortality, including age, sex, BMI, ethnicity, poverty level, education, alcohol consumption, smoking status, hypertension, diabetes, family history of diseases, activity level, total cholesterol, postmenopausal status, nutritional status, and co-exposure with other metals (i.e., arsenic or cadmium). Failure to account for these factors may attenuate or strengthen

2. HEALTH EFFECTS

the apparent associations between Pb exposure and the outcome, depending on the direction of the effect of the variable on the outcome.

Measures of Exposure. Studies examining the association between Pb exposure and mortality evaluate exposure by measurement of PbB.

Characterization of Effects. Numerous epidemiological studies have assessed associations between PbB and mortality. Studies of general populations and workers are briefly summarized in Table 2-1. In the general population, at PbB ≤ 10 $\mu\text{g/dL}$, a positive dose-response relationship was suggested for all-cause mortality and mortality due to coronary heart disease (Khalil et al. 2009, 2010; Menke et al. 2006; Schober et al. 2006), although Weisskopf et al. (2009) did not show an increased risk for all-cause mortality. At >10 $\mu\text{g/dL}$, results of occupational exposure and general population studies are mixed and do not establish a pattern of effects or exposure-response relationships. In the general population, findings of the Lustberg and Silbergeld (2002) study suggested dose-response for PbB and all-cause mortality. In Pb workers, a dose-effect relationship was observed for all-cause mortality and mortality due to endocrine disease, infection, and digestive disease (Chowdhury et al. 2014; Kim et al. 2015), although Malcolm and Barnett (1982) did not observe a dose-effect relationship between Pb and all-cause mortality in Pb battery workers.

2. HEALTH EFFECTS

Table 2-1. Summary of Epidemiological Studies Evaluating Death^a

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Mortality outcome	Effects ^b
PbB $\leq 10 \mu\text{g}/\text{dL}$			
Cheung et al. 2013 Cross-sectional study; n=3,482 (NHANES III)	Mean (SE): 4.44 (0.14)	All-cause mortality ^c	OR: 1.045 (1.013 1.079)*
Khalil et al. 2009, 2010 Prospective cohort study; n=533 women (age 65–87 years)	Quintiles <ul style="list-style-type: none"> • Q1: <4 • Q2: 4 • Q3: 5 • Q4: 6–7 • Q5: >7 	All-cause mortality ^c	HR Q1 (reference) HR Q2: 0.80 (0.45, 1.42) HR Q3: 0.70 (0.39, 1.24) HR Q4: 0.60 (0.34, 1.06) HR Q5: 1.20 (0.69, 2.09) p-trend=0.905*
Khalil et al. 2009 Prospective cohort study; n=533 women (age 65–87 years)	Mean: 5.3 <8 (n=453) ≥ 8 (n=79)	All-cause mortality ^c	Adjusted HR $\geq 8 \mu\text{g}/\text{dL}$: 1.59 (1.02, 2.49); p=0.041*
		All-cause mortality excluding deaths due to cancer and cardiovascular disease	Adjusted HR $\geq 8 \mu\text{g}/\text{dL}$: 1.22 (0.48, 3.10); p=0.673
Menke et al. 2006 Longitudinal study; n=13,946 (NHANES 1988–1994; mean age 44.4 years)	Mean: 2.58 Tertiles: <ul style="list-style-type: none"> • T1: <1.93 • T2: 1.94–3.62 • T3: ≥ 3.62 	All-cause mortality ^c	Adjusted HR T1 (reference) T2: 0.91 (0.72, 1.15) T3: 1.25 (1.04, 1.51)* p-trend=0.002*
Neuberger et al. 2009 Retrospective cohort study; mortality data from Oklahoma State Department of Health; 1999–2001	5.8	Tuberculosis	SMR: 0.0 (0.0, 10.80)
		Bronchitis, emphysema, asthma	SMR: 1.10 (0.863, 13.84)
		Kidney disease	SMR: 0.984 (0.573, 1.576)

2. HEALTH EFFECTS

Table 2-1. Summary of Epidemiological Studies Evaluating Death^a

Reference and study population	PbB ($\mu\text{g/dL}$)	Mortality outcome	Effects ^b
Schober et al. 2006 Longitudinal study; n=9,757 (NHANES III; age ≥ 40 years)	Tertiles <ul style="list-style-type: none"> T1: <5; mean 2.6 T2: 5–9; mean 6.3 T3: >10, mean 11.8 	All-cause mortality ^c	RR T2: 1.24 (1.05, 1.48)* RR T3: 1.59 (1.28, 1.98); p-trend<0.001
Weisskopf et al. 2009 Longitudinal study; n=868 men (Normative Aging Study; age 21–80 years)	Mean (SD): 5.6 (3.4) Tertiles: <ul style="list-style-type: none"> T1: <4 T2: 4–6 T3: >6 	All-cause mortality ^c	Adjusted HR <ul style="list-style-type: none"> T1: 1 (reference) T2: 0.99 (0.71–1.37) T3: 1.01 (0.71–1.44) p-trend=0.92
PbB >10 $\mu\text{g/dL}$			
Chowdhury et al. 2014 Survey study; n=58,368 male workers (mean age 38.9 years)	Quartiles <ul style="list-style-type: none"> Q1: 0- <5 Q2: 5- <25 Q3: 25- <40 Q4: ≥ 40 	All-cause mortality ^c	SMR Q4: 0.80 (0.75, 0.84) SMR overall: 0.69 (0.66, 0.71)
		Chronic obstructive pulmonary disease	SMR Q4: 0.86 (0.64, 1.12) SMR overall: 0.65 (0.54, 0.78)
		Chronic renal disease	SMR Q4: 1.01 (0.58, 1.64) SMR overall: 0.65 (0.44, 0.93)
Cooper 1988; Cooper et al. 1985 Cohort study; n=4,519 battery workers; 2,300 smelters	Mean <ul style="list-style-type: none"> Battery (n=1326): 62.7 Smelters (n=537): 79.7 	Nonmalignant respiratory disease	Battery PMR: 0.90 (0.74, 1.10) Smelter PMR: 0.76 (0.53, 1.11)
		Cirrhosis of the liver	Battery PMR: 1.29 (0.96, 1.73) Smelter PMR: 0.63 (0.35, 1.15)
		Chronic or unspecified nephritis	Battery PMR: 2.06 (1.26, 3.18)*; p<0.01 Smelter PMR: 1.86 (0.80, 3.66)
		Chronic nephritis	Battery PMR: 1.48 (0.88, 2.49) Smelter PMR: 1.20 (0.50, 2.86)

2. HEALTH EFFECTS

Table 2-1. Summary of Epidemiological Studies Evaluating Death^a

Reference and study population	PbB (µg/dL)	Mortality outcome	Effects ^b
Kim et al. 2015 Cross-sectional study; n=81,067 inorganic Pb workers (54,788 males; 26,279 females; age 20–≤50 years)	Mean (SD)	All-cause mortality ^c	Males: RR T3: 1.36 (1.03, 1.79)*; p<0.05 Females: RR T3: 1.30 (0.41, 4.16)
	• Males: 8.8 (8.5)	Non-malignant death	Males: RR T3: 0.95 (0.56, 1.51) Females RR T3: 0.99 (0.13, 7.19)
	• Females 5.8 (5.4)	Infection	Males: RR T2: 3.73 (1.06, 13.06)*; p<0.05 Females: Not reported
	Tertiles:	Endocrine disease	Males: RR T3: 4.25 (0.90, 20.04)*; p<0.1 Females: Not reported
	• T1: <10	Respiratory disease	Males: RR T2: 1.46 (0.28, 7.49) Females: RR T2: 3.49 (0.31, 39.05)
	• T2: 10–20	Digestive disease	Males: RR T3: 3.23 (1.33, 7.86)*; p<0.05 Females: RR T2: 3.66 (0.33, 40.70)
• T3: >20			
Lundstrom et al. 1997 Retrospective cohort study; n=3,979 workers	Mean:	All-cause mortality ^c	Total cohort SMR: 0.9 (0.8, 1.0)
	• In 1950: 62.2	Respiratory disease	Total cohort SMR: 0.4 (0.2, 0.8)
	• In 1987: 33.2	Digestive organs	Total cohort SMR: 0.6 (0.3, 1.1)
Lustberg and Silbergeld 2002 Longitudinal study; n=4,292; age 30–74 years (NHANES II)	Tertiles:	All-cause mortality ^c	RR T2: 1.17 (0.90, 1.52) RR T3: 1.46 (1.14, 1.86)*
	• T1 (n=818): <10		
• T2 (n=2,735): 10–19			
• T3 (n=637): 20–29			
Malcolm and Barnett 1982 Retrospective cohort study; n=754 Pb battery workers	Group1 (non-occupational exposed): not reported Group 2: (light occupational lead exposure): mean 57 Group 3: (high occupational lead exposure): not reported	All-cause mortality ^c	Group 3 SMR: 1.07; p=0.134

2. HEALTH EFFECTS

Table 2-1. Summary of Epidemiological Studies Evaluating Death^a

Reference and study population	PbB (µg/dL)	Mortality outcome	Effects ^b
McDonald and Potter 1996 Prospective cohort study; n=454 pediatric patients diagnosed with Pb poisoning, Massachusetts, 1923–1966, followed through 1991	Mean 113	Diseases of the blood and blood forming organs	SMR: 9.68 (1.95, 28.28)*
		Nervous-system and sense-organ diseases	SMR: 2.86 (0.57, 8.35)
		Respiratory diseases	SMR: 1.95 (0.78, 4.02)
		Pneumonia	SMR: 2.10 (0.68, 4.90)
		Digestive system diseases	SMR: 1.37 (0.44, 3.21)
		Genitourinary system diseases	SMR: 1.69 (0.02, 9.43)
		Chronic nephritis	SMR: 5.00 (0.06, 27.82)
		All-cause mortality ^c	SMR: 1.74 (1.40, 2.15)*
McElvenny et al. 2015 Cohort study; n=9,122 workers; mean age 29.2 years	Mean (SD): 44.3 (22.7) Range: 2.3–321.5	All-cause mortality ^c	Males: SMR 1.10 (1.06, 1.14)* Females: SMR 1.00 (0.91, 1.09) Total SMR: 1.09 (1.05, 1.12)*
		Respiratory system diseases	Males: SMR: 1.17 (1.06, 1.30)* Females: SMR: 1.24 (0.98, 1.57) Total SMR: 1.18 (1.08, 1.30)*
		Digestive system diseases	Males: SMR: 1.22 (1.03, 1.45)* Females: SMR: 0.84 (0.52, 1.35) Total SMR: 1.16 (0.99, 1.36)
		Genitourinary diseases	Males: SMR: 1.02 (0.72, 1.44) Females: SMR: 0.67 (0.28, 1.60) Total SMR: 0.95 (0.69, 1.31)
		Non-malignant kidney disease	Males: SMR: 1.30 (0.76, 2.24) Total SMR: 1.29 (0.79, 2.11)

2. HEALTH EFFECTS

Table 2-1. Summary of Epidemiological Studies Evaluating Death^a

Reference and study population	PbB (µg/dL)	Mortality outcome	Effects ^b
Selevan et al. 1985 Retrospective cohort study; n=1,987 male workers	Mean: 56.3	All tuberculosis	SMR: 1.39 (0.69, 2.49)
		Diseases of the central nervous system	SMR: 0.84 (0.61, 1.12)
		Diseases of the respiratory system	SMR: 1.25 (0.92, 1.66)
		Other respiratory diseases	SMR: 1.87 (1.28, 2.64)*
		Diseases of the digestive system	SMR: 0.51 (0.26, 0.89)
		Diseases of the genitourinary system	SMR: 0.93 (0.42, 1.77)
		Chronic and unspecified nephritis and other renal sclerosis	SMR: 1.92 (0.88, 3.64)
		All other	SMR: 0.88 (0.67, 1.14)
Steenland et al. 1992 Cohort study (same cohort as Selevan et al. 1985); n=1,990 male smelter workers	Mean: 56.3	All-cause mortality ^c	SMR: 1.07 (1.00, 1.14)*
		Non-malignant respiratory disease	SMR: 1.44 (1.16, 1.77)*
		Emphysema	SMR: 2.20 (1.45, 3.20)*
		Pneumonia and other respiratory disease	SMR: 1.88 (1.34, 2.56)*
		Acute kidney disease	SMR: 0.91 (0.02, 5.07)
		Chronic kidney disease	SMR: 1.26 (0.54, 2.49)

2. HEALTH EFFECTS

Table 2-1. Summary of Epidemiological Studies Evaluating Death^a

Reference and study population	PbB (µg/dL)	Mortality outcome	Effects ^b
Wong and Harris et al. 2000	Mean:	All-cause mortality ^c	SMR: 1.045 (1.012, 1.08)*; p<0.01
Cohort study; n=4,519 battery workers; 2,300 smelters (same cohort as Cooper et al. 1985)	<ul style="list-style-type: none"> • All workers: 64.0 • Battery workers: 62.7 • Smelters: 79.7 		

^aStudies assessing death due to cardiovascular disease and cancer are discussed in Sections 2.5 and 2.19, respectively.

^bAsterisk and **bold** indicate association with Pb; unless otherwise specified, values in parenthesis are 95% CIs.

^cIncludes cancer and/or cardiovascular deaths.

CI = confidence interval; HR = hazard ratio; NHANES = National Health and Nutrition Examination Survey; OR = odds ratio; Pb = lead; PbB = blood lead concentration; PMR = proportionate mortality ratio; RR = rate ratio or relative risk; SD = standard deviation; SE = standard error; SMR = standard mortality ratio

2. HEALTH EFFECTS

2.4 BODY WEIGHT

Overview. Compared to other health effect endpoints, there is little information on Pb exposure and body weight measures. However, a few epidemiological studies have evaluated effects of Pb exposure on body weight in children, adolescents, and adults. The studies reviewed below focused on effects at PbB ≤ 10 $\mu\text{g/dL}$. Negative associations have been observed between PbB and BMI, and decreased risks of being overweight or obese have been reported. However, some studies did not observe associations and one study reported a positive association between PbB and the risk of obesity in women.

Note that studies evaluating the effects of exposure to Pb on birth weight are reviewed in Section 2.18 (Developmental).

The following effects on body weight have been associated with PbB ≤ 10 $\mu\text{g/dL}$:

- Decreased BMI and risk of being overweight or obese in children and adolescents; observed in a few studies.
- Decreased BMI and risk of being overweight or obese in adults; not corroborated.
- Increased risk of obesity in women; not corroborated.

Measures of Exposure. Most studies evaluating effects of chronic Pb exposure on body weight evaluate exposure by measurement of PbB. A few other studies examining associations between Pb exposure and body weight used Pb concentration in urine, bone, and/or dentin as biomarkers of exposure; however, these studies did not report PbB (Kim et al. 1995; Padilla et al. 2010; Shao et al. 2017).

Confounding Factors and Effect Modifiers. Numerous factors contribute to body weight (or BMI), including age, sex, race, nutrition, diet, daily activity level, intercurrent illness, genetic pre-disposition for body type, income level, education, and alcohol and tobacco use. Failure to account for these factors may attenuate or strengthen the apparent associations between Pb exposure and the outcome, depending on the direction of the effect of the variable on the outcome.

2. HEALTH EFFECTS

Effects at Blood Pb Levels ≤ 10 $\mu\text{g}/\text{dL}$. Results of studies evaluating effects of PbB ≤ 10 $\mu\text{g}/\text{dL}$ on body weight are briefly summarized in Table 2-2 and an overview of results is provided in Table 2-3; study details are provided in the *Supporting Document for Epidemiological Studies for Lead*, Table 1. Studies have been conducted in children and adolescents (Burns et al. 2017; Cassidy-Bushrow et al. 2016; Hauser et al. 2008; Scinicariello et al. 2013) and adults (Scinicariello et al. 2013; Wang et al. 2015). The largest study evaluating associations between PbB and body weight is a study of children, adolescents, and adults participating in NHANES, 1999–2006; this study included adjustments for numerous confounding factors (see the *Supporting Document for Epidemiological Studies for Lead*, Table 1) (Scinicariello et al. 2013). In children and adolescents (n=10,693), results show a negative association between PbB and BMI-Z score and risk of being overweight or obese. In a smaller study in children (n=131), negative associations were observed between PbB and BMI and BMI-Z score (Cassidy-Bushrow et al. 2016). Other studies in small populations of boys showed no associations between weight, BMI and/or BMI-Z score (Burns et al. 2017; Hauser et al. 2008). Results of studies in adults are mixed. The largest study in adults (n=15,899) shows negative associations between PbB and BMI and risk of being overweight and obese, with a negative trend (p-trend: ≤ 0.01) over quartiles (Scinicariello et al. 2013). No association was observed between PbB and BMI in a small study on women (n=107) (Ronco et al. 2010) or a larger study in men (n=2235) (Wang et al. 2015). In contrast, the risk of being obese was increased in a large population (n=3323) of women (Wang et al. 2015). Thus, except for the Wang et al. (2015) study, available studies show either no association or a negative association between PbB ≤ 10 $\mu\text{g}/\text{dL}$ and body weight and/or BMI.

Mechanisms of Action. The mechanisms involved in the development of Pb-induced changes in body weight have not been established. However, alterations of the hypothalamic-pituitary-adrenal axis, stress-induced elevations in glucocorticoid levels, oxidative stress, and altered lipid metabolism have been proposed (reviewed by Scinicariello et al. 2013; Shao et al. 2017; Wang et al. 2015).

2. HEALTH EFFECTS

Table 2-2. Summary of Epidemiological Studies Evaluating Effects on Body Weight at Mean Blood Lead Concentrations (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^b
Burns et al. 2017	Median 3.0	HT-Z score	Adjusted β (95% CI), HT-Z score per unit lnPbB: -0.26 (-0.40, -0.13); p<0.001*
Prospective cohort of 481 Russian boys enrolled at age 8–9 years and followed until age 18 years		BMI-Z score	Adjusted β (95% CI), BMI-Z score per unit lnPbB: -0.14 (-0.31, 0.04); p=0.12
Cassidy-Bushrow et al. 2016	Mean (SD): 2.45 (2.53)	BMI	Adjusted RR (95% CI) for BMI $\geq 85^{\text{th}}$ percentile 0.57 (0.33, 0.98); p=0.041*
Birth cohort of 131 children, 2–3 years of age		BMI-Z score	Adjusted β (95% CI) for BMI Z-score: -0.35 (-0.60, -0.10); p=0.012*
Hauser et al. 2008	Mean: 3	Weight	Adjusted β (95% CI), per unit log-PbB: -0.761 (-1.54, 0.02); p=0.067
Cross-sectional study of 489 boys, 8–9 years of age		BMI	Adjusted β (95% CI), per unit log-PbB: -0.107 (-0.44, 0.23); p=0.53
Ronco 2010	Median	BMI	No differences in PbB were observed between BMI categories
Cross-sectional study of 107 women of childbearing age (median age: 27 years) from Chile; data collection period not reported	<ul style="list-style-type: none"> • All: 1.0 • Low weight: 1.7 • Normal weight: 2.3 • Overweight: 1.0 		

2. HEALTH EFFECTS

Table 2-2. Summary of Epidemiological Studies Evaluating Effects on Body Weight at Mean Blood Lead Concentrations (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^b
Scinicariello et al. 2013 Cross-sectional study of children and adolescents (n=10,693; age 3–19 years) adults (n=15,899, age ≥ 20 years) using NHANES data (1999–2006)	Gmean (SE) • Children/adolescents: 1.12 (0.02) • Adults: 1.59 (0.02) • Quartiles (all): ○ Q1: ≤ 0.70 ○ Q2: 0.71–1.09 ○ Q3: 1.10–1.60 ○ Q4: ≥ 1.61	BMI-Z score (children and adolescents)	Adjusted β (SE) (BMI Z-score per PbB quartile): • Q3: -0.15 (0.06) ; $p=0.01^*$ • Q4: -0.33 (0.07) ; $p \leq 0.01^*$ • p-trend: $\leq 0.01^*$
		Overweight (children and adolescents)	Adjusted OR for Q4: 0.67 (0.52, 0.88)*
		Obesity (children and adolescents)	Adjusted OR • Q3: 0.70 (0.54, 0.90)* • Q4: 0.42 (0.30, 0.59)*
		BMI (adults)	Adjusted β (SE) (BMI per quartile): • Q2: -0.90 (0.20) ; $p \leq 0.01^*$ • Q3: -1.41 (0.22) ; $p \leq 0.01^*$ • Q4: -2.58 (0.25) ; $p \leq 0.01^*$ • p-trend: $\leq 0.01^*$
		Overweight (adults)	Adjusted OR for Q4: 0.79 (0.65–0.95)*
		Obesity (adults)	Adjusted OR • Q2: 0.76 (0.66–0.87)* • Q3: 0.66 (0.56–0.77)* • Q4: 0.42 (0.35–0.50)*

2. HEALTH EFFECTS

Table 2-2. Summary of Epidemiological Studies Evaluating Effects on Body Weight at Mean Blood Lead Concentrations (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^b
Wang et al. 2015 Cross-sectional study of 5,558 adults (men: 2,235, ages 39–65 years; women: 3,323, ages 40–65 years) from 16 locations in China	PbB: Men <ul style="list-style-type: none"> • Median: 4.40 • Quartiles: <ul style="list-style-type: none"> ○ Q1: ≤ 2.90 ○ Q2: 2.90–4.40 ○ Q3: 4.40–6.22 ○ Q4: ≥ 6.23 Women: <ul style="list-style-type: none"> • Median: 3.78 • Quartiles: <ul style="list-style-type: none"> ○ Q1: ≤ 2.51 ○ Q2: 2.51–3.77 ○ Q3: 3.78–5.43 ○ Q4: ≥ 5.44 	BMI	β (SE) per PbB quartile <ul style="list-style-type: none"> • Men <ul style="list-style-type: none"> ○ Q4: 0.01 (0.20) ○ p-trend: 0.82 • Women <ul style="list-style-type: none"> ○ Q4: 0.59 (0.17); $p < 0.05^*$ ○ p-trend: $< 0.001^*$
		Overweight	Adjusted OR <ul style="list-style-type: none"> • Men <ul style="list-style-type: none"> ○ Q4: 0.95 (0.72, 1.26) ○ p-trend: 0.74 • Women <ul style="list-style-type: none"> ○ Q4: 1.16 (0.92, 1.46) ○ p-trend: 0.07
		Obesity	Adjusted OR <ul style="list-style-type: none"> • Men <ul style="list-style-type: none"> ○ Q4: 0.88 (0.48, 1.61) ○ p-trend: 0.99 • Women <ul style="list-style-type: none"> ○ Q4: 1.86 (1.16, 2.98)[*] ○ p-trend: $< 0.01^*$

^aSee the *Supporting Document for Epidemiological Studies for Lead*, Table 1 for more detailed descriptions of studies.

^bAsterisk and **bold** indicate association with Pb.

BMI = body mass index; BMI-Z = BMI z-scores; CI = confidence interval; HR = hazard ratio; NHANES = National Health and Nutrition Examination Survey; OR = odds ratio; Pb = lead; RR = risk ratio; SD = standard deviation; SE = standard error

2. HEALTH EFFECTS

Table 2-3. Effects on Body Weight Associated with Mean Blood Lead Concentrations (PbBs) $\leq 10 \mu\text{g}^{\text{a}}$

Mean PbB ($\mu\text{g}/\text{dL}$)	Population (n) ^b	BMI-Z					Reference
		Weight	BMI	score	Overweight	Obese	
3.0	C (481 boys)	–	–	0	–	–	Burns et al. 2017
2.45	C (131)	–	↓	↓	–	–	Cassidy-Bushrow et al. 2016
3	C (489 boys)	0	0	–	–	–	Hauser et al. 2008
1.0	A (107 women)	–	0	–	–	–	Ronco et al. 2010
1.12	C, Ad (10,693) ^c	–	–	↓	↓	↓	Scinicariello et al. 2013
1.59	A (15,899) ^c	–	↓	–	↓	↓	Scinicariello et al. 2013
4.40	A (2,235, men)	–	0	–	0	0	Wang et al. 2015
3.78	A (3,323, women)	–	0	–	0	↑	Wang et al. 2015

^a↑ = increased; ↓ = decreased; 0 = no change; – = not assessed.

^bUnless otherwise specified, study was conducted in males and females.

^cParticipants from the National Health and Nutrition Examination Survey 1999–2006.

A = adults; Ad = adolescents; BMI = body mass index; BMI-Z = BMI z-scores; C = children

2.5 RESPIRATORY

Overview. Few epidemiological studies have evaluated respiratory effects associated with exposure to Pb; those that are available include cross-sectional studies in adults and prospective and cross-sectional studies in children. Associations have been observed between PbB and decreased lung function, increased bronchial hyperreactivity, increased number and severity of symptoms of respiratory disease, and increased risk of respiratory diseases (e.g., asthma and obstructive lung disease). Although most studies found associations between respiratory effects and PbB, other studies did not observe associations.

The following respiratory effects have been associated with PbB:

- $\leq 10 \mu\text{g}/\text{dL}$:
 - Decreased lung function; corroborated in a few studies.
 - Increased bronchial hyperreactivity.
 - Increased risk of asthma and obstructive lung disease; evaluated in a few studies with mixed results.

2. HEALTH EFFECTS

- >10 µg/dL:
 - Decreased lung function.
 - Symptoms of respiratory disease (e.g., shortness of breath).
 - Increased risk/prevalence of asthma; evaluated in a few studies with mixed results.

Measures of Exposure. Studies evaluating the association between respiratory effects and Pb exposure evaluate exposure by measurement of PbB.

Confounding Factors and Effect Modifiers. The etiology for most respiratory diseases is multifactorial; therefore, several factors may contribute to clinical findings. Factors that may contribute to the development of respiratory diseases include poor housing conditions, exposure to allergens (e.g., pet dander, seasonal allergies), exposure to tobacco smoke and other respiratory irritants, and asthma compounded by obesity (Ali and Ulirk 2013). In addition, Aligne et al. (2000) reported that children living in urban settings have an increased risk of asthma. Failure to account for these factors may attenuate or strengthen the apparent associations between Pb exposure and the outcome, depending on the direction of the effect of the variable on the outcome.

Characterization of Effects. General trends for studies showing a relationship between PbB and respiratory effects are shown in Table 2-4. Compared to other toxicological endpoints (e.g., neurological or cardiovascular effects), few studies have evaluated adverse respiratory effects associated with PbB. Data are from cross-sectional studies in adults (Bagci et al. 2004; Bener et al. 2001; Chung et al. 2015; Min et al. 2008a; Pugh Smith and Nriagu 2011; Rokadia and Agarwal 2013), and prospective (Joseph et al. 2005; Rabinowitz et al. 1990) and cross-sectional (Wells et al. 2014) studies in children. Over a range of PbBs that includes PbB ≤10 µg/dL and PbB >50 µg/dL, studies provide evidence for effects in Pb workers compared to controls or associations between PbB and decreased pulmonary function tests indicative of obstructive pulmonary disease (forced expiratory volume in 1 second [FEV₁], FEV₁/forced vital capacity [FVC] ratio, forced expiratory flow at 25–75% of FVC [FEF_{25–75}]), increased bronchial hyperreactivity (indicative of asthma), symptoms of respiratory disease (cough, shortness of breath), and increased risk of respiratory diseases (e.g., asthma and obstructive lung disease). With the exception of a prospective study in children, which showed no increased risk of asthma at umbilical cord PbB ≥10 µg/dL compared to <10 µg/dL (Rabinowitz et al. 1990), studies showed positive associations between PbB and respiratory effects.

2. HEALTH EFFECTS

Table 2-4. Overview of Respiratory Effects in Adults and Children Chronically Exposed to Lead (Pb)

Mean blood lead concentration (PbB) ($\mu\text{g}/\text{dL}$)	Effects associated with Pb exposure	References
≤ 10	Decreased lung function Increased bronchial responsiveness Lung disease (asthma and obstructive lung disease)	Chung et al. 2015 Min et al. 2008a Joseph et al. 2005; Rokadia and Agarwal 2013; Wells et al. 2014
$>10\text{--}30$	Lung disease (asthma)	Pugh Smith and Nriagu 2011
$>30\text{--}50$	Decreased lung function	Bagci et al. 2004
>50	Symptoms of lung disease (phlegm) Lung disease (asthma)	Bener et al. 2001 Bener et al. 2001

Effect at Blood Pb Levels $\leq 10 \mu\text{g}/\text{dL}$. Results of studies evaluating respiratory effects of PbB $\leq 10 \mu\text{g}/\text{dL}$ are summarized in Table 2-5, with study details provided in the *Supporting Document for Epidemiological Studies for Lead*, Table 2. Studies show associations between PbB $\leq 10 \mu\text{g}/\text{dL}$ and decreased lung function, increased bronchial hyperreactivity, and increased risk of asthma; findings are consistent with obstructive lung disease. In adults, a cross-sectional study evaluating lung function showed an increased FEV₁/FVC ratio in a population with mean PbB of $2.50 \mu\text{g}/\text{dL}$; results are consistent with obstructive airway disease (Chung et al. 2015). Increased bronchial reactivity in response to methacholine challenge, consistent with a diagnosis of asthma, was observed in adults with mean PbB of $2.96 \mu\text{g}/\text{dL}$ (Min et al. 2008a). In addition, risk of obstructive lung disease was observed in a large NHANES population of adults with a mean PbB of $1.73 \mu\text{g}/\text{dL}$ (Rokadia and Agarwal 2013). Studies in children examining associations between PbB and risk of asthma do not provide consistent results. A large prospective study showed an increased risk of asthma in black children with PbB < 5 and $\geq 5 \mu\text{g}/\text{dL}$ compared to white children with PbB $< 5 \mu\text{g}/\text{dL}$; however, no increased risk was observed for white children with PbB $\geq 5 \mu\text{g}/\text{dL}$ compared to white children with PbB $< 5 \mu\text{g}/\text{dL}$. A large cross-sectional study of children participating in NHANES did not observe an association between PbB (mean $1.07 \mu\text{g}/\text{dL}$) and asthma, with or without atopy (Wells et al. 2014).

Mechanisms of Action. General mechanisms of respiratory toxicity of Pb (reviewed in Section 2.21) are likely involved in the development of toxicity to the respiratory system. EPA (2014c) specifically noted that oxidative stress through reactive oxygen species (ROS), resulting in tissue damage and inflammation and immune effects, is a plausible mechanism for the underlying cause of respiratory damage. Increased

2. HEALTH EFFECTS

Table 2-5. Summary of Epidemiological Studies Evaluating Respiratory Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^b	
Decreased lung function				
Chung et al. 2015	<ul style="list-style-type: none"> • Mean: 2.50 • Tertiles: <ul style="list-style-type: none"> ○ T1: <2.03 ○ T2: 2.03–2.81 ○ T3: >2.81 	FVC%	Correlation coefficient: 0.070	
Cross-sectional study; n=870 adults		FEV ₁ %	Correlation coefficient: 0.00	
		FEV ₁ /FVC ratio	Correlation coefficient: -0.115; p<0.01*	
			OR T3: 0.006 (0, 0.286)*	
		p-trend: 0.03*		
Increased bronchial responsiveness				
Min et al. 2008a	Mean (SD): 2.96 (1.59)	BR	A 1 $\mu\text{g/dL}$ increase in PbB was associated with a higher BR; β (SE): 0.018 (0.007).*	
Cross-sectional study; n=523 adults				
Asthma				
Joseph et al. 2005	Mean	Asthma	All compared to PbB <5 $\mu\text{g/dL}$ in white children	
Prospective study; n=4,634 children (ages 3 months to 3 years)	<ul style="list-style-type: none"> • White: 3.2 • Black: 5.5 			HR white (PbB ≥ 5): 2.3 (0.8, 6.7); p=0.12
				HR black (PbB <5): 1.8 (1.3, 2.4); p<0.01*
				HR black (PbB ≥ 5): 1.5 (1.2, 1.8); p<0.01*
		HR black (PbB ≥ 10): 3.0 (1.2, 7.1); p=0.01*		
Rokadia and Agarwal 2013^c	Mean	OLD	OR for all OLD: 1.94 (1.10, 3.42)*	
Pooled cross-sectional study; n=9,575 adults (8,411 without OLD; 1,164 with OLD)	<ul style="list-style-type: none"> • Non-OLD: 1.18 • OLD: 1.73 		OR for mild OLD: 1.21 (0.55, 2.65)	
			OR for moderate-severe OLD: 3.49 (1.70, 7.15)*	

2. HEALTH EFFECTS

Table 2-5. Summary of Epidemiological Studies Evaluating Respiratory Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^b
Wells et al. 2014^c	Geometric mean: 1.07	Asthma	OR for asthma with atopy: 0.97 (0.61, 1.55)
Cross-sectional study; NHANES 2005–2006; n=1,430 children (ages 4–12 years)			OR for asthma with no atopy: 1.07 (0.86, 1.33)

^aSee the *Supporting Document for Epidemiological Studies for Lead*, Table 2 for more detailed descriptions of studies.

^bAsterisk and **bold** indicate association with Pb; unless otherwise specified, values in parenthesis are 95% CIs.

^cStudy population was from NHANES.

BR = bronchial responsiveness; CI = confidence interval; FEV₁ = forced expiratory volume in 1 second (L/s); FEV₁% = percent of predicted FEV₁; FVC = forced vital capacity (L); FVC% = percent of predicted FVC; HR = hazard ratio; NHANES = National Health and Nutrition Examination Survey; OLD = obstructive lung disease; OR = odds ratio; SD = standard deviation; SE = standard error

2. HEALTH EFFECTS

ROS, along with depletion of antioxidants, results in inflammation and production and release of metabolites and cytokines. Immune-mediated inflammation is observed with asthma and bronchial hyperreactivity.

2.6 CARDIOVASCULAR

Overview. A large number of epidemiological studies showing adverse effects on the cardiovascular system associated with Pb exposure have been published. Most studies evaluated effects in adults, although a few studies in children have been conducted. The effect of Pb exposure on blood pressure is the most studied cardiovascular outcome, with results providing consistent evidence of positive associations between lead exposure and blood pressure. Other cardiovascular endpoints (atherosclerosis, cardiac conduction, cardiovascular disease, and mortality due to cardiovascular disease) also show positive and negative associations with PbB, although the majority of studies had positive associations. In some cases, although no associations between PbB and cardiovascular outcomes were observed, associations were observed for bone Pb, a biomarker of cumulative lead exposure that, among individuals with high historical lead exposures, typically remains elevated for many years after the PbB declines to ≤ 10 $\mu\text{g}/\text{dL}$; these cases are noted in the discussions below.

The following cardiovascular effects have been associated with PbB:

- ≤ 10 $\mu\text{g}/\text{dL}$:
 - Greater systolic and diastolic blood pressure:
 - In adults; corroborated in multiple studies.
 - In children; evaluated in a few studies.
 - During pregnancy; evaluated in a few studies.
 - Greater risk of hypertension:
 - In adults, including during pregnancy; evaluated in a numerous studies.
 - Greater risk of atherosclerosis; evaluated in a few studies.
 - Altered cardiac conduction; evaluated in a few studies.
 - Greater risk of mortality due to cardiovascular diseases; evaluated in a few studies with mixed results.

2. HEALTH EFFECTS

- >10 µg/dL:
 - Increased systolic and diastolic blood pressure:
 - In adults; corroborated in multiple studies and meta-analyses.
 - In children; evaluated in a few studies.
 - Increased risk of hypertension; corroborated in multiple studies.
 - Atherosclerosis; evaluated in a few studies.
 - Increased risk or prevalence of heart disease; evaluated in a few studies.
 - Increased mortality due to cardiovascular diseases; corroborated in multiple studies.

Measures of Exposure. PbB and bone Pb concentrations have been used as biomarkers to evaluate cardiovascular effects of Pb exposure. However, PbB may not provide the ideal biomarker for long-term exposure to target tissues that contribute a hypertensive effect of Pb. Because the development of cardiovascular effects has a long latency period, associations between PbB and cardiovascular disease at concurrent PbB ≤ 10 µg/dL may be related to higher past Pb exposures. Bone Pb, a metric of cumulative or long-term exposure to Pb, appears to be a better predictor of Pb-induced elevations in blood pressure and alterations in cardiac conduction than PbB.

Confounding Factors and Effect Modifiers. Numerous factors affect blood pressure, including age, body mass, race, smoking, alcohol consumption, ongoing or family history of cardiovascular/renal disease, LDL cholesterol levels, and various dietary factors (e.g., dietary calcium). In addition, renal disease, as well as Pb-induced renal damage, can lead to cardiovascular effects, including increased blood pressure (EPA 2014c; NTP 2012); thus, interpretation of studies examining cardiovascular outcomes is complicated by the link between cardiovascular and renal function. Failure to account for these factors may attenuate or strengthen the apparent associations between Pb exposure and the outcome, depending on the direction of the effect of the variable on the outcome (e.g., Møller and Kristensen 1992). For example, adjusting for alcohol consumption will decrease the apparent association between PbB and blood pressure, if alcohol consumption contributes to Pb intake and, thereby, PbB (Bost et al. 1999; Hense et al. 1993; Hertz-Picciotto and Croft 1993; Wolf et al. 1995). Varying approaches and breadth of inclusion of these may account for the disparity of results that have been reported. Measurement error may also be an important factor. Blood pressure estimates based on multiple measurements or, preferably, 24-hour ambulatory measurements, are more reproducible than single measurements (Staessen et al. 2000).

2. HEALTH EFFECTS

Characterization of Effects. General trends between studies showing a relationship between PbB and cardiovascular effects are shown in Table 2-6. Over the PbB range of ≤ 10 – >50 $\mu\text{g/dL}$, results of epidemiological studies provide evidence for increased blood pressure and hypertension, atherosclerosis (increased intimal medial thickening and peripheral artery disease), heart disease (myocardial infarction, ischemic heart disease, left ventricular hypertrophy, cardiac arrhythmias, and angina), and increased risk of mortality due to cardiovascular diseases. The effect of Pb exposure on blood pressure is the most studied cardiovascular outcome. A review by Navas-Acien et al. (2007) concluded that that available literature provides evidence that “is sufficient to infer a causal relationship of lead exposure and hypertension” and evidence that “is suggestive but not sufficient to infer a causal relationship of lead exposure with clinical cardiovascular outcomes” (cardiovascular, coronary heart disease, and stroke mortality; and peripheral arterial disease). Well-controlled studies in laboratory animals provide additional support regarding effects of Pb on blood pressure; see EPA (2014c) for additional information.

Table 2-6. Overview of Cardiovascular Effects in Adults and Children Associated with Chronic Exposure to Lead (Pb)

Mean blood lead concentration (PbB) ($\mu\text{g/dL}$)	Effects associated with Pb exposure	References
≤ 10	Increased blood pressure and hypertension	Al-Saleh et al. 2005; Bost et al. 1999; Bushnik et al. 2014; Cheng et al. 2001; Chu et al. 1999; Den Hond et al. 2002; Elmarsafawy et al. 2006; Faramawi et al. 2015; Gerr et al. 2002; Glenn et al. 2003; Gump et al. 2005, 2011; Hense et al. 1993; Hu et al. 1996a; Korrick et al. 1999; Martin et al. 2006; Muntner et al. 2005; Nash et al. 2003; Park et al. 2009b; Perlstein et al. 2007; Proctor et al. 1996; Rothenberg et al. 2002b; Schwartz 1995; Scinicariello et al. 2010, 2011; Vupputuri et al. 2003; Wells et al. 2011; Yazbeck et al. 2009; Zhang et al. 2011; Zota et al. 2013
	Atherosclerosis ^a	Ari et al. 2011; Muntner et al. 2005; Navas-Acien et al. 2004;
	Heart disease ^b	Cheng et al. 1998; Eum et al. 2011; Jain et al. 2007; Park et al. 2009a
	Mortality due to cardiovascular disease	Aoki et al. 2016; Khalil et al. 2009; Lanphear et al. 2018; Menke et al. 2006; Schober et al. 2006; Weisskopf et al. 2009

2. HEALTH EFFECTS

Table 2-6. Overview of Cardiovascular Effects in Adults and Children Associated with Chronic Exposure to Lead (Pb)

Mean blood lead concentration (PbB) ($\mu\text{g}/\text{dL}$)	Effects associated with Pb exposure	References
>10–30	Increased blood pressure and hypertension	Coate and Fowles 1989; Factor-Litvak et al. 1999; Grandjean et al. 1989; Harlan et al. 1985; Møller and Kristensen 1992; Pirkle et al. 1985; Rabinowitz et al. 1987
	Atherosclerosis ^a	Pocock et al. 1988; Poreba et al. 2011, 2012
	Heart disease ^b	Poreba et al. 2013
	Mortality due to cardiovascular disease	Lustberg and Silbergeld 2002; Schober et al. 2006
>30–50	Increased blood pressure and hypertension	Aiba et al. 1999; Al-Saleh et al. 2005; Factor-Litvak et al. 1996, 1999; Ghiasvand et al. 2013; Glenn et al. 2006; Rapisarda et al. 2016; Weaver et al. 2008; Weiss et al. 1986, 1988
	Heart disease ^b	Bockelmann et al. 2002; Jain et al. 2007
	Mortality due to cardiovascular disease	Gerhardsson et al. 1995a
>50	Increased blood pressure and hypertension	Kirby and Gyntelberg 1985; Were et al. 2014
	Atherosclerosis ^a	Kirby and Gyntelberg 1985
	Mortality due to cardiovascular disease	Cooper 1988; Cooper et al. 1985; Fanning 1988; Gerhardsson et al. 1995a; McDonald and Potter 1996

^aAtherosclerosis includes increased intimal medial thickening and peripheral artery disease.

^bHeart disease includes myocardial infarction, ischemic heart disease, left ventricular hypertrophy, cardiac arrhythmias, and angina.

Numerous studies provide a weight of evidence for associations between PbB and increased blood pressure over a wide PbB range in adults (Table 2-6). Results of meta-analyses estimate small but consistent increases in blood pressure per doubling of PbB. The largest meta-analysis of 31 studies published between 1980 and 2001 included a total of 58,518 subjects (Nawrot et al. 2002); blood pressure data from studies included in the analysis are shown in Table 2-7 and Figures 2-2 and 2-3. Nawrot et al. (2002), in an update of an earlier meta-analysis by Staessen et al. (1994), estimated the increase in systolic pressure per doubling of PbB to be 1 mmHg (95% CI 0.5, 1.4) and the increase in diastolic pressure to be 0.6 mmHg (95% CI 0.4, 0.8). The range of mean (or median) PbBs for studies included in the analysis was 2.28–63.82 $\mu\text{g}/\text{dL}$. Although a PbB mean was not estimated for the entire study population, only nine studies had a mean PbB <10 $\mu\text{g}/\text{dL}$; therefore, it is likely that the overall PbB mean for the entire study population was >10 $\mu\text{g}/\text{dL}$. Similar outcomes were observed in two other meta-analyses (Schwartz 1995; Staessen et al. 1994). A meta-analysis reported by Staessen et al. (1994)

2. HEALTH EFFECTS

included 23 studies (published between 1984 and 1993; 33,141 subjects) and found a 1 mmHg (95% CI 0.4, 1.6) increase in systolic blood pressure and 0.6 mmHg (95% CI 0.2, 1.0) increase in diastolic pressure per doubling of PbB. Schwartz (1995) conducted a meta-analysis that encompassed a similar time frame (15 studies published between 1985 and 1993) and found a 1.25 mmHg (95% CI 0.87, 1.63) increase in systolic blood pressure per doubling of PbB (diastolic not reported). The latter analysis included only those studies that reported a standard error (SE) on effect measurement (e.g., increase in blood pressure per doubling of PbB). Of the 15 studies included in the Schwartz (1995) analysis, 8 were also included in the Staessen et al. (1994) analysis. The estimated increase in blood pressure per doubling of PbB in these meta-analyses is small; however, on a population basis, the consequences of increased blood pressure includes increased risks of serious and potentially fatal effects, including atherosclerosis, stroke, and myocardial infarction. Increased blood pressure during pregnancy has been associated with PbB and bone Pb (Rothenberg et al. 2002b; Wells et al. 2011; Yazbeck et al. 2009); these studies are discussed in more detail below (*Effect at Blood Pb Levels $\leq 10 \mu\text{g/dL}$*).

Table 2-7. Characteristics of the Study Population in Meta-Analyses of Effects of Lead (Pb) on Blood Pressure

Reference	Number ^a	Population ^b	Men (%) ^c	Age HT ^d (years) ^e	SBP ^f	DBP ^f	Lead ($\mu\text{g/dL}$) ^g
1 ^h Pocock et al. 1984 ^{ij} ; Shaper et al. 1981	7,379	GP	100	Y 49 (40–59)	145	82	15.13 (2.07–66.3) ^{Ae}
2 Kromhout 1988 ^{ij} ; Kromhout et al. 1985 ⁱ	152	GP	100	Y 67 (57–76)	154	92	18.23 (10.77–27.97) ^{Ac}
3 Moreau et al. 1982 ^j , 1988; Orssaud et al. 1985 ^{ij}	431	WC	100	Y 41 (24–55)	131	75	18.23 (8.91–49.94) ^{Ae}
4 Weiss et al. 1986 ⁱ , 1988 ⁱ	89	WC	100	Y 47 (30–64)	122	83	24.45 (18.65–29.01) ^{Mx}
5 de Kort and Zwennis 1988 ^{ij} ; de Kort et al. 1987 ⁱ	105	BC	100	N 40 (25–80)	136	83	29.22 (4.35–83.29) ^{Ae}
6 Lockett and Arbuckle 1987 ⁱ	116	BC	100	Y 32 (?–?)	119	80	37.5 (14.92–95.52) ^{Ae}
7 Parkinson et al. 1987 ⁱ	428	BC	100	Y 36 (18–60)	127	80	27.97 (6.01–49.52) ^{Ac}
8 Rabinowitz et al. 1987 ⁱ	3,851	GP	0	Y 28 (18–38)	121	76	7.04 (3.73–10.15) ^{Ac}
9 Elwood et al. 1988a ^{ij} , 1988b ^k	1,136	GP	100	Y 56 (49–65)	146	87	12.64 (6.01–26.11) ^{Gc}

2. HEALTH EFFECTS

Table 2-7. Characteristics of the Study Population in Meta-Analyses of Effects of Lead (Pb) on Blood Pressure

Reference	Number ^a	Population ^b	Men (%) ^c	HT ^d	Age (years) ^e	SBP ^f	DBP ^f	Lead (µg/dL) ^g
10 Elwood et al. 1988a, 1988b ^{i,j,l}	1,721	GP	50	Y	41 (18–64)	127	78	10.15 (4.56–23.21) ^{Gc}
11 Gartside et al. 1988 ⁱ ; Harlan 1988; Harlan et al. 1985; Pirkle et al. 1985; Ravnskov 1992 ^m	6,289	GP	53	Y	30 (10–74)	127	80	13.47 (2.07–95.93) ^{Ge}
12 Neri et al. 1988 ^{i,j,n}	288	BC	100	?	? (?–?)	?	?	45.17 (6.01–65.06) ^{Ae}
13 Neri et al. 1988 ^{i,o}	2,193	GP	?	Y	45 (25–65)	?	?	23.41 (0–47.03) ^{Me}
14 Grandjean et al. 1989, 1991 ^{i,p}	1,050	GP	48	Y	40 (40–40)	?	?	11.6 (3.94–60.09) ^{Ae}
15 Reimer and Tittelbach 1989 ⁱ	58	BC	100	?	32 (?–?)	134	81	39.99 (12.85–70.24) ^{Ac}
16 Apostoli et al. 1990 ⁱ	525	GP	48	Y	45 (21–60)	132	84	13.05 (2.07–28.18) ^{Ae}
17 Morris et al. 1990 ^{i,j}	251	GP	58	Y	? (23–79)	?	?	7.46 (4.97–38.95) ^{Ae}
18 Sharp et al. 1988 ^{i,j} , 1989 ⁱ , 1990 ⁱ	249	WC	100	N	43 (31–65)	128	83	6.63 (2.07–14.92) ^{Pe}
19 Staessen et al. 1984 ^{i,q}	531	WC	75	Y	48 (37–58)	126	78	11.4 (4.14–35.22) ^{Ge}
20 Møller and Kristensen 1992 ^{i,j,r}	439	GP	100	Y	40 (40–40)	?	?	13.68 (4.97–60.09) ^{Ae}
21 Hense et al. 1993 ^{i,j}	3,364	GP	51	Y	48 (28–67)	129	80	7.87 (1.24–37.09) ^{Ae}
22 Maheswaran et al. 1993 ⁱ	809	BC	100	Y	43 (20–65)	129	84	31.7 (0–98.01) ^{Ae}
23 Menditto et al. 1994	1,319	GP	100	Y	63 (55–75)	140	84	11.19 (6.22–24.66)
24 Hu et al. 1996a; Proctor et al. 1996 ^s	798	GP	100	Y	66 (43–93)	134	80	5.59 (0.41–35.02) ^{Pe}
25 Staessen et al. 1996a ⁱ , 1996b ^{i,t}	728	GP	49.3	Y	46 (20–82)	130	77	9.12 (1.66–72.52) ^{Ge}
26 Sokas et al. 1997 ^u	186	BC	99	Y	43 (18–79)	130	85	7.46 (2.07–30.04) ^{Pe}
27 Bost et al. 1999	5,326	GP	48	Y	48 (16–?)	135	75	63.82 (?–?) ^G
28 Chu et al. 1999	2,800	GP	53	Y	44 (15–85)	123	78	6.42 (0.41–69) ^{Ae}
29 Rothenberg et al. 1999a, 1999b	1,627	GP	0	Y	27 (?–?)	110	59	2.28 (?–?) ^G

2. HEALTH EFFECTS

Table 2-7. Characteristics of the Study Population in Meta-Analyses of Effects of Lead (Pb) on Blood Pressure

Reference	Number ^a	Population ^b	Men (%) ^c	HT ^d	Age (years) ^e	SBP ^f	DBP ^f	Lead (µg/dL) ^g
30 Schwartz et al. 2000 ^c	543	BC	100	Y	58 (41–73)	128	77	4.56 (1.04–20.1) ^{Ae}
31 Den Hond et al. 2001 ^v	13,781	GP	53.2	Y	48 (20–90)	125	73	3.11 (0.62–55.94) ^{Ge}

^aNumber of persons in whom relevant data were available.

^bStudy population: BC = blue collar workers; GP = sample from general population; WC = white collar employees.

^cMen: Percentage of men.

^dHT: Indicates whether the sample included (Y = yes) or did not include (N = no) hypertensive patients.

^eAge: Mean age or midpoint of age span (range or approximate range given between parentheses).

^fSBP, DBP: Mean systolic and diastolic blood pressures.

^gLead: Measure of central tendency: A = arithmetic mean; G = geometric mean; M = midpoint of range; P = P₅₀ (median). The spread of blood lead is given between parentheses: c = P₅–P₀₅ interval; P₁₀–P₉₀ interval, or interval equal to 4 times the standard deviation; e = extremes; x = approximate limits of distribution.

^hNumber refers to reference in Figures 2-2 and 2-3.

ⁱIncluded in the Staessen et al. (1994) meta-analysis.

^jIncluded in the Schwartz (1995) meta-analysis.

^kCaerphilly Study.

^lWelsh Heart Program.

^mNHANES (National Health and Nutrition Examination Survey).

ⁿFoundry workers.

^oCanadian Health Survey.

^pGlostrup Population Study, cross-sectional analysis (1976).

^qLondon Civil Servants.

^rGlostrup Population Study, longitudinal analysis (1976–1987).

^sNormative Aging Study.

^tPheeCad (Public Health and Environmental Exposure to Cadmium) Study.


^uBecause of missing information, only the effect in whites is included.

^vNHANES III Survey.

Source: Nawrot et al. 2002

2. HEALTH EFFECTS

Figure 2-2. Change in the Systolic Pressure Associated with a Doubling of the Blood Lead Concentration (PbB)*




*Data were digitized from Nawrot et al. 2002. Circles represent means (mmHg) of individual groups; squares represent combined groups; and open circles represent nonsignificant associations (plotted as zero). Bars represent 95% confidence limits. See Table 2-7 for more details on study groups.

B = blacks; C = Caerphilly Study; CS = civil servants; FW = foundry workers; HP = Welsh Heart Program; I = immigrants; NI = non-immigrants; P = Public Health and Environmental Exposure to Cadmium Study; W = whites

2. HEALTH EFFECTS

Figure 2-3. Change in the Diastolic Pressure Associated with a Doubling of the Blood Lead Concentration (PbB)*



*Data were digitized from Nawrot et al. 2002. Circles represent means (mmHg) of individual groups; squares represent combined groups; and open circles represent nonsignificant associations (plotted as zero). Bars represent 95% confidence limits. See Table 2-7 for more details on study groups.

B = blacks; C = Caerphilly Study; CS = civil servants; FW = foundry workers; HP = Welsh Heart Program; I = immigrants; N = non-immigrants; P = Public Health and Environmental Exposure to Cadmium Study; W = whites

2. HEALTH EFFECTS

Within individual studies, dose-effect relationships are evident at PbB ≤ 10 $\mu\text{g/dL}$. A positive dose-effect was observed for PbB and diastolic blood pressure (Zota et al. 2013). An observed positive dose-effect was observed for tibia Pb concentration and hypertension (Hu et al. 1996a). No dose-effect was observed for PbB and pulse pressure (PP), although a positive dose-effect was observed for tibia Pb and PP (Perlstein et al. 2007). In a cross-sectional study of women, diastolic hypertension was observed to have a positive dose-effect when pre- and postmenopausal women were analyzed together and when postmenopausal women were analyzed alone. In contrast, a dose-effect relationship was not observed for PbB and hypertension in a cross-sectional study of men and women (Muntner et al. 2005). A positive dose-effect relationship was observed for PbB and peripheral artery disease (PAD) (Muntner et al. 2005). In men, tibia blood levels had a positive dose-effect relationship with QT interval, but a negative dose-effect relationship with atrioventricular conduction defect (Eum et al. 2011). Studies have also found positive dose-effect relationships between mortality due to cardiovascular disease, myocardial infarction, and stroke and PbB (Menke et al. 2006; Schober et al. 2006).

Several studies have evaluated associations between PbB and cardiovascular function in children (Factor-Litvak et al. 1999, 1996; Gump et al. 2005, 2011; Kapuku et al. 2006; Khalil et al. 2009, 2010; Lustberg and Silbergeld 2002; Menke et al. 2006; Schober et al. 2006; Zhang et al. 2011). Results show alterations in cardiovascular function, including increases in blood pressure and altered cardiovascular function under stress (decreased stroke volume and cardiac output) over a PbB range from <10 to approximately 40 $\mu\text{g/dL}$.

Effect at Blood Pb Levels ≤ 10 $\mu\text{g/dL}$. Studies investigating relationships between PbB ≤ 10 $\mu\text{g/dL}$ and cardiovascular effects have evaluated effects on blood pressure (including hypertension), atherosclerosis, heart disease (alterations in cardiac conduction and ischemic heart disease), and death due to cardiovascular disease.

Increased blood pressure and hypertension. Numerous studies of large populations show associations between PbB ≤ 10 $\mu\text{g/dL}$ and increased systolic and/or diastolic blood pressure and increased risk of hypertension (see Table 2-8). The lowest PbB range positively associated with systolic and diastolic blood pressure is 1.41 – 1.75 $\mu\text{g/dL}$ (Scinicariello et al. 2011). A few studies did not show associations between PbB and blood pressure parameters; however, positive associations between bone Pb concentrations and blood pressure at concomitant PbB ≤ 10 $\mu\text{g/dL}$ were observed (Gerr et al. 2002; Hu et al. 1996a; Korrick et al. 1999; Zhang et al. 2011). Studies are briefly summarized in Table 2-8, with additional details provided in the *Supporting Document for Epidemiological Studies for Lead*, Table 3.

2. HEALTH EFFECTS

Table 2-8. Summary of Epidemiological Studies Evaluating Effects on Blood Pressure at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^{a,b}
Women and men combined (not stratified by sex)^c			
Faramawi et al. 2015^d Cross-sectional study; n=13,757	Mean: 3.44	SBP	β (SE), mmHg for change in blood pressure SD per $\mu\text{g}/\text{dL}$: 0.07 (0.02); p<0.01*
		DBP	β (SE), for change in blood pressure SD per $\mu\text{g}/\text{dL}$: 0.04 (0.03); p=0.08
Martin et al. 2006 Cross-sectional study; n=964 (ages 50–70 years)	Mean: 3.5	SBP	β, mmHg per 1 $\mu\text{g}/\text{dL}$: 0.99 (0.47, 1.51); p<0.01*
		DBP	β, mmHg per 1 $\mu\text{g}/\text{dL}$: 0.51 (0.24, 0.79); p<0.01*
Zota et al. 2013^d Cross-sectional study; n=8,194 (ages 40–65 years)	Mean: 1.69 Quintiles: • Q1: ≤ 1.05 • Q2: 1.06–1.44 • Q3: 1.45–1.90 • Q4: 1.91–2.69 • Q5: >2.70	Elevated SBP (≥ 140 mmHg)	OR (Q5): 1.23 (0.92, 1.65); p-trend: 0.06
		Elevated DBP (≥ 90 mmHg)	OR (Q3): 1.56 (1.11, 2.19)* OR (Q4): 1.80 (1.24, 2.60)* OR (Q5): 1.77 (1.25, 2.50)* p-trend 0.0002
Women and men (stratified by sex)^c			
Bost et al. 1999 Cross-sectional study; n=2,563 males and 2,763 females	Mean • M: 3.7 • F: 2.6	SBP	M: no association with PbB (regression coefficient not reported) F: no association with PbB (regression coefficient not reported)
		DBP	M: β, per doubling of PbB: 0.78 (0.01, 1.55)* F: regression coefficients not reported

2. HEALTH EFFECTS

Table 2-8. Summary of Epidemiological Studies Evaluating Effects on Blood Pressure at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^{a,b}
Bushnik et al. 2014 Population-based survey; n=2,214 males and 2,336 females	Mean <ul style="list-style-type: none"> All: 1.64 Non-hypertensive: 1.59 Hypertensive: 1.74 	SBP	All β , mmHg per 1 $\mu\text{g}/\text{dL}$: 1.85 (-0.20, 3.90); p=0.075
			M β , mmHg per 1 $\mu\text{g}/\text{dL}$: 2.17 (-0.08, 4.42); p=0.058
			F β , mmHg per 1 $\mu\text{g}/\text{dL}$: 0.76 (-2.72, 4.24); p=0.656
		DBP	All β, mmHg per 1 $\mu\text{g}/\text{dL}$: 1.91 (0.75, 3.08); p=0.002*
			M β, mmHg per 1 $\mu\text{g}/\text{dL}$: 2.36 (0.94, 3.79); p=0.002*
			F β , mmHg per 1 $\mu\text{g}/\text{dL}$: 1.43 (-0.51, 3.38); p=0.142
Hypertension	All β, mmHg per 1 $\mu\text{g}/\text{dL}$: -3.87 (-7.46, -0.29); p=0.035*		
	M β , mmHg per 1 $\mu\text{g}/\text{dL}$: -6.37 (-15.02, 2.29); p=0.142		
	F β , mmHg per 1 $\mu\text{g}/\text{dL}$: -4.18 (-8.78, 0.42); p=0.073		
Chu et al. 1999 Population-based survey study; n=1,471 males and 1,329 females	Mean <ul style="list-style-type: none"> M: 7.3 F: 5.7 	SBP	M β (SE), mmHg per 1 \log_{10} $\mu\text{g}/\text{dL}$: 0.185 (0.076); p=0.015*
			F β (SE), mmHg per 1 \log_{10} $\mu\text{g}/\text{dL}$: -0.057 (0.109); p=0.603
		DBP	M β (SE), mmHg per 1 \log_{10} $\mu\text{g}/\text{dL}$: 0.075 (0.053); p=0.159
			F β (SE), mmHg per 1 \log_{10} $\mu\text{g}/\text{dL}$: -0.083 (0.072); p=0.250

2. HEALTH EFFECTS

Table 2-8. Summary of Epidemiological Studies Evaluating Effects on Blood Pressure at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^{a,b}
Hense et al. 1993 Population-based survey study; n=1,703 males and 1,661 females	Mean • M: 8.3 • F: 6.0	SBP	M β, mmHg per 1 $\mu\text{g}/\text{dL}$: 0.29 (0.08, 0.49)*
		DBP	F β , mmHg per 1 $\mu\text{g}/\text{dL}$: 0.17 (-0.14, 0.48) M β , mmHg per 1 $\mu\text{g}/\text{dL}$: 0.08 (-0.06, 0.23) F β, mmHg per 1 $\mu\text{g}/\text{dL}$: 0.29 (0.09, 0.49)*
Men only^c			
Cheng et al. 2001^e Longitudinal study; n=833 men Analysis for hypertension limited to 474 participants who had no history of definite hypertension; analysis for SBP limited to 519 participants who were free from definite hypertension at baseline	PbB mean (all): 6.09 Tibia Pb ($\mu\text{g}/\text{g}$) • Borderline: 23.46 • Definite: 22.69 Patella Pb ($\mu\text{g}/\text{g}$) • Borderline: 33.73 • Definite: 32.72	Hypertension (borderline and definite)	RR, per 1 SD increase in PbB: 1.00 (0.76, 1.33)
			RR, per 1 SD increase in tibia Pb: 1.22 (0.95, 1.57)
			RR, per 1 SD increased in patella Pb: 1.29 (1.04, 1.61); p<0.05*
	SBP	RR, per 1 SD increase in PbB: -0.13 (-1.35, 1.09)	
		RR, per 1 SD increase in tibia Pb: 1.37 (0.02, 2.73); p<0.05*	
		RR, per 1 SD increased in patella Pb: 0.57 (-0.71, 1.84)	
Elmarsafawy et al. 2006^e Cross-sectional study; n=471	Mean • Low Ca^{2+} intake: 6.6 • High Ca^{2+} intake: 6.6	Hypertension	Low Ca^{2+}: OR: 1.07 (1.00, 1.15)* High Ca^{2+} : OR: 1.03 (0.97, 1.11)
Glenn et al. 2003 Occupational longitudinal study; n=496	Mean: 4.6	SBP	β (SE; 95% CI), per 1 SD increased in PbB: 0.64 (0.25; 0.14, 1.14)*
		DBP	β (SE; 95% CI); per 1 SD increased in PbB: 0.09 (0.17; -0.24, 0.43)

2. HEALTH EFFECTS

Table 2-8. Summary of Epidemiological Studies Evaluating Effects on Blood Pressure at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^{a,b}
Hu et al. 1996a^e Case-control study of men (n=146) with hypertension and controls (n=444)	Mean <ul style="list-style-type: none"> Cases: 6.9 Controls: 6.1 	Hypertension	Risk of hypertension based on tibia Pb: logistic β (SE): 0.19 (0.0078); p=0.01* PbB was not associated with hypertension OR (95% CL) for 1 $\mu\text{g}/\text{g}$ change in tibia Pb: 1.019 (1.004, 1.035)* OR (95% CL) for quintile range (8–37 $\mu\text{g}/\text{g}$): 1.5 (1.1, 1.8)*
Perlstein et al. 2007^e Cross-sectional study; n=593	Mean: 6.12	PP	PbB: no trend over quintiles (p=0.82) Bone Pb: p-trend=0.02*
Proctor et al. 1996^e Cross-sectional study; ≤ 74 years (n=681); >74 years (n=117)	Mean (SD) <ul style="list-style-type: none"> All: 6.5 ≤ 74 years: 6.5 >74 years: 6.3 	SBP	All β , mmHg per 1 ln $\mu\text{g}/\text{dL}$ PbB: 0.85 (-1.1, 2.7); p>0.05 ≤ 74 β , mmHg per 1 ln $\mu\text{g}/\text{dL}$ PbB: 1.2 (-0.86, 3.2); p>0.05
		DBP	All β, mmHg per 1 ln $\mu\text{g}/\text{dL}$ PbB: 1.2 (0.11, 2.2); p\leq0.05* ≤ 74 β, mmHg per 1 ln $\mu\text{g}/\text{dL}$ PbB: 1.6 (0.42, 2.7); p\leq0.01*
Women only^c			
Al-Saleh et al. 2005 Case-control study of women with hypertension (n=100) and control subjects (n=85)	Mean <ul style="list-style-type: none"> Hypertension: 4.75 Controls: 4.56 	Hypertension	OR for PbB ≥ 3.85 compared to PbB < 3.85 : 5.27 (0.93, 29.86); p=0.06

2. HEALTH EFFECTS

Table 2-8. Summary of Epidemiological Studies Evaluating Effects on Blood Pressure at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^{a,b}
Korrick et al. 1999 Case-control study of women with hypertension (n=89) and control subjects (n=195)	Mean (all): 3	Hypertension	PbB: no increased risk (ORs not reported) Patella Pb OR per 1 $\mu\text{g}/\text{g}$ increase in PbB: 1.03 (1.00, 1.05); p=0.02*
Nash et al. 2003 Cross-sectional study; n=2,165 all; 1,084 premenopausal, and 663 postmenopausal	Mean (all): 2.9 Quartiles; mean (range) • Q1: 1.0 (0.5–1.6) • Q2: 2.1 (1.7–2.5) • Q3: 3.2 (2.6–3.9) • Q4: 6.4 (4.0–31.1)	SBP	All β (SE), mmHg per 1 ln $\mu\text{g}/\text{dL}$ PbB: 0.32 (0.16); p=0.03* Premenopausal β (SE), mmHg per 1 ln $\mu\text{g}/\text{dL}$ PbB: 0.14 (0.26); p=0.59 Postmenopausal β (SE), mmHg per 1 ln $\mu\text{g}/\text{dL}$ PbB: 0.42 (0.21); p=0.29
		DBP	All β (SE): 0.25 (0.09), mmHg per 1 ln $\mu\text{g}/\text{dL}$ PbB; p=0.009* Premenopausal β (SE), mmHg per 1 ln $\mu\text{g}/\text{dL}$ PbB: 0.38 (0.25); p=0.12 Postmenopausal β (SE) mmHg per 1 ln $\mu\text{g}/\text{dL}$ PbB: 0.14 (0.13); p=0.04*
		Hypertension	Percent of total population with hypertension: p-trend<0.001 (Q1: 19.4; Q2: 20.6; Q3: 25.5 Q4: 28.3)

2. HEALTH EFFECTS

Table 2-8. Summary of Epidemiological Studies Evaluating Effects on Blood Pressure at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^{a,b}
Women and men stratified by race^c			
Den Hond et al. 2002^d Cross-sectional study n=4,685 MW; 5,138 FW; 1,761 MB; and 2,197 FB	Mean <ul style="list-style-type: none"> • MW: 3.6 • FW: 2.1 • MB: 4.2 • FB: 2.3 	SBP	MW β , per doubling of PbB: 0.3 (-0.2, 0.7); p=0.29
			FW β , per doubling of PbB: 0.1 (-0.4, 0.5); p=0.80
			MB β, per doubling of PbB: 0.9 (0.04, 1.8); p=0.04*
			FB β, per doubling of PbB: 1.2 (0.4, 2.0); p=0.004*
		DBP	MW β, per doubling of PbB: -0.6 (-0.9, -0.3); p=0.0003*
			FW β , per doubling of PbB: -0.2 (-0.5, 0.1); p=0.13
			MB β , per doubling of PbB: 0.3 (-0.3, 1.0); p=0.28
			FB β, per doubling of PbB: 0.5 (0.01, 1.1); p=0.047*
Muntner et al. 2005^d Cross-sectional study of 9,961 (men and women), stratified by race (W, B, MA)	Mean: 1.64 Quartiles: <ul style="list-style-type: none"> • Q1: <1.06 • Q2: 1.06–1.63 • Q3: 1.63–2.47 • Q4: ≥ 2.47 	Hypertension	W (Q4) OR: 1.10 (0.87, 1.41); p-trend=0.61
			B (Q4) OR: 1.44 (0.89, 2.32); p-trend=0.06
			MA (Q4) OR: 1.54 (0.99, 2.39); p-trend=0.04*

2. HEALTH EFFECTS

Table 2-8. Summary of Epidemiological Studies Evaluating Effects on Blood Pressure at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^{a,b}
Park et al. 2009b^d Cross-sectional study; n=12,500 all, 2,130 MW (<50 years old); 2,152 MW (≥ 50 years old); 1,048 MB (<50 years old); 540 MB (≥ 50 years old); 2,429 FW (<50 years old); 2,180 FW (≥ 50 years old); 1,409 FB (<50 years old); and 612 FB (≥ 50 years old)	Mean <ul style="list-style-type: none"> • MW (<50 years old) 4.02 • MW (≥ 50 years old) 4.92 • MB (<50 years old) 4.55 • MB (≥ 50 years old) 7.57 • FW (<50 years old) 2.09 • FW (≥ 50 years old) 3.53 • FB (<50 years old) 2.52 • FB (≥ 50 years old) 4.49 	Hypertension	MW OR: 1.06 (0.92, 1.22)
			FW OR: 1.16 (1.04, 1.29)*
			MB OR: 1.17 (0.98, 1.38)
			FB OR: 1.19 (1.04, 1.38)*
			M (<50 years old) OR: 0.98 (0.80, 1.22)
			M (>50 years old) OR: 1.20 (1.02, 1.41)*
			F (<50 years old) OR: 1.23 (1.04, 1.46)*
F (>50 years old) OR: 1.09 (0.94, 1.26)			
Scinicariello et al. 2010^d Cross-sectional study; n=6,016 (stratified by race)	Mean <ul style="list-style-type: none"> • W 2.87 • B 3.59 • MA 3.33 	SBP	W β (SE), mmHg per ln $\mu\text{g}/\text{dL}$ PbB: 1.05 (0.37); p=0.01*
		B β (SE), mmHg per ln $\mu\text{g}/\text{dL}$ PbB: 2.55 (0.49); p=0.001*	
		MA β (SE), mmHg per ln $\mu\text{g}/\text{dL}$ PbB: 0.84 (0.46); p=0.08	
		DBP	W β (SE), mmHg per ln $\mu\text{g}/\text{dL}$ PbB: -0.14 (0.49); p=0.77
		B β (SE), mmHg per ln $\mu\text{g}/\text{dL}$ PbB: 1.99 (0.44); p=0.0002*	
		MA β (SE), mmHg per ln $\mu\text{g}/\text{dL}$ PbB: 0.74 (0.74); p=0.06	

2. HEALTH EFFECTS

Table 2-8. Summary of Epidemiological Studies Evaluating Effects on Blood Pressure at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^{a,b}
Scinicariello et al. 2011^d Cross-sectional study; n=16,222 all; 4,538 MW; 4,319 FW; 1,767 MB; 1,854 FB; 1,925 MMA; and 1,819 FMA	Mean <ul style="list-style-type: none"> • All 1.41 • MW 2.20 • FW 1.55 • MB 2.44 • FB 1.81 • MMA 2.47 • FMA 1.56 	SBP	All β (SE), per ln $\mu\text{g}/\text{dL}$ PbB: 1.07 (0.35); $p < 0.05^*$
		MW β (SE), per ln $\mu\text{g}/\text{dL}$ PbB: 0.87 (0.53); $p > 0.05$	
		FW β (SE), per ln $\mu\text{g}/\text{dL}$ PbB: 0.89 (0.55); $p > 0.05$	
		MB β (SE), per ln $\mu\text{g}/\text{dL}$ PbB: 2.30 (0.71); $p < 0.05^*$ 	
		FB β (SE), per ln $\mu\text{g}/\text{dL}$ PbB: 2.40 (1.14); $p < 0.05^*$ 	
		MMA β (SE), per ln $\mu\text{g}/\text{dL}$ PbB: 0.10 (0.70); $p > 0.05$	
		FMA β (SE), per ln $\mu\text{g}/\text{dL}$ PbB: -0.03 (0.64); $p > 0.05$	
		DBP	All β (SE): 0.71 (0.27); $p < 0.05^*$
		MW β (SE): 0.90 (0.45); $p < 0.05^*$	
		FW β (SE): 0.95 (0.38); $p < 0.05^*$	
		MB β (SE): 2.75 (0.82); $p < 0.05^*$	
		FB β (SE), per ln $\mu\text{g}/\text{dL}$ PbB: 0.30 (0.81); $p > 0.05$	
		MMA β (SE), per ln $\mu\text{g}/\text{dL}$ PbB: -1.34 (0.66); $p < 0.05^*$ 	
		FMA β (SE), per ln $\mu\text{g}/\text{dL}$ PbB: -0.74 (0.44); $p > 0.05$	

2. HEALTH EFFECTS

Table 2-8. Summary of Epidemiological Studies Evaluating Effects on Blood Pressure at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$

Reference and study population	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^{a,b}
Vupputuri et al. 2003^d Cross-sectional study; n=14,952 total; n=5,360 MW; 5,188 FW; 2,104 MB; and 2,300 FB	Mean <ul style="list-style-type: none"> • MW 4.4 • FW 3.0 • MB 5.4 • FB 3.4 	SBP	MW β , per 1 SD (3.3 $\mu\text{g/dL}$) increase of PbB: 0.29 (-0.24, 0.83)
			FW β , per 1 SD (3.3 $\mu\text{g/dL}$) increase of PbB: 0.34 (-0.49, 1.17)
			MB β, per 1 SD (3.3 $\mu\text{g/dL}$) increase of PbB: 0.82 (0.19, 1.44); $p < 0.05^*$
			FB β, per 1 SD (3.3 $\mu\text{g/dL}$) increase of PbB: 1.55 (0.47, 2.64); $p < 0.01^*$
		DBP	MW β , per 1 SD (3.3 $\mu\text{g/dL}$) increase of PbB: 0.01 (-0.38, 0.40); $p \geq 0.05$
			FW β , per 1 SD (3.3 $\mu\text{g/dL}$) increase of PbB: -0.04 (-0.56, 0.47) $p \geq 0.05$
			MB β, per 1 SD (3.3 $\mu\text{g/dL}$) increase of PbB: 0.64 (0.08, 1.20); $p < 0.05^*$
			FB β, per 1 SD (3.3 $\mu\text{g/dL}$) increase of PbB: 1.07 (0.37, 1.77); $p < 0.01^*$
		Hypertension	MW OR: 1.04 (0.93, 1.16); $p = 0.47$
			FW OR: 1.32 (1.14, 1.52) $p < 0.001^*$
	MB OR: 1.08 (0.99, 1.19); $p = 0.08$		
	FB OR: 1.39 (1.21, 1.61); $p < 0.001^*$		

2. HEALTH EFFECTS

Table 2-8. Summary of Epidemiological Studies Evaluating Effects on Blood Pressure at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^{a,b}
Children and young adults^c			
Gerr et al. 2002 Cross-sectional study; n=508 young adults (ages 19–29 years)	PbB mean associated with the following bone Pb concentrations: <ul style="list-style-type: none"> • <1 $\mu\text{g}/\text{g}$: 1.91 (1.58) • 1–5 $\mu\text{g}/\text{g}$: 2.31 (2.06) • 6–10 $\mu\text{g}/\text{g}$: 2.43 (2.36) • >10 $\mu\text{g}/\text{g}$: 3.15 (2.28) 	SBP	Increase (mmHg) associated with bone Pb >10 $\mu\text{g}/\text{g}$ (SE): 4.26 (1.48); $p=0.004^*$
		DBP	Increase (mmHg) associated with bone Pb >10 $\mu\text{g}/\text{g}$ (SE): 2.80 (1.25); $p=0.03^*$
Gump et al. 2005 Prospective study; n=122 children assessed at 9 years of age	Cord PbB mean: 2.97	SBP	β (SE), mmHg log $\mu\text{g}/\text{dL}$: 12.16 (4.96); $p=0.016^*$
		DBP	β (SE), mmHg per log $\mu\text{g}/\text{dL}$: 8.45 (4.54); $p=0.066$
Gump et al. 2011 Cross-sectional study; n=140 children (ages 9–11 years)	Mean: 1.01 Quartiles: <ul style="list-style-type: none"> • Q1: 0.14–0.68 • Q2: 0.69–0.93 • Q3: 0.94–1.20 • Q4: 1.21–3.76 	SBP	Under acute stress, p-trend over quartiles: 0.31
		DBP	Under acute stress, p-trend over quartiles: 0.29
		TPR	Under acute stress, p-trend over quartiles: 0.03*

2. HEALTH EFFECTS

Table 2-8. Summary of Epidemiological Studies Evaluating Effects on Blood Pressure at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^{a,b}
Zhang et al. 2011 Prospective longitudinal study; n=457 mother-child pairs; children evaluated at ages 7–15 years	<ul style="list-style-type: none"> • Mean umbilical cord: 5.51 • Mean child concurrent: 2.96 • Median maternal postnatal tibia Pb ($\mu\text{g}/\text{g}$): 9.3 	SBP	Maternal tibia Pb, boys, β , mmHg increased per maternal tibia Pb (13 $\mu\text{g}/\text{g}$): -0.34 (-1.98, 1.30)
		DBP	<p>Maternal tibia Pb, girls, β mmHg increased per maternal tibia Pb (13 $\mu\text{g}/\text{g}$): 2.11 (0.69, 3.52); p=0.025*</p> <p>Maternal tibia Pb, boys, β, mmHg increased per maternal tibia Pb (13 $\mu\text{g}/\text{g}$): -0.83 (-2.05, 0.38)</p> <p>Maternal tibia Pb, girls, β, mmHg increased per maternal tibia Pb (13 $\mu\text{g}/\text{g}$): 1.60 (0.28, 2.91); p=0.007*</p>
Blood pressure during pregnancy^c			
Rothenberg et al. 2002b Longitudinal study; n=667 pregnant women	Mean: 1.9 Bone (calcaneous) Pb ($\mu\text{g}/\text{g}$) mean:10.7	SBP	Ln-PbB, β : -0.04 (-1.26, 1.18)
		DBP	<p>Bone Pb, β: 0.70 (0.04, 1.36)*</p> <p>Ln-PbB, β: 0.20 (-0.78, 1.18)</p> <p>Bone Pb, β: 0.54 (0.01, 1.08)*</p>
Wells et al. 2011 Cross-sectional study; n=285 pregnant women during labor	Umbilical cord PbB <ul style="list-style-type: none"> • mean: 0.66 • Quartiles: <ul style="list-style-type: none"> ○ Q1: <0.46 ○ Q2: 0.47–0.65 ○ Q3: 0.66–0.95 ○ Q4: 0.96–6.47 	SBP	<p>Q4 versus Q1 increase in SBP in mmHg at admission: 6.87 (1.51, 12.21); p<0.05*</p> <p>Q4 versus Q4 maximum increase in SBP in mmHg: 7.72 (1.83, 13.60); p<0.05*</p>
		DBP	<p>Q4 versus Q1 increase in DBP in mmHg at admission: 4.40 (0.21, 8.59); p<0.05*</p> <p>Q4 versus Q4 maximum increase in DBP in mmHg: Q4: 8.33 (1.14, 15.53); p<0.05*</p>

2. HEALTH EFFECTS

Table 2-8. Summary of Epidemiological Studies Evaluating Effects on Blood Pressure at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^{a,b}
Yazbeck et al. 2009 Cross-sectional study; n=971 pregnant women	Mean <ul style="list-style-type: none"> • Participants with PIH: 2.2 • Participants without PIH: 1.9 	PIH	OR for PIH for an increase of 1 \log_{10} $\mu\text{g}/\text{dL}$ in PbB; 3.29 (1.11, 9.74); $p=0.03^*$

^aAsterisk and **bold** indicate association with Pb; unless otherwise specified, values in parenthesis are 95% CIs.

^bIf bone Pb is noted under results, study did not show associations between PbB and blood pressure parameters; however, results showed associations between bone Pb concentrations and increased blood pressure at concomitant PbB ≤ 10 $\mu\text{g}/\text{dL}$.

^cSee the *Supporting Document for Epidemiological Studies for Lead*, Table 3 for more detailed descriptions of studies.

^dStudy population was from NHANES.

^eStudy population was from the Normative Aging Study.

B = black; CI = confidence interval; CL = confidence limit; DBP = diastolic blood pressure; F = female(s); M = male(s); MA = Mexican American; NHANES = National Health and Nutrition Examination Survey; OR = odds ratio; Pb = lead; PIH = pregnancy-induced hypertension; PP = pulse pressure; SBP = systolic blood pressure; SD = standard deviation; SE = standard error; TPR = total peripheral resistance; W = white

2. HEALTH EFFECTS

The magnitude of effect on blood pressure observed in individual large-scale, cross-sectional studies is consistent with results of meta-analyses (see discussion above on *Characterization of Effects*). For example, Martin et al. (2006) reported that systolic and diastolic blood pressure increased by 0.99 (95% CI 0.47, 1.51; $p < 0.01$) mmHg and 0.51 (95% CI 0.24, 0.79; $p < 0.01$) mmHg, respectively, per 1 $\mu\text{g}/\text{dL}$ increase in PbB.

Several studies have examined the relationship between PbB and blood pressure with study populations stratified according to gender, race, and/or age. For example, within study populations, positive associations were observed between PbB and systolic and diastolic blood pressure in men but not in women (Bushnik et al. 2014; Chu et al. 1999; Hense et al. 1993). However, other studies did not find differences between men and women (Bost et al. 1999; Scinicariello et al. 2011). Stratification by sex and age indicates additional differences between men and women. For example, Park et al. (2009b) reported a greater risk of hypertension in men >50 years of age (odds ratio [OR] 1.20; 95% CI 1.02, 1.41), but not in men <50 years of age (OR 0.98; 95% CI 0.80, 1.22), whereas in women, the opposite effect of age was observed, with a greater risk of hypertension in women <50 years of age (OR 1.23; 95% CI 1.04, 1.46) but not >50 years of age (OR 1.09; 95% CI 0.94, 1.26). Studies that stratify populations by race have found race differences in effect sizes on blood pressure. Large-scale cross-sectional studies based on data from NHANES have found larger effect sizes in non-Hispanic blacks and Mexican-Americans than in whites (Den Hond et al. 2002; Muntner et al. 2005; Scinicariello et al. 2011; Vupputuri et al. 2003). Cross-sectional studies based on data from NHANES have consistently shown elevations of systolic blood pressure in association with increasing PbB among black males and females, with less consistency in findings for other demographic groups or for diastolic blood pressure (Den Hond et al. 2002; Nash et al. 2003; Scinicariello et al. 2010, 2011; Vupputuri et al. 2003). Scinicariello et al. (2011) estimated increases in systolic blood pressure ranging from 1.07 to 2.4 per 1 ln increase in PbB (equivalent to approximately 0.7–1.66 per doubling of PbB). The largest effects sizes were observed in black males (2.3; SE 0.71 per ln PbB) and black females (2.4; SE 1.14). Den Hond et al. (2002) estimated the effect size for systolic blood pressure in black males and females to be 0.9 mmHg (95% CI 0.04, 1.8) and 1.2 mmHg (95% CI 0.4, 2.0) per doubling of PbB, respectively. Vupputuri et al. (2003) estimated the effect size for systolic blood pressure in black males and females to be 0.82 mmHg (95% CI 0.19, 1.44) and 1.55 mmHg (95% CI 0.47, 2.64) per 1 standard deviation (SD) increase (3.3 $\mu\text{g}/\text{dL}$) of PbB, respectively. As discussed above (see *Confounding Factors and Effect Modifiers*), numerous co-variables and confounders affect studies of associations between PbB and blood pressure, complicating comparisons between studies.

2. HEALTH EFFECTS

Few studies have evaluated effects of chronic Pb exposure in children or young adults on blood pressure parameters at PbB at ≤ 10 $\mu\text{g}/\text{dL}$ (Gerr et al. 2002; Gump et al. 2005, 2011; Zhang et al. 2011). Studies are briefly summarized in Table 2-8, with additional details provided in the *Supporting Document for Epidemiological Studies for Lead*, Table 3. Population sizes in these studies are small ($n=122$ – 508) compared to studies in adults. Positive associations were observed between concurrent PbB and increased systolic and diastolic blood pressure in young adults (Gerr et al. 2002). Two prospective studies suggest that prenatal exposure to Pb is associated with increased blood pressure in childhood (Gump et al. 2005; Zhang et al. 2011). Umbilical cord PbB was positively associated with increased systolic, but not diastolic, blood pressure in children (Gump et al. 2005). Maternal postnatal bone Pb concentration was associated with increased systolic and diastolic blood pressure in girls, but not boys; however, no association was observed between umbilical cord PbB or patella Pb concentration and increased blood pressure (Zhang et al. 2011).

Effects of Pb on blood pressure and hypertension at PbB at ≤ 10 $\mu\text{g}/\text{dL}$ have also been evaluated during pregnancy (Rothenberg et al. 2002b; Wells et al. 2011; Yazbeck et al. 2009). Studies are briefly summarized in Table 2-8, with additional details provided in the *Supporting Document for Epidemiological Studies for Lead*, Table 3. Increases in systolic and diastolic blood pressure during pregnancy and labor were associated with PbB ≤ 10 $\mu\text{g}/\text{dL}$ umbilical cord PbB, or bone Pb concentrations with concomitant PbB ≤ 10 $\mu\text{g}/\text{dL}$ (Rothenberg et al. 2002b; Wells et al. 2011; Yazbeck et al. 2009). Pregnancy-induced hypertension has been positively associated with PbB ≤ 10 $\mu\text{g}/\text{dL}$ (Yazbeck et al. 2009).

Atherosclerosis. Few studies have evaluated associations between PbB ≤ 10 $\mu\text{g}/\text{dL}$ and atherosclerosis (Ari et al. 2011; Muntner et al. 2005; Navas-Acien et al. 2004). Studies are briefly summarized in Table 2-9, with additional details provided in the *Supporting Document for Epidemiological Studies for Lead*, Table 3. Ari et al. (2011) reported a positive correlation between PbB and intimal medial thickening of the greater carotid artery in non-diabetic hemodialysis patients at a concurrent PbB of 0.41 $\mu\text{g}/\text{dL}$. Peripheral artery disease was positively associated with PbB levels ≥ 2.47 $\mu\text{g}/\text{dL}$, with a positive trend across quartiles, in a study of a large NHANES 1999–2002 (age 18 years or older) population (Muntner et al. 2005), whereas analyses restricted to adult (≥ 40 years old) participants of NHANES 1999–2000 reported a positive trend for the risk of peripheral artery disease, although ORs for PbB quartiles (highest PbB quartile > 2.90 $\mu\text{g}/\text{dL}$) were not associated with peripheral artery disease (Navas-Acien et al. 2004).

2. HEALTH EFFECTS

Table 2-9. Summary of Epidemiological Studies Evaluating Atherosclerosis at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^b
Ari et al. 2011 Clinical study; n=50 adult male and female hemodialysis patients and 48 age- and sex-matched controls	Mean <ul style="list-style-type: none"> Hemodialysis patients: 0.41 Controls: 0.10 	Greater carotid artery intima-media thickness	β (SE), mm per $\mu\text{g/dL}$ PbB: 0.101 (0.040); p=0.013*
Muntner et al. 2005^c Cross-sectional study; n=9,961 participants	Mean: 1.64 Quartiles: <ul style="list-style-type: none"> Q1: <1.06 Q2: 1.06–1.63 Q3: 1.63–2.47 Q4: ≥ 2.47 	PAD	OR for prevalence in Q4: 1.92 (1.02–3.61)* p-trend (across quartiles): <0.001
Navas-Acien et al. 2004^c Cross-sectional study; n=2,125 participants	Mean: 2.07 Quartiles: <ul style="list-style-type: none"> Q1: <1.45 Q2: 1.45–2.07 Q3: 2.07–2.90 Q4: >2.90 	PAD	OR for prevalence in Q4: 2.88 (0.87, 9.47) p-trend (across quartiles) for risk: 0.02*

^aSee the *Supporting Document for Epidemiological Studies for Lead*, Table 3 for more detailed descriptions of studies.

^bAsterisk and **bold** indicate association with Pb; unless otherwise specified, values in parenthesis are 95% CIs.

^cStudy population was from NHANES.

CI = confidence interval; NHANES = National Health and Nutrition Examination Survey; OR = odds ratio; PAD = peripheral artery disease; SE = standard error

2. HEALTH EFFECTS

Heart disease. A series of studies conducted in men from the Normative Aging Study in the greater Boston, Massachusetts area evaluated associations between PbB ≤ 10 $\mu\text{g/dL}$ and alterations in cardiac conduction and ischemic heart disease (Cheng et al. 1998; Eum et al. 2011; Jain et al. 2007; Park et al. 2009a). Studies are briefly summarized in Table 2-10, with additional details provided in the *Supporting Document for Epidemiological Studies for Lead*, Table 2. Studies show positive associations between bone Pb concentrations (at concomitant PbB ≤ 10 $\mu\text{g/dL}$) and changes to electrocardiograms (prolonged QT and QRS intervals) and atrioventricular conduction defect; however, no associations were observed between PbB and conduction abnormalities (Cheng et al. 1998; Eum et al. 2011; Park et al. 2009a). For ischemic heart disease, increased risks were associated with PbB and with tibia and patella Pb concentrations (Jain et al. 2007). A 1 SD increase in PbB was associated with a 1.27-fold increase in risk for ischemic heart disease.

Mortality due to cardiovascular disease. Mortality due to cardiovascular disease at PbB ≤ 10 $\mu\text{g/dL}$ has been examined in large prospective and longitudinal studies, which provide mixed results. Studies are briefly summarized in Table 2-11, with additional details provided in the *Supporting Document for Epidemiological Studies for Lead*, Table 3. Three of these were conducted in large studies of men and women participating in NHANES (Aoki et al. 2016; Lanphear et al. 2018; Menke et al. 2006; Schober et al. 2006). Aoki et al. (2016), Lanphear et al. (2018), and Menke et al. (2006) observed positive associations of mortality due to cardiovascular disease, including ischemic heart disease, myocardial infarction, and stroke and at PbB ≤ 10 $\mu\text{g/dL}$, including positive trends for mortality with increasing PbB. In contrast, Schober et al. (2006) did not find increased cardiovascular mortality risk at PbB < 10 $\mu\text{g/dL}$, although risk was increased at PbB ≥ 10 $\mu\text{g/dL}$ and a positive trend for mortality was observed with increasing PbB. For PbB, no increased risk or positive trend for mortality due to cardiovascular was observed in men from the Normative Aging Study (Weisskopf et al. 2009). In women, the risk of mortality due to coronary heart disease was increased at PbB ≥ 8 $\mu\text{g/dL}$ compared to PbB < 8 $\mu\text{g/dL}$ (Khalil et al. 2009).

2. HEALTH EFFECTS

Table 2-10. Summary of Epidemiological Studies Evaluating Heart Disease at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^{b,c}
Cheng et al. 1998^d Longitudinal study; n=775 men (n=277 for men <65 years of age)	PbB mean: 5.8 Bone Pb, $\mu\text{g}/\text{g}$, mean (SD) • Tibia: 22.2 (13.4) • Patella: 30.8 (19.2)	QT interval	β , msec per 10-fold increase in PbB: -0.65 (-10.40, 9.10); p=0.90
			β, msec per 10-fold increase in tibia Pb: 5.03 (0.83, 9.22); p=0.02*
			β, msec per 10-fold increase in patella Pb: 3.00 (0.16, 5.84); p=0.04*
		QRS interval	β , msec per 1 unit increase in PbB: -3.49 (-10.72, 3.75); p=0.35
			β, msec per 1-fold increase in tibia Pb: 4.83 (1.83, 7.83); p<0.01*
			β, msec per 1-fold increase in patella Pb: 2.23 (0.10, 4.36); p=0.04*
		IVCD	OR for a 10-fold increase in tibia Pb: 2.23 (1.28, 3.90); p<0.01*
Eum et al. 2011^d Prospective longitudinal study; n=600 men	PbB baseline mean: 5.8 PbB Tertiles: • T1: <4 • T2: 4–6 • T3: >6 Tibia Pb ($\mu\text{g}/\text{g}$) baseline mean: 21.6 Tertiles: • T1: <16 • T2: 16–23 • T3: >23	QT interval	PbB OR for T3: 1.31 (0.69, 2.48); p-trend: 0.41
			Tibia OR for T3: 2.53 (1.22, 5.25)*; p-trend: 0.003*
		Atrioventricular conduction defect	PbB OR for T3: 0.52 (0.19, 1.45); p-trend: 0.16
			Tibia OR for T3: 0.23 (0.06, 0.87); p-trend: 0.03

2. HEALTH EFFECTS

Table 2-10. Summary of Epidemiological Studies Evaluating Heart Disease at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^{b,c}
Jain et al. 2007^d Longitudinal prospective study; n=837 men	PbB Baseline mean	Ischemic heart disease	PbB β per 1 SD increase in PbB: 1.27 (1.01, 1.59)*
	<ul style="list-style-type: none"> • Non-cases 6.2 • Cases 7.0 		
	Patella Pb ($\mu\text{g/g}$) baseline mean		
	<ul style="list-style-type: none"> • Non-cases 30.6 • Cases 36.8 		PbB HR per 1 log increased in PbB: 1.45 (1.01, 2.06); p=0.05*
			Patella Pb HR per 1 log increased in bone Pb: 2.64 (1.09, 6.37); p=0.05*
Park et al. 2009a^d Longitudinal prospective study; n=613 men	<ul style="list-style-type: none"> • PbB median (IQR): 5 (4–7) • Patella Pb ($\mu\text{g/dL}$), median (IQR): 26 (18–37) • Tibia Pb ($\mu\text{g/dL}$), median (IQR): 19 (14–27) 	QT interval	PbB β for msec increase per IQR: 1.3 (-0.76, 3.36)
			Patella β for msec increase per IQR: 2.64 (0.13, 5.15)*
			Tibia β for msec increase per IQR: 2.85 (0.29, 5.40)*

^aSee the *Supporting Document for Epidemiological Studies for Lead*, Table 3 for more detailed descriptions of studies.

^bAsterisk and **bold** indicate association with Pb; unless otherwise specified, values in parenthesis are 95% CIs.

^cIf bone Pb is noted under results, study did not show associations between PbB and blood pressure parameters; however, results showed associations between bone Pb concentrations and increased blood pressure at concomitant PbB ≤ 10 $\mu\text{g/dL}$.

^dStudy population was from the Normative Aging Study.

CI = confidence interval; HR = hazard ratio; IQR = intraquartile range; IVCD = intraventricular conduction defect; OR = odds ratio; Pb = lead; SD = standard deviation

2. HEALTH EFFECTS

Table 2-11. Summary of Epidemiological Studies Evaluating Mortality due to Cardiovascular Disease at Mean Blood Lead Concentrations (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^b
Aoki et al. 2016^c Prospective study; n=18,602	Mean: 1.73	Mortality due to cardiovascular disease	RR, per 10-fold increase in PbB: 1.44 (1.05, 1.98)*
Khalil et al. 2009 Prospective study; n=533 women	Mean: 5.3	Mortality due to coronary heart disease	PbB ≥ 8.0 compared to women with PbB < 8.0. HR: 3.08 (1.23, 7.70); p=0.016*
Menke et al. 2006^c Longitudinal study; n=13,946	Baseline mean: 2.58 Tertiles: <ul style="list-style-type: none"> • T1: < 1.93 • T2: 1.94–3.62 • T3: ≥ 3.63 	Mortality due to cardiovascular disease	HR for T3 versus T1: 1.55 (1.08, 2.24)*; p-trend: 0.003*
		Mortality due to myocardial infarction	HR for T3 versus T1: 1.89 (1.04, 3.43)*; p-trend: 0.007*
		Mortality due to stroke	HR for T3 versus T1: 2.51 (1.20, 5.26)*; p-trend: 0.017*
Lanphear et al. 2018^c Longitudinal study; n=14,289	Mean: 2.71	Mortality due to cardiovascular disease	HR for PbB increase from 1.0 to 6.7 $\mu\text{g}/\text{dL}$: 1.70 (1.30, 2.22)*
		Mortality due to ischemic heart disease	HR for PbB increase from 1.0 to 6.7 $\mu\text{g}/\text{dL}$: 2.08 (1.52, 2.85)*

2. HEALTH EFFECTS

Table 2-11. Summary of Epidemiological Studies Evaluating Mortality due to Cardiovascular Disease at Mean Blood Lead Concentrations (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^b
Weisskopf et al. 2009^d Longitudinal study; n=868 men	Mean: 5.6 Tertiles <ul style="list-style-type: none"> • T1: <4 • T2: 4–6 • T3: >6 	Mortality due to cardiovascular disease	HR for T3 versus T1: 1.10 (0.67, 1.80); p-trend: 0.72

^aSee the *Supporting Document for Epidemiological Studies for Lead*, Table 3 for more detailed descriptions of studies.

^bAsterisk and **bold** indicate association with Pb; unless otherwise specified, values in parenthesis are 95% CIs.

^cStudy population was from NHANES.

^dStudy population was from the Normative Aging Study.

CI = confidence interval; HR = hazard ratio; NHANES = National Health and Nutrition Examination Survey; Pb = lead; RR = risk ratio

2. HEALTH EFFECTS

Associations Between Bone Pb and Cardiovascular Effects. Several studies have evaluated associations between bone Pb concentration and blood pressure and cardiac outcomes. Results provide evidence that long-term exposure to Pb produces adverse effects on the cardiovascular system.

Increased blood pressure and hypertension. Numerous studies show associations between bone Pb concentration and increased blood pressure and increased risk of hypertension (see Table 2-12). The most studied population is older men participating in the Normative Aging Study. Results consistently show positive associations between tibia Pb and systolic blood pressure (Cheng et al. 2001), pulse pressure (Jhun et al. 2015; Perlstein et al. 2007; Zhang et al. 2010), and risk of hypertension (Cheng et al. 2001; Elmarsafawy et al. 2006; Hu et al. 1996a; Peters et al. 2007). The association between bone Pb and elevated pulse pressure suggests that Pb may alter cardiovascular function through loss of arterial elasticity (Jhun et al. 2015; Perlstein et al. 2007; Zhang et al. 2010). Associations between patella Pb and blood pressure outcomes have been somewhat less consistent, with some studies showing positive associations (Hu et al. 1997; Jhun et al. 2015; Perlstein et al. 2007; Peters et al. 2007; Zhang et al. 2010) and other studies showing no associations (Cheng et al. 2001; Elmarsafawy et al. 2006). Other study populations examined include adults (Martin et al. 2006), young adults (Gerr et al. 2002), current and former Pb workers (Glenn et al. 2003; Lee et al. 2001), women (Korrick et al. 1999), pregnant women (Rothenberg et al. 2002b), and mother-child pairs (Zhang et al. 2001). Although study results are not consistent, positive associations between bone Pb and blood pressure and risk of hypertension have been reported. Navas-Acien et al. (2008) conducted a meta-analysis of 10 studies (see Table 2-12 for studies included in the analysis) to evaluate associations between tibia and patella Pb and blood pressure outcomes. Positive associations were observed between tibia Pb and systolic blood pressure and hypertension risk, but no associations were observed between tibia Pb and diastolic blood pressure or between patella Pb and systolic blood pressure, diastolic blood pressure, or hypertension risk.

Table 2-12. Associations Between Bone Pb and Blood Pressure Outcomes

Reference	Population	Blood pressure outcome			
		Systolic blood pressure	Diastolic blood pressure	Pulse pressure	Hypertension
Cheng et al. 2001 ^a	833 men ^b	↑ T 0 P	–	–	↑ T 0 P

2. HEALTH EFFECTS

Table 2-12. Associations Between Bone Pb and Blood Pressure Outcomes

Reference	Population	Blood pressure outcome			
		Systolic blood pressure	Diastolic blood pressure	Pulse pressure	Hypertension
Elmarsafawy et al. 2006	471 men ^b	–	–	–	↑ T (at low dietary calcium) 0 P (at high dietary calcium)
Gerr et al. 2002 ^a	508 young adults ^c	↑ T	↑ T	–	–
Glenn et al. 2003 ^a	496 male Pb workers ^d	↑ T ↑ P	0 T 0 P	–	–
Glenn et al. 2006 ^a	575 adult Pb workers ^e	↓ T	0 T	–	–
Hu et al. 1996a ^a	590	–	–	–	↑ T ↑ P
Jhun et al. 2015	727 men ^b	–	–	↑ T ↑ P	–
Korrick et al. 1999 ^a	689 women (214 cases; 475 controls) ^f	–	–	–	0 T ↑ P
Lee et al. 2001 ^a	924 adult Pb workers (789 cases; 135 controls) ^e	↑ T	0 T	–	↑ T
Martin et al. 2006 ^a	964 adults	0 T	0 T	–	↑ T
Perlstein et al. 2007	593 men ^b	–	–	↑ T ↑ P	–
Peters et al. 2007	512 men ^b	–	–	–	↑ T (with high stress) ↑ P (with high stress)
Rothenberg et al. 2002b ^a	1,006 pregnant women	–	–	–	↑ C (3 rd trimester) 0 T (3 rd trimester)
Schwartz et al. 2000c ^a	543 male Pb workers ^d	0 T	0 T	–	0 T
Weaver et al. 2008	652 Pb workers ^e	0 P	0 P	–	0 P
Zhang et al. 2010	612 men ^b	–	–	↑ T ↑ P	–

2. HEALTH EFFECTS

Table 2-12. Associations Between Bone Pb and Blood Pressure Outcomes

Reference	Population	Blood pressure outcome			
		Systolic blood pressure	Diastolic blood pressure	Pulse pressure	Hypertension
Zhang et al. 2011	457 mother-child pairs ^g	↑ T (girls) 0 T (boys)	↑ T (girls) 0 T (boys)	–	–

^aIncluded in the Navas-Acien et al. (2008) meta-analysis.

^bParticipants in the Normative Aging Study.

^c19–29 years of age.

^dCurrent and former Pb workers in the United States.

^eCurrent and former Pb workers in South Korea.

^fNurses Health Study.

^gBased on maternal bone Pb measurement.

↑ = positive association; ↓ = negative association; 0 = no association; – = not reported; C = calcaneous bone; P = patella; Pb = lead; T = tibia

Cardiac function. Several studies evaluating associations between bone Pb and cardiac function, disease, and mortality were conducted in participants of the Normative Aging Study (see Table 2-13). For tibia Pb, positive associations have been observed for QT and QRS intervals (Cheng et al. 1998; Eum et al. 2011; Park et al. 2009a), atrioventricular and intraventricular block (Cheng et al. 1998), and ischemic heart disease (Jain et al. 2007). For patella Pb, positive associations were observed for QT and QRS intervals (Cheng et al. 1998; Park et al. 2009a). Both tibia Pb and patella Pb were positively associated with ischemic heart disease (Jain et al. 2007). However, no association was observed between tibia or patella Pb and all cardiovascular mortality or mortality due to ischemic heart disease (Weisskopf et al. 2009).

Table 2-13. Associations Between Bone Pb and Cardiac Function, Disease, and Mortality

Reference	Population	Outcome		
		Function	Disease	Mortality
Cheng et al. 1998	775 men ^a	↑ T (QT and QRS intervals; AV block; IV block) ↑ P (QT and QRS intervals) 0 P (AV block; IV block)	–	–
Eum et al. 2011	600 men ^a	↑ T (QT and QRS	–	–

2. HEALTH EFFECTS

Table 2-13. Associations Between Bone Pb and Cardiac Function, Disease, and Mortality

Reference	Population	Function	Outcome	
			Disease	Mortality
		intervals) 0 P (QT and QRS intervals)		
Jain et al. 2007	837 men ^a	–	↑ T (IHD) ↑ P (IHD)	–
Park et al. 2006	413 men ^a	0 T (HRV with MetS) 0 T (HRV without MetS) ↑ P (HRV with MetS) 0 P (HRV without MetS)	–	–
Park et al. 2009a	613 men ^a	↑ T (QT interval) ↑ P (QT interval)	–	–
Weisskopf et al. 2009	868 men ^a	–	–	0 T (all cardiovascular or IHD deaths) 0 P (all cardiovascular or IHD deaths)

^aParticipants in the Normative Aging Study.

↑ = positive association; ↓ = negative association; 0 = no association; – = not reported; AV = atrioventricular; HRV = heart rate variability; IHD = ischemic heart disease (defined as myocardial infarction or angina pectoris); IV = intraventricular; MetS = metabolic syndrome (three or more of the following: obesity, diabetes, hypertension, and dyslipidemia); P = patella; Pb = lead; T = tibia

Mechanisms of Action. Several studies and recent reviews include discussions of mechanisms that may be involved in Pb-induced effects on cardiovascular function (Faramawai et al. 2015; Ghiasvand et al. 2013; Nawrot et al. 2002; Shiue et al. 2014; Weisskopf et al. 2009; Xu et al. 2015; Zota et al. 2013). Control of cardiovascular function is multi-factorial; therefore, numerous mechanisms are likely involved in Pb-induced cardiovascular effects. Specific mechanisms for cardiovascular effects include: impairment of renal function; effects on vascular smooth muscle, including constrictive effects and disruption of NO-induced vasodilatory actions; increase of sympathetic nervous system activity; and altered regulation of the renin-angiotensin-aldosterone axis and the renal kallikrein system. In addition, general mechanisms of toxicity of Pb, including oxidative stress, inflammation, and altered transport of ions across cellular membranes, also are likely to be involved (see Section 2.21).

2. HEALTH EFFECTS

2.7 GASTROINTESTINAL

Overview. Few epidemiological studies have evaluated gastrointestinal effects associated with chronic exposure to Pb. Almost all available studies were conducted in small numbers of workers with PbB >10 µg/dL, although one study included a group of workers with PbB ≤10 µg/dL. Study results consistently show gastrointestinal symptoms (abdominal colic/pain, nausea, vomiting, diarrhea, and/or constipation) associated with PbB ranging from 8.04 µg/dL to approximately 100 µg/dL. As reviewed in Section 2.2 (Acute Lead Toxicity), acute exposure to Pb is associated with gastrointestinal symptoms and intestinal paralysis.

The following gastrointestinal effects have been associated with PbB:

- ≤10 µg/dL:
 - Gastrointestinal symptoms (abdominal colic/discomfort).
- >10 µg/dL:
 - Gastrointestinal symptoms (abdominal colic/pain, nausea, vomiting, diarrhea and/or constipation); corroborated in a few studies.

Measures of Exposure. Studies examining the association between gastrointestinal effects of Pb exposure evaluate exposure by measurement of PbB.

Confounding Factors and Effect Modifiers. Most epidemiological studies on gastrointestinal effects of Pb are survey or cross-sectional studies of small populations of workers. In general, studies did not consider factors, such as age, diet, nutritional factors, alcohol use, and potential exposure to other occupational chemicals or limitations such as study design (cross-sectional and survey). Failure to account for these factors may attenuate or strengthen the apparent associations between Pb exposure and the outcome, depending on the direction of the effect of the variable on the outcome.

Characterization of Effects. In contrast to the large number of epidemiological studies evaluating effects of Pb on other organ systems (e.g., neurological and cardiovascular outcomes), few epidemiological studies have investigated the gastrointestinal effects of chronic exposure to Pb (see Table 2-14). With the exception of a survey study conducted in 497 workers (Rosenman et al. 2003), studies were conducted in small worker populations (n=69–155). Increased gastrointestinal symptoms (abdominal colic/pain,

2. HEALTH EFFECTS

Table 2-14. Summary of Studies Evaluating Gastrointestinal Symptoms Associated with Chronic Exposure to Lead (Pb)

Reference and study population	PbB (µg/dL)	Outcomes evaluated ^a	Effects ^b
Awad el Karin 1986 Cross-sectional study; n=92 exposed; 40 controls	Range of means (by job category): 48.1–80.7 Controls mean: 21.2	Abdominal colic	<ul style="list-style-type: none"> Exposed (% reporting symptom) 41.3; exposed versus control p=0.01* Control (% reporting symptom): 7.5
		Constipation	<ul style="list-style-type: none"> Exposed (% reporting symptom) 41.4; exposed versus control p=0.01* Control (% reporting symptom): 10.0
Baker et al. 1979 Survey study; n=160 Pb workers	Range of means (by job category): 41.8–87.2	Gastrointestinal symptoms	<ul style="list-style-type: none"> Mean PbB at which symptoms are present: 101.24 µg/dL (p<0.01)* PbB, symptom absent: 65.98 µg/dL
		Abdominal pain	<ul style="list-style-type: none"> PbB, symptoms present: 100.77 µg/dL (p<0.01)* PbB, symptom absent: 68.25 µg/dL
Kuruville et al. 2006 Cross-sectional study; n=155; exposed workers: n=105 (52 battery workers; 53 painters); controls: n=50	Mean <ul style="list-style-type: none"> Battery workers:42.40 Painters: 8.04 Controls: 5.76 	Abdominal colic	<ul style="list-style-type: none"> Battery workers (% reporting symptom): 17.3; p<0.01 Painters (% reporting symptom):18.9; p<0.01* Controls (% reporting symptom): 0
		Abdominal discomfort	<ul style="list-style-type: none"> Battery workers (% reporting symptom): 19.2; p<0.01* Painters (% reporting symptom): 26.4; p<0.001* Controls (% reporting symptom): 2
		Vomiting	<ul style="list-style-type: none"> Battery workers (% reporting symptom): 1.9 Painters (% reporting symptom): 1.9 Controls (% reporting symptom): 0
		Constipation	<ul style="list-style-type: none"> Battery workers (% reporting symptom): 0 Painters (% reporting symptom): 1.9 Controls (% reporting symptom): 2

2. HEALTH EFFECTS

Table 2-14. Summary of Studies Evaluating Gastrointestinal Symptoms Associated with Chronic Exposure to Lead (Pb)

Reference and study population	PbB (µg/dL)	Outcomes evaluated ^a	Effects ^b
Matte et al. 1989 Survey study; n=69 (46 manufacturing and 23 battery repair workers)	<ul style="list-style-type: none"> • Mean: not reported • Workers stratified by PbB <60 and ≥60 	Nausea	<ul style="list-style-type: none"> • PbB <60 (% reporting symptom): 7 • PbB ≥60 (% reporting symptom): 14 • PR (95% CI): 2.0 (0.5, 7.9)
		Abdominal pain	<ul style="list-style-type: none"> • PbB <60 (% reporting symptom): 12 • PbB ≥60 (% reporting symptom): 18 • PR (95% CI): 1.5 (0.5, 4.6)
Rosenman et al. 2003 Survey study; n=497 workers	<ul style="list-style-type: none"> • Range 10–70 • Stratification by PbB: <ul style="list-style-type: none"> ○ 10–24 (n=139) ○ 25–29 (n=98) ○ 30–39 (n=171) ○ 40–49 (n=58) ○ 50–59 (n=22) ○ ≥60 (n=9) 	Abdominal pain	AdjOR (95% CI) for PbB: <ul style="list-style-type: none"> • 10–24: 1 (reference) • 25–29: 0.62 (0.28, 1.37) • 30–39: 0.98 (0.53, 1.82) • 40–49: 2.15 (1.03, 4.49)* • 50–59: 1.54 (0.52, 5.23) • ≥60: NR

^aGastrointestinal symptoms include abdominal colic, nausea, vomiting, diarrhea, and/or constipation.

^bAsterisk and **bold** indicate association with Pb.

AdjOR = adjusted odds ratio (adjusted by age, ethnicity group, company screening, and smoking status); CI = confidence interval; NR = not reported; PbB = blood lead concentration; PR: prevalence ratio

2. HEALTH EFFECTS

nausea, vomiting, diarrhea, and/or constipation) were observed in all studies. The lowest PbB associated with increased gastrointestinal symptoms showed an increased percentage of workers reporting abdominal colic and discomfort at a mean PbB of 8.04 $\mu\text{g}/\text{dL}$, compared to controls (PbB 5.76 $\mu\text{g}/\text{dL}$) (Kuruvilla et al. 2006). For example, 18.9% of painters reported abdominal colic compared to 0 in the control group.

Effect at Blood Pb Levels $\leq 10 \mu\text{g}/\text{dL}$. See discussion above on Kuruvilla et al. (2006).

Mechanisms of Action. General mechanisms of toxicity of Pb (reviewed in Section 2.21) are likely involved in the development of gastrointestinal toxicity. EPA (2014c) specifically noted that oxidative stress through ROS could result in gastrointestinal toxicity; as a result, damage to the intestinal mucosa epithelium is possible.

2.8 HEMATOLOGICAL

Overview. Pb-induced toxicity to the hematological system has long been established. Pb inhibits heme synthesis, leading to the development of microcytic, hypochromic anemia. Numerous epidemiological studies have evaluated hematological effects associated with exposure to Pb in adults and children. Most studies were cross-sectional in design and evaluated effects on heme synthesis and subsequent changes in erythrocyte hemoglobin parameters and anemia. Studies in adults (general populations and workers) and children consistently show inhibition of heme synthesis enzymes, particularly δ -ALAD, and subsequent decreases in blood hemoglobin, red blood cell parameters (e.g., mean cell hemoglobin, mean cell volume), and development of anemia. Other hematological effects observed in epidemiological studies include alterations in erythrocyte function (decreased activities of pyrimidine 5'-nucleotidase and membrane $\text{Ca}^{2+}/\text{Mg}^{2+}\text{ATPase}$), changes in serum EPO concentration, and decreased platelet count.

The following hematological effects have been associated with PbB:

- $\leq 10 \mu\text{g}/\text{dL}$:
 - Inhibition of δ -ALAD; demonstrated in a few studies.
 - Decreased blood hemoglobin; evaluated in several studies with mixed results.
 - Decreased platelet count.
 - Decreased plasma EPO in adult males.

2. HEALTH EFFECTS

- >10 µg/dL:
 - Dose-dependent decreased heme synthesis due to inhibition of δ -ALAD and other heme metabolism enzymes; demonstrated in numerous studies.
 - Anemia and decreased blood hemoglobin; demonstrated in numerous studies.
 - Decreased activity of other erythrocyte enzymes (pyrimidine 5'-nucleotidase or red blood cell membrane $\text{Ca}^{2+}/\text{Mg}^{2+}$ ATPase); demonstrated in a few studies.
 - Altered plasma EPO concentration:
 - Decreased in adult males; evaluated in a few studies with mixed results.
 - Decreased in pregnant females; demonstrated in one study, but findings not corroborated.
 - Mixed results (both increases and decreases observed) in children; evaluated in a few studies.

Measures of Exposure. Studies evaluating the association between hematological effects and Pb exposure most commonly evaluate exposure by measurement of PbB.

Confounding Factors and Effect Modifiers. In general, available epidemiological studies on hematological effects do not control for factors, including concomitant exposure to other chemicals, that may affect the hematological system. In addition, dietary insufficiency of iron is the primary cause of microcytic, hypochromic anemia; however, few studies evaluated this as an effect modifier. Age and renal function are also confounding factors, as impairment of renal function can affect renal EPO synthesis and PbB. Failure to account for these factors may attenuate or strengthen the apparent associations between Pb exposure and the outcome, depending on the direction of the effect of the variable on the outcome.

Characterization of Effects. General trends for studies showing a relationship between PbB and hematological effects are shown in Table 2-15. Most epidemiological studies of hematological effects have examined effects on heme metabolism and its consequences, with fewer studies examining other hematological endpoints (altered serum levels of EPO, altered erythrocyte function, and decreased platelet count). As noted above, Pb-induced toxicity to the hematological system, specifically inhibition of heme synthesis enzymes and resulting anemia and decreased erythrocyte hemoglobin, have long been established. Numerous epidemiological studies in adults and children provide consistent evidence that δ -ALAD activity is inversely correlated with PbB over a PbB range of <10–>50 µg/dL (see Table 2-15) with δ -ALAD inhibition and subsequent effects of inhibition showing concentration-dependence for PbB

2. HEALTH EFFECTS

(Murata et al. 2009; Schwartz et al. 1990). A few studies have reported other hematological effects, including decreased platelet count in Pb workers at PbB of 5.4 µg/dL (Conterato et al. 2013) and >41 µg/dL (Barman et al. 2014). Inhibition of non-heme metabolism enzymes in erythrocytes was also associated with PbB. In Pb workers, membrane Ca²⁺/Mg²⁺ATPase was inhibited at a PbB range of approximately 29–42 µg/dL (Abam et al. 2008), and pyrimidine 5'-nucleotidase was inhibited at a PbB of >50 µg/dL (Buc and Kaplan 1978). Pyrimidine 5'-nucleotidase also was inhibited in children (aged 1–5 years) with a PbB range of 30–72 µg/dL (Angle et al. 1982).

Table 2-15. Overview of Hematological Effects Associated with Chronic Exposure to Lead (Pb)

Mean blood lead concentration (PbB) (µg/dL)	Effects associated with Pb exposure	References
≤10	Altered heme synthesis ^a	Ahamed et al. 2006; Ergurhan-Ilhan et al. 2008; Wang et al. 2010
	Anemia and/or decreased measures of RBC hemoglobin ^b	Ahamed et al. 2006; Conterato et al. 2013; Olivero-Verbel et al. 2007; Queirolo et al. 2010; Riddell et al. 2007; Ukaejiofo et al. 2009
	Decreased platelet count	Conterato et al. 2013
	Decreased EPO	Sakata et al. 2007
>10–30	Altered heme synthesis ^a	Ahamed et al. 2005, 2006; Counter et al. 2008, 2009; Grandjean and Lintrup 1978; Lauwerys et al. 1978; Mohammad et al. 2008; Murata et al. 2009; Piomelli et al. 1982; Rabinowitz et al. 1985; Roels et al. 1975, 1976; Roels and Lauwerys 1987; Schumacher et al. 1997; Stuik 1974
	Anemia and/or decreased measures of RBC hemoglobin ^b	Adebonojo 1974; Ahamed et al. 2007; Karita et al. 2005; Schwartz et al. 1990; Shah et al. 2010
	Altered RBC function ^c	Abam et al. 2008; Huel et al. 2008
	Decreased platelet count	Barman et al. 2014
	Decreased EPO	Graziano et al. 1991; Liebelt et al. 1999
Increased EPO	Factor-Litvak et al. 1999;	
>30–50	Altered heme synthesis ^a	Ademuyiwa et al. 2005; Alessio et al. 1976; Conterato et al. 2013; Fukumoto et al. 1983; Griffin et al. 1975; Murata et al. 2009; Roels et al. 1976; Secchi et al. 1974; Solliway et al. 1996
	Anemia and/or decreased measures of RBC hemoglobin ^b	Conterato et al. 2013; Schwartz et al. 1990; Solliway et al. 1996
	Altered RBC function	Abam et al. 2008; Angle et al. 1982; Buc and Kaplan 1978

2. HEALTH EFFECTS

Table 2-15. Overview of Hematological Effects Associated with Chronic Exposure to Lead (Pb)

Mean blood lead concentration (PbB) (µg/dL)	Effects associated with Pb exposure	References
>50	Decreased EPO	Romeo et al. 1996
	Increased EPO	Factor-Litvak et al. 1998; Graziano et al. 2004;
	Altered heme synthesis ^a	Cools et al. 1976; Gurer-Orhan et al. 2004; Jin et al. 2006; Meredith et al. 1978; Murata et al. 2009; Pagliuca et al. 1990; Schwartz et al. 1990
	Anemia and/or decreased measures of RBC hemoglobin ^b	Baker et al. 1979; Lilis et al. 1978; Malekirad et al. 2013; Grandjean 1979; Patil et al. 2006; Roels et al. 1979
	Decreased EPO	Romeo et al. 1996
	Altered RBC function ^c	Buc and Kaplan 1978

^aInhibition of heme synthesis measured by decreased δ -ALAD activity, elevated RBC levels or urinary levels of heme precursors (e.g., protoporphyrin, erythrocyte protoporphyrin, free erythrocyte protoporphyrin), and/or increased RBC zinc protoporphyrin/heme ratio.

^bDecreased blood hemoglobin, hematocrit, erythrocyte count, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and/or mean cell volume.

^cAltered erythrocyte function includes inhibition of pyrimidine 5'-nucleotidase or decreased RBC membrane $\text{Ca}^{2+}/\text{Mg}^{2+}$ ATPase.

ALAD = aminolevulinic acid dehydratase; EPO = serum erythropoietin; RBC = red blood cell

Several studies have evaluated the relationship between PbB and serum EPO levels in adults (Graziano et al. 1991; Osterode et al. 1999; Romeo 1991; Sakata et al. 2007) and children (Factor-Livak 1998, 1999; Graziano et al. 2004; Liebelt et al. 1999). Erythropoietin is a glycoprotein hormone produced in renal proximal tubules that regulates steady-state and accelerated erythrocyte production. As a compensatory response to conditions producing low blood oxygen (e.g., anemia), proximal tubular cells release EPO, resulting in stimulated erythrocyte production. However, if renal function is compromised due to disease or toxicity (e.g., Pb-induced renal damage), the compensatory increases in serum EPO may be diminished or absent. Results of three cross-sectional studies in adult male workers are inconsistent, showing decreased serum EPO levels at PbB 6.4–65.1 µg/dL (Romeo et al. 1996; Sakata et al. 2007), but no effect on EPO at a PbB of 45.5 µg/dL (Osterode et al. 1999). Study populations in these cross-sectional studies were small (n for exposed groups=10–27). In a subgroup of 48 pregnant women (selected from a larger cohort of 1,502 pregnant women), serum EPO was decreased; the range of PbB means based on hemoglobin stratifications was 23.1–36.2 µg/dL (Graziano et al. 1991). Studies in children have yielded mixed results on associations between PbB and serum EPO. Results of a series of prospective studies of children (n=280) in former Yugoslavia indicate that serum EPO levels in Pb-exposed children exhibit age-dependence (Factor-Litvak et al. 1998, 1999; Graziano et al. 2004). Serum EPO was increased in

2. HEALTH EFFECTS

children 4.5 (mean PbB: 39.3 µg/dL) and 6.5 years of age (mean PbB: 36.2 µg/dL), but not in children 9.5 (mean PbB: 28.1 µg/dL) or 12 years of age (mean PbB: 30.6 µg/dL) (Factor-Litvak et al. 1998, 1999; Graziano et al. 2004). The study authors suggested that the capacity for compensatory increases in EPO in response to Pb-induced anemia declines over time, possibly due to Pb-induced damage to the renal proximal tubule. In contrast to increases in EPO levels observed in the Yugoslavian cohort, Liebelt et al. (1999) showed decreased EPO levels in a group of children ages 1–6 years (n=95) who had a mean PbB of 18 µg/dL.

Effect at Blood Pb Levels ≤10 µg/dL. Epidemiological studies evaluating hematological effects of PbB ≤10 µg/dL are summarized in Table 2-16, with additional details provided in the *Supporting Document for Epidemiological Studies for Lead*, Table 4. Studies were conducted in small populations (n for exposed groups=25–391), except for two larger (n=855–2,861) cross-sectional studies in children (Liu et al. 2015a; Riddell et al. 2007). In general, studies show negative associations between PbB ≤10 µg/dL and δ-ALAD activity and blood hemoglobin in adults and children, although results are mixed. Negative correlations between PbB and δ-ALAD activity (measured by plasma δ-ALAD activity or zinc protoporphyrin:heme ratio) have been observed in children (Wang et al. 2010), adolescent males (Ahamed et al. 2006), and adults (Wang et al. 2010) at mean PbB of 5.95–9.96 µg/dL; however, no effect on δ-ALAD activity was observed in children with a mean PbB of 7.11 µg/dL (Ahamed et al. 2005). Differences in δ-ALAD activity were observed for male automotive repair workers (mean PbB: 7.9 µg/dL) and male controls (mean PbB: 2.6 µg/dL). Additionally, two studies in adults showed that blood hemoglobin concentration was lower in Pb workers (mean PbB: 5.4–7.0 µg/dL) compared to controls (mean PbB: 1.5–3.0 µg/dL) (Conterato et al. 2013; Ukaejiofo et al. 2009). In children with mean PbB of 6.9–9.0 µg/dL, there was a negative association between blood hemoglobin concentrations and PbB (Queirolo et al. 2010; Riddell et al. 2007) and erythrocyte Pb concentration (Liu et al. 2015a). At lower PbB in newborns (PbB 3.9 µg/dL) and children (PbB 5.5 µg/dL), no correlation was found; however, these study population were small (n=50–189) (Olivero-Verbel et al. 2007; Zentner et al. 2006). Thus, data are not adequate to establish an exposure-response relationship for decreased hemoglobin at PbB ≤10 µg/dL. Studies in small groups of workers (n=27–50) showed lower platelet count (PbB 5.4 µg/dL) and serum EPO concentrations (PbB 6.4 µg/dL) compared to controls (Conterato et al. 2013; Sakata et al. 2007). Although these findings have not been evaluated in other studies with PbB ≤10 µg/dL, similar effects have been observed at PbB >10 µg/dL.

2. HEALTH EFFECTS

Table 2-16. Summary of Epidemiological Studies Evaluating Hematological Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^b
Heme metabolism			
Ahamed et al. 2005 Cross-sectional study; n=62 children (ages 4–12 years)	Mean (SD) • Group 1: 3.93 (0.61) • Group 2: 7.11 (1.25)	δ -ALAD activity	No difference between groups: • Group 1: 4.82 (1.25) • Group 2: 4.56 (1.20)
Ahamed et al. 2006 Cross-sectional study; n=39 adolescent males (ages 15–18 years)	Mean (SD): 9.96 (3.63) Range: 4.62–18.64	δ -ALAD activity	A negative correlation between PbB and blood δ-ALAD activity: $r = -0.592$; $p < 0.001$*
Ergurhan-Ilhan et al. 2008 Cross-sectional study; n=25 male automotive repair workers (mean age 16.8 years); 24 male controls (mean age 16.3 years)	Mean (SD) • Controls: 2.6 (2.0) • Workers: 7.9 (5.2)	ALAD index ZPP:heme ratio	• Controls: 0.40 (0.34) • Workers: 0.73 (0.47); $p = 0.048$* • Controls: 26.4 (7) • Workers: 37.2 (15.9); $p = 0.045$*
Wang et al. 2010 Cross-sectional study of 307 children and 391 adults from China	Median • Children: 6.83 • Adults: 5.95	δ -ALAD activity ZPP	Pearson correlation coefficients: • Children: -0.256; $p < 0.05$* • Adults: -0.213; $p < 0.05$* Pearson correlation coefficients: • Children: 0.135; $p < 0.05$* • Adults: 0.083; $p < 0.05$*
Blood hemoglobin			
Conterato et al. 2013 Cross-sectional; n=50 painters; 36 controls	Mean (SE) • Control: 1.5 (0.1) • Painters: 5.4 (0.4)	Hb	Mean (SE), $\mu\text{g}/\text{dL}$ • Control: 15.4 (0.2) • Painters: 15.0 (0.1); $p < 0.05$*

2. HEALTH EFFECTS

Table 2-16. Summary of Epidemiological Studies Evaluating Hematological Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^b
Liu et al. 2015a Cross-sectional study; n=855 children (age range: 3–7 years)	PbB quartiles: <ul style="list-style-type: none"> • Q1: 2.20–5.16 • Q2: 5.16–7.33 • Q3: 7.33–10.62 • Q4: 10.62–37.78 Erythrocyte Pb quartiles: <ul style="list-style-type: none"> • Q1: 5.98–13.52 • Q2: 13.52–19.35 • Q3: 19.35–28.42 • Q4: 28.42–101.01 	Hb	Change in Hb compared to Q1: <ul style="list-style-type: none"> • PbB Q3: 1.45 (-0.28, 3.18) • Erythrocyte Pb <ul style="list-style-type: none"> ○ Q3: -3.01 (-4.71, 1.31); p<0.05*,c ○ Q4: -3.97 (-5.68, -2.27); p<0.05*
Olivero-Verbel et al. 2007 Cross-sectional study; n=189 children (age range 5–9 years)	Mean (SE): 5.49 (0.23)	Hb	Spearman correlation coefficient: 0.069; p=0.348
Queirolo et al. 2010 Cross-sectional study; n=222 children (age: 5–45 months)	Mean (SD): 9.0 (6.0)	Hb	Blood Hb <10.5 g/L was a predictor of PbB. β (95% CI): 2.40 (0.77, 4.03); p<0.01*
Riddell et al. 2007 Cross-sectional study; n=2,861 children (age 6 months–5 years)	Mean: 6.9	Hb	A 1 g/dL increase in Hb was associated with a 3% decrease in PbB ($p=0.043$)*
Ukajiofo et al. 2009 Cross-sectional study; n=81 Pb workers; 30 controls	Mean (SD) <ul style="list-style-type: none"> • Controls: 3.00 (0.19) • Workers: 7.00 (0.07) 	Hb	Mean (SE), g/dL <ul style="list-style-type: none"> • Controls: 12.96 (0.089) • Workers: 12.05 (1.62); p<0.001*
Zentner et al. 2006 Cross-sectional study; n=55 newborns	Umbilical mean (SD): 3.9 (3.6)	Hb	Pearson correlation coefficient: -0.04; p=0.721

2. HEALTH EFFECTS

Table 2-16. Summary of Epidemiological Studies Evaluating Hematological Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^b
Other hematological effects			
Conterato et al. 2013 Cross-sectional; n=50 painters; 36 controls	Mean (SE) • Control: 1.5 (0.1) • Painters: 5.4 (0.4)	Platelet count	Mean (SE), % • Control: 244.3 (8.3) • Painters: 203.7 (6.5); p<0.05*
Sakata et al. 2007 Cross-sectional studies: n=27 exposed workers; 9 controls	Mean (SD); range • Controls: 2.4 (1.1) • Workers: 6.4 (2.2)	EPO	Mean (SD), mU/mL: • Controls: 18.8 (4.6) • Workers: 12.7 (3.5); p<0.01*

^aSee the *Supporting Document for Epidemiological Studies for Lead*, Table 4 for more detailed descriptions of studies.

^bAsterisk and **bold** indicate association with Pb.


^cThe discrepancy between the 95% confidence limits and the p-value appears to be caused by an error in the reporting of the upper confidence limit (i.e., -1.31, rather than 1.31).

ALAD index = $\log(\text{active } \delta\text{-ALAD}/\text{non-activated } \delta\text{-ALAD})$; $\delta\text{-ALAD}$ = δ -aminolevulinic acid dehydratase; EPO = serum erythropoietin; Hb = hemoglobin; Pb = lead; SD = standard deviation; SE = standard error; ZPP = zinc-protoporphyrin

2. HEALTH EFFECTS

Mechanisms of Action. Pb inhibits heme synthesis by inhibiting δ -ALAD and ferrochelatase (see Figure 2-4). As a consequence, the activity of the rate-limiting enzyme of the pathway, δ -aminolevulinic synthetase (δ -ALAS), which is feedback inhibited by heme, is subsequently increased. The end results of these changes in enzyme activities are increased urinary porphyrins, coproporphyrin, and δ -aminolevulinic acid (δ -ALA), increased blood and plasma δ -ALA, increased erythrocyte protoporphyrin (EP), and decreased hemoglobin. The impairment of heme synthesis by Pb may have a far-ranging impact not limited to the hematopoietic system. EPA (1986) provided an overview of the known and potential consequences of the reduction of heme synthesis as shown in Figure 2-5. Solid arrows indicate well-documented effects, whereas dashed arrows indicate effects considered to be plausible further consequences of the impairment of heme synthesis.

Figure 2-4. Pb Interactions in the Heme Synthesis Pathway




Abbreviations as noted in Ahamed and Siddiqui (2007): δ -ALAS = delta-aminolevulinic acid synthetase; δ -ALAD = delta-aminolevulinic dehydratase; CoA = coenzyme A

*Activity of enzymes inhibited by lead.

Source: Reprinted from Ahamed and Siddiqui (2007) with permission from Elsevier.

2. HEALTH EFFECTS

Figure 2-5. Multiorgan Impact of Reduction of Heme Body Pool by Lead

Source: EPA 1986

In addition to decreased hemoglobin synthesis, general mechanisms of toxicity of Pb (reviewed in Section 2.21) are likely involved in the development of adverse effects to the hematological system. EPA (2014c) specifically noted effects of oxidative stress (altered antioxidant enzymes, decreased cellular glutathione, and lipid peroxidation) as an important mechanism for hematological effects. As reviewed in Section 3.2.3 (Toxicokinetics, Distribution), 99% of Pb in blood is distributed to erythrocytes, providing a toxicokinetic mechanism for hematological effects (Bergdahl et al. 1997a, 1998, 1999; Hernandez-Avila et al. 1998; Manton et al. 2001; Schutz et al. 1996; Smith et al. 2002).

2. HEALTH EFFECTS

2.9 MUSCULOSKELETAL

Overview. Few epidemiological studies have evaluated musculoskeletal effects associated with Pb exposure; thus, limited data are available to fully describe the exposure-response relationship or evaluate the weight-of-evidence for certain effects. Studies provide evidence of bone loss, increased markers of bone metabolism/turnover, and adverse periodontal and dental effects (periodontal bone loss, tooth loss, periodontal disease, dental caries). However, within dose ranges (≤ 10 , 10–30, 30–50, and >50 $\mu\text{g/dL}$), few studies examined the same endpoints. Available studies include a prospective study in women and cross-sectional studies in adults and children, with some studies in large populations.

The following musculoskeletal effects have been associated with PbB:

- ≤ 10 $\mu\text{g/dL}$:
 - Bone loss or markers of increased bone or joint tissue metabolism.
 - Periodontal bone loss.
 - Tooth loss.
 - Dental caries.
 - Periodontitis.
- >10 $\mu\text{g/dL}$:
 - Muscle soreness/weakness.
 - Osteoporosis/decreased bone mineral density (BMD) in adults.
 - Increased BMD in children.
 - Periodontal disease.
 - Dental caries.

Measures of Exposure. Most studies examining the association between musculoskeletal effects and Pb exposure have evaluated exposure by measurement of PbB, although some studies also evaluated exposure by bone Pb concentration.

Confounding Factors and Effect Modifiers. A complicating factor in the interpretation of studies examining associations between PbB and bone loss or measures of bone metabolism is that increased bone metabolism (bone turnover or loss) can result in higher PbB due to Pb released from bone into the blood (reverse causality). This contributes to confounding from other factors that are associated with

2. HEALTH EFFECTS

bone loss, including nutrition, age, pregnancy and menopause, and activity. Results of studies examining Pb-induced periodontal or dental effects need to account for dental hygiene, diet/nutrition, and previous dental interventions. For example, interpretation of results on associations between dental caries and PbB would be uncertain if daily fluoride intake or prophylactic dental treatments (e.g., fluoride treatments or coating of molars during childhood) were not considered as confounding factors. Studies that rely on *in vivo* estimates of bone Pb (e.g., XRF) as the exposure metric for changes in BMD should also consider the potential for changes in BMD affecting the measurement of the concentration of Pb in bone mineral (Hu et al. 2007).

Characterization of Effects. Studies evaluating musculoskeletal effects associated with PbB provide evidence of bone loss, altered bone or joint tissue metabolism, and adverse periodontal and dental effects (periodontal bone loss, tooth loss, periodontal disease, dental caries). Due to the small number of studies, it is difficult to establish exposure-response relationships; in addition, within specific dose-ranges (≤ 10 , 10–30, 30–50, and >50 $\mu\text{g/dL}$), few studies examined the same endpoints. Effects associated with chronic Pb exposure are shown in Table 2-17. In adults, decreased BMD has been observed over a PbB range of ≤ 10 – >50 $\mu\text{g/dL}$ (Campbell and Auinger 2007; Dongre et al. 2013; Khalil et al. 2008), although BMD was not decreased in women at PbB ≤ 10 $\mu\text{g/dL}$ (Pollack et al. 2013). BMD was increased in a single study in children with a mean PbB of 23.6 $\mu\text{g/dL}$ (Campbell et al. 2004). The study authors suggested that the effect may represent accelerated bone maturation due to Pb-induced inhibition of parathyroid hormone-related peptide and transforming growth factor β -1. The study authors also noted that the accelerated bone maturation may be a predisposing factor for osteoporosis later in life. Sun et al. (2008a, 2008b) showed that PbB was associated with increased prevalence of osteoporosis (mean PbB men: 20.22 $\mu\text{g/dL}$; women 15.50 $\mu\text{g/dL}$). Periodontal disease (including periodontitis), periodontal bone loss, tooth loss, and dental caries have been reported over a PbB range of ≤ 10 –30 $\mu\text{g/dL}$ (Arora et al. 2009; Campbell et al. 2000a; Dye et al. 2002; Gemmel et al. 2002; Kim and Lee 2013; Moss et al. 1999; Youravong and Teanpaisan 2015). Most studies examining periodontal and dental effects of Pb are conducted in populations with PbB ≤ 10 $\mu\text{g/dL}$. Muscle soreness and weakness has also been reported, although at higher PbB (40–49 $\mu\text{g/dL}$) (Rosenman et al. 2003).

2. HEALTH EFFECTS

Table 2-17. Overview of Musculoskeletal Effects Associated with Chronic Exposure to Lead (Pb)

Mean blood lead concentration (PbB) ($\mu\text{g/dL}$)	Effects associated with Pb exposure	References
≤ 10	Bone loss/increased bone metabolism Tooth loss Periodontal bone loss Periodontitis Dental caries	Khalil et al. 2008; Machida et al. 2009; Nelson et al. 2009 Arora et al. 2009 Dye et al. 2002 Kim and Lee 2013 Gemmel et al. 2002; Moss et al. 1999
$>10\text{--}30$	Osteoporosis Decreased bone mineral density (adults) Increased bone mineral density (children) Periodontal disease Dental caries	Sun et al. 2008a, 2008b Campbell and Auinger 2007 Campbell et al. 2004 Youravong and Teanpaisan 2015 Campbell et al. 2000a
$>30\text{--}50$	Muscle soreness/weakness Decreased bone mineral density	Rosenman et al. 2003 Campbell and Auinger 2007
>50	Decreased bone mineral density	Dongre et al. 2013

Effects at Blood Pb Levels $\leq 10 \mu\text{g/dL}$. Epidemiological studies of musculoskeletal effects associated with $\text{PbB} \leq 10 \mu\text{g/dL}$ have examined effects on bone and periodontal and dental health; studies are briefly summarized in Table 2-18, with additional details provided in the *Supporting Document for Epidemiological Studies for Lead*, Table 5. A prospective study in women reported an increased rate of bone loss at PbB ranges of 4–7 and 8–21 $\mu\text{g/dL}$ and an increased risk of non-spine fractures at a PbB range of 8–21 $\mu\text{g/dL}$ (Khalil et al. 2008). In cross-sectional studies, markers of bone metabolism were positively associated with PbB in women at mean PbBs of <2 and $2.9 \mu\text{g/dL}$, although no relationship was observed for these markers and PbB in men (mean PbB $1.2 \mu\text{g/dL}$) (Machida et al. 2009; Nelson et al. 2011). No associations between PbB and BMD have been observed in cross-sectional studies in women (Machida et al. 2009; Pollack et al. 2013). Studies examining periodontal and dental effects include large ($n=3,966\text{--}10,033$) cross-sectional studies in adults and children (Dye et al. 2002; Kim and Lee 2013; Moss et al. 1999). Positive associations have been observed between PbB and presence of dental furcations in male and female adults (mean PbB $1.9\text{--}3.3 \mu\text{g/dL}$) (Dye et al. 2002), periodontitis in adult males (PbB mean $3.1 \mu\text{g/dL}$), but not females (mean PbB 2.2) (Kim and Lee 2013), and dental

2. HEALTH EFFECTS

Table 2-18. Summary of Epidemiological Studies Evaluating Musculoskeletal Effects at Mean Blood Lead Concentration (PbB) ≤10 µg/dL^a

Reference and study population	PbB (µg/dL)	Outcome evaluated	Result ^{b,c}
Bone metabolism			
Khalil et al. 2008 Prospective cohort study; n=533 women (age range: 65–87 years).	PbB: Mean (SD): 5.3 (2.3) Tertiles: • T1 (n=122): ≤3 (reference) • T2 (n=332): 4–7 • T3 (n=79): 8–21	Bone loss	Percentage rate of calcaneus bone loss • T1: -1.01 (-1.27, -0.74)* • T2: -1.41 (-1.57, -1.24)* • T3: -1.49 (-1.86, -1.10)*; p=trend: 0.03*
		Non-spine fractures	HR T3: 2.50 (1.25, 5.03)*; p-trend: 0.016
Machida et al. 2009 Cross-sectional study; n=1,225 female Japanese farmers (age range: 35–75 years)	PbB: Median • Premenopausal (n=261): 1.6 • Perimenopausal (n=319): 2.0 • Younger postmenopausal (n=397): 1.8 • Older postmenopausal (n=248): 1.7	BALP	Spearman's correlation coefficients • All women: 0.143; p=0.000* • Perimenopausal women: 0.234; p=0.000*
		OC	Spearman's correlation coefficients • All women: 0.191; p=0.000* • Perimenopausal women: 0.391; p=0.000*
		NTx	Spearman's correlation coefficients • All women: 0.181; p=0.000* • Perimenopausal women: 0.261; p=0.000*
		BMD	Spearman's correlation coefficients • All women: -0.016; p=0.570 • Perimenopausal women: -0.101; p=0.071

2. HEALTH EFFECTS

Table 2-18. Summary of Epidemiological Studies Evaluating Musculoskeletal Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^{b,c}
Nelson et al. 2011 Cross-sectional study of 329 males (mean age: 65 years and 342 females (mean age: 62 years)	Median (range) • Males: 2.2 (0.5–25.1) • Females: 1.9 (0.5–25.4)	uNTX-I	β , change in biomarker per 5 $\mu\text{g}/\text{dL}$ increase in ln-PbB • Males: 1.06 (0.95, 1.18) • Females: 1.45 (1.21, 1.74)*
		uCTX-II	β , change in biomarker per 5 $\mu\text{g}/\text{dL}$ increase in ln-PbB • Males: 1.07 (0.97, 1.18) • Females: 1.28 (1.04, 1.58)*
		C2C (65 years)	β , change in biomarker per 5 $\mu\text{g}/\text{dL}$ increase in ln-PbB • Males: 1.00 (0.94, 1.04) • Females: 1.00 (0.92, 1.08)
		CPII	β , change in biomarker per 5 $\mu\text{g}/\text{dL}$ increase in ln-PbB • Males: 0.99 (0.93, 1.05) • Females: 1.09 (0.97, 1.22)
		HA	β , change in biomarker per 5 $\mu\text{g}/\text{dL}$ increase in ln-PbB • Males: 1.01 (0.88, 1.05) • Females: 0.96 (0.71, 1.29)
		COMP	β , change in biomarker per 5 $\mu\text{g}/\text{dL}$ increase in ln-PbB • Males: 1.08 (1.00, 1.18)* • Females: 0.96 (0.87, 1.06)
Pollack et al. 2013 Cross-sectional study of 249 premenopausal women (ages 18–44 years)	Mean (SD): 1.03 (0.64)	BMD	β per log-unit increase in PbB: 0.004 (-0.029, 0.020).

2. HEALTH EFFECTS

Table 2-18. Summary of Epidemiological Studies Evaluating Musculoskeletal Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^{b,c}
Periodontal and dental effects			
Arora et al. 2009 Cross-sectional study of 333 men (age range: 50–94 years)	PbB Tertiles <ul style="list-style-type: none"> • T1: ≤ 4.0 (reference) • T2: 4.2–6.4 • T3: 7.0–35.0 Bone Pb ($\mu\text{g}/\text{g}$) Tertiles for tibia <ul style="list-style-type: none"> • T1: ≤ 15.0 (reference) • T2: 16.0–23.0 • T3: 24.0–96.0 Tertiles for patella <ul style="list-style-type: none"> • T1: ≤ 22.0 (reference) • T2: 23.0–36.0 • T3: 37.0–126.0 	Tooth loss	OR PbB (compared to T1) <ul style="list-style-type: none"> • T3: 0.88 (0.52, 1.50); p-trend=0.57 <hr/> OR Tibia Pb (compared to T1) <ul style="list-style-type: none"> • T2: 1.81 (1.02, 3.18)* • T3: 3.03 (1.60, 5.76)*; p-trend=0.001* <hr/> OR Patella Pb (compared to T1) <ul style="list-style-type: none"> • T3: 2.41 (1.30, 4.49)*; p-trend 0.005*
Dye et al. 2002 Cross-sectional study in 10,033 participants in NHANES III (ages 20–69 years)	Mean (SE) <ul style="list-style-type: none"> • Males: 3.3 (0.12) • Females: 1.9 (0.05) 	Presence of dental furcations	β (SE), for presence of dental furcations (combined men and women): 0.13 (0.05); p=0.005*
Gemmel et al. 2002 Cross-sectional study in 498 children (age range: 6–10 years) from rural (n=239) and urban (n=259) settings.	Mean (SD) <ul style="list-style-type: none"> • Rural: 1.7 (1.0) • Urban: 2.9 (2.0) 	Dental caries	Regression coefficient (SE): <ul style="list-style-type: none"> • Rural: -0.15 (0.09); p=0.09 • Urban: -0.22 (0.08); p=0.005*

2. HEALTH EFFECTS

Table 2-18. Summary of Epidemiological Studies Evaluating Musculoskeletal Effects at Mean Blood Lead Concentration (PbB) ≤10 µg/dL^a

Reference and study population	PbB (µg/dL)	Outcome evaluated	Result ^{b,c}
Kim and Lee 2013 Cross-sectional of 3,966 adults (≥20 years of age)	PbB: Mean (SE): • Men ○ no periodontitis: 2.625 (0.028) ○ periodontitis: 3.118 (0.057); p<0.001 • Women, ○ no periodontitis: 1.906 (0.025) ○ periodontitis: 2.222 (0.052); p<0.001	Periodontitis	OR (95% CI), per doubling of PbB: • Men: 1.699 (1.154, 2.503)* • Women: 1.242 (0.833, 1.850)
Moss et al. 1999 Cross-sectional study of 24,901 participants (2–5 years old: n=3,547; 6–11 years old: n=2,894; ≥12 years: n=18,460) in NHANES III	Mean (SE): • Age 2–5 years: 2.9 (0.12) • Age 6–11 years: 2.1 (0.08) • Age 12–17 years: 2.5 (0.06)	Dental caries in children (ages 5–17 years)	OR per 5 µg/dL increased in PbB: 1.8 (95% CI 1.3, 2.5)*

^aSee the *Supporting Document for Epidemiological Studies for Lead*, Table 5 for more detailed descriptions of studies.

^bAsterisk and **bold** indicate association with Pb.

^cIf bone Pb is noted under results, study did not show associations between PbB and musculoskeletal effects; however, results showed associations between bone Pb concentrations and musculoskeletal effects at concomitant PbB ≤10 µg/dL.

BALP = bone-specific alkaline phosphatase (marker of bone metabolism); BMD = bone mineral density; C2C = serum cleavage neopeptide of type II collagen (marker of joint tissue metabolism); COMP = serum cartilage oligomeric matrix protein (marker of joint tissue metabolism); CPII = serum type II procollagen synthesis C-propeptide (marker of joint tissue metabolism); HA = serum hyaluronic acid (marker of joint tissue metabolism); HR = hazard ratio; NHANES = National Health and Nutrition Examination Survey; NTx = N-telopeptide cross-linked collagen type I (marker of bone metabolism); OC = osteocalcin (marker of bone metabolism); OR = odds ratio; Pb = lead; SD = standard deviation; SE = standard error; uCTX-II = C-telopeptide urine fragments of type II collagen (marker of joint tissue metabolism); uNTX-I = urine cross-linked N telopeptide of type I collagen (marker of joint tissue metabolism)

2. HEALTH EFFECTS

caries in children ages 6–17 years (PbB 2.1–2.4 µg/dL) (Moss et al. 1999). One study in adult males showed an association between bone Pb and tooth loss, but not PbB and tooth loss (Arora et al. 2009).

Mechanisms of Action. In bone and teeth, Pb substitutes for calcium (see Section 3.1.2, Toxicokinetics, Distribution). As reviewed by EPA (2014c), several mechanisms may be involved in the development of bone and periodontal/dental effects. Possible mechanisms include the following:

- Alterations in plasma growth hormones and calcitropic hormones (e.g., 1,25-[OH]₂D₃) leading to altered bone cell differentiation and function.
- Suppression in bone cell proliferation due to altered growth factors and hormones, including growth hormone, epidermal growth factor, transforming growth factor-beta 1 (TGF-β), and parathyroid hormone-related protein.
- Alterations in vitamin D-stimulated production of osteocalcin production, with inhibition of secreted bone-related proteins (e.g., osteonectin and collagen).
- Increased chondrogenesis through alterations of multiple signaling pathways, including TGF-β, bone morphogenic protein, activator protein-1, and nuclear factor kappa B.
- Inhibition of the post-eruptive enamel proteinases.
- Decreased microhardness of tooth surface enamel.

2.10 HEPATIC

Overview. Few epidemiological studies have evaluated hepatic effects associated with exposure to Pb, with most available studies comparing hepatic effects in small numbers of workers with PbB >10 µg/dL to controls with PbB lower than workers. Results of studies evaluating effects of Pb on liver function tests are inconsistent and do not demonstrate exposure-response relationships. Liver enlargement and increased gall bladder wall thickness was observed in workers with mean PbB of ≥28.66 µg/dL. Observed effects are consistent with oxidative stress. Histopathological effects of the liver associated with Pb have not been established.

The following hepatic effects have been associated with PbB >10 µg/dL:

- Greater plasma liver enzymes; evaluated in a few studies with mixed results.
- Greater total cholesterol.
- Enlarged liver and increased thickness of gall bladder wall.

2. HEALTH EFFECTS

Measures of Exposure. Studies examining the association between hepatic effects Pb exposure evaluate exposure by measurement of PbB.

Confounding Factors and Effect Modifiers. Most epidemiological studies on hepatic effects of Pb were of small populations of workers using cross-sectional designs. In general, studies did not consider factors, such as age, diet, concurrent diseases, and potential exposure to other workplace chemicals that could affect hepatic function in association with, or independent of, Pb exposure. Failure to account for these factors may attenuate or strengthen the apparent associations between Pb exposure and the outcome, depending on the direction of the effect of the variable on the outcome.

Characterization of Effects. In contrast to the large number of epidemiological studies evaluating effects of Pb on other organ systems (e.g., neurological and cardiovascular outcomes), few studies have investigated the hepatic effects of Pb. Brief study descriptions are provided in Table 2-19. Available studies were conducted in small populations (n=23–100) of workers with mean PbB of 5.4–77.5 µg/dL. The most serious effects reported for Pb-induced hepatic damage are liver enlargement and greater gall bladder wall thickness observed in workers with low PbB (28.66 µg/dL) and high PbB (40.58 µg/dL), respectively, compared to the control group (PbB 8.34 µg/dL) (Kasperczyk et al. 2013). However, these findings have not been corroborated in other studies. The study authors stated that no signs consistent with liver necrosis were observed. Most studies evaluated hepatic toxicity by liver function tests measuring plasma levels of liver enzymes. As shown in Table 2-20, results on effects of Pb on liver function tests are inconsistent and do not demonstrate exposure-response relationships. For example, Patil et al. (2007) reported greater alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in spray painters with a mean PbB of 22.32 µg/dL, but no change in ALT or AST in battery workers or silver jewelry workers with higher mean PbB (53.64 and 48.56 µg/dL, respectively), compared to controls (mean PbB: 12.52 µg/dL). Similarly, AST was elevated in painters with a mean PbB of 5.4 µg/dL, but no change in AST was observed in battery workers with a mean PbB of 49.9, compared to controls with a mean PBB of 1.5 µg/dL (Conterato et al. 2013). Effects in painters with lower PbB compared to other workers with higher PbB may be due to co-exposure to other occupational chemicals. In addition to liver enzymes, total serum cholesterol and high-density lipoprotein (HDL)-cholesterol were greater in workers with a mean PbB of 26.99–42.3 µg/dL, compared to controls with a mean PbB 2.7–14.81 µg/dL (Can et al. 2008; Kristal-Boneh et al. 1999).

Effect at Blood Pb Levels ≤10 µg/dL. See discussion above on Conterato et al. (2013).

2. HEALTH EFFECTS

Table 2-19. Summary of Epidemiological Studies Evaluating Hepatic Effects Associated with Blood Lead Concentration (PbB)

Reference and study population	PbB (µg/dL)	Outcomes evaluated	Effects ^b
Al-Neamy et al. 2001 Cross-sectional study; n=100 workers; 100 controls	Mean (SD) • Workers: 77.5 (42.8) • Controls: 19.8 (12.3)	LFTs	<ul style="list-style-type: none"> • Greater: LDH, AP • No difference: ALT, AST, GGT, bilirubin, albumin
Can et al. 2008 Cross-sectional study; n=22 battery workers; 38 muffler repair workers; 24 controls	Mean (SD) • Battery workers: 36.83 (8.13) • Muffler workers: 26.99 (9.42) • Controls: 14.81 (3.01)	LFTs	Battery workers ^a <ul style="list-style-type: none"> • Greater LDH, AP, TC Muffler workers: <ul style="list-style-type: none"> • Greater^a LDH, AP
Conterato et al. 2013 Cross-sectional study; n=50 painters; 23 battery workers; and 36 controls	Mean (SE) • Painters: 5.4 (0.4) • Battery workers 49.8 (4.0) • Controls: 1.5 (0.1)	LFTs	Painters: <ul style="list-style-type: none"> • Greater: AST • No difference: GGT Battery workers: <ul style="list-style-type: none"> • No difference: AST, GGT
Hsiao et al. 2001 Longitudinal study (baseline 1989; follow-up 1999); n=30 battery workers	Baseline: 60 Follow-up: 30	LFTs	No correlation of PbB to ALT
Kasperczyk et al. 2013 Cross-sectional study; n (from Pb- Zn processing facility): 57 low Pb exposure; 88 high Pb exposure; and 36 controls	Mean (SD); range • Low Pb: 28.66 (6.60); 20–35 • High Pb: 40.58 (6.74); 35–60 • Control: 8.34 (2.91)	Liver size	<ul style="list-style-type: none"> • Low PbB: Greater • High Pb: Greater
		Gall bladder wall thickness	<ul style="list-style-type: none"> • Low PbB: Greater • High PbB: Greater
		LFTs	<ul style="list-style-type: none"> • Low PbB: <ul style="list-style-type: none"> ○ No difference: ALT, AST, LDH, GGT, bilirubin • High PbB: <ul style="list-style-type: none"> ○ No difference: ALT, LDH, AST, bilirubin ○ Greater AST, GGT

2. HEALTH EFFECTS

Table 2-19. Summary of Epidemiological Studies Evaluating Hepatic Effects Associated with Blood Lead Concentration (PbB)

Reference and study population	PbB (µg/dL)	Outcomes evaluated	Effects ^b
Khan et al. 2008 Cross-sectional study; n=87 workers; 61 controls	Median (range) <ul style="list-style-type: none"> Workers: 29.1 (9.0–61.1) Controls: 8.3 (1.0–21.7) 	LFTs	<ul style="list-style-type: none"> Greater ALT, GGT, albumin No change: AP, bilirubin
Kristal-Boneh et al. 1999 Cross-sectional study; n=56 exposed; 87 controls	Mean (SD) <ul style="list-style-type: none"> Workers: 42.3 (14.9) Controls: 2.7 (3.6) 	Cholesterol and lipoproteins	<ul style="list-style-type: none"> Greater: TC, HDL No change: LDL, TG, HDL:TC ratio
Patil et al. 2007 Cross-sectional study; n=30 battery workers; 30 silver jewelry workers; 30 spray painters ^a ; 35 controls	Mean (SD) <ul style="list-style-type: none"> Battery workers: 53.63 (16.98) Silver jewelry workers: 48.56 (7.39) Spray painters: 22.32 (8.87) Controls: 12.52 (4.08) 	LFTs	<p>Battery workers:</p> <ul style="list-style-type: none"> Greater percentage change: albumin, bilirubin No change: ALT, AST <p>Silver jewelry workers:</p> <ul style="list-style-type: none"> Lesser percentage change: albumin compared to controls No change: ALT, AST, bilirubin compared to controls <p>Spray painters:</p> <ul style="list-style-type: none"> Greater percentage change: ALT, AST Decreased: albumin No change: bilirubin

^aReporting inconsistencies regarding number of spray painters evaluated; reported as 30 and 35.

^bAll comparisons are to control groups.

ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase; GGT = gamma-glutamyl transpeptidase; HDL = high-density lipoprotein; LDH = lactate dehydrogenase; LDL = low-density lipoprotein; LFT = liver function test (plasma activity of hepatic enzymes); Pb = lead; SD = standard deviation; SE = standard error; TC = total cholesterol; TG = triglycerides; Zn = zinc

2. HEALTH EFFECTS

Table 2-20. Effects on Liver Function Tests Associated with Chronic Exposure to Lead (Pb)^a

Mean PbB (µg/dL)	Population (n) ^b	ALT	AST	GGT	LDH	AP	Reference
5.4	P (50)	–	↑	0	–	–	Conterato et al. 2013
22.32	P (35) ^c	↑	↑	–	–	–	Patil et al. 2007
26.99	Pb-A (38)	0	0	0	↑	↑	Can et al. 2008
28.66	Pb-Zn (57)	0	0	0	0	0	Kasperczyk et al. 2013
29.1	Pb (87)	↑	–	↑	–	0	Khan et al. 2008
30	B (30)	0	–	–	–	–	Hsiao et al. 2001
36.83	B (22)	0	0	0	↑	0	Can et al. 2008
40.58	Pb-Zn (88)	0	↑	↑	0	↑	Kasperczyk et al. 2013
48.56	J (30)	0	0	–	–	–	Patil et al. 2007
9.8	B (23)	0	0	0	–	–	Conterato et al. 2013
53.63	B (30)	0	0	–	–	–	Patil et al. 2007
77.5	Pb (100)	0	0	0	↑	↑	Al-Neamy et al. 2001

^aReporting inconsistencies regarding number of spray painters evaluated; reported as 30 and 35.

↑ = increased; 0 = no change; – = not assessed; ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase; B = battery workers; G = general population; GGT = gamma-glutamyl transpeptidase; J = silver jewelry workers; LDH = lactate dehydrogenase; MDA: malondialdehyde; P = painters; Pb = Pb-exposed industrial workers; Pb-A = Pb-exposed auto workers; Pb-Zn = Pb-zinc processors

Mechanisms of Action. General mechanisms of toxicity of Pb (reviewed in Section 2.21) are likely involved in the development of hepatic toxicity. EPA (2014c) specifically noted that oxidative stress through ROS can result in damaged function and histopathological damage to the liver, including peroxidation of lipid membranes.

2.11 RENAL

Overview. Numerous epidemiologic studies in adults show that exposure to Pb can cause altered kidney function and contribute to the development of chronic kidney disease (CKD). A few studies in children also show decreases in renal function. Pb-induced nephrotoxicity is characterized by proximal tubular nephropathy, glomerular sclerosis, and interstitial fibrosis (Diamond 2005; Goyer 1989; Loghman-Adham 1997). Functional deficits in humans that have been associated with excessive Pb exposure include enzymuria, low- and high-molecular weight proteinuria, impaired transport of organic anions and glucose, and depressed GFR. A few studies have revealed histopathological features of renal injury in humans, including intranuclear inclusion bodies and cellular necrosis in the proximal tubule and interstitial fibrosis (Biagini et al. 1977; Cramer et al. 1974; Wedeen et al. 1975, 1979). Studies show consistent evidence of renal damage and reduced renal function associated over a wide range of PbB

2. HEALTH EFFECTS

(≤ 10 – >50 $\mu\text{g}/\text{dL}$), with the overall dose-effect pattern suggesting an increasing severity of nephrotoxicity associated with increasing PbB.

The following renal effects have been associated with PbB:

- ≤ 10 $\mu\text{g}/\text{dL}$:
 - Decreased GFR; corroborated in numerous studies.
 - Proteinuria; demonstrated in a few studies.
- >10 $\mu\text{g}/\text{dL}$:
 - Decreased GFR; corroborated in numerous studies.
 - Enzymuria; corroborated in numerous studies.
 - Proteinuria; corroborated in numerous studies.
 - Impaired tubular transport; demonstrated in a few studies.
 - Histopathological damage; demonstrated in a few studies.

Measures of Effect. Endpoints demonstrating renal damage include various measures of glomerular and tubular dysfunction. Effects on GFR typically are assessed from measurements of creatinine clearance, serum creatinine concentration, or blood urea nitrogen (BUN). Increased excretion of albumin (albuminuria) is an indication of damage to the glomerular endothelium or basement membrane, resulting in increased filtration of albumin, or impaired function of the proximal tubule, resulting in decreased reabsorption of filtered albumin. Increased excretion of low molecular weight serum proteins (e.g., $2\mu\text{G}$ or retinol-binding protein) are an indication of impaired reabsorption of protein in the proximal tubule. Increased excretion of enzymes associated with the renal tubule (renal tubular enzymuria) is an indication of injury to renal tubular cells resulting in release of membrane or intracellular enzymes into the tubular fluid. Pb-induced renal tubular enzymuria is most commonly evaluated from measurements of urinary N-acetyl-D-glucosaminidase (NAG). Increased excretion of NAG has been found in Pb-exposed workers in the absence of increased excretion of other proximal tubule enzymes (e.g., alanine aminopeptidase, alkaline phosphatase, glutamyltransferase) (Pergande et al. 1994). Indices of impaired transport include altered clearance or transport maxima for organic anions (e.g., p-aminohippurate, urate) or glucose (Biagini et al. 1977; Hong et al. 1980; Wedeen et al. 1975). Proximal tubular injury can also be confirmed through histopathological examination of renal tissue, although few studies provide this information (Biagini et al. 1977; Cramer et al. 1974; Wedeen et al. 1975, 1979).

2. HEALTH EFFECTS

Measures of Exposure. Most studies evaluating renal damage use PbB as the biomarker for exposure, although more recent epidemiological studies have explored associations between toxicity and bone Pb concentrations. These studies provide a basis for establishing PbB, and, in some cases, bone Pb concentration ranges associated with specific nephrotoxicity outcomes.

Confounding Factors and Effect Modifiers. Inconsistencies in the reported outcomes for renal effects across studies may derive from several causes, including failure to account for confounding factors and effect modifiers. Various factors can affect kidney function, including age, underlying diseases (e.g., hypertension), and concomitant exposure to other nephrotoxicants (e.g., cadmium). Results of epidemiological studies of general populations have shown an effect of age on the relationship between GFR (assessed from creatinine clearance of serum creatinine concentration or cystatin C) and PbB (Kim et al. 1996a; Muntner et al. 2003; Payton et al. 1994; Staessen et al. 1990, 1992). Pb-induced decrements in renal function can lead to higher Pb body burden due to decreased excretion of Pb (i.e., reverse causality) (Bellinger 2011; Evans and Elinder 2011; Marsden 2003). Thus, reverse causality potentially confounds interpretation of the dose-response relationship between PbB and decreased renal function. Pb exposure has also been associated with increases in GFR (Hsiao et al. 2001; Roels et al. 1994). This may represent a benign outcome or a potentially adverse hyperfiltration, which may contribute to subsequent adverse renal effects. Hypertension can be both a confounder in studies of associations between Pb exposure and creatinine clearance (Perneger et al. 1993) and a covariable with Pb exposure (Harlan et al. 1985; Muntner et al. 2003; Payton et al. 1994; Pirkle et al. 1985; Pocock et al. 1984, 1988; Tsaih et al. 2004; Weiss et al. 1986). Renal damage can cause increased blood pressure, which in turn can result in further damage to the kidneys. In addition, varying uncertainty also exists across studies in exposure history of subjects and in the biomarkers assessed.

Characterization of Effects. A large number of studies showing decrements in renal function associated with Pb exposure in humans have been published (Table 2-21). Most of these studies are of adults whose exposures were of occupational origin; however, a few environmental, mixed, and/or unknown exposures are represented, and a few studies of children are also included. Although these studies demonstrate adverse renal effects across the PbB range, some studies did not find associations (Buchet et al. 1980; de Kort et al. 1987; Fadrowski et al. 2010; Gennart et al. 1992; Huang et al. 2002; Karimooy et al. 2010; Omae et al. 1990). However, collectively, the body of evidence demonstrates that long-term exposure to Pb is nephrotoxic. General trends regarding the relationship between PbB and qualitative aspects of the kidney response are shown in Table 2-21. Decreased GFR and proteinuria have been observed in association with PbB ≤ 10 $\mu\text{g}/\text{dL}$; the significance of these studies is discussed in greater detail below.

2. HEALTH EFFECTS

Enzymuria and proteinuria have been observed in association with PbB >10–≤50 µg/dL. Functional deficits, including enzymuria, proteinuria, impaired transport, and depressed GFR have been observed at PbB >50 µg/dL. Histopathological findings, including tubular atrophy, focal sclerosis of glomeruli, and periglomerular and interstitial fibrosis have also been observed at PbB >50 µg/dL. The overall dose-effect pattern suggests an increasing severity of nephrotoxicity associated with increasing PbB, with effects on glomerular filtration evident at PbBs <10 µg/dL, enzymuria and proteinuria becoming evident >10 µg/dL, and severe deficits in function and pathological changes occurring in association with PbBs >50 µg/dL.

Table 2-21. Overview of Renal Effect Associated with Chronic Exposure to Lead (Pb)

Mean blood lead concentration (PbB) (µg/dL)	Effects associated with Pb exposure	References
≤10	Increased GFR	de Burbure et al. 2006
	Decreased GFR	Akesson et al. 2005; Fadrowski et al. 2010; Lin et al. 2001; Khan et al. 2010a; Kim et al. 1996a; Lin et al. 2003; Lin-Tan et al. 2006a, 2006b; Muntner et al. 2003; Navas-Acien et al. 2009; Payton et al. 1994; Pollack et al. 2015; Spector et al. 2011; Staessen et al. 1992, 2001; Yu et al. 2004
	Proteinuria	Navas-Acien et al. 2009; Pollack et al. 2015
>10–≤30	Decreased GFR	Kim et al. 1996a; Staessen et al. 1990
	Enzymuria	Bernard et al. 1995; Chia et al. 1994; Sonmez et al. 2002; Sun et al. 2008b
	Proteinuria	Bernard et al. 1995; Chia et al. 1995a, 1995b
>30–≤50	Increased GFR	Hsiao et al. 2001; Roels et al. 1994
	Decreased GFR	Orisakwe et al. 2007; Weaver et al. 2003a, 2003b, 2005a; Wedeen et al. 1975
	Enzymuria	Cardenas et al. 1993; Cardozo dos Santos et al. 1994; Fels et al. 1994; Garcon et al. 2007; Gerhardsson et al. 1992; Kim et al. 1996a; Kumar and Krishnaswamy 1995; Lin and Tai-yi 2007; Mortada et al. 2001; Pergande et al. 1994; Roels et al. 1994; Verberk et al. 1996; Verschoor et al. 1987; Weaver et al. 2003a, 2003b, 2005a
	Proteinuria	Factor-Litvak et al. 1999; Fels et al. 1998; Garcon et al. 2007; Gerhardsson et al. 1992; Kumar and Krishnaswamy 1995; Mortada et al. 2001; Pergande et al. 1994; Verschoor et al. 1987
	Impaired tubular transport	Pinto de Almeida et al. 1987

2. HEALTH EFFECTS

Table 2-21. Overview of Renal Effect Associated with Chronic Exposure to Lead (Pb)

Mean blood lead concentration (PbB) (µg/dL)	Effects associated with Pb exposure	References
>50	Decreased GFR	Baker et al. 1979; Biagini et al. 1977; Cramer et al. 1974; Ehrlich et al. 1998; Hong et al. 1980; Lilis et al. 1968, 1980; Onuegbu et al. 2011; Wedeen et al. 1975, 1979
	Enzymuria	Cabral et al. 2012; Gao et al. 2010; Garcon et al. 2007
	Proteinuria	Cabral et al. 2012; Gao et al. 2010; Garcon et al. 2007
	Impaired tubular transport	Biagini et al. 1977; Ehrlich et al. 1998; Hong et al. 1980; Wedeen et al. 1975
	Histopathological changes	Biagini et al. 1977; Cramer et al. 1974; Wedeen et al. 1975, 1979

GFR = glomerular filtration rate

Effects at Blood Pb Levels ≤ 10 µg/dL. Studies of renal function in populations with PbB ≤ 10 µg/dL provide evidence for effects of Pb on GFR in children and adults. Results are summarized in Table 2-22, with study details provided in the *Supporting Document for Epidemiological Studies for Lead*, Table 6. Most studies found that increasing PbB was associated with decreased GFR; however, one study found evidence for increasing GFR in children (de Burbure et al. 2006).

A few studies have examined associations between low PbB and GFR in children and adolescents (de Burbure et al. 2006; Fadrowski et al. 2010; Khan et al. 2010a; Staessen et al. 2001). de Burbure et al. (2006) examined serum creatinine in a cross-sectional study of approximately 800 children (age range 8.5–12.3 years) who resided near nonferrous smelters. Serum creatinine and cystatin C decreased (indicating an increase in GFR) by approximately 7% in the upper quartile PbB group (mean 7.8 µg/dL) compared to the lowest quartile (< 2.84 µg/dL). Fadrowski et al. (2010) examined adolescents (12–20 years, n=769). GFR (estimated from serum cystatin C) decreased with increasing PbB. In the upper quartile PbB group (> 2.9 µg/dL), the decrease was 6.6 mL/minute/1.73 m², which represented approximately a 6% decrease in GFR. In a smaller study of younger children of Pb-exposed workers (ages 1–6 years; n=123; PbB: 8.1 µg/dL), serum creatinine was higher compared to controls (ages 1–6 years; n=123; PbB: 6.7 µg/dL) (Khan et al. 2010), indicating decreased GFR. Several factors may have contributed to the different outcomes in these studies (decrease or increase in GFR), including a different age range of the study groups, different approaches to adjusting outcome metrics for confounders, and different exposures (e.g., co-exposure to Pb, cadmium, and mercury in the de Burbure et al. 2006 study).

2. HEALTH EFFECTS

Table 2-22. Summary of Epidemiological Studies Evaluating Renal Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$)	Outcome evaluated ^c	Result ^d
Akesson et al. 2005 Cross-sectional study; n=820 adult women	Median: 2.2	CCr	Linear regression β coefficient (mL/minute per $\mu\text{g/dL}$): -0.018 (95% CI -0.03, -0.006)*
		GFR	Linear regression β coefficient (mL/minute per $\mu\text{g/dL}$): -0.02 (95% CI -0.03, -0.009)*
		UPHC	Linear regression β coefficient ($\mu\text{g/L}$ per $\mu\text{g/dL}$): reported as NS
		UNAG	Linear regression β coefficient (U/g creatinine per $\mu\text{g/dL}$): reported as NS
de Burbure et al. 2006 Cross-sectional study; n>800 children (ages 8.5–12.3 years)	Mean range (three locations) Control: 2.81–3.81 Exposure: 3.64–6.51	SCr	Decreased 7% (p<0.01) in Q4 (PbB >5.59 $\mu\text{g/dL}$), compared to Q1 (PbB <2.85 $\mu\text{g/dL}$)*
		S β 2M	Decreased 9% (p<0.01) in Q4 (PbB >5.86 $\mu\text{g/dL}$), compared to Q1 (PbB <3.10 $\mu\text{g/dL}$)*
Fadowski et al. 2010 Cross-sectional study; n=769 adolescents (ages 12–20 years)	Median: 1.5 Quartiles: • Q1: <1.0 • Q2: 1.0–1.5 • Q3: 1.6–2.9 • Q4: >2.9	GFR	<ul style="list-style-type: none"> • Change in GFR (mL/minute/1.73 m²) Q4 compared to Q1: -6.6 (-12.6, -0.7)* • p-Trend across Q1-Q4=0.009* • Mean difference in GFR associated with a 2-fold increase in blood lead level: -2.9 (-5.0, -0.7)*
Kim et al. 1996a Retrospective cohort study; n=459 men	Mean: 9.9	SCr	<ul style="list-style-type: none"> • Regression coefficient (SE) for all participants ($\mu\text{mol/L}$ per $\mu\text{g/dL}$): 0.033 (0.012); p=0.005* • Regression coefficient (SE) for PbB ≤ 10 ($\mu\text{mol/L}$ per $\mu\text{g/dL}$): 0.060 (0.019); p=0.002*

2. HEALTH EFFECTS

Table 2-22. Summary of Epidemiological Studies Evaluating Renal Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$)	Outcome evaluated ^c	Result ^d
Khan et al. 2010 Cross sectional study children (ages 1–6 years) of Pb workers (n=123) and controls (n=123)	Median <ul style="list-style-type: none"> Control: 6.7 Exposed: 8.10 	SCr	<ul style="list-style-type: none"> Serum creatinine ($\mu\text{mol/L}$): control: 52; exposed: 56; $p \leq 0.01^*$ Spearman's correlation coefficient: $r=0.13$; $p \leq 0.05^*$
Lin et al. 2001 Prospective, longitudinal study; n=110 patients with chronic renal insufficiency	Low PbB mean: 3.9 High PbB mean: 6.6	CCr	<ul style="list-style-type: none"> 18 Months CCr (mL/second) mean\pmSD: low Pb: 0.72 ± 0.25; high Pb: 0.59 ± 0.22 $\mu\text{g/dL}$ ($p=0.007$)[*] 21 Months CCr (mL/second) mean\pmSD: low Pb: 0.70 ± 0.24; High Pb: 0.57 ± 0.22 $\mu\text{g/dL}$ ($p=0.006$)[*] 24 Months CCr (mL/second) mean\pmSD: low Pb: 0.70 ± 0.24; High Pb: 0.55 ± 0.22 $\mu\text{g/dL}$ ($p=0.001$)[*]
Lin et al. 2003 Prospective, longitudinal study; n=202 patients with chronic renal insufficiency	Baseline: 5.3 After 24-month observation, prior to chelation ^e <ul style="list-style-type: none"> Placebo: 5.9 Chelation: 6.1 	GFR	<ul style="list-style-type: none"> GFR (mL/minute/1.73 m²) following treatment (mean\pmSD): placebo 25.5 ± 12.3; chelation 34.4 ± 14.7 ($p=0.01$)[*] Change in GFR (mL/minute/1.73 m²) following treatment (mean\pmSD): placebo -6.0 ± 5.8; chelation 2.1 ± 5.7 ($p > 0.001$)[*]
Lin et al. 2006a Prospective, longitudinal study; n=124 patients with chronic renal insufficiency	After 24-month observation, prior to chelation ^e <ul style="list-style-type: none"> Placebo: 3.0 Chelation: 2.6 	GFR	<ul style="list-style-type: none"> GFR (mL/minute/1.73 m²) following treatment (mean\pmSD): placebo 38.0 ± 8.9; chelation 47.9 ± 17.0 ($p=0.0493$)[*] Change in GFR (mL/minute/1.73 m²) following treatment (mean\pmSD): placebo -4.6 ± 4.3; chelation 6.6 ± 10.7 ($p > 0.0005$)[*]
		UP (24-hour)	<ul style="list-style-type: none"> Urine protein (g) following chelation: placebo 1.11 ± 1.63; chelation: 0.92 ± 1.16 ($p=0.6236$)

2. HEALTH EFFECTS

Table 2-22. Summary of Epidemiological Studies Evaluating Renal Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$)	Outcome evaluated ^c	Result ^d
Lin et al. 2006b Prospective, longitudinal study; n=238 patients with type II diabetes and progressive diabetic neuropathy	End of 12-month observation, prior to chelation ^e • Placebo: 5.9 • Chelation: 7.5	GFR	<ul style="list-style-type: none"> • GFR (mL/minute/1.73 m²) following treatment (mean\pmSD): placebo 13.1\pm4.5; chelation 18.0\pm7.3 (p=0.0352)* • Decrements in GFR (mL/minute/1.73 m²) following treatment (mean\pmSD): placebo 13.2\pm7.6; chelation 4.4\pm6.8 (p>0.0045)*
Lin-Tan et al. 2007 Placebo-controlled clinical study; n=116 non-diabetic patients with chronic kidney disease	Mean after 51-month chelation • Placebo: 6.0 • Chelation: 3.5	GFR	<ul style="list-style-type: none"> • GFR (mL/minute/1.73 m²) following treatment (mean\pmSD): placebo 23.7\pm10.8; Chelation 35.4\pm17.0 (p<0.0001)* • Change in GFR (mL/minute/1.73 m²) following treatment (mean\pmSD): placebo -12.7\pm8.4; chelation -1.8\pm8.8 (p>0.0001)*
		UP (24-hour)	UP (mean \pm SD): placebo 0.96 \pm 1.04; chelation: 0.81 \pm 0.86 (p=0.3369)
Muntner et al. 2003 Cross-sectional study; n=4,813 hypertensive; n=10,398 normotensive adults ^g	Normotensive Mean: 3.30 \pm 0.10 Quartiles • Q1 (reference): 0.7–1.6 • Q2: 1.7–2.8 • Q3: 2.9–4.6 • Q4: 4.7–52.9 Hypertensive Mean: 4.21 \pm 0.14 Quartiles: • Q1 (reference): 0.7–2.4 • Q2: 2.5–3.8 • Q3: 3.9–5.9 • Q4: 6.9–56.0	GFR	Estimated GFR, mL/minute (mean \pm SD) • Normotensive: 115 \pm 0.7 • Hypertensive: 95\pm0.7 (p<0.001)*
		SCr	OR for elevated SCr in hypertensive patients: Q2: 1.47 (1.03, 2.10)* Q3: 1.80 (1.34, 2.42)* Q4: 2.41 (1.46, 3.97)* p-trend: <0.001*
		CKD	OR for elevated CKD in hypertensive patients: Q2: 1.44 (1.00, 2.09) Q3: 1.85 (1.32, 2.59)* Q4: 2.60 (1.52, 4.45)* p-trend: <0.001*

2. HEALTH EFFECTS

Table 2-22. Summary of Epidemiological Studies Evaluating Renal Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$)	Outcome evaluated ^c	Result ^d
Navas-Acien et al. 2009^f Cross-sectional study; n=14,778 adults	Mean: 1.58 Quartiles: • Q1 (reference): ≤ 1.1 • Q2: >1.1–1.6 • Q3: >1.6–2.4 • Q4: >2.4	GFR	ORs for reduced GFR • Q2: 1.10 (0.80, 1.51) • Q3: 1.36 (0.99, 1.85) • Q4: 1.56 (1.17, 2.08)* • p-trend: <0.001*
		Albuminuria	ORs for albuminuria • Q2: 0.83 (0.66, 1.04) • Q3: 0.92 (0.76, 1.12) • Q4: 1.19 (0.96, 1.47) • p-trend: <0.001*
Payton et al. 1994 Cross-sectional study; n=744 men	Mean: 8.1	CCr	Regression coefficient, β (SE), mL/minute per $\mu\text{g/dL}$: -0.0403 (0.0198); p=0.0426*

2. HEALTH EFFECTS

Table 2-22. Summary of Epidemiological Studies Evaluating Renal Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated ^c	Result ^d
Pollack et al. 2015 Prospective cohort study; n=257 premenopausal women	Median: 0.88 Tertiles: • T1 (reference): <0.72 • T2: 0.72–1.10 • T3: >1.10	GFR	<ul style="list-style-type: none"> • Regression β coefficient (% change per twofold increase in PbB): -3.73 (-6.55, -0.83)* • Regression β coefficient (% change per 2-fold increase in PbB) by tertile: <ul style="list-style-type: none"> ○ T2: -8.28 (-14.07, -2.5); p<0.05* ○ T3: -6.79 (-13.10, -0.49); p<0.05*
		SCr	Regression β coefficient (% change per 2-fold increase in PbB): 3.47 (0.86, 6.16)
		BUN	Regression β coefficient (% change per 2-fold increase in PbB): -0.13 (-4.97, 4.96)
		Blood albumin	Regression β coefficient (% change per 2-fold increase in PbB): -0.38 (-1.28, 0.52)
		Blood glucose	Regression β coefficient (% change per 2-fold increase in PbB): 0.93 (-0.28, 2.15)
		Blood protein	Regression β coefficient (% change per 2-fold increase in PbB): -0.76 (-1.61, 0.09)
Spector et al. 2011^f Cross-sectional study; n=3,941 adults	Mean (all): 1.7 Mean (≥ 60 years): Tertiles (all): • T1 (reference): ≤ 1.3 • T2: >1.3–2.2 • T3: >2.2	GFR	<ul style="list-style-type: none"> • All participants: change in GFR (mL/minute/1.73 m²) per 2-fold increase in PbB: -1.9 (-3.2, -0.7)* • All participants: OR for reduced GFR by tertiles <ul style="list-style-type: none"> ○ T2: -1.6 (-4.2, 1.0) ○ T3: -3.3 (-5.3, -1.4)* ○ p-trend: 0.001* • Participants ≥ 60 years: change in GFR (mL/minute/1.73 m²) per 2-fold increase in PbB: -4.5 (-5.6, -3.3)

2. HEALTH EFFECTS

Table 2-22. Summary of Epidemiological Studies Evaluating Renal Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$)	Outcome evaluated ^c	Result ^d
Staessen et al. 1992 Cross-sectional study; n=1,981 adults (965 men; 1,016 women)	Mean men: 11.4 Mean women: 7.5	CCr	Partial regression coefficient (SE) for CCr (mL/minute per log $\mu\text{g Pb/L}$): <ul style="list-style-type: none"> • Men: -13.1 (4.0); $p \leq 0.001^*$ • Women: -30.1 (3.4); $p \leq 0.001^*$
Staessen et al. 2001 Cross-sectional study; n=200 17-year-old adolescents girls	Mean control: 1.4 Mean exposed area 1: 1.8 Mean exposed area 2: 2.7	Serum cystatin C Urine β_2 -microglobulin	Change in per 2-fold increase in PbB: +3.6% (1.5, 5.7)* Change per 2-fold increase in PbB: +16.0% (2.7, 31)*
Tsaih et al. 2004 Prospective study; n=448 (66–72 years of age); n=26 participants with diabetes, and n=115 participants with hypertension	Mean at baseline: 6.5 Mean at follow-up: 4.5	SCr	Baseline regression β coefficients (mg/dL per ln $\mu\text{g/dL}$): <ul style="list-style-type: none"> • All participants: 0.009 (SE 0.006) • Participants with diabetes: 0.076 (SE 0.023); $p < 0.05^*$ • Participants with hypertension: 0.008 (0.010); Follow-up (4–8 years) regression β coefficients (mg/dL per ln $\mu\text{g/dL}$): <ul style="list-style-type: none"> • Participants with diabetes: 0.223 (SE 0.183); • Participants with hypertension: 0.352 (0.097); $p < 0.05^*$

2. HEALTH EFFECTS

Table 2-22. Summary of Epidemiological Studies Evaluating Renal Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated ^c	Result ^d
Yu et al. 2004 Prospective longitudinal study; n=121 patients with chronic renal insufficiency; progression of renal insufficiency was evaluated for 48 months	Mean: 4.2	GFR	Change in GFR (mL/minute/1.73 m² per 1 $\mu\text{g}/\text{dL}$): -4.0 (p=0.0148)*

^aSee the *Supporting Document for Epidemiological Studies for Lead*, Table 6 for more detailed descriptions of studies.

^bParticipants had no known occupational exposure to Pb.

^cA variety of methods are used to estimate GFR (Chao et al. 2015). Each has limitations for application to both clinical evaluations and epidemiology. The preferred method is to measure the clearance of substance from plasma that is known to be eliminated solely by glomerular filtration and is not reabsorbed in the renal tubule. Typically, in the clinical setting, this is accomplished with intravenous administration of GFR markers, such as ¹²⁵I-iothalamate, for the radiocontrast agent (e.g., iohexol). These procedures are feasible in the clinical setting, but not in epidemiology studies in which invasive procedures and administration of such agents is not practical or possible. Clearance of endogenous creatinine is an alternative that has had wide use in epidemiology. However, it requires concurrent measurements of serum creatinine and the rate of urinary excretion of creatinine, which can be accurately determined only with a carefully timed urine sample that can represent the amount of glomerular filtrate formed over a given time interval. Achieving accurately timed urine samples requires a rigidly implemented and supervised collection protocol, which is not always feasible, particularly in large-scale epidemiology studies. Alternatives to clearance methods are measurement of endogenous metabolites in plasma whose clearance approximates GFR. Typically, this is achieved with endogenous creatinine or cystatin C. The serum concentration of these two metabolites strongly correlates with GFR; however, the relationship between concentration and GFR is also affected by other variables, including age, sex, race, and creatinine muscle mass. Several approaches have been developed to improve estimates of GFR from serum creatinine that attempt to account for these co-variables. These methods rely on multiple variable regression models that relate GFR to serum creatinine and other significant determinants of GFR (Cockcroft and Gault 1976; Levey et al. 1999, 2009). An evaluation of two of the more commonly used methods for estimating GFR from serum creatinine, the CKD-EPI and MDRDS equations, found that both achieved a median difference between calculated and measured GFR (from clearance measurements) that range from 2 to 6 mL/minute per 1.73 m² (Levey et al. 2009). The interquartile range in the difference was approximately 18 mL/minute per 1.73 m² in a validation dataset consisting of data for 3,986 study subjects. This suggests that approximately 25% of the GFR estimates from these methods are expected to be in error of the true GFR by >18 mL/minute (or approximately 15% of the GFR in a healthy adult, 120 mL/minute).

^dAsterisk and **bold** indicate association with Pb; unless otherwise specified, values in parenthesis are 95% CIs.

^eBlood lead estimated by EDTA mobilization.

^fPopulation from NHANES.

BUN = blood urea nitrogen; CCr = creatinine clearance; CI = confidence interval; CKD = chronic kidney disease; EDTA = ethylenediaminetetraacetic acid; GFR = glomerular filtration rate; NHANES = National Health and Nutrition Examination Survey; NR = not reported; NS = not statistically significant; OR = odds ratio; Pb = lead; S β 2M = serum β ₂-microglobulin; SCr = serum creatinine concentration; SD = standard deviation; SE = standard error; UP = urine protein; UPHC = urine human complex-forming protein (α 1-microglobulin); UNAG = urine N-acetyl- β -D-glucosaminidase

2. HEALTH EFFECTS

A smaller study of adolescents (17 years of age, n=200) also found evidence for higher serum cystatin C (indicating lower GFR) in a group with a mean PbB of 2.7 µg/dL compared to a group with a mean PbB of 1.4 µg/dL (Staessen et al. 2001).

A larger number of studies have been conducted in adult populations (Table 2-22). These include several prospective studies (Lin et al. 2001, 2003, 2006a, 2006b; Lin-Tan et al. 2007; Pollack et al. 2015; Tsaih et al. 2004; Yu et al. 2004). Most of these studies have examined changes in GFR in patients who had ongoing renal disease and depressed GFR (Lin et al. 2001, 2003, 2006a, 2006b; Lin-Tan et al. 2007; Yu et al. 2004). In adult patients who had indications of renal insufficiency (e.g., serum creatinine concentration >1.5 mg/dL), GFR increased following repeated chelation therapy with calcium disodium ethylenediaminetetraacetic acid (EDTA) (Lin et al. 2003, 2006b). Yu et al. (2004) estimated the decline in GFR in patients with renal insufficiency to be approximately 4 mL/minute/1.73 m² per 1 µg/dL increase in PbB. A prospective study of premenopausal women estimated the decline in GFR to be approximately 3.73% per doubling of PbB (Pollack et al. 2015). The median PbB in the cohort was 0.88 µg/dL. A prospective study of older males found an association between increased serum creatinine (indicative in decreasing GFR) and PbB in subjects diagnosed with hypertension or diabetes. Mean PbBs were 6.5 µg/dL at baseline and 4.5 µg/dL at follow-up (Tsaih et al. 2004).

Several large cross-sectional studies have examined associations between PbB and GFR in adults (Table 2-22). Three large studies relied on data collected in the NHANES (Munter et al. 2003; Navas-Acien et al. 2009; Spector et al. 2011). The Munter et al. (2003) study, which included 4,813 hypertensive subjects and 10,938 normotensive subjects, found an association between increasing PbB and decreasing GFR in the hypertensive group. Navas-Acien et al. (2009) included 14,788 adult subjects and reported decreased GFR (<60 mL/minute/1.73 m²) among participants in the highest PbB quartile (mean >2.4 µg/dL). Spector et al. (2011) included 3,941 adults. In the age group ≥60 years, the estimate for the decline in GFR was 4.5 mL/minute/1.73 m² per doubling of PbB. The mean PbB in this group was 2.2 µg/dL. Several smaller cross-sectional studies have also found associations between increasing PbB and decreasing GFR in adult populations in which mean or median PbBs were <10 µg/dL (Akesson et al. 2005; Payton et al. 1994; Staessen et al. 1992). Collectively, these studies indicate that Pb exposure is associated with decreasing GFR, and effects on GFR are evident in populations with PbB <10 µg/dL. People with on-going renal disease or hypertension may be more vulnerable to the effects of Pb. Estimates of the decline in GFR associated with increasing PbB vary across studies, with some studies indicating declines of 3–6 mL/minute/1.73 m² at PbB <10 µg/dL (Pollack et al. 2015; Spector et

2. HEALTH EFFECTS

al. 2011; Yu et al. 2004). However, as noted above, the estimates may be inflated by reverse causality for associations between decreasing GFR and increasing Pb body burden.

Associations Between Bone Pb and Renal Effects. Studies evaluating associations between bone Pb and renal function are summarized in Table 2-23. Weaver et al. (2003a, 2005a, 2005c, 2006, 2009) conducted a series of studies evaluating associations between bone Pb and metrics of renal GFR (e.g., serum creatinine concentration, creatinine clearance calculated from serum creatinine concentration, BUN) and renal tubular injury (urinary NAG) in current and former Pb workers in South Korea. These studies provide evidence that tibia Pb is positively associated with serum creatinine concentration in older workers (Weaver et al. 2003a, 2005a, 2005c) and in male, but not female, workers (Weaver et al. 2009); and negatively associated with tibia Pb and creatinine clearance in male workers (Weaver et al. 2009) and in workers with vitamin D receptor (VDR) genotypes BB and Bb (Weaver et al. 2006). Tibia Pb was also positively associated with urinary NAG in older workers (Weaver et al. 2005a). Studies of participants of the longitudinal Normative Aging Study have found positive associations between tibia Pb and serum creatinine concentration in participants with diabetes (Tsaih et al. 2004) and with ALAD genotypes 1-2 and 2-2 (Wu et al. 2003a). A small case-control study did not find an association between tibia Pb and end-stage renal disease. Taken together, the results suggest that long-term exposure to Pb is associated with diminished renal function.

Table 2-23. Associations Between Bone Pb and Renal Function

Reference	Population	Effect					
		SCr	CCr	NAG	RBP	BUN	ESRD
Muntner et al. 2007	55 adult ESRD patients; 53 controls	–	–	–	–	–	0 T
Tsaih et al. 2004	448 men ^a	0 T ↑ T (diabetics) 0 P 0 P (diabetics)	–	–	–	–	–
Weaver et al. 2003a	803 adult Pb workers; 135 controls ^b	0 T (all workers) ↑ T (>46 years ^c)	0 T ^c	0 T ^c	0 T ^c	0 T ^c	–
Weaver et al. 2005a	803 adult Pb workers ^b	↑ T (>46 years ^c)	–	↑ T (>46 years) ^c	–	–	–
Weaver et al. 2005c	795 adult Pb workers ^b	↑ T (>40.6 years)	–	–	–	–	–

2. HEALTH EFFECTS

Table 2-23. Associations Between Bone Pb and Renal Function

Reference	Population	Effect					
		SCr	CCr	NAG	RBP	BUN	ESRD
Weaver et al. 2006	647 adult Pb workers ^b	0 T (VDR ^d) 0 T (VDR ^e) 0 P (VDR ^d) 0 P (VDR ^e)	0 T (VDR ^d) ↓ T (VDR ^e) 0 P (VDR ^d) 0 P (VDR ^e)	–	–	–	–
Weaver et al. 2009	398 adult male and 139 female Pb workers ^b	↑ T (M) 0 T (F)	↓ T (M) 0 T (F)	–	–	0 T (M) ↑ T (F)	–
Wu et al. 2003a	709 men ^a	↑ T (ALAD ^f) 0 P	0 T ↓ P	–	–	–	–

^aParticipants in the Normative Aging Study.

^bCurrent and former Pb workers in South Korea.

^cData were analyzed for all study participants and by age tertiles (Tertile 1: ≤36 years old; Tertile 2: 36.1–46 years old; Tertile 3: >46 years old). Any association observed in a specific age tertile are noted. If no association was observed for all participants and for all age tertiles, this is noted with a single entry of 0.

^dVitamin D receptor genotype bb.

^eVitamin D receptor genotypes BB and Bb.

^fInteraction between ALAD genotype (ALAD 1-2/2-2 versus ALAD 1-1).

↑ = positive association; ↓ = negative association; 0 = no association; – = not reported; ALAD = aminolevulinic acid dehydratase; BUN = blood urea nitrogen; CCr = creatinine clearance; ESRD = end-stage renal disease; F = female; M = male; NAG = N-acetyl-D-glucosaminidase; P = patella; Pb = lead; RBP = retinol binding protein; SCr = serum creatinine concentration; T = tibia; VDR = vitamin D receptor

Mechanisms of Action. Several mechanisms have been established or proposed as mechanisms for kidney damage associated with exposure to Pb, including general mechanisms of Pb-induced toxicity (reviewed in Section 2.21). Mechanisms of renal damage associated with Pb exposure were recently reviewed in detail by EPA (2014c), including oxidative stress, inflammation, apoptosis of glomerular and tubular cells, alterations in renal gangliosides (plasma membrane lipids that play a role in the control of GFR), changes in renal vascular tone, and alterations in the renin-angiotensin-aldosterone system. As discussed in Pb Section 3.1.2 (Toxicokinetics, Distribution), Pb is distributed to the kidney, providing a toxicokinetic mechanism for direct effects to the kidney.

2.12 DERMAL

No epidemiological studies evaluating adverse dermal effects of chronic exposure to Pb were identified.

2. HEALTH EFFECTS

2.13 OCULAR

Few epidemiological studies have evaluated non-neurological ocular effects of Pb exposure, with studies examining associations with macular degeneration (Erie et al. 2009; Park et al. 2015) and cataract development (Schaumberg et al. 2004). In a cross-sectional study of 3,865 participants with a mean PbB of 2.69 µg/dL participating in the Korea National Health and Nutrition Examination study (2008–2011), the risks of age-related early (adjusted OR 1.12; 95% CI 1.02, 1.23; p=0.009) and late (adjusted OR 1.25; 95% CI 1.05, 1.50; p=0.015) macular degeneration were increased (Park et al. 2015). A cross-sectional study of human donor eyes with (n=25) and without (n=36) age-related macular degeneration found no association between Pb concentration in the retinal pigment epithelium-choroid complex and subjects with age-related macular degeneration and normal subjects (Erie et al. 2009). A prospective study of 642 men participating in the Normative Aging Study found no association between PbB (range: 1.0–35.0 µg/dL) and risk of cataracts, although the risk of cataracts was increased in association with tibia Pb levels (Schaumberg et al. 2004).

2.14 ENDOCRINE

Effects of chronic exposure to Pb on reproductive hormones are reviewed in Section 2.16 (Reproductive).

Overview. Effects on endocrine systems have been evaluated in several epidemiological studies in adults (general populations and workers), adolescents, and children. Investigations have focused on effects on thyroid function, cortisol levels, vitamin D levels, serum levels of other growth factors, and diabetes. Associations between PbB and thyroid function, assessed by measurement of serum thyroid hormone levels, is the most investigated endocrine outcome, although results do not demonstrate a consistent pattern of effect or dose-response relationships. Other endocrine endpoints have been evaluated in only a few studies.

The following endocrine effects have been associated with PbB:

- ≤10 µg/dL:
 - Altered serum levels of thyroid hormones (thyroxine [T4], triiodothyronine [T3], thyroid-stimulating hormone [TSH]); evaluated in multiple studies. Few effects were observed and results do not demonstrate consistent patterns of effects or exposure-response relationships.
 - Altered salivary cortisol awakening response in pregnant women.

2. HEALTH EFFECTS

- Increased stress-induced salivary cortisol response in children.
- Decreased serum levels of insulin-like growth factor-1 (IGF-1) in children.
- >10 µg/dL:
 - Altered serum levels of thyroid hormones (T4, T3, TSH); evaluated in a few studies; results do not demonstrate consistent patterns of effects or exposure-response relationships.
 - Increased thyroid peroxidase antibodies.
 - Decreased serum levels of vitamin D; evaluated in a few studies in children with consistent results.

Measures of Exposure. Studies evaluating the association between endocrine effects and Pb exposure evaluate exposure by measurement of PbB.

Confounding Factors and Effect Modifiers. Results of epidemiological studies on endocrine effects have not been consistent. In general, statistical analyses were not rigorous and potential confounding factors and effect modifiers were not fully considered. Exposure to other metals and other chemical with endocrine effects is an important confounding factor to consider when interpreting study results. Although a few studies were of large populations (e.g., NHANES participants); most studies examined relatively small populations and used cross-sectional designs.

Characterization of Effects. General trends for studies showing a relationship between PbB and endocrine effects are shown in Table 2-24. Several studies have evaluated associations between PbB and effects on serum levels of thyroid hormones (T4, T3, and TSH) at mean PbB ranging from <1 to 71 µg/dL; an overview of study results is presented in Table 2-25. Based on evaluation of thyroid hormones, it is unclear if PbB is associated with altered thyroid function. At PbB ≤10 µg/dL, results of epidemiological studies, including cross-sectional studies of large NHANES populations, show associations between PbB and some alterations in serum levels of thyroid hormones; however, results do not demonstrate apparent patterns or exposure response relationships (see discussion below on *Effect at Blood Pb Levels ≤10 µg/dL*). Epidemiological studies at PbB >10 µg/dL, conducted in smaller populations (n=25–309), show more effects on thyroid hormones than observed at PbB ≤10 µg/dL. However, similar to studies at lower PbB, results are inconsistent. Khan et al. (2014) found decreased T4 (p<0.0001) and increased thyroid peroxidase antibodies (TPO; p=0.0002) during the second trimester of pregnancy in women (n=144) with mean PbB 20.00 µg/dL compared to women (n=147) with PbB of 5.57 µg/dL; no increase in TSH was observed. The adjusted OR (95% CI) for testing positive for TPO

2. HEALTH EFFECTS

antibodies was 2.41 (1.563, 3.82). Results indicate that autoimmunity is a potential mechanism for altered thyroid function. This finding has not been corroborated in other studies.

Table 2-24. Overview of Endocrine Effects Associated with Chronic Exposure to Lead (Pb)

Mean PbB (µg/dL)	Effects associated with Pb exposure	References
≤10	Altered levels of thyroid hormones ^a	Abdelouahab et al. 2008; Dundar et al. 2006; Luo and Hendryx 2014; Mendy et al. 2013; Yorita Christensen 2013
	Altered salivary cortisol levels	Braun et al. 2014; Gump et al. 2008
	Decreased serum IGF-1	Fleisch et al. 2013
>10–30	Altered levels of thyroid hormones ^a and increased TPO antibodies	Gustafson et al. 1989; Khan et al. 2014; Lamb et al. 2008; Lopez et al. 2000
>30–50	Decreased serum vitamin D level	Mahaffey et al. 1982; Rosen et al. 1980
>50	Altered levels of thyroid hormones ^a	Pekcici et al. 2010; Robins et al. 1983; Singh et al. 2000; Tuppurainen et al. 1988
	Decreased serum vitamin D level	Rosen et al. 1980

^aThyroid hormones: T4, T3, and/or TSH.

IGF-1 = insulin-like growth factor-1; PbB = blood lead concentration; T3 = triiodothyronine; T4 = thyroxine; TSH = thyroid-stimulating hormone; TPO = thyroid peroxidase

Table 2-25. Effects on Thyroid Hormones Associated with Blood Lead Concentration (PbB) ≤10 µg/dL

Mean PbB (µg/dL)	Number of participants	T4		T3		TSH	Reference
		Total	Free	Total	Free		
PbB ≤10 µg/dL							
0.93	1,109 adolescents ^a	0	0	0	0	0	Chen et al. 2013
1.3	1,587 adults ^a	↓	0	0	0	0	Yorita Christensen 2013
1.52	4,652 adults ^a	↓	0	0	0	0	Mendy et al. 2013
1.74	87 women	0	–	0	–	↓	Abdelouahab et al. 2008
1.75	4,409 adults ^a	0	0	0	0	0	Chen et al. 2013
1.82	6,231 adults ^a	–	0	–	↑	0	Luo and Hendryx 2014
6.3 ^b	24 infants ^b	–	0	–	–	0	Iijama et al. 2007
7.3	42 adolescents	–	↓	–	0	0	Dundar et al. 2006
PbB >10 µg/dL							
20.00	291 adults	–	↓	–	–	0	Khan et al. 2014
20.56	309 pregnancy ^c	–	↓	–	–	–	Lamb et al. 2008
24.1	151 adults	0	0	–	–	0	Schumacher et al. 1998

2. HEALTH EFFECTS

Table 2-25. Effects on Thyroid Hormones Associated with Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$

Mean PbB	Number of	T4		T3		TSH	Reference
25	68 children	0	0	–	–	–	Siegel et al. 1989
31	77 adults	–	0	–	0	0	Erfurth et al. 2001
<33.19 ^c	6,231 adults ^a	0	–	–	↑	0	Luo and Hendryx 2014
39.5	25 adults	↑	–	–	–	↑	Gustafson et al. 1989
50.9	75 adults	↑	↓	0	–	0	Lopez et al. 2000
51.9	47 adults	↓	↓	–	–	0	Robins et al. 1983
51.9	58 adults	0	–	↓	–	↑	Singh et al. 2000
56.1	176 adults	↓	↓	0	–	0	Tuppurainen et al. 1988
71.1	65 adults	–	↑	–	↑	↑	Pekcici et al. 2010

^aNHANES population.

^bUmbilical cord PbB; assessments in infants.

^cMean not reported.

↑ = Increased; ↓ = decreased; 0 = no change; – = not assessed; NHANES = National Health and Nutrition Examination Survey; T3 = triiodothyronine; T4 = thyroxine; TSH = thyroid-stimulating hormone

Studies also have investigated alterations in serum levels of vitamin D at PbB >30 $\mu\text{g}/\text{dL}$ (Mahaffey et al. 1982). In children and adolescents, serum levels of 1,25-dihydroxycholecalciferol were negatively associated with PbB over a range of 30–120 $\mu\text{g}/\text{dL}$ (Mahaffey et al. 1982). Similar results were observed for vitamin D in children with PbB >50 $\mu\text{g}/\text{dL}$ (Rosen et al. 1980). However, in children with PbB <10 $\mu\text{g}/\text{dL}$, no associations between PbB and vitamin D levels were observed (Kemp et al. 2007) (see discussion below on *Effect at Blood Pb Levels ≤ 10 $\mu\text{g}/\text{dL}$*). Studies investigating associations between PbB and other endocrine outcomes (salivary cortisol levels, serum levels of growth factors and diabetes) were conducted in populations with PbB ≤ 10 $\mu\text{g}/\text{dL}$ (see discussion below on *Effect at Blood Pb Levels ≤ 10 $\mu\text{g}/\text{dL}$*).

Effect at Blood Pb Levels ≤ 10 $\mu\text{g}/\text{dL}$. Epidemiological studies of endocrine effects associated with PbB ≤ 10 $\mu\text{g}/\text{dL}$ have examined thyroid function, as assessed by serum levels of thyroid hormones (Abdelouahab et al. 2008; Chen et al. 2013; Dundar et al. 2006; Iijama et al. 2007; Luo and Hendryx 2014; Mendy et al. 2013; Yorita Christensen 2013), cortisol levels and cortisol responses to stress (Braun et al. 2014; Gump et al. 2008), vitamin D levels (Kemp et al. 2007), IGF-1 levels (Fleisch et al. 2013), and diabetes (Moon 2013); study details are summarized in *Supporting Document for Epidemiological Studies for Lead*, Table 7. Studies examining thyroid function, including several large cross-sectional studies of NHANES populations (Chen et al. 2013; Mendy et al. 2013; Luo and Hendryx 2014; Yorita Christensen 2013), report inconsistent results; see Table 2-25. Results of NHANES studies at low PbB

2. HEALTH EFFECTS

(range of means: 0.93–1.82) are mixed, showing decreased total T4 and no change for free T4 (Mendy et al. 2013; Yorita Christensen 2013), and no change for total or free T4 (Chen et al. 2013; Luo and Hendryx 2014). The NHANES studies did not show associations between PbB and T3 or TSH levels, except for an increase in FT3 (Luo and Hendryx 2014). In smaller studies, decreased TSH and increased free T4 were observed at PbB of 3.10 and 7.3 µg/dL, respectively (Abdelouahab et al. 2008; Dundar et al. 2006). Thus, few effects on measures of thyroid function have been observed at PbB 10 µg/dL, and results do not demonstrate consistent patterns of effects or exposure-response relationships. Results of studies examining other endocrine effects associated with PbB have not been corroborated. Study findings include: associations between PbB and decreased cortisol awakening response during pregnancy at PbB ≥ 5.1 µg/dL (Braun et al. 2014); enhanced salivary cortisol response to cold stress in children at PbB 1.1–6.2 µg/dL (Gump et al. 2008); no association between PbB and serum vitamin D in children at PbB means 4.94–4.94 µg/dL (Kemp et al. 2007); decreased serum IGF-1 in children at PbB 5–9 µg/dL (Fleisch et al. 2013); and no association between PbB and diabetes in children at mean PbB 4.08 µg/dL (Moon 2013).

Mechanisms of Action. Adverse effects on the endocrine system (non-reproductive effects) associated with chronic Pb exposure have not been established; therefore, mechanisms of toxicity have not been identified. Thyroid function could be decreased through stimulation of autoimmunity to the thyroid gland, as shown by increased thyroid peroxidase antibodies (Kahn et al. 2014). In addition, general mechanisms of toxicity (reviewed in Section 2.21) of Pb would likely be involved in any endocrine toxicity.

2.15 IMMUNOLOGICAL

Overview. This section of the profile summarizes the immunological effects of Pb, exclusive of asthma, which is summarized in Section 2.5. Studies conducted in animal models have shown that Pb can perturb the humoral and cell-mediated immune systems, leading to decreased resistance to disease, sensitization, autoimmunity, and inflammation (EPA 2014c). These studies support epidemiological evidence of associations between Pb exposures (as indexed to PbB) and changes in biomarkers of humoral and cell-mediated immunity.

2. HEALTH EFFECTS

The following immunological effects have been associated with PbB:

- ≤ 10 $\mu\text{g}/\text{dL}$:
 - Increases in susceptibility to infections.
 - Sensitization to allergens.
 - Changes in indicators of humoral immunity (immunoglobulins, B-cells); demonstrated in several studies.
 - Changes in indicators of cell-mediated immunity (T-cells, eosinophils, neutrophils); demonstrated in several studies.
 - Changes in indicators of inflammatory response (circulating inflammation cytokines).
- > 10 $\mu\text{g}/\text{dL}$:
 - Changes in indicators of humoral immunity (immunoglobulins, B-cells).
 - Changes in indicators of cell-mediated immunity (T-cells, natural killer [NK]-cells, neutrophils).
 - Changes in indicators of inflammatory response (inflammatory response of activated monocytes).
 - Decreases in circulating complement.

Measures of Exposure. Studies of associations between Pb exposure and immunological outcomes have relied on PbB as a biomarker of exposure. Most studies have been cross-sectional in design, which increases uncertainty in the interpretation of the results since the exposure history of the subjects is not necessarily indicated by the cross-sectional PbB measurement.

Confounding Factors and Effect Modifiers. The immune system is responsive to a multitude of environmental and physiological factors, which can be confounding factors or effect modifiers in studies of associations between Pb exposure and immunological outcomes. Factors that have been considered in some studies, but not consistently across studies, include age, sex, smoking, physical activity, allergen exposures, history of inflammatory disease, SES factors, recreational activities, and co-exposures to other chemicals.

Characterization of Effects. Table 2-26 lists epidemiological studies that have found associations between PbB and immunological outcomes, grouped by population PbB (typically mean or geometric mean). Several studies have found alterations in immunological endpoints in association with PbB over the range <10 – 50 $\mu\text{g}/\text{dL}$.

2. HEALTH EFFECTS

Table 2-26. Overview of Immunological Effects Associated with Chronic Exposure to Lead (Pb)

Mean PbB (µg/dL)	Effects associated with Pb exposure	References
≤10	Increased susceptibility to infections	Kruger and Wade 2016
	Sensitization to allergens	Jedrychowski et al. 2011; Pizent et al. 2008
	Changes in indicators of humoral immunity ^a	Hon et al. 2009, 2010; Karmaus et al. 2005; Min and Min 2015; Pizent et al. 2008; Sarasua et al. 2000; Wells et al. 2014; Xu et al. 2015
	Changes in indicators of cell-mediated immunity ^b	Boscolo et al. 2000; Conterato et al. 2013; Hsiao et al. 2011; Karmaus et al. 2005; Sarasua et al. 2000; Wells et al. 2014
	Changes in indicators of inflammatory response ^c	Kim et al. 2007, Sirivarasai et al. 2013; Songdej et al. 2010
>10–30	Changes in indicators of humoral immunity ^a	Heo et al. 2004, Lutz et al. 1999; Sun et al. 2003
	Changes in indicators of cell-mediated immunity ^b	Alomran and Shleamoon 1988; Bergeret et al. 1990; Boscolo et al. 1999; Di Lorenzo et al. 2006; Fischbein et al. 1993; Kimber et al. 1986; Mishra et al. 2003; Queiroz et al. 1993, 1994; Sata et al. 1998; Valentino et al. 1991, 2007; Zhao et al. 2004
	Changes indicators of inflammatory response ^c	Valentino et al. 2007
>30–50	Changes in indicators of humoral immunity ^a	Ewers et al. 1982; Heo et al. 2004; Pinkerton et al. 1998
	Changes in indicators of cell-mediated immunity ^b	Fischbein et al. 1993; Conterato et al. 2013; Garcia-Leston et al. 2012; Niu et al. 2015; Pinkerton et al. 1998
>50	Changes in indicators of humoral immunity ^a	Basaran and Undeger 2000
	Changes in indicators of cell-mediated immunity ^b	Basaran and Undeger 2000; Mishra et al. 2010; Undeger et al. 1996
	Decreases in circulating complement levels	Ewers et al. 1982; Undeger et al. 1996

^aImmunoglobulins, B-cells.

^bT-cells, natural killer (NK) cells, eosinophils, neutrophils and related receptors and cytokines.

^cCirculating cytokines (e.g., C-reactive protein [CRP], interleukin-6 [IL-6], tumor necrosis factor-alpha [TNFα]).

Humoral immunity. Numerous epidemiological studies have examined associations between Pb exposure and circulating levels of immunoglobulins. These studies provide evidence that exposure to Pb is associated with increases in circulating IgE in children (Hon et al. 2009, 2010; Karmaus et al. 2005; Lutz et al. 1999; Sun et al. 2003) and in adults (Heo et al. 2004; Sarasua et al. 2000). IgE is an important mediator of hypersensitivity reactions and inflammation and Pb-induced perturbations in IgE may

2. HEALTH EFFECTS

contribute to associations between Pb exposure and sensitization and inflammation. Although some studies have found changes in levels of other immunoglobins, the evidence for these effects is not as strong as for IgE (Alomran and Shleamoon 1988; Anetor and Adeniyi 1998; Ewers et al. 1982; Kimber et al. 1986; Pinkerton et al. 1998; Queiroz et al. 1994b; Ündeger et al. 1996). The association between circulating IgE levels and PbB appears to extend to PbB levels <10 µg/dL (Karmaus et al. 2005; Min and Min 2015; Pizent et al. 2008; Sarasua et al. 2000; Wells et al. 2014).

T-cells. T-cells are important mediators of immunity to self-cells (e.g., cancer cells and cells infected with virus) and for activation of B-cells and humoral immunity. Epidemiological studies provide evidence that exposure to Pb is associated with decreases in T-cell abundance in children (Karmaus et al. 2005; Lutz et al. 1999; Sarasua et al. 2000; Zhao et al. 2004) and increases in abundance in adults (Boscolo et al. 1999, 2000; Sarasua et al. 2000). Several studies in adults found no consistent effect on T-cell abundance (Fischbein et al. 1993; Mishra et al. 2010; Pinkerton et al. 1998; Ündeger et al. 1996; Yücesoy et al. 1997b). Most of the studies on T-cell abundance did not differentiate specific classes of T-cell population affected; however, evidence is stronger for effects on CD3+ cells (Karmaus et al. 2005; Lutz et al. 1999; Sarasua et al. 2000; Zhao et al. 2004), with some studies finding effects on abundances of CD4+ (T helper) or CD8+ (T cytotoxic) cells (Boscolo et al. 1999, 2000; Karmaus et al. 2005; Sarasua et al. 2000). The association between circulating T-cell abundance and PbB appears to extend to PbB levels ≤10 µg/dL (Boscolo et al. 2000; Karmaus et al. 2005; Sarasua et al. 2000).

Neutrophils. Neutrophils are phagocytic cells that function in the immune defense against bacterial infections. Epidemiological studies have found associations between Pb exposure and neutrophil function. The effects on cultured human PMNs in populations that had mean PbB >10 µg/dL includes suppression of chemotaxis, phagocytosis, respiratory oxidative burst, and antigen killing (Alomran and Shleamoon 1988; Bergeret et al. 1990; Fischbein et al. 1993; Kimber et al. 1986; Queiroz et al. 1993, 1994; Valentino et al. 1991). In a worker population having mean PbB ≤10 µg/dL, increasing PbB was associated with decreases in circulating neutrophil abundance (Conterato et al. 2013), whereas in a worker population having mean PbB >10 µg/dL, PbB was associated with increases in neutrophil abundance (DiLoenzo et al. 2006) and decreases in circulating complement levels (Ewers et al. 1982; Undeger et al. 1996).

NK cells. NK cells contribute to the immune defense (cytotoxicity) against tumor cells and viral infected cells. Although a few studies have found associations between PbB and NK cell abundance (Boscolo et al. 1999, 2000), most studies have found no associations (Fischbein et al. 1993; Garcia-Leston et al. 2011;

2. HEALTH EFFECTS

Karmaus et al. 2005; Kimber et al. 1986; Mishra et al. 2003; Pinkerton et al. 1998; Sarasua et al. 2000; Undeger et al. 1996; Yucesoy et al. 1997) at population mean PbBs ≤ 10 or >10 $\mu\text{g/dL}$.

Lymphocyte activation. A few epidemiological studies have found associations between exposure to Pb and increased lymphocyte activation (HLA-DR expression) and proliferation in children (Lutz et al. 1999) and adults (Alomran and Shleamon 1988; Boscolo et al. 1999; Cohen et al. 1989; Fischbein et al. 1993; Kimber et al. 1986; Mishra et al. 2003). These studies found effects in populations that had PbB >10 $\mu\text{g/dL}$.

Sensitization. Epidemiological studies provided evidence for associations between exposure to Pb and sensitization. This evidence includes increased risk of atopy to airborne allergens in children (Jedrychowski et al. 2011) and adults (Pizent et al. 2008). Consistent with findings in animal studies which found that Pb exposure suppresses delayed type hypersensitivity (DTH), Hsiao et al. (2011) found that higher PbB was associated with decreases in circulating levels of IFN- γ γ T-helper cytokine known to be important in DTH). The above effects related to sensitization have been observed in populations that had mean PbB ≤ 10 $\mu\text{g/dL}$.

Inflammation. A few epidemiological studies have examined possible associations between Pb exposure and biomarkers of inflammation. Results for these studies suggests that Pb exposure can modify the control of inflammatory responses, including modifying macrophage NO release and ROS production in macrophages harvested from exposed children (Pineda-Zavaleta et al. 2004), and in adults, decreases in abundance of circulating monocytes (Conterato et al. 2013; Pinkerton et al. 1998), and lower circulating levels of HLA-DR+ (Fischbein et al. 1993) in adults. Three studies found evidence for effects indicative of enhancement or stimulation of inflammation in adults at mean PbB ≤ 10 $\mu\text{g/dL}$. Outcomes include increases in circulating tumor necrosis factor-alpha (TNF α) (Kim et al. 2007) and C-reactive protein (CRP) in men (Songdej et al. 2010; Sirivarasai et al. 2013).

Effect at Blood Pb Levels ≤ 10 $\mu\text{g/dL}$. Epidemiological studies that have evaluated immunological effects associated with exposures to Pb that resulted in PbB ≤ 10 $\mu\text{g/dL}$ are summarized in Table 2-27, with additional details provided in the *Supporting Document for Epidemiological Studies for Lead*, Table 8. Outcomes that have been observed in populations with PbB ≤ 10 $\mu\text{g/dL}$ include susceptibility to infections, sensitization in children and adults, humoral and cell-mediated immunity in children and adults, and inflammation in children and adults.

2. HEALTH EFFECTS

Table 2-27. Summary of Epidemiological Studies Evaluating Immunological Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^b
Sensitization			
Jedrychowski et al. 2011 Prospective study, n=244 children of women recruited in the 2 nd trimester of pregnancy	Gmean (95% CL): Cord: 1.16 (1.12, 1.22) Maternal: 1.60 (1.52, 1.67)	Atopy	Adjusted RR: • Cord PbB: 2.28 (1.12, 4.62)* • Maternal PbB: 1.72 (0.98, 3.00)
Pizent et al. 2008 Cross-sectional study, n=216 adults (age range 19–67 years)	Gmean (95% CL): • Male: 3.17 (0.99, 7.23) • Female: 2.16 (0.56, 7.35)	SPT	Adjusted OR for positive SPT: 0.92 (0.86, 0.98)*
Humoral immunity			
Karmaus et al. 2005 Cross-sectional study, n=671 children (age 7–10 years)	Gmean (95% CL): • Males: 2.78 (1.48, 4.82) • Females: 2.54 (1.10, 4.38)	IgE B-cells	Mean serum IgE levels were higher ($p \leq 0.05$) in PbB strata >2.84 and >3.41 $\mu\text{g}/\text{dL}$.* B-cell abundance was lower ($p \leq 0.05$) in PbB stratum 2.21–2.83 compared to <2.2 $\mu\text{g}/\text{dL}$.*
Min and Min 2015 Cross-sectional study, n=4,287 adults (age ≥ 22 years) ^c	Gmean (95% CL): • 1.46 (1.44, 1.50)	IgE	β for 1 \log_{10} increase in IgE per 1 \log_{10} increase in PbB (95% CL): • Q2 (1.1–1.69 $\mu\text{g}/\text{dL}$): 0.20 (0.05, 0.34)* • Q3 (1.7–2.6 $\mu\text{g}/\text{dL}$): 0.26 (0.10, 0.42)* • Q4 (2.61–26.4 $\mu\text{g}/\text{dL}$): 0.35 (0.20, 0.51)*
Pizent et al. 2008 Cross-sectional study, n=216 adults (age range 19–67 years)	Gmean (95% CL): • Male: 3.17 (0.99, 7.23) • Female: 2.16 (0.56, 7.35)	IgE	β log increase in IgE per log increase in PbB $\mu\text{g}/\text{L}$ (SE), females not taking oral contraceptives or hormone replacement therapy: 0.600 (0.298); $p=0.046^*$

2. HEALTH EFFECTS

Table 2-27. Summary of Epidemiological Studies Evaluating Immunological Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^b
Sarasua et al. 2000 Cross-sectional study, n=1,561 residents of communities with elevated levels of Cd or Pb in soil (age range 6 months–75 years) (1991)	Gmean (95% CL): <ul style="list-style-type: none"> Age 6–35 months: 7.0 (1.7, 16.1) Age 36–71 months: 6.0 (1.6, 14.1) Age 6–15 years: 4.0 (1.1, 9.2) 	IgA	β per 1 $\mu\text{g}/\text{dL}$ PbB, age 6–35 months: 0.8, p<0.01*
		IgG	<ul style="list-style-type: none"> β per 1 $\mu\text{g}/\text{dL}$ PbB, age 6–35 months: 0.8; p<0.01* β per 1 $\mu\text{g}/\text{dL}$ PbB, age 6–15 years: 7.5; p=0.02*
		IgM	β per 1 $\mu\text{g}/\text{dL}$ PbB, age 6–35 months: 1.0; p=0.03*
		B-cell count	β per 1 $\mu\text{g}/\text{dL}$ PbB, age 6–35 months: 16.9; p<0.01*
		B-cell%	β per 1 $\mu\text{g}/\text{dL}$ PbB, age 6–35 months: 0.19; p=0.02*
Wells et al. 2014 Cross-sectional study, n=1,788 children (age 2–12 years) ^c	Gmean (95% CL): <ul style="list-style-type: none"> 1.13 (1.04, 1.22) 	IgE	β per 1 $\mu\text{g}/\text{dL}$ PbB for % increase per 1 $\mu\text{g}/\text{dL}$: 10.27 (3.52, 17.47)*
Xu et al. 2015 Cross-sectional study, n=590 children (age 3–7 years)	Gmean (SD of log PbB): <ul style="list-style-type: none"> Male: 6.61 (0.19) Female: 6.16 (0.18) 	Hepatitis B virus	Antibody titers decreased with increasing PbB β signal to cut-off ratio per 1 $\mu\text{g}/\text{dL}$ (SE) at two assessment dates: <ul style="list-style-type: none"> 2011: -0.4467 (0.0225); p<0.001* 2012: 0.3661 (0.0193); p<0.001*

2. HEALTH EFFECTS

Table 2-27. Summary of Epidemiological Studies Evaluating Immunological Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^b
Cell-mediated immunity			
Boscolo et al. 2000 Cross-sectional study, n=30 atopic women (age range 19–49 years) and 30 non-atopic women	Median: <ul style="list-style-type: none"> Atopic: 6.4 (4.9, 7.9) Control: 5.5 (4.4, 6.7) 	T-cell abundance	Positive correlation between PbB and T-cell abundances in non-atopic subjects (r for cell count): <ul style="list-style-type: none"> CD4+CD45RO-: 0.464; p<0.05* CD3+ CD8+: 0.430; p<0.05* CD3- HLA-DR+>: 0.435; p<0.05*
Conterato et al. 2013 Cross-section study of battery manufacture workers (n=59), and automobile painters (n=23); ages 15–61 years	Median: <ul style="list-style-type: none"> Battery workers: 49.8 (4.0) Painters: 5.4 (0.4) Controls: 1.5 (0.1) 	Neutrophil abundance	Mean (SE), $10^3/\text{mm}^3$: <ul style="list-style-type: none"> Battery workers: 2.87 (0.27); p<0.05* Painters: 3.07 (0.13); p<0.05* Controls: 3.75 (2.49)
Hsiao et al. 2011 Cross-sectional study, n=214 children (primary school grades 5–6)	Mean (SD): <ul style="list-style-type: none"> Allergic and residing near oil refinery: 8.80 (0.45) Non-allergic and residing near oil refinery: 5.23 (0.36) Other rural or urban groups, allergic or not: 3.16–3.83 	IFN- γ IL-12 IL-4 IL-25	Compared to all other groups, allergic group residing near the refinery had: <hr/> >96% decrease in serum IFN-γ; p<0.05* <hr/> >96% decrease; p<0.05* <hr/> >500% increase; p<0.05* <hr/> >500% increase; p<0.05*
Karmaus et al. 2005 Cross-sectional study, n=67 children (age 7–10 years)	Gmean (95% CL): <ul style="list-style-type: none"> Males: 2.78 (1.48, 4.82) Females: 2.54 (1.10, 4.38) 	T-cell and T _c	Lower (p\leq0.05) in PbB stratum 2.21–2.83 compared to <2.2 $\mu\text{g}/\text{dL}$*

2. HEALTH EFFECTS

Table 2-27. Summary of Epidemiological Studies Evaluating Immunological Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^b
Sarasua et al. 2000 Cross-sectional study, n=1,561; age range 6 months–75 years)	Gmean (95% CL):	T-cell%	β per 1 $\mu\text{g/dL}$ PbB: -0.18; p=0.03*
	Age	T-cell count	β per 1 $\mu\text{g/dL}$ PbB: 7.2; p=0.59
	• 6–35 months: 7.0 (1.7, 16.1)	NK-cell%	β per 1 $\mu\text{g/dL}$ PbB: 0.00; p=0.99
	• 36–71 months: 6.0 (1.6, 14.1)	NK-cell count	β per 1 $\mu\text{g/dL}$ PbB: 1.3; p=0.60
	• Age 6–15 years: 4.0 (1.1, 9.2)		
Wells et al. 2014 Cross-sectional study, n=1,788 children (age 2–12 years) ^c	Gmean (95% CL): 1.13 (1.04, 1.22)	Eosinophils %	β for % increase per 1 $\mu\text{g/dL}$ (95% CL): 4.61 (2.44, 6.83)*
Inflammation			
Kim et al. 2007 Cross-sectional study, n=300 adults (mean age 24 \pm 2 years)	Mean (range):		In males for PbB stratum >2.51 relative to lower PbB stratum. % per 1 $\mu\text{g/dL}$ increase in PbB:
	• Q1: 1.46 (0.337, 1.885)	TNF α	23% (4, 55); p=0.015*
	• Q2: 2.22 (1.886, 2.511)	WBC	15% (0, 35); p=0.004*
	• Q3: 2.77 (2.513, 3.103)	IL-6	26% (0, 55%); p=0.082
	• Q4: 3.93 (3.110, 10.470)		
Sirivarasai et al. 2013 Cross-sectional study, n=924 male adults (mean age 43 years)	Mean: 5.45	CRP	CRP was higher in upper quartile PbB stratum compared to Q1 and Q2 (p<0.001). In Q4 stratum, adjusted OR was elevated for GSTM1 and GSTT1 null genotypes (95% CL):
	Quartiles, mean (range):		• -GSTM1-/- and GSTT1-/-: 1.98 (1.47, 2.55)*
	• Q1: 2.44 (1.23, 3.47)		• -GSTM1-/-: 1.32 (1.03, 1.69)*
	• Q2: 3.95 (3.48, 4.55)		• -GSTT1-/-: 1.65 (1.17, 2.35)*
	• Q3: 5.77 (4.56, 6.47)		
	• Q4: 9.21 (6.48, 24.62)		

2. HEALTH EFFECTS

Table 2-27. Summary of Epidemiological Studies Evaluating Immunological Effects at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^b
Songdej et al. 2010	Gmean: 1.89		OR for <1.16 versus >3.09 $\mu\text{g/dL}$:
Cross-sectional study, n=9,145 adults (age >40 years) ^c		CRP	<ul style="list-style-type: none"> • Males: 2.85 (1.49, 5.45)* • Females: 0.57 (0.43, 0.76)
		Fibrinogen	<ul style="list-style-type: none"> • Males: 1.15 (0.61, 2.16) • Females: 0.87 (0.57, 1.33)
		WBC	<ul style="list-style-type: none"> • Males: 1.55 (0.96, 2.49) • Females: 0.84 (0.62, 1.13)

^aSee the *Supporting Document for Epidemiological Studies for Lead*, Table 8 for more detailed descriptions of studies.

^bAsterisk and **bold** indicate association with Pb; unless otherwise specified, values in parenthesis are 95% CIs.

^cStudy of NHANES participants.

Cd = cadmium; CI = confidence interval; CL = confidence limit; CRP = C-reactive protein; Gmean = geometric mean; GPx = glutathione peroxidase; GSTM1 = glutathione S-transferase Mu 1; GSTT1 = glutathione S-transferase theta 1; Ig = immunoglobulin antibody; IL = interleukin; IFN- γ = interferon gamma; NHANES = National Health and Nutrition Examination Survey; NK = natural killer; OR = odds ratio; Pb = lead; SD = standard deviation; SE = standard error; SPT = skin prick test; TNF α = tumor necrosis factor-alpha; WBC = white blood cell

2. HEALTH EFFECTS

Susceptibility to infections. A cross-sectional study of data from NHANES (1999–2012) found a trend for increasing OR for being seropositive for *H. pylori*, *T. gondii*, and *Hepatitis B* virus in a population that has a geometric mean PbB of 1.5 µg/dL (Krueger and Wade 2016).

Humoral immunity. Several studies have found associations between circulating IgE levels and PbB in populations in which mean or geometric mean PbB levels ≤ 10 µg/dL (Karmaus et al. 2005; Min and Min 2015; Pizent et al. 2008; Sarasua et al. 2000; Wells et al. 2014). In general, these studies found increases in serum IgE levels in association with increasing PbB in children (Karmaus et al. 2005; Sarasua et al. 2000; Wells et al. 2014) and adults (Min and Min 2015; Pizent et al. 2008). A cross-sectional study of children (3–7 years of age) found an association between increasing PbB and decreasing *Hepatitis B* virus antibody titers (Xu et al. 2015).

T-cells, neutrophils, and NK cells. Several studies have found associations between T-cell abundance and PbB in populations in which mean or geometric mean PbB levels ≤ 10 µg/dL. In studies of children, T-cell abundances decreased (Karmaus et al. 2005), whereas in a study of adults, T-cell abundance increased (Boscolo et al. 2000). In a study of Pb workers, neutrophil abundance was lower in Pb workers compared to controls (Contertato et al. 2013). The worker populations included a group of painters in which the mean PbB was 5.4 ± 0.4 (SE) µg/dL, compared to the control group (1.5 ± 0.1 , SE). A study of a population of atopic adult women with median PbB 6.6 µg/dL (25th–75th percentile range: 4.9–7.9), found an association between increasing PbB and increasing abundance of NK cells (CD4+CD45RO+; Boscolo et al. 2000).


Sensitization. Exposures to Pb that resulted in population geometric mean PbB ≤ 10 µg/dL was associated increased risk of atopy to airborne allergens in children (Jedrychowski et al. 2011) and adults (Pizent et al. 2008). Higher PbB was associated decreases in circulating levels of IFN- γ (a T-helper cytokine known to be important in DTH) in a population of children with a mean PbB 8.8 ± 0.45 (SD) µg/dL (Hsaio et al. 2011).

Inflammation. A few studies have found evidence for increases in circulating TNF α (Kim et al. 2007) and CRP (Songdej et al. 2010; Sirivarasai et al. 2013) in adults at mean PbB < 10 µg/dL. These outcomes are indicative of enhancement or stimulation of inflammation.

2. HEALTH EFFECTS

Mechanisms of Action. Studies conducted in animal models and cell cultures have shown that Pb can disrupt the immune response through diverse mechanisms (EPA 2014c). Figure 2-6 shows the various potential pathways by which Pb may perturb the immune system and increase risk of atopy and inflammation, autoimmunity, and host resistance. In addition to its effects on T-cells, dendritic cells, and macrophages, Pb may also alter immune function at many other processes in the pathways shown in Figure 2-6.

Figure 2-6. Immunological Pathways by which Pb Exposure Potentially may Increase Risk of Immune-Related Diseases



Note: As shown in the figure, immunological pathways may increase risk of diseases such as cancer and inflammatory diseases in the cardiovascular, renal, and hepatic systems.

Source: EPA 2014c

2.16 NEUROLOGICAL

Overview. The literature on the neurobehavioral effects of Pb is extensive. With the improvement in analytical methods to detect Pb in the various biological media and in study designs, the concentrations of Pb, particularly in blood, associated with alterations in neurobehavioral outcomes continue to decrease, suggesting that there may be no threshold for the effects of Pb on intellectual function (CDC 2012d). Due

2. HEALTH EFFECTS

to the enormous size of the database on neurobehavioral effects of Pb, this discussion has been limited to representative and/or major studies published on specific topics crucial to understanding dose-response relationships in the lower exposure ranges (e.g., PbB ≤ 10 $\mu\text{g/dL}$). For additional information, the reader is referred to a recent review of this topic (EPA 2014c).

Numerous epidemiological studies have evaluated effects of Pb on neurological function in children and adults. These studies show consistent evidence of associations between decrements in cognitive and neuromotor/neurosensory function with PbBs that range from ≤ 10 to >50 $\mu\text{g/dL}$. The PbB-effect relationship for cognitive effects in children extends well below 10 $\mu\text{g/dL}$, with no evidence for a threshold. In several PbB-effect models, the slope for decrements in cognitive function in children show greater increases at lower PbB concentration ranges. These models predict that larger decrements in cognitive function would occur when PbB increases from 1 to 10 $\mu\text{g/dL}$, than when PbB increases to levels >10 $\mu\text{g/dL}$. All of the cognitive and neurobehavioral effects of Pb observed in children have also been observed in adults; however, it is not certain what life-stage exposures contribute most to outcomes in adults. A few studies that have followed children to early adulthood provide evidence of associations between childhood Pb exposure (e.g., PbB) and behavioral and neuroanatomical changes in adults, suggesting a possible role of exposures in childhood to adult outcomes. Other studies have found evidence of associations between cumulative Pb exposures (e.g., bone Pb) and neurological outcomes in adults.

The following neurobehavioral effects in children have been associated with PbB:

- ≤ 10 $\mu\text{g/dL}$:
 - Decreased cognitive function including full scale IQ (FSIQ).
 - Altered mood and behaviors that may contribute to learning deficits, including attention deficits, hyperactivity, autistic behaviors, conduct disorders, and delinquency.
 - Altered neuromotor and neurosensory function, including gross and fine motor skills, visual-motor integration, and hearing threshold.
- >10 $\mu\text{g/dL}$:
 - Decreased cognitive function including FSIQ.
 - Altered mood and behaviors, including attention deficits, hyperactivity, autistic behaviors, conduct disorders, and delinquency.
 - Altered neuromotor and neurosensory function, including gross and fine motor skills, visual-motor integration, hearing threshold, and visual evoked potentials.

2. HEALTH EFFECTS

- Peripheral neuropathy.
- Encephalopathy.

The following neurobehavioral effects in adults have been associated with increasing PbB:

- ≤ 10 $\mu\text{g}/\text{dL}$:
 - Decreased cognitive function including attention, memory, and learning.
 - Altered neuromotor and neurosensory function including decreased reaction time and walking speed, tremor, and increased risk of amyotrophic lateral sclerosis (ALS).
 - Altered mood and behavior including risk of various psychiatric symptoms including anxiety, depression, and schizophrenia.
- >10 $\mu\text{g}/\text{dL}$:
 - Reduced brain volume and altered brain neurochemistry.
 - Decreased cognitive function.
 - Altered neuromotor and neurosensory function.
 - Decreased peripheral nerve conduction velocity.

Measures of Exposure. Studies conducted in children have relied heavily on PbB as an exposure metric. Although bone or tooth Pb measurements may be informative, few studies have been conducted in children (Bellinger et al. 1994; Campbell et al. 2000b; Fergusson et al. 1993; Kim et al. 1995; Needleman et al. 1979, 1990, 1996, 2002; Wasserman et al. 2003). Maternal bone Pb has been used as an exposure metric for evaluating outcomes in children (Gomaa et al. 2002; Xu et al. 2015). Bone Pb has been used as metric of cumulative exposure in a growing number of epidemiological studies of adults (see Section 3.3.1, Biomarkers of Exposure). An association between a health outcome and bone Pb does not necessarily infer an association between the outcome and PbB (or *vice versa*) as indicated by studies in which associations are not consistent for the two metrics. These differences may reflect the relative importance of cumulative exposure on the given outcome, or differences in error associated with measurements of blood and bone Pb concentrations. A review by Shih et al. (2007) concluded that negative associations between Pb and cognitive function are stronger for bone Pb (specifically tibia Pb) for environmental exposures and for PbB for occupational exposures.

Confounding Factors and Effect Modifiers. Various factors have the potential to contribute to bias in estimates of associations between PbB and neurobehavioral outcomes. Failure to account for these factors may attenuate or strengthen the apparent associations between Pb exposure and the outcome,

2. HEALTH EFFECTS

depending on the direction of the effect of the variable on the outcome. Neurological function can be influenced by numerous factors that may also correlate with lead exposure in the population studied. A contributor to these correlations is the influence of SES-related factors on Pb exposure. Confounding factors that are typically evaluated in all high-quality studies include maternal education and IQ, SES, and HOME score (parental care). However, other factors have also been explored in some studies, including maternal substance abuse (including prenatal alcohol) and psychopathology, birth weight, exposure to tobacco smoke, nutritional status, and ALAD allele type. The relatively strong correlation between SES and PbB can result in overcontrol in studies of populations that have wide SES variability. Overcontrol will tend to attenuate the estimated association between PbB and the outcome (Bellinger 2004). However, SES may also modify the effect of Pb on neurological function (Bellinger et al. 1990; Ris et al. 2004; Tong et al. 2000). If this were to occur, then SES would also be an effect-modifier.

Characterization of Effects in Children. A large number of studies showing decrements in neurological function in children have been published (Table 2-28). Collectively, these studies support the concept that Pb affects cognitive function in children prenatally exposed to PbB ≤ 10 $\mu\text{g}/\text{dL}$, with numerous studies providing evidence for effects at PbB ≤ 5 $\mu\text{g}/\text{dL}$. Neurobehavioral functions that have been associated with PbB ≤ 10 $\mu\text{g}/\text{dL}$ include decrements in cognitive function (learning and memory), altered behavior and mood (e.g., attention, hyperactivity, impulsivity, irritability, delinquency), and altered neuromotor and neurosensory function (visual-motor integration, dexterity, postural sway, changes in hearing and visual thresholds). These outcomes also have been observed in association with PbB > 10 $\mu\text{g}/\text{dL}$. In children who have been followed to early adulthood, mean childhood PbBs of 13 $\mu\text{g}/\text{dL}$ were associated with altered brain volume and neurochemistry (Brubaker et al. 2010; Cecil et al. 2008, 2011). PbBs > 30 $\mu\text{g}/\text{dL}$ are associated with a variety of decrements in cognitive function, behavior (e.g., depression, aggression), and nerve function (e.g., decrements in fine and gross motor skills, peripheral neuropathy). Encephalopathy has been observed in children who have experienced severe Pb poisoning typical of PbB > 80 $\mu\text{g}/\text{dL}$ (NAS 1972b).

2. HEALTH EFFECTS

Table 2-28. Overview of Neurological Effects in Children Associated with Chronic Exposure to Lead (Pb)

Mean PbB (µg/dL)	Effects associated with Pb exposure	References
≤10	Intellectual deficits ^a	Baghurst et al. 1992; Bellinger and Needleman 2003; Bellinger et al. 1992; Boucher et al. 2014; Braun et al. 2012; Canfield et al. 2003; Chandramouli et al. 2009; Chiodo et al. 2004; Dietrich et al. 1986, 1987, 1989, 1991, 1992, 1993a; Emory et al. 2003; Evens et al. 2015; Gomaa et al. 2002; Hong et al. 2015; Hu et al. 2006; Jedrychowski et al. 2009; Jusko et al. 2008; Kordas et al. 2011; Krieg et al. 2010; Lanphear et al. 2000a, 2005; Lin et al. 2013; Liu et al. 2014b; Mazumdar et al. 2011; McLaine et al. 2013; Min et al. 2009; Miranda et al. 2009; Schnaas et al. 2006; Sobin et al. 2015; Tellez-Rojo et al. 2006; Vigeh et al. 2014; Wang et al. 2008; Wasserman et al. 1994, 1997, 2003; Zhang et al. 2013
	Altered mood and behavior ^b	Boucher et al. 2012; Braun et al. 2006, 2008; Choi et al. 2016; Dietrich et al. 2001; Froehlich et al. 2009; Hong et al. 2015; Kim et al. 2013a, 2016; Liu et al. 2014a, 2015b; Sioen et al. 2013; Wang et al. 2008
	Altered neuromotor neurosensory function ^c	Chiodo et al. 2004; Dietrich et al. 1987, 1989, 1993b; Ethier et al. 2012; Fraser et al. 2006; Kim et al. 2013b; Osman et al. 1999 Tellez-Rojo et al. 2006;
	Altered brain anatomical development and activity	Cecil et al. 2008, 2011
>10–30	Intellectual deficits ^a	Baghurst et al. 1992; Bellinger et al. 1987, 1990, 1991; Chen et al. 2005, 2007; Dietrich et al. 1992, 1993a; Factor-Litvak et al. 1999; Hornung et al. 2009; Kordas et al. 2006; Magzamen et al. 2013, 2015; Marques et al. 2014; McMichael et al. 1988; Roy et al. 2011; Schnaas et al. 2000; Shen et al. 1998; Tong et al. 1996; Wasserman et al. 1994, 1997, 2000, 2003
	Altered mood and behavior ^b	Amato et al. 2013; Chen et al. 2007; Dietrich et al. 1993b, 2001; McFarlane et al. 2013; Neugebauer et al. 2015; Rothenberg et al. 1989; Roy et al. 2009
	Altered neuromotor neurosensory function ^c	Baghurst et al. 1995; Bhattacharya et al. 2006; Otto et al. 1985; Palaniappan et al. 2011; Parajuli et al. 2013, Ris et al. 2004; Robinson et al. 1985; Schwartz and Otto 1987, 1991
>30–50	Intellectual deficits ^a	do Nascimento et al. 2016; Royal et al. 2013

2. HEALTH EFFECTS

Table 2-28. Overview of Neurological Effects in Children Associated with Chronic Exposure to Lead (Pb)

Mean PbB (µg/dL)	Effects associated with Pb exposure	References
>50	Intellectual deficits ^a	Hou et al. 2013
	Altered mood and behavior ^b	Hou et al. 2013
	Altered neuromotor neurosensory function ^c	Hou et al. 2013;
	Peripheral neuropathy ^d	Erenberg et al. 1974; Landrigan et al. 1976; Schwartz et al. 1988; Seto and Freeman 1964
>80	Encephalopathy	NAS 1972b

^aIntellectual deficits include decreased IQ, cognitive function, verbal comprehension, language development, perceptual organization, processing speed, decreased math and reading aptitude, educational attainment, school performance, and memory.

^bAltered mood and behavior includes hyperactivity, ADHD, decreased adaptive skills and emotional functioning, externalizing behaviors, internalizing behaviors, social problems, delinquent behavior, impulsive behavior, irritability, autistic behavior, altered sleep, and associations between child PbB and adult behavior (see McFarlane et al. (2013).

^cAltered neuromotor neurosensory function includes decreased integrated motor activities, gross motor skills; fine motor speed and dexterity, and visual-motor integration.

^dPeripheral neuropathy includes decreased motor and sensory nerve conduction velocity.

ADHD = attention-deficit/hyperactivity disorder; IQ = intelligence quotient; PbB = blood lead concentration

Characterization of Effects in Adults. A large number of studies showing decrements in neurological function in adults have been published (Table 2-29). These studies have found neurobehavioral effects in populations whose PbBs were ≤ 10 µg/dL. Neurobehavioral functions that have been associated with PbB ≤ 10 µg/dL include decreased cognitive function, altered behavior and mood, and altered neuromotor and neurosensory function. These outcomes also have been observed in association with PbB >10 µg/dL. PbBs in the range of 10–20 µg/dL, measured either during childhood or in adulthood, have been associated with decreased brain volume and changes in brain neurochemistry (Brubaker et al. 2010; Cecil et al. 2008; 2011; Hsieh et al. 2009). PbBs >30 µg/dL are associated with a variety of decrements in cognitive function, behavior and nerve function, including postural sway and stability; decreased walking speed; decreased visuospatial function and visual-motor performance; decrements in hearing; peripheral neuropathy; psychiatric symptoms (depression, panic disorders, anxiety, hostility, confusion, anger, and schizophrenia); and changes in regional brain volumes and neurochemistry.

2. HEALTH EFFECTS

Table 2-29. Overview of Neurological Effects in Adults Associated with Chronic Exposure to Lead (Pb)

Mean PbB (µg/dL)	Effects associated with Pb exposure	References
≤10	Intellectual deficits ^a	Muldoon et al. 1996; Payton et al. 1998; Power et al. 2014; Seo et al. 2014; Shih et al. 2006; Weisskopf et al. 2007; Weuve et al. 2006a, 2006b; Wright et al. 2003b
	Altered mood and behavior ^b	Bouchard et al. 2009; Buser and Scinicariello 2017; Golub et al. 2010; Opler et al. 2004; Rajan et al. 2007, 2008; Rhodes et al. 2003
	Altered neuromotor neurosensory function ^c	Hwang et al. 2009; Ji et al. 2013; Krieg et al. 2005
	Neurological diseases (ALS)	Fang et al. 2010
>10–30	Intellectual deficits ^a	Mantere et al. 1982; Reuben et al. 2017
	Altered mood and behavior ^b	Beckley et al. 2018; Yoon and Ahn et al. 2016
	Altered neuromotor neurosensory function ^c	Chuang et al. 2007; Yokoyama et al. 1997
	Altered brain architecture and metabolism	Brubaker et al. 2010; Cecil et al. 2008, 2011; Hsieh et al. 2009
>30–50	Intellectual deficits ^a	Baker et al. 1983; Barth et al. 2002; Campara et al. 1984; Fazli et al. 2014; Goodman et al. 2002; Hogstedt et al. 1983; Meyer-Baron and Seeber 2000; Schwartz et al. 2005
	Altered mood and behavior ^b	Baker et al. 1983; Lucchini et al. 2000; Maizlish et al. 1995; Malekirad et al. 2013; Parkinson et al. 1986
	Altered neuromotor neurosensory function ^c	Baker et al. 1983; Barth et al. 2002; Chia et al. 1996b; Choi et al. 2012; Haenninen et al. 1978; Iwata et al. 2005
	Altered nerve conduction	Araki et al. 1980, 1987, 2000; Chia et al. 1996b; Hirata and Kosaka et al. 1993; Pasternak et al. 1989; Stollery et al. 1989, 1991
>50	Intellectual deficits ^a	Arnvig et al. 1980; Campara et al. 1984; Matte et al. 1989; Valciukas et al. 1978
	Altered mood and behavior ^b	Awad el Karin et al. 1986; Zimmerman-Tansella et al. 1983
	Altered neuromotor neurosensory function ^c	Hanninen et al. 1998
	Altered nerve conduction	Triebig et al. 1984
	Altered brain architecture	Jiang et al. 2008

^aIntellectual deficits include decreased IQ, cognitive function, learning ability, verbal reasoning, logic, memory, and concentration.

^bAltered mood and behavior include depression, panic disorders, anxiety, hostility, confusion, anger, and schizophrenia.

^cAltered neuromotor neurosensory function includes postural sway; postural stability, decreased walking speed, decreased visuospatial function and visual-motor performance, hearing loss, and altered hearing threshold.

ALS = amyotrophic lateral sclerosis; PbB = blood lead concentration

2. HEALTH EFFECTS

Effects at Blood Pb Levels $\leq 10 \mu\text{g/dL}$ in Children. Numerous prospective and large cross-sectional studies provide a weight of evidence for decreased cognitive function, altered mood and behavior, and altered neuromotor and neurosensory function in children in association with exposures that result in PbB $< 10 \mu\text{g/dL}$, with some studies showing effects at PbB $\leq 5 \mu\text{g/dL}$. Study details are reviewed in the *Supporting Document for Epidemiological Studies for Lead*, Table 9. The cognitive outcome metric that has been most extensively studied and compared across studies is FSIQ. Tests of memory, learning, and executive function have also been used to assess cognitive function. Studies that attempt to identify associations between PbB and cognitive function must control for major factors known to influence or correlate with cognitive development and function, including SES, parental education and IQ, quality of caregiving, nutrition, and birth weight. Many of these same factors correlate with PbB and can confound associations between PbB and outcomes. Relationships between PbB and outcomes appear to be nonlinear. Greater decrements in cognitive function per unit change in PbB are seen with PbB increases within lower PbB concentration ranges than increases within higher PbB concentration ranges. Decrements in cognitive function in children have been associated with increasing PbB measured at various life stages, including prenatal and various metrics of child PbB including peak, concurrent, and cumulative. No specific life stage has been conclusively identified as the critical time period for exposure.

Cognitive function in infancy. Several prospective studies have evaluated cognitive function in infancy and early child cohorts having mean PbB $< 10 \mu\text{g/dL}$ (Table 2-30). In general, these studies provide evidence for decrements in cognitive function in association with increasing PbB. Several studies used the Mental Development Index (MDI) score from the Bayley Scales of Infant Development (BSID), allowing comparison of results across studies (Dietrich et al. 1986, 1987, 1989; Gomaa et al. 2002; Hu et al. 2006; Jedrychowski et al. 2009; Liu et al. 2014b). Each study found decreases in MDI scores measured from 6 to 36 months in association with increasing prenatal (e.g., maternal) or neonatal PbB. Cohort mean PbB ranged from 1.2 to 7.1 $\mu\text{g/dL}$. In a cohort that had a mean PbB of 1.23 $\mu\text{g/dL}$ (range 0.44–6.9 $\mu\text{g/dL}$), the change in MDI score measured at 24 months of age was -7.6 (95% confidence limit [CL] -14.7, -0.62) points per 1 \log_{10} increase in cord PbB (Jedrychowski et al. 2009). The largest effect size was reported for a cohort that had a mean PbB of 8 ± 3.8 (SD) $\mu\text{g/dL}$; the change in MDI score measured at age 6 months was -15 ± 5.1 (SE, $p < 0.03$) points per cord $\ln\text{PbB}$ (Dietrich et al. 1986). Studies that repeatedly measured MDI scores longitudinally within the same birth cohorts found that the associations observed at 6 months persisted to later ages (Dietrich et al. 1986, 1987, 1989, 1991; Jedrychowski et al. 2009; Liu et al. 2014b).

2. HEALTH EFFECTS

Cognitive function in early childhood - FSIQ. Prospective studies initiated at time of pregnancy or birth have consistently found decrements in child FSIQ in association with increasing cohort mean PbB <10 µg/dL measured at various stages of development (Table 2-30). Collectively, these studies provide evidence for effect sizes ranging from -1 to -6 FSIQ points in association with a 10-fold increase in PbB and larger effect sizes in cohorts or cohort strata having a lower mean PbB. These studies do not consistently point to a specific life stage as being more or less vulnerable, as negative associations with FSIQ have been observed with PbB measured during pregnancy, infancy, and childhood, and measured previous to or concurrently with the FSIQ evaluation. Results of an adult follow-up of a birth cohort suggest that FSIQ decrements observed in childhood may persist to adulthood (Mazumdar et al. 2011). FSIQ was assessed at age 28–30 years in 43 members of the Boston prospective study cohort (Bellinger et al. 1992). The change in FSIQ was -1.89 points (95% CL -3.00, -0.47) per µg/dL increase in late child PbB (mean 6.7±3.6 at age 4 years, 3.0±2.7 at age 10 years). After adjustment for maternal IQ, the change in FSIQ was -1.11 (95% CL -2.29, 0.06).

The largest study was a pooled analysis from seven individual prospective studies that evaluated FSIQ (Baghurst et al. 1992; Bellinger et al. 1992; Canfield et al. 2003; Dietrich et al. 1993a; Ernhart et al. 1989; Schnaas et al. 2000; Wasserman et al. 1997). The pooled cohort consisted for 1,333 children who were evaluated for FSIQ between ages 4.8 and 6 years (Lanphear et al. 2005). Co-variables considered in the analysis included study, maternal IQ, HOME score (Home Observation for Measurement of the Environment Inventory score), maternal education, marital status, birth weight, birth order, maternal age, race, and prenatal tobacco exposure. Of these, maternal IQ, HOME, and birth weight were included in the final models. When the full cohort was considered (PbB range 0.1–72 µg/dL), the adjusted change in FSIQ was loglinear, with greater changes in IQ per unit change in PbB a lower PbB. Several blood Pb metrics were explored in regression modeling, and slopes were significant for childhood, peak, lifetime average, or concurrent (with IQ testing) PbB. The model that used concurrent PbB had the highest r^2 (not reported). The covariate adjusted regression β for this model was -2.70 (95% CL -3.74, -1.66) IQ points per 1 lnPbB. The unadjusted β was -4.66 (-5.72, -3.60). The concurrent PbB model predicts a decrease of 6.2 points in FSIQ when PbB increased from 1 to 10 µg/dL and a decrease of 4.4 points when PbB increases from 1 to 5 µg/dL. In a PbB stratum 0.9 to 7.4 µg/dL, the mean change in FSIQ was -2.9 (95% CI -5.2, -0.71) per 1 µg/dL change in PbB measured at the age of IQ testing. Re-analyses of the pooled cohort reported in Lanphear et al. (2005) have been conducted (Crump et al. 2013; EPA 2014e). EPA (2014e) made several corrections to the dataset and obtained β coefficients that were similar to those reported in Lanphear et al. (2005). The results of the EPA (2014e) reanalysis are presented in Table 2-30.

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Intellectual deficits			
Baghurst et al. 1992 Prospective cohort, n=494 children followed from birth to age 7 years	Quartile range: <ul style="list-style-type: none"> • Birth: 4.3, 15.0 • Mean 0–2 years: 11.6, 27.1 • Mean 0–3 years: 12.2, 28.2 • Mean 0–4 years: 12.2, 27.7 • Lifetime average (7 years): 10.8, 24.8 	FSIQ	β (SE) for PbB metrics per each 1n PbB increase: <ul style="list-style-type: none"> • Prenatal: 0.6 (1.4), p=0.68 • Mean 0–2 years: -4.6 (2.1), p=0.03* • Mean 0–3 years: -4.8 (2.3), p=0.04* • Mean 0–4 years: -4.6 (2.4), p=0.05* • Lifetime average: -3.7 (2.5), p=0.14
Bellinger et al. 1992; Bellinger and Needleman 2003 Prospective cohort, n=148 children followed from birth to age 10 years	Mean (SE): <ul style="list-style-type: none"> • 6 months: 6.7 (7.0) • 1 years: 7.7 (6.5) • 2 years: 6.5 (4.9) 	FSIQ	β (SE) for PbB metrics per each 1 $\mu\text{g}/\text{dL}$ increase in PbB: <ul style="list-style-type: none"> • Prenatal: -2.55 (2.56), p=0.57 • 6 months: -0.13 (0.15), p=0.39 • 2 years: -0.58 (0.21), p<0.007* • Peak <10 $\mu\text{g}/\text{dL}$: -1.56 (p=0.03)* • Peak >10 $\mu\text{g}/\text{dL}$: -0.58 (p=NA)
Boucher et al. 2014 Prospective cohort, n=93 infants	Umbilical cord PbB: <ul style="list-style-type: none"> • Mean (SD): 4.8 (3.5) • Range: 0.5–17.8 	FT-II-Fixed duration	β 0.21 (0.07, 0.35); p\leq0.01*
Braun et al. 2012 Prospective cohort, n=1,035 mother-infant pairs	Median (5 th , 95 th percentile) at age: <ul style="list-style-type: none"> • 1 years: 4.2 (1.3, 10.6) • 2 years: 4.6 (1.5, 13.4) • 3 years: 5.5 (2.3, 13.8) • 4 years: 5.9 (2.5, 12.8) 	GCI	Coefficient for change in GCI (measured at year 4) per 10 $\mu\text{g}/\text{dL}$ increase in PbB for PbB measured at each year: <ul style="list-style-type: none"> • PbB at 1 year: -2.5 (-5.6, 0.5) • PbB at 2 years: -3.8 (-6.3, -1.4)* • PbB at 3 years: -0.7 (-3.1, 1.6) • PbB at 4 years: -2.5 (-5.1, 0.1)

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Canfield et al. 2003 Prospective cohort, n=172 children, followed from age 24–40 months to 5 years	Mean (SD): Lifetime average at age 5: 7.4 (4.3) Peak: 11.1 (7.1) Concurrent with FSIQ: 5.8 (4.1)	FSIQ	β per IQ for each 1 $\mu\text{g}/\text{dL}$ increase in PbB at 5 years of age: Full cohort (n=172): <ul style="list-style-type: none"> • Lifetime average: -0.57 (-0.93, -0.20); p=0.003* • Peak: -0.26 (-0.47, -0.05); p=0.02* • Concurrent: -0.61 (-0.99, -0.24); p <0.001 Peak PbB <10 (n=101) <ul style="list-style-type: none"> • Lifetime average: -1.52 (-2.94, -0.09); p=0.04* • Peak: -1.44 (-2.55, -0.33); p=0.01* • Concurrent: -1.79 (-3.00, -0.60); p=0.004*
Chandramouli et al. 2009 Prospective study, n=488 children followed from age 4–30 months (born 1992) to age 7–8 years	Mean (SD) at age 30 months: 4.22 (3.12)	Reading	<ul style="list-style-type: none"> • PbB 2–5 $\mu\text{g}/\text{dL}$ OR: 0.88 (0.54, 1.43); p=0.608 • PbB 5–10 $\mu\text{g}/\text{dL}$ OR: 0.51 (0.32, 0.82); p=0.006*
		Writing	<ul style="list-style-type: none"> • PbB 2–5 $\mu\text{g}/\text{dL}$ OR: 1.08 (0.69, 1.71); p=0.729 • PbB 5–10 $\mu\text{g}/\text{dL}$ OR: 0.49 (0.31, 0.78); p=0.003*
		Standard assessment test scores	A 2-fold increase in PbB was associated with a 0.3-point (95% CI -0.5, -0.1) decrease in scores.
Chiodo et al. 2004 Prospective study, n=237 children, age 7.5 years	Mean (SD, range): 5.4 (3.3, 1–25)	FSIQ	β (SE): <ul style="list-style-type: none"> • <3 $\mu\text{g}/\text{dL}$: -0.10; p\leq0.1* • <5 $\mu\text{g}/\text{dL}$: -0.12; p\leq0.1* • <7.5 $\mu\text{g}/\text{dL}$: -0.14; p\leq0.05* • <10 $\mu\text{g}/\text{dL}$: -0.18; p\leq0.01* • Cohort: -0.20; p\leq0.01*

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) $\leq 10 \mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^c
Dietrich et al. 1986 Prospective study, n=280 mother-infant pairs	Prenatal (maternal): • Mean (SD): 8.0 (3.8) • Range: 1–27 Neonatal (age 10 days): • Mean (SD): 4.5 (2.9) • Range: 1–22	MDI	Associations with maternal PbB (n=245), β per lnPbB (SE): -14.978 (6.114); p<0.02* Associations with neonatal PbB (n=280), β per lnPbB (SE): -15.110 (5.083); p<0.003* In males: F (1,122): 4.95; p=0.03*
Dietrich et al. 1987 Prospective study, n=185 mother-infant pairs	Mean (SD, range): • Prenatal (maternal): 8.3 (3.8, 1–27) • Neonatal (10 days): 4.9 (3.3, 1–24) • Neonatal (3 months): 6.3 (3.8, 1–22) • Neonatal (6 months): 8.1 (5.2, 1–36)	MDI PDI Motor maturity	β per lnPbB (SE): • 3-month: -12.113 (4.727); p=0.01* • 6-month: -2.117 (0.916); p=0.02* • β (SE): -13.248 (4.250); p=0.002* • β (SE): -0.570 (0.260); p=0.03*
Dietrich et al. 1989 Prospective study, n=192 mother-infant pairs	Mean (SD, range): • Prenatal (maternal): 8.2 (3.6, 1–27) • Neonatal (10 days): 4.8 (3.1, 1–23) • Neonatal (3 months): 6.0 (3.5, 1–20) • Neonatal (6 months): 7.9 (4.8, 1–35) • Neonatal (9 months): 11.5 (6.9, 2–57) • Neonatal (12 months): 14.2 (7.3, 4–47)	MDI	Structural Equation Model indicated associations ($p \leq 0.05$) between increasing prenatal PbB and 12-month MDI through decreasing birth weight. Standardized regression coefficients: • Prenatal PbB --> birth weight: -0.15, p\leq0.05* • Birth weight ---> 12-month MDI: 0.18, p\leq0.05*

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Dietrich et al. 1991 Prospective study, n=258 4-year-old children	Mean (SD, range): (based on Dietrich et al. 1992) <ul style="list-style-type: none"> Maternal (6–7 months): 8.2 (3.8, 1–27) Neonatal (10 days): 4.8 (3.3, 1–26) 	K-ABC scores	Coefficients per $\mu\text{g}/\text{dL}$ neonatal PbB: <ul style="list-style-type: none"> Mental processing composite: -0.63; $p < 0.01^*$ Sequential processing: -0.68, $p < 0.01^*$ Simultaneous processing: -0.50; $p < 0.05^*$ Nonverbal: -0.63; $p < 0.01^*$ Achievement: -0.28; $p < 0.05^*$
Dietrich et al. 1992 Prospective study, n=259 5-year-old children	Mean (SD, range): <ul style="list-style-type: none"> Maternal (6–7 months): 8.2 (3.8, 1–27) Neonatal (10 days): 4.8 (3.3, 1–26) Postnatal (5 years): 11.9 (6.4, 3–38) 	FWS scores	Coefficients per $\mu\text{g}/\text{dL}$ neonatal PbB: <ul style="list-style-type: none"> FWS(T): -0.26 $p < 0.1^*$ FWS(L): -0.20, $p < 0.01^*$ FWS(R) -0.13, $p < 0.1^*$ Coefficients per $\mu\text{g}/\text{dL}$ concurrent PbB: <ul style="list-style-type: none"> FWS(T): -0.11 $p < 0.1^*$ FWS(L): -0.06, $p < 0.1^*$ FWS(R) -0.08, $p < 0.05^*$
Dietrich et al. 1993a Prospective study, n=253 6–7-year-old children	Mean (SD): <ul style="list-style-type: none"> Maternal: 8.3 (3.7) Birth: 5 (3.4) 4–5 years: 11.8 (6.3) 	FSIQ	Adjusted β (SE) in IQ per each 1 $\mu\text{g}/\text{dL}$: <ul style="list-style-type: none"> Prenatal: 0.15 (0.21), Lifetime average: -0.13 (0.11); Concurrent: -0.33 (0.14); $p \leq 0.05^*$
Emory et al. 2003 Retrospective study, n=79 African-American mother-infant pairs	Mean (SD, 5 th –95 th percentile): <ul style="list-style-type: none"> Maternal: 0.72 (0.86, 0.28–1.18) 	FTII, Scaled Novelty Risk (risk of mental retardation later in life)	Score: PbB (SD): <ul style="list-style-type: none"> Low risk: 0.65 $\mu\text{g}/\text{dL}$ (0.80) Medium risk: 0.89 $\mu\text{g}/\text{dL}$ (0.88) High risk: 1.01 $\mu\text{g}/\text{dL}$ (0.126)

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
EPA 2014e (re-analysis of pooled cohort from Lanphear et al. 2005 with corrections to the database) Prospective; pooled-analysis; n=1,333 children from seven prospective studies	Mean (95% CL): <ul style="list-style-type: none"> • Lifetime average: 12.4 (4.1, 34.8) • Peak: 18.0 (6.2, 47.0) • Concurrent with FSIQ: 9.7 (2.5, 33.2) 	FSIQ	β in IQ for per each 1 $\mu\text{g}/\text{dL}$ increase in PbB (95% CL): <ul style="list-style-type: none"> • 6–24 months: -2.21 (-3.38, -1.304)* • Lifetime average: -3.14 (-4.39, -1.88)* • Peak: -2.86 (-4.10, -1.61)* • Concurrent: -2.65 (-3.69, -1.61)* FSIQ change for concurrent PbB range: <ul style="list-style-type: none"> • 2.4–10 $\mu\text{g}/\text{dL}$: -3.8 points (-2.3, -5.3)* • 10–20 $\mu\text{g}/\text{dL}$: -1.8 points (-1.1, -2.6)* • 20–30 $\mu\text{g}/\text{dL}$: -1.1 (-0.7, -1.5)*
Evens et al. 2015 Population-based retrospective cohort study, n=47,168 children	Mean (SD): 4.81 (2.22): Participants with PbB <10: 100%	ISAT reading scores Math	Regression coefficient (SE): -0.60 (0.03); p<0.0001* Adjusted RR: <ul style="list-style-type: none"> • 1 $\mu\text{g}/\text{dL}$: 1.06 (1.05, 1.07)* • 5 $\mu\text{g}/\text{dL}$: 1.32 (1.26, 1.39)* Regression coefficient (SE): -0.50 (0.03); p<0.0001* Adjusted RR: <ul style="list-style-type: none"> • 1 $\mu\text{g}/\text{dL}$: 1.06 (1.05, 1.07)* • 5 $\mu\text{g}/\text{dL}$: 1.32 (1.26, 1.39)*
Gomaa et al. 2002 Prospective study, n=197 children followed from birth to age 2 years	Umbilical cord mean (SD): 6.7 (3.4) Participants with PbB ≥ 10 : 15.7%	MDI	β (SE): -4.48 (2.04); p=0.03*
Hong et al. 2015 Cross-sectional study, n=1,001 children (ages 8–11 years)	Gmean (GSD): 1.80 (1.40) 5 th –95 th percentile range: 0.53–6.16	IQ	Regression coefficients per 10-fold increase in PbB: <ul style="list-style-type: none"> • Verbal IQ: -2.64 (-4.98, -0.30); p=0.027* • Full-scale IQ: -7.23 (-13.39, -1.07); p=0.021*

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
<p>Hu et al. 2006</p> <p>Prospective study, n=146 mother-child pairs</p>	<p>Mean\pmSD (range):</p> <ul style="list-style-type: none"> • Umbilical cord: 6.20\pm3.88 (0.9–20.0) • Child 12-month: 5.22\pm3.41 (0.9–20.4) • Child 24-month: 4.79\pm3.71 (0.8–36.8) • Maternal 1st trimester: 7.07\pm5.10 (1.49–43.6) • Maternal 2nd trimester: 6.08\pm3.15 (1.58–22.4) • Maternal 3rd trimester: 6.86\pm4.23 (1.53–33.1) 	MDI	<p>β per 1 SD change in ln PbB:</p> <ul style="list-style-type: none"> • Umbilical cord: -0.35 (-4.72, 4.03); p=0.88 • Child 12-month: -2.38 (-6.24, 1.49); p=0.23 • Child 24-month: -1.00 (-3.93, 1.94); p=0.50 • Maternal 1st trimester: -4.13 (-8.10, -0.17); p=0.04* • Maternal 2nd trimester: -4.08 (-8.29, 0.12); p=0.06 • Maternal 3rd trimester: -2.42 (-6.38, 1.54); p=0.23
<p>Jedrychowski et al. 2009</p> <p>Prospective study, n=444 children followed prenatally to age 3 years</p>	<p>Umbilical cord PbB</p> <ul style="list-style-type: none"> • Gmean: 1.29 • Median: 1.23 • Range: 0.44–6.90 	MDI	<p>β per lg cord PbB\pmSE:</p> <ul style="list-style-type: none"> • 12 months: -5.419\pm2.935 (-11.188, 0.3495); p=0.066 • 24 months: -7.653\pm3.577 (-14.684, -0.623); p=0.033* • 36 months: -6.717\pm2.964 (-12.546, -0.889); p=0.024* • All participants with PbB <5 (combination of all testing times): -6.618\pm2.499 (-11.517, -1.719); p=0.008*

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Jusko et al. 2008 Prospective study, n=174 children recruited at age 24–30 months and evaluated for FSIQ at 6 years	Lifetime average: <ul style="list-style-type: none"> • Mean (SD): 7.2 (4.1) • Range: 1.4–27.1 • Participants <10: 77% 	FSIQ	<ul style="list-style-type: none"> • Associations between increasing PbB and decreasing FSIQ measured at age 6 years ($p=0.003$)* • Comparison of children with PbB of 5–9.9 (high) to those with PbB <5 (low) showed a 4.9-point decrease in FSIQ score (low: 91.3; high 86.4; $p=0.04$)* • Adjusted changes in IQ for each 1 $\mu\text{g}/\text{dL}$ increase in peak lifetime PbB (p not reported): <ul style="list-style-type: none"> ○ 2.1–10 $\mu\text{g}/\text{dL}$: -1.2 ○ 10–20 $\mu\text{g}/\text{dL}$: -0.32 ○ 20–30 $\mu\text{g}/\text{dL}$: -0.15
Kim et al. 2013b Prospective birth cohort; n=884 mother infant pairs	Gmean (GSD): Early pregnancy: 1.4 (1.5) Late pregnancy: 1.3 (1.5)	MDI	β per 1 $\mu\text{g}/\text{dL}$ change in late pregnancy PbB: -1.94 (-3.60, -0.29); $p=0.02$*
Kordas et al. 2011 Prospective study, n=186 children followed prenatally (to age 4 years)	Mean (SD): <ul style="list-style-type: none"> • Umbilical cord: 6.6 (3.3) • 24 months: 8.1 (4.4) • 48 months: 8.1 (3.6) 	MDI (24 months)	<ul style="list-style-type: none"> • β (SE) Cord PbB: -0.7 (0.3); $p<0.05$* • β (SE) Concurrent PbB: -0.1 (0.2)
		PDI (24 months)	<ul style="list-style-type: none"> • β (SE) Cord PbB: -0.4 (0.2) • β (SE) Concurrent PbB: -0.2 (0.2)
		GCI (48 months)	<ul style="list-style-type: none"> • β (SE) Cord PbB: -0.2 (0.3) • β (SE) Concurrent PbB: -0.6 (0.2); $p<0.05$*
		Memory score	<ul style="list-style-type: none"> • β (SE) Cord PbB: 0.1 (0.1) • β (SE) Concurrent PbB: -0.3 (0.1)

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Lanphear et al. 2000a Cross-sectional study, n=4,853 children (ages 6–16 years)	Gmean: 1.9 Participants with PbB • ≥ 5 : 9.7% • ≥ 10 : 2.1%	Arithmetic	Regression coefficients (SE): • PbB <2.5: -1.28 (0.98), p=0.20 • PbB <5.0: -1.06 (0.48); p=0.03* • PbB <7.5: -1.06 (0.39); p=0.01* • PbB <10: -0.89 (0.32); p=0.008*
		Reading	Regression coefficients (SE): • PbB <2.5: -1.71 (0.93); p=0.07 • PbB <5.0: -1.66 (0.36); p<0.001* • PbB <7.5: -1.53 (0.31); p<0.001* • PbB <10: -1.44 (0.30); p<0.001*
		Block design	Regression coefficients (SE): • PbB <2.5: -0.08 (0.22); p=0.72 • PbB <5.0: -0.05 (0.07); p=0.45 • PbB <7.5: -0.11 (0.06); p=0.04* • PbB <10: -0.13 (0.06); p=0.03*
		Digit span	Regression coefficients (SE): • PbB <2.5: -0.25 (0.17); p=0.17 • PbB <5.0: -0.09 (0.07), p=0.20 • PbB <7.5: -0.09 (0.05); p=0.11 • PbB <10: -0.08 (0.04); p=0.03*
Lanphear et al. 2005 (same cohorts used for Budtz-Jorgensen et al. 2013) Prospective; pooled-analysis; n=1,333 children from seven prospective studies	Mean (96% CL): • Lifetime average: 12.4 (4.1, 34.8) • Peak: 18.0 (6.2, 47.0) • Concurrent with FSIQ: 9.7 (2.5, 33.2)	FSIQ	β in IQ for per each 1 $\mu\text{g}/\text{dL}$ increase in PbB: • 6–24 months: -2.04 (-3.27, -0.81)* • Lifetime average: -3.04 (-4.33, -1.75) • Peak: -2.85 (-4.10, -1.60)* • Concurrent: -2.70 (-3.74, -1.66)* FSIQ change for lifetime average PbB: • 2.4–10 $\mu\text{g}/\text{dL}$: -3.9 points (-2.4, -5.3)* • 10–20 $\mu\text{g}/\text{dL}$: -1.9 points (-1.2, -2.6)* • 20–30 $\mu\text{g}/\text{dL}$: -1.1 (-0.7, -1.5)*

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Lin et al. 2013 Prospective (Taiwan Birth Panel Study; birth dates: April 2004–January 2005) of 230 mother-infant pairs from Taipei, Taiwan, followed until age 2	Umbilical cord <ul style="list-style-type: none"> • Mean (SD): 1.30 (0.75) • Range: 0.016–4.32 	Cognitive score	Regression analysis comparing PbB ≥ 1.645 (75 th percentile) and PbB < 1.645 . Adjusted β (SE): <ul style="list-style-type: none"> • Total score: -4.23 (1.82); $p < 0.05^*$ • Cognitive: -5.35 (2.19); $p < 0.05^*$ • Language: -2.53 (1.89); $p \geq 0.05$
Liu et al. 2014b Prospective study; n=243 infants followed from birth to age 3 years	Umbilical cord (mean \pm SD): <ul style="list-style-type: none"> • Low PbB group: 1.35\pm0.26 • High PbB group: 5.63\pm0.32 	MDI	Regression coefficients: <ul style="list-style-type: none"> • 6 months: -1.647 (-2.094, -1.200); $p = 0.016^*$ • 12 months: -1.458 (-1.832, -1.084); $p = 0.023^*$ • 24 months: -1.385 (-1.683, -1.087) $p = 0.033^*$ • 36 months: -1.291 (-1.550, -1.032); $p = 0.036^*$ <p>Increasing PbB at ages 24 and 36 months was associated with decreasing MDI scores measured at 24 and 36 months, respectively; β:</p> <ul style="list-style-type: none"> • 24 months: -1.403; $p = 0.026^*$ • 36 months: -1.298; $p = 0.036^*$
Mazumdar et al. 2011 A prospective of 43 adults followed from birth (1979–1981) to age 28–30 years	Mean (SD): <ul style="list-style-type: none"> • Cord: 6.5 (5.3) • 6 months: 8.0 (5.3) • 12 months: 10.0 (6.7) • Age 2 years: 7.7 (4.0) • Age 4 years: 6.7 (3.6) • Age 10 years: 3.0 (2.7) 	FSIQ	Change in FSIQ per 1 $\mu\text{g}/\text{dL}$ increase in PbB. β (95% CL) for average late childhood PbB (mean of 4- and 10-year PbB): <ul style="list-style-type: none"> • Unadjusted: -1.89 (-3.30, -0.47), $p < 0.01^*$ • Adjusted for maternal IQ: -1.11 (-2.29, 0.06) • Other adjustments: 95% UCLs < 0
		PDI	Regression coefficients at 36 months: -1.302 (-1.572, -1.031); $p = 0.041^*$

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
McLaine et al. 2013 Population-based retrospective cohort study, n=3,406 children	Median: 4.2 Interquartile range: 2.6, 6.0	PALS-K scores	Mean differences (95% CI) in PALS-K scores (85% CL), compared to PbB <5: <ul style="list-style-type: none"> PbB 5–9: -4.51 (-6.61, -2.85); p>0.182 PbB ≥ 10: -10.13 (-13.30, -6.96); p>0.182 PR for falling below the PALS-K benchmark, compared to PbB <4: <ul style="list-style-type: none"> PbB 5–9: 1.21 (1.19, 1.23); p<0.001* PbB ≥ 10: 1.56 (1.51, 1.60); p<0.001*
Min et al. 2009 Prospective study, n=267 children followed prenatally age 11 years	Mean (SD): <ul style="list-style-type: none"> 4 years: 7.0 $\mu\text{g}/\text{dL}$ (4.1) 	FSIQ	Regression coefficient (SE): <ul style="list-style-type: none"> 4 years: -0.50 (0.20), p<0.05* 9 years: -0.41 (0.19), p<0.05* 11 years: -0.54 (0.19); p<0.01*
Miranda et al. 2009 Population-based retrospective cohort study, n=57,678 4 th grade children	Mean: 4.8 Median: 4 Range: 1–16	EOG scores	Multivariate regression coefficients for PbB ($\mu\text{g}/\text{dL}$) of: <ul style="list-style-type: none"> PbB 2: -0.30 (-0.58, -0.01); p<0.0001* PbB 3: -0.46 (-0.73, -0.19); p<0.0001* PbB 4: -0.52 (-0.79, -0.24); p<0.0001* PbB 5: -0.80 (-1.08, -0.51); p<0.0001* PbB 6: -0.99 (-1.29, -0.68); p<0.0001* PbB 7: -1.07 (-1.40, -0.74); p<0.0001* PbB 8: -1.35 (-1.73, -0.97); p<0.0001* PbB 9: -1.20 (-1.64, -0.75); p<0.0001* PbB ≥ 10: -1.75 (-2.09, -1.41); p<0.0001*

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
<p>Schnaas et al. 2006</p> <p>Prospective study, n=150 followed from birth to age 10 years</p>	<p>Maternal during full pregnancy</p> <ul style="list-style-type: none"> Gmean (range): 8.0 (1–33) <p>Maternal PbB during pregnancy weeks 28–36</p> <ul style="list-style-type: none"> Gmean (95% CI): 7.3 (1.5–17.4) <p>Child 1–5 years</p> <ul style="list-style-type: none"> Gmean (range): 9.8 (2.8–36.4) <p>Child 6–10 years</p> <ul style="list-style-type: none"> Gmean (range): 6.2 (2.2–18.6) 	FSIQ	<p>β assessed at age 6–10 years:</p> <ul style="list-style-type: none"> Ln maternal PbB (28 weeks pregnancy): -4.00 (-6.37, -1.65); p= 0.001* Ln child PbB (6–10 years): -2.45 (-4.09, -0.81); p= 0.003*
<p>Sobin et al. 2015</p> <p>Cross-sectional; n=252 children (age 5.1–11.8 years)</p>	<p>Mean (SD):</p> <ul style="list-style-type: none"> Females: 2.7 (1.5) Males: 2.4 (1.0) 96% <5.0 $\mu\text{g}/\text{dL}$ 	Working memory	β (SE): 0.11 (0.03), p<0.01*
<p>Tellez-Rojo et al. 2006</p> <p>Prospective study, n=294 children followed from birth to age 2 years</p>	<p>Mean (SD):</p> <ul style="list-style-type: none"> Cord: 4.85 (3.0) 12 months: 4.27 (2.14) 24 months: 4.28 (2.25) 	MDI	<p>β per ln PbB 12 months:</p> <ul style="list-style-type: none"> <10 $\mu\text{g}/\text{dL}$: -0.15, p=0.57 ≥ 10 $\mu\text{g}/\text{dL}$: -0.71, p=0.17 <p>β per lnPbB 24 mo:</p> <ul style="list-style-type: none"> <10 $\mu\text{g}/\text{dL}$: -1.04, p<0.01* ≥ 10 $\mu\text{g}/\text{dL}$: 0.07, p=0.84

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Vigeh et al. 2014 Prospective study, n=174 mother-child pairs, birth to 36 months	Mean \pm SD (range): <ul style="list-style-type: none"> 1st trimester: 4.15\pm2.43 (1.6–20.5) 2nd trimester: 3.44\pm1.28 (1.1–7.5) 3rd trimester: 3.78\pm1.40 (1.5–8.0) Umbilical cord: 2.86\pm1.09 (1.2–6.9). 	ECDI score	OR 1st trimester: 1.74 (1.18–2.57); p=0.005*
Wasserman et al. 1994, 1997, 2003 Prospective study, n=332 children age 4 years, 261 children age 7 years, 167 children age 10–12 years	Mean (SD): <ul style="list-style-type: none"> Age 4 years: 9.6, Pristina Age 7 years: 39.9, K. Mitrovica Age 10–12 years: 6.1 (1.9), Pristina Age 10–12 years: 30.9 (9.6), K. Mitrovica 	FSIQ	β (SE) for each ln PbB increase: <ul style="list-style-type: none"> 4 years: -9.43 (2.44); p=0.000* Lifetime AUC 7 years: -8.59 (1.89); p<0.05* Lifetime average 10–12 years: -5.31 (1.98); p<0.05*
Zhang et al. 2013 Population-based retrospective cohort study, n=8,831, 7,708, and 4,742 students in grades 3, 5, and 8, respectively	Mean (SD): 7.12 (7.26) Analysis: academic achievement	Math Science Reading	<ul style="list-style-type: none"> OR 1–5 PbB ($\mu\text{g}/\text{dL}$): 1.42 (1.24, 1.63)* OR 6–10 PbB ($\mu\text{g}/\text{dL}$): 2.00 (1.74, 2.30)* OR >10 PbB ($\mu\text{g}/\text{dL}$): 2.40 (2.07, 2.77)* <hr/> <ul style="list-style-type: none"> OR 1–5 PbB ($\mu\text{g}/\text{dL}$): 1.33 (1.10, 1.62)* OR 6–10 PbB ($\mu\text{g}/\text{dL}$): 2.22 (1.82, 2.72)* OR >10 PbB ($\mu\text{g}/\text{dL}$): 2.26 (1.84, 2.78)* <hr/> <ul style="list-style-type: none"> OR 1–5 PbB ($\mu\text{g}/\text{dL}$): 1.45 (1.27, 1.67)* OR 6–10 PbB ($\mu\text{g}/\text{dL}$): 2.21 (1.92, 2.55)* OR >10 PbB ($\mu\text{g}/\text{dL}$): 2.69 (2.31, 3.12)*

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^c
Mood and behavior			
Boucher et al. 2012 Prospective study, n=272 children (mean age 11.3 years)	Mean \pm SD (range): <ul style="list-style-type: none"> • Umbilical cord: 4.7\pm3.3 (0.8–20.9) • Current: 2.7\pm2.2 (0.4–12.8) 	ADHD-inattentive type ADHD-hyperactive-impulsive type ODD and/or CD Behavior problem scores	Adjusted ORs: <ul style="list-style-type: none"> • T2 (n=94): 1.06 (0.42, 2.66) • T3 (n=91): 1.01 (0.38, 2.64) <hr/> <ul style="list-style-type: none"> • T2(n=94): 4.01 (1.06, 15.23)* • T3(n=91): 5.52 (1.38, 22.12)* <hr/> <ul style="list-style-type: none"> • T2 (n=94): 1.90 (0.88, 4.11) • T3 (n=91): 1.53 (0.67, 3.49) <hr/> Umbilical cord PbB was not associated with associated with behavior problem scores (data not reported).
Braun et al. 2006 Cross-sectional study, n=4,704 children (ages 4–15 years)	Quintiles: <ul style="list-style-type: none"> • Q1 (reference): ND–0.7 • Q2: 0.8–1.0 • Q3: 1.1–1.3 • Q4: 1.4–2.0 • Q5: ≥ 2.0 	ADHD	Adjusted ORs: <ul style="list-style-type: none"> • Q2: 1.1 (0.4, 3.4); p=0.804 • Q3: 2.1 (0.7, 6.8); p= 0.195 • Q4: 2.7 (0.9, 8.4);p=0.086 • Q5: 4.1 (1.2, 14.0); p= 0.026* • p-trend: 0.012*
Braun et al. 2008 Cross-sectional study, n=3,082 children (ages 8–15 years)	Quartiles: <ul style="list-style-type: none"> • Q1 (reference): 0.2–0.7 • Q2: 0.8–1.0 • Q3: 1.1–1.4 • Q4: >2.0 	Conduct disorder	Adjusted ORs: <ul style="list-style-type: none"> • Q2: 7.24 (1.06, 49.47)* • Q3: 12.37 (2.37, 64.56*) • Q4: 8.64 (1.87, 40.04)*

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Choi et al. 2016 Longitudinal study, n=2,159 children (ages 7–9 years)	Gmean (GSD): <ul style="list-style-type: none"> All participants >7 years: 1.62 (1.52) Boys: 1.65 (1.75) Girls: 1.47 (1.76); p<0.001, compared to boys 	ADHD	<ul style="list-style-type: none"> RR for PbB ≥ 2.17 (compared to PbB <2.17): 1.552 (1.002, 2.403)*
Dietrich et al. 2001 Prospective study, n=195 subjects (age 15–17 years)	Categories: Lowest: <10 Low: 10–15 Medium: 16–20 High: >20	SRDBS scores	β (SE): <ul style="list-style-type: none"> Prenatal PbB: 0.192 (0.076); p=0.002* 78-month PbB: 0.193 (0.061); p=0.002* Average child PbB: 0.101 (0.047); p=0.036*
Froehlich et al. 2009 Cross-sectional study, n=2,588 children (ages 8–15 years)	Tertiles T1: 0.2–0.8 T2: 0.9–1.3 T3: >1.3	ADHD	Adjusted ORs: <ul style="list-style-type: none"> T2: 1.7 (0.97, 2.9); p=0.06 T3: 2.3 (1.5, 3.8); p=0.001*
Hong et al. 2015 A cross-sectional study, n=1,001 children (age 8–11 years)	Gmean (GSD): 1.80 (1.40) Range: 0.53–6.16	ADHD-hyperactive-impulsive type	PbB (log-transformed) OR: 3.66 (1.18, 6.13); p=0.004*
		ADHD-inattentive type	<ul style="list-style-type: none"> OR: 2.72 (-0.12, 5.56); p=0.060
		Total score	<ul style="list-style-type: none"> OR: 6.38 (1.36, 11.40); p=0.013*
Kim et al. 2016 Prospective study, n=2,473 children (age 7–8 years)	Mean (95% CI): <ul style="list-style-type: none"> Ages 7–8 years: 1.64 (1.60, 1.68) Ages 9–10 years: 1.58 (1.55, 1.61) Ages 11–12 years: 1.58 (1.55, 1.61) 	ASSQ	PbB (log transformed) β (SE): <ul style="list-style-type: none"> 7–8 years: 0.151 (0.061, 0.242)* 9–10 years: -0.023 (-0.143, 0.097) 11–12 years: 0.054 (-0.061, 0.170)
		SRS	<ul style="list-style-type: none"> PbB at 7–8 years: 2.489 (1.378, 3.600)* PbB at 9–10 years: 1.295 (-0.235, 2.825) PbB at 11–12 years: β (SE): 0.724 (-0.727, 2.176)

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Liu et al. 2014a Prospective study, n=332 mother-infant pairs	Mean (SD): <ul style="list-style-type: none"> • Low PbB group <ul style="list-style-type: none"> ○ 1st trimester: 1.22 (0.28) ○ 2nd trimester: 1.01 (0.19) ○ 3rd trimester: 1.19 (0.23) ○ Delivery: 1.26 (0.25) • High PbB group <ul style="list-style-type: none"> ○ 1st trimester: 6.49 (0.62) ○ 2nd trimester: 5.63 (0.43) ○ 3rd trimester: 6.31 (0.51) ○ Delivery: 6.65 (0.55) 	NBNA score	β : <ul style="list-style-type: none"> • 1st trimester: -4.86 (-8.831, -0.889); p=0.03* • 2nd trimester: -3.98 (-8.180, 0.220); p=0.07* • 3rd trimester: -3.65 (-6.609, 1.309); p=0.21 • Delivery: -3.39 (-7.531, 0.751); p=0.11
Liu et al. 2015b Prospective study, n=665 children (ages 3–13 years)	Mean (SD): 6.26 (2.54)	Sleep onset delay	β: 0.033 (0.009, 0.056); p= 0.006*
Sioen et al. 2013 Prospective study, n=270 children, followed newborn to 8 years	Umbilical cord mean (25 th –75 th percentiles): 1.43 (0.73–2.53)	Hyperactivity	OR: 2.940 (1.172, 7.380); p=0.022*

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^c
Wang et al. 2008 Case-control study, n=630 children (ages 4–12 years)	Means (SE): <ul style="list-style-type: none"> ADHD cases: 8.77 (3.89) Controls: 5.76 (3.36) Cases versus control: $p < 0.05$ Tertiles: <ul style="list-style-type: none"> T1 (reference): ≤ 5 T2: 5–10 T3: ≥ 10 	ADHD	OR: <ul style="list-style-type: none"> T2: 4.92 (3.47, 6.98); $p < 0.01^*$ T3: 6.00 (4.11, 8.77); $p < 0.01^*$
Neuromotor neurosensory function			
Chiodo et al. 2004 Prospective study, n=237 children (age 7.5 years)	Mean (SD, range): 5.4 (3.3, 1–25)	Battery test performance	Tests with declines (β) at < 3 , < 5 , < 7.5 , or < 10 $\mu\text{g/dL}$: <ul style="list-style-type: none"> Block design: < 10, < 5; $p \leq 0.05^*$ Digit span backwards: < 7.5; $p \leq 0.05^*$ Beery visual-motor integration: < 10, < 5; $p \leq 0.05^*$ MFF (number correct): < 5; $p \leq 0.05^*$ Attention-TRF: < 3; $p \leq 0.05^*$ Barkley-inattention: < 5 < 3; $p \leq 0.05^*$ Withdrawn-TRF: < 7.5, < 3; $p \leq 0.05^*$ Barkley off-task: < 10, < 5; $p \leq 0.05^*$ Sternberg RT “Yes”: < 5, < 3; $p \leq 0.05^*$ Color naming: < 5; $p \leq 0.05^*$ CPT visual (number correct): none Seashore rhythm: < 3; $p \leq 0.05^*$ Mental rotation RT “forward”: < 10, < 7.5; $p \leq 0.05^*$

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) $\leq 10 \mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^c
Dietrich et al. 1987 Prospective study, n=185 mother-infant pairs	Mean (SD, range): <ul style="list-style-type: none"> • Prenatal (maternal): 8.3 (3.8, 1–27) • Neonatal (10 days): 4.9 (3.3, 1–24) • Neonatal (3 months): 6.3 (3.8, 1–22) • Neonatal (6 months): 8.1 (5.2, 1–36) 	Motor maturity PDI	Associations with 3-month ln PbB, β (SE): <ul style="list-style-type: none"> • PDI: -13.248 (4.250); p=0.002* • Motor maturity: -0.570 (0.260); p=0.03* Associations with 6-month ln PbB, β (SE): <ul style="list-style-type: none"> • PDI: -2.117 (0.916); p=0.02* • Motor maturity: -0.092 (0.056); p=0.11 Associations with 3-month ln PbB, β (SE): <ul style="list-style-type: none"> • PDI: -13.248 (4.250); p=0.002* Associations with 6-month ln PbB, β (SE): <ul style="list-style-type: none"> • PDI: -2.117 (0.916); p=0.02*
Dietrich et al. 1989 Prospective study, n=192 mother-infant pairs	Mean (SD, range): <ul style="list-style-type: none"> • Prenatal (maternal): 8.2 (3.6, 1–27) • Neonatal (10 days): 4.8 (3.1, 1–23) • Neonatal (3 months): 6.0 (3.5, 1–20) • Neonatal (6 months): 7.9 (4.8, 1–35) • Neonatal (9 months): 11.5 (6.9, 2–57) • Neonatal (12 months): 14.2 (7.3<4–47) 	PDI	β (SE), 12 months: -14.09 (7.26); p=0.054 SEM indicated associations between increasing prenatal PbB and race and 12-month PDI. <ul style="list-style-type: none"> • Prenatal PbB --> 12-month PDI: -0.47, p\leq0.05* • Prenatal PbB x race --> birth weight: 0.97, p\leq0.05* • Race --> 12-month MDI: -0.72, p\leq0.05*

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Dietrich et al. 1993b Prospective study, n=245 children (age 6 years)	Mean (SD): <ul style="list-style-type: none"> • Prenatal (maternal: 8.4 (3.8)) • Neonatal: 4.8 (3.1) • Life average • 6 years: 10.1 (5.6) • Lifetime average quartile range: 7–22 	Motor performance	Tests with ($p \leq 0.05$) declines (β) associated with neonatal (N), mean lifetime (L) or concurrent (C) PbB: <ul style="list-style-type: none"> • Bilateral coordination: N, M • Visual motor control: C • Upper limb speed and dexterity: C, M, N • Fine motor composite: C, M, N
Ethier et al. 2012 Prospective longitudinal, n=149 children (age 10–13 years)	Mean (SD, range): <ul style="list-style-type: none"> • Cord: 4.6 (3.1, 0.8–19.5) • 11 years: 2.6 (2.3, 0.4–12.8) 	Delay of N150 latency of VEP	Association between increasing cord PbB and delay of N150 latency of VEP at multiple contracts. Mean latency (estimated from reported bar plot): <ul style="list-style-type: none"> • ≥ 4.15 $\mu\text{g}/\text{dL}$: ~160 ms, $p < 0.05^*$ • < 4.15 $\mu\text{g}/\text{dL}$: ~153 ms (reference)
Fraser et al. 2006 Prospective study, n=101 children (age 5 years)	Mean (SD): Cord: 4.9 (3.7) Child: 5.3 (4.9)	Hand movements Sway velocity Transversal sway	β -0.30, $p \leq 0.01^*$ β -0.28, $p \leq 0.01^*$ β 0.24, $p \leq 0.05^*$
Kim et al. 2013b Prospective birth cohort, n=884 mother infant pairs	Gmean (GSD): Early pregnancy: 1.4 (1.5) Late pregnancy: 1.3 (1.5)	PDI	β per 1 $\mu\text{g}/\text{dL}$ change in PbB (95% CL): -1.69 (-3.65, -0.27); $p=0.09$

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Osman et al. 1999 Retrospective study, n=155 children (age 4–14 years)	Median (range): • 7.2 (1.9–28.1)	Hearing threshold	<p>β per 1 change in PbB for right ear (95% CL) for full cohort:</p> <ul style="list-style-type: none"> • 0.5 kHz: 0.054 (0.035, 0.074)* • 1 kHz: 0.044 9 (0.026, 0.062)* • 2 kHz: 0.048 (0.029, 0.066)* • 4 kHz: 0.060 (0.039, 0.081)* • 6 kHz: 0.068 (0.044, 0.092)* • 8kHz: 0.072 (0.050, 0.094)* <p>β per 1 change in PbB for left ear (95% CL):</p> <ul style="list-style-type: none"> • 0.5 kHz: 0.051 (0.026, 0.075)* • 1 kHz: 0.032 (0.014, 0.050)* • 2 kHz: 0.036 (0.019, 0.053)* • 4 kHz: 0.039 (0.020, 0.059)* • 6 kHz: 0.004 (0.044, 0.049)* • 8kHz: 0.047 (0.024, 0.080)* <p>Association ($p < 0.05$) between increasing PbB and increasing hearing threshold at all frequencies in PbB stratum < 10 $\mu\text{g}/\text{dL}$ (thresholds not reported)*</p>
Tellez-Rojo et al. 2006 Prospective study, n=294 children (followed from birth to age 2 years)	Mean (SD): • Cord: 4.85 (3.0) • 12 months: 4.27 (2.14) • 24 months: 4.28 (2.25)	PDI	<p>β per 1 ln change in PbB:</p> <p>12 months:</p> <ul style="list-style-type: none"> • < 10 $\mu\text{g}/\text{dL}$: -0.01, $p=0.98$ • ≥ 10 $\mu\text{g}/\text{dL}$: -1.19, $p=0.01$* <p>24 months:</p> <ul style="list-style-type: none"> • < 10 $\mu\text{g}/\text{dL}$: -1.18, $p < 0.01$* • ≥ 10 $\mu\text{g}/\text{dL}$: 0.04, $p=0.89$

2. HEALTH EFFECTS

Table 2-30. Summary of Epidemiological Studies Evaluating Neurological Effects in Children at Mean Blood Lead Concentration (PbB) $\leq 10 \mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^c
Altered brain structure and chemistry			
Cecil et al. 2008 Prospective study, n=157 adults, age 19–24 years from a birth cohort born 1979–1984 from Cincinnati, Ohio	Mean (SD, range): • 6 month–6.5 years: 13.3 (5.9, 4.6–37.2)	Brain volume	Association ($p \leq 0.001$) between increasing childhood mean PbB and decreasing brain volume affecting 1.2% of the total gray matter. Effects were greater in males than females. Largest effects were in the anterior cingulate cortex.
Cecil et al. 2011 Prospective study, n=159 adults, age 19–24 years from a birth cohort born 1979–1984 from Cincinnati, Ohio	Mean (SD, range): • 6 months–6.5 years: 13.3 (6.1, 4.7–37.2)	Brain metabolism	Association ($p < 0.05$) between increasing childhood mean PbB and decreasing regional levels of gray matter N-acetyl aspartate, glutamate-glutamine, creatine and phosphocreatine, and white matter cholines. Areas affected include the basal ganglia, cerebellum vermis, parietal white matter, and frontal white matter.

^aSee the *Supporting Document for Epidemiological Studies for Lead*, Table 9 for more detailed descriptions of studies.

^bParticipants had no known occupational exposure to Pb.

^cAsterick indicates association with PB; unless otherwise specified, values in parenthesis are 95% CIs.

ADHD = attention-deficit/hyperactivity disorder; ASSQ = Autism Spectrum Screening Development Questionnaire; AUC = area under the curve; CD = Conduct Disorder; CI = confidence interval; CL = confidence limit; CPT = Continuous Performance Test; EOG = End of Grade; FSIQ = full-scale IQ; FSIQ = Full-Scale intelligence quotient; FTII = Fagan Test of Infant Intelligence; FWS = Filtered Word Subtest; Gmean = geometric mean; GSD = geometric standard deviation; IQ = intelligence quotient; ISAT = Illinois Standard Achievement Test; GCI = General Cognitive Index; K-ABC = Kaufman Assessment Battery for Children; MDI = Mental Development Index; MFF = Matching Familiar Figures; NBNA = Neonatal Behavioral Neurological Assessment; ND = not detected; ODD = Oppositional Defiant Disorder; OR = odds ratio; PALS-K = Phonological Awareness Literacy Screening-Kindergarten; PDI = Psychomotor Development Index; PR = prevalence ratio; RR = relative risk; SD = standard deviation; SE = standard error; SRDBS = Self-Reported Delinquent Behavior Survey; SRS = Social Responsiveness Scale; TRF = Teacher Report Form from the Child Behavior Checklist; UCL = upper confidence limit; VEP = visual evoked potential

2. HEALTH EFFECTS

The model that used early childhood PbB (6–24 months) had the highest r^2 (0.6433), although the r^2 was similar to concurrent PbB (0.6414). A benchmark dose (BMD) analysis of the pooled data from Lanphear et al. (2005) estimated BMDLs (95% lower one-sided confidence limit on BMD) ranging from 0.1 to 1 $\mu\text{g}/\text{dL}$ for a 1% decrease in FSIQ for the best-fitting models (Budtz-Jorgensen et al. 2013). This BMD analysis provides supporting evidence that exposures to Pb may produce effects on cognitive function in populations whose PbBs are well below 5 $\mu\text{g}/\text{dL}$, and may extend to levels below 1 $\mu\text{g}/\text{dL}$.

In addition to the seven prospective studies included in the Lanphear et al. (2005) pooled analysis, more recent prospective studies have evaluated associations between PbB and FSIQ in children (Braun et al. 2012; Chiodo et al. 2004; Jusko et al. 2008; Kordas et al. 2011; Min et al. 2009; Schnaas et al. 2006; Table 2-30). Each of these studies found significant associations between increasing PbB <10 $\mu\text{g}/\text{dL}$ and decreasing measures of FSIQ. The largest of these studies combined four Mexico City birth cohorts for a total of 1,035 mother-infant pairs (Braun et al. 2012). Cognitive function assessed at age 4 years (McCarthy General Cognitive Index [GCI]) decreased with increasing PbB measured at age 2 years. The adjusted effect of concurrent PbB was estimated as -3.8 (95% CI -6.3, -1.4) points when PbB increased by 10 $\mu\text{g}/\text{dL}$. Similar to the findings of the Lanphear et al. (2005) study, covariate adjustment decreased the regression β by approximately 40% (from -6.4 to -3.8). The cohort mean PbB was 4.6 $\mu\text{g}/\text{dL}$ (5th–95th percentile range 1.3–13.4). Studies of smaller cohorts from Mexico City found similar associations (Kordas et al. 2011; Schnaas et al. 2006). Schnaas et al. (2006) estimated the effect size to be a -4.0 (95% CL -6.37, -1.65) point change in FSIQ measured at ages 6–10 years in association with a natural log increase in maternal PbB; the cohort geometric mean was 7.3 $\mu\text{g}/\text{dL}$ (95% CL 1.5, 17.4). Kordas et al. (2011) estimated the effect size to be -0.6 (SE 0.2) for a 1 $\mu\text{g}/\text{dL}$ increase in concurrent PbB (mean 8.1 $\mu\text{g}/\text{dL}$ \pm 4.4 SE). Prospective studies conducted in Cleveland, Ohio (Min et al. 2009) and Rochester, New York (Jusko et al. 2008) also found similar effect sizes for the associations between increasing PbB and decreasing IQ. In the Rochester study, the changes in FSIQ were larger at lower PbB, consistent with the outcomes of the Lanphear et al. (2005) study (Jusko et al. 2008). For the PbB range 2.1–10 $\mu\text{g}/\text{dL}$, the change in FSIQ measured at age 6 years was -1.2 per 1 $\mu\text{g}/\text{dL}$ increase in PbB. This decreased to -0.32 and -0.15 for the ranges 10–20 and 20–30 $\mu\text{g}/\text{dL}$, respectively. In the Cleveland study, the change was -0.50 ± 0.20 (SE) in FSIQ measured at age 4 years per 1 $\mu\text{g}/\text{dL}$ increase in concurrent PbB (Min et al. 2009). A study conducted in Detroit, Michigan estimated the change in FSIQ to be -0.20 per 1 SD change in PbB (Chiodo et al. 2004). The decrement was significant ($p \leq 0.05$) in PbB strata <7.5 and <10 $\mu\text{g}/\text{dL}$.

2. HEALTH EFFECTS

A cross-sectional study conducted in South Korea evaluated PbB and FSIQ in 1,001 children 8–11 years of age (Hong et al. 2015). The estimated effect of PbB on FSIQ was -7.23 points (95% CL -13.39, -1.07) per 10-fold increase in PbB. The 5th–95th percentile range for the cohort PbB was 0.53–6.16 µg/dL.

Cognitive function in early childhood—other than FSIQ. Several studies have examined outcomes other than IQ and have found associations between PbB and changes in cognitive function in children whose PbBs were <10 µg/dL (Table 2-30). These include prospective studies that used the same outcome metric, the BSID MDI, allowing comparison of outcomes across studies (Dietrich et al. 1986, 1987, 1989; Kim et al. 2013b, Tellez-Rojo et al. 2006). A prospective study of 884 children conducted in South Korea found negative associations between PbB in late pregnancy (geometric mean 1.3±1.5, geometric standard deviation [GSD]) and MDI scores measured at age 6 months (Kim et al. 2013b). A prospective study of 294 children conducted in Mexico City found negative associations between concurrent PbB (mean 4.27±2.14, SD) and MDI measured at 24 months in a PbB stratum <10 µg/dL (Tellez-Rojo et al. 2006). A prospective study conducted in Cincinnati, Ohio (approximately 190 infants) also found declines in MDI scores at age 6 and 12 months in association with increasing maternal, neonatal, or infant PbB (Dietrich et al. 1986, 1987, 1989).

Several large-scale retrospective studies linked academic performance for individual children with their corresponding blood Pb data recorded in state or local blood Pb registries (Evens et al. 2015; Miranda et al. 2009; Zhang et al. 2013; Table 2-30). Evens et al. (2015) linked individual 3rd grade Illinois Standard Achievement Test (ISAT) scores and PbB data (birth–72 months) for a population of 47,158 children in Chicago, Illinois. All children had PbB <10 µg/dL and the population mean was 4.8±2.2 µg/dL (SD). Increasing PbB was negatively associated with decreasing covariate adjusted scores in math and reading. The adjusted relative risks (RRs) for failing scores was also significant for a 1 or 5 µg/dL increase in PbB. Miranda et al. (2009) linked 4th grade reading End of Grade (EOG) scores and PbB data collected (birth–36 months) for a population of 57,678 children in North Carolina. The population mean PbB was 4.8 µg/dL (range 1–16 µg/dL); 94% of children had PbB <10 µg/dL. Increasing PbB was associated with decreasing covariate adjusted scores in all PbB strata, the lowest of which was 2 µg/dL. The effect size (change in score/µg/dL PbB) increased with increasing PbB. Zhang et al. (2013) linked Michigan Educational Assessment Program (MEAP) scores and PbB data (birth–72 months) of age for a population of approximately 21,000 children in Detroit, Michigan. Covariate adjusted ORs for failing scores in mathematics, science, and reading were significant for PbB strata 1–5, 6–10, and >10 µg/dL. A cross-sectional study of data from NHANES III examined associations between PbB and scores on tests of cognitive function (Wide Range Achievement Test-Revised [WRAT-R], Wechsler Intelligence Scales for

2. HEALTH EFFECTS

Children-Revised [WISC-R]) in approximately 5,000 children 6–16 years of age (Lanphear et al. 2000a). Increasing PbB was significantly associated with decreasing scores in reading in blood strata <5.0, <7.5, and <10 µg/dL. McLaine et al. (2013) examined associations between PbB (9–72 months) and kindergarten readiness assessed from Phonological Awareness Literacy Screening-Kindergarten (PALS-K) scores in approximately 3,400 children in Providence, Rhode Island. The population median PbB was 4.2 µg/dL (interquartile range 2.9–6.0); 93% of children had PbB <10 µg/dL. Mean difference in covariate adjusted scores in blood strata 5–9 and ≥10 µg/dL compared to <4 µg/dL were in the negative direction and adjusted prevalence ratios for test failure was significant in both strata.

Altered mood and behavior. Numerous studies have examined possible associations between neonatal and child PbB risk of behaviors that may contribute to learning deficits, including attention deficits, hyperactivity, autistic behaviors, conduct disorders, and delinquency (Table 2-30).

Several studies have examined attention-deficit/hyperactivity disorder (ADHD) as an outcome, allowing comparisons of outcomes across studies (Boucher et al. 2012; Braun et al. 2006; Choi et al. 2016; Froehlich et al. 2009; Hong et al. 2015; Wang et al. 2008). Collectively, the ADHD studies indicate that risk of childhood ADHD increases in association with increasing PbB <10 µg/dL (Table 2-30). In a case-control study conducted in China (630 cases), covariate adjusted ORs for ADHD in children 4–14 years of age were 4.92 (95% CL 3.47, 6.98) for the PbB range 5–10 µg/dL and 6.00 (4.11, 8.77) for PbB ≥10 µg/dL compared to <5 µg/dL (Wang et al. 2008). A prospective study of 272 children (mean age 11 years) conducted in Nunavik, Canada found elevated covariate adjusted ORs of 4.01 (95% CL 1.06, 15.23) for a PbB stratum 1.6–2.7 µg/dL and 5.52 (95% CL 1.38, 22.12) for the stratum 2.7–12.8 µg/dL (Boucher et al. 2012). A longitudinal study examined ADHD outcomes of 2,159 South Korean children (ages 7–9 years) who did not exhibit ADHD symptoms at recruitment (Choi et al. 2016). Two years following baseline assessment, the covariate adjusted relative risk of ADHD was estimated to be 1.552 (95% CL 1.002, 2.403) for children having PbB ≥2.17 µg/dL compared to ≤2.17 µg/dL. The geometric mean PbB for the cohort was 1.62 µg/dL ±1.52 (GSD). Several cross-sectional studies have also found associations between concurrent PbB and risk of ADHD (Braun et al. 2006; Froehlich et al. 2009; Hong et al. 2014). A study of data on approximately 4,700 children (age 4–15 years) reported in the 1999–2002 NHANES found elevated risk of ADHD in association with concurrent PbB >2 µg/dL and a significant trend in risk with increasing PbB (Braun et al. 2006). Froehlich et al. (2009) examined data for children 8–15 years of age from the 2001–2004 NHANES. Covariate adjusted ORs of ADHD were elevated for the PbB stratum >1.3 µg/dL (compared to ≥0.8 µg/dL). A cross-sectional study conducted in South Korea examined associations between PbB and ADHD rating scores of 1,001 children of age 8–

2. HEALTH EFFECTS

11 years (Hong et al. 2015). One \log_{10} increase of PbB was associated with increases in teacher-rated ADHD hyperactivity (OR 3.66; 95% CI 1.18, 6.13) and total ADHD score (OR 6.38; 95% CI 1.36, 11.40). The cohort geometric mean PbB was 1.8 ± 1.4 $\mu\text{g/dL}$ (SD).

Prospective studies have also provided evidence for associations between neonatal or early childhood PbB and other neurobehavioral outcomes, including neonatal behavior, sleep disorders, hyperactivity, autistic behavior, and delinquency (Dietrich et al. 2001; Kim et al. 2016; Liu et al. 2014b, 2015b; Sioen et al. 2013).

Altered neuromotor-neurosensory function. Numerous studies have examined possible associations between neonatal and child PbB and neuromotor or neurosensory function (Table 2-30). Several studies used the Psychomotor Development Index (PDI) score from the BSID, allowing comparison of results across studies (Dietrich et al. 1987, 1989; Kim et al. 2013b; Tellez-Rojo et al. 2006). Each study found negative associations for PDI scores measured from 6 to 12 months in association with increasing prenatal (e.g., maternal) or neonatal PbB. Studies that repeatedly measured PDI scores longitudinally within the same birth cohorts found that associations observed at 6 months persisted to later ages (Dietrich et al. 1987, 1989, 1991; Tellez-Rojo et al. 2006). A prospective study conducted in China administered a neurobehavioral test battery to a birth cohort of 237 children at age 7 years (Chiodo et al. 2004). Significant declines in performance ($p \leq 0.05$) were observed in PbB strata that ranged from <3 $\mu\text{g/dL}$ at the lowest to <10 $\mu\text{g/dL}$; most tests that showed significant declines at <10 $\mu\text{g/dL}$, also showed declines at <5 $\mu\text{g/dL}$ ($p \leq 0.05$). A prospective study conducted in Nunavik, Canada evaluated fine motor control in a birth cohort at 5 years (Fraser et al. 2006). Significant changes in motor control assessed from sway and reaction times were associated with increasing concurrent PbB ($p \leq 0.01$). The cohort PbB mean was 5.3 $\mu\text{g/dL} \pm 4.9$ (SD). This birth cohort also exhibited changes in visual evoked potentials that were associated in increasing cord PbB (Ethier et al. 2012). The cohort cord PbB mean was 4.6 ± 3.1 (SD).

Altered brain structure and neurochemistry. A follow-up to the Cincinnati prospective study (Dietrich et al. 1986) estimated whole brain volumes and imaged brain metabolites in 157–159 adults at age 19–24 years (Brubaker et al. 2010; Cecil et al. 2008, 2011; Table 2-30). Decreasing covariate adjusted brain volume was associated with increased childhood mean PbB (measured between ages 6 months and 6 years). Brain volume reductions that were associated with childhood PbB compromised approximately 1.2% of the total gray matter and were more severe in males compared to females. The largest effects were observed in the anterior cingulate cortex. This region of the brain is involved in controlling

2. HEALTH EFFECTS

executive function, mood, and decision-making. Increasing childhood PbB was also associated with decreasing concentrations of various metabolites in brain known to be important in supporting metabolic structural integrity of neurons (e.g., lipid metabolism and myelin production). These included decreased N-acetyl aspartate (NAA) in the basal ganglia and cerebellar hemisphere, decreased glutamate-glutamine in the vermis and parietal white matter, decreased creatine and phosphocreatine in the basal ganglia, and decreased cholines in the cerebellum, parietal white matter, and frontal white matter. These changes in association with childhood PbB suggest that childhood Pb exposure may be indicators of longer-term changes in brain glutamate-associated lipid metabolism or neuronal architecture (Cecil et al. 2011).

Associations Between Bone Pb and Neurological Effects in Children. Few studies have been conducted to assess possible associations between bone Pb and neurological function in children (Table 2-31). Prospective studies of outcomes in children of mother-infant pairs have found associations between maternal or child bone Pb cognitive function (Campbell et al. 2000b; Gomaa et al. 2002; Needleman et al. 1996; Wasserman et al. 2003; Xu et al. 2015). Increasing bone Pb measured at age 24 months was associated with decrements in cognitive development (Gomaa et al. 2002) and behaviors indicative of attention deficit hyperactivity disorder assessed at age 7–15 years (Xu et al. 2015). Increasing child bone Pb measured later in childhood (ages 11–14 years) was associated with decrements in language processing (Campbell et al. 2000b); full scale, verbal, and performance IQ (Wasserman et al. 2003); and delinquent, aggressive, internalizing, externalizing behaviors (Needleman et al. 1996). A case-control study of adjudicated delinquency at age 12–18 years found associations between increasing bone Pb and delinquency (Needleman et al. 2002).

Table 2-31. Associations Between Bone Pb and Neurological Outcomes in Children

Reference	Population	Neurological outcome			
		Intellectual deficits	Altered neuromotor or neurosensory function	Altered mood or behavior	Outcome measures
Campbell et al. 2000b	156 males, age: 11–14 years	↑ T	–	–	Language processing
Gomaa et al. 2002	197 mother-infant pairs	↑ P ^a 0 T ^a	–	–	24-month MDI ^b

2. HEALTH EFFECTS

Table 2-31. Associations Between Bone Pb and Neurological Outcomes in Children

Reference	Population	Neurological outcome			
		Intellectual deficits	Altered neuromotor or neurosensory function	Altered mood or behavior	Outcome measures
Needleman et al. 1996	301 males, age: 9–13 years	–	–	↑ T	Delinquent, aggressive, internalizing, externalizing behaviors
Needleman et al. 2002	194 male cases, 145 controls, age: 12–18 years	–	–	↑ T	Adjudicated delinquency
Wasserman et al. 2003	167 children, age: 10–12 years	↑ T	–	–	IQ (full scale, verbal, performance) ^c
Xu et al. 2015	197 mother-infant pairs	–	–	↑ P ^a	Attenuation of effect of maternal self-esteem on ADHD assessed at age 7–15 years ^d

^aMaternal bone lead measured within 1 month of birth.

^bBayley Scale.

^cWechsler Intelligence Scale for Children-III.

^dMaternal self-esteem was evaluated with Coopersmith Self-Esteem Inventory. ADHD was evaluated with Conners' Parent Rating Scale-Revised and Behavior Rating Inventory of Executive Function.

↑ = positive association; ↓ = negative association; 0 = no association; – = not reported; ADHD = Attention deficit hyperactivity disorder; C = calcaneous bone; MDI = Mental Developmental Index; P = patella; Pb = lead; T = tibia; O = other

Effects at Blood Pb Levels $\leq 10 \mu\text{g/dL}$ in Adults. Numerous longitudinal and large cross-sectional studies in adults provide a weight of evidence for decreased cognitive function, altered mood and behavior, and altered neuromotor and neurosensory function in association with exposures that result in PbB $< 10 \mu\text{g/dL}$, with some studies showing effects in the 3–5 $\mu\text{g/dL}$ range. Study details are reviewed in the *Supporting Document for Epidemiological Studies for Lead*, Table 10. Cognitive, neuromotor, and neurosensory outcomes have been evaluated with tests of memory, learning, executive function, reaction time, walking speed, and tremor. Pb exposure has been associated with risk of various psychiatric symptoms including anxiety, depression, and schizophrenia, and with risk of ALS. In some studies, associations were found between outcomes and PbB and/or bone Pb. Several studies have examined cohorts of people who had mean ages within the range 50–70 years. Studies of cognitive function in elderly populations must

2. HEALTH EFFECTS

control for factors that contribute to age-related decrements in function, including confounding from the relationship between age and bone Pb, which increases with age. Longitudinal studies offer advantages over cross-sectional studies in that they can provide measurement changes in function of individual subjects with age.

Cognitive function. Numerous studies have examined possible associations between Pb exposure and cognitive function in adults (Table 2-32). Most of these studies have found associations between increasing Pb exposure, indicated by blood or bone Pb, and indications of decreased cognitive function (Muldoon et al. 1996; Payton et al. 1998; Power et al. 2014; Seegal et al. 2013; Seo et al. 2014; Shih et al. 2006; Weisskopf et al. 2007; Weuve et al. 2006, 2009; Wright et al. 2003b). However, one of the largest cross-sectional studies analyzed data from NHANES III (1988–1994) and found no associations between PbB and performance neurobehavioral tests (Krieg et al. 2005). This study compared scores from several tests from the Neurobehavioral Evaluation System (NBES) and concurrent PbB in approximately 5,700 adults (age 20–50 years). Implemented tests measured processing speed, attention, learning, and memory (reaction time, symbol-digit substitution, serial digit learning). The geometric mean PbB was 2.51 $\mu\text{g/dL}$ (range 0.7–42) and 96% of the cohort was $<10 \mu\text{g/dL}$. No significant associations (defined as $p \leq 0.05$) between PbB and cognitive outcomes were found. Several studies have examined smaller cohorts from longitudinal studies designed to evaluate health in aging populations. Studies of male cohorts of from the Normative Aging Study have found significant ($p \leq 0.05$) associations between increasing blood and/or bone Pb and decreasing scores on cognitive tests, including short-term memory, verbal memory, and visuoconstruction (Payton et al. 1998; Weisskopf et al. 2007; Weuve et al. 2006). Cohort sizes in these studies ranged from approximately 600 to 1,100 and the mean PbB ranged from 2.9 ± 1.9 to $5.5 \pm 3.5 \mu\text{g/dL}$. Weuve et al. (2006) found that decreases in cognitive performance were associated with PbB in a cohort of ALAD-2 carriers, but not in a cohort that carried the wildtype ALAD allele. Studies of female cohorts (approximately 600 subjects) from the longitudinal Nurses' Health Study have found mixed outcomes (Power et al. 2014; Weuve et al. 2009). Weuve et al. (2009) found significant association between increasing tibia Pb, but not PbB, and scores on a telephone survey of cognitive function (the Telephone Interview for Cognitive Status, TIC). The TIC has been used to assess memory and executive function and has been used to evaluate dementia. The effect size was -0.051 (95% CL -0.099, -0.003) points per 1 SD of tibia Pb. Power et al. (2014) used the same telephone survey instrument and found no associations between blood or bone Pb and cognitive function; the effect size for PbB was -0.013 (95% CL -0.044, 0.017) and the cohort mean PbB was 2.9 ± 1.9 (SD) $\mu\text{g/dL}$. A cross-sectional study of approximately 1,000 adults from the Boston Memory Study found negative

2. HEALTH EFFECTS

Table 2-32. Summary of Epidemiology Studies Evaluating Neurodevelopmental Effects in Adults at Mean Blood Lead Concentration (PbB) $\leq 10 \mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^c
Cognitive abilities			
Krieg et al. 2005 Cross-sectional study, n=5,662 adults, age 20–59 years	Gmean (range): 2.51 (0.7, 41.8)	Simple visual reaction time	No associations between PbB and performance scores <ul style="list-style-type: none"> • Mean reaction time: p=0.24
		Symbol-digit substitution	<ul style="list-style-type: none"> • Mean total latency: p=0.27 • Number of errors: p=0.82
		Serial digit learning	<ul style="list-style-type: none"> • Trials to criterion: p=0.26 • Total score: p=0.24
Muldoon et al. 1996 Cross-sectional study, n=530 adult women, mean age 70 years	Mean (SD): <ul style="list-style-type: none"> • All: 4.8 (0.4) • Rural: 4.5 (0.4) • Urban: 5.4 (0.4) • Low: 4 • Medium: 4–7 • High: >7 	Trailmaking B	<ul style="list-style-type: none"> • Urban <ul style="list-style-type: none"> ○ Medium PbB OR: 0.97 (0.40, 2.40) ○ High PbB OR: 0.79 (0.20, 3.04) • Rural <ul style="list-style-type: none"> ○ Medium PbB OR: 2.05 (1.05, 4.02)* ○ High PbB OR: 2.60 (1.04, 6.49)*
		Digit symbol (correct)	<ul style="list-style-type: none"> • Urban <ul style="list-style-type: none"> ○ Medium PbB OR: 0.61 (0.25, 1.50) ○ High PbB OR: 0.64 (0.16, 2.47) • Rural <ul style="list-style-type: none"> ○ Medium PbB OR: 2.03 (1.06, 3.88)* ○ High PbB OR: 3.73 (1.57, 8.84)*
		Incidental memory	<ul style="list-style-type: none"> • Urban <ul style="list-style-type: none"> ○ Medium PbB OR: 0.50 (0.22, 1.16) ○ High PbB OR: 0.99 (0.28, 1.16) • Rural <ul style="list-style-type: none"> ○ Medium PbB OR: 1.37 (0.77, 2.41) ○ High PbB OR: 1.89 (0.83, 3.41)

2. HEALTH EFFECTS

Table 2-32. Summary of Epidemiology Studies Evaluating Neurodevelopmental Effects in Adults at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Payton et al. 1998 Longitudinal study, n=141 males, mean age 67 years	Mean (SD): • 5.5 (3.5) • Q1: 1.4 • Q2: 3.5 • Q3: 5.4 • Q4: 9.8	Pattern recognition	• β (95% CL): 0.074 (0.032) , p=0.02*
		Vocabulary	• β (95% CL): -0.841 (0.20) , p=0.0001*
		Word list memory	• β (95% CL): -0.182 (0.086) , p=0.036*
		Boston naming test	• β (95% CL): -0.036 (0.016) , p=0.028*
		Verbal fluency	• β (95% CL): -0.230 (0.120), p=0.09
Power et al. 2014 Longitudinal study, n=584 adults females, mean age 61 years	Mean (SD): • 2.9 (1.9) Tibia Pb ($\mu\text{g}/\text{g}$): Mean (SD): • 10.5 (9.7) Patella Pb ($\mu\text{g}/\text{g}$) mean (SD): • 12.6 (11.7)	Overall cognition	β for 1-age year change in score per 1 SD PbB: -0.013 (-0.044, 0.017)
		Verbal memory	β for 1-age year change in score per 1 SD PbB: 0.006 (-0.037, 0.050)
Seo et al. 2014 Cross-sectional study, n=31 retired female Pb workers, mean age 60.4 years, and 34 controls	Gmean (range): Exposed: 4.07 (0.88–13.5) Controls: 2.00 (1.24–6.47)	Verbal memory	Accuracy % (SD), exposed versus control: • 1-back test: 55.9 (19.8) versus 65.4 (19.4), p=0.056 • 2-back test: 61.4 (20.1) versus 77.2 (15.6) , p=0.001*

2. HEALTH EFFECTS

Table 2-32. Summary of Epidemiology Studies Evaluating Neurodevelopmental Effects in Adults at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^c
Shih et al. 2006 Cross-sectional study, n=985 adults, mean age 59.4 years	Mean (SD): • 3.46 (2.23) Tibia Pb ($\mu\text{g/g}$) mean (SD): • 18.72 (11.24)	Language	• β per 1 $\mu\text{g/g}$ tibia Pb: -0.0083 (0.0023), $p \leq 0.01^*$
		Processing speed	• β per 1 $\mu\text{g/g}$ tibia Pb: -0.0042 (0.0021), $p < 0.01^*$
		Eye-hand	• β per 1 $\mu\text{g/g}$ tibia Pb: -0.0079 (0.0020), $p \leq 0.01^*$
		Executive function	• β per 1 $\mu\text{g/g}$ tibia Pb: -0.0075 (0.0019), $p \leq 0.01^*$
		Verbal memory and learning	• β per 1 $\mu\text{g/g}$ tibia Pb: -0.0078 (0.0024), $p \leq 0.01^*$
		Visual memory	• β per 1 $\mu\text{g/g}$ tibia Pb: -0.0067 (0.0023), $p \leq 0.01^*$
		Visuoconstruction	• β per 1 $\mu\text{g/g}$ tibia Pb: -0.0122 (0.0027), $p \leq 0.01^*$
Weisskopf et al. 2007 Longitudinal study cohort, n=1,089 males, mean age 68.7 years	Median (IQ range): • 5 (3–6) Tibia Pb ($\mu\text{g/g}$) median (IQ range): • 20 (13–28) Patella Pb ($\mu\text{g/g}$) median (IQ range): • 25 (17–37)	Vocabulary	β per 3 $\mu\text{g/dL}$ increase in PbB: -1.26 (-2.08, -0.44), $p=0.003^*$
		Visuoconstruction (patella Pb)	β per IQR: -0.067 (-0.11, -0.02), $p=0.0041^*$
		Pattern comparison latency (tibia Pb)	β: 0.079 (0.04, 0.12), $p=0.0004^*$
Weuve et al. 2006 Longitudinal study cohort, n=915 males, mean age 68.7 years	Median (IQ range): • 5.2 (2.9) • 94% <10	Cognitive function	Change in MMSE score per IQR in PbB, 3 $\mu\text{g/dL}$: • ALAD-2: IQR (95% CL): -0.29 (-0.56, -0.02)* • ALAD wildtype: IQR (95% CL): -0.05 (-0.16, 0.06)

2. HEALTH EFFECTS

Table 2-32. Summary of Epidemiology Studies Evaluating Neurodevelopmental Effects in Adults at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^c
Weuve et al. 2009 Longitudinal study cohort, n=587 females, mean age 61 years	Mean (SD): • 2.9 (1.9) Tibia Pb ($\mu\text{g/g}$) median (SD): • 10.5 (9.7) Patella Pb ($\mu\text{g/g}$) median (SD): • 12.6 (11.6)	Cognitive function	Change in score per 1 SD in PbB or bone Pb: • PbB: -0.016 (-0.071, 0.039), p=0.57 • Tibia: -0.051 (-0.099, -0.003), p=0.04* • Patella Pb: -0.033 (-0.080, 0.014), p=0.17
Wright et al. 2003b Longitudinal study cohort, n=736 males, mean age 68.2 years	Mean (SD): • All: 4.5 (2.5) • Q1: 2.5 • Q2: 4.0 • Q3: 5.9 • Q4: 8.9 Tibia Pb ($\mu\text{g/g}$) median (SD): • 22.4 (15.3) Patella Pb ($\mu\text{g/g}$) median (SD): • 29.5 (21.2)	MMSE score	Adjusted OR with 1 $\mu\text{g/dL}$ increase in PbB or 1 $\mu\text{g/g}$ increase in bone Pb: • PbB: 1.21 (1.07, 1.36)* • Patella Pb: 1.02 (1.00, 1.03)* • Tibia Pb: 1.02 (1.00, 1.04)* Effect of age increased with increasing PbB. β for age with increasing Pb for PbB quartile (95% CL): • Q1 -0.04 (-0.07, -0.02)* • Q2 -0.04 (-0.08, -0.01)* • Q3 -0.09 (-0.13, -0.06)* • Q4 -0.12 (-0.17, -0.02)*

2. HEALTH EFFECTS

Table 2-32. Summary of Epidemiology Studies Evaluating Neurodevelopmental Effects in Adults at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^c
Mood and behavior			
Bouchard et al. 2009 Cross-sectional study, n=1,987 adults (age 20–39 years)	Gmean \pm GSD (range): <ul style="list-style-type: none"> • 1.24 (1.96) • 99%\leq10 • Q1: 0.6 • Q2: 0.9 • Q3: 1.2 • Q4: 1.3 • Q5: 3.0 	Major depressive disorder	<ul style="list-style-type: none"> • Adjusted ORs for PbB for Q5 relative to Q1: 2.32 (1.13, 4.75); p-trend=0.05* • Eliminating current smokers, adjusted ORs for PbB for Q5 relative to Q1: 2.93 (1.24, 6.92); p-trend=0.03*
		Panic disorder	<ul style="list-style-type: none"> • Adjusted ORs for PbB for Q5 relative to Q1: 4.94 (1.32, 18.48); p-trend=0.02* • Eliminating current smokers, adjusted ORs for PbB for Q5 relative to Q1: 9.57 (1.28, 71.43); p-trend=0.01*
		Generalized anxiety disorder	<ul style="list-style-type: none"> • Adjusted ORs for PbB for Q5 relative to Q1: 1.53 (0.39, 5.96); p-trend=0.78 • Eliminating current smokers, adjusted ORs for PbB for Q5 relative to Q1: 1.59 (0.19, 13.31); p-trend=0.44
Buser and Scinicariello 2017 Cross-sectional study of 3,905 adults (age ≥ 20 years) from NHANES 2011–2012	Cohort stratified into PbB quartiles: <ul style="list-style-type: none"> • Q1: <0.7 • Q2: 0.70–1.06 • Q3: 1.07–1.67 • Q4: >1.67 	Depression	Adjusted OR for depression symptoms in adult females (age 20–47 years) associated with increasing PbB: <ul style="list-style-type: none"> • Q3: 1.86 (1.01, 3.41, p<0.05* • Q4: 2.97 (1.01, 8.74), p<0.05*
Golub et al. 2010 Cross-sectional study of 4,195 adults (age ≥ 20 years) from NHANES 2005–2006	Cohort stratified into PbB quartiles: <ul style="list-style-type: none"> • Q1: <0.88 • Q2: 0.89–1.40 • Q3: 1.41–2.17 • Q4: 2.18–26.4 		Adjusted OR for depression symptoms was elevated in PbB quartile 3 (95% CI): <ul style="list-style-type: none"> • Q3: 1.25 (1.07, 1.47)*

2. HEALTH EFFECTS

Table 2-32. Summary of Epidemiology Studies Evaluating Neurodevelopmental Effects in Adults at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Opler et al. 2004 Case-control study, n=44 schizophrenia cases and 75 matched controls from birth cohorts	Cohort stratified into <15 or ≥ 15 $\mu\text{g}/\text{dL}$ based on 2 nd trimester ALA measurements	Schizophrenia	Adjusted OR for schizophrenia associated with high (≥ 15 $\mu\text{g}/\text{dL}$) prenatal PbB: 2.43 (0.99, 5.96), p=0.051
Opler et al. 2008 Case-control study, n=71 schizophrenia cases and 129 matched controls	Cohort stratified into <15 or ≥ 15 $\mu\text{g}/\text{dL}$ based on 2 nd trimester ALA measurements	Schizophrenia	Adjusted OR for schizophrenia associated with high (≥ 15 $\mu\text{g}/\text{dL}$) prenatal PbB: 1.92 (1.05, 3.87), p=0.03*
Rajan et al. 2007 Longitudinal study cohort, n=1,075 males, mean age 67.1 years	Mean (SD): • All: 6.2 (4.1) Tibia Pb ($\mu\text{g}/\text{g}$) median (SD): • 22.1 (13.8) Patella Pb ($\mu\text{g}/\text{g}$) median (SD): • 31.4 (19.6)	Somatization, tibia Pb	Adjusted OR for inter quartile increases in tibia Pb (14 $\mu\text{g}/\text{g}$) or patella Pb (20 $\mu\text{g}/\text{g}$): 1.21 (1.01, 1.46)*
		Global severity index, patella Pb	OR: 1.23 (1.02, 1.47)*
Rhodes et al. 2003 Longitudinal study cohort, n=526 males, mean age 67.1 years	Mean (SD): • 6.3 (4.2) Tibia Pb ($\mu\text{g}/\text{g}$) median (SD): • 21.9 (13.5) Patella Pb ($\mu\text{g}/\text{g}$) median (SD): • 32.1 (19.8)	Phobic anxiety	Adjusted OR (95% CL) for inter quintile increases in patella Pb (8.9 $\mu\text{g}/\text{dL}$): 1.91 (1.01, 3.61)*
		Combined symptoms	Adjusted OR (95% CL) for inter quintile increases • PbB OR: 2.91 (1.39, 6.09)* • Tibia Pb OR: 2.08 (1.06, 4.07)* • Patella Pb OR: 3.62 (1.62, 8.08)*

2. HEALTH EFFECTS

Table 2-32. Summary of Epidemiology Studies Evaluating Neurodevelopmental Effects in Adults at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Scinicariello and Buser 2015 Cross-sectional study of 2,892 adults (age 20–39 years) from NHANES 2007–2010	PbB: Gmean (GSD) • 0.96 (0.02).	Depression	Adjusted OR for depression symptoms was not associated with increasing PbB (ORs were not reported).
Neuromotor neurosensory function			
Hwang et al. 2009 Cross-sectional study, n=259 male steel workers, mean age 36.0 years	Mean (SD): 5.43 (3.46)	Hearing loss	Adjusted OR for hearing loss (>25 dB) at 3,000–8,000 Hz in PbB categories relative to ≤ 4 $\mu\text{g}/\text{dL}$: Loss at 3000 Hz • 4–7 $\mu\text{g}/\text{dL}$: 0.75 (0.17, 3.29) • ≥ 7 $\mu\text{g}/\text{dL}$: 4.49 (1.28, 15.8); p<0.005* Loss at 4000 Hz: • 4–7 $\mu\text{g}/\text{dL}$: 3.54 (1.40, 8.97)* (p-value not reported) • ≥ 7 $\mu\text{g}/\text{dL}$: 6.26 (2.35, 16.6); p<0.005* Loss at 6000 Hz: • 4–7 $\mu\text{g}/\text{dL}$: 2.11 (0.94, 4.47) • ≥ 7 $\mu\text{g}/\text{dL}$: 3.06 (1.27, 7.39); p<0.05*
Ji et al. 2013 Cross-sectional study, n=1,795 males and 1,798 females, age >50 years (median 61.2)	Mean (SD): • Females: 2.17 (0.06) • Males: 3.18 (0.12)	Walking speed	Mean change in walking speed (ft/sec) for PbB quintile relative to Q1 (≤ 1.2 $\mu\text{g}/\text{dL}$): • PbB 1.3– ≤ 1.6 . β : -0.024 (-0.112, 0.064), p=0.58 • PbB 1.7– ≤ 2.1 . β : -0.027 (-0.118, 0.063), p=0.54 • PbB 2.2–≤ 2.9. β: -0.104 (-0.187, -0.021), p=0.02* • PbB 3.3–≤ 53.0. β: -0.114 (-0.191, -0.038), p=0.01* • P-trend=0.005*

2. HEALTH EFFECTS

Table 2-32. Summary of Epidemiology Studies Evaluating Neurodevelopmental Effects in Adults at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Ji et al. 2015 Longitudinal study cohort, n=807 males, mean age 69 years	Mean (SD): 5.0 (2.7) • % <10: 96% Bone Pb, $\mu\text{g}/\text{g}$ (SD) • Patella: 28.0 (18.4) Tibia: 21.2 (13.3)	Tremor	OR for tremor by PbB quintile (95% CL): • Q5 (8–28), PbB: 0.84 (0.38, 1.86), $p=0.72$ • Q5 (40–165), patella Pb: 0.83 (0.31, 2.19), $p=0.41$ • Q5 (30–126): tibia Pb: 1.08 (0.46, 2.53), $p=0.60$
Muldoon et al. 1996 Cross-sectional study, n=530 adult women, mean age 70 years	Mean (SD): • All: 4.8 (0.4) • Rural: 4.5 (0.4) • Urban: 5.4 (0.4) • Low: <4 • Medium: 4–7 • High: >7	Pegboard	OR for poor performance (low PbB reference) in the rural cohort: ANOVA, $p=0.98$ • Medium PbB: OR (95% CL): 1.37 (0.71, 2.65) • High PbB: OR (95% CL): 1.16 (0.45, 3.01)
		Upper extremity	ANOVA, $p<0.01$, in the rural cohort • Medium PbB: OR (95% CL): 1.39 (0.73, 2.65) • High PbB: OR (95% CL): 2.43 (1.01, 5.83)*
		Lower extremity	ANOVA, $p<0.01$, in the rural cohort • Medium PbB: OR (95% CL): 1.29 (0.68, 2.47) • High PbB: OR (95% CL): 2.84 (1.19, 6.74)*
Neurological disease			
Fang et al. 2010 Case-control study, n=184 male ALS cases and 194 matched controls, mean age 63 years	Mean (range): • Controls: 1.76 (0.32– 6.90) • Cases: 2.41 (0.72– 7.58)	ALS	Adjusted OR for ALS for doubling of PbB: • All cases (n=184): 1.9 (1.3, 2.7)* • Excluding progressive muscular atrophy and primary lateral sclerosis (n=151): 1.8 (1.2, 2.5)*

2. HEALTH EFFECTS

Table 2-32. Summary of Epidemiology Studies Evaluating Neurodevelopmental Effects in Adults at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Kamel et al. 2002 Case-control study, n=109 ALS cases and 256 matched controls, age 30–80 years	Mean (range): <ul style="list-style-type: none"> Cases: 3 of 194 had PbB >10 Controls: <10 $\mu\text{g}/\text{dL}$ 	ALS	<ul style="list-style-type: none"> Adjusted OR for ALS (for a 1 $\mu\text{g}/\text{dL}$ increase in PbB: 1.9 (1.4, 2.6)* Adjusted OR for ALS relative to <2 $\mu\text{g}/\text{dL}$: <ul style="list-style-type: none"> 3–4 $\mu\text{g}/\text{dL}$: 14.3 (3.0, 69.3)* 5–14 $\mu\text{g}/\text{dL}$: 24.5 (4.3, 139.3)*

^aSee the *Supporting Document for Epidemiological Studies for Lead*, Table 10 for more detailed descriptions of studies.

^bParticipants had no known occupational exposure to Pb.

^cAsterick indicates association with Pb; unless otherwise specified, values in parenthesis are 95% CIs.

ALA = aminolevulinic acid; ALAD-2 = delta-aminolevulinic acid dehydratase allele; ALS = amyotrophic lateral sclerosis; ANOVA = analysis of variance; CI = confidence interval; CL = confidence limit; Gmean = geometric mean; GSD = geometric standard deviation; IQ = intelligence quotient; IQR = interquartile range; MMSE = Mini-Mental Status Examination; OR = odds ratio; Pb = lead; RR = relative risk; SD = standard deviation; SE = standard error

2. HEALTH EFFECTS

associations ($p \leq 0.05$) between performance on cognitive tests and increasing tibia Pb, but not for PbB (Shih et al. 2006). The cohort mean blood Pb was 3.46 ± 2.2 (SD) $\mu\text{g/dL}$. Cognitive function evaluated included language, processing speed, executive function, verbal memory and learning, and visuoconstruction. The effect sizes were substantially attenuated by race/ethnicity and years of educational and were no longer significant ($p < 0.05$) when adjusted for these covariates. A cross-sectional study of approximately 500 adult females from the Study of Osteoporotic Fractures found significant associations ($p \leq 0.05$) between performance on cognitive tests and increasing PbB (Muldoon et al. 1996). The odds of performing worse on visual attention and short-term memory tests were significantly decreased ($p \leq 0.05$) in a PbB stratum 4–7 and to >7 $\mu\text{g/dL}$ compared to stratum <4 $\mu\text{g/dL}$.

Altered mood and behavior. Several studies have examined associations between Pb exposure assessed from blood or bone Pb and symptoms of psychiatric disorders (Table 2-32). Several studies have analyzed cross-sectional data from NHANES to explore associations between depression symptoms and PbB (Bouchard et al. 2009; Buser and Scinicariello 2017; Golub et al. 2010; Scinicariello and Buser 2015). Three studies found associations between PbB and depression in adult populations that had geometric mean PbBs that were 2–3 $\mu\text{g/dL}$ compared to populations that have PbBs <1 (Bouchard et al. 2009; Buser and Scinicariello 2017; Golub et al. 2010). Buser and Scinicariello (2017) found stronger associations in adult women than in men. Associations between psychiatric disorders and Pb exposure metrics have also been studied in longitudinal studies (Rajan et al. 2007; Rhodes et al. 2003). Two studies of cohorts from the Normative Aging Study found significant ORs for blood or bone Pb and various psychiatric symptoms in males (mean age 67 ± 7 , SD), including somatization, phobic anxiety, and composite indices of distress. Mean PbBs in these cohorts were 6 ± 4 (SD) $\mu\text{g/dL}$. Associations between PbB and psychiatric disorders have also been found in case-control studies (Opler et al. 2004, 2008). The largest was a study of 71 schizophrenia cases and 129 matched controls (Opler et al. 2008). The adjusted OR for schizophrenia was 1.92 (95% CI 1.05, 3.87) for the PbB stratum ≥ 15 $\mu\text{g/dL}$ compared to 15 $\mu\text{g/dL}$. Because individual PbB data were not available, subjects were categorized into the high (<15 $\mu\text{g/dL}$) or low (15 $\mu\text{g/dL}$) PbB categories based on measurements of serum ALA and a regression model relating PbB and ALA derived from a different population (Graziano et al. 1990). Although the accuracy of the method for assigning subjects from Graziano et al. (1990) into low or high categories was, on average, approximately 90%, uncertainty in the actual regression model is likely to have resulted in some misclassification of individuals.

Altered neuromotor neurosensory function. Several studies have examined associations between Pb exposure assessed from blood or bone Pb and performance on tests of neuromotor or neurosensory

2. HEALTH EFFECTS

function (Table 2-32). The largest study analyzed data from NHANES III (1988–1994) and found no association ($p=0.34$) between concurrent PbB and simple visual reaction time in a cohort of 5,700 adults (age 20–50 years; Krieg et al. 2005). The geometric mean PbB was 2.51 $\mu\text{g/dL}$ (range 0.7–42) and 96% of the cohort was $<10 \mu\text{g/dL}$. A more recent analysis of data from NHANES (1999–2002) examined walking speed in cohorts of approximately 1,800 males or females and found a significant association between increasing PbB and decreasing walking speed in females in a PbB stratum 2.2– \leq 2.9 $\mu\text{g/dL}$ compared to 1.6 $\mu\text{g/dL}$; there was a significant trend with increasing PbB (Ji et al. 2013). This outcome is consistent with a smaller cross-sectional study of women (mean age 70 ± 4 years) that found significant decreases in upper and lower extremity reaction times in association with increasing PbB (Muldoon et al. 1996). A longitudinal study of a cohort from the Normative Aging Study found no significant associations between bone or blood Pb and hand tremor in males (mean age 60 ± 7 years; Ji et al. 2015). The mean PbB for the cohort was 5.0 ± 2.7 (SD) $\mu\text{g/dL}$.

Neurological diseases. Possible associations between Pb exposure and risk of ALS have been examined in case-control studies (Fang et al. 2010; Kamel et al. 2002). A case-control study of 184 male ALS cases and 194 matched controls found a significant association between increasing PbB and ALS (Fang et al. 2010). The mean PbB for cases was 2.41 $\mu\text{g/dL}$ (range 0.72–7.58 $\mu\text{g/dL}$). A case-control study of 109 ALS cases (43 females, 66 males) and 194 matched controls estimated the OR for ALS to be 1.9 (95% CL 1.4, 2.6) for a 1 $\mu\text{g/dL}$ increase in PbB (Kamel et al. 2002).

Associations Between Bone Pb and Neurological Effects in Adults. Decrements in neurological function in adults have also been associated with bone Pb (Table 2-33). In general, these studies provide further support for associations between Pb exposure and neurobehavioral function, including decrements in cognitive function, altered neuromotor and neurosensory function, and altered behavior and mood. Most of these studies are of cohorts from longitudinal health studies: Boston Memory Study (Bandeem-Roche et al. 2009; Glass et al. 2009; Shih et al. 2006), Nurses' Health Study (Power et al. 2014; Weuve et al. 2009), or Normative Aging Study (Eum et al. 2013; Grashow et al. 2013a, 2013b, 2015; Ji et al. 2015; Park et al. 2010; Payton et al. 1998; Power et al. 2014; Rajan et al. 2007, 2008; Rhodes et al. 2003; Schwartz et al. 2005; Wang et al. 2007; Weisskopf et al. 2004, 2007; Wright et al. 2003b). These studies have provided both cross-sectional and longitudinal assessments of associations between bone Pb (and PbB) and neurological function in adult populations. Longitudinal designs are particularly important because they allow age-related declines in cognitive function to be assessed. Longitudinal studies have found that associations between bone Pb and cognitive function (learning, memory) persist when adjustments are made for age (Bandeem-Roche et al. 2009; Dorsey et al. 2006; Eum et al. 2013; Grashow

2. HEALTH EFFECTS

et al. 2013a; Khalil et al. 2009; Payton et al. 1998; Power et al. 2014; Rajan et al. 2008; Schwartz et al. 2005; Seegal et al. 2013; Shih et al. 2006; Stewart et al. 2002; van Wijngaarden et al. 2009; Weisskopf et al. 2007; Weuve et al. 2009, 2013; Wright et al. 2003b). Rates of decrement in cognitive function with age have been found to be more severe in association with increasing bone Pb (Power et al. 2014; Schwartz et al. 2005; Wang et al. 2007; Weisskopf et al. 2004, 2007; Wright et al. 2003b).

Table 2-33. Associations Between Bone Pb and Neurological Outcomes in Adults

Reference	Population	Neurological outcome			Outcome measures
		Intellectual deficits	Altered neuromotor or neurosensory function	Altered mood or behavior	
Bandeem-Roche et al. 2009	965 adults, age: 50–70 years ^a	↑ T	–	–	Learning, memory, executive function, eye-hand coordination
Coon et al. 2006	121 adult cases, 414 controls, age: 50–>80 years	–	↑ 0 ^d	–	Parkinson's disease
Dorsey et al. 2006	652 adult lead workers, age: 20–70 years	↑ P ↑ T	↑ P ↑ T	↑ P ↑ T	Reaction time, executive function, manual dexterity, vibration threshold, depression
Eum et al. 2013	789 adult males ^b , age: 68 years (median)	↑ P ↑ T	–	–	Memory, verbal and written skills, executive function
Eum et al. 2015	100 adult cases, 194 controls, age: 60 years (mean)	–	↑ P ↑ T	–	Interaction between lead, amyotrophic lateral sclerosis and hemochromatosis gene polymorphisms
Glass et al. 2009	1,001 adults ^a , age: 50–70 years	↑ T	↑ T	–	Interaction between lead and psychosocial hazard scale for eye-hand coordination, executive function, language

2. HEALTH EFFECTS

Table 2-33. Associations Between Bone Pb and Neurological Outcomes in Adults

Reference	Population	Neurological outcome			
		Intellectual deficits	Altered neuromotor or neurosensory function	Altered mood or behavior	Outcome measures
Grashow et al. 2013a	51 adult males ^b , age: 75 years (mean)	↑ P 0 T	–	–	Fear conditioning
Grashow et al. 2013b	362 adult males ^b , age: 69 years (mean)	–	↑ P ↑ T	–	Manual dexterity
Grashow et al. 2015	164 adult males ^b , age: 80 years (mean)	–	0 P ↑ T	–	Olfactory function
Ji et al. 2015	672 adult males ^b , age: 50–98 years	–	0 P 0 T	–	Tremor (no association in adjusted models)
Kamel et al. 2002	109 adult cases, 256 controls, age: 30–80 years	–	0 P 0 T	–	Amyotrophic lateral sclerosis (no association in adjusted models)
Khalil et al. 2009	83 adult workers and 51 controls, age: >55 years	↑ T	–	–	Learning, memory
Park et al. 2010	448 adult males ^b , age: 65 years (mean)	–	↑ P ↑ T	–	Hearing function
Payton et al. 1998	141 adult males ^b , age: 67 years (mean)	↑ T	–	–	Memory, visual-spatial performance
Power et al. 2014	584 adult females ^c , age: 60–74 years	0 P 0 T	–	–	Learning, memory, executive function
Rajan et al. 2007	1,075 adult males ^b , age: 48–94 years	–	–	↑ P ↑ T	Psychiatric symptoms
Rajan et al. 2008	982 adult males ^b , age: 49–>72 years	0 P ↑ T	–	–	Visual-spatial performance
Rhodes et al. 2003	536 adult males ^b , age: 48–70 years	–	–	↑ P ↑ T	Anxiety
Schwartz et al. 2000b	535 lead workers,	↑ T	↑ T	–	Memory, executive function, manual

2. HEALTH EFFECTS

Table 2-33. Associations Between Bone Pb and Neurological Outcomes in Adults

Reference	Population	Neurological outcome			
		Intellectual deficits	Altered neuromotor or neurosensory function	Altered mood or behavior	Outcome measures
	age: 56 years (mean)				dexterity
Schwartz et al. 2001	803 exposed lead workers and 135 controls, age: 40 years (mean)	0 T	0 T	0 T	Learning, memory, executive function, manual dexterity, grip strength, mood and depression
Schwartz et al. 2005	576 exposed lead workers, age: 41 years (mean)	↑ T	↑ T	↑ T	Executive function, manual dexterity, vibration threshold, depression
Seegal et al. 2013	241 capacitor workers, age: 64 years (mean)	↑ T	↑ T	–	Learning, memory, executive function, manual dexterity
Shih et al. 2006	991 adults ^a , age: 50–70 years	↑ T	↑ T	–	Learning, memory, executive function, manual dexterity
Stewart et al. 2002	529 lead workers, age: 40–>70 years	↑ T	↑ T	–	Learning, memory, executive function, reaction time, manual dexterity
van Wijngaarden et al. 2009	47 adults, age: 55–67 years	↑ C	–	–	Learning, memory
Wang et al. 2007	358 adult males ^b , age: 67 years (median)	↑ T	–	–	Interaction between lead and hemochromatosis gene polymorphisms on learning, memory, executive function
Weisskopf et al. 2004	466 adult males ^b , age: 68 years (mean)	↑ P	–	–	Memory, verbal and written skills, executive function
Weisskopf et al. 2007	761 adult males ^b , age: 69 years (mean)	↑ P ↑ T	–	–	Memory, visual-spatial performance
Weisskopf et al. 2010	330 adult cases and 308 controls,	–	↑ T	–	Parkinson's disease

2. HEALTH EFFECTS

Table 2-33. Associations Between Bone Pb and Neurological Outcomes in Adults

Reference	Population	Neurological outcome			
		Intellectual deficits	Altered neuromotor or neurosensory function	Altered mood or behavior	Outcome measures
	age: 67 years (mean)				
Weuve et al. 2009	587 adult females ^c , age: 47–74 years	0 P ↑ T	–	–	Learning, memory
Weuve et al. 2013	101 cases and 50 controls, age: 55–80 years	0 P ↑ T	–	–	Learning, memory (stronger association with lead among Parkinson's disease cases)
Wright et al. 2003b	736 adult males ^b , age: 68 years (mean)	↑ P ↑ T	–	–	Memory, verbal and written skills, executive function

^aBoston Memory Study.

^bNormative Aging Study.

^cNurses Health Study.

^dWhole-body lead predicted from bone lead.

↑ = positive association; ↓ = negative association; 0 = no association; – = not reported; C = calcaneous bone; P = patella; Pb = lead; T = tibia; O = other

Bone Pb has been associated with declines in neuromotor and neurosensory function. Neuromotor outcomes that have been associated with bone Pb include tremor, Parkinson's disease, and ALS (Coon et al. 2006; Eum et al. 2015; Weisskopf et al. 2010; Weuve et al. 2013). Neurosensory outcomes include decrements in olfactory and hearing function, vibration threshold, and manual dexterity (Dorsey et al. 2006; Grashow et al. 2013b, 2015; Park et al. 2010; Schwartz et al. 2000b; 2005; Shih et al. 2006; Stewart et al. 2002). Bone Pb has also been associated with increased risk or odds of psychiatric symptoms such as anxiety and depression (Dorsey et al. 2006; Rajan et al. 2007; Rhodes et al. 2003; Schwartz et al. 2005).

Mechanisms of Action. Numerous cellular mechanisms are likely involved in Pb-induced alterations in neurological function. Pb disrupts cellular function through diverse mechanisms, including displacement of metal ion co-factors from protein, enzyme inhibition, inhibition of ion transport, disruption of cell and

2. HEALTH EFFECTS

mitochondrial membrane potentials, disruption of intracellular calcium homeostasis oxidative stress, and inflammation and endocrine disruption (see Section 2.21). All of these Pb mechanisms have been demonstrated in neuronal tissues, although there is no consensus on which mechanisms dominate. Evidence for various mechanisms that may participate in Pb neurotoxicity are summarized in this section. The reader is referred to references cited therein for more detailed information (Bouton and Pevsner 2000; Bressler et al. 1999; Cory-Slechta 1995, 2003; EPA 2014c; Gilbert and Lasley 2002; Lasley and Gilbert 2000; Nihei and Guilarte 2002; Suszkiw 2004; Toscano and Guilarte 2005; Zawia et al. 2000; Zhang et al. 2015).

Pb can affect the nervous system by multiple mechanisms, one of the most important of which is by mimicking calcium action and/or disruption of calcium homeostasis. Because calcium is involved as a cofactor in many cellular processes, it is not surprising that many cell-signaling pathways are affected by Pb. One pathway that has been studied in more detail is the activation of protein kinase C (PKC). PKC is a serine/threonine protein kinase involved in many processes important for synaptic transmission such as the synthesis of neurotransmitters, ligand-receptor interactions, conductance of ionic channels, and dendritic branching. The PKC family is made up of 12 isozymes, each with different enzymatic cofactor requirements, tissue expression, and cellular distributions. The γ -isoform is one of several calcium-dependent forms of PKC and is a likely target for Pb neurotoxicity; it is neuron-specific and is involved in long-term potentiation (see below), spatial learning, and memory processes. Pb has the capacity to both activate and inhibit PKCs. Studies have shown that micromolar concentrations of Pb can activate PKC-dependent phosphorylation in cultured brain microvessels, whereas picomolar concentrations of Pb activate preparations of PKC *in vitro*. Interestingly, studies in rats exposed to low Pb levels have shown few significant changes in PKC activity or expression, suggesting that the whole animal may be able to compensate for Pb PKC-mediated effects compared to a system *in vitro*. PKC induces the formation of the AP-1 transcriptional regulatory complex, which regulates the expression of a large number of target genes via AP-1 promoter elements. A gene regulated by Pb via AP-1 promoters is the glial fibrillary acidic protein (GFAP), an astrocytic intermediate filament protein that is induced during periods of reactive astrocytic gliosis. Astrocytes, along with endothelial cells, make up the blood-brain barrier. Studies in rats exposed chronically to low Pb levels have reported alterations in the normal pattern of GFAP gene expression in the brain, and the most marked long-lasting effects occurred when the rats were exposed during the developmental period. In immature brain microvessels, most of the protein kinase C is in the cytosol, whereas in mature brain microvessels, this enzyme is membrane-bound. Activation of protein kinase C in other systems is known to result in a change in distribution from cytosol to membrane, and has been observed with exposure of immature brain microvessels to Pb. An inhibition of

2. HEALTH EFFECTS

microvascular formation has been observed with Pb concentrations that are effective in activating PKC. Thus, it appears that premature activation of PKC by Pb may impair brain microvascular formation and function, and at high levels of Pb exposure, may account for gross defects in the blood-brain barrier that contribute to acute Pb encephalopathy. The blood-brain barrier normally excludes plasma proteins and many organic molecules, and limits the passage of ions. With disruption of this barrier, molecules such as albumin freely enter the brain, and ions and water follow. Because the brain lacks a well-developed lymphatic system, clearance of plasma constituents is slow, edema occurs, and intracranial pressure rises. The particular vulnerability of the fetus and infant to the neurotoxicity of Pb may be due in part to immature brain microvessels, which affect the blood brain barrier, and to the lack of the high-affinity Pb-binding protein in astroglia, which sequester Pb.

Another enzyme altered by Pb is calmodulin, a major intracellular receptor for calcium in eukaryotes. Normally, calcium induces a conformational change in calmodulin that converts the protein to an active form; Pb improperly activates the enzyme. Some studies suggest that activation of calmodulin by Pb results in protein phosphorylation in the rat brain and brain membrane preparations and can alter proper functioning of cAMP messenger pathways. It has been shown that calmodulin can mediate gene expression via calmodulin-dependent kinases. The effects of Pb on gene expression via activation of calmodulin are not as marked as those via PKC because activation of calmodulin requires 100-fold more Pb than activation of PKC.

Pb also can substitute for zinc in some enzymes and in zinc-finger proteins, which coordinate one or more zinc cations as cofactors. The substitution of Pb for zinc in zinc-finger proteins can have significant effects on *de novo* expression of the bound proteins and in any genes transcriptionally-regulated by a particular protein. Pb has been found to alter the binding of zinc-finger transcriptional regulator Sp1 to its specific DNA sequences. This is accompanied by aberrant expression of Sp1 target genes such as myelin basic protein and proteolipid protein. Another gene regulated by Sp1 is the β -amyloid precursor protein (APP) gene. Recently, it was shown that Pb exposure in neonatal rats transiently induces APP mRNA, which is overexpressed with a delay of 20 months after exposure to Pb has ceased. In contrast, APP expression, and Sp1 activity, as well as APP and β -amyloid protein levels, were unresponsive to Pb during old age, suggesting that exposures occurring during brain development may predetermine the expression and regulation of APP later in life. It has been suggested that the multiple responses to Pb exposure are due to Pb specifically targeting zinc-finger proteins found in enzymes, channels, and receptors.

2. HEALTH EFFECTS

Pb affects virtually every neurotransmitter system in the brain, but most information on changes is available on the glutamatergic, dopaminergic, cholinergic, and gamma-aminobutyric acid (GABA). Of these, special attention has been paid to the glutamatergic system and its role in hippocampal long-term potentiation (LTP). Hippocampal LTP is a cellular model of learning and memory characterized by a persistent increase in synaptic efficacy following delivery of brief tetanic stimulation (high-frequency stimulation). LTP provides a neurophysiological substrate for learning and storing information and is thought to utilize the same synaptic mechanisms as the learning process. LTP is established only with complex patterns of stimulation but not with single pulse stimulation. While it has been studied primarily in the hippocampal subregions CA1 and dentate gyrus, it can also be evoked in cortical areas. Exposure of intact animals or tissue slices to Pb diminishes LTP by a combination of three actions: increasing the threshold for induction, reducing the magnitude of potentiation, and shortening its duration by accelerating its rate of decay. This effect on LTP involves actions of Pb on glutamate release (presynaptic effects) and on the N-methyl-D-aspartate (NMDA) receptor function. Pb exposure inhibits release of glutamate from pre-synaptic endings, which may be mediated, in part, by altered pre-synaptic vesicle formation or activation. Studies have shown that the effects of Pb vary as a function of the developmental exposure period and that Pb exposure early in life is critical for production of impaired LTP in adult animals. LTP is more readily affected by Pb during early development, but exposure initiated after weaning also affects synaptic plasticity. Studies also have shown that both LTP magnitude and threshold exhibit a U-shape type response with increasing Pb doses. While LTP is primarily a glutamatergic phenomenon, it can be modulated through input from extrahippocampal sources including noradrenergic, dopaminergic, and cholinergic sources.

Studies in animals treated with Pb (PbB 30–40 µg/dL) have shown that induction of pair-pulse facilitation in the dentate gyrus is impaired. Since the phenomenon is mediated primarily by increased glutamate release, the reasonable assumption is that Pb reduces glutamate release. Support for this assumption is also derived from studies in which depolarization-induced hippocampal glutamate release was reduced in awake animals with similar PbB. This inhibition of glutamate release was shown to be due to Pb-related decrements in a calcium-dependent component. The exact mechanism for the inhibition of glutamate release by Pb is not known, but is consistent with Pb at nanomolar concentrations preventing maximal activation of PKC, rather than Pb blocking calcium influx into the presynaptic terminal through voltage-gated calcium channels. Reduced glutamate release can be observed in rats exposed from conception through weaning and tested as adults, when Pb was no longer present, suggesting that a direct action of Pb is not necessary and that other mechanisms, such as reductions in synaptogenesis, also may be involved. As with LTP, depolarization-evoked hippocampal glutamate release in rats treated chronically

2. HEALTH EFFECTS

with several dose levels of Pb exhibited a U-shaped response. That is, glutamate release was inhibited in rats treated with the lower Pb doses, but not in those exposed to the higher concentrations of Pb.

Although speculative, this was interpreted as Pb at the higher doses mimicking calcium in promoting transmitter release and overriding the inhibitory effects of Pb that occur at lower Pb levels.

The findings regarding the effects of Pb on postsynaptic glutamatergic function have been inconsistent across laboratories, but a direct inhibitory action of Pb on the NMDA receptor is unlikely at environmentally relevant exposure levels. Some studies have shown that continuous exposure of rats from gestation to adulthood results in a significant increase in NMDA receptor numbers in cortical areas, hippocampus, and forebrain. This was observed in the forebrain at PbB of 14 µg/dL. Other studies, however, have reported changes in the opposite direction and the reason for the discrepancy in results may be due to the different exposure protocols used. From a functional point of view, it seems plausible that a Pb-induced reduction in presynaptic transmitter release be compensated by a postsynaptic increase in number or density of receptors in order to maintain a viable function.

The dopaminergic system also has a role in aspects of cognitive function since lesions of dopaminergic neurons impair behavior in various types of learning and cognitive tasks. Also, individuals who suffer from Parkinson's disease, a disease associated with dopamine depletion in the striatum, sometimes show difficulties in cognitive functions. Most of the evidence available suggests that Pb may impair regulation of dopamine synthesis and release, indicating a presynaptic site of action. Studies in animals often report opposing effects of Pb on nigrostriatal and mesolimbic dopamine systems regarding receptor binding, dopamine synthesis, turnover, and uptake. Postweaning exposure of rats to Pb resulted in supersensitivity of D1 and D2 dopamine receptors, which can be interpreted as a compensatory response to decreased synthesis and/or release of dopamine. Lesions to the nucleus accumbens (a terminal dopamine projection area) and the frontal cortex result in perseverative deficits, suggesting that the mesolimbic system is preferentially involved in the effects of Pb. Results of studies using dopaminergic compounds seem to indicate that changes in dopamine systems do not play a role in the effects of Pb on learning. Instead, it has been suggested that changes in dopaminergic systems may play a role in the altered response rates on Fixed-Interval (FI) schedules of reinforcement that have been observed in animals exposed to Pb. This type of change has been thought to represent a failure to inhibit inappropriate responding.

It is widely accepted that the cholinergic system plays a role in learning and memory processes. Some cognitive deficits observed in patients with Alzheimer's disease have been attributed to impaired cholinergic function in the cortex and hippocampus. Exposure to Pb induces numerous changes in

2. HEALTH EFFECTS

cholinergic system function, but the results, in general, have been inconsistently detected, or are of opposite direction in different studies, which may be attributed to the different exposure protocols used in the different studies. However, it is clear that Pb blocks evoked release of acetylcholine and diminishes cholinergic function. This has been demonstrated in central and peripheral synapses. Studies with the neuromuscular junction showed that Pb reduces acetylcholine release by blocking calcium entry into the terminal. At the same time, Pb prevents sequestration of intracellular calcium by organelles, which results in increased spontaneous release of the neurotransmitter. Studies *in vitro* show that Pb can block nicotinic cholinergic receptors, but it is unclear whether such effects occur *in vivo* or whether Pb alters the expression of nicotinic cholinergic receptors in the developing brain. Evidence for an involvement in Pb-induced behavioral deficits has been presented based on the observation that intrahippocampal transplants of cholinergic-rich septal and nucleus basalis tissue improve the deficits and that treatment with nicotinic agonists can improve learning and memory impairments following perinatal Pb treatment of rats. Chronic exposure of rats to Pb has resulted in decreased muscarinic-receptor expression in the hippocampus. Whether or not Pb exposure during development alters muscarinic receptor sensitivity is unclear as there are reports with opposite results. The preponderance of the binding data suggests that Pb does not directly affect muscarinic receptors with the exception of the visual cortex, where Pb may have a direct inhibitory effect on muscarinic receptors from rods and bipolar cells of the retina.

Pb exposure decreases spontaneous and evoked release of GABA in rats and in hippocampal cultures and brain slices. In general, GABA functions in the brain as a post-synaptic inhibitory transmitter. The role of changes in GABA release in the neurotoxicity of Pb has not been firmly established.

Various other mechanisms may also contribute to Pb neurotoxicity. Exposure to Pb has also been shown to stimulate inflammation in a variety of tissues, including neuronal tissue (see Section 2.21).

Contributing mechanisms include alterations in levels of ROS, activation of nuclear activation factor NF κ B, cytokine release, and alterations in prostaglandin metabolism. Pb exposure has been shown to alter neuronal nitric oxide signaling (NOS) and the hormone levels regulated by the hypothalamic-pituitary-thyroid axis.

2.17 REPRODUCTIVE

Overview. Numerous epidemiological studies have evaluated effects of Pb on male and female reproductive function. In males, most exposures were occupational, with mean PbB >10 μ g/dL. In general, studies in males show consistent evidence of reproductive effects on sperm (production, motility,

2. HEALTH EFFECTS

viability, and morphology), semen quantity and composition, serum reproductive hormone levels, and fertility, with severity of effects increasing with increasing PbB. In contrast to exposure of males, most exposures of females were non-occupational, with mean PbB ≤ 10 $\mu\text{g/dL}$. Studies investigating effects on serum reproductive hormone levels, fertility, spontaneous abortion, and preterm birth provide mixed results; thus, dose-dependence of effects in females is difficult to assess.

The following reproductive effects in males have been associated with PbB:

- ≤ 10 $\mu\text{g/dL}$:
 - Increased serum testosterone; evaluated in a few studies with mixed results.
 - Effects on sperm (decreased sperm count, concentration, motility, and viability, and increased immature sperm concentration and percentage of morphologically abnormal sperm); evaluated in a few studies with mixed results.
- > 10 $\mu\text{g/dL}$:
 - Altered serum concentrations of reproductive hormones (testosterone, FSH, LH); evaluated in a several studies with mixed results.
 - Effects on sperm (decreased sperm count, concentration, motility, and viability, and increased immature sperm concentration and percentage of morphologically abnormal sperm); corroborated in several studies.
 - Alterations in semen quality (decreased semen volume and altered composition of seminal fluid); evaluated in a few studies.
 - Decreased fertility; evaluated in a few studies.
 - Histopathological changes to the testes (peritubular fibrosis, oligospermia, and vacuolization of Sertoli cells); evaluated in a few studies.

The following reproductive effects in females have been associated with PbB:

- ≤ 10 $\mu\text{g/dL}$:
 - Increased serum levels of estradiol, FSH, and LH; studies have mixed results.
 - Decreased fertility; studies have mixed results.
 - Increased spontaneous abortion; studies have mixed results.
 - Increased preterm birth; studies have mixed results.
 - Decreased age at onset of menopause; demonstrated in a few studies.

2. HEALTH EFFECTS

- >10 µg/dL:
 - Decreased fertility; studies have mixed results.
 - Increased preterm birth; studies have mixed results.

Measures of Exposure. Most studies evaluating effects on male and female reproductive systems used PbB as the biomarker for exposure. More recent studies in men have explored the relationship between the concentration of Pb in semen or spermatozoa and adverse effects (Table 2-34). It has been suggested that semen levels of Pb may be a better biomarker for assessment of male reproductive effects, particularly at low PbB, because no relationship between PbB and Pb levels in semen or spermatozoa has been observed (Hernandez-Ochoa et al. 2005; Mendiola et al. 2011). In women, other biomarkers of exposure include concentration of Pb in plasma (Lamadrid-Figueroa et al. 2007), red blood cells (Perkins et al. 2014), and placenta (Gundacker et al. 2010), and plasma/blood ratio (Lamadrid-Figueroa et al. 2007).

Confounding Factors and Effect Modifiers. Numerous factors may add uncertainty in the interpretation of studies examining associations between PbB and reproductive effects, including overall health, body weight, nutrition, and SES. Exposures to other substances, including recreational drugs, alcohol, therapeutic agents, industrial chemicals, insecticides, and pesticides, also may affect fertility (Foster and Gray 2008). Failure to account for these factors may attenuate or strengthen the apparent associations between Pb exposure and the outcome, depending on the direction of the effect of the variable on the outcome. Some studies examining effects on sperm (discussed below) were conducted on samples obtained at fertility clinics; therefore, other causes for sperm effects could be effect modifiers (additional details are provided in the *Supporting Document for Epidemiological Studies for Lead*, Table 11). In addition, because sperm counts can vary by geographical location, it is important that control and exposed groups are matched for geographic location.

Characterization of Effects in Males. General trends regarding the relationship between PbB and male reproductive effects are shown in Table 2-34. Overall, the dose-effect pattern suggests an increasing severity of toxicity associated with increasing PbB, with effects on sperm at ≤ 10 µg/dL (discussed in more detail below). At increasing PbB, effects become more severe, with decreased fertility observed at PbB >10 µg/dL and histopathological changes of the testes at PbB of approximately 30 µg/dL. Effects on sperm, including decreased sperm count, concentration, motility, and viability, and increased immature sperm concentration and percentage of morphologically abnormal sperm, have been observed at PbB of ≤ 10 –>50 µg/dL (Alexander et al. 1998; Assennato et al. 1987; Bonde et al. 2002; Cullen et al. 1984;

2. HEALTH EFFECTS

Hernández-Ochoa et al. 2005; Kasperczyk et al. 2008; Lancranjan et al. 1975; Lerda 1992; Li et al. 2015; Meeker et al. 2008; Moran-Martinez et al. 2013; Telisman et al. 2007; Wildt et al. 1983). However, a few studies showed no association between PbB and adverse effects on sperm (Lancranjan et al. 1975; Mendiola et al. 2011). Decreased semen volume and altered composition of seminal fluid have been observed at PbB >10 µg/dL (Bonde et al. 2002; Naha and Chowdhury 2006; Telisman et al. 2000; Wildt et al. 1983). Decreased fertility has been reported in association with PbB >10–>50 µg/dL (Sallmén et al. 2000b; Shiao et al. 2004), although no effect on fertility was observed in one study of workers with PbB >40 µg/dL (Coste et al. 1991). Histopathological assessment of biopsied testicular tissue from Pb workers (mean PbB 29.0 µg/dL) showed peritubular fibrosis, oligospermia, and vacuolization of Sertoli cells (Braunstein et al. 1978). Evaluations of associations between PbB and serum levels of reproductive hormones show inconsistent results (Table 2-35). At PbB ≤10 µg/dL, positive associations between PbB and serum testosterone levels have been observed (Kresovich et al. 2015; Lewis and Meeker 2015; Meeker et al. 2010; Telisman et al. 2007), whereas negative associations or no effects were reported at PbB >10 µg/dL. No effects on FSH or LH were reported at PbB ≤10 µg/dL, and inconsistent results were observed at PbB >10 µg/dL. Changes in serum levels of reproductive hormones may indicate disruption of the hypothalamic-pituitary-gonadal axis; however, due to inconsistent findings, an association between PbB and endocrine disruption in males has not been firmly established.

Table 2-34. Overview of Effects on the Male Reproductive System Associated with Chronic Exposure to Lead (Pb)

Mean blood lead concentration (PbB) (µg/dL)	Effects associated with Pb exposure	References
≤10	Effects on sperm (decreased sperm concentration, motility, and viability; increased morphologic abnormalities)	Hernández-Ochoa et al. 2005; Li et al. 2015; Meeker et al. 2008; Telisman et al. 2007
	Effects on hormones (increased serum levels of testosterone and estradiol; decreased serum prolactin and sex-hormone binding globulin)	Kresovich et al. 2015; Lewis and Meeker 2015; Meeker et al. 2010; Telisman et al. 2007
>10–30	Effects on sperm (decreased sperm count, concentration, density, motility, and viability; morphologic abnormalities)	Alexander et al. 1998; Bonde et al. 2002; Moran-Martinez et al. 2013
	Effects on semen (decreased volume)	Bonde et al. 2002
	Decreased fertility	Sallmén et al. 2000b

2. HEALTH EFFECTS

Table 2-34. Overview of Effects on the Male Reproductive System Associated with Chronic Exposure to Lead (Pb)

Mean blood lead concentration (PbB) (µg/dL)	Effects associated with Pb exposure	References
>30–50	Effects on sperm (decreased count, concentration, motility, viability; morphologic abnormalities)	Hsu et al. 2009; Lancranjan et al. 1975; Lerda 1992; Telisman et al. 2000
	Effects on composition of seminal fluid	Telisman et al. 2000
	Effects on hormones (increased estradiol, LH, FSH; decreased testosterone)	Braunstein et al. 1978; Ng et al. 1991; Telisman et al. 2000
	Histopathological changes to testes (peritubular fibrosis, oligospermia, vacuolization of Sertoli cells)	Braunstein et al. 1978
	Decreased fertility	Sallmén et al. 2000b; Shiao et al. 2004
>50	Effects on sperm (decreased count, concentration, motility, viability; morphologic abnormalities)	Assennato et al. 1987; Cullen et al. 1984; Kasperczyk et al. 2008; Lancranjan et al. 1975; Lerda 1992; Naha and Chowdhury 2006; Wildt et al. 1983
	Effects on semen (decreased volume; altered composition)	Naha and Chowdhury 2006; Wildt et al. 1983
	Effects on hormones (altered serum levels of testosterone, FSH, LH, prolactin)	Assennato et al. 1987; Rodamilans et al. 1988
	Decreased fertility	Sallmén et al. 2000b

FSH = follicle-stimulating hormone; LH = luteinizing hormone

Table 2-35. Effects on Reproductive Hormones Associated with Chronic Exposure to Lead (Pb) in Males

PbB (µg/dL)	Hormone							Reference
	T	FSH	LH	E	P	A	SHBG	
≤10	↑	0	–	–	–	0	0	Kresovich et al. 2015
	↑	0	0	–	–	–	0	Meeker et al. 2010
	↑	–	–	↑	0	–	–	Telisman et al. 2007
	↑	–	–	–	–	–	–	Lewis and Meeker 2015
	0	0	0	–	–	–	–	Mendiola e al. 2011
10–30	0	0	0	–	–	–	–	Hsieh et al. 2009a
	0	0	0	–	–	–	–	Alexander et al. 1998

2. HEALTH EFFECTS

Table 2-35. Effects on Reproductive Hormones Associated with Chronic Exposure to Lead (Pb) in Males

PbB (µg/dL)	Hormone							Reference
	T	FSH	LH	E	P	A	SHBG	
30–50	↓	0	0	–	0	–	–	Braunstein et al. 1978
	0	0	0	–	0	–	–	Erfurth et al. 2001
	0	↓	↓	–	–	–	–	Gustafson et al. 1989
	0	↑	↑	–	–	–	–	McGregor and Mason 1990
	↓	↑	↑		0	–	–	Ng et al. 1991
				↑	–	–	–	Telisman et al. 2000
	0	0	0	0	–	–	–	Sadeghnait Haghghi et al. 2013
	↓	–	–	–	–	–	–	Rodamilans et al. 1988

0 = no effect; ↑ = increased serum level; ↓ = decreased serum level; – = not evaluated; A = androstenedione; E = estradiol; FSH = follicle stimulating hormone; LH = luteinizing hormone; P = prolactin; SHBG = sex hormone binding globulin; T = testosterone

Effects in Males at Blood Pb Levels ≤ 10 µg/dL. Cross-sectional studies evaluating adverse effects of non-occupational exposures to Pb on the male reproductive system show that damage to sperm, decreased semen volume, and increased serum testosterone are associated with mean PbB ≤ 10 µg/dL or with Pb concentrations in semen or spermatozoa when PbBs are ≤ 10 µg/dL. Results are summarized in Table 2-36, with study details provided in the *Supporting Document for Epidemiological Studies for Lead*, Table 11. None of the studies evaluated associations between PbB and male fertility parameters (i.e., pregnancy). In general, study populations were small (n=61–240), although two studies using NHANES data were of larger populations (Kresovich et al. 2015; Lewis and Meeker 2015). In addition, for a few studies, participants were selected from infertility clinics and it is unclear how this may have biased study results (Meeker et al. 2008, 2010; Mendiola et al. 2011). Despite these limitations, taken together, results of non-occupational exposure studies support that adverse effects to the male reproductive system occur at PbB ≤ 10 µg/L.

Sperm and semen. A significant association between an increase in PbB ≤ 10 µg/dL and increasing percentages of morphologically abnormal sperm, wide sperm, and round sperm was observed in a population of Croatian men (Telisman et al. 2007). The mean PbB was 4.92 µg/dL; although the maximum PbB value in this study was 14.9 µg/dL, over 90% of participants had PbB < 10 µg/dL. Li et al. (2015) found small, but significant negative associations between PbB and sperm count, sperm

2. HEALTH EFFECTS

Table 2-36. Summary of Epidemiological Studies Evaluating Effects on the Male Reproductive System at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Effects on serum hormone levels			
Kresovich et al. 2015 Cross-sectional study; n=869	Median:2.0 Quartiles: • Q1: ≤ 1.4 (reference) • Q2: 1.4–2.1 • Q3: 2.10–3.20 • Q4: > 3.20	Testosterone	<ul style="list-style-type: none"> • β coefficient ng/mL per $\mu\text{g}/\text{dL}$ (SE) • Q3: 0.54 (0.21); $p < 0.05^*$ • Q4: 0.79 (0.22); $p < 0.05^*$; $p\text{-trend} = 0.00268^*$
Lewis and Meeker 2015 Cross-sectional study; n=484	Gmean:1.06 Quartiles: • Q1: < 0.71 • Q2: 0.71–1.00 • Q3: 1.00–1.59 • Q4: 1.59–33.67	Testosterone	<ul style="list-style-type: none"> • Percent change in serum testosterone concentration associated with a doubling (100% increase) in PbB: 6.65% (2.09, 11.41); $p < 0.004^*$; $p\text{-trend across quartiles} = 0.003^*$
Meeker et al. 2010 Cross-sectional study; n=219	Median:1.5 Quartiles • Q1: 1.1 (reference) • Q2: 1.1–1.5 • Q3: 1.5–2.0 • Q4: 2.0–16.2	Testosterone FSH LH Inhibin B SHBG FAI	<p>Regression coefficient Q4 (ng/dL per $\mu\text{g}/\text{dL}$): 39.9 (3.32, 76.4)*</p> <p>Regression coefficient Q4 (mIU/mL per $\mu\text{g}/\text{dL}$): 0.07 (-0.18, 0.31)</p> <p>Regression coefficient Q4 (mIU/m per $\mu\text{g}/\text{dL}$): 0.08 (-0.14, 0.29)</p> <p>Regression coefficient Q4 (pg/mL per $\mu\text{g}/\text{dL}$): -7.79 (-29.0, 13.4)</p> <p>Regression coefficient Q4 (nmol/L per $\mu\text{g}/\text{dL}$): 0.07 (-0.10, 0.23)</p> <p>Regression coefficient Q4 (per $\mu\text{g}/\text{dL}$): 0.08 (-0.05, 0.21)</p>

2. HEALTH EFFECTS

Table 2-36. Summary of Epidemiological Studies Evaluating Effects on the Male Reproductive System at Mean Blood Lead Concentration (PbB) $\leq 10 \mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^c
Mendiola et al. 2011 Case-control study; n=61	Gmean: 2.8	Testosterone	β coefficient (ng/mL per $\mu\text{g/L}$): -0.12 (-0.40, 0.14)
		FSH	β coefficient (IU/L per $\mu\text{g/L}$): -0.20 (-0.64, 0.25)
		LH	β coefficient (IU/L per $\mu\text{g/L}$): -0.07 (-0.49, 0.31)
Telisman et al. 2007 Cross-sectional study; n=240	Median: 4.92	Testosterone	β coefficient (nmol/L per $\mu\text{g/L}$): 0.21; $p < 0.003^*$
		Estradiol	β coefficient (nmol/L per $\mu\text{g/L}$): 0.22; $p < 0.0008^*$
		Prolactin	β coefficient (μg per $\mu\text{g/L}$): -0.18; $p < 0.007$
Sperm and semen quality			
Herandez-Ochoa et al. 2005 Cross-sectional study; n=68	Mean: 9.3 SPZ Pb: 0.047 ng/10 ⁶ cells SF Pb: 2.02 $\mu\text{g/L}$	Log sperm concentration	β coefficient SPZ Pb (10⁶ cells/mL per ng/10⁶ cells): -17.17 ($p < 0.05$)*
		Sperm motility	β coefficient PbB (% per $\mu\text{g/dL}$): -0.006 β coefficient SPZ Pb (% per ng/10⁶ cells): -2.12 ($p < 0.05$)*
		Sperm morphology (abnormal)	β coefficient PbB (% per $\mu\text{g/dL}$): -0.001 β coefficient SPZ Pb (% per ng/10⁶ cells): -1.42 ($p < 0.05$)*
		Sperm viability	β coefficient PbB (% per $\mu\text{g/dL}$): -0.095 β coefficient SPZ Pb (% per ng/10⁶ cells): -0.130 ($p < 0.05$)*
		Semen volume	β coefficient PbB (mL per $\mu\text{g/dL}$): -0.043 β coefficient SF Pb (mL per $\mu\text{g/L}$): -0.183 mL; $p < 0.05^*$

2. HEALTH EFFECTS

Table 2-36. Summary of Epidemiological Studies Evaluating Effects on the Male Reproductive System at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Li et al. 2015 Cross-sectional study; n=154	Mean: All participants: 2.78 Low-quality semen group: 3.43 High-quality semen group: 2.38	Low quality sperm	OR: 1.040 (1.011, 1.069); p=0.0061*
		Decreased sperm concentration	OR: 1.046 (1.015, 1.078); p=0.0032*
		Decreased sperm number	OR: 1.041 (1.012, 1.071); p=0.0048*
		Decreased motile sperm	OR: 1.057 (1.026, 1.089); p=0.0003*
		Decreased morphologically normal sperm	OR: 1.071 (1.025, 1.118); p=0.0021*
Meeker et al. 2008 Cross-sectional study; n=219	Median:1.50 • Quartiles (Q): ○ Q1: <1.10 ○ Q2: 1.10–1.50 ○ Q3: 1.50–2.00 ○ Q4: 2.00–16.2	Sperm concentration	Regression coefficient ($10^6/\text{mL}$ per $\mu\text{g}/\text{dL}$) Q4: 0.02 (-0.39, 0.43)
		Sperm motility	Regression coefficient (% per $\mu\text{g}/\text{dL}$) Q4: 1.10 (-4.56, 6.75)
		Sperm morphology	Regression coefficient (% per $\mu\text{g}/\text{dL}$) Q4: -0.16 (-1.58, 1.26)
		Semen volume	Regression coefficient (mL per $\mu\text{g}/\text{dL}$) Q4: 0.17 (-0.41, 0.74)
Mendiola et al. 2011 Case-control study; n=61	Gmean: 2.8 Median: 2.9	Sperm concentration	β coefficient ($10^6/\text{mL}$ per $\mu\text{g}/\text{L}$): 0.08 (-4.1, 5.2)
		Immobile sperm	β coefficient (% per $\mu\text{g}/\text{L}$): -0.49 (-1.8, 0.62)
		morphologically normal sperm	β coefficient(% per $\mu\text{g}/\text{L}$): -0.8 (-3.5, 3.4)

2. HEALTH EFFECTS

Table 2-36. Summary of Epidemiological Studies Evaluating Effects on the Male Reproductive System at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Telisman et al. 2007 Cross-sectional study; n=240	Median: 4.92	Immature sperm	β coefficient ($10^6/\text{mL}$ per $\mu\text{g}/\text{L}$): 0.13 ($p < 0.07$)
		Pathologic sperm	β coefficient (% per $\mu\text{g}/\text{L}$): 0.31 ($p < 0.0002$)*
		Wide sperm	β coefficient (% per $\mu\text{g}/\text{L}$): 0.32 ($p < 0.0001$)*
		Round sperm	β coefficient (% per μ): 0.16 ($p < 0.03$)*

^aSee the *Supporting Document for Epidemiological Studies for Lead*, Table 11 for more detailed descriptions of studies.

^bParticipants had no known occupational exposure to Pb.

^cAsterick indicates association with PB; unless otherwise specified, values in parenthesis are 95% CIs.

CI = confidence interval; FAI = free androgen index; FSH = follicle-stimulating hormone; Gmean = geometric mean; Inhibin B = gonadal dimeric polypeptide hormone; LH = luteinizing hormone; OR = odds ratio; Pb = lead; SF = seminal fluid; SE = standard error; SHBG = sex hormone-binding globulin; SPZ = spermatozoa

2. HEALTH EFFECTS

concentration, motile sperm, and morphologically normal sperm in 154 men from a reproductive clinic in Taiwan. The median PbB was 2.78 µg/dL (SD 1.85); range and percentiles were not reported. Other studies have shown associations between Pb levels in semen and/or spermatozoa and increased percentages of morphologically abnormal sperm and decreased sperm motility and viability, although no associations were observed between PbB and these outcomes (Hernandez-Ochoa et al. 2005; Mendiola et al. 2011); mean PbB levels were 9.3 µg/dL in the Hernandez-Ochoa et al. (2005) study and 2.8 µg/dL in the Mendiola et al. (2011) study. No associations were observed between PbB and sperm concentration, motility, or morphologic abnormalities in men at a median PbB of 1.5 µg/dL (Meeker et al. 2008). Semen volume (mL) was negatively associated with PbB at a mean PbB of 9.3 µg/dL; however, 48% of participants had PbB >10 µg/dL (Hernandez-Ochoa et al. 2005).

Serum testosterone levels. Significant associations have also been observed between PbB ≤10 µg/dL and increased serum testosterone levels (Table 2-34). Studies using NHANES data found significant positive associations between PbB and serum testosterone levels (Kresovich et al. 2015; Lewis and Meeker 2015). Examined by PbB quartiles, Kresovich et al. (2015) observed significant positive associations between PbB and serum testosterone (ng/L) for PbBs of 2.10–3.20 and >3.2 µg/dL; the median PbB of the study population was 2.0 µg/dL. A doubling of PbB was positively associated with a 6.65% change in serum testosterone; the mean PbB of the study population was 1.06 µg/dL (Lewis and Meeker 2015). The toxicological significance of the observed associations between PbB and serum testosterone has not been established.

Characterization of Effects in Females. As noted above, most epidemiological studies evaluated effects at PbB ≤10 µg/dL, with few studies of PbB >10 µg/dL. Studies of PbB ≤10 µg/dL are discussed in detail in the section below. General trends for studies showing a relationship between PbB ≤10–50 µg/dL and female reproductive effects are shown in Table 2-37. Effects associated with PbB include increased serum levels of estradiol, FSH, and LH at PbB ≤10 µg/dL (Chang et al. 2006; Krieg et al. 2007), decreased fertility at PbB ≤10 µg/dL (Chang et al. 2006), increased time to pregnancy at PbB >30–40 µg/dL (Sallmén et al. 1995), increased spontaneous abortion at PbB ≤10–30 µg/dL (Borja-Aburto et al. 1999; Yin et al. 2008), decreased number of gestational days at PbB >10–40 µg/dL (Jelliffe-Pawlowski et al. 2006), and increased preterm birth at PbB ≤10–50 µg/dL (McMichael et al. 1986; Jelliffe-Pawlowski et al. 2006; Rabito et al. 2014). Although epidemiological studies demonstrate effects on reproductive function, results are inconsistent, with several studies reporting no association between PbB and female reproductive effects (Baghurst et al. 1987; Bloom et al. 2010, 2011, 2015; Garcia-Esquinas et al. 2014; Jackson et al. 2007; Murphy et al. 1990; Perkins et al. 2014; Pollack et al. 2011; Sallmén et al. 1995;

2. HEALTH EFFECTS

Taylor et al. 2015; Vigeh et al. 2010). Dose-dependence has not been firmly established within the relatively narrow range of PbB (≤ 10 $\mu\text{g}/\text{dL}$) in most studies.

Table 2-37. Overview of Effects on the Female Reproductive System and Pregnancy Outcomes Associated with Chronic Exposure to Lead (Pb)

Mean blood lead concentration (PbB) ($\mu\text{g}/\text{dL}$)	Effects associated with Pb exposure	References
≤ 10	Increased serum hormones (estradiol, FSH, LH) Decreased fertility Increased spontaneous abortion Increased preterm birth Decreased age at menopause	Chang et al. 2006; Krieg et al. 2007 Chang et al. 2006 Yin et al. 2008 Rabito et al. 2014 Eum et al. 2014; Popovic et al. 2005
>10 – 30	Increased spontaneous abortion Decreased number of gestational days Increased preterm birth	Borja-Aburto et al. 1999 Jelliffe-Pawlowski et al. 2006 McMichael et al. 1986
>30 – 40	Increased time to pregnancy Decreased number of gestational days Increased preterm birth	Sallmén et al. 1995 Jelliffe-Pawlowski et al. 2006 Jelliffe-Pawlowski et al. 2006
>40 – 50	Increased preterm birth	Jelliffe-Pawlowski et al. 2006

FSH = follicle-stimulating hormone; LH = luteinizing hormone

Effects in Females at Blood Pb Levels ≤ 10 $\mu\text{g}/\text{dL}$. As discussed above, most epidemiology studies evaluating adverse effects of Pb on female reproductive function reported mean PbB ≤ 10 $\mu\text{g}/\text{dL}$. Although some studies provide evidence showing associations between PbB ≤ 10 $\mu\text{g}/\text{dL}$ and effects on serum reproductive hormones (Chang et al. 2006; Krieg 2007), fertility (Chang et al. 2006), spontaneous abortion (Lamadrid-Figueroa et al. 2007; Yin et al. 2008), and preterm birth (Rabito et al. 2014; Taylor et al. 2015; Vigeh et al. 2011), many studies show no associations between PbB and these outcomes. In general, most studies are limited by small sample sizes, although, as discussed below, some studies were of larger populations. The basis for differences in study outcomes is not readily apparent, although several factors may contribute, including low samples size, timing of evaluations in menstrual and life cycles, and inclusion of study participants identified from fertility clinics. Results are summarized in Table 2-38, with study details provided in the *Supporting Document for Epidemiological Studies for Lead* Table 12.

2. HEALTH EFFECTS

Table 2-38. Summary of Epidemiological Studies Evaluating Effects on the Female Reproductive System at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^c
Effects on serum hormone levels			
Chang et al. 2006 Case control study; n=147	Mean: 3.55	Estradiol	β coefficient $\mu\text{g/mL}$ per $\mu\text{g/dL}$ (SE): 1.18 (0.60); p=0.049*
Jackson et al. 2011 Longitudinal cohort study; n=252	Mean: 0.87	FSH	β coefficient (IU/L per $\mu\text{g/dL}$): -2.5 (-11.2, 7.0)
		LH	β coefficient (mg/L per $\mu\text{g/dL}$): 2.5 (-12.3, 19.9)
		Estradiol	β coefficient ($\mu\text{g/mL}$ per $\mu\text{g/dL}$): 4.9 (-5.0, 15.9)
		Progesterone	β coefficient (ng/mL per $\mu\text{g/dL}$): 4.6 (-12.2, 24.6)
Krieg 2007 Cross-sectional study; n=3,375	Gmean: 2.2	FSH	<ul style="list-style-type: none"> • Slope pre-menopausal (IU/L per $\mu\text{g/dL}$): 8.3 (2.2); 95% CI 3.8, 12.7; p=0.0006* • Slope post-menopausal (IU/L per $\mu\text{g/dL}$): 22.2 (4.3); 95% CI 13.5, 30.8; p=0.0000* • Slope both ovaries removed (IU/L per $\mu\text{g/dL}$): 32.6 (11.2); 95% CI 10.1, 55.1; p=0.0054*
		LH	<ul style="list-style-type: none"> • Slope pre-menopausal (IU/L per $\mu\text{g/dL}$): 1.7 (1.2); 95% CI -0.6, 4.1; p=0.1486 • Slope post-menopausal (IU/L per $\mu\text{g/dL}$): 6.2 (1.6); 95% C: 3.0, 9.5; p=0.0003* • Slope both ovaries removed (IU/L per $\mu\text{g/dL}$): 10.0 (4.4); 95% CI 1.1, 18.9; p=0.0279*

2. HEALTH EFFECTS

Table 2-38. Summary of Epidemiological Studies Evaluating Effects on the Female Reproductive System at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^c
Pollack et al. 2011 Longitudinal cohort study; n=252	Mean: 0.93	Estradiol	β coefficient (pg/mL per $\mu\text{g/dL}$): 0.03 (-0.05, 0.11)
		FSH	β coefficient (mIU/mL per $\mu\text{g/dL}$): -0.01 (-0.07, 0.06)
		LH	β coefficient (ng/mL per $\mu\text{g/dL}$): 0.02 (-0.06, 0.10)
		Progesterone	β coefficient (ng/mL per $\mu\text{g/dL}$): 0.06 (-0.04, 0.17)
Fertility			
Bloom et al. 2010 Longitudinal cohort study; n=15	Mean: 0.82	Oocyte fertilization (<i>in vitro</i>)	RR: 1.09 (0.72, 1.65).
Bloom et al. 2011 Longitudinal cohort study; n=80	Mean: 1.54	Achieving pregnancy over 12 menstrual cycles	β coefficient (probability of pregnancy per $\mu\text{g/dL}$): -0.031 (95% CI -1.066, 1.004); p=0.954
Chang et al. 2006 Case control study of 147	Mean: • All: 3.12 • Controls: 2.78 • Cases: 3.55	Infertility	OR for PbB >2.5 versus ≤ 2.5 $\mu\text{g/dL}$: 2.94 (95% CI 1.18, 7.34); p=0.021*
Pregnancy outcome			
Bloom et al. 2015 Case control study of 235	Mean: 0.71 Tertiles (mean): • T1: not reported • T2: 0.55 • T3: 0.73	Duration of gestation	Regression coefficient gestational age per $\mu\text{g/dL}$ T3: 0.14 (-0.81, 1.09)

2. HEALTH EFFECTS

Table 2-38. Summary of Epidemiological Studies Evaluating Effects on the Female Reproductive System at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$)	Outcome evaluated	Result ^c
Garcia-Esquinas et al. 2014 Birth cohort study; n=100	Gmean: 1.83	Duration of gestation	Mean difference in gestational age (weeks) per 2-fold increase in PbB: 0.02 (95% CI -0.44, 0.47)
Gundacker et al. 2010 Cross-sectional study; n=30	Median PbB: 2.5 Median PbPI: 25.8	Spontaneous abortion	PbPI in women with a history of miscarriage was higher (n=8; p=0.039) than in women with no history of miscarriage (n=22)*
Lamadrid-Figueroa et al. 2007 Cross-sectional study; n=207	Mean PbB: 6.24 (4.48) Mean plasma Pb: 0.014 Mean plasma/blood Pb ratio: 0.22% (tertile values not reported)	Spontaneous abortion	IRR PbB: 0.93; p=0.56 IRR Plasma Pb: 1.12; p=0.22 Plasma/blood Pb ratio: 1.18; p=0.02* IRR for T2 plasma/blood Pb ratio: 1.161; p=0.612 IRR for T3 plasma/blood Pb ratio: 1.903; p=0.015*
Perkins et al. 2014 Birth cohort; n=949	Estimated mean PbB: 0.4 Mean RBC: 1.22 $\mu\text{g}/\text{dL}$ Quartile RBC ($\mu\text{g}/\text{dL}$): • Q1: 0.65 • Q2: 0.96 • Q3: 1.27 • Q4: 2.02	Duration of gestation	β coefficient Q4 gestational age (weeks) per $\mu\text{g}/\text{dL}$: -0.17 (-0.51, 0.16)
Rabito et al. 2014 Birth cohort; n=98	Second trimester mean: 0.42 Third trimester mean: 0.45	Preterm birth	OR second trimester: 1.66 (1.23, 2.23); p<0.01* OR third trimester: 1.24 (1.01, 1.52); p=0.04*
Taylor et al. 2013, 2015 Longitudinal cohort study; n=3,870	Mean: 3.67 Median: 3.42	Preterm birth	OR for PbB ≥ 5.0: 2.0 (1.35, 3.00); p=0.001*

2. HEALTH EFFECTS

Table 2-38. Summary of Epidemiological Studies Evaluating Effects on the Female Reproductive System at Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$)	Outcome evaluated	Result ^c
Vigeh et al. 2010 Longitudinal cohort study; n=351	Mean: 3.8	Spontaneous abortion	OR (log PbB): 0.331 (0.011, 10.096); p=0.53
Vigeh et al. 2011 Longitudinal cohort study; n=44 women with preterm birth; n=304 women with term birth	Mean: • Term birth: 3.72 • Preterm birth: 4.52	Preterm birth	OR: 1.41 (1.08, 1.84)*
Yin et al. 2008 Case-control study; n=80	Control (term birth): 4.5 Spontaneous abortion: 5.3	Spontaneous abortion	PbB was higher in cases of anembryonic pregnancy during gestational weeks 8–13 compared to controls with term births (p=0.03).*
Zhu et al. 2010 Retrospective cohort; n=43,288 mother-infant pairs (n=3,519 preterm birth; n=39,769 term birth)	PbB Mean: 2.1 Quartiles: • Q1: ≤ 1.0 • Q2: 1.1–2.0 • Q3: 2.1–3.0 • Q4: 3.1–9.9	Preterm birth	Adjusted ORs did not show an increased risk of preterm birth for any quartile. Q4: 1.04 (0.89, 1.22)

^aSee the *Supporting Document for Epidemiological Studies for Lead*, Table 12 for more detailed descriptions of studies.

^bParticipants had no known occupational exposure to Pb.

^cAsterick indicates association with PB; unless otherwise specified, values in parenthesis are 95% CIs.

CI = confidence interval; FSH = follicle-stimulating hormone; Gmean = geometric mean; IRR = incidence rate ratio; LH = luteinizing hormone; OR = odds ratio; Pb = lead; PbPl = Pb concentration in placenta ($\mu\text{g/kg}$); RBC = red blood cell; RR = relative risk; SE = standard error

2. HEALTH EFFECTS

Serum hormone levels and estrus cycle. Results of epidemiological studies on associations between PbB ≤ 10 $\mu\text{g/dL}$ and serum hormone levels show conflicting results (Table 2-38). The strongest evidence showing that chronic Pb exposure alters serum hormone levels is from a large cross-sectional study (mean PbB 2.2 $\mu\text{g/dL}$) participating in the NHANES III study (Krieg 2007). Serum levels of FSH (IU/L) increased with PbB in both pre-menopausal and post-menopausal women. Serum levels of LH increased with PbB in post-menopausal women, but not pre-menopausal women. The lowest PbBs associated with a significant increase in FSH in pre- and post-menopausal women were 4.1 $\mu\text{g/dL}$ and 2.4 $\mu\text{g/dL}$, respectively. The lowest PbB associated with a significant increase in FSH in post-menopausal women was 2.8 $\mu\text{g/dL}$ (slope \pm SE 8.6 \pm 3.3; 95% CI 2.1, 15.2; p=0.0109). Increases in serum FSH and LH were also observed in women who had total ovariectomy, indicating that increased hormone levels may be related to effects on the hypothalamus or pituitary (Krieg 2007). No associations were observed between Pb and serum levels of FSH, LH, estradiol, or progesterone or menstrual cycle length in a smaller study of pre-menopausal women with a mean PbB of 0.87 $\mu\text{g/dL}$ (Jackson et al. 2011). In this same study population, when PbB was examined by tertiles, increased serum progesterone levels were observed in the second PbB tertile (0.73–1.10 $\mu\text{g/dL}$) compared to the lowest tertile (0.30–0.72 $\mu\text{g/dL}$), but no effects were observed in the highest PbB tertile (1.11–6.20 $\mu\text{g/dL}$) compared to the lowest (Pollack et al. 2011). In this study population, no association was observed between PbB and anovulation. In a case-control study of women attending a fertility clinic, a significant association was observed between PbB and serum estradiol concentrations (Chang et al. 2006).

Fertility. Little epidemiological information is available on the effects of PbB ≤ 10 $\mu\text{g/dL}$ on female fertility. A prospective cohort study with a mean Pb of 1.5 $\mu\text{g/dL}$ showed no effect on achieving pregnancy over 12 menstrual cycles (Bloom et al. 2011). A case-control study of women from a fertility clinic showed a 2.9-fold risk of infertility for PbB > 2.5 $\mu\text{g/dL}$ compared to PbB ≤ 2.5 $\mu\text{g/dL}$ (Chang et al. 2006). In a study of women undergoing *in vitro* fertilization, no association was observed between PbB and oocyte fertilization; however, only 15 women were included in this study. Available epidemiological studies on the effects of PbB ≤ 10 $\mu\text{g/dL}$ on fertility are limited due to small numbers of participants and study populations of women undergoing fertility treatment; thus, data are not sufficient to determine if fertility in women is affected at PbB ≤ 10 $\mu\text{g/dL}$.

Spontaneous abortion. Few epidemiological studies have evaluated associations between PbB ≤ 10 $\mu\text{g/dL}$ and spontaneous abortion (Table 2-38). Although studies provide some evidence suggesting associations between PbB ≤ 10 $\mu\text{g/dL}$ or plasma/blood Pb ratio and spontaneous abortion, results are inconsistent. In a case-control study, PbB was significantly higher in cases of spontaneous abortion (PbB 5.3 $\mu\text{g/dL}$;

2. HEALTH EFFECTS

$p=0.03$) during weeks 8–13, compared to women with term birth (PbB 4.5 $\mu\text{g}/\text{dL}$) (Yin et al. 2008). A cross-sectional study reported that the risk of miscarriage per 1 SD increase of plasma/blood Pb ratio [mean plasma/blood Pb ratio \pm SD (%): 0.22 \pm 0.14] was associated with an 18% greater incidence of spontaneous abortion, although the association between risk of spontaneous abortion and PbB (mean 6.24) was not significant (Lamadrid-Figueroa et al. 2007). In contrast, results of a longitudinal cohort study showed no association between PbB and spontaneous abortion during gestational weeks 13–19 (Vigeh et al. 2010).

Preterm birth. Several studies have evaluated associations between PbB ≤ 10 $\mu\text{g}/\text{dL}$ and preterm birth (<37 weeks of gestation), including two studies of larger study populations ($n=705$ – $3,870$) (Perkins et al. 2014; Taylor et al. 2015). Results of these studies are mixed (Table 2-38). The strongest evidence showing that chronic Pb exposure is associated with preterm birth is from a large, longitudinal cohort study (Taylor et al. 2013, 2015). When stratified into groups of PbB <5 and ≥ 5.0 $\mu\text{g}/\text{dL}$, there was a 2-fold increase in the risk of preterm birth for PbB ≥ 5.0 $\mu\text{g}/\text{dL}$ compared to PbB <5 $\mu\text{g}/\text{dL}$. In the PbB ≥ 5.0 $\mu\text{g}/\text{dL}$ group, the maximum PbB was 19.14 $\mu\text{g}/\text{dL}$, although very few PbBs were >10 $\mu\text{g}/\text{dL}$; however, the group mean PbB was not reported. The risk of preterm birth also was increased in a longitudinal cohort study (Vigeh et al. 2011). Mean PbB in women with preterm birth was significantly higher than in women with term birth (preterm PbB: 4.52 $\mu\text{g}/\text{dL}$; term birth PbB: 3.72 $\mu\text{g}/\text{dL}$). A cohort study showed increased odds of preterm birth associated with PbB measured in the 2nd (mean: 0.42 $\mu\text{g}/\text{dL}$) and 3rd (mean: 0.45 $\mu\text{g}/\text{dL}$) trimesters (Rabito et al. 2014). ORs for risks of preterm birth were 1.66 ($p<0.01$) and 1.24 ($p=0.04$) for 2nd and 3rd trimester PbB, respectively. Other studies reported no associations between PbB and preterm birth at mean PbB of 0.71–1.22 $\mu\text{g}/\text{dL}$ (Bloom et al. 2015; Perkins et al. 2014; Zhu et al. 2010), including a large retrospective cohort study (Zhu et al. 2010) and a large case-control study (Perkins et al. 2014).

Age at menopause. A few studies had evaluated associations between Pb exposure and age at menopause (Eum et al. 2014; Popovic et al. 2005). Eum et al. (2014) found a negative association between tibia Pb and age at onset of natural menopause (e.g., non-surgical) in a population of 434 participants in the Nurses Health Study cohort. In the highest tibia Pb tertile, the age at onset of menopause was 1.21 years earlier than controls. However, no associations were observed between PbB (mean PbB: <5 $\mu\text{g}/\text{dL}$) or patella Pb. In a study of 108 former smelters (mean PbB: 2.73 $\mu\text{g}/\text{dL}$), the age at onset of combined natural and surgical menopause was lower by 7 years ($p=0.001$) compared to controls ($n=99$; PbB: 1.25 $\mu\text{g}/\text{dL}$) (Popovic et al. 2005). No difference was observed between the age at onset and natural menopause between the exposed and control groups.

2. HEALTH EFFECTS

Mechanisms of Action. General mechanisms of toxicity of Pb (reviewed in Section 2.21) are likely involved in the development of toxicity to male and female reproductive systems. Oxidative stress through ROS is a plausible mechanism for reproductive effects, as is the disruption of calcium homeostasis. Mechanisms for alterations in circulating hormone levels have been not been established. However, EPA (2014c) and NRC (2012) noted several possible mechanisms that may be involved in alterations of serum hormones, including direct inhibition of LH secretion; reduced expression of steroidogenic acute regulatory protein (a protein required in maintaining gonadotropin-stimulated steroidogenesis); altered release of pituitary hormones due to interference with cation-dependent second messenger systems; and altered binding of hormones to receptors. Pb is distributed to, and has been measured in, semen, spermatozoa, the fetus, umbilical cord blood, placenta, and follicular fluid (see Section 3.1.2, Toxicokinetics, Distribution), providing a toxicokinetic mechanism for direct effects to reproductive tissues.

2.18 DEVELOPMENTAL

This section discusses developmental effects of Pb other than neurodevelopmental defects. Neurodevelopmental effects are discussed in Section 2.16 (Neurological Effects). The term “developmental” used in the discussion that follows refers to effects other than neurodevelopmental.

Overview. Numerous epidemiological studies have evaluated developmental effects (birth outcomes, birth defect, neural tube defects, decreased anthropometric measures in children, and delayed puberty) associated with Pb exposure, with the database for developmental effects dominated by environmental exposure studies with PbB ≤ 10 $\mu\text{g/dL}$. In general, studies provide mixed evidence for effects on birth outcomes (e.g., infant size) and anthropometric measures in children, but more consistent evidence for delayed puberty. Although studies provide evidence of associations between PbB and developmental outcomes, results are inconsistent, and several studies, including prospective studies, with PbB ≤ 10 $\mu\text{g/dL}$ show no associations with developmental outcomes.

The following developmental effects have been associated with PbB:

- ≤ 10 $\mu\text{g/dL}$:
 - Effects on birth outcomes (decreased birth weight, head circumference, and crown-heel length); results are mixed when compared across studies.

2. HEALTH EFFECTS

- Decreased anthropometric measures in children (weight, height, head circumference, trunk length, leg length, arm length, BMI); results are mixed when compared across studies.
- Delayed puberty in females (breast development, pubic hair development, onset of menarche); corroborated in multiple studies.
- Delayed puberty in males (testicular volume, genitalia development, pubic hair development); a few studies with equivocal results.
- >10 µg/dL (based on few studies):
 - Effects on birth outcomes (low birth weight).
 - Decreased anthropometric measures in children (decreased weight, height, head circumference, chest circumference).
 - Delayed puberty in females (breast development).
 - Delayed puberty in males (decreased testicular size, delayed pubic hair development, delayed penile development).

Measures of Exposure. Most studies evaluating developmental effects used maternal PbB and/or cord, infant, or child PbB as the biomarker for exposure. In some studies, Pb concentrations in red blood cells (Perkins et al. 2014), maternal bone (Afeiche et al. 2011; Cantonwine et al. 2010b; Hernandez-Avila et al. 2002; Kordas et al. 2009), or hair (Sanín et al. 2001; Sanna and Vallascas 2011) were used as biomarkers.

Confounding Factors and Effect Modifiers. Numerous complicating factors may add uncertainty in the interpretation of studies examining associations between PbB and developmental effects. These factors include nutrition during pregnancy, prenatal care, adequate nutrition during infancy and childhood, SES, intercurrent diseases, alcohol consumption, smoking status, and potential exposure to other chemicals. Failure to account for these factors may attenuate or strengthen the apparent associations between Pb exposure and the outcome, depending on the direction of the effect of the variable on the outcome.

Characterization of Effects. As noted above, most epidemiological studies evaluated developmental effects at PbB ≤10 µg/dL, with few studies of PbB >10 µg/dL. Studies of PbB ≤10 µg/dL are discussed in detail in the section below. General trends for studies showing a relationship between PbB ≤10–50 µg/dL and developmental effects are shown in Table 2-39. Effects on birth outcomes, including decreased birth weight, head circumference, and crown-heel length have been observed at maternal PbBs of ≤10–50 µg/dL. Decreased anthropometric measures in infants and children, including decreased weight, height, head circumference, trunk length, leg length, arm length, and BMI, have been observed

2. HEALTH EFFECTS

over the PbB range of ≤ 10 – $30 \mu\text{g/dL}$. Delayed onset of puberty in males and females was observed over the PbB range of ≤ 10 – $30 \mu\text{g/dL}$. Very little data are available regarding *in utero* exposure to Pb and birth defects. Two studies that examined neural tube defects did not find associations with Pb exposure at mean blood levels over for PbB means ranging from 2.4 to $24 \mu\text{g/dL}$ (Brender et al. 2006; Zeyrek et al. 2009). As discussed below, although epidemiological studies demonstrate developmental effects of Pb, results across studies are inconsistent, with several studies reporting no association between PbB and developmental effects. For example, results of effects on birth outcomes in study populations with maternal PbB $\leq 10 \mu\text{g/dL}$ are equivocal (see Tables 2-40 and 2-41). For studies with maternal PbB $> 10 \mu\text{g/dL}$, equivocal results also were observed for associations between PbB and birth weight and length (Factor-Litvak et al. 1991; Hernandez-Avila et al. 2002; McMichael et al. 1986; Murphy et al. 1990). Dose-dependence has not been firmly established within the relatively narrow range of PbB ($\leq 10 \mu\text{g/dL}$) in most studies.

Table 2-39. Overview of Developmental Effects Associated with Chronic Exposure to Lead (Pb)

Mean blood lead concentration (PbB) ($\mu\text{g/dL}$)	Effects associated with Pb exposure	References
≤ 10	Effects on birth outcome (decreased birth weight, crown-heel length, head circumference)	Bornschein et al. 1989; Gonzales-Cossio et al. 1997; Nishioka et al. 2014; Odland et al. 1999; Taylor et al. 2013, 2015; Xie et al. 2013; Zhu et al. 2010
	Minor congenital anomalies	Needleman et al. 1984
	Decreased anthropometric measures in children (decreased weight, height, head circumference, trunk length, leg length, arm length, body mass index)	Afeiche et al. 2011; Dallaire et al. 2014; Hauser et al. 2008; Hong et al. 2014; Ignasiak et al. 2006; Little et al. 2009; Min et al. 2008b; Olivero-Verbel et al. 2007; Schell et al. 2009; Yang et al. 2013a
	Delayed puberty in females (breast development, pubic hair development, onset of menarche)	Denham et al. 2005; Den Hond et al. 2011; Gollenberg et al. 2010; Naicker et al. 2010; Selevan et al. 2003; Wu et al. 2003b
	Delayed puberty in males (testicular volume, genitalia development, pubic hair development)	Hauser et al. 2008; Williams et al. 2010

2. HEALTH EFFECTS

Table 2-39. Overview of Developmental Effects Associated with Chronic Exposure to Lead (Pb)

Mean blood lead concentration (PbB) (µg/dL)	Effects associated with Pb exposure	References
>10–30	Effects on birth outcome (decreased birth weight)	Chen et al. 2006; Hernandez-Avila et al. 2002
	Decreased anthropometric measures in children (decreased weight, height, head circumference, chest circumference)	Frisancho and Ryan 1991; Tomoum et al. 2010
	Delayed puberty in females (breast development)	Tomoum et al. 2010
	Delayed puberty in males (decreased testicular size, delayed pubic hair development; delayed penile development)	Tomoum et al. 2010
>30–50	Effects on birth outcome (low birth weight)	Jelliffe-Pawlowski et al. 2006

Table 2-40. Effects on Birth Outcomes at Blood Lead Concentration (PbB) ≤10 µg/dL

Reference (population size)	Birth outcome			
	Birth weight	Height or C-H length	SGA	Head circumference
Al-Saleh et al. 2014 (n=1,577)	0 ^a	0	0	0
Bloom et al. 2015 (n=235)	0 ^a	0	–	0
Bornschein et al. 1989 (n=202)	↓ ^a	↓	–	0
Garcia-Esquinas et al. 2014 (n=97)	0 ^a	0	–	–
Gonzalez-Cossio et al. 1997 (n=272)	0 ^b	–	–	–
Nishioka et al. 2014 (n=386)	↓ ^b	–	–	–
Odland et al. 1999 (n=50)	↓ ^{a,b}	–	–	–
Perkins et al. 2014 (n=949)	0 ^{a,b}	0	–	0
Rabito et al. 2014 (n=98)	0 ^a	–	–	–
Taylor et al. 2015 (n=4,285)	↓ ^b	↓	–	↓
Thomas et al. 2015 (n=1,835)	–	–	0	–
Xie et al. 2013 (n=252)	↓ ^b	0	–	0
Zhu et al. 2010 (n=43,288)	↓ ^b	–	0	–

^aBirth weight not adjusted for gestational age

^bBirth weight adjusted for gestational age

↓ = decrease in outcome measure; 0 = no effect on outcome measure; – = not assessed; C-H = crown-heel; SGA = small for gestational age

2. HEALTH EFFECTS

Table 2-41. Summary of Epidemiological Studies Evaluating Birth Outcomes Effects of Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$) ^c	Outcome evaluated	Result ^d
Al-Saleh et al. 2014 Cross-sectional study; n=1578 mother-infant pairs	Maternal PbB mean: 2.897	Birth weight	OR: 1.107 (0.797, 1.538); p=0.545
		Birth height	OR: 1.299 (0.945, 1.786); p=0.107
		Crown-heel length	OR: 1.061 (0.795, 1.415); p=0.689
		SGA	OR: 1.168 (0.837, 1.631); p=0.362
		Head circumference	OR: 1.007 (0.724, 1.400); p=0.968
		Apgar	OR: 1.027 (0.787, 1.341); p=0.842
Bloom et al. 2015 Case-control study; n=235 mother-infant pairs	Maternal PbB mean: 0.71 Tertiles: <ul style="list-style-type: none"> • T1: <0.55 (reference) • T2: 0.55-<0.73 • T3: 0.73–2.23 	Birth weight	Linear regression coefficient (g per $\mu\text{g/dL}$) T3: -34.85 (-97.76, 128.06); p-trend=0.202
		Birth length	Linear regression coefficient (cm per $\mu\text{g/dL}$) T3: 0.14 (-0.81, 1.09); p-trend:0.671
		Head circumference	Linear regression coefficient (cm per $\mu\text{g/dL}$) T3: -0.33 (-1.07, 0.41); p-trend: 0.132
Bornschein et al. 1989 Prospective study; n=202 mother-infant pairs	PbB: Mean (SD): 7.5	Birth weight	Regression coefficient (g per ln $\mu\text{g/dL}$) for all births: -114; p<0.001*. Regression coefficient (g per ln $\mu\text{g/dL}$) with significant interaction with maternal age (p=0.0073)*: maternal age 18 years: -58* maternal age 30 years: -601*
		Birth length	Regression coefficient (cm per ln $\mu\text{g/dL}$): -2.5; p=0.019*
		Head circumference	Regression coefficient (cm per ln PbB $\mu\text{g/dL}$): 0.0 p=0.97

2. HEALTH EFFECTS

Table 2-41. Summary of Epidemiological Studies Evaluating Birth Outcomes Effects of Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$) ^c	Outcome evaluated	Result ^d
Garcia-Esquinas et al. 2014 Birth cohort study; n=100 mother-infant pairs	Maternal PbB Gmean: 1.83	Birth weight	Adjusted mean difference in grams for a 2-fold increase in PbB ($\mu\text{g/L}$): 62.4 (-73.1, 197.8)
		Birth length	Adjusted mean difference in cm for a 2-fold increase in PbB ($\mu\text{g/L}$): 0.17 (-0.56, 0.91)
		Abdominal diameter	Adjusted mean difference in cm for a 2-fold increase in PbB ($\mu\text{g/d}$): 0.31 (-0.52, 1.15)
		Cephalic diameter	Adjusted mean difference in cm for a 2-fold increase in PbB ($\mu\text{g/L}$): 0.15 (-0.21, 0.51)
Gonzalez-Cossio et al. 1997 Birth cohort study; n=272 mother-infant pairs	PbB: <ul style="list-style-type: none"> • Maternal <ul style="list-style-type: none"> ○ Mean (SD): 8.9 (4.1) ○ Quartiles: <ul style="list-style-type: none"> ▪ Q1: ≤ 5.8 ▪ Q2: 5.9–8.0 ▪ Q3: 8.1–11.0 ▪ Q4: ≥ 11.1 • Umbilical cord <ul style="list-style-type: none"> ○ Mean (SD): 7.1 (3.5) ○ Quartiles <ul style="list-style-type: none"> ▪ Q1: ≤ 4.6 ▪ Q2: 4.7–6.1 ▪ Q3: 6.2–8.5 ▪ Q4: ≥ 8.6 	Birth weight	Regression coefficient: <ul style="list-style-type: none"> • Maternal PbB for Q4: -98.30 (59.55); p=0.100 • Umbilical cord PbB for Q4: -41.74 (64.04); p=0.514
Nishioka et al. 2014 Cohort study; n=386 mother-infant pairs	Maternal PbB mean at gestational weeks: <ul style="list-style-type: none"> • 12 weeks: 0.98 • 25 weeks: 0.92 • 36 weeks: 0.99 	Birth weight	Regression coefficient based on log $\mu\text{g/dL}$: <ul style="list-style-type: none"> • Infant males: -0.151 (p<0.05)* • Infant females: -0.098 (p>0.05)

2. HEALTH EFFECTS

Table 2-41. Summary of Epidemiological Studies Evaluating Birth Outcomes Effects of Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$) ^c	Outcome evaluated	Result ^d
Odland et al. 1999 Cohort study; n=262 mother-infant pairs	Maternal, mean (range); p-values compare Russian and Norwegian cohorts <ul style="list-style-type: none"> Russian cohort: 2.9 (0.83–13.5) Norwegian cohort: 2.3 (0.41–3.9); p<0.001 	Birth weight	Regression coefficient, combined Russian and Norwegian cohorts [g per $\mu\text{mol/L}$ (g per 20.7 $\mu\text{g/dL}$): -1,068 (95% CI -2,134, -2); p<0.05*
Perkins et al. 2014 Birth cohort study; n=829 mother-infant pairs	Maternal RBC Pb concentration ($\mu\text{g/dL}$) mean: 1.22 Quartiles for RBC Pb; mean: <ul style="list-style-type: none"> Q1: 0.65 Q2: 0.96 Q3: 1.27 Q4: 2.02 Estimated maternal PbB mean: 0.4	Birth weight	Linear regression β coefficient for RBC ($\mu\text{g/dL}$) Q4: -47 (-128, 35); p-trend: 0.27
		Birth length	Linear regression β coefficient for RBC ($\mu\text{g/dL}$) Q4: -0.15 (-0.54, 0.23); p-trend: 0.37
		Head circumference	Linear regression β coefficient for RBC ($\mu\text{g/dL}$) Q4: -0.08 (-0.33, 0.16); p-trend: 0.56
Rabito et al. 2014 Birth cohort study; n=98 mother-infant pairs	Maternal 2 nd trimester PbB mean: 0.42 Maternal 3 rd trimester PbB mean: 0.45	Birth weight	Linear regression β coefficient, g per $\mu\text{g/dL}$ maternal: <ul style="list-style-type: none"> 2nd trimester: -43.21 (-88.6, 2.18); p=0.06 3rd trimester: β not reported; p=0.68 Delivery: β not reported; p=0.83

2. HEALTH EFFECTS

Table 2-41. Summary of Epidemiological Studies Evaluating Birth Outcomes Effects of Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$) ^c	Outcome evaluated	Result ^d
Taylor et al. 2013, 2015 Longitudinal cohort study; n= 4,285 mother-infant pairs	Maternal PbB mean: 3.67 Population stratified by PbB <5.0 and ≥ 5.0	Birth weight	β coefficient (g per $\mu\text{g/dL}$): -13.23 (-23.75, -2.70); p=0.014*
		Head circumference	β coefficient (cm per $\mu\text{g/dL}$): -0.04 (-0.07, -0.06)^e; p=0.021*
		Crown-heel length	β coefficient (cm per $\mu\text{g/dL}$): -0.05 (-0.10, -0.00); p=0.034*
Thomas et al. 2015 Prospective cohort; n=1,835 mother-infant pairs	Maternal PbB median: 0.59 Tertiles: <ul style="list-style-type: none"> • T1: <0.52 • T2: 0.52–1.04 • T3: >1.04–4.04 	SGA	Adjusted RR for T3 (95% CI): 1.19 (0.65, 2.18)
Xie et al. 2013 Birth cohort study; n=252 mother-infant pairs	Maternal PbB mean: 3.53	Birth weight	β coefficient (g per square root $\mu\text{g/dL}$): -148.99 (-286.33, -11.66); p=0.03*
		Birth length	β coefficient (cm per square root $\mu\text{g/dL}$): -0.46 (-1.25, 0.34); p=0.26
		Head circumference	β coefficients (cm per square root $\mu\text{g/dL}$): -0.37 (-0.78, 0.19); p=0.24

2. HEALTH EFFECTS

Table 2-41. Summary of Epidemiological Studies Evaluating Birth Outcomes Effects of Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$) ^c	Outcome evaluated	Result ^d
Zhu et al. 2010	Maternal PbB mean: 2.1	Birth weight	β coefficient g per $\mu\text{g/dL}$ (95% CI): 0: reference 1: -27.4 (-17.1, -37.8)* 2: -38.8 (-24.1, -53.4)* 3: -47.5 (-29.6, -65.4)* 4: -54.8 (-34.2, -75.5)* 5: -61.3 (-38.2, -84.4)* 6: -67.2 (-41.8, -92.5)* 7: -72.5 (-45.2, -99.9)* 8: -77.6 (-48.3, -106.8)* 9: -82.3 (-51.2, -113.3)* 10: -86.7 (-54.0, -119.4)*
Retrospective cohort study; n=43,288 mother-infant pairs		SGA	Adjusted OR for Q4: 1.07 (0.93, 1.23)

^aSee the *Supporting Document for Epidemiological Studies for Lead*, Table 13 for more detailed descriptions of studies.

^bParticipants had no known occupational exposure to Pb.

^cValues are for maternal PbB, unless otherwise specified.

^dAsterick indicates association with Pb; unless otherwise specified, values in parenthesis are 95% CIs.

^eValues are reported; the value for the β coefficient is outside of the 95% CI.

CI = confidence interval; NS = not statistically significant; OR = odds ratio; Pb = lead; RBC = red blood cell; RR = relative risk; SGA = small for gestational age

2. HEALTH EFFECTS


Effect at Blood Pb Levels $\leq 10 \mu\text{g/dL}$. Epidemiology studies have reported developmental effects, including birth outcomes, birth defects, anthropometric measures in children, and delayed onset of puberty, at mean PbB $\leq 10 \mu\text{g/dL}$. Study details are provided in *Supporting Document for Epidemiological Studies for Lead*, Table 13. Results of studies on associations between PbB and adverse effects on birth outcomes and anthropometric measures are mixed when compared across studies. Delayed onset of puberty in females has been corroborated in several studies. Fewer studies are available regarding effects of Pb on onset of puberty in males, with equivocal results. Exposure to Pb has not been shown to cause birth defects in humans. Neural tube defects have not been associated with Pb exposure and findings of a single study showing minor anomalies have not been corroborated.

Birth outcomes. An overview of results of studies that evaluated associations between Pb exposure and birth outcomes (infant weight, height or crown-heel length, small for gestation age [SGA], and head circumference) at maternal PbB $\leq 10 \mu\text{g/dL}$ is shown in Table 2-40, with more detailed results in Table 2-41. Studies include two prospective studies (Bornschein et al. 1989; Thomas et al. 2015), several studies of large populations ($n=829\text{--}43,288$) (Al-Saleh et al. 2014; Perkins et al. 2014; Taylor et al. 2015; Thomas et al. 2015; Zhu et al. 2010), and cohort and case-control studies of smaller ($n=98\text{--}386$) populations (Bloom et al. 2015; Garcia-Esquinas et al. 2014; Gonzalez-Cossio et al. 1997; Nishioka et al. 2014; Rabito et al. 2014). As shown in Table 2-41, results of these studies show either decreases or no change in birth outcomes. In a small ($n=202$) prospective study, Bornschein et al. (1989) reported associations between maternal PbB (mean $7.5 \mu\text{g/dL}$) and decreased birth weight and length. The size of the effect of PbB varied with maternal age ($p<0.007$), with a 58 g per lnPbB decrease for pregnancies at age 18 years and a 601 g decrease per ln PbB ($\mu\text{g/dL}$) for pregnancies at age 30 years. In the complete birth cohort from this study, which included mothers who declined participation in the infant follow-up ($n=861$), the decline in birth weight was $-114 \text{ g per ln PbB}$. Results of the largest cohort study, a retrospective study of $>43,000$ participants (mean PbB $2.1 \mu\text{g/dL}$), showed a negative association between PbB and birth weight (Zhu et al. 2010). The best fitting model was a linear change in birth weight with square root of PbB (Figure 2-7). The model predicts a 34 g decrease in birth weight for an increase in PbB from 1 to $5 \mu\text{g/dL}$ and a 59 g decrease for an increase in PbB from 1 to $10 \mu\text{g/dL}$ (adjusted for confounders). Results of a longitudinal cohort study of 4,285 mother-infant pairs (maternal PbB mean: $2.1 \mu\text{g/dL}$; range $0.42\text{--}19.14$) showed negative associations between birth weight, crown-heel length, and head circumference for participants with PbB $\geq 5 \mu\text{g/dL}$ compared to PbB $<5 \mu\text{g/dL}$ (Taylor et al. 2015). Other smaller cohort studies also showed associations between maternal PbB $\leq 10 \mu\text{g/dL}$ and decreased birth weight (Nishioka et al. 2014; Odland et al. 1999). In contrast, other studies, including a prospective study and cohort studies of large populations, did not find associations between PbB and birth outcome

2. HEALTH EFFECTS

measures. A prospective study of 1,835 mother-infant pairs did not find an association between PbB and SGA, with PbB data stratified by tertiles (range for highest tertile: 1.04–4.04 $\mu\text{g}/\text{dL}$) (Thomas et al. 2015). Similarly, no associations between maternal PbB and decreased birth weight, length, or head circumference were observed in a cohort study of 829 participants (estimated PbB mean of 0.4 $\mu\text{g}/\text{dL}$) (Perkins et al. 2014), or in a cross-sectional study of 1,578 participants (Al-Saleh et al. 2014). Smaller cohort studies also report no associations between PbB and adverse birth outcome measures (Bloom et al. 2015; Garcia-Esquinas et al. 2014; Gonzalez-Cossio et al. 1997; Rabito et al. 2014). Equivocal findings for birth outcomes in studies examining effects at maternal PbB ≤ 10 $\mu\text{g}/\text{dL}$ are not surprising, given that prospective studies at maternal PbB >10 $\mu\text{g}/\text{dL}$ also have reported conflicting results for adverse effects on birth outcomes (Factor-Litvak et al. 1991; Hernandez-Avila et al. 2002; McMichael et al. 1986; Murphy et al. 1990). For example, two prospective studies found no associations between PbB and birth weight in birth cohorts that had mean maternal PbBs >10 $\mu\text{g}/\text{dL}$ (Factor-Litvak et al. 1991; McMichael et al. 1986).

Figure 2-7. Relationship Between Blood Lead Concentration (PbB) and Birth Weight at PbB ≤ 10 $\mu\text{g}/\text{dL}$



Source: Zhu et al. 2010

2. HEALTH EFFECTS

Birth defects. Few studies have evaluated associations between *in utero* exposure to Pb and birth defects. Details of studies evaluating PbB ≤ 10 $\mu\text{g/dL}$ are provided in the *Supporting Document for Epidemiological Studies for Lead*, Table 13. No association was observed between PbB and neural tube defects in a case-control study ($n=409$) with mean maternal PbB of 2.5 $\mu\text{g/dL}$ (Brender et al. 2006). Other epidemiological studies that have reported associations between Pb in exposure media (e.g., water, soil) and neural tube defects are limited by the lack of PbB measurement (Bound et al. 1997; Huang et al. 2011; Irgens et al. 1998). An early cross-sectional study of birth outcomes examined associations between PbB and congenital anomalies using hospital records on 5,183 deliveries in Boston, Massachusetts (Needleman et al. 1984). The RR of an anomaly increased with increasing cord PbB; the RR (relative to PbB 0.7 $\mu\text{g/dL}$) was 1.87 (95% CI 1.44, 2.42) for PbB of 6.3 $\mu\text{g/dL}$ and increased to 2.39 (95% CI 1.66, 3.43) at 15 $\mu\text{g/dL}$ and 2.73 (95% CI 1.80, 4.16) at 24 $\mu\text{g/dL}$. The anomalies were considered to be minor (hemangiomas, lymphangiomas, hydrocele, minor skin anomalies, undescended testicle) and no specific anomaly was associated with PbB. Limitations of this study are that it was a cross-sectional study of a convenience sample with outcomes obtained from hospital records. Associations between PbB and congenital anomalies have not been corroborated.

Anthropometric measures in children. An overview of results of studies evaluating associations between Pb exposure and growth of infants and children (aged 0.5–15 years) at maternal and/or offspring PbB ≤ 10 $\mu\text{g/dL}$ is shown in Table 2-42, with more detailed results in Table 2-43. Studies include two prospective studies (Dallaire et al. 2014; Lamb et al. 2008), cross-sectional studies of large ($n=899$ – $1,050$) populations (Afeiche et al. 2011; Hong et al. 2014; Ignakiak et al. 2006), and several smaller ($n=108$ – 489) cohort and cross-sectional studies (Hauser et al. 2008; Little et al. 2009; Min et al. 2008b; Olivero-Verbel et al. 2007; Schell et al. 2009; Yang et al. 2013a). Most studies report negative associations between Pb exposure and height, with mixed results for weight and BMI (Table 2-42). A small ($n=290$) prospective study showed an association between cord PbB (mean 4.8 $\mu\text{g/dL}$) and small decreases in height and head circumference, but not for weight or BMI (Dellaire et al. 2014). Similarly, Lamb et al. (2008) did not find an association between maternal PbB and height or BMI at maternal PbB means of 5.60–20.56 $\mu\text{g/dL}$ (means for different geographic locations). In contrast, results of large case-control studies showed negative associations between maternal bone Pb and weight (Afeiche et al. 2011), maternal PbB and weight and height (Hong et al. 2014), and child PbB and several growth measures, including weight, height, and BMI (Ignasiak et al. 2006). The largest negative association for decreased weight was observed for maternal bone Pb in females assessed at 2–5 years of age; the mean PbB in children was 3.8 $\mu\text{g/dL}$ (Afeiche et al. 2011). At the 5-year assessment, body weight in females was decreased by approximately 172 g for each 1-SD increase in maternal bone Pb. Smaller case-control and

2. HEALTH EFFECTS

cohort studies reported consistent negative associations between PbB and height, with equivocal findings for weight, and no associations for BMI.

Table 2-42. Overview of Decreased Anthropometric Measures in Children at Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$

Reference	Age at time of assessment (years)	Anthropometric measurements		
		Weight	Height	BMI
Afeiche et al. 2011	1–5	↓ (F); 0 (M)	–	–
Dallaire et al. 2014	8–14	0	↓	0
Hauser et al. 2008	8–9	0	↓	0
Hong et al. 2014	0.5–2	↓	↓	–
Ignasiak et al. 2006	7–15	↓ (F); 0 (M)	↓ (F); 0 (M)	↓
Lamb et al. 2008	1–10	0	0	0
Little et al. 2008	2–12	↓	–	–
Min et al. 2008b	5–13	0	↓	–
Olivero-Verbel et al. 2007	5–9	0	↓	–
Schell et al. 2009	0.5–1	0	↓	–
Yang et al. 2013a	3–9	↓	↓	0

↓ = decrease in outcome measure; 0 = no effect on outcome measure; – = not assessed; BMI = body mass index; F = females; M = males

Delayed puberty. Results of studies that evaluated associations between Pb exposure and sexual maturation in boys and girls at child PbB ≤ 10 $\mu\text{g}/\text{dL}$ are summarized in Table 2-44. In girls, delayed onset of puberty, as measured by breast development, pubic hair development, and attainment of menarche, has been corroborated in multiple cross-sectional studies (Den Hond et al. 2011; Denham et al. 2005; Gollenberg et al. 2010; Naicker et al. 2010; Selevan et al. 2003; Wu et al. 2003b). Mean PbB in these studies ranged from 0.49 to 4.9 $\mu\text{g}/\text{dL}$. Delays in the predicted attainment of menarche ranged from 3.6 to 10.6 months (Denham et al. 2005; Selevan et al. 2003). Fewer studies examining associations between Pb exposure and sexual maturation in boys at child PbB ≤ 10 $\mu\text{g}/\text{dL}$ are available. Results of these studies are equivocal. Delayed sexual maturation, measured by genitalia development, testicular volume, and pubic hair development, was observed in two cross-sectional studies of the same study population of 489 boys; the median child PbB was 3 $\mu\text{g}/\text{dL}$ (Hauser et al. 2008; Williams et al. 2010). However, no association between PbB and the onset of puberty was observed in a cross-sectional study of 887 boys with a median PbB of 2.5 $\mu\text{g}/\text{dL}$ (Den Hond et al. 2011).

2. HEALTH EFFECTS

Table 2-43. Summary of Epidemiological Studies Evaluating Anthropometric Measurements in Infants and Children with Mean Blood Lead Concentration (PbB) $\leq 10 \mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$) ^c	Outcome evaluated	Result ^d
Afeiche et al. 2011 Cross-sectional study; n=999 mother-child pairs	<ul style="list-style-type: none"> Child PbB mean: 3.8 Maternal bone Pb (patella) mean ($\mu\text{g/g}$): 10.4 	Weight (females)	Associations between a 1-SD increase in maternal bone Pb ($\mu\text{g/g}$) and child weight (g) for children aged: <ul style="list-style-type: none"> 12 months: -70.9 (-147.9, 6.0) 24 months: -96.1 (-170.4, -21.8)* 36 months: -121.3 (-200.0, -42.6)* 48 months: -146.4 (-235.5, -57.4)* 60 months: -171.6 (-275.2, -68.0)*
		Weight (males)	Associations between a 1-SD increase in maternal bone Pb ($\mu\text{g/g}$) and child weight (g) for children aged: <ul style="list-style-type: none"> 12 months: 29.4 (-42.1, 100.8) 24 months: 27.8 (-43.5, 99.1) 36 months: 7.9 (-67.3, 83.1) 48 months: -13.6 (-97.9, 70.8) 60 months: -35.0 (-132.4, 62.3)
Dallaire et al. 2014 Prospective cohort study; n=290 children (aged 8–14 years)	<ul style="list-style-type: none"> Cord PbB mean: 4.8 Child PbB mean: 2.7 	Height	β coefficients (cm per $\mu\text{g/dL}$ cord): -1.57; p=0.004*
		Head circumference	β coefficients (cm per $\mu\text{g/dL}$ cord): -0.005; p=0.04*
		Weight	β coefficients (kg per $\mu\text{g/dL}$ cord): β not reported; p=0.70
		BMI	β coefficients (kg/m ² per $\mu\text{g/dL}$ cord): 0.07; p=0.23

2. HEALTH EFFECTS

Table 2-43. Summary of Epidemiological Studies Evaluating Anthropometric Measurements in Infants and Children with Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$) ^c	Outcome evaluated	Result ^d
Hauser et al. 2008 Cross-sectional study n=489 children (aged 8–9 years)	Child PbB, mean: 3	Height	Regression coefficient (cm per $\mu\text{g}/\text{dL}$): -1.439 (-2.25, -0.63); p<0.001*
		Weight	Regression coefficient (kg per $\mu\text{g}/\text{dL}$): -0.761 (-1.54, 0.02); p=0.067
		BMI	Regression coefficient (kg/m^2 per $\mu\text{g}/\text{dL}$): -0.107 (-0.44, 0.23); p=0.53
Hong et al. 2014 Cross-sectional study; n=1,150 infants (aged 6–24 months)	Maternal PbB mean: 1.25	Weight	Weight z score: -0.28 (-0.48, -0.09); p<0.05*
		Height	Height z score: -0.28 (-0.49, -0.06); p<0.05*
Ignasiak et al. 2006 Cross-section study; n=899 children (aged 7–15 years)	Child PbB mean: 7.7	Weight	<ul style="list-style-type: none"> Slope boys (kg per \log_{10} $\mu\text{g}/\text{dL}$): 4.00 (2.45); p=0.10 Slope girls (kg per \log_{10} $\mu\text{g}/\text{dL}$): -6.59 (2.09); p=0.001*
		Height	<ul style="list-style-type: none"> Slope boys (cm per \log_{10} $\mu\text{g}/\text{dL}$): -6.26 (1.40); p=0.002 Slope girls (cm per \log_{10} $\mu\text{g}/\text{dL}$): -5.54 (2.05); p=0.007*
		BMI	<ul style="list-style-type: none"> Slope boys (kg/m^2 per \log_{10} $\mu\text{g}/\text{dL}$): -0.39 (0.82); p=NS Slope girls (kg/m^2 per \log_{10} $\mu\text{g}/\text{dL}$): -1.86 (0.75); p=0.01*
		Trunk length	<ul style="list-style-type: none"> Slope (boys (cm per \log_{10} $\mu\text{g}/\text{dL}$): -2.21 (0.97); p=0.02* Slope girls (cm per \log_{10} $\mu\text{g}/\text{dL}$): -1.47 (1.00); p=NS

2. HEALTH EFFECTS

Table 2-43. Summary of Epidemiological Studies Evaluating Anthropometric Measurements in Infants and Children with Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$) ^c	Outcome evaluated	Result ^d
		Leg length	<ul style="list-style-type: none"> • Slope boys (cm per \log_{10} $\mu\text{g}/\text{dL}$): -4.05 (1.27); $p=0.002^*$ • Slope girls (cm per \log_{10} $\mu\text{g}/\text{dL}$): -4.08 (1.27) $p=0.0001^*$
		Arm length	<ul style="list-style-type: none"> • Slope boys (cm per $\mu\text{g}/\text{dL}$): -3.20 (0.97); $p=0.0001^*$ • Slope girls (cm per \log_{10} $\mu\text{g}/\text{dL}$): -2.61 (0.98); $p=0.008^*$
		Trunk-length ratio	<ul style="list-style-type: none"> • Slope boys (per \log_{10} $\mu\text{g}/\text{dL}$): 0.71 (0.34); $p=0.04^*$ • Slope girls (per \log_{10} $\mu\text{g}/\text{dL}$): 1.03 (0.34); $p=0.003^*$
Lamb et al. 2008 Population-based prospective cohort; n=309 children (aged 1–10) years	Maternal PbB mean for towns of: <ul style="list-style-type: none"> • Pristina: 5.60 • Mitrovica: 20.56 	Height/BMI	Pristina (β coefficients per \log $\mu\text{g}/\text{dL}$): <ul style="list-style-type: none"> • Age 1 year: -0.61 (-2.24, 1.03) • Age 10 years: -0.09 (-3.69, 3.52) Mitrovica (β coefficients per \log $\mu\text{g}/\text{dL}$): <ul style="list-style-type: none"> • Age 1 year: -0.30 (-2.55, 1.96) • Age 10 years: -2.87 (-6.21, 0.47)
Little et al. 2009 Cross-sectional study; n=360 children (aged 2–12 years)	Child PbB mean <ul style="list-style-type: none"> • 1980 cohort: 23.6 • 2002 cohort: 1.6 • Pooled cohort PbB mean not reported 	Height	β coefficient (cm per 10 $\mu\text{g}/\text{dL}$ PbB decrease): 2.1 (1.9, 2.3); $p<0.0001^*$
		Weight	β coefficient (kg per 10 $\mu\text{g}/\text{dL}$ PbB decrease): 1.9 (1.7, 2.1); $p<0.0001^*$
		BMI	β coefficient (kg/m^2 per 10 $\mu\text{g}/\text{dL}$ PbB decrease): 0.5 (0.4, 0.7); $p<0.0001^*$

2. HEALTH EFFECTS

Table 2-43. Summary of Epidemiological Studies Evaluating Anthropometric Measurements in Infants and Children with Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$) ^c	Outcome evaluated	Result ^d
Min et al. 2008b Cross-sectional study; n=108 children (aged 5–13 years)	Child PbB mean: 2.4	Height	Regression coefficient cm per $\mu\text{g}/\text{dL}$ (SE): -1.449 (0.639); p=0.026*
		Weight	Regression coefficient kg per $\mu\text{g}/\text{dL}$ (SE): -0.646 (0.718); 0.370
		BMI	Regression coefficient kg/m^2 per $\mu\text{g}/\text{dL}$ (SE): -0.006 (0.272); p=0.982
		Arm length	Regression coefficient cm per $\mu\text{g}/\text{dL}$ (SE): -1.804 (0.702); p=0.012*
Olivero-Verbel et al. 2007 Cross-sectional study; n=189 children (aged 5–9 years)	Child PbB mean: 5.53	Height	Correlation coefficient: -0.224; p=0.002*
		Weight	Correlation coefficient: -0.126; p=0.087
Schell et al. 2009 Longitudinal cohort study; n=244 children (aged 3–12 months)	Maternal PbB mean: 2.8	Length	Regression coefficients (SE): <ul style="list-style-type: none"> • 6 months (cm per log $\mu\text{g}/\text{dL}$): 0.149 (0.076); p=0.05* • 12 months (cm per log $\mu\text{g}/\text{dL}$): 0.073 (0.083); p=0.38
		Weight-for-age	Regression coefficients (SE): <ul style="list-style-type: none"> • 6 months (kg per $\mu\text{g}/\text{dL}$): 0.013 (0.098); p=0.89 • 12 months (kg per $\mu\text{g}/\text{dL}$): 0.124 (0.107); p=0.25
		Weight for length	Regression coefficients (SE): <ul style="list-style-type: none"> • 6 months(per $\mu\text{g}/\text{dL}$): -0.158 (0.111); p=0.16 • 12 months (per $\mu\text{g}/\text{dL}$): 0.084 (0.111); p=0.45

2. HEALTH EFFECTS

Table 2-43. Summary of Epidemiological Studies Evaluating Anthropometric Measurements in Infants and Children with Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$) ^c	Outcome evaluated	Result ^d
		Head circumference	Regression coefficients (SE): <ul style="list-style-type: none"> • 6 months (cm per $\mu\text{g}/\text{dL}$): -0.242 (0.094); p=0.01* • 12 months (cm per $\mu\text{g}/\text{dL}$): -0.220 (0.109); p=0.05*
		Upper arm circumference	Regression coefficients (SE): <ul style="list-style-type: none"> • 12 months (cm per $\mu\text{g}/\text{dL}$): -0.132 (0.114); p=0.25
Yang et al. 2013a	Child PbB mean: 7.30	Height	β coefficient (cm per $\mu\text{g}/\text{dL}$): -0.10; p=0.02*
Cross sectional study; n=246 children (aged 3–8 years)		Weight	β coefficient (kg per $\mu\text{g}/\text{dL}$): -0.14; p=0.01*
		BMI	β coefficient (kg/m ² per $\mu\text{g}/\text{dL}$): -0.08; p=0.24

^aSee the *Supporting Document for Epidemiological Studies for Lead*, Table 13 for more detailed descriptions of studies.

^bParticipants had no known occupational exposure to Pb.

^cValues are for maternal PbB, unless otherwise specified.

^dAsterick indicates association with Pb; unless otherwise specified, values in parenthesis are 95% CIs.

BMI = body mass index; CI = confidence interval; NS = not statistically significant; OR = odds ratio; Pb = lead; SD = standard deviation; SE = standard error

2. HEALTH EFFECTS

Table 2-44. Summary of Epidemiological Studies Evaluating the Onset of Puberty at Children with Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g/dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g/dL}$) ^c	Outcome evaluated	Result ^d
Onset of puberty in females			
Den Hond et al. 2011 Cross-sectional study; n=792 girls (aged 14–15 years)	Median: 1.81	Pubic hair development	OR: 0.65 (0.45, 0.93); p=0.020*
Denham et al. 2005 Cross-sectional study; n=138 girls (aged 10–16.9 years)	Mean: 0.49	Attainment of menarche	β coefficient (SE) predicting likelihood of attaining menarche (per ln $\mu\text{g/dL}$): -1.29 (0.494); p=0.01*
Gollenberg et al. 2010 Cross-sectional study; n=705 girls (aged 6–11 years)	Median: 2.5 Tertiles • T1: <1.0 • T2: 1–4.99 • T3: ≥ 5.00	Inhibin B pubertal cutoff value	OR for exceeding pubertal cutoff value: • T2 (OR): 0.38 (0.12, 1.15)* • T3 (OR): 0.26 (0.11, 0.60)*
Naicker et al. 2010 Cross-sectional, longitudinal study; n=682 girls (aged 13 years)	Mean: 4.9	Breast development Pubic hair development Attainment of menarche	Trend analysis over ages 8–16 years: p<0.001* Trend analysis over ages 8–16 years: p<0.001* Trend analysis over ages 8–16 years: p<0.001*

2. HEALTH EFFECTS

Table 2-44. Summary of Epidemiological Studies Evaluating the Onset of Puberty at Children with Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$) ^c	Outcome evaluated	Result ^d
Selevan et al. 2003 Cross-sectional study; n=2,186 girls (aged 8–18 years)	Gmean • NHW: 1.4 • NHAA: 2.1 • MA: 1.7	Breast development	<ul style="list-style-type: none"> • NHW OR: 0.82 (0.47, 1.42) • NHAA OR: 0.64 (0.42, 0.97); p<0.05* • MA OR: 0.76 (0.63, 0.91); p<0.05*
		Pubic hair development	<ul style="list-style-type: none"> • NHW OR: 0.75 (0.37, 1.51) • NHAA OR: 0.62 (0.41, 0.96); P<0.05 • MA OR: 0.70 (0.54, 0.91); p<0.05
		Age of menarche	<ul style="list-style-type: none"> • NHW HR: 0.74 (0.55, 1.002) • NHAA HR: 0.78 (0.63, 0.98); p<0.05 (age at menarche delayed 3.6 months)* • MA HR: 0.90 (0.73, 1.11)
Wolff et al. 2008 Cross-sectional study; n=192 girls (aged 9 years)	Median: 2.4	Breast development	PR for breast stage ≥ 2 versus stage 1: 1.01 (0.79, 1.30)
		Pubic hair development	PR for pubic hair stage ≥ 2 versus stage 1: 1.25 (0.83, 1.88)
Wu et al. 2003b Cross-sectional study; n=1,706 girls (aged 8–16 years)	Mean: 2.5 Tertiles: • T1: 0.7–2.0 (reference) • T2: 2.1–4.9 • T3: 5.0–21.7	Breast development	<ul style="list-style-type: none"> • OR for T2: 1.51 (0.90, 2.53) • OR for T3: 1.20 (0.51, 2.85)
		Pubic hair development	<ul style="list-style-type: none"> • OR for T2: 0.48 (0.25, 0.92)* • OR for T3: 0.27 (0.08, 0.93)*
		Attainment of menarche	<ul style="list-style-type: none"> • OR for T2: 0.42 (0.18, 0.97)* • OR for T3: 0.19 (0.08, 0.43)*
Onset of puberty in males			
Den Hond et al. 2011 Cross-sectional study; n=887 boys (aged 12–15 years)	Median: 2.50	Onset of puberty	No association between PbB and the onset of puberty (specific data not reported)

2. HEALTH EFFECTS

Table 2-44. Summary of Epidemiological Studies Evaluating the Onset of Puberty at Children with Mean Blood Lead Concentration (PbB) ≤ 10 $\mu\text{g}/\text{dL}$ ^a

Reference and study population ^b	PbB ($\mu\text{g}/\text{dL}$) ^c	Outcome evaluated	Result ^d
Hauser et al. 2008 Cross-sectional study; n=489 peripubertal boys (aged 8–9 years)	Median: 3	Genitalia development	OR for having entered genitalia stage G2 for PbB ≥ 5 compared to PbB < 5: 0.57 (0.34, 0.95); p=0.03*
Williams et al. 2010 Longitudinal cohort; n=489 peripubertal boys (aged 8–9 years)	Median: 3	Testicular volume	HR for testicular volume < 3 mL for PbB ≥ 5 $\mu\text{g}/\text{dL}$ compared to PbB < 5 $\mu\text{g}/\text{dL}$: 0.73 (0.55, 0.97); p=0.03*
		Genitalia stage	HR for having entered genitalia stage G2 for PbB ≥ 5 $\mu\text{g}/\text{dL}$ compared to PbB < 5 $\mu\text{g}/\text{dL}$: 0.76 (0.59, 0.98); p=0.04*
		Pubic hair stage	HR for having entered pubic hair stage G2 for PbB ≥ 5 $\mu\text{g}/\text{dL}$ compared to PbB < 5 $\mu\text{g}/\text{dL}$: 0.69 (0.44, 1.07); p=0.10

^aSee the *Supporting Document for Epidemiological Studies for Lead*, Table 13 for more detailed descriptions of studies.

^bParticipants had no known occupational exposure to Pb.

^cValues are for maternal PbB, unless otherwise specified.

^dAsterick indicates association with Pb; unless otherwise specified, values in parenthesis are 95% CIs.

CI = confidence interval; MA = Mexican Americans; NHW = Non-Hispanic whites; NHAA = Non-Hispanic African Americans; NS = not statistically significant; OR = odds ratio; Pb = lead; PR = prevalence ratio; SE = standard error

2. HEALTH EFFECTS

Associations Between Bone Pb and Birth Outcome and Post-Natal Growth. Studies evaluating associations between maternal bone Pb and birth outcome (birth weight and length, head circumference) and postnatal growth (infant and child weight gain) are summarized in Table 2-45. Studies were conducted in mother-infant/child pairs residing in Mexico City. Maternal tibia Pb was negatively associated with birth weight (Cantonwine et al. 2010b; Gonzalez-Cossio et al. 1997; Kordas et al. 2009), birth length (Hernandez-Avila et al. 2002), and head circumference (Hernandez-Avila et al. 2002; Kordas et al. 2009). Maternal patella Pb was associated with decreased head circumference (Hernandez-Avila et al. 2002), but not birth weight (Afeiche et al. 2011; Gonzalez-Cossio et al. 1997) or birth length (Hernandez-Avila et al. 2002). Infant weight gain measured at 1 month of age was negatively associated with maternal patella Pb, but not maternal tibia Pb (Sanin et al. 2001); no associations between maternal tibia or patella Pb were observed from birth to 12 months of age (Afeiche et al. 2011). Maternal patella Pb was negatively associated with weight gain in girls, but not boys, at 5 years of age; however, no associations were observed for maternal tibia Pb for boys or girls. Taken together, results of these studies provide evidence that long-term maternal Pb exposure is negatively associated with infant size and post-natal growth.

Table 2-45. Associations Between Maternal Bone Pb and Birth Outcome and Postnatal Growth

Reference	Population ^a	Effect				
		Birth weight	Birth length	Head circumference	Infant weight gain	Child weight gain ^b
Afeiche et al. 2011	Mother-infant pairs (522 boys; 477 girls)	0 T (M, F) 0 P (M, F)	–	–	0 T (M, F) ^c 0 P (M, F) ^c	0 T (M, F) 0 P (M) ↓ P (F)
Cantonwine et al. 2010b	538 mother-infant pairs	↓ T	–	–	–	–
Gonzalez-Cossio et al. 1997	272 mother-infant pairs	↓ T 0 P	–	–	–	–
Hernandez-Avila et al. 2002	223 mother-infant pairs	–	↓ T 0 P	↓ T ↓ P	–	–
Kordas et al. 2009	474 mother-infant pairs	↓ T	0 T	↓ T	–	–

2. HEALTH EFFECTS

Table 2-45. Associations Between Maternal Bone Pb and Birth Outcome and Postnatal Growth

Reference	Population ^a	Effect				
		Birth weight	Birth length	Head circumference	Infant weight gain	Child weight gain ^b
Sanin et al. 2001	329 mother-infant pairs	–	–	–	0 T ^d ↓ P ^d	–

^aFrom Mexico City.

^bMeasured at 5 years of age.

^cMeasured from birth to 12 months of age.

^dMeasured at 1 month of age.

↓ = negative association; 0 = no association; – = not reported; F = female; M = male; P = patella; Pb = lead; T = tibia

Mechanisms of Action. General mechanisms of toxicity of Pb (reviewed in Section 2.21) are likely involved in adverse development effects. EPA (2014c) specifically noted that delayed puberty may result from alterations in pulsatile release of sex hormones and that insulin-like growth factor 1 (IGF-1) may play a role in this effect. Pb is distributed to the fetus and has been measured in umbilical cord blood, placenta, and follicular fluid (See Section 3.1.2, Toxicokinetics, Distribution), providing a toxicokinetic mechanism for direct exposure of the fetus.

2.19 CANCER

Overview. Numerous epidemiological studies have investigated associations between Pb exposure and cancer. Studies include exposure of workers and general populations, with many studies reporting PbB. In most studies, mean PbBs in these studies are <10 µg/dL. Although studies provide limited evidence of carcinogenicity of Pb in humans, results are inconsistent and interpretation may be limited due to confounding factors.

Many studies of occupational cohorts and cancer risks do not report PbB data. These studies have reported associations between occupational exposure to Pb and cancer, including overall cancer mortality and cancers of the lung, brain, stomach, kidney, and bladder. However, results are inconsistent and interpretation may be limited due to confounding factors.

2. HEALTH EFFECTS

The following cancers have been associated with PbB:

- ≤ 10 $\mu\text{g/dL}$:
 - Increased risk of all cancer; evaluated in multiple studies with mixed results.
 - Increased risk of lung cancer; evaluated in multiple studies with mixed results.
- >10 $\mu\text{g/dL}$:
 - Increased risk of all cancer; evaluated in multiple studies with mixed results.
 - Increased risk of respiratory tract cancers (bronchus, trachea, lung); evaluated in multiple studies with mixed results.
 - Increased risk of stomach cancer; evaluated in multiple studies with mixed results.
 - Increased risk of intestinal cancer.
 - Increased risk of cancer of the larynx.
 - Increased risk of glioma.

Carcinogenicity Classifications of Pb and Pb Compounds. IARC has classified inorganic Pb compounds as probably carcinogenic to humans (Group 2A) based on sufficient evidence in animals and limited evidence in humans; evidence for organic Pb compounds was considered to be inadequate in humans and animals (IARC 2006). The National Toxicology Program 14th Report on Carcinogens classified Pb and Pb compounds as reasonably anticipated to be human carcinogens (NTP 2016). As the basis of the Group 2A classification for inorganic Pb compounds, IARC (2006) cited multiple animal studies showing kidney cancer following chronic oral and parenteral exposure (Azar et al. 1973; Balo et al. 1965; Fears et al. 1989; Kasprzak et al. 1985; Koller et al. 1985; Van Esch and Kroes 1969; Zawirska 1981; Zollinger 1953), renal tubular adenoma in offspring of mice exposed during gestation and lactation (Waalkes et al. 1995), and brain gliomas following oral exposure of rats (Zawirska 1981; Zawirska and Medras 1972). For epidemiological studies of occupational cohorts, IARC (2006) noted limited evidence of carcinogenicity of the lung, stomach, kidney, and brain/nervous system, although studies yielded inconsistent results, and interpretation of results was compromised due to potential confounding factors (e.g., smoking, occupational exposure to other carcinogens such as arsenic).

Confounding Factors and Effect Modifiers. Numerous factors can influence results of epidemiological studies evaluating associations between Pb exposure and cancer, including smoking status, family history of cancer, and co-exposure to other carcinogens. Failure to account for these factors may attenuate or strengthen the apparent associations between Pb exposure and the outcome, depending on the direction of the effect of the variable on the outcome. For example, many occupational studies include smelters where

2. HEALTH EFFECTS

exposure to arsenic and other carcinogenic metals (e.g., cadmium) can be correlated with exposure to Pb. Exposures to Pb occur throughout the lifetime and a cross-sectional evaluation of PbB may not adequately represent the exposure history of the individual.

Measures of Exposure. Numerous studies evaluating cancer in general populations and Pb-exposed workers report PbB as a measure of exposure. A few studies measured exposure by bone Pb concentrations, cumulative blood Pb index, or cumulative exposure (Bhatti et al. 2009; Englyst et al. 2001; Ionescu et al. 2007; Rajaraman et al. 2006); however, these studies did not report PbB.

Characterization of Effects. Numerous epidemiological studies have assessed associations between PbB and cancer. Studies of general populations and workers are briefly summarized in Table 2-46. Studies of general populations include large cross-sectional studies (n=5,482–13,946) of NHANES participants (Cheung et al. 2013; Jemal et al. 2002; Menke et al. 2013; Schober et al. 2006). Mean PbBs in most studies are <10 µg/dL, although in some studies that stratify by PbB, the highest exposure categories are >10 µg/dL (Jemal et al. 2002; Kelly et al. 2013; Schober et al. 2006). Results of two studies with PbB <10 µg/dL show increased risks of all cancer and of lung cancer (Cheung et al. 2013; Schober et al. 2006), although other studies show no increases in cancer risk (Jemal et al. 2002; Khalil et al. 2009; Kelly et al. 2013; Menke et al. 2013; Santibanez et al. 2008; Wiesskoph et al. 2009). Results of occupational exposure studies are mixed and do not establish a pattern of effects of exposure-response relationships. PbBs in these studies generally are >40 µg/dL. Studies have reported associations between PbB and all cancer (Anttila et al. 1995; Lundstrom et al. 1997; Lustberg and Silbergeld 2002; McElvenny et al. 2015; Wong and Harris et al. 2000), cancers of the bronchus, trachea, and lung (Anttila et al. 1995; Chowdhury et al. 2014; Kim et al. 2015; Lundstrom et al. 1997; McElvenny et al. 2015; Steenland and Boffetta 2000), cancer of the larynx (Chowdhury et al. 2014), stomach cancer (Cooper et al. 1985; Steenland and Boffetta 2000; Wong and Harris et al. 2000), intestinal cancer (Kim et al. 2015), and gliomas (Anttila et al. 1996).

Many studies of occupational cohorts with high exposure to Pb and cancer risks do not report PbB data (Bertazzi and Zocchetti 1980; Bhatti et al. 2009; Cocco et al. 1994, 1997, 1998a, 1998b, 1999a, 1999b; Davies 1984a, 1984b; Dingwall-Fordyce and Lane 1963; Fayerweather et al. 1997; Hu et al. 1999; Jones et al. 2007; Kauppinen et al. 1992; Lin et al. 2009; McElroy et al. 2008; Michaels et al. 1991; Pan et al. 2011; Partanen et al. 1991; Pesch et al. 2000; Rajaraman et al. 2006; Risch et al. 1988; Rousseau et al. 2007; Sankila et al. 1990; Sheffet et al. 1982; Siemiatycki 1991; Sweeney et al. 1986; van Wijngaarden and Dosemeci 2006; Wingren and Englander 1990). Although results of these studies are mixed and

2. HEALTH EFFECTS

Table 2-46. Summary of Epidemiological Studies Evaluating Cancer Endpoints and Blood Lead Concentration (PbB)

Reference and study population	PbB ($\mu\text{g/dL}$)	Cancer outcomes	Effects ^a
General population			
Cheung et al. 2013	Mean (SE): 4.44 (0.14)	All cancer	OR: 1.071 (1.036, 1.106)*
Cross-sectional study; n=3,482 (NHANES III)		Lung cancer	OR: 1.090 (1.054, 1.127)*
Jemal et al. 2002	Quartiles: • Q1: ≤ 9.8 • Q2: 9.9–12.9 • Q3: 13.0–16.9 • Q4: ≥ 17.0	All cancer	Adjusted RR Q4: 1.50 (0.75, 3.01)
Cross-sectional study; n=3,592 (NHANES II, age 6 months–74 years)			
Khalil et al. 2009	Mean: 5.3 <8 (n=453) ≥ 8 (n=79)	All cancer	Adjusted HR PbB ≥ 8 (versus <8): 1.64 (0.73, 3.71)
Prospective cohort study; n=532 women (age 65–87 years)			
Kelly et al. 2013	Mean (range) • Males: 6.18 (1.54, 67.2) • Females: 5.27 (1.1, 40.1) Quartiles • Q1: 1.54–3.93 • Q2: 3.93–5.88 • Q3: 5.88–8.72 • Q4: 8.75–40.1	NHL MM	OR Q4: 0.93 (0.43, 2.02) p-trend=0.849 OR Q4: 1.63 (0.45, 5.94) p-trend=0.533
Nested case-control study; n=194 cases NHL; 76 cases MM; and 270 controls (mean age 53.08 years)			
Menke et al. 2006	Mean: 2.58 Tertiles: • T1: <1.93 • T2: 1.94–3.62 • T3: ≥ 3.62	All cancer	Adjusted OR • T2: 0.72 (0.46, 1.12); p-trend=0.130 • T3: 1.10 (0.82, 1.47); p-trend=0.101
Cross-sectional study; n=13,946 (NHANES 1988–1994; mean age 44.4 years)			

2. HEALTH EFFECTS

Table 2-46. Summary of Epidemiological Studies Evaluating Cancer Endpoints and Blood Lead Concentration (PbB)

Reference and study population	PbB ($\mu\text{g/dL}$)	Cancer outcomes	Effects ^a
Santibanez et al. 2008 Case-control study; n=185 esophageal cancer patients; 285 controls (age 30–80 years)	Low: ≤ 4.9 High: >4.9	Esophageal	Adjusted OR <ul style="list-style-type: none"> Low: 0.79 (0.43, 1.46) High: 1.69 (0.57, 5.03)
Schober et al. 2006 Cross-sectional study; n=9,757 (NHANES III; age ≥ 40 years)	Tertiles <ul style="list-style-type: none"> T1: <5 (mean 2.6) T2: 5–9 (mean 6.3) T3: >10 (mean 11.8) 	All cancer	Adjusted RR <ul style="list-style-type: none"> T2: 1.44 (1.12, 1.86)* T3: 1.69 (1.14, 2.52)* p-trend $<0.01^*$
Weisskopf et al. 2009 Prospective study; n=868 men (Normative Aging Study; age 21–80 years)	Mean (SD): 5.6 (3.4) Tertiles: <ul style="list-style-type: none"> T1: <4 T2: 4–6 T3: >6 	All cancer	Adjusted HR T3: 0.48 (0.25–0.91)*; p-trend=0.02
Workers			
Anttila et al. 1995 Cross-sectional study; n=20,700 workers (age 30–74 years)	Tertiles: <ul style="list-style-type: none"> T1: 0–18.6 T2: 20.7–39.4 T3: 41.1–161.6 	All cancer <hr/> Lung, trachea	SMR T2: 1.4 (1.1, 1.8)* SMR T3: 1.2 (0.9, 1.8) <hr/> SMR T2: 2.0 (1.2, 3.2)* SMR T3: 1.5 (0.8, 2.1)
Anttila et al. 1996 Cross-sectional study; n=20,741 workers (age 18–74 years)	Tertiles: <ul style="list-style-type: none"> T1: 2.1–14.5 T2: 16.6–26.9 T3: 29.0–89.1 	All nervous system cancers <hr/> Glioma	Adjusted OR T3: 2.2 (0.7, 6.6) p-trend=0.17 <hr/> Adjusted OR T3: 11 (1.0, 626)* p-trend: 0.037

2. HEALTH EFFECTS

Table 2-46. Summary of Epidemiological Studies Evaluating Cancer Endpoints and Blood Lead Concentration (PbB)

Reference and study population	PbB ($\mu\text{g/dL}$)	Cancer outcomes	Effects ^a
Chowdhury et al. 2014 Survey study/cross-sectional; n=58,368 male workers (mean age 38.9 years)	Quartiles • Q1: 0–<5 • Q2: 5–<25 • Q3: 25–<40 • Q4: \geq 40	Lung	SMR Q4: 1.20 (1.03, 1.39)*
		Brain	SMR Q4: 0.83 (0.41, 1.49)
		Kidney	SMR Q4: 0.72 (0.33, 1.37)
		Stomach	SMR Q4: 0.92 (0.44, 1.69)
		Esophagus	SMR Q4: 0.65 (0.32, 1.16)
		Larynx	SMR Q4: 2.11 (1.05, 3.77)*
		Bladder	SMR Q4: 0.70 (0.28, 1.45)
		Cooper et al. 1985 Cohort study; n=4,519 battery workers; 2,300 smelters	Mean • Battery (n=1,326): 62.7 • Smelters (n=537): 79.7
Stomach	Battery PMR: 1.54 (1.11, 2.15)* Smelters PMR: 1.03 (0.75, 1.42)		
Large intestine	Battery PMR: 0.98 (0.69, 1.40) Smelters PMR: 1.19 (0.62, 2.28)		
Larynx	Battery PMR: 1.19 (0.54, 2.65) Smelters PMR (95% CI): 1.06 (0.27, 4.21)		
Bronchus, trachea, lung	Battery PMR: 1.16 (0.97, 1.39) Smelters PMR: 1.13 (0.84, 1.51)		
Brain and other CNS	Battery PMR: 1.09 (0.55, 2.18) Smelters PMR: 0.97 (0.32, 3.01)		

2. HEALTH EFFECTS

Table 2-46. Summary of Epidemiological Studies Evaluating Cancer Endpoints and Blood Lead Concentration (PbB)

Reference and study population	PbB ($\mu\text{g/dL}$)	Cancer outcomes	Effects ^a
Kim et al. 2015 Cross-sectional study; n=81,067 inorganic Pb workers (54,788 males; 26,279 females; age 20–≤50 years)	Mean (SD) • Males: 8.8 (8.5) • Females 5.8 (5.4) Tertiles: • T1: <10 • T2: 10–20 • T3: >20	All cancer Stomach Colo-rectal Liver Bronchus, lung	Males: RR T3: 0.95 (0.56, 1.61) Females RR T3: 1.68 (0.40, 7.13) Males: RR T3: 0.80 (0.23, 2.71) Females RR T2: 1.82 (0.20, 16.36) Females T3: No cases Males: RR T3: 1.86 (0.35, 9.79) Females RR T2: 13.42 (1.21, 149.4)*; p<0.05 Females T3: No cases Males: RR T3: 1.72 (0.72, 4.14) Females T2 RR: 0.83 (0.10, 6.56) Females T3: No cases Males: RR T3: 0.46 (0.10, 2.01) Females RR T2: 10.45 (1.74, 62.93)*; p<0.05 Females RR T3: 12.68 (1.69, 147.86)*; p<0.05
Lundstrom et al. 1997 Cross-sectional; n=3979 workers	Mean: • In 1950: 62.2 • In 1987: 33.2	All cancer Lung	SMR: 1.2 (1.0, 1.5)* SMR: 2.8 (2.0, 3.8)*
Lundstrom et al. 2006 Nested case-referent study; 3,979 smelter workers	Peak: Cases (n=40): 49.7 Referents (n=114): 55.9	Lung	OR: 0.93 (0.60, 1.44)
Lustberg and Silbergeld 2002 Cross-sectional study; n=4,292; age 30–74 years (NHANES II)	Tertiles: • T1 (n=818): <10 • T2 (n=2,735): 10–19 • T3 (n=637): 20–29	All cancer (rate ratio)	RR T2: 1.46 (0.87, 2.48) RR T3: 1.68 (1.02, 2.78)*

2. HEALTH EFFECTS

Table 2-46. Summary of Epidemiological Studies Evaluating Cancer Endpoints and Blood Lead Concentration (PbB)

Reference and study population	PbB (µg/dL)	Cancer outcomes	Effects ^a
McElvenny et al. 2015 Cohort study; n=9,122 workers; mean age 29.2 years	Mean (SD): 44.3 (22.7) Range: 2.3–321.5	All cancer	SMR: 1.13 (1.07, 1.20)*
		Esophagus	SMR: 1.05 (0.78, 13.8)
		Stomach	SMR: 1.11 (0.86, 1.43)
		Colon	SMR: 0.98 (0.77, 1.26)
		Kidney	SMR: 1.30 (0.91, 1.86)
		Bladder	SMR: 0.95 (0.67, 1.35)
		Bronchus, trachea, lung	SMR: 1.42 (1.29, 1.57)*
		Brain	SMR: 0.92 (0.61, 1.38)
Selevan et al. 1985 Retrospective cohort study; n=1,987 male workers	Mean: 56.3	All cancer	SMR: 0.95 (0.78, 1.14)
		Digestive organs	SMR: 0.77 (0.52, 1.10)
		Respiratory system	SMR: 1.11 (0.80, 1.51)
		Kidney	SMR: 2.04 (0.75, 4.44)
		Bladder	SMR: 1.44 (0.53, 3.14)
Steenland and Boffetta 2000 Meta-analysis; data from eight studies on Pb workers; n=36,027 workers	Range of study means: 26–80	Lung	RR: 1.14 (1.04, 1.25)*
		Stomach	RR: 1.34 (1.14, 1.57)*
		Brain	RR: 1.06 (0.81, 1.40)
Steenland et al. 1992 Cohort study (same cohort as Selevan et al. 1985); n=1,990 male smelter workers	Mean: 56.3	All Cancer	SMR: 0.98 (0.84, 1.12)
		Colon	SMR: 0.48 (0.22, 0.90)
		Lung	SMR: 1.18 (0.92, 1.48)
		Kidney	SMR: 1.93 (0.88, 3.67)

2. HEALTH EFFECTS

Table 2-46. Summary of Epidemiological Studies Evaluating Cancer Endpoints and Blood Lead Concentration (PbB)

Reference and study population	PbB ($\mu\text{g/dL}$)	Cancer outcomes	Effects ^a
Wong and Harris et al. 2000 Cohort study; n=4,519 battery workers; 2,300 smelters (same cohort as Cooper et al. 1985)	Mean: <ul style="list-style-type: none"> • All workers: 64.0 • Battery workers: 62.7 • Smelters: 79.7 	All cancer	SMR: 1.045 (1.012, 1.080)*
		Stomach	SMR: 1.474 (1.125, 1.898)*
		Large intestine	SMR: 0.994 (0.789, 1.235)
		Bronchus, trachea, lung	SMR: 1.164 (1.039, 1.299)
		Kidney	SMR: 0.636 (0.339, 1.087)
		CNS	SMR: 0.748 (0.419, 1.234)

^aAsterick indicates association with Pb; unless otherwise specified, values in parenthesis are 95% CIs.

CI = confidence interval; CNS = central nervous system; HR = hazard ratio; MM = multiple myeloma; NHANES = National Health and Nutrition Examination Survey; NHL = non-Hodgkin's lymphoma; OR = odds ratio; Pb = lead; PMR = proportionate mortality ratio; RR = rate ratio or relative ratio; SD = standard deviation; SE = standard error; SMR = standard mortality ratio

2. HEALTH EFFECTS

interpretation may be limited due to confounding factors, associations have been reported between occupational exposure to Pb and cancer, including overall cancer mortality and cancers of the lung, brain, stomach, kidney, and bladder.

Mechanisms of Action. Numerous mechanisms for Pb-induced carcinogenicity have been proposed (EPA 2014c); however, it is likely that a combination of mechanisms, rather than a single mechanism, is involved. Although Pb is considered to be only weakly mutagenic, it has been shown to produce DNA damage (single and double strand breaks), sister chromatid exchanges (SCEs), chromosome aberrations, micronuclei (MN) formation, and cytogenetic damage. Epigenetic mechanisms (e.g., changes in gene expression in the absence of changes to DNA), post-translational alterations to protein structure, and immune modulation of tumorigenesis in response to Pb-induced ROS oxidative damage and inflammation have also been proposed as possible mechanisms involved in Pb-induced carcinogenesis.

2.20 GENOTOXICITY

The genotoxicity of Pb has been studied in Pb workers and the general population, in *in vivo* animal models, and *in vitro* cultures of microorganisms and mammalian cells. For the following discussions, data from epidemiological studies on genotoxicity were obtained from the primary literature. Information on *in vitro* studies and *in vivo* animal studies was taken from comprehensive reviews of Pb genotoxicity (EPA 2014c; Garcia-Leston et al. 2010; IARC 2006; NTP 2003).

Epidemiological Studies

Overview. Epidemiological studies have examined genotoxic effects associated with Pb exposure in adults (general populations and workers) and children. Most studies were conducted in small populations of workers. Numerous studies with PbB ≥ 10 $\mu\text{g/dL}$ report positive associations for exposure to Pb and genotoxic endpoints (gene mutation, DNA damage, SCE, MN formation, and DNA methylation); results are generally positive, although some negative associations have been reported. Few epidemiology studies have evaluated genotoxicity at PbB ≤ 10 $\mu\text{g/dL}$.

2. HEALTH EFFECTS

The following genotoxic effects have been associated with PbB:

- ≤ 10 $\mu\text{g}/\text{dL}$:
 - Gene mutation.
 - DNA damage; evaluated in a few studies with mixed results.
 - DNA methylation; positive results, corroborated in a few studies.
- > 10 $\mu\text{g}/\text{dL}$:
 - DNA damage; corroborated in numerous studies.
 - Decreased telomere length.
 - Chromosomal aberrations; evaluated in numerous studies with mainly positive results.
 - Sister chromatid exchange; evaluated in numerous studies with mainly positive results.
 - Micronuclei formation; evaluated in numerous studies with mainly positive results.

Measures of Exposure. Studies evaluating the association between genotoxic effects and Pb exposure typically evaluate exposure by measurement of PbB.

Confounding Factors and Effect Modifiers. Most epidemiological studies evaluating genotoxic effects were conducted in worker populations. Therefore, potential co-exposure to other genotoxic compounds (such as arsenic) could occur, complicating interpretation of results. In addition, many studies were conducted in small populations ($n < 100$).

Characterization of Effects. General trends for studies demonstrating associations between PbB and genotoxic effects are shown in Table 2-47. Additional study details are provided in the *Supporting Document for Epidemiological Studies for Lead*, Table 14. Although few studies have evaluated genotoxic effects at PbB ≤ 10 $\mu\text{g}/\text{dL}$ (see discussion below), numerous studies in adult workers with mean PbBs ranging from 20 to > 50 $\mu\text{g}/\text{dL}$ provide evidence of increased DNA damage, chromosomal aberrations, SCEs, and MN. One study reported decreased telomere length in workers (Pawlas et al. 2016). A few studies in workers reported negative findings for chromosomal aberrations (Anwar and Kamal 1988; Bulsma and DeFrance 1976; Mäki-Paakkanen et al. 1981; Schwanitz et al. 1975) and SCEs (Grandjean et al. 1983; Mäki-Paakkanen et al. 1981); however, positive results for these endpoints were reported in other studies at similar PbBs.

2. HEALTH EFFECTS

Table 2-47. Overview of Epidemiology Studies Evaluating Genotoxicity Associated with Chronic Exposure to Lead (Pb)

Mean PbB (µg/dL)	Effects associated with Pb exposure	References
≤10	Gene mutation	Van Larebeke et al. 2004
	DNA damage/repair	Jasso-Pineda et al. 2012
	Decreased telomere length	Pawlas et al. 2015
	DNA methylation	Hanna et al. 2012; Li et al. 2016; Pilsner et al. 2009
	MN	Mielzynska et al. 2006
>10–30	DNA damage/repair	Chinde et al. 2014; Danadevi et al. 2003; Jannuzzi and Alpertunga 2016; Kašuba et al. 2012; Kayaalti et al. 2015b; Méndez-Gómez et al. 2008; Shaik and Jamil 2009
	Chromosomal aberrations	Pinto et al. 2000
	SCE	Anwar and Kamal 1988; Pinto et al. 2000
	MN	Chinde et al. 2014; Khan et al. 2010b; Kašuba et al. 2012; Nordenson et al. 1978; Pinto et al. 2000
>30–50	DNA damage/repair	Fracasso et al. 2002; Grover et al. 2010
	Decreased telomere length	Pawlas et al. 2016
	Chromosomal aberrations	Forni et al. 1976; Grover et al. 2010; Schwanitz et al. 1970
	SCE	Duydu et al. 2001, 2005; Wiwanitkit et al. 2008; Wu et al. 2002
	MN	Grover et al. 2010; Hamurcu et al. 2001; Minozzo et al. 2004
>50	DNA damage/repair	de Restrepo et al. 2000
	Chromosomal aberrations	Al-Hakkak et al. 1986; Forni et al. 1976; Huang et al. 1988; Nordenson et al. 1978; Schwanitz et al. 1970
	SCE	Huang et al. 1988
	MN	Shaik and Jamil 2009; Singh et al. 2013; Vaglenov et al. 1998, 2001

DNA = deoxyribonucleic acid; MN = micronuclei; PbB = blood lead concentration; SCE = sister chromatid exchange

Results of genotoxicity studies conducted in small populations of children (n=12–103) are inconsistent; for study details, see the *Supporting Document for Epidemiological Studies for Lead*, Table 14. Mixed results were observed for studies on DNA damage, with positive associations at mean PbBs of 7.3 and 28.5 µg/dL (Méndez-Gómez et al. 2008; Jasso-Pineda et al. 2012) and no associations at a mean PbB of 19.5 µg/dL (Méndez-Gómez et al. 2008). No associations were observed for chromosome aberrations at a PbB range of 12–33 µg/dL (Bauchinger et al. 1977) and for SCE at mean PbBs of 7.69 and 62.7 µg/dL (Dalpra et al. 1983; Mielzynska et al. 2006). MN formation was positively associated with a mean PbB of 7.69 µg/dL (Mielzynska et al. 2006), and altered DNA methylation was found in newborns at mean umbilical cord PbB of 6.6 µg/dL (Pilsner et al. 2009).

2. HEALTH EFFECTS

Effect at Blood Pb Levels $\leq 10 \mu\text{g/dL}$. Results of studies evaluating genotoxic effects of PbB $\leq 10 \mu\text{g/dL}$ are summarized in Table 2-48, with study details provided in the *Supporting Document for Epidemiological Studies for Lead*, Table 14. Few studies have evaluated genotoxicity at PbB $\leq 10 \mu\text{g/dL}$. Some endpoints were only evaluated in a single study; therefore, it is difficult to draw conclusions. With the exception of a large study conducted in NHANES participants (Zota et al. 2015), genotoxic effects were evaluated in small study populations (n=12–103). Gene mutations were observed in a single study of Finnish women at a PbB range of 1.6–5.2 $\mu\text{g/dL}$ (Van Larebeke et al. 2004). Results of studies on DNA damage are mixed, with no associations in adult workers at PbB means of 2.1–4.4 $\mu\text{g/dL}$ (Al Bakheet et al. 2013; Hengstler et al. 2003), and positive associations in a small study of children with a mean PbB of 7.3 $\mu\text{g/dL}$ (Jasso-Pineda et al. 2012). No effect on telomere length was observed in a large NHANES study of adults with a mean PbB of 1.67 $\mu\text{g/dL}$ (Zota et al. 2015). No associations were observed for SCE in a single study in workers with a mean PbB of 9.3 $\mu\text{g/dL}$ and for MN in children with a mean PbB of 7.69 $\mu\text{g/dL}$ (Meilzynska et al. 2006; Wu et al. 2002). Studies on DNA methylation showed positive associations in adult women undergoing *in vitro* fertilization (median PbB 2.88 $\mu\text{g/dL}$), in children (mean PbB 1.36 $\mu\text{g/dL}$), and in newborns (mean umbilical cord PbB 6.6 $\mu\text{g/dL}$) (Hanna et al. 2012; Li et al. 2016; Pilsner et al. 2009).

***In Vivo* Animal Models and *In Vitro* Cultures of Mammalian Cells and Microorganisms.** Numerous studies have investigated the genotoxicity of Pb using *in vivo* animal models and cultured mammalian cells and microorganisms. Rather than reviewing these numerous studies, an overview of findings is summarized below. This information was taken from the following reviews: EPA 2006, 2014c; IARC 2006; NTP 2016.

In vivo studies in animals. DNA damage has been observed in several *in vivo* exposure studies in rodents. DNA damage (single strand breaks), as measured in comet assays, was observed in various organ systems, bone marrow, leukocytes, and spermatozoa of mice and rats following repeated inhalation or oral exposures to Pb or Pb acetate. Global hypomethylation in hepatic DNA of rats was observed following single intravenous injection of Pb nitrate; hypomethylation was associated with an increase in cell proliferation. Exposure to Pb compounds is correlated with increased DNA synthesis and cell proliferation in the mammalian liver following intravenous injection. Numerous studies have assessed Pb compounds for chromosomal damage. Chromosomal aberrations were observed in bone marrow cells and spermatocytes of mice and rats following single or repeated exposure (intraperitoneal, gavage, dietary); however, the increase in aberrations did not consistently demonstrate dose-dependence.

2. HEALTH EFFECTS

Table 2-48. Results of Genotoxicity Studies at Blood Lead Concentration (PbB) ≤10 µg/dL

PbB or range (µg/dL)	Population (n)	Gene mutation	DNA damage	Telomere length	SCE	MN	DNA methylation	Reference
1.6–5.2	Women (99)	↑	NA	NA	NA	NA	NA	Van Larebeke et al. 2004
2.1	Men (40)	NA	0	NA	NA	NA	NA	Al Bakheet et al. 2013
3.28	Children (99)	NA	NA	↓	NA	NA	NA	Pawlas et al. 2015
4.4	Workers (78)	NA	0	NA	NA	NA	NA	Hengstler et al. 2003
7.3	Children (12)	NA		NA	NA	NA	NA	Jasso-Pineda et al. 2012
1.67	Adults (6,796) ^a	NA	NA	0	NA	NA	NA	Zota et al. 2015
9.3	Workers (34)	NA	NA	NA	0	NA	NA	Wu et al. 2002
7.69	Children	NA	NA	NA	NA	0	NA	Meilzysja et al. 2006
>0.73	Women (43)	NA	NA	NA	NA	NA	↓	Hanna et al. 2012
1.45	Adults (78) ^b	NA	NA	NA	NA	NA	↓	Li et al. 2016
6.6 ^c	Newborns (103)	NA	NA	NA	NA	NA	↑↓	Pilsner et al. 2009

^aNHANES participants.

^bProspective study; genotoxicity assessed in adults and evaluated against PbB obtained during childhood (birth–78 months).

^cUmbilical cord PbB.

↑ = increase observed for specific effect; ↓ = decrease observed for specific effect; ↑↓ = decreased DNA methylations at some differentially methylated regions, and increased DNA methylation at other regions; 0 = no effect observed; DNA = deoxyribonucleic acid; MN = micronuclei; NA = not assessed; NHANES = National Health and Nutrition Examination Survey; SCE = sister chromatid exchange

2. HEALTH EFFECTS

Exposure to Pb compounds has been associated with SCEs in bone marrow of mice and rats following intravenous exposure. Studies assessing Pb compounds for MN formation in bone marrow erythrocytes of rats and mice were positive for multiple exposure routes (gavage, drinking water, intraperitoneal).

In vitro studies in human cell lines. *In vitro* studies in human cells lines have yielded mixed results. Pb acetate was weakly mutagenic in keratinocytes in the presence of 6-thioguanine, but not mutagenic in human foreskin, fibroblasts, or lung carcinoma cells. Results of assays assessing Pb compounds for DNA damage in human cell cultures were inconsistent. Double or single DNA strand breaks have been observed in peripheral blood lymphocytes, endothelial cells, hTERT-immortalized human skin fibroblasts, and HepG2 cells, but not in HeLa cells. DNA-protein crosslinks were observed in lymphoma cells exposed to 100 μM Pb acetate, although cross-links were not observed for Pb nitrate at concentrations up to 10,000 μM . Studies investigating SCEs and MN formation in human lymphocytes were positive following exposure to Pb nitrate and Pb chloride; however, no SCEs were observed in human lung cells or primary lymphocytes exposed to Pb. Interpretation of *in vitro* studies is challenging because concentrations used in these studies typically are very high and are not relevant to environmental or occupational exposures. As discussed in Section 3.1.2 (Toxicokinetics, Distribution), >99% of Pb in blood is bound to erythrocytes, leaving <1% available in plasma. Thus, plasma levels of Pb are far lower (at least two orders of magnitude) than the concentrations examined in *in vitro* studies in human cell lines. This leads to the introduction of considerable bias when interpreting study results (Bannon and Williams 2017).

In vitro studies in prokaryotic and mammalian cells. Mutagenicity tests of Pb compounds in prokaryotic organisms have mostly yielded negative results. Studies assessed gene mutation and DNA damage in *Salmonella typhimurium*, *Escherichia coli*, and *Bacillus subtilis* and gene conversion and mitotic recombination in *Saccharomyces cerevisiae* in the presence or absence of metabolic activation. The only Pb compound that yielded positive results for gene mutation in *S. typhimurium* and *E. coli* was Pb bromide. Results of *in vitro* studies in mammalian cells for Pb compounds are mixed. Mutagenicity assays (hypoxanthine phosphoribosyl transferase [HPRT] and glutamate pyruvate transaminase [gpt] assays) were mutagenic in Chinese hamster ovary (CHO) and CHV79 cells at higher concentrations (>100 μM) and negative at lower concentrations (<100 μM). Pb chloride was the only Pb compound that was consistently mutagenic (gpt assay) in CHO cells at low concentrations (0.1–1.1 μM ; equivalent to 2.3–23 $\mu\text{g}/\text{dL}$). Comet assays assessing Pb acetate for DNA damage (single strand breaks) in undifferentiated PC12 cells and mouse bone marrow mesenchymal stem cells were positive. Concentration-dependent increases in DNA-protein crosslinks were observed in hepatoma cells exposed

2. HEALTH EFFECTS

to Pb nitrate, although Pb acetate did not induce single or double DNA strand breaks or DNA crosslinks in CHV79 cells. Exposure to Pb nitrate or Pb glutamate did not induce chromosomal aberrations in CHO cells. Assays assessing Pb compounds for SCEs in CHV79 cells were negative when fewer cells per concentration were utilized (25–30 cells), but were positive when the number of cells per concentration was increased (100 cells). Conflicting results were reported for MN formation in Chinese hamster cells.

Mechanisms of Action. Several mechanisms of action are likely involved in the genotoxic effects of Pb (EPA 2014c; IARC 2006; NTP 2016). Studies in occupationally exposed populations have found significant correlations between DNA breaks, decreased glutathione levels in the lymphocytes, and increased production of ROS, which may indicate oxidative stress as a possible mechanism for this response. The production of ROS after Pb exposure is a multi-pathway process, which results from oxidation of ALA, membrane and lipid oxidation, NAD(P)H oxidase activation, and antioxidant enzyme depletion. Disruption of functional metal ions that form enzymes (superoxide dismutase [SOD], catalase [CAT], and glutathione peroxidase [GPx]) may occur as part of this process.

2.21 GENERAL CELLULAR MECHANISMS OF ACTION

2.21.1 Perturbation of Ion Homeostasis

Pb exerts many of its adverse effects by perturbing ion homeostasis. This perturbation occurs when Pb displaces other metal ions such as iron, calcium, zinc, magnesium, selenium, and manganese, interfering with the critical biological processes mediated by the ions themselves or by enzymes and proteins that require these ions (reviewed by EPA 2014c; Flora et al. 2012). Among the biological processes that Pb has been shown to affect via its impact on ion homeostasis are: calcium homeostasis; transportation of ions across cell membranes; cellular energetics; and the functioning of numerous proteins involved in cell signaling, growth and differentiation, gene expression, energy metabolism, and biosynthetic pathways.

Calcium Homeostasis. Many of Pb's adverse effects can be traced back to its ability to displace calcium, leading to perturbations of numerous calcium-dependent cellular functions, including energy metabolism, apoptosis, cellular motility, signal transduction, and hormonal regulation (reviewed by EPA 2014c). In addition, intracellular migration of Pb has been shown in several cell lines (HEK293, HeLa, and PC12) to occur via calcium channels; higher Pb permeation correlated with lower calcium concentrations, suggesting that Pb competed with calcium for the channel binding sites.

2. HEALTH EFFECTS

Ion Transport. Pb has been shown to disrupt the transportation of critical cations across the cell membrane by decreasing the activity of ATPases (including Na⁺/K⁺-, Ca²⁺, and Mg²⁺-ATPases; reviewed by EPA 2014c). Pb-induced inhibition of ATPase activities has been shown in the kidneys, livers, erythrocytes, and brain synaptosomes of rats exposed to Pb in drinking water; in testes of rat pups exposed during lactation and postweaning; in primary cerebellar granule neuronal cultures of rat pups exposed pre- and postnatally; in rabbit kidney membranes and sarcoplasmic reticulum exposed *in vitro*; and in human erythrocyte ghosts. Furthermore, blood or hair Pb levels were inversely correlated with ATPase activities in erythrocytes in several human epidemiological studies.

In addition to ATPases, Pb's action on ion transport includes competitive inhibition of voltage-gated calcium channels (reviewed by EPA 2014c). A number of *in vitro* studies have demonstrated inhibition of calcium transport via voltage gated channels in cultured neurons and neuroblastoma cells, bovine adrenal chromaffin cells, and human embryonic kidney cells. Inhibition of calcium transportation via voltage-gated channels can disrupt release of neurotransmitters, and impaired neurotransmitter release has, in fact, been shown with Pb exposure at low *in vitro* levels. In addition to inhibiting calcium-dependent neurotransmitter release, Pb may mimic calcium, thereby increasing neurotransmitter release in some circumstances. For example, Pb exposure *in vitro* has been shown to induce the spontaneous release of norepinephrine from bovine adrenal chromaffin cells and increase the release of catecholamine from PC12 cells. It has been suggested that Pb may trigger spontaneous neurotransmitter release via activation of calcium/calmodulin-dependent protein kinase II-dependent phosphorylation of synapsin I, or by directly activating synaptotagmin I (a calcium-sensing protein that regulates neurotransmitter release). Intracellular migration of Pb has been shown to occur via calcium channels; higher Pb permeation in several cell lines (HEK293, HeLa, and PC12) correlated with lower calcium concentrations, suggesting that Pb competed with calcium for the channel binding sites.

Pb also disrupts the activity of calcium-dependent potassium channels, as shown by increased efflux of potassium from inverted erythrocyte vesicles, and alterations in potassium channel activation in erythrocytes exposed to Pb (reviewed by EPA 2014c). The nature of the effect on potassium channels is dose-dependent; at low Pb concentrations (<10 μM), potassium channels are activated, while inhibition of the channels is seen at higher Pb concentrations. As with calcium channels, alterations in potassium channel activity may also disrupt neurotransmitter release. In rats exposed to Pb *in utero* and postnatally, potassium-stimulated release of hippocampal GABA was decreased at low exposure levels, but enhanced GABA release was observed at higher exposures (in the absence of calcium).

2. HEALTH EFFECTS

Cellular Energetics. Evidence indicating that Pb exposure perturbs mitochondrial function and cellular energy metabolism is abundant (as reviewed by EPA 2014c). In rats exposed to Pb via diet or drinking water, renal tubular and epididymal mitochondria exhibited swelling, rupture of the outer membrane, distorted cristae or loss of cristae, vacuolization, inclusion bodies, and fusion with nearby mitochondria. As discussed further in Section 2.21.6, Apoptosis, Pb exposure has been shown to open the mitochondrial transmembrane pore, initiating the apoptotic caspase cascade. Evidence for Pb's effect on energy metabolism includes decreased ATP levels and/or adenylate energy charge (AEC) (along with increased ADP, AMP, and/or adenosine levels) in forebrain synaptosomes from rats exposed via drinking water, in cerebellar granule neuronal cultures from rats exposed by drinking water, in PC-12 cells exposed *in vitro*, and in isolated mitochondria exposed *in vitro*. In osteoblasts exposed *in vitro*, Pb inhibited both coupled and uncoupled respiratory oxygen use in mitochondria. Pb has been proposed to behave as a classic chemical uncoupler of respiration, abolishing the proton gradient necessary for oxidative phosphorylation. In the muscles of rats exposed to Pb in drinking water, decreased activities of the enzymes of complex I and IV of the respiratory chain were observed. However, in forebrain synaptosomes from rats exposed to Pb *in vivo*, oxidative phosphorylation was not inhibited, despite the fact that ATP levels were decreased.

Pb may affect cellular energetics via perturbation of the glycolysis pathway. Decreased glycolysis was observed in osteoblasts and erythrocytes exposed to Pb *in vitro* (reviewed by EPA 2014c). However, increased levels of glycolytic enzymes were noted in workers with higher blood Pb levels, when compared with workers with lower blood Pb, suggesting that Pb may activate anaerobic glycolysis.

Depletion of cellular nucleotide pools required for ATP synthesis has also been observed after Pb exposure of human erythrocytes *in vitro* and in rats exposed via drinking water (reviewed by EPA 2014c). This effect may be mediated by Pb-induced inhibition of enzymes involved in nucleotide biosynthesis in erythrocytes, including adenine phosphoribosyltransferase (see Impaired Protein Function below) and NAD synthetase (which depends on magnesium for activity). In support of the latter mechanism, in humans exposed to Pb, PbB levels were inversely correlated with NAD synthetase activity.

Impaired Protein Function. Pb impairs the functions of numerous proteins, with concomitant effects on signaling, growth and differentiation, gene expression, energy metabolism, and biosynthetic pathways. The mechanisms by which Pb alters protein activity are by displacing metal cofactors or binding to sulfhydryl groups (reviewed by EPA 2014c). Table 2-49 shows proteins known to be bound to or

2. HEALTH EFFECTS

Table 2-49. Effects of Lead (Pb) on Function of Various Proteins

Protein	General function	Effect of Pb; summary of evidence
Calcium-dependent proteins		
Calcium binding proteins (CABPs I and II)	Regulation of calcium signaling, especially in neuronal cells	No data -Ca ²⁺ displacement shown <i>in vitro</i> .
Ca ²⁺ -dependent K ⁺ channel	Ion transport; activation of channels regulates neuron firing and neurotransmitter release	Activates or inhibits channel -Pb promoted efflux of K ⁺ from inverted red blood cell vesicles. -Pb induced activation of K ⁺ channel in erythrocytes at low Pb concentrations and inhibited activity at high concentrations.
Calmodulin	Cell signaling, including structural integrity, gene expression, and maintenance of membrane potential	Amplifies calmodulin activity -Pb activated calmodulin-dependent phosphodiesterase and cyclic nucleotide phosphodiesterase activities. -Pb stimulated brain membrane phosphorylation. -Pb increased binding of calmodulin to brain membranes.
Mitochondrial transmembrane pore (MTMP)	Triggers mitochondrial apoptosis cascade when open	Opens MTMP, triggering apoptosis -Pb increased mitochondria-regulated apoptotic indicators (cytochrome c, caspases) in rat retinal rod cells and hepatic oval cells <i>in vitro</i> .
NAD(P)H oxidase	Inflammatory mediator; triggers oxidative burst (via production of superoxide) in response to infection	Increases activity, leading to ROS generation -Pb increased protein levels of glycosylated subunit of NAD(P)H oxidase in brain, heart, and renal cortex of rats exposed via drinking water and in human coronary artery endothelial cells <i>in vitro</i> .
Osteocalcin	Bone resorption, osteoclast differentiation, and bone growth	Alters binding of osteocalcin to hydroxyapatite -Pb exposure has been shown to both increase and decrease binding of osteocalcin to hydroxyapatite.
Parvalbumin	Unclear; may buffer Ca ²⁺ levels; expressed at high levels in interneurons	No data -Ca ²⁺ displacement shown <i>in vitro</i> .
Phospholipase A ₂	Hydrolyze fatty acids from membrane phospholipids; released fatty acids are metabolized to bioactive lipid mediators	No data -Ca ²⁺ displacement shown <i>in vitro</i> .

2. HEALTH EFFECTS

Table 2-49. Effects of Lead (Pb) on Function of Various Proteins

Protein	General function	Effect of Pb; summary of evidence
Protein kinase C (PKC)	Cell signaling, especially growth and differentiation	Increases or decreases activity -Pb shown to activate PKC <i>in vitro</i> in bovine adrenal chromaffin cells, rat brain microvessels, human erythrocytes, and rabbit mesenteric arteries. -Pb decreased PKC activity in mouse macrophages and rat brain cortex.
Synaptotagmin I	Ca ²⁺ sensor regulating neurotransmitter release	No data -Ca ²⁺ displacement shown <i>in vitro</i> .
Troponin C	Ca ²⁺ sensor regulating muscle contraction	No data -Ca ²⁺ displacement shown <i>in vitro</i> .
Heme-dependent proteins		
Catalase	Antioxidant; scavenger of hydrogen peroxide	Increases or decreases activity -Pb shown to increase activity in some studies and decrease activity in others, possibly due to differences in species, exposure duration, dose, or other study design variations.
Guanylate cyclase	Catalyzes synthesis of cGMP, which stimulates vasorelaxation in vascular tissues	Impairs production of cGMP -Pb reduced cGMP in plasma and urine of rats exposed by drinking water. -Pb decreased protein levels of soluble guanylate cyclase in vascular tissue.
Hemoglobin	Oxygen transportation	Impairs heme production needed for synthesis of hemoglobin -Pb binding to hemoglobin demonstrated in human blood.
Magnesium-dependent proteins		
Adenine and hypoxanthine/guanine phosphoribosyltransferases	Recycling of nucleotides	Inhibits activity -Pb inhibited phosphoribosyltransferase activities in erythrocytes of rats exposed via drinking water and in human erythrocytes <i>in vitro</i> .
NAD synthetase (Mg)	Nucleotide biosynthesis	Decreases activity -Blood Pb was inversely correlated with NAD synthetase activity in humans.
Pyrimidine 5'-nucleotidase	Dephosphorylates pyrimidine nucleotides in erythrocytes, preserving purine nucleotides (e.g., ATP, ADP) necessary for energy	Alters protein conformation and amino acid positioning at active site, possibly by occupying active site -Pb binding and protein conformation changes observed <i>in vitro</i> . -Pyrimidine nucleotide accumulation in erythrocytes is seen in lead poisoning.

2. HEALTH EFFECTS

Table 2-49. Effects of Lead (Pb) on Function of Various Proteins

Protein	General function	Effect of Pb; summary of evidence
Zinc-dependent proteins		
δ -ALA (δ -ALAD or porphobilinogen synthase)	Heme biosynthesis (converts δ -ALA to porphobilinogen)	Depletes δ -ALAD, preventing heme biosynthesis and leading to accumulation of δ -ALA. - δ -ALAD shown to be major binding target of Pb in erythrocytes.
GATA zinc finger proteins	Activation/suppression of DNA transcription	Decreases ability of GATA proteins to bind to DNA and regulate transcription -Pb binding to cysteine residues and displacement of Zn from GATA proteins observed <i>in vitro</i> . -Pb-bound GATA proteins exhibited reduced DNA binding.
Transcription factors TFIIIA, Sp1, and Erg-1	Activation/suppression of DNA transcription	Decreases ability of TFIIIA, Sp1, and Erg-1 to bind to DNA and regulate transcription -Pb exposure caused dissociation of TFIIIA-DNA adducts. -Pb exposure altered DNA binding profile of Sp-1 and Erg-1 in rat pups exposed via lactation, leading to changes in gene expression.
Proteins altered by lead interaction with via other cations or sulfhydryl groups		
ATPases (Ca ²⁺ -, Mg ²⁺ -, and Na ⁺ /K ⁻ -)	Ion transport	Decreases activity -Pb decreased ATPase activities in brain, kidneys, liver, testes, and erythrocytes (cells or tissues).
cGMP phosphodiesterase (Zn, Mg)	Hydrolysis of cGMP	Inhibits activity -Decreased activity observed in homogenized bovine retinas exposed to Pb <i>in vitro</i> .
Ferrochelatase (Fe)	Heme biosynthesis; incorporates Fe ²⁺ into protoporphyrin IX to form heme	Inhibits insertion of Fe into protoporphyrin ring, leading to substitution by Zn -Zn-protoporphyrin levels correlated with blood Pb levels in humans.
Glutathione peroxidase and glutathione S-transferase (Se)	Antioxidants	Reduces uptake of Se and depletes cellular GSH and protein thiols, resulting in altered GST and GPx enzyme activities -Decreased activity, often with compensatory upregulation of the enzymes, seen in Pb-exposed animals and humans.

2. HEALTH EFFECTS

Table 2-49. Effects of Lead (Pb) on Function of Various Proteins

Protein	General function	Effect of Pb; summary of evidence
Metallothionein (Zn, Cu)	Trace element homeostasis; free radical scavenging	Sequestered by metallothionein, providing protective effect -Pb toxicity is seen at lower blood Pb levels in humans with low expression of metallothionein or low Pb binding to metallothionein. -Pb induced production of metallothionein in mice exposed via intraperitoneal or intravenous injection and in rats exposed via intraperitoneal injection, but not in rats exposed via drinking water. -Presence of zinc metallothionein reduced effect of Pb on membrane integrity in hepatocytes exposed <i>in vitro</i> . -Pb nephrotoxicity and preneoplastic and neoplastic lesions in the testes, bladder, and kidneys were more severe or seen at increased incidences in metallothionein-null mice compared with wild-type.
Superoxide dismutase	Antioxidant; catalyzes conversion of superoxide to hydrogen peroxide; inhibits oxidative inactivation of nitric oxide	Increased or decreased activity -Pb shown to increase activity in several studies and decrease activity in others, possibly due to differences in species, exposure duration, dose, or other study design variations.
Thymosin β -4	Actin regulation; exerts angiogenic, anti-inflammatory, and cardioprotective effects on the heart	No data -Pb binding observed <i>in vitro</i> .

ADP = adenosine diphosphate; δ -ALA = aminolevulinic acid; δ -ALAD = aminolevulinic acid dehydratase; ATP = adenosine triphosphate; ATPase = family of phosphatase enzymes that breakdown ATP and ADP; cGMP = cyclic guanosine monophosphate; DNA = deoxyribonucleic acid; Erg-1 = early growth response protein 1; GST = glutathione S-transferase; GSH = glutathione; GPx = glutathione peroxidase; NAD = nicotinamide adenine dinucleotide; NAD(P)H = the reduced form of nicotinamide adenine dinucleotide phosphate; ROS = reactive oxygen species; Sp1 = Transcription factor specificity protein 1; TFIIIA = transcription factor IIIA

Sources: EPA 2014c; Ahamed and Siddiqui 2007; Flora et al. 2012; Gonick 2011

2. HEALTH EFFECTS

otherwise altered by Pb, along with their functions and brief summaries of the evidence for Pb-induced alterations. As the table suggests, Pb-induced alterations in proteins may play a role in its adverse effects on the neurological, hematological, cardiovascular, and skeletal systems.

Through its displacement of calcium, Pb perturbs the function of several calcium-dependent proteins, including protein kinase C, calmodulin, osteocalcin, the mitochondrial transmembrane pore, and NAD(P)H oxidase (reviewed by EPA 2014c). The protein kinase C family of enzymes is important to cell signaling, growth, and differentiation. Pb exposure has been shown to activate PKC in a number of cell types tested *in vitro* (see table), and to decrease its activity in mouse macrophages and rat brain cortex. Pb stimulates calmodulin activity, as shown by increased activity of several calmodulin-dependent enzymes, and increased binding of calmodulin to brain membranes. In experiments testing the affinity of metal cations to bind calmodulin, Pb was more potent than mercury, cadmium, iron, and even calcium. Pb binding to calmodulin has been postulated as a mechanism for its stimulatory effect on Ca²⁺/Mg²⁺ ATPase. Calmodulin plays an essential role in maintaining calcium homeostasis and regulating calcium-dependent cell signaling important to structural integrity, gene expression, and maintaining membrane potential (reviewed by EPA 2014c).

Skeletal effects of Pb may be mediated in part by Pb's interference with another calcium-dependent protein: osteocalcin (reviewed by EPA 2014c). The binding of Pb to osteocalcin is much stronger than binding of calcium, and Pb binding alters the structure of osteocalcin. The conformational change in osteocalcin induced by Pb has been postulated as the mechanism by which Pb exposure diminishes the adsorption of osteocalcin to hydroxyapatite.

Other calcium-dependent proteins bound to or impaired by Pb include parvalbumin, phospholipase A2, synaptotagmin I (see *Ion Transport* above), troponin C, the mitochondrial transmembrane pore (see Section 2.21.6, Apoptosis), and NAD(P)H oxidase (see Section 2.21.3, Oxidative Stress) (reviewed by EPA 2014c).

Pb also displaces zinc in a number of critical proteins, including ALAD, GATA proteins, and several zinc-binding transcription factors (TFIIIA, Sp1, and Erg-1) (reviewed by EPA 2014c). Section 2.8 provides a detailed discussion of Pb's effects on ALAD and heme biosynthesis. Binding of Pb to zinc-binding domains in GATA proteins and transcription factors inhibits their binding to DNA and impairs their ability to regulate gene expression (see Section 2.21.5, *Epigenetic Effects*, below for further detail).

2. HEALTH EFFECTS

Through competitive inhibition of magnesium-dependent proteins, Pb also affects the activities of adenine and hypoxanthine/guanine phosphoribosyltransferases, cyclic guanosine monophosphate (cGMP) phosphodiesterase, and pyrimidine 5'-nucleotidase (reviewed by EPA 2014c). In erythrocytes, adenine phosphoribosyltransferase catalyzes the synthesis of nucleotides via the adenine salvage pathway; Pb exposure has been shown to decrease nucleotide pools in human erythrocytes *in vitro* and in erythrocytes from rats exposed via drinking water. Inhibition of cGMP phosphodiesterase, a magnesium-dependent enzyme regulating cGMP signaling in smooth muscle contraction and relaxation, has been observed in homogenized bovine retinas cultured with Pb. Pb inhibits magnesium binding in pyrimidine 5'-nucleotidase, inhibiting its activity by changing its active site conformation. Pyrimidine 5'-nucleotidase occurs at high levels in erythrocytes, where it dephosphorylates pyrimidine nucleotides while leaving purine nucleotides (used as an energy source in erythrocytes, as they lack mitochondria), intact. Basophilic stippling of erythrocytes, a common feature of Pb poisoning, is also seen in individuals with inherited pyrimidine-5'-nucleotidase deficiency (Rees et al. 2003), providing supporting evidence that Pb inactivates the enzyme.

2.21.2 Protein Binding/Sequestration

A number of low molecular-weight proteins, including metallothionein, have been shown to bind (through thiol residues) to Pb, forming inclusion bodies in the kidney, liver, lung, and glial cells (reviewed by EPA 2014c; Gonick 2011). In the case of metallothionein, the effect of the binding is to sequester Pb, protecting the exposed cells and tissues. The strongest evidence for the protective effect of metallothionein comes from studies of metallothionein-null mice, which exhibit more severe Pb-induced renal toxicity, as well as increased incidences of neoplastic and nonneoplastic lesions in the testes, bladder, and kidneys, compared with wild-type mice. Supporting this finding is the observation that higher blood Pb levels, as well as more pronounced Pb-induced effects on systolic blood pressure and kidney function, were observed in exposed workers with a metallothionein mutation (compared with those exhibiting normal metallothionein genotype). Metallothionein levels have been shown to be induced by Pb exposure in mice and in rats pretreated with zinc.

In erythrocytes, the major Pb-binding protein is ALAD; hemoglobin also binds Pb (reviewed by EPA 2014c; Gonick 2011). In exposed humans, polymorphisms in the ALAD gene that increase the Pb-binding capacity of its protein product (e.g., ALAD-2) were observed to decrease blood Pb levels and biomarkers for Pb toxicity, including plasma levulinic acid, zinc protoporphyrin, cortical bone Pb levels,

2. HEALTH EFFECTS

and dimercaptosuccinic acid-chelatable Pb levels. Other proteins that bind Pb in erythrocytes include pyrimidine 5'-nucleotidase and acyl-coenzyme A binding protein.

In rat kidneys, inclusion bodies consisting of Pb-bound proteins have been observed in a number of studies (reviewed by EPA 2014c; Gonick 2011). These inclusion bodies are initially observed in the cytosol, but appear to translocate to the nucleus, as they disappear concomitantly with the appearance of intranuclear inclusion bodies. The primary Pb-bound protein in the kidney (a 32 kDa protein with an isoelectric point of 6.3, named p32/6.3) has not been identified, but has been shown to be enriched in the brain and is highly conserved across species (rats, mice, dogs, chickens, and humans). Studies in rats exposed by food or drinking water showed that p32/6.3 is not found in the kidneys of untreated rats but rather is induced by Pb exposure. Other Pb-binding proteins identified in the kidneys of rats or humans include acyl-CoA binding protein and thymosin β -4 (the latter is involved in actin regulation).

2.21.3 Oxidative Stress

Pb exposure has resulted in oxidative damage in several tissues in humans and rats, including the brain, kidneys, reproductive organs, heart, and erythrocytes (reviewed by EPA 2014c; Ahamed and Siddiqui 2007). Oxidative damage may play a role in Pb-induced toxicity in these tissues, including neurological effects, hypertension and other cardiovascular effects, and diminished fertility. Pb induces oxidative stress through several mechanisms, including increased production of ROS via inhibition of heme biosynthesis and activation of NAD(P)H oxidase; stimulation of lipid peroxidation and alteration of lipids enhancing their susceptibility to lipid peroxidation; and inactivation and/or depletion of antioxidant enzymes. Through the increased production of ROS, which sequesters nitric oxide, Pb exposure also leads to perturbation of nitric oxide signaling that is critical to vasodilation.

Exposure to Pb triggers increased production of ROS via its effects on heme biosynthesis. In erythrocytes, Pb has been shown to bind to δ -ALAD as well as to inhibit its activity by interfering with the zinc ions the enzyme requires for heme biosynthesis; in fact, inhibition of δ -ALAD activity is inversely correlated with PbB levels in humans (reviewed by EPA 2014c; Ahamed and Siddiqui 2007). δ -ALAD catalyzes the conversion of δ -ALA to porphobilinogen; thus, its inhibition results in accumulation of δ -ALA in blood and in urine. In these environments, δ -ALA undergoes autoxidation, yielding superoxide and hydroxyl radicals, as well as hydrogen peroxide and an ALA radical. In addition, through subsequent reduction of ferricytochrome c and transfer of electrons from oxyhemoglobin, methemoglobin, and ferric and ferrous iron complexes, oxidized δ -ALA also produces ROS.

2. HEALTH EFFECTS

Pb may also increase intracellular ROS by upregulating expression of NAD(P)H oxidase, an enzyme that produces superoxide anion via reaction of NAD(P)H and molecular oxygen, but data are limited (reviewed by EPA 2014c). Increased protein expression of the glycosylated subunit of NAD(P)H oxidase was observed in tissues of rats exposed to Pb in drinking water, and in human endothelial cells *in vitro*.

ROS produced via Pb effects on δ -ALA and/or NAD(P)H oxidase can damage membrane lipids through peroxidation. In addition, however, Pb has been shown to catalyze ferrous ion-initiated lipid peroxidation (reviewed by EPA 2014c). Furthermore, there is evidence that Pb exerts effects on membrane lipids that render them more vulnerable to peroxidation (reviewed by EPA 2014c; Ahamed and Siddiqui 2007). For example, Pb has been shown to alter the composition of fatty acids in chicks exposed by drinking water, such that a higher fraction of longer fatty acids (such as arachidonic acid) and lower fraction of shorter fatty acids (compared with controls) were observed. Oxidative potential of fatty acids is correlated with both length and desaturation (i.e., the number of double bonds; the hydrogen on a double bond is easier to remove). It has been proposed that Pb may stimulate both elongation and desaturation of fatty acids, increasing their susceptibility to peroxidation. Alterations in lipid composition may also affect membrane permeability and functions, including the activity of membrane-associated enzymes, solute transport functions, endo- and exocytosis, and signal transduction.

Increased circulating ROS (specifically, superoxide anion) can inactivate nitric oxide, an endogenously produced molecule that plays an important role in vasodilation (reviewed by EPA 2014c). Depletion of nitric oxide has been observed in animals exposed to Pb, as well as in human and animal immune cells treated *in vitro*. In addition, nitric oxide depletion is believed to be the mechanism behind Pb-induced upregulation of nitric oxide synthases seen in vascular tissues after Pb exposure. Nitric oxide depletion occurs when it reacts with superoxide anion to form the highly reactive peroxynitrite anion, which itself damages DNA and proteins. Levels of nitrotyrosine, which results from peroxynitrite-induced nitration of tyrosine residues in proteins, were increased in plasma and other tissues after *in vivo* exposure to Pb. In vascular tissues, nitric oxide induces vasorelaxation via cGMP signaling (reviewed by EPA 2014c). Exposure of rats to Pb in drinking water for 1–3 months markedly reduced cGMP levels in both blood and urine. Synthesis of cGMP is catalyzed by soluble guanylate cyclase, a heme-dependent enzyme. Pb exposure has been shown to reduce protein levels of soluble guanylate cyclase in vascular tissues; alleviation of this effect by antioxidant treatment (ascorbic acid) demonstrated that this finding was mediated, at least in part, by increased oxidative stress.

2. HEALTH EFFECTS

In human epidemiological studies, the ratio of oxidized glutathione (glutathione disulfide or GSSG) to reduced glutathione (GSH), a measure of oxidative stress, was positively correlated with blood Pb levels (reviewed by EPA 2014c; Ahamed and Siddiqui 2007; Flora et al. 2012). The effects of Pb on oxidative stress levels may occur through depletion of antioxidant levels in addition to stimulation of ROS, as oxidative stress occurs when the antioxidant capacity of the body is exceeded. Pb forms covalent bonds with sulfhydryl groups in antioxidant enzymes such as GSH, glutathione reductase (GR), and glutathione S-transferase (GST) (reviewed by EPA 2014c; Ahamed and Siddiqui 2007; Flora et al. 2012). In humans, animals, and *in vitro* studies, decreased GSH in blood and organs has been associated with Pb exposure. After long-term exposure to Pb, increased GSH levels, attributed to compensatory upregulation of GSH biosynthesis, have been reported. Like GSH, GR (which reduces GSSG back to GSH) and GST also have disulfides at their active site that could be bound by Pb. Studies examining GR and GST activity after Pb exposure used varying study designs and showed both increases and decreases; it is not clear whether the differences in results reflect species, strain, dose, or duration differences.

Pb's capacity to compete with cations and its interference with heme biosynthesis have also been suggested as potential mechanisms for its ability to alter levels of SOD, CAT, GPx, and GST (reviewed by EPA 2014c; Flora et al. 2012; Ahamed and Siddiqui 2007). SOD forms require copper, zinc, or manganese, cations that Pb may displace, while catalase is a heme-dependent enzyme. Several studies in humans and animals have shown alterations in SOD and CAT activity, with some evidence for a nonlinear dose-response relationship. EPA (2014c) suggested that increased SOD and CAT may occur at low doses as a result of ROS generation by Pb, while at higher doses, Pb may inactivate the enzymes. Pb exposure also alters activities of GPx and GST, potentially by reducing the uptake of selenium (required by GPx) and/or disrupting protein thiols (necessary for GST function). Decreased GPx and GST activities have been observed, along with compensatory upregulation of these enzymes, in Pb-exposed humans and animals.

2.21.4 Inflammation

Increasing oxidative stress through ROS generation and depletion of antioxidant enzymes may be one mechanism by which Pb induces an inflammatory response (reviewed by EPA 2014c). Inflammation, considered a hallmark of Pb exposure (EPA 2014c), may also be triggered by pro-inflammatory signaling and cytokine production. Inflammation has been seen after Pb exposure in many different cell types, as well as in the kidneys of rats exposed to Pb in drinking water.

2. HEALTH EFFECTS

Oxidative stress is known to activate the pro-inflammatory nuclear transcription factor kappa B (NFκB). In the rat kidney, Pb-induced inflammation was accompanied by activation of NFκB as well as lymphocyte and macrophage infiltration (reviewed by EPA 2014c). Pb has been shown to stimulate the expression of pro-inflammatory signal mediators including NFκB, activator protein-1 (AP-1), and c-Jun, and to stimulate phosphorylation of the Erk/MAPK pathway. In addition, exposure to Pb is associated with increased production of prostaglandins, which also mediate pro-inflammatory messaging. Increases in arachidonic acid production, leading to increases in prostaglandins E2 and F2 and thromboxane levels, have been seen in Pb-exposed workers as well as in animals and in cultured cells systems exposed to Pb. In vascular smooth muscle cells, Pb has been shown to activate phospholipase A2, which may explain its ability to stimulate the release of arachidonic acid.

In both human epidemiological and laboratory animal studies, Pb exposure has been demonstrated to increase cytokine production (reviewed by EPA 2014c). In these studies, a fairly consistent picture of decreasing Th-1 cytokines and increasing Th-2 cytokines has emerged. EPA (2014c) outlined three modes by which Pb influences cytokine production: (1) direct action on macrophages to increase pro-inflammatory cytokines such as TNF-α and interleukin 6 (IL-6); (2) skew the ratio of IL-12 to IL-10, leading to suppression of Th-1 cell responses and stimulate Th-2 cell responses; and (3) during acquired immune response occurring after Pb exposure, production of cytokines by Th-1 lymphocytes is suppressed, and Th-2 cytokines are increased. The net result of these changes is consistent with the pro-inflammatory picture seen with Pb exposure.

Human epidemiological studies have provided evidence that Pb exposure skews immune responses toward Th-2 pro-inflammatory responses (reviewed by EPA 2014c). Higher blood Pb levels in children were associated with increased serum levels of IL-4 (which induces differentiation of Th0 cells to the Th-2 phenotype) and lower levels of interferon gamma (IFN-γ). In adult students in Korea, higher blood Pb levels were positively associated with increased TNF-α and IL-6; a 1 μg/dL increase in blood Pb was associated with a 23% increase in log TNF-α and a 26% increase in IL-6. Finally, in occupationally-exposed workers, higher blood Pb levels were associated with increases in IL-2, IL-10, IL-6, TNF-α, and granulocyte colony stimulating factor (G-CSF), and, in one study, lower levels of Th1 cytokines IL-1β and IFN-γ. Similar effects were seen in mice exposed to Pb in feed; blood levels of Th-1 cytokines (IL-2 and IFN-γ) were decreased at low dietary doses, while increases in IL-4 were seen as the Pb dose increased. Based on these data, EPA (2014c) suggested that the immune system response to Pb may exhibit nonlinearities at low doses. In rats exposed to Pb via intraperitoneal injection, increased levels of

2. HEALTH EFFECTS

TNF- α were seen in the hippocampus, and increased IL-6 was noted in the forebrain. *In vitro* data have also shown alterations in cytokine production after exposure to Pb.

2.21.5 Epigenetic Effects

In a small number of studies, Pb has been shown to induce epigenetic effects, including perturbations in DNA methylation as well as alterations in mitogenesis (reviewed by EPA 2014c; Bakulski et al. 2013). In human studies, maternal blood Pb was correlated with decreased DNA methylation of Alu retrotransposable elements in umbilical cord blood, and bone Pb levels were correlated with decreased DNA methylation of LINE-1 retrotransposons in elderly men, while higher blood Pb was associated with increased methylation of p16 tumor suppressor gene promoters in occupationally exposed individuals. Other evidence for effects of Pb on DNA methylation include a study in primates in which the activity of DNA methyltransferase 1 was decreased by early life Pb exposure, and *in vitro* data showing decreased global DNA methylation in rat pheochromocytoma cells. Hypomethylation of DNA has been shown to trigger changes in gene expression that may lead to alterations in tissue differentiation.

Pb exposure also induces effects on mitogenesis, including both increases in cell proliferation and decreases in some systems (reviewed by EPA 2014c). Increased cell proliferation and/or DNA synthesis have been reported in workers exposed to Pb, in hepatocytes of rats exposed by intravenous injection of Pb nitrate, and in mouse lung after exposure to Pb acetate via inhalation. In *in vitro* studies, results were mixed: in some cases cell proliferation was decreased, as Pb exposure resulted in cell cycle arrest. Effects of Pb exposure on gene expression have been demonstrated in several studies (reviewed by EPA 2014c). Although the exact mechanisms by which Pb alters gene expression have not been elucidated, Pb is known to interfere with GATA proteins and several transcription factors (TFIIIA, Sp1, and Erg-1) through its interaction with zinc-binding domains, reducing the ability of these proteins to bind to DNA and exert their transcriptional regulation functions. *In vivo* and *in vitro* studies have shown that Pb alters the transcription of genes for metabolic enzymes including GST-P and GST-Ya, CYPs 1A1 and 1A2, and NAD(P)H:quinone oxidoreductase, as well as genes involved in the pentose phosphate pathway and amino acid metabolism.

2.21.6 Apoptosis

As discussed earlier, Pb is capable of opening the mitochondrial transmembrane pore (MTMP, the first step in the mitochondrial apoptosis cascade), possibly by displacing calcium on the matrix side of the pore (reviewed by EPA 2014c). Evidence for this effect includes observations of mitochondrial swelling

2. HEALTH EFFECTS

and decreased membrane potential in rat primary cerebellar granule neuronal cultures, astroglia, proximal tubule cells, and retinal rod photoreceptor cells. In addition, release of cytochrome c and activation of caspases 3 and 9 were observed in rat retinal rod cells and hepatic oval cells exposed to Pb *in vitro*. In lymphocytes of Pb-exposed humans, increased apoptosis, karyorrhexis, and karyolysis (early indicators of apoptosis) were observed. Other tissues have also exhibited increased apoptosis after Pb exposure, including liver, fibroblasts, and alveolar macrophages.

CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

3.1 TOXICOKINETICS

Overview. The toxicokinetics of Pb in humans has been extensively studied and several models have been published that simulate the absorption and complex distribution and elimination of Pb from blood, soft tissues, and bone.

- Absorption:
 - Respiratory tract: Inorganic Pb in submicron size particles can be almost completely absorbed through the respiratory tract, whereas larger particles may be moved after deposition in the respiratory tract by mucociliary clearance toward the oropharynx and swallowed.
 - Gastrointestinal tract: The fraction of ingested Pb absorbed from the gastrointestinal tract depends on many factors, including age, diet, nutrition, and physiological characteristics of Pb in the medium ingested.
 - Children can absorb 40–50% of an oral dose of water-soluble Pb compared to 3–10% for adults.
 - Gastrointestinal absorption of inorganic Pb occurs primarily in the duodenum by saturable mechanisms.
 - Dermal: Inorganic Pb can be absorbed following inhalation, oral, and dermal exposure, but the latter route is much less efficient than the former two, with the exception of hand-to-mouth behavior. Studies in animals have shown that organic Pb is absorbed through the skin.

- Distribution:
 - The distribution of Pb in the body is route-independent and, in adults, approximately 94% of the total body burden of Pb is in the bones compared to approximately 73% in children.
 - Pb in blood is primarily in red blood cells. Conditions such as pregnancy, lactation, menopause, and osteoporosis increase bone resorption and consequently also increase Pb in blood.

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

- Pb can be transferred from the mother to the fetus and also from the mother to infants via maternal milk.
- Metabolism:
 - Metabolism of inorganic Pb consists of formation of complexes with a variety of protein and nonprotein ligands.
 - Organic Pb compounds are actively metabolized in the liver by oxidative dealkylation by P-450 enzymes.
- Excretion:
 - Pb is excreted primarily in urine and feces regardless of the route of exposure. Minor routes of excretion include sweat, saliva, hair, nails, breast milk, and seminal fluid.
 - Elimination of Pb is multiphasic, reflecting pools of Pb in the body that have varying retention times. The apparent elimination half-time in blood varies with age and exposure history and ranges from 1 week to 2 years. Elimination of Pb from bone occurs with an apparent half-time of 1–2 decades.
- Toxicokinetics models:
 - Several models of Pb pharmacokinetics have been proposed to characterize such parameters as intercompartmental Pb exchange rates, retention of Pb in various tissues, and relative rates of distribution among the tissue groups.
 - Some models are currently being used or are being considered for broad application in Pb risk assessment.

3.1.1 Absorption

Inhalation Exposure

Inorganic Pb. Inorganic Pb in ambient air consists of aerosols of particulates that can be deposited in the respiratory tract when the aerosols are inhaled. Amounts and patterns of deposition of particulate aerosols in the respiratory tract are affected by the size of the inhaled particles, age-related factors that determine breathing patterns (e.g., nose versus mouth breathing), airway geometry, and air-stream velocity within the respiratory tract (James et al. 1994). Absorption of deposited Pb is influenced by particle size and solubility as well as the pattern of regional deposition within the respiratory tract. Larger particles

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

(>2.5 μm) that are deposited in the ciliated airways (nasopharyngeal and tracheobronchial regions) can be transferred by mucociliary transport into the esophagus and swallowed. Smaller particles (2.5 to <1 μm), which can be deposited in the alveolar region, can be absorbed after extracellular dissolution or ingestion by phagocytic cells (Bailey and Roy 1994).

Deposition in, and clearance from, the respiratory tract have been measured in adult humans (Chamberlain et al. 1978; Hursh and Mercer 1970; Hursh et al. 1969; Morrow et al. 1980; Wells et al. 1975). In these studies, exposures were to Pb-bearing particles having mass median aerodynamic diameters (MMADs) below 1 μm and, therefore, deposition of the inhaled Pb particles can be assumed to have been primarily in the bronchiolar and alveolar regions of the respiratory tract (James et al. 1994) where transport of deposited Pb to the gastrointestinal tract is likely to have been only a minor component of particle clearance (Hursh et al. 1969). Approximately 25% of inhaled Pb chloride or Pb hydroxide (MMAD 0.26 and 0.24 μm , respectively) was deposited in the respiratory tract in adult subjects who inhaled an inorganic Pb aerosol through a standard respiratory mouthpiece for 5 minutes (Morrow et al. 1980). Approximately 95% of deposited inorganic Pb that was inhaled as submicron particles was absorbed (Hursh et al. 1969; Wells et al. 1975). Rates of clearance from the respiratory tract of inorganic Pb inhaled as submicron particles of Pb oxide, or Pb nitrate, were described with half-times ($t_{1/2}$) of 0.8 hours (22%), 2.5 hours (34%), 9 hours (33%), and 44 hours (12%) (Chamberlain et al. 1978). These rates are thought to represent, primarily, absorption from the bronchiolar and alveolar regions of the respiratory tract. Absorption half-times have been estimated in adults who inhaled aerosols of Pb and bismuth isotopes generated from decay of ^{220}Rn or ^{222}Rn (Butterweck et al. 2002; Marsh and Birchall 1999). The absorption half-time was approximately 10 hours in subjects who inhaled aerosols having an activity median particle diameter of approximately 160 nm (range 50–500 nm), and approximately 68 minutes for aerosols having diameters of approximately 0.3–3 nm.

Rates and amounts of absorption of inhaled Pb particles >2.5 μm will be determined, primarily by rates of transport to and absorption from the gastrointestinal tract. Absorption of Pb from the gastrointestinal tract varies with the chemical form ingested, age, meal status (e.g., fed versus fasted), and nutritional factors (see Section 3.1.1 *Oral Exposure*).

Organic Pb. Following a single exposure to vapors of radioactive (^{203}Pb) tetraethyl Pb (approximately 1 mg/m^3 breathed through a mouthpiece for 1–2 minutes) in four male subjects, 37% of inhaled ^{203}Pb was initially deposited in the respiratory tract, of which approximately 20% was exhaled in the subsequent 48 hours (Heard et al. 1979). One hour after the exposure, approximately 50% of the ^{203}Pb burden was

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

associated with liver, 5% was associated with kidney, and the remaining burden was widely distributed throughout the body (determined by external gamma counting), suggesting near complete absorption of the Pb that was not exhaled. In a similar experiment conducted with (^{203}Pb) tetramethyl Pb, 51% of the inhaled ^{203}Pb dose was initially deposited in the respiratory tract, of which approximately 40% was exhaled in 48 hours. The distribution of ^{203}Pb 1 hour after the exposure was similar to that observed following exposure to tetraethyl Pb.

The relatively rapid and near complete absorption of tetraalkyl Pb that is inhaled and deposited in the respiratory tract is also supported by studies conducted in animal models (Boudene et al. 1977; Morgan and Holmes 1978).

Oral Exposure

Inorganic Pb. The extent and rate of gastrointestinal absorption of ingested inorganic Pb are influenced by physiology (e.g., age, fasting, nutritional calcium and iron status, pregnancy), physicochemical characteristics of the medium ingested (e.g., particle size, mineralogy, solubility, and Pb species) and the ingested Pb dose.

Mechanisms of Absorption. Gastrointestinal absorption of inorganic Pb occurs primarily in the duodenum (Mushak 1991). The exact mechanisms of absorption are unknown and may involve active transport and/or diffusion through intestinal epithelial cells (transcellular) or between cells (paracellular), and may involve ionized Pb (Pb^{+2}) and/or inorganic or organic complexes of Pb. *In vitro* studies of Pb speciation in simulated human intestinal chyme indicate that the concentration of ionized Pb is negligible at Pb concentrations below 10^{-3} M (207 mg/L) and that Pb phosphate and bile acid complexes are the dominant forms when inorganic Pb salts (e.g., Pb nitrate) are added to chyme (Oomen et al. 2003a). However, these complexes may be sufficiently labile to provide ionized Pb for transport across cell membranes (Oomen et al. 2003b). Saturable mechanisms of absorption have been inferred from measurements of net flux kinetics of Pb in *in situ* perfused mouse intestine, *in situ* ligated chicken intestine, and *in vitro* isolated segments of rat intestine (Aungst and Fung 1981; Barton 1984; Flanagan et al. 1979; Mykkänen and Wasserman 1981). By analogy to other divalent cations, saturable transport mechanisms for Pb^{+2} may exist within the mucosal and serosal membranes and within the intestinal epithelial cell. For calcium and iron, these are thought to represent membrane carriers (e.g., Ca^{2+} - Mg^{2+} -ATPase, Ca^{2+} / Na^{+} exchange, DMT1) or facilitated diffusion pathways (e.g., Ca^{2+} channel) and

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

intracellular binding proteins for Ca^{2+} (Bronner et al. 1986; Fleming et al. 1998b; Gross and Kumar 1990; Teichmann and Stremmel 1990).

Effect of Age. Gastrointestinal absorption of water-soluble Pb appears to be higher in children than in adults. Estimates derived from dietary balance studies conducted in infants and children (ages 2 weeks to 8 years) indicate that approximately 40–50% of ingested Pb is absorbed (Alexander et al. 1974; Ziegler et al. 1978). In adults, estimates of absorption of ingested water-soluble Pb compounds (e.g., Pb chloride, Pb nitrate, Pb acetate) ranged from 3 to 10% in fed subjects (Heard and Chamberlain 1982; James et al. 1985; Rabinowitz et al. 1980; Watson et al. 1986). Data available on Pb absorption between childhood and adulthood ages are very limited. While no absorption studies have been conducted on subjects in this age range, the kinetics of the change in stable isotope signatures of blood Pb in mothers and their children, as both come into equilibrium with a novel environmental Pb isotope profile, suggest that children ages 6–11 years and their mothers may absorb a similar percentage of ingested Pb (Gulson et al. 1997b).

Studies in experimental animals provide additional evidence for an age-dependency of gastrointestinal absorption of Pb. Absorption of Pb, administered as Pb acetate (6.37 mg Pb/kg, gavage), was higher in juvenile Rhesus monkeys (38% of dose) compared to adult female monkeys (26% of the dose) (Pounds et al. 1978). Rat pups absorb approximately 40–50 times more Pb from the diet than do adult rats (Aungst et al. 1981; Forbes and Reina 1972; Kostial et al. 1978). This age difference in absorption may be due, in part, to the shift from the neonatal to adult diet, and to postnatal physiological development (enzymes, transporters, gastric pH) of the gastrointestinal tract (Weis and LaVelle 1991).

Effect of Fasting. The presence of food in the gastrointestinal tract decreases absorption of water-soluble Pb (Blake and Mann 1983; Blake et al. 1983; Heard and Chamberlain 1982; James et al. 1985; Maddaloni et al. 1998; Rabinowitz et al. 1980). In adults, absorption of a tracer dose of Pb acetate in water was approximately 63% when ingested by fasted subjects and 3% when ingested with a meal (James et al. 1985). Heard and Chamberlain (1982) reported nearly identical results. The arithmetic mean of reported estimates of absorption in fasted adults was 57% (calculated by ATSDR based on Blake et al. 1983; Heard and Chamberlain 1982; James et al. 1985; Rabinowitz et al. 1980). Reported fed/fasted ratios for absorption in adults range from 0.04 to 0.2 (Blake et al. 1983; Heard and Chamberlain 1983; James et al. 1985; Rabinowitz et al. 1980). Mineral content is one contributing factor to the lower absorption of Pb when Pb is ingested with a meal; in particular, the presence of calcium and phosphate in a meal will depress the absorption of ingested Pb (Blake and Mann 1983; Blake et al. 1983; Heard and Chamberlain

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

1982). Suppression of absorption by meals may explain the observation of lower PbB in children (age 3–5 years) who ate breakfast compared to children who went without breakfast, after controlling for nutritional variables (Liu et al. 2011).

Effect of Nutrition. Pb absorption in children is affected by nutritional iron status. Children who are iron deficient have higher PbBs than similarly exposed children who are iron replete, which would suggest that iron deficiency may result in higher absorption of Pb or, possibly, other changes in Pb biokinetics that would contribute to lower PbBs (Mahaffey and Annett 1986; Marcus and Schwartz 1987). Genetic variation in genes involved in iron metabolism appear to affect PbBs; however, it is not certain if these associations are caused by changes in Pb absorption. These include variants in the hemochromatosis (HFE) and transferrin genes, which have been associated with higher PbBs in children (Hopkins et al. 2008), and with lower PbBs and bone Pb levels in elderly men (Wright et al. 2004).

Evidence for the effect for iron deficiency on Pb absorption has been provided from animal studies. In rats, iron deficiency increases the gastrointestinal absorption of Pb, possibly by enhancing binding of Pb to iron binding proteins in the intestine (Bannon et al. 2003; Barton et al. 1978b; Morrison and Quaterman 1987). Interactions between iron and Pb appear to involve either intracellular transfer or basolateral transfer mechanisms. Iron (FeCl₂) added to the mucosal fluid of the everted rat duodenal sac decreases serosal transfer, but not mucosal uptake of Pb (Barton 1984). When mRNA for DMT1, a mucosal membrane carrier for iron (which also transports other divalent metal cations), was suppressed in Caco 2 cells (a human gastrointestinal cell line), the rate of iron and cadmium uptake decreased by 50% compared to cells in which DMT1 mRNA was not suppressed; however, DMT1 mRNA suppression did not alter the rate of Pb uptake by Caco 2 cells, indicating that Pb may enter Caco 2 cells through a mechanism that is independent of DMT1 (Bannon et al. 2003). The above observations suggest that rate-limiting saturable mechanisms for Pb absorption are associated with transfer of Pb from cell to blood rather than with mucosal transfer. Similar mechanisms may contribute to Pb-iron and Pb-calcium absorption interactions in humans, and possibly interactions between Pb and other divalent cations such as cadmium, copper, magnesium, and zinc.

Dietary calcium intake affects Pb absorption. An inverse relationship has been observed between dietary calcium intake and PbBs in children, suggesting that children who are calcium-deficient may absorb more Pb than calcium-replete children (Elias et al. 2007; Mahaffey et al. 1986; Schell et al. 2004; Ziegler et al. 1978). An effect of calcium on Pb absorption is also evident in adults. In experimental studies of adults, absorption of a single dose of Pb (100–300 µg Pb chloride) was lower when the Pb was ingested together

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

with calcium carbonate (0.2–1 g calcium carbonate) than when the Pb was ingested without additional calcium (Blake and Mann 1983; Heard and Chamberlain 1982). A similar effect of calcium occurs in rats (Barton et al. 1978a). Complexation with calcium (and phosphate) in the gastrointestinal tract and competition for a common transport protein have been proposed as possible mechanisms for this interaction (Barton et al. 1978a; Heard and Chamberlain 1982). Absorption of Pb from the gastrointestinal tract is enhanced by dietary calcium depletion or administration of cholecalciferol (Mykkänen and Wasserman 1981, 1982). This "cholecalciferol-dependent" component of Pb absorption appears to involve a stimulation of the serosal transfer of Pb from the epithelium, not stimulation of mucosal uptake of Pb (Mykkänen and Wasserman 1981, 1982). This is similar to the effects of cholecalciferol on calcium absorption (Bronner et al. 1986; Fullmer and Rosen 1990).

In a study of young children (ages 6–12 months), PbBs increased in association with lower dietary Zn levels (Schell et al. 2004); however, it is not certain if these associations were caused by changes in Pb absorption.

Effect of Pregnancy. Absorption of Pb may increase during pregnancy. Although there is no direct evidence for this in humans, an increase in Pb absorption may contribute, along with other mechanisms (e.g., increased mobilization of bone Pb), to the increase in PbBs that has been observed during the latter half of pregnancy (see Section 3.1.2, *Pb Distribution during Pregnancy and Maternal-Fetal-Infant Transfer*).

Effect of Dose. Pb absorption in humans may be a capacity-limited process, in which case, the percentage of ingested Pb that is absorbed may decrease with increasing rate of Pb intake. Studies, to date, do not provide a firm basis for discerning if the gastrointestinal absorption of Pb is limited by dose. Numerous observations of nonlinear relationships between PbB and Pb intake in humans provide support for the existence of a saturable absorption mechanism or some other capacity-limited process in the distribution of Pb in humans (Pocock et al. 1983; Sherlock and Quinn 1986; Sherlock et al. 1984) (see Section 3.1.2, *Pb in Blood* and *Pb in Plasma* for discussion of saturable uptake of Pb in red blood cells). However, in immature swine that received oral doses of Pb in soil, Pb dose-blood Pb relationships were curvilinear, whereas dose-tissue Pb relationships for bone, kidney, and liver were linear. The same pattern (nonlinearity for PbB and linearity for tissues) was observed in swine administered Pb acetate intravenously (Casteel et al. 1997, 2006). These results suggest that the nonlinearity in the Pb dose-blood Pb relationship may derive from an effect of Pb dose on some aspect of the biokinetics of Pb other than absorption. In fasted rats, absorption was estimated at 42 and 2% following single oral administration of

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

1 and 100 mg Pb/kg, respectively, as Pb acetate, suggesting a limitation on absorption imposed by dose (Aungst et al. 1981). Evidence for capacity-limited processes at the level of the intestinal epithelium (Aungst and Fung 1981; Barton 1984; Flanagan et al. 1979; Mykkänen and Wasserman 1981) suggests that the intake-uptake relationship for Pb is likely to be nonlinear; however, the dose at which absorption becomes appreciably limited in humans is not known.

Effect of Particle Size. Particle size influences the degree of gastrointestinal absorption (Ruby et al. 1999). In rats, an inverse relationship was found between absorption and particle size of Pb in diets containing metallic Pb particles that were ≤ 250 μm in diameter (Barltrop and Meek 1979). Tissue Pb concentration was a 2.3-fold higher when rats ingested an acute dose (37.5 mg Pb/kg) of Pb particles that were < 38 μm in diameter than when rats ingested particles having diameters in the range of 150–250 μm (Barltrop and Meek 1979). Dissolution kinetics experiments with Pb-bearing mine waste soil suggest that surface area effects control dissolution rates for particles sizes of < 90 μm diameter; however, dissolution of 90–250 μm particle size fractions appeared to be controlled more by surface morphology (Davis et al. 1994). Similarly, Healy et al. (1982) found that the solubility of Pb sulfide in gastric acid *in vitro* was much greater for particles that were 30 μm in diameter than for particles that were 100 μm in diameter.

Absorption from Soil. Absorption of Pb from the gastrointestinal tract involves absorptive transport of soluble Pb species (e.g., Pb^{2+}) across the gastrointestinal tract epithelium. In order for Pb to be absorbed from soil, it must first be made bioaccessible in the gastrointestinal tract. The process of rendering soil Pb bioaccessible may involve: (1) physical and/or chemical digestion of the soil particles to expose Pb deposits to gastrointestinal tract fluids; (2) transfer of Pb minerals from exposed surfaces on soil particles to the aqueous environment of the gastrointestinal tract; and (3) chemical transformation of Pb minerals to soluble Pb species (e.g., Pb^{2+}) that are substrates for absorptive transport. Although absorptive transport of Pb occurs predominantly, if not solely, in the upper small intestine, bioaccessibility processes occurring in the stomach appear to be major determinants of Pb absorption.

Adult subjects who ingested soil (particle size < 250 μm) collected from the Bunker Hill National Priorities List (NPL) site absorbed 26% of the resulting 250 $\mu\text{g}/70$ kg body weight Pb dose when the soil was ingested in the fasted state, and 2.5% when the same soil Pb dose was ingested with a meal (Maddaloni et al. 1998). The value reported for fasted subjects (26%) was approximately half that reported for soluble Pb ingested by fasting adults, or approximately 60% (Blake et al. 1983; Heard and Chamberlain 1983; James et al. 1985; Rabinowitz et al. 1980). Measurements of the absorption of soil Pb in infants or children have not been reported.

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

Absorption of Pb from ingested soils and surface dust has been studied more extensively in animals (Bannon et al. 2009; Barltrop and Meek 1979; Bradham et al. 2016; Brown et al. 2004; Casteel et al. 1997, 2006; Freeman et al. 1992, 1994, 1996; Healy et al. 1982; Hettiearachchi et al. 2003; Juhasz et al. 2009; Ryan et al. 2004; Weis and Lavelle 1991). These studies have shown that absorption of soil Pb varies depending upon the Pb mineralogy and physical characteristics of the Pb in the soil (e.g., encapsulated or exposed, particle size). Studies conducted in swine and other animal models have provided estimates of relative bioavailability (RBA) of Pb in soils collected from sites impacted by a variety of sources of Pb contamination including ore and ore processing, shooting of Pb munitions, and Pb-based paint (Bannon et al. 2009; Barltrop and Meek 1979; Bradham et al. 2016; Brown et al. 2004; Casteel et al. 1997, 2006; Freeman et al. 1992, 1994, 1996; Healy et al. 1982; Hettiearachchi et al. 2003; Juhasz et al. 2009; Ryan et al. 2004; Weis and Lavelle 1991). RBA is the ratio of the absolute bioavailability (or absorption fraction) of Pb in soil to that of a water-soluble reference (Pb acetate). RBA has been measured in animals models using various approaches, including measurement of blood and tissue Pb in animals following dosing with soil or Pb acetate. RBA estimates from these studies ranged from 1 to 100% (mean 60%, n=33, calculated by ATSDR). RBA for soils from firing ranges where the predominant form of Pb was Pb carbonate were approximately 100% (Bannon et al. 2009). A soil amended with NIST paint standard (a mixture of Pb carbonate and Pb oxide) had an RBA of 92%. Smelter slag and soils in which the dominant source of Pb was smelter slag had relatively low RBA (14–40%). Galena (lead sulfide) in soil also had relatively low RBA (1–6%).

Casteel et al. (2006) estimated Pb RBA of 19 soils in swine and categorized the RBA according to Pb mineral associations. Electron microprobe analyses of Pb-bearing grains in the various soils revealed that the grains ranged from as small as 1–2 μm up to a maximum of 250 μm (the sieve size used in preparation of the samples) and that Pb was present in a wide range of different mineral associations (phases), including various oxides, sulfides, sulfates, and phosphates. These variations in size and mineral content of the Pb-bearing grains are the suspected cause of variations in the gastrointestinal absorption of Pb from different samples of soil. Based on these very limited data, the RBA of Pb mineral phases were rank-ordered (Table 3-1).

Table 3-1. Ranking of Relative Bioavailability of Lead (Pb) Mineral Phases in Soil^a

Low bioavailability (RBA<0.25)	Medium bioavailability (RBA=0.25–0.75)	High bioavailability (RBA>0.75)
Anglesite Fe(M) oxide Fe(M) sulfate Galena Pb(M) oxide	Pb oxide Pb phosphate	Cerussite Mn(M) oxide

^aEstimates are based on studies of immature swine.

Fe = iron; M = metal; Mn = manganese; RBA = relative bioavailability (compared to Pb acetate)

Source: Casteel et al. 2006

Several studies have shown that elevating the phosphate concentration of soil can decrease soil Pb RBA (Brown et al. 2004; Hettiarachichi et al. 2003; Ryan et al. 2004). The mechanism for the effect is thought to be the formation of a relatively insoluble form of Pb in soil, pyromorphite, which has a low RBA (Scheckel et al. 2013).

Bioaccessibility in Soil and its Relationship to Relative Bioavailability. Empirical evidence supporting the importance of gastric bioaccessibility in Pb absorption comes from studies of relationships between extractability of Pb from soil measured *in vitro* and Pb RBA measured in animals. *In vitro* extractability of Pb from soil (*in vitro* bioaccessibility, IVBA) strongly correlates with RBA measured swine assays when the extraction is performed at gastric pH ($r^2=0.92$, $n=18$; Drexler and Brattin 2007). Bioaccessibility estimates obtained from IVBA assays are sensitive to assay conditions such as pH, liquid:soil ratios, inclusion or absence of food material, and differences in methods used to separate dissolved and particle-bound Pb (e.g., centrifugation versus filtration); as a result, different assays can yield different results when applied to the same soils or surface dusts (Dong et al. 2016; Juhasz et al. 2011; Lu et al. 2011; Roussel et al. 2010; Saikat et al. 2007; Smith et al. 2011; Van de Wiele et al. 2007). For this reason, application of IVBA assays for predicting RBA must be supported by demonstration of a strong correlation between IVBA and RBA (Drexler and Brattin 2007). Even in the absence of validation of RBA predictions, IVBA assays may be useful for predicting relative differences in RBA between soils. For example, the relative change in Pb RBA resulting from treatment of soils with phosphate amendments was predicted from IVBA measurements even though the IVBA assay performed poorly at predicting the actual RBA of the soils (Juhasz et al. 2016). Bioaccessibility measured with IVBA assays has been shown to increase with decreasing particle size (varied from <2,000 to <50 μm) (Juhasz et al. 2011) and increase with increasing soil acidity and organic matter content (Jin et al. 2005).

Dermal Exposure

Inorganic Pb. Dermal absorption of inorganic Pb compounds is generally considered to be much less than absorption by inhalation or oral routes of exposure; however, few studies have provided quantitative estimates of dermal absorption of inorganic Pb in humans, and the quantitative significance of the dermal absorption pathway as a contributor to Pb body burden in humans remains an uncertainty. Pb was detected in the upper layers of the stratum corneum of Pb-battery workers, prior to their shifts and after cleaning of the skin surface (Sun et al. 2002), suggesting adherence and/or possible dermal penetration of Pb. Following skin application of ²⁰³Pb-labeled Pb acetate in cosmetic preparations (0.12 mg Pb in 0.1 mL or 0.18 mg Pb in 0.1 g of a cream) to eight male volunteers for 12 hours, absorption was ≤0.3%, based on whole-body, urine, and blood ²⁰³Pb measurements, and was predicted to be 0.06% during normal use of such preparations (Moore et al. 1980). Most of the absorption took place within 12 hours of exposure. Pb also appears to be absorbed across human skin when applied to the skin as Pb nitrate; however, quantitative estimates of absorption have not been reported. Pb (4.4 mg, as Pb nitrate) was applied (vehicle or solvent not reported) to an occluded filter placed on the forearm of an adult subject for 24 hours, after which, the patch was removed, the site cover and the forearm were rinsed with water, and total Pb was quantified in the cover material and rinse (Stauber et al. 1994). The amount of Pb recovered from the cover material and rinse was 3.1 mg (70% of the applied dose). Based on this recovery measurement, 1.3 mg (30%) of the applied dose remained either in the skin or had been absorbed in 24 hours; the amount that remained in or on the skin and the fate of this Pb (e.g., exfoliation) was not determined. Exfoliation has been implicated as an important pathway of elimination of other metals from skin (e.g., inorganic mercury; Hursh et al. 1989). Pb concentrations in sweat collected from the right arm increased 4-fold following the application of Pb to the left arm, indicating that some Pb had been absorbed (amounts of sweat collected or total Pb recovered in sweat were not reported; Stauber et al. 1994). In similar experiments with three subjects, measurements of ²⁰³Pb in blood, sweat, and urine, made over a 24-hour period following dermal exposures to 5 mg Pb as ²⁰³Pb nitrate or acetate, accounted for <1% of the applied (or adsorbed) dose (Stauber et al. 1994). This study also reported that absorption of Pb could not be detected from measurements of Pb in sweat following dermal exposure to Pb as Pb carbonate.

Information on relative dermal permeability of inorganic and organic Pb salts of Pb comes from studies of *in vitro* preparations of excised skin; the rank ordering of penetration rates through excised human skin

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

was: Pb nuolate (Pb linoleic and oleic acid complex) > Pb naphthanate > Pb acetate > Pb oxide (nondetectable) (Bress and Bidanset 1991).

Studies conducted in animals provide additional evidence that dermal absorption of inorganic Pb is substantially lower than absorption from the inhalation or oral route. In a comparative study of dermal absorption of inorganic and organic salts of Pb conducted in rats, approximately 100 mg of Pb was applied in an occluded patch to the shaved backs of rats. Based on urinary Pb measurements made prior to and for 12 days following exposure, Pb compounds could be ranked according to the relative amounts absorbed (i.e., percent of dose recovered in urine; calculated by ATSDR): Pb naphthalene (0.17%), Pb nitrate (0.03%), Pb stearate (0.006%), Pb sulfate (0.006%), Pb oxide (0.005%), and metal Pb powder (0.002%). This rank order (i.e., Pb naphthalene > Pb oxide) is consistent with a rank ordering of penetration rates of inorganic and organic Pb salts through excised skin from humans and guinea pigs: Pb nuolate (Pb linoleic and oleic acid complex) > Pb naphthanate > Pb acetate > Pb oxide (nondetectable) (Bress and Bidanset 1991). The estimates for percent of dose excreted underestimate actual absorption as these estimates do not account for the Pb retained in bone and other tissues.

Following application of Pb acetate to the shaved clipped skin of rats, the concentration of Pb in the kidneys was found to be higher relative to controls, suggesting that absorption of Pb had occurred (Laug and Kunze 1948). This study also observed that dermal absorption of Pb from Pb arsenate was significantly less than from Pb acetate, and that mechanical injury to the skin significantly increased the dermal penetration of Pb.

Organic Pb. Relative to inorganic Pb and organic Pb salts, tetraalkyl Pb compounds have been shown to be rapidly and extensively absorbed through the skin of rabbits and rats (Kehoe and Thamann 1931; Laug and Kunze 1948). A 0.75-mL amount of tetraethyl Pb, which was allowed to spread uniformly over an area of 25 cm² on the abdominal skin of rabbits, resulted in 10.6 mg of Pb in the carcass at 0.5 hours and 4.41 mg at 6 hours (Kehoe and Thamann 1931). Tetraethyl Pb was reported to be absorbed by the skin of rats to a much greater extent than Pb acetate, Pb oleate, and Pb arsenate (Laug and Kunze 1948). Evidence for higher dermal permeability of organic Pb compounds compared to inorganic organic salts of Pb also comes from *in vitro* studies conducted with excised skin. The rank order of absorption rates through excised skin from humans and guinea pigs was as follows: tetrabutyl Pb > Pb nuolate (Pb linoleic and oleic acid complex) > Pb naphthanate > Pb acetate > Pb oxide (nondetectable) (Bress and Bidanset 1991).

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

3.1.2 Distribution

Inorganic Pb. Absorbed inorganic Pb appears to be distributed in essentially the same manner regardless of the route of absorption (Chamberlain et al. 1978; Kehoe 1987); therefore, the distribution of absorbed Pb (i.e., by any route) is discussed in this section, rather than in separate sections devoted to specific routes of exposure. The expression “body burden” is used here to refer to the total amount of Pb in the body. Most of the available information about the distribution of Pb to major organ systems (e.g., bone, soft tissues) derives from autopsy studies conducted in the 1960s and 1970s and reflect body burdens accrued during periods when ambient and occupational exposure levels were much higher than current levels (Barry 1975, 1981; Gross et al. 1975; Schroeder and Tipton 1968). A more recent autopsy study found lower Pb concentrations in autopsies performed during the period 2004–2013 (Mari et al. 2014). In general, these studies indicate that the distribution of Pb appears to be similar in children and adults, although a larger fraction of the Pb body burden of adults resides in bone. Several models of Pb pharmacokinetics have been proposed to characterize such parameters as intercompartmental Pb exchange rates, retention of Pb in various tissues, and relative rates of distribution among the tissue groups (see Section 3.1.5 for further discussion of models).

Pb in Blood. Concentrations of Pb in blood vary considerably with age, physiology/life stage (e.g., pregnancy, lactation, menopause), and numerous factors that affect exposure to Pb. PbBs in various demographic strata of the U.S. population are periodically estimated from the NHANES. Based on data from NHANES (2015–2016, CDC 2018a), the geometric mean PbB of U.S. adults, age ≥ 20 years, was 0.920 $\mu\text{g}/\text{dL}$ (95% CI 0.862, 0.982). The geometric mean PbB of U.S. children, age 1–5 years, was 0.758 (95% CI 0.675, 0.850). PbBs in the United States have decreased considerably in the last several decades as a result of removal of Pb from gasoline and restrictions placed on the use of Pb in residential paints (Brody et al. 1994; CDC 2011, 2018a; Pirkle et al. 1994, 1998; Schwartz and Pitcher 1989). While historically, the geometric mean PbB in U.S. children has been higher than that of the adult population, recent estimates indicate that geometric means in children have fallen below that of adults.

Pb in Red Blood Cells. Pb in blood is primarily in the red blood cells (99%) (Bergdahl et al. 1997a, 1998, 1999; Hernandez-Avila et al. 1998; Manton et al. 2001; Schutz et al. 1996; Smith et al. 2002). Although the mechanisms by which Pb crosses cell membranes have not been fully elucidated, results of studies in intact red blood cells and red blood cell ghosts indicate that there are two, and possibly three, pathways for facilitated transfer of Pb across the red cell membrane. The major proposed pathway is an anion exchanger that is dependent upon HCO_3^- and is blocked by anion exchange inhibitors (Bannon et al.

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

2000, Simons 1985, 1986a, 1986b, 1993). A second minor pathway, which does not exhibit HCO_3^- dependence and is not sensitive to anion exchange inhibitors, may also exist (Simons 1986b). Pb and calcium may also share a permeability pathway, which may be a Ca^{2+} -channel (Calderon-Salinas et al. 1999). Pb is transferred out of the erythrocyte by an active transport pathway, most likely a $(\text{Ca}^{2+}, \text{Mg}^{2+})$ -ATPase (Simons 1988).

Pb in erythrocytes binds to several intracellular proteins. ALAD is the primary binding ligand for Pb in erythrocytes (Bergdahl et al. 1997a, 1998; Sakai et al. 1982; Xie et al. 1998). Pb binding to ALAD is saturable; the binding capacity has been estimated to be approximately 85 $\mu\text{g}/\text{dL}$ red blood cells (or approximately 40 $\mu\text{g}/\text{dL}$ whole blood) and the apparent dissociation constant has been estimated to be approximately 1.5 $\mu\text{g}/\text{L}$ (Bergdahl et al. 1998). Two other Pb-binding proteins have been identified in erythrocytes, a 45 kDa protein (K_d 5.5 $\mu\text{g}/\text{L}$) and a smaller protein(s) having a molecular weight <10 kDa (Bergdahl et al. 1996, 1997a, 1998). Of the three principal Pb-binding proteins identified in erythrocytes, ALAD has the strongest affinity for Pb (Bergdahl et al. 1998) and appears to dominate the ligand distribution of Pb (35–84% of total erythrocyte Pb) at blood Pb levels below 40 $\mu\text{g}/\text{dL}$ (Bergdahl et al. 1996, 1998; Sakai et al. 1982). The decrease in hematocrit that occurs in early infancy (51% at birth to 35% at 6 months) may decrease the total binding capacity of blood and PbBs over the first postnatal 6 months (Simon et al. 2007).

Pb binds to and inhibits the activity of ALAD (Gercken and Barnes 1991; Gibbs et al. 1985; Jaffe et al. 2000; Sakai et al. 1982, 1983). Binding of zinc is essential for ALAD activity, and Pb inhibits activity of ALAD by displacing zinc (Jaffe et al. 2000). Synthesis of ALAD appears to be induced in response to inhibition of ALAD and, therefore, in response to binding of Pb to ALAD (Boudene et al. 1984; Fujita et al. 1982). Several mechanisms may participate in the induction of ALAD, including (1) inhibition of ALAD directly by Pb; (2) inhibition by protoporphyrin, secondary to accumulation of protoporphyrin as a result of Pb inhibition of ferrochelatase; and (3) accumulation of ALA (a substrate of ALAD), secondary to inhibition of ALAD, which may stimulate ALAD synthesis in bone marrow cells (Boudene et al. 1984; Fujita et al. 1982).

ALAD is a polymorphic enzyme with two alleles (ALAD 1 and ALAD 2) and three genotypes (ALAD 1,1, ALAD 1,2, and ALAD 2,2) (Battistuzzi et al. 1981, Scinicariello et al. 2007). Numerous studies have examined the relationship between ALAD genotype and PbBs and the results of these studies are mixed with some studies finding higher PbBs in association with the ALAD 2 allele and other studies finding no associations or lower PbBs associated with the ALAD 2 allele (see Section 3.2). One possible

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

mechanism by which ALAD polymorphism could affect PbBs is by allelic variation in Pb binding to ALAD (Bergdahl et al. 1997b). However, competitive displacement studies with recombinant human ALAD 1 and ALAD 2 did not indicate differences in affinity for Pb relative to zinc (Jaffe et al. 2000).

Pb in Blood Plasma. Pb binds to several constituents in plasma and it has been proposed that Pb in plasma exists in four states: loosely bound to serum albumin or other proteins with relatively low affinity for Pb, complexed to low molecular weight ligands such as amino acids and carboxylic acids, tightly bound to a circulating metalloprotein, and as free Pb^{2+} (Al-Modhefer et al. 1991). Free ionized Pb (i.e., Pb^{2+}) in plasma represents an extremely small percentage of total plasma Pb. The concentration of Pb^{2+} in fresh serum, as measured by an ion-selective Pb electrode, was reported to be 1/5,000 of the total serum Pb (Al-Modhefer et al. 1991). Approximately 40–75% of Pb in the plasma is bound to plasma proteins, of which albumin appears to be the dominant ligand (Al-Modhefer et al. 1991; Ong and Lee 1980). Pb also binds to transferrins and γ -globulins (Guo et al. 2014; Ong and Lee 1980). Pb in serum that is not bound to protein exists largely as complexes with low molecular weight sulfhydryl compounds (e.g., cysteine, homocysteine). Other potential low molecular weight Pb-binding ligands in serum may include citrate, cysteamine, ergothioneine, glutathione, histidine, and oxylate (Al-Modhefer et al. 1991).

Saturable binding to red blood cell proteins contributes to curvature to the blood Pb-plasma Pb relationship with an increase in the plasma/blood Pb ratio with increasing PbB (Barbosa et al. 2006a; Bergdahl et al. 1997b, 1998, 1999; DeSilva 1981; Jin et al. 2008; Kang et al. 2009; Manton et al. 2001; Rentschler et al. 2012; Smith et al. 2002; Tian et al. 2013). The curvature becomes evident at PbBs well above 10 $\mu\text{g}/\text{dL}$. As binding sites for Pb in red blood cells become saturated, a larger fraction of the blood Pb is available in plasma to distribute to brain and other Pb-responsive tissues. This contributes to a curvature in the relationship between Pb intake and PbB, with the blood Pb/intake slope decreasing with increasing Pb intake, which has been observed in children (Sherlock and Quinn 1986) and immature swine (Casteel et al. 2006). Saturable binding of Pb to red blood cell proteins also contributes to a curvilinear relationship between blood Pb and urinary Pb, whereas the relationship between plasma Pb concentration and urine Pb is linear (Bergdahl et al. 1997b).

Pb in Bone. In human adults, approximately >90% of the total body burden of Pb is found in the bones. Based on analyses of post-mortem tissues, bone accounted for 94% of the total Pb body burden of adults and 73% of the body burden in children (Barry 1975). Pb concentrations in bone increase with age, indicative of a relatively slow turnover of Pb in adult bone (Barry 1975, 1981; Gross et al. 1975; Schroeder and Tipton 1968; Wilker et al. 2011). A portion of Pb in bone readily exchanges with the

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

plasma Pb pool and, as a result, bone Pb is a reservoir for replenishment of Pb eliminated from blood by excretion (Alessio 1988; Behinaein et al. 2012, 2014; Chettle et al. 1991; Hryhorczuk et al. 1985; Nie et al. 2005; Nilsson et al. 1991; Rabinowitz et al. 1976). Pb in adult bone can serve to maintain blood Pb levels long after exposure has ended (Fleming et al. 1997; Inskip et al. 1996; Kehoe 1987; O'Flaherty et al. 1982; Smith et al. 1996). It can also serve as a source of Pb transfer to the fetus when maternal bone is resorbed for the production of the fetal skeleton (Franklin et al. 1997; Gulson et al. 1997b, 1999b, 2003).

Pb forms highly stable complexes with phosphate and can replace calcium in the calcium-phosphate salt, hydroxyapatite, which comprises the primary crystalline matrix of bone (Bres et al. 1986; Lloyd et al. 1975; Meirer et al. 2011; Miyake 1986; Verbeek et al. 1981). As a result, Pb deposits in bone during the normal mineralization process that occurs during bone growth and remodeling and is released to the blood during the process of bone resorption (Aufderheide and Wittmers 1992; O'Flaherty 1991b, 1993). During infancy and childhood, bone calcification is most active in trabecular bone, whereas in adulthood, calcification occurs at sites of remodeling in cortical and trabecular bone. This suggests that Pb accumulation will occur predominantly in trabecular bone during childhood, and in both cortical and trabecular bone in adulthood (Aufderheide and Wittmers 1992). The association of Pb uptake and release from bone with the normal physiological processes of bone formation and resorption renders Pb biokinetics sensitive to these processes. Physiological states (e.g., pregnancy, menopause, advanced age) or disease-related states (e.g., osteoporosis, prolonged immobilization) that are associated with increased bone resorption will tend to promote the release of Pb from bone, which, in turn, may contribute to an increase in the concentration of Pb in blood (Berkowitz et al. 2004; Bonithon-Kopp et al. 1985; Garrido Latorre et al. 2003; Hernandez-Avila et al. 2000; Jackson et al. 2010; Markowitz and Weinberger 1990; Mendola et al. 2013; Nash et al. 2004; Nie et al. 2009; Popovic et al. 2005; Silbergeld et al. 1988; Symanski and Hertz-Picciotto 1995; Thompson et al. 1985).

Two physiological compartments appear to exist for Pb in cortical and trabecular bone, to varying degrees. In one compartment, bone Pb is essentially inert, having an elimination half-time of several decades. A labile compartment exists as well that allows for maintenance of an equilibrium of Pb between bone and soft tissue or blood (Rabinowitz et al. 1976). Although a high bone formation rate in early childhood results in the rapid uptake of circulating Pb into mineralizing bone, bone Pb is also recycled to other tissue compartments or excreted in accordance with a high bone resorption rate (O'Flaherty 1995a). Thus, most of the Pb acquired early in life is not permanently fixed in the bone (O'Flaherty 1995a). In general, bone turnover rates decrease as a function of age, resulting in slowly increasing bone Pb levels among adults (Barry 1975; Gross et al. 1975; Schroeder and Tipton 1968).

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

Bone Pb burdens in adults are slowly lost by diffusion (heteroionic exchange) as well as by resorption (O'Flaherty 1995a, 1995b). An XRF study of tibia Pb concentrations in individuals >10 years old showed a gradual increase in bone Pb after age 20 (Kosnett et al. 1994). In 60–70-year-old men, the total bone Pb burden may be ≥ 200 mg, while children <16 years old have been shown to have a total bone Pb burden of 8 mg (Barry 1975). However, in some bones (i.e., mid femur and pelvic bone), the increase in Pb content plateaus at middle age and then decreases at higher ages; the decrease with age was more pronounced in females (Drasch et al. 1987). Osteoporosis and release of Pb from resorbed bone to blood may contribute to decreasing bone Pb content in females (Gulson et al. 2002).

Evidence for the exchange of bone Pb and soft tissue Pb stores comes from analyses of stable Pb isotope signatures of Pb in bone and blood. A comparison of blood and bone Pb stable isotope signatures in five adults indicated that bone Pb stores contributed to approximately 40–70% of the Pb in blood (Smith et al. 1996). During pregnancy, the mobilization of bone Pb increases, as the bone is resorbed to produce the fetal skeleton. Analysis for kinetics of changes in the stable isotope signatures of blood Pb in pregnant women as they came into equilibrium with a novel environmental Pb isotope signature indicated that 10–88% of the Pb in blood may derive from the mobilization of bone Pb store and approximately 80% of cord blood may be contributed from maternal bone Pb (Gulson 2000; Gulson et al. 1997b, 1999c, 2003). The mobilization of bone Pb during pregnancy may contribute, along with other mechanisms (e.g., increased absorption), to the increase in Pb concentration that has been observed during the later stages of pregnancy (Gulson et al. 1997b, 2016; Lagerkvist et al. 1996; Schuhmacher et al. 1996). Bone resorption during pregnancy can be reduced by ingestion of calcium supplements (Janakiraman et al. 2003). Additional evidence for increased mobilization of bone Pb into blood during pregnancy is provided from studies in nonhuman primates and rats (Franklin et al. 1997; Maldonado-Vega et al. 1996). Direct evidence for transfer of maternal bone Pb to the fetus has been provided from stable Pb isotope studies in *Cynomolgus* monkeys (*Macaca fascicularis*) that were dosed with Pb having a different stable isotope ratio than the Pb to which the monkeys were exposed at an earlier age; approximately 7–39% of the maternal Pb burden that was transferred to the fetus appeared to have been derived from the maternal skeleton (Franklin et al. 1997).

In addition to pregnancy, other states of increased bone resorption appear to result in release of bone Pb to blood; these include lactation, osteoporosis, and severe weight loss. Analysis of kinetics of changes in the stable isotope signatures of blood Pb in postpartum women as they came into equilibrium with a novel environmental Pb isotope signature indicated that the release of maternal bone Pb to blood appears to accelerate during lactation (Gulson et al. 2002, 2003, 2004). This is consistent with declines in patella

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

bone Pb (measured by XRF) during lactation without calcium supplementation (Henandez-Avila et al. 1996). Similar approaches have detected increased release of bone Pb to blood in women, in association with menopause (Gulson et al. 2002). These observations are consistent with epidemiological studies that have shown increases in PbB after menopause and in association with decreasing bone density in postmenopausal women (Berkowitz et al. 2004; Garrido Latorre et al. 2003; Hernandez-Avila et al. 2000; Korrick et al. 2002; Nash et al. 2004; Popovic et al. 2005; Symanski and Hertz-Picciotto 1995). In a prospective study of women who were scheduled to undergo bilateral oophorectomy for benign conditions, blood and tibia bone Pb (measured by XRF and adjusted for bone mineral density) did not change 6–18 months post-surgery, regardless of whether patients were given estrogen replacement therapy (Berkowitz et al. 2004). Severe weight loss (28% of BMI in 6 months) in women, which increased bone turnover, increased PbB (Riedt et al. 2009).

Pb in Soft Tissues. Several studies have compared soft tissue concentrations of Pb in autopsy samples of soft tissues (Barry 1975, 1981; Gross et al. 1975; Schroeder and Tipton 1968). These studies were conducted in the 1960s and 1970s and, therefore, reflect burdens accrued during periods when ambient and occupational exposure levels were much higher than current levels. A more recent autopsy study found lower Pb concentrations in autopsies performed during the period 2004–2013 (Mari et al. 2014). Average PbBs reported in the adult subjects were approximately 20 µg/dL in the Barry (1975) and Gross et al. (1975) studies, whereas more current estimates of the average for adults in the United States are <5 µg/dL (CDC 2018a). Levels in other soft tissues also appear to have decreased substantially since these studies were reported (Barregård et al. 1999; Mari et al. 2014). For example, average Pb concentrations in kidney cortex of male adults were 0.78 µg/g wet tissue and 0.79 µg/g, as reported by Barry (1975) and Gross et al. (1975), respectively (samples in the Barry study were from subjects who had no known occupational exposures). An analysis of kidney biopsy samples collected in Sweden found that the mean level of lead in kidney cortex among subjects not occupationally exposed to Pb was 0.18 µg/g (maximum, 0.56 µg/g) (Barregård et al. 1999). Mari et al. (2014) reported a value of 0.18 µg/g for mean kidney Pb concentration in 20 autopsies performed in Spain. In spite of the downward trends in soft tissue Pb levels, the autopsy studies provide a basis for describing the relative soft tissue distribution of Pb in adults and children. Most of the Pb in soft tissue is in liver. Relative amounts of Pb in soft tissues as reported by Schroeder and Tipton (1968), expressed as percent of total soft tissue Pb, were: liver, 33%; skeletal muscle, 18%; skin, 16%; dense connective tissue, 11%; fat, 6.4%; kidney, 4%; lung, 4%; aorta, 2%; and brain, 2% (other tissues were <1%). The highest soft tissue concentrations in adults also occur in liver and kidney cortex (Barry 1975; Gerhardsson et al. 1986a, 1995b; Gross et al. 1975; Mari et al. 2014; Oldereid et al. 1993). The relative distribution of Pb in soft tissues, in males and

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

females, expressed in terms of tissue:liver concentration ratios, were: liver, 1.0 (approximately 1 µg/g wet weight); kidney cortex, 0.8; kidney medulla, 0.5; pancreas, 0.4; ovary, 0.4; spleen, 0.3; prostate, 0.2; adrenal gland, 0.2; brain, 0.1; fat, 0.1; testis, 0.08; heart, 0.07; and skeletal muscle, 0.05 (Barry 1975; Gross et al. 1975). In contrast to Pb in bone, which accumulates Pb with continued exposure in adulthood, concentrations in soft tissues (e.g., liver and kidney) are relatively constant in adults (Barry 1975; Treble and Thompson 1997), reflecting a faster turnover of Pb in soft tissue, relative to bone.

Mechanisms by which Pb enters soft tissues have not been fully characterized (Bressler et al. 2005). Studies conducted in preparations of mammalian small intestine support the existence of saturable and nonsaturable pathways of Pb transfer and suggest that Pb can interact with transport mechanisms for calcium and iron (see Section 3.1.1). Pb can enter cells through voltage-gated L-type Ca²⁺ channels in bovine adrenal medullary cells (Legare et al. 1998; Simons and Pocock 1987; Tomsig and Suszkiw 1991) and through store-operated Ca²⁺ channels in pituitary GH3, glial C3, human embryonic kidney, and bovine brain capillary endothelial cells (Kerper and Hinkle 1997a, 1997b). Anion exchangers may also participate in Pb transport in astrocytes (Bressler et al. 2005). In addition to the small intestine, DMT1 is expressed in the kidney (Canonne-Hergaux et al. 1999); however, little information is available regarding the transport of Pb across the renal tubular epithelium. In Madin-Darby canine kidney cells (MDCK), Pb has been shown to undergo transepithelial transport by a mechanism distinct from the anion exchanger that has been identified in red blood cells (Bannon et al. 2000). The uptake of Pb into MDCK cells was both time and temperature dependent. Overexpression of DMT1 in the human embryonic kidney fibroblast cells (HEK293) resulted in increased Pb uptake compared to HEK293 cells in which DMT1 was not overexpressed (Bannon et al. 2002). Based on this limited information, it appears that DMT1 may play a role in the renal transport of Pb.

Pb in other soft tissues such as kidney, liver, and brain exists predominantly bound to protein. High affinity cytosolic Pb binding proteins have been identified in rat kidney and brain (DuVal and Fowler 1989; Fowler 1989; Gonick et al. 2011). The Pb binding proteins of rat are cleavage products of α₂µ-globulin, a member of the protein superfamily known as retinol-binding proteins (Fowler and DuVal 1991). α₂µ-Globulin is synthesized in the liver under androgen control and has been implicated in the mechanism of male rat hyaline droplet nephropathy produced by certain hydrocarbons (EPA 1991; Swenberg et al. 1989); however, there is no evidence that Pb induces male-specific nephropathy or hyaline droplet nephropathy. The precise role for Pb binding proteins in the toxicokinetics and toxicity of Pb has not been firmly established; however, it has been proposed that binding proteins may serve as a cytosolic Pb "receptor" that, when transported into the nucleus, binds to chromatin and modulates gene

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

expression (Fowler and DuVal 1991; Mistry et al. 1985, 1986). Other high-affinity Pb binding proteins (Kd approximately 14 nM) have been isolated in human kidney, two of which have been identified as a 5 kD peptide, thymosin 4, and a 9 kD peptide, acyl-CoA binding protein (Smith et al. 1998b). Pb also binds to metallothionein, but does not appear to be a significant inducer of the protein in comparison with the inducers of cadmium and zinc (Eaton et al. 1980; Waalkes and Klaassen 1985). *In vivo*, only a small fraction of the Pb in the kidney is bound to metallothionein, and appears to have a binding affinity that is less than Cd²⁺, but higher than Zn²⁺ (Ulmer and Vallee 1969); thus, Pb will more readily displace zinc from metallothionein than cadmium (Goering and Fowler 1987; Nielson et al. 1985; Waalkes et al. 1984).

Pb Distribution during Pregnancy and Maternal-Fetal-Infant Transfer. PbBs tend to be lower in pregnant women compared to non-pregnant women of similar age, BMI, iron status, and smoking status (Jain 2013a; Liu et al. 2013). This difference may reflect increased elimination of Pb from the maternal system (Jain 2013b). Maternal PbB changes during and following pregnancy. A U-shaped temporal pattern has been observed in which maternal PbBs decrease during the second trimester and increase during the third trimester and postpartum period (Gulson et al. 2004, 1997, 2016; Hertz-Picciotto et al. 2000; Lagerkvist et al. 1996; Lamadrid-Figueroa et al. 2006; Rothenberg et al. 1994a). Several factors appear to contribute to these changes. During the second trimester, increased plasma volume contributes to hemodilution of maternal blood Pb and a lowering in the PbB (Hyttén 1985; Rothenberg et al. 1994b). During the third trimester, growth of the fetal skeleton accelerates, which results in increased mobilization of calcium and Pb from the maternal skeleton, increasing maternal PbB (Gulson et al. 1998b, 2003). Postpartum calcium demand increases further during lactation and breastfeeding, which promotes further mobilization of calcium and Pb from bone and sustains or increases maternal PbBs (Gulson et al. 1998b; Hansen 2011; Tellez-Rojo et al. 2002). Increased demand for calcium in the third trimester and postpartum (to supply calcium for breast milk) is also evident from studies of the effects of dietary calcium supplementation during pregnancy. Calcium supplementation of the maternal diet decreased or delayed the onset of the increase in maternal PbB during the third trimester and postpartum period and delayed mobilization of maternal bone Pb in the third trimester (Ettinger et al. 2009; Gulson et al. 2004, 2016; Manton et al. 2003). The increase in PbB associated with late pregnancy was greater in older women who had a longer history of Pb exposure and, presumably, higher bone Pb levels (Miranda et al. 2010). Pb has been detected in follicular fluid at concentrations similar to that in blood plasma (Silberstein et al. 2006).

A portion of the maternal Pb burden is transferred to the placenta and fetus during pregnancy (Esteban-Vasallo et al. 2012; Franklin et al. 1997; Gulson et al. 2003, 2016; Kayaalti et al. 2016; Kazi et al. 2014;

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

O'Flaherty 1998; Reddy et al. 2014). Measurements of stable Pb isotope ratios in pregnant women and cord blood, as they came into equilibrium with a novel environmental Pb isotope signature, indicated that approximately 80% of Pb in fetal cord blood appears to derive from maternal bone stores (Gulson et al. 1997b, 1999c, 2000, 2003, 2016). Stable isotope studies have also demonstrated transfer of Pb from the maternal skeleton to fetus in nonhuman primates (Franklin et al. 1997; O'Flaherty 1998). Transplacental transfer of Pb may be facilitated by an increase in the plasma/PbB ratio during pregnancy (Lamadrid-Figueroa et al. 2006; Montenegro et al. 2008).

Fetal and maternal PbBs and placental Pb concentrations are correlated (Amaral et al. 2010; Baeyens et al. 2014; Baranowska-Boisiacka et al. 2016; Carbone et al. 1998; Chen et al. 2014; Goyer 1990; Graziano et al. 1990; Gulson et al. 2016; Kayaalti et al. 2015b; Kazi et al. 2014; Kim et al. 2015; Kordas et al. 2009; Patel and Prabhu 2009; Reddy et al. 2014). Estimates of the maternal/fetal PbB ratio, based on cord blood Pb measurements at the time of delivery, range from 0.7 to 1.0 at mean maternal PbBs ranging from 1 to 9 µg/dL. In one of the larger studies of fetal PbB, maternal and cord PbB were measured at delivery in 888 mother-infant pairs; the cord/maternal ratio was relatively constant, 0.93, over a blood Pb range of approximately 3–40 µg/dL (Graziano et al. 1990). An analysis of data from 159 mother-infant pairs revealed that higher blood pressure and alcohol consumption late in pregnancy were associated with higher concentrations of Pb in cord blood relative to maternal blood, while higher hemoglobin and sickle cell trait were associated with lower cord blood Pb relative to maternal blood Pb (Harville et al. 2005). No associations were found for calcium intake, physical activity, or smoking. Placental Pb concentrations were found to correlate with ALAD polymorphisms, with higher concentrations observed in association with ALAD2 (Kayaalti et al. 2015b).

Maternal Pb is transferred to infants during breastfeeding. Stable Pb isotope dilution studies suggested that Pb in breast milk can contribute substantially to the isotope profile of infant blood (approximately 40–80%; Gulson et al. 1998b). Numerous studies have reported Pb concentrations in maternal blood and breast milk. In general, these studies indicate that Pb concentrations in breast milk are correlated with Pb concentrations in maternal blood or plasma. Milk/maternal concentration ratios are <0.1, although values of 0.9 have been reported (Baranowska-Boisiacka et al. 2016; Counter et al. 2014; Ettinger et al. 2006, 2014; Gulson et al. 1998a; Koyashiki et al. 2010). Ettinger et al. (2004, 2006) assessed factors influencing breast milk Pb concentration in a group of 367 women and found that PbB (mean 8–9 µg/dL; range 2–30) was a stronger predictor of breast milk Pb (mean 0.9–1.4 µg/dL; range 0.2–8 µg/dL) than bone Pb, and that tibia Pb (mean 9.5 µg/g; range <1–76.5 µg/dL) was a stronger predictor of breast milk Pb than patella bone Pb (mean 14.6 µg/dL; range <1–67.2 µg/dL). Dietary intake of polyunsaturated fatty

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

acids (PUFA) may decrease transfer of Pb from bone to breast milk (Arora et al. 2008). Pb concentrations in maternal blood and breast milk have been shown to correlate with PbBs in breastfeeding infants (Ettinger et al. 2014; Farhat et al. 2013). Breast milk Pb concentrations explained 37% of the variation in infant blood Pb of breastfeeding infants (Ettinger et al. 2014).

Organic Pb. Information on the distribution of Pb in humans following exposures to organic Pb is extremely limited. One hour following 1–2-minute inhalation exposures to ^{203}Pb tetraethyl or tetramethyl Pb (1 mg/m^3), approximately 50% of the ^{203}Pb body burden was associated with liver and 5% was associated with kidney; the remaining ^{203}Pb was widely distributed throughout the body (Heard et al. 1979). The kinetics of ^{203}Pb in blood of these subjects showed an initial declining phase during the first 4 hours (tetramethyl Pb) or 10 hours (tetraethyl Pb) after the exposure, followed by a phase of gradual increase in PbB that lasted for up to 500 hours after the exposure. Radioactive Pb in blood was highly volatile immediately after the exposure and transitioned to a nonvolatile state thereafter. These observations may reflect an early distribution of organic Pb from the respiratory tract, followed by a redistribution of de-alkylated Pb compounds (see Section 3.1.3 for further discussion of alkyl Pb metabolism).

In a man and woman who accidentally inhaled a solvent containing 31% tetraethyl Pb (17.6% Pb by weight), Pb concentrations in the tissues, from highest to lowest, were liver, kidney, brain, pancreas, muscle, and heart (Bolanowska et al. 1967). In another incident, a man ingested a chemical containing 59% tetraethyl Pb (38% Pb w/w); Pb concentration was highest in the liver followed by kidney, pancreas, brain, and heart (Bolanowska et al. 1967).

3.1.3 Metabolism

Inorganic Pb. Metabolism of inorganic Pb consists of formation of complexes with a variety of protein and nonprotein ligands (see Section 3.1.2 for further discussion). Major extracellular ligands include albumen and nonprotein sulfhydryls. The major intracellular ligand in red blood cells is ALAD. Pb also forms complexes with proteins in the cell nucleus and cytosol.

Organic Pb. Alkyl Pb compounds are actively metabolized in the liver by oxidative dealkylation catalyzed by cytochrome P-450. Relatively few studies that address the metabolism of alkyl Pb compounds in humans have been reported. Studies of workers who were exposed to tetraethyl Pb have shown that tetraethyl Pb is excreted in the urine as diethyl Pb, ethyl Pb, and inorganic Pb (Turlakiewicz

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

and Chmielnicka 1985; Vural and Duydu 1995; Zhang et al. 1994). Trialkyl Pb metabolites were found in the liver, kidney, and brain following exposure to the tetraalkyl compounds in workers; these metabolites have also been detected in brain tissue of nonoccupational subjects (Bolanowska et al. 1967; Nielsen et al. 1978). In volunteers exposed by inhalation to 0.64 and 0.78 mg Pb/m³ of ²⁰³Pb-labeled tetraethyl and tetramethyl Pb, respectively, Pb was cleared from the blood within 10 hours, followed by a re-appearance of radioactivity back into the blood after approximately 20 hours (Heard et al. 1979). The high level of radioactivity initially in the plasma indicates the presence of tetraalkyl/trialkyl Pb. The subsequent rise in blood radioactivity, however, probably represents water-soluble inorganic Pb and trialkyl and dialkyl Pb compounds that were formed from the metabolic conversion of the volatile parent compounds (Heard et al. 1979).

3.1.4 Excretion

Independent of the route of exposure, absorbed Pb is excreted primarily in urine and feces; sweat, saliva, hair and nails, breast milk, and seminal fluids are minor routes of excretion (Chamberlain et al. 1978; Griffin et al. 1975; Hernandez-Ochoa et al. 2005; Hursh and Suomela 1968; Hursh et al. 1969; Kehoe 1987; Rabinowitz et al. 1976; Sears et al. 2012; Stauber et al. 1994). Fecal excretion accounts for approximately one-third of total excretion of absorbed Pb (fecal/urinary excretion ratio of approximately 0.5), based on intravenous injection studies conducted in humans (Chamberlain et al. 1978). A similar value for fecal/urinary excretion ratio, approximately 0.5, has been observed following inhalation of submicron Pb particles (Chamberlain et al. 1978; Hursh et al. 1969). Contributors to fecal excretion may include secretion into the bile, gastric fluid, and saliva (Rabinowitz et al. 1976). Biliary excretion of Pb has been observed in the dog, rat, and rabbit (Klaassen and Shoeman 1974; O'Flaherty 1993).

Mechanisms by which inorganic Pb is excreted in urine have not been fully characterized. Such studies have been hampered by the difficulties associated with measuring ultrafilterable Pb in plasma and thereby in measuring the GFR of Pb. Renal plasma clearance was approximately 20–30 mL/minute in a subject who received a single intravenous injection of a ²⁰³Pb chloride tracer (Chamberlain et al. 1978). Urinary Pb excretion is strongly correlated with the GFR of Pb (Araki et al. 1986) and plasma Pb concentration (Bergdahl et al. 1997b; Rentschler et al. 2012) (i.e., urinary excretion is proportional to GFR x plasma Pb concentration). Estimates of plasma-to-urine clearance of Pb range from 13 to 22 L/day, with a mean of 18 L/day (Araki et al. 1986; Manton and Cook 1984; Manton and Malloy 1983; Chamberlain et al. 1978). The rate of urinary excretion of Pb was less than the GFR of ultrafilterable Pb, suggesting renal tubular reabsorption of Pb from the glomerular filtrate (Araki et al. 1986, 1990). Measurement of the renal

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

clearance of ultrafilterable Pb in plasma indicates that in dogs, Pb undergoes glomerular filtration and net tubular reabsorption (Araki et al. 1986, 1990; Vander et al. 1977; Vicitry et al. 1979). Net tubular secretion of Pb has been demonstrated in dogs made alkalotic by infusions of bicarbonate (Vicitry et al. 1979). Renal clearance of blood Pb increases with increasing PbBs >25 µg/dL (Chamberlain 1983). The mechanism for this has not been elucidated and could involve a shift in the distribution of Pb in blood towards a fraction having a higher GFR (e.g., lower molecular weight complex), a capacity-limited mechanism in the tubular reabsorption of Pb, or the effects of Pb-induced nephrotoxicity on Pb reabsorption.

Excretion and Routes of Exposure

Inhalation Exposure

Inorganic Pb. Inorganic Pb inhaled as submicron particles is deposited primarily in the bronchiolar and alveolar regions of the respiratory tract, from where it is absorbed and excreted primarily in urine and feces (Chamberlain et al. 1978; Hursh et al. 1969; Kehoe 1987). Fecal/urinary excretion ratios were approximately 0.5 following inhalation of submicron Pb-bearing particles (Chamberlain et al. 1978; Hursh et al. 1969). Higher fecal-urinary ratios would be expected following inhalation of larger particle sizes (e.g., >1 µm) as these particles would be cleared to the gastrointestinal tract from where a smaller percentage would be absorbed (Kehoe 1987; see Section 3.1.1).

Organic Pb. Pb derived from inhaled tetraethyl and tetramethyl Pb is excreted in exhaled air, urine, and feces (Heard et al. 1979). Following 1–2-minute inhalation exposures to ²⁰³Pb tetraethyl (1 mg/m³), in four male subjects, 37% of inhaled ²⁰³Pb was initially deposited in the respiratory tract, of which approximately 20% was exhaled in the subsequent 48 hours (Heard et al. 1979). In a similar experiment conducted with (²⁰³Pb) tetramethyl Pb, 51% of the inhaled ²⁰³Pb dose was initially deposited in the respiratory tract, of which approximately 40% was exhaled in 48 hours. Pb that was not exhaled was excreted in urine and feces. Fecal/urinary excretion ratios were 1.8 following exposure to tetraethyl Pb and 1.0 following exposure to tetramethyl Pb (Heard et al. 1979). Occupational monitoring studies of workers who were exposed to tetraethyl Pb have shown that tetraethyl Pb is excreted in the urine as diethyl Pb, ethyl Pb, and inorganic Pb (Turlakiewicz and Chmielnicka 1985; Vural and Duydu 1995; Zhang et al. 1994).

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

Oral Exposure

Inorganic Pb. Much of the available information on the excretion of ingested Pb in adults derives from studies conducted on five male adults who received daily doses of ²⁰⁷Pb nitrate for periods up to 210 days (Rabinowitz et al. 1976). The dietary intakes of the subjects were reduced to accommodate the tracer doses of ²⁰⁷Pb without increasing daily intake, thus preserving a steady state with respect to total Pb intake and excretion. Total Pb intakes (diet plus tracer) ranged from approximately 210 to 360 µg/day. Urinary excretion accounted for approximately 12% of the daily intake (range for five subjects: 7–17%) and fecal excretion, approximately 90% of the daily intake (range, 87–94%). Based on measurements of tracer and total Pb in saliva, gastric secretions, bile, and pancreatic secretions (samples collected from three subjects by intubation), gastrointestinal secretion of Pb was estimated to be approximately 2.4% of intake (range, 1.9–3.3%). In studies conducted at higher ingestion intakes, 1–3 mg/day for up to 208 weeks, urinary Pb excretion accounted for approximately 5% of the ingested dose (Kehoe 1987). Elimination of Pb is multiphasic, reflecting pools of Pb in the body that have varying retention times. Elimination from blood and soft tissues is faster than bone (Nilsson et al. 1991; Rabinowitz et al. 1976). As a result, after an abrupt decrease in exposure, PbB declines at an apparent rate that reflects excretion of Pb from blood and replenishment of Pb in blood from bone stores. The elimination half-time of Pb in blood in retired lead workers was tri-exponential, with approximately 22% of elimination occurring at a half-time of 34 days (95% CL 29, 41), 28% at a half-time of 1.2 years (95% CL 0.85, 1.8), and 50% at a half-time of 13 years (95% CL 10, 18) (Nilsson et al. 1991). The corresponding mono-exponential half-time for finger bone (XRF) in these same subjects was 16 years (85% CL 12, 23). Apparent elimination half-times for blood Pb in children also vary considerably, dependent in part on age and exposure history of the child that establishes levels of Pb in bone (Manton et al. 2000; Specht et al. 2018). Manton et al. (2000) estimated apparent elimination half-times for PbB in children (ages 2–3 years at time of exposure) that ranged from 8 to 38 months. However, these estimates reflect both excretion of Pb from blood as well as transfer of Pb from bone to blood; the latter would tend to increase the apparent blood elimination half-time. Specht et al. (2018) estimated blood Pb elimination half-times for Pb transferred from bone to blood (estimated with XRF measurements and biokinetics modeling). Estimated blood Pb half-times were 6.9±4 (SD) in children 1–3 years old and 19.3±14.1 days in children >3 years old (Specht et al. 2018).

Dermal Exposure. Inorganic Pb is excreted in sweat and urine following dermal exposure to Pb nitrate or Pb acetate (Moore et al. 1980; Stauber et al. 1994).

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models

PBPK models use mathematical descriptions of the uptake and disposition of chemical substances to quantitatively describe the relationships among critical biological processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry models. PBPK models are increasingly used in risk assessments, primarily to predict the concentration of potentially toxic moieties of a chemical that will be delivered to any given target tissue following various combinations of route, dose level, and test species (Clewell and Andersen 1985). Physiologically based pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to quantitatively describe the relationship between target tissue dose and toxic endpoints.

Early Pb modeling applications relied on classical pharmacokinetics. Compartments representing individual organs or groups of organs that share a common characteristic were defined as volumes, or pools, that are kinetically homogeneous. For example, the body could be represented by a central compartment (e.g., blood plasma), and one or two peripheral compartments, which might be “shallow” or “deep” (i.e., they may exchange relatively rapidly or relatively slowly with blood plasma) (O’Flaherty 1987). One of the first of such models was proposed by Rabinowitz et al. (1976) based on a study of the kinetics of ingested stable Pb isotope tracers and Pb balance data in five healthy adult males. The Rabinowitz model included three compartments: a central compartment representing blood and other tissues and spaces in rapid equilibrium with blood (e.g., interstitial fluid); a shallow tissue compartment, representing soft tissues and rapidly exchanging pools within the skeleton; and a deep tissue compartment, representing, primarily, slowly exchanging pools of Pb within bone. Excretion pathways represented in the model included urinary, from the central compartment, and bile, sweat, hair, and nails, from the shallow tissue compartment. The model predicted pseudo-first-order half-times for Pb of approximately 25, 28, and 10^4 days in the central, shallow tissue, and deep compartments, respectively. The slow kinetics of the deep tissue compartment leads to the prediction that it would contain most of the Pb burden after lengthy exposures (e.g., years), consistent with Pb measurements made in human autopsy samples (see Section 3.1.2 Distribution). Note that this model did not simulate the distribution of Pb within blood (e.g., erythrocytes and plasma), nor did it simulate subcompartments within bone or physiological processes of bone turnover that might affect kinetics of the deep tissue compartment.

Marcus (1985b) reanalyzed the data from stable isotope tracer studies of Rabinowitz et al. (1976) and derived an expanded multicompartiment kinetic model for Pb that included separate compartments for cortical (slow, $t_{1/2}$ 1.2×10^4 – 3.5×10^4 days) and trabecular (fast, $t_{1/2}$ 100–700 days), an approach

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

subsequently adopted in several models (Bert et al. 1989; EPA 1994a, 1994b; Leggett 1993; O'Flaherty 1993, 1995a). A more complex representation of the Pb disposition in bone included explicit simulation of diffusion of Pb within the bone volume of the osteon and exchange with blood at the canaliculus (Marcus 1985a). The bone diffusion model was based on Pb kinetics data from studies conducted in dogs. Marcus (1985c) also introduced nonlinear kinetics of exchange of Pb between plasma and erythrocytes. The blood model included four blood subcompartments: diffusible Pb in plasma, protein-bound Pb in plasma, a "shallow" erythrocyte pool, and a "deep" erythrocyte pool. This model predicted the curvilinear relationship between plasma and PbBs observed in humans (see Section 3.1.2 Distribution for further discussion of plasma-erythrocyte Pb concentrations).

Additional information on Pb biokinetics, bone mineral metabolism, and Pb exposures has led to further refinements and expansions of these earlier modeling efforts. Four pharmacokinetic models, in particular, are currently being used or are being considered for broad application in Pb risk assessment: (1) the O'Flaherty Model, which simulates Pb kinetics from birth through adulthood (O'Flaherty 1993, 1995a); (2) the EPA Integrated Exposure Uptake BioKinetic (IEUBK) Model for Lead in Children developed by EPA (1994a, 1994b); (3) the Leggett Model, which simulates Pb kinetics from birth through adulthood (Leggett 1993); and (4) the EPA All Ages Lead Model (AALM, EPA 2014a). The structure and parameterization of the O'Flaherty Model is distinct from both the IEUBK Model and Leggett Model. The AALM is an update of the O'Flaherty and Leggett models, extended to include a multi-media exposure model.

The IEUBK Model simulates multimedia exposures, uptake, and kinetics of Pb in children ages 0–7 years for predicting pseudo-steady state relationships between Pb exposure and PbB; the model is not intended for use in predicting short-term kinetics of blood Pb or Pb concentrations in tissues other than whole blood. The O'Flaherty Model, Leggett Model, and AALM are lifetime models, and include parameters that simulate uptake and kinetics of Pb during infancy, childhood, adolescence, and adulthood. Pb exposure (e.g., residence-specific environmental Pb concentrations, childhood activity patterns) is not readily described by current versions of the O'Flaherty and Leggett models. The IEUBK Model and AALM include parameters for simulating exposures and uptake to estimate average daily uptake of Pb ($\mu\text{g}/\text{day}$) among populations potentially exposed via soil and dust ingestion, air inhalation, tap water ingestion, diet, and miscellaneous (other) intakes. All four models have been calibrated, to varying degrees, against empirical physiological data on animals and humans, and data on PbBs in individuals and/or populations (Beck et al. 2001; Bowers and Mattuck 2001; Cal EPA 2013; EPA 1994a, 1994c, 2014a, 2014b, 2016; Griffin et al. 1999; Hogan et al. 1998; Leggett 1993; Li et al. 2016; MacMillan et al.

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

2015; O'Flaherty 1993, 1995, 1998, 2000; Pounds and Leggett 1998; White et al. 1998; Von Lindern et al. 2003, 2016).


The focus on relying on PbBs for model evaluation and calibration derives from several concerns. The empirical basis for a relationship between low levels of Pb exposure and behavioral dysfunction largely consists of prospective epidemiological studies relating various indices of dysfunction with PbB (see Section 3.3). In this context, PbB has been related to health effects of Pb, and this is the main reason that the focus of interest in the models has been on estimating PbBs. Also, the most available data with which to calibrate and validate the models have been data relating exposure and/or Pb intake to blood concentration. Thus, there is greater confidence in the validity of the models for estimating blood concentrations, rather than Pb levels in other physiologic compartments. Although the principal adverse health effects of Pb have been related to concentrations of Pb in blood, other biomarkers of Pb exposure, such as bone Pb concentrations, are also of value in assessing associations between Pb exposure and health; hence, there is a need for models that predict concentrations of Pb in tissues other than blood (see Section 3.3).

The following four pharmacokinetic models are discussed in great detail below: (1) the O'Flaherty Model (O'Flaherty 1993, 1995a); (2) the IEUBK Model for Lead in Children (EPA 1994a, 1994b); (3) the Leggett Model (Leggett 1993); and (4) AALM (EPA 2014a).

3.1.5.1 O'Flaherty Model

The O'Flaherty Model simulates Pb exposure, uptake, and disposition in humans, from birth through adulthood (O'Flaherty 1993, 1995a). Figure 3-1 shows a conceptualized representation of the O'Flaherty Model, including the movement of Pb from exposure media (i.e., intake via inhalation or ingestion) to the lungs and gastrointestinal tract, followed by the subsequent exchanges between blood plasma, liver, kidney, richly-perfused tissues, poorly-perfused tissues, bone compartments, and excretion from liver and/or kidney. The model simulates both age- and media-specific absorption. Because many of the pharmacokinetic functions are based on body weight and age, the model can be used to estimate PbBs across a broad age range, including infants, children, adolescents, and adults. The model uses physiologically based parameters to describe the volume, composition, and metabolic activity of blood, soft tissues, and bone that determine the disposition of Pb in the human body.

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

Figure 3-1. Compartments and Pathways of Lead (Pb) Exchange in the O'Flaherty Model*

*Schematic model for Pb kinetics in which Pb distribution is represented by flows from blood plasma to liver, kidney, richly-perfused tissues, poorly-perfused tissues, and cortical and trabecular bone. The model simulates tissue growth with age, including growth and resorption of bone mineral.

Sources: O'Flaherty 1991b, 1993, 1995a

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

A central feature of the model is the growth curve, a logistic expression relating body weight to age. The full expression relating weight to age has five parameters (constants), so that it can readily be adapted to fit a range of standardized growth curves for men and women. Tissue growth and volumes are linked to body weight; this provides explicit modeling of concentrations of Pb in tissues. Other physiologic functions (e.g., bone formation) are linked to body weight, age, or both.

Pb exchange between blood plasma and bone is simulated as parallel processes occurring in cortical (80% of bone volume) and trabecular bone (20% of bone volume). Uptake and release of Pb from trabecular bone and metabolically active cortical bone are functions of bone formation and resorption rates, respectively. Rates of bone formation and resorption are simulated as age-dependent functions, which gives rise to an age-dependence of Pb kinetics in bone. The model simulates an age-related transition from immature bone, in which bone turnover (formation and resorption) rates are relatively high, to mature bone, in which turnover is relatively slow. Changes in bone mineral turnover associated with senescence (e.g., postmenopausal osteoporosis) are not represented in the model. In addition to metabolically active regions of bone, in which Pb uptake and loss is dominated by bone formation and loss, a region of slow kinetics in mature cortical bone is also simulated, in which Pb uptake and release to blood occur by heteroionic exchange with other minerals (e.g., calcium). Heteroionic exchange is simulated as a radial diffusion in bone volume of the osteon. All three processes are linked to body weight, or the rate of change of weight with age. This approach allows for explicit simulation of the effects of bone formation (e.g., growth) and loss, changes in bone volume, and bone maturation on Pb uptake and release from bone. Exchanges of Pb between blood plasma and soft tissues (e.g., kidney and liver) are represented as flow-limited processes. The model simulates saturable binding of Pb in erythrocytes; this replicates the curvilinear relationship between plasma and erythrocyte Pb concentrations observed in humans (see Section 3.1.2). Excretory routes include kidney to urine and liver to bile. Total excretion (clearance from plasma attributable to bile and urine) is simulated as a function of GFR. Biliary and urinary excretory rates are proportioned as 70 and 30% of the total plasma clearance, respectively.

The O'Flaherty Model simulates Pb intake from inhalation and ingestion. Inhalation rates are age-dependent. Absorption of inhaled Pb is simulated as a fraction (0.5) of the amount inhaled, and is independent of age. The model simulates ingestion exposures from infant formula, soil and dust ingestion, and drinking water ingestion. Rates of soil and dust ingestion are age-dependent, increasing to approximately 130 mg/day at age 2 years, and declining to <1 mg/day after age 10 years. Gastrointestinal absorption of Pb in diet and drinking water is simulated as an age-dependent fraction, declining from

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

0.58 of the ingestion rate at birth to 0.08 after age 8 years. These values can be factored to account for relative bioavailability when applied to absorption of Pb ingested in dust or soil.

The O'Flaherty Model, as described in O'Flaherty (1993, 1995a), utilizes point estimates for parameter values and yields point estimates as output; however, a subsequent elaboration of the model has been developed that utilizes a Monte Carlo approach to simulate variability in exposure, absorption, and erythrocyte Pb binding capacity (Beck et al. 2001). This extension of the model can be used to predict the probability that children exposed to Pb in environmental media will have PbBs exceeding a health-based reference value (e.g., 5 µg/dL).

The model was designed to operate with an exposure time step on 1 year (the smallest time interval for a single exposure event). However, the implementation code allows constructions of simulations with an exposure time step as small as 1 day, which would allow simulation of rapidly changing intermittent exposures (e.g., an acute exposure event).



The O'Flaherty Model was initially calibrated to predict blood, bone, and tissue Pb concentrations in rats (O'Flaherty 1991a), and subsequently modified to reflect anatomical and physiological characteristics in children (O'Flaherty 1995a), adults (O'Flaherty 1993), and Cynomolgus monkeys (*M. fascicularis*) (O'Flaherty et al. 1998). Model parameters were modified to correspond with available information on species- and age-specific anatomy and physiological processes described above. Comparisons of predicted and observed PbB in children and adults are reported in O'Flaherty (1993, 1995a). MacMillan et al. (2015) evaluated performance of the model for predicting population blood and bone Pb levels in a convenience sample of 263 individuals (age range 1–83 years) who experienced low chronic exposure. Based on this evaluation, model performance for predicting general trends in population PbBs and cortical bone Pb concentrations was improved by revising parameters that determine binding of Pb in red blood cells. Revisions included decreasing the maximum and affinity constants (*BIND* and *KBIND*, respectively) and increasing clearance of Pb from blood to bone by increasing the permeability constant for Pb diffusion across the canaliculi-bone interface from canaliculi to bone (P_0).

3.1.5.2 EPA IEUBK Model

The EPA IEUBK Model for Lead in Children simulates Pb exposure, uptake, and disposition in human children from birth to age 7 years (EPA 1994a, 1994b, 2002a; White et al. 1998). Figure 3-2 shows a conceptualized representation of the IEUBK Model. The model has four major submodels: (1) exposure

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

Figure 3-2. Structure of the IEUBK Model for Lead (Pb) in Children*



*Schematic for integrated Pb exposure-kinetics model in which simulated multi-media exposures are linked to simulations of lead uptake (i.e., absorption into the plasma-extracellular fluid), tissue distribution, and excretion).

Sources: EPA 1994a, 1994b

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

model, in which average daily intakes of Pb ($\mu\text{g}/\text{day}$) are calculated for each inputted exposure concentration (or rates) of Pb in air, diet, dust, soil, and water; (2) uptake model, which converts environmental media-specific Pb intake rates calculated from the exposure model into a media-specific time-averaged uptake rate ($\mu\text{g}/\text{day}$) of Pb to the central compartment (blood plasma); (3) biokinetic model, which simulates the transfer of absorbed Pb between blood and other body tissues, elimination of Pb from the body (via urine, feces, skin, hair, and nails), and predicts an average PbB for the exposure time period of interest; and (4) blood Pb probability model, which applies a log-normal distribution (using geometric mean and geometric standard deviation for parameters) to predict probabilities for the occurrence of a specified given PbB in a population of similarly exposed children.

Exposure Model. The exposure model simulates intake of Pb ($\mu\text{g}/\text{day}$) for inputted exposures to Pb in air ($\mu\text{g}/\text{m}^3$), drinking water ($\mu\text{g}/\text{L}$), soil-derived dust ($\mu\text{g}/\text{g}$), or diet ($\mu\text{g}/\text{day}$). The exposure model operates on a 1-year time step, the smallest time interval for a single exposure event. The model accepts inputs for media intake rates (e.g., air volumes, breathing rates, drinking water consumption rate, soil and dust ingestion rate). The air exposure pathway is partitioned in exposures to outdoor air and indoor air, with age-dependent values for time spent outdoors and indoors (hours/day). Exposure to Pb to soil-derived dust is also partitioned into outdoor and indoor contributions. The intakes from all ingested exposure media (diet, drinking water, soil-derived dust) are summed to calculate a total intake to the gastrointestinal tract, for estimating capacity-limited absorption (see description of the uptake model).

Uptake Model. The uptake model simulates Pb absorption for the gastrointestinal tract as the sum of capacity-limited (represented by a Michaelis-Menten type relationship) and unlimited processes (represented by a first-order, linear relationship). These two terms are intended to represent two different mechanisms of Pb absorption, an approach that is in accord with limited available data in humans and animals that suggest a capacity limitation to Pb absorption (see Section 3.2.1). One of the parameters for the capacity-limited absorption process (that represents that maximum rate of absorption) is age-dependent. The above representation gives rise to a decrease in the fractional absorption of ingested Pb as a function of total Pb intake as well as an age-dependence of fractional Pb absorption. Absorption fractions are also medium-specific. At 30 months of age, at low intakes ($<200 \mu\text{g}/\text{day}$), below the rates at which capacity-limitation has a significant impact on absorption, the fraction of ingested Pb in food or drinking water that is absorbed is 0.5 and decreases to approximately 0.11 (intake, $>5,000 \mu\text{g}/\text{day}$). For Pb ingested in soil or dust, fractional absorption is 0.35 at low intakes ($<200 \mu\text{g}/\text{day}$) and decreases to 0.09 (intake, $>5,000 \mu\text{g}/\text{day}$).

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

The uptake model assumes that 32% of inhaled Pb is absorbed. This value was originally assigned based on a scenario of exposure to active smelter emissions, which assumed the particle size distribution in the vicinity of an active Pb smelter (<1 μm , 12.5%; 1–2.5 μm , 12.5%; 2–15 μm , 20%; 15–30 μm , 40%; >30 μm , 15%); size-specific deposition fractions for the nasopharyngeal, tracheobronchial, and alveolar regions of the respiratory tract; and region-specific absorption fractions. Pb deposited in the alveolar region is assumed to be completely absorbed from the respiratory tract, whereas Pb deposited in the nasopharyngeal and tracheobronchial regions (30–80% of the Pb particles in the size range 1–15 μm) is assumed to be transported to the gastrointestinal tract.

Biokinetics Model. The biokinetics model includes a central compartment, six peripheral body compartments, and three elimination pools (urine, feces, lumped pool representing skin, hair, and nails). The body compartments include plasma and extracellular fluid (central compartment), red blood cells, kidney, liver, trabecular bone, cortical bone, and other soft tissue (EPA 1994a). The model simulates growth of the body and tissues, compartment volumes, and Pb masses and concentrations in each compartment. PbB at birth (neonatal) is assumed to be 0.85 of the maternal blood Pb. Neonatal Pb masses and concentrations are assigned to other compartments based on a weighted distribution of the neonatal PbB. Exchanges between the central compartment and tissue compartments are simulated as first-order processes, which are parameterized with unidirectional, first-order rate constants. Bone is simulated as two compartments: a relatively fast trabecular bone compartment (representing 20% of bone volume) and a relatively slow cortical bone compartment (representing 80% of the bone volume). Saturable uptake of Pb into erythrocytes is simulated, with a maximum erythrocyte Pb concentration of 12 $\mu\text{g}/\text{dL}$. Excretory routes simulated include urine, from the central compartment; bile-feces, from the liver; and a lumped excretory pathway representing losses from skin, hair and nail, from the other soft tissue compartment.

Blood Pb Probability Model. Inputs to the IEUBK Model are exposure point estimates that are intended to represent time-averaged central tendency exposures. The output of the model is a central tendency estimate of PbB for children who might experience the inputted exposures. However, within a group of similarly exposed children, PbBs would be expected to vary among children as a result of inter-individual variability in media intakes, absorption, and biokinetics. The model simulates the combined impact of these sources of variability as a lognormal distribution of PbB for which the geometric mean is given by the central tendency PbB outputted from the biokinetics model and the GSD is an input parameter. The resulting lognormal distribution also provides the basis for predicting the probability of occurrence of given PbB within a population of similarly exposed children. The model can be iterated for varying

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

exposure concentrations (e.g., a series of increasing soil Pb concentrations) to predict the media concentration that would be associated with a probability of 0.05 for the occurrence of a PbB exceeding 10 µg/dL. A subsequent elaboration of the model has been developed that utilizes a Monte Carlo approach to simulate variability and uncertainty in exposure and absorption (Goodrum et al. 1996; Griffin et al. 1999). This extension of the model provides an alternative to the blood Pb probability model for incorporating, explicitly, estimates of variability (and uncertainty in variability) in exposure and absorption into predictions of an expected probability distribution of PbBs. More recently, Zartarian et al. (2017) provided an analysis coupling the IEUBK model with EPA's Stochastic Human Exposure and Dose Simulation (SHEDS)-Multimedia Model that considered general U.S. childhood exposures probabilistically and assessed primary sources of Pb exposure across the distribution of PbB.

Performance of the IEUBK Model has been evaluated for predicting observed PbBs in children (Hogan et al. 1998; Li et al. 2016; Von Lindern et al. 2003, 2016). The largest evaluation utilized longitudinal exposure and blood Pb data for approximately 2,200 children who resided near a former smelter in northern Idaho (Bunker Hill site) during a 14-year period of remediation activities (Von Lindern et al. 2003, 2016). The observed annual blood Pb geometric means ranged from 2.5 to 10.6 µg/dL. The model predicted the time course of the observed PbBs as the remediation progressed when the gastrointestinal absorption fraction was calibrated to agree with blood Pb observations (Von Lindern et al. 2003). A similar outcome was obtained in a subsequent analysis in which the gastrointestinal absorption fraction was adjusted to agree with site measurements of soil Pb RBA, and soil and dust ingestion rates were calibrated to the blood Pb observations (Von Lindern et al. 2016). The mean difference between predicted and observed annual geometric mean PbBs (predicted - observed) was -0.31 µg/dL (range: -1.07, 1.93) and the mean relative percent difference was -8.4% (range: -23–21%). Applications of the IEUBK Model to the Bunker Hill site were reviewed by the National Research Council (NRC 2005). Hogan et al. (1998) evaluated the IEUBK Model performance based on residential exposure and blood data for approximately 478 children who resided near three Pb mining and smelting sites. The observed geometric means for the three sites ranged from 5.2 to 6.8 µg/dL. The IEUBK Model predictions agreed reasonably well with observations for children whose exposures were predominantly from their residence (e.g., who spent no more than 10 hours/week away from home). The mean difference between predicted and observed site geometric mean PbBs (predicted-observed) was 0.03 µg/dL (range -0.6–0.7) and the mean relative percent difference was -0.4% (range -12–10%). The predicted geometric mean PbBs were within 0.7 µg/dL of the observed geometric means at each site. The prediction of the percentage of children expected to have PbBs exceeding 10 µg/dL were within 4% of the observed percentage at each site. Li et al. (2016) compared predictions of PbB to observations in a cohort

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS


of 760 children in Central China. The observed residence area geometric means ranged from 5 to 14 $\mu\text{g}/\text{dL}$. When exposure parameters for set to the study population (e.g., exposure media Pb concentration and intakes), predicted and observed PbBs were not significantly different. The mean difference between predicted and observed geometric mean PbBs for 21 residence areas (predicted-observed) was 0.55 $\mu\text{g}/\text{dL}$ (range -2.0–3.2) and the mean relative percent difference was 3.5% (range -32–28%). These evaluations provide support for the validity of the IEUBK Model for estimating PbBs in children at sites where their exposures can be adequately characterized. Similar empirical comparisons of the IEUBK Model have shown that agreement between model predictions and observed PbBs at specific locations is influenced by numerous factors, including the extent to which the exposure and blood Pb measurements are adequately matched, and site-specific factors (e.g., soil characteristics, behavior patterns, bioavailability) that may affect Pb intake or uptake in children (Bowers and Mattuck 2001; Von Lindern et al. 2003, 2016). In addition to the above empirical comparisons, the computer code used to implement the IEUBK Model (IEUBK version 0.99d) has undergone an independent validation and verification and has been shown to accurately implement the conceptual IEUBK Model (Zaragoza and Hogan 1998).

3.1.5.3 Leggett Model

The Leggett Model simulates Pb intake, absorption, and disposition in humans, from birth through adulthood (Leggett 1993). Figure 3-3 shows a conceptualized representation of the model, including the movement of Pb from exposure media (i.e., intake via inhalation or ingestion) to the lungs and gastrointestinal tract, followed by the subsequent exchanges between diffusible blood plasma, soft tissues, bone compartments, and excretion from liver, kidneys, and sweat. A detailed exposure module is not linked to the Leggett Model; rather, Pb exposure estimates are incorporated into the model as age-specific point estimates of average daily intake ($\mu\text{g}/\text{day}$) from inhalation and ingestion. A description of the model and its potential application to risk assessment are provided below.

The Leggett Model includes a central compartment, 15 peripheral body compartments, and 4 elimination pools (urine, feces, sweat, and lumped pool representing skin, hair, and nails), as illustrated in Figure 3-3. Transport of Pb from blood plasma to tissues is assumed to follow first-order kinetics. Transfer rate constants vary with age and PbB. Above a nonlinear threshold concentration in red blood cells (assumed to be 60 $\mu\text{g}/\text{dL}$), the rate constant for transfer to red blood cells declines and constants to all other tissues increase proportionally (Leggett 1993). This replicates the nonlinear relationship between plasma and red blood cells observed in humans (see Section 3.1.2). The model simulates blood volume as an age-

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

Figure 3-3. Compartments and Pathways of Lead (Pb) Exchange in the Leggett Model*

*Schematic model for Pb kinetics in which Pb distribution is represented by exchanges between the central plasma-extracellular fluid and tissue compartments. Bone is represented as having surface (which rapidly exchanges with plasma-extracellular fluid) and volume compartments; the latter simulates slow exchange with the surface and slow return of Pb to the plasma-extracellular fluid from bone resorption.

GI = gastrointestinal; RBC = red blood cell; RT = respiratory

Source: Leggett 1993

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

dependent function, which allows simulation of plasma and PbBs. Pb masses are simulated in all other tissues (tissue volumes are not simulated).

Unidirectional, first-order transfer rates (day^{-1}) between compartments were developed for six age groups, and intermediate age-specific values are obtained by linear interpolation. The total transfer rate from diffusible plasma to all destinations combined is assumed to be $2,000 \text{ day}^{-1}$, based on isotope tracer studies in humans receiving Pb via injection or inhalation. Values for transfer rates in various tissues and tissue compartments are based on measured deposition fractions or instantaneous fractional outflows of Pb between tissue compartments (Leggett 1993).

The Leggett Model was developed from a biokinetic model originally developed for the International Commission on Radiological Protection (ICRP) for calculating radiation doses from environmentally important radionuclides, including radioisotopes of Pb (Leggett 1993). The Leggett Model simulates age-dependent bone physiology using a model structure developed for application to the alkaline earth elements, but parameterized using data specific to Pb where possible. The model simulates both rapid exchange of Pb with plasma via bone surface and slow loss by bone resorption. Cortical bone volume (80% of bone volume) and trabecular bone volume (20% of bone volume) are simulated as bone surface compartments, which rapidly exchange Pb with the blood plasma, and bone volume, within which are *exchangeable* and *nonexchangeable* pools. Pb enters the exchangeable pool of bone volume via the bone surface and can return to the bone surface, or move to the nonexchangeable pool, from where it can return to the blood only when bone is resorbed. Rate constants for transfer of Pb from the nonexchangeable pools and blood plasma vary with age to reflect the age-dependence of bone turnover.

The liver is simulated as two compartments: one compartment has a relatively rapid uptake of Pb from plasma and a relatively short removal half-time (days) for transfers to plasma and to the small intestine by biliary secretion, and a second compartment simulates a more gradual transfer to plasma of approximately 10% of Pb uptake in liver. The kidney is simulated as two compartments: one that exchanges slowly with blood plasma and accounts for Pb accumulation in kidney tissue, and a second compartment that receives Pb from blood plasma and rapidly transfers Pb to urine, with essentially no accumulation (urinary pathway). Other soft tissues are simulated as three compartments representing rapid, intermediate, and slow turnover rates (without specific physiologic correlates). Other excretory pathways (hair, nails, and skin) are represented as a lumped pathway from the intermediate turnover rate soft tissue compartment.

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

The Leggett Model simulates Pb intakes from inhalation, ingestion, or intravenous injection. The latter was included to accommodate model evaluations based on intravenous injection studies in humans and animal models. The respiratory tract is simulated as four compartments into which inhaled Pb is deposited and absorbed with half-times of 1, 3, 10, and 48 hours. Four percent of the inhaled Pb is assumed to be transferred to the gastrointestinal tract. These parameter values reflect the data on which the model was based, which were derived from studies in which human subjects inhaled submicron Pb-bearing particles (Chamberlain et al. 1978; Hursh and Mercer 1970; Hursh et al. 1969; Morrow et al. 1980; Wells et al. 1975). These assumptions would not necessarily apply to exposures to large airborne particles (see Section 3.1.1). Absorption of ingested Pb is simulated as an age-dependent fraction of the ingestion rate, declining from 0.45 at birth to 0.3 at age 1 year (to age 15 years), and to 0.15 after age 25 years.

Output from the Leggett Model has been compared with data in children and adult subjects exposed to Pb in order to calibrate model parameters (Leggett et al. 1993; Pounds and Leggett 1998). Nie et al. (2005) evaluated performance of the Leggett Model for predicting bone Pb concentrations in 539 Pb workers. The data included periodic monitoring of PbBs and XRF bone Pb measurements made in 1994 and 1999. Pb intakes of each individual were calibrated to agree with measured PbBs. The Leggett Model underpredicted observed cortical bone Pb concentrations by a factor of 3–4, and underpredicted trabecular bone Pb concentration by a factor of 12–18. EPA (2014a) evaluated performance of the Leggett Model for predicting PbBs in children and blood and bone Pb concentrations in adults. The evaluation of predictions for children used data on blood lead concentrations reported in the NHANES for the years 2007–2008, and required making assumptions about Pb exposures in this population. The Leggett Model overpredicted observed PbBs in children 1–7 years of age by a factor of 2–3. Cal EPA (2013) evaluated the Leggett Model for predicting PbBs in smelter workers whose occupational exposures were interrupted during a workers strike. Pre-hire background Pb intakes and pre-strike intakes were calibrated to agree with measured PbBs and the predicted rate of decline in blood Pb that occurred during the strike period was compared to observations. Cal EPA (2013) reported “the average difference between the measured and predicted post-strike BLL was unacceptably large and indicated significant under-prediction of BLLs”. The average difference was $>4 \mu\text{g}/\text{dL}$ in a cohort that had a mean post-strike PbB of $31 \mu\text{g}/\text{dL}$ (no further details were provided). Performance was substantially improved when various parameters were calibrated to the observations. These included parameters that control transfers between plasma and bone and red blood cell saturation (see Cal EPA [2013] for details of parameter values changes). The mean difference between predicted and observed annual geometric mean PbBs (predicted-observed) was $-0.9 \mu\text{g}/\text{dL}$ (range -26 – 32) and the mean relative percent difference was -8.8% (range: -55 – 320%).

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

Cal EPA (2013) reported several other evaluations of their recalibrated model, including observed and predicted relationships between plasma and whole PbBs in adults, and predicted distribution of Pb in bone and soft tissues compared to estimates from human autopsy studies.

3.1.5.4 EPA All Ages Lead Model (AALM)

The AALM simulates blood and tissue Pb masses (μg) and concentrations ($\mu\text{g/g}$) resulting from exposures to Pb in air, drinking water, surface dust (e.g., indoor dust, soil dust), food, or miscellaneous Pb ingestion pathways. The AALM exposure module allows the user to simulate multi-pathway exposures that are constant or that vary in time increments as small as 1 day and that occur at any age from birth to 90 years. The user can select to run a systemic biokinetics simulation based on either the Leggett (AALM-LG) or O'Flaherty (AALM-OF) biokinetics models. Parameters in both systemic models were re-calibrated with observations of blood, bone, and soft tissue Pb concentrations in children and adults (EPA 2014a). The version of the AALM described in EPA (2014a) was implemented in Advanced Continuous Simulation Language (acslX, ver. 3.1.4.2). The ICRP Human Respiratory Tract Model (HRTM) deposition and absorption parameters are used in both the AALM-LG and AALM-OF, which allows simulation of inhaled Pb particles of specified size ranges and absorption kinetics (ICRP 1994). The gastrointestinal tract model includes age-dependent absorption fractions and parameters for RBA of Pb from all ingestion pathways.

The structures of the two systemic biokinetics models in AALM-OF and AALM-LG are based on the O'Flaherty and Leggett models, respectively, with the following modifications. Growth parameters from the O'Flaherty Model are used in both models to simulate age-dependent body weight tissue weights. This provides a means for calculating tissue concentrations as the Pb mass (μg) divided by the tissue weight (g). Concentrations of Pb in bone wet weight are converted to concentration per g bone mineral by dividing the wet weight concentration by the ash fraction of bone. This conversion provides a means for comparing model predictions of bone Pb concentration with bone XRF data, which is typically reported in units of Pb per g bone mineral. Parameters for RBA of Pb in each intake medium include the gastrointestinal tract model. This provides a means for independently adjusting the absorption fraction for each of the intake pathways (including respiratory tract-to-gastrointestinal tract) and maintains mass balance for fecal excretion of unabsorbed Pb. Inhalation, deposition, mucociliary clearance, and absorptive clearance of airborne Pb is simulated with a simplified implementation of the ICRP HRTM.

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

The AALM systemic biokinetic models were recalibrated from the original Leggett and O'Flaherty Models (EPA 2014b). The sequential recalibration utilized several sources of data on blood and bone Pb concentrations in humans. Parameters that control the uptake and retention of Pb in red blood cells were recalibrated using paired data on whole blood and plasma Pb concentrations in children and adults (Bergdahl et al. 1997c, 1998, 1999; Hernández-Avila et al. 1998; Manton et al. 2001; Schütz et al. 1996; Smith et al. 2002). Parameters that control plasma-to-urine clearance were recalibrated based on clearance estimates from studies that measured paired plasma concentration and urinary Pb excretion in adults (Araki et al. 1986; Chamberlain et al. 1978; Manton and Cook 1984; Manton and Malloy 1983). Autopsy data from children and adults were used to evaluate parameters that control the relationship between of tissue Pb concentrations and bone Pb concentrations (Barry 1975). The relationship between bone and plasma Pb concentrations was evaluated with paired data for plasma Pb concentration and XRF bone Pb in adults (Cake et al. 1996; Hernández-Avila et al. 1998). The long-term rate elimination of Pb from blood and bone was evaluated with data on blood and XRF bone Pb in retired Pb workers (Nilsson et al. 1991).

The calibrated AALM was evaluated with data on PbBs measured in infants (Ryu et al. 1983; Sherlock and Quinn 1986) or adults (Rabinowitz et al. 1976) who consumed known quantities of Pb. In the Ryu et al. (1983) study, PbBs were monitored in formula-fed infants who were fed measured quantiles of formula. PbBs predicted from the AALM-LG were within 1 SD of the group means and the r^2 for predictions was 0.85. Predictions from the AALM-OF were uniformly higher than observations and the r^2 for predictions was 0.76. Sherlock and Quinn (1986) measured PbB in infants at age 13 weeks and estimated dietary intake of Pb for each infant based on Pb measurements made in duplicate diet samples collected daily during week 13. The observed dose-blood Pb relationship was predicted with r^2 values of 0.95 for AALM-LG and 0.98 for AALM-OF. Rabinowitz et al. (1976) conducted a pharmacokinetics study in which four adults ingested daily doses of [^{207}Pb] nitrate for periods up to 124 days. Concentrations of ^{207}Pb in blood, urine, and feces were then monitored during and following cessation of exposure, and data on daily intakes and blood concentrations for each subject were reported. Absorption fractions for Pb were estimated for each individual based on mass balance in feces. AALM-LG predictions are closer to the observations; r^2 values ranged from 0.92 to 0.98 for four subjects in the study. The AALM-OF predicted a slower accrual and decline of blood Pb, and lower peak PbBs ($r^2 < 0.25$).


3.1.5.5 Model Comparisons

The O'Flaherty, IEUBK, and Leggett Model differ considerably in the way each represents tissues, exchanges of Pb between tissues, and Pb exposure. The AALM includes biokinetics models based on, but updated from, the O'Flaherty and Leggett models.

Figure 3-4 compares the PbBs predicted by each model for a hypothetical child who ingests 100 µg Pb/day in soil for a period of 1 year beginning at the age of 2 years (e.g., equivalent to ingestion of 100 µg soil/day at a soil Pb concentration of 1,000 mg Pb/g soil). The 100-µg/day exposure is superimposed on a baseline exposure that yields a PbB of approximately 2 µg/dL at 2 years of age. All five models predict an increase in PbB towards a quasi-steady state during the exposure period, followed by a decline towards the pre-exposure baseline PbB with an apparent half-time of approximately 1 month. Predicted PbBs at the end of the 12-month soil exposure period were 10, 23, 5.9, 23, 9.4, and 10.4 µg/dL for the IEUBK Model, Leggett Model, O'Flaherty Model, AALM-LG, and AALM-OF, respectively. Differences in the magnitude of the predicted impact of the soil exposure on PbB reflect differences in assumptions about Pb biokinetics and cannot be attributed solely to different assumptions about Pb bioavailability.


Bioavailability assumptions in the models for the age range 2–3 years are: O'Flaherty Model, 45% (50% at age 2 years, decreasing to 40% at age 3 years); IEUBK Model, 30% (soil Pb at low intakes); Leggett Model, 30%; and AALM-LG and AALM-OF 34% (38% at age 2 years and decreasing to 30% at age 3 years). A comparison of model predictions for a similar exposure during adulthood (100 µg Pb/day for 1 year, beginning at age 25) is shown in Figure 3-5. Predicted PbBs at the end of the 12-month soil exposure period were 8.4, 3.3, 4.0, and 4.8 µg/dL for the Leggett Model, O'Flaherty Model, AALM-LG, and AALM-OF, respectively. All four models predict a smaller change in PbB in adults, compared to children, for a similar increment in exposure. This is attributed, in part, to assumptions of lower Pb bioavailability in adults (i.e., O'Flaherty, 8%; Leggett, 15%; AALM-LG and AALM-OF, 8%).

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

Figure 3-4. Blood Lead Concentrations (PbBs) in Children Predicted by the IEUBK, Leggett, and O'Flaherty Models and AALM*

*The simulations are of a hypothetical child who has a PbB of 2 $\mu\text{g/dL}$ at age 2 years, and then experiences a 1-year exposure to 100 $\mu\text{g Pb/day}$. The 100 $\mu\text{g/day}$ exposure was simulated as an exposure to lead in soil in the IEUBK Model. Default bioavailability assumptions were applied in all three models.

Figure 3-5. Blood Lead Concentrations (PbBs) in Adults Predicted by the Leggett and O'Flaherty Models and AALM*



*The simulations are of a hypothetical adult who has a PbB of 2 µg/dL at age 25 years, and then experiences a 1-year exposure to 100 µg Pb/day. Default bioavailability assumptions were applied in all three models.

3.1.5.6 Slope Factor Models

Slope factor models have been used as simpler alternatives to compartmental models for predicting PbBs, or the change in PbB, associated with a given exposure (Abadin et al. 1997; Bowers et al. 1994; Carlisle and Wade 1992; EPA 2017d; Maddaloni et al. 2005; Stern 1994, 1996). In slope factor models, Pb biokinetics is represented with a simple linear relationship between the PbB and either Pb uptake (biokinetic slope factor, BSF) or Pb intake (intake slope factor, ISF). The models take the general mathematical forms:

$$PbB = E \cdot ISF$$

$$PbB = E \cdot AF \cdot BSF$$

where E is an expression for exposure (e.g., soil intake x soil Pb concentration) and AF is the absorption fraction for Pb in the specific exposure medium of interest. Intake slope factors are based on ingested Pb, rather than absorbed Pb and, therefore, integrate both absorption and biokinetics into a single slope factor,

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

whereas models that utilize a biokinetic slope factor (BSF) to account for absorption in the relationship include an absorption parameter. Slope factors used in various models are presented in Table 3-2. Of the various models presented in Table 3-2, the Bowers et al. (1994) and EPA (2003b) models implement BSFs. The slope factors used in both models (approximately 0.4 $\mu\text{g}/\text{dL}$ per μg Pb/day) are similar to BSFs predicted from the O'Flaherty Model (0.65 $\mu\text{g}/\text{dL}$ per μg Pb uptake/day) and Leggett Model (0.43 $\mu\text{g}/\text{dL}$ per μg Pb uptake/day) for simulations of adult exposures (Maddaloni et al. 2005).

Table 3-2. Comparison of Slope Factors in Selected Slope Factor Models

Model	Receptor	Intake route	Slope factor		Absorption fraction
			Intake	Biokinetics	
Bowers et al. 1994	Adult	Ingestion of soil/dust	ND	0.375	0.08
Carisle and Wade 1992	Child	Ingestion of soil/dust	0.07	ND	ND
		Ingestion of water	0.04		
Carisle and Wade 1992	Adult	Ingestion of soil/dust	0.018	ND	ND
		Ingestion of water	0.04		
Cal EPA 2017	Child	Ingestion of soil/dust	ND	0.16	0.44
		Inhalation of respirable dust	0.192	ND	ND
		Dermal contact	0.0001	ND	ND
EPA 2017d; Maddaloni et al. 2005	Adult	Ingestion of soil/dust	ND	0.4	0.12
Stern 1994	Child	Ingestion of soil/dust	T (0.056, 0.16, 0.18)	ND	ND
Stern 1996	Adult	Ingestion of soil dust	U (0.014, 0.034)	ND	ND

ND = no data; T = triangular probability distribution function (PDF); U = uniform PDF

3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE

This section discusses potential health effects from exposures during the period from conception to maturity at 18 years of age in humans. Potential effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect effects on the fetus and neonate resulting from maternal exposure during gestation and lactation. Children may be more or less susceptible than adults to health effects from exposure to hazardous substances and the relationship may change with developmental age.

This section also discusses unusually susceptible populations. A susceptible population may exhibit different or enhanced responses to certain chemicals than most persons exposed to the same level of these chemicals in the environment. Factors involved with increased susceptibility may include genetic

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke). These parameters can reduce detoxification or excretion or compromise organ function.

Populations at greater exposure risk to unusually high exposure levels to Pb are discussed in Section 5.7, Populations with Potentially High Exposures.

Age. Children and the elderly are likely to have increased susceptibility to Pb compared to non-elderly adults. As reviewed in Section 3.1.2 (Distribution), Pb crosses the placenta and is distributed to the fetus; neonates are also exposed to Pb in breast milk. Epidemiological studies show that umbilical cord PbB (reflective of neonatal PbB) and PbB in infants are associated with adverse health outcomes during childhood, including decrements in neurological function (reviewed in Chapter 2). Results of a few studies that have followed children to early adulthood show an association between child PbB and behavioral and neuroanatomical changes in adults, suggesting a possible role of exposures in childhood to adult outcomes. Children are likely to be more susceptible than adults to Pb for the following reasons: (1) it is generally accepted that developing systems are more susceptible than mature systems; (2) absorption of Pb is higher in children compared to adults (see Section 3.1.1, Absorption); and (3) children exhibit behaviors that increase ingestion of Pb surface dusts (e.g., hand-to-mouth activity, pica behavior [the compulsive, habitual consumption of nonfood items]), proximity of breathing zone to entrained surface dust).

Regarding the elderly, it is well-established that physiological functions (e.g., renal, neurological, cardiovascular) decline with age. Thus, populations with age-related compromises in physiological function would be anticipated to be more susceptible to Pb than younger populations. Furthermore, because aging is associated with bone loss, Pb is mobilized into blood, resulting in potential increases in PbB.

Sex. As reviewed in Chapter 2, some epidemiological studies examined health outcomes in populations stratified by sex. However, studies have not demonstrated clear sex-related susceptibilities to Pb-induced toxicity for any health effect outcome. In women, pregnancy, lactation, and post-menopausal status may increase bone demineralization, mobilizing bone Pb into the blood and potentially redistributing Pb to other tissues.

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

Nutritional Status. As discussed in Sections 3.1 (Toxicokinetics) and 3.4 (Interactions with other Chemicals), dietary calcium and nutritional status of iron and zinc can affect absorption of Pb, potentially leading to alterations in PbB and health effects. See Sections 3.1 and 3.4 for additional details.

Pre-existing Conditions, Diseases, and Exposure to Other Substances. Because health effects associated with Pb are observed in every organ system, it is assumed that any condition or disease that compromises physiological functions could cause increased susceptibility to Pb. Examples of underlying conditions include diseases of the kidney (e.g., glomerular nephritis), neurological system (e.g., autism), hematological system (e.g., anemia, thalassemia), and cardiovascular system (e.g., hypertension, cardiac conduction disorders). Similarly, increased susceptibility to Pb would be anticipated due to use of alcohol, tobacco, or any other substance that causes deficits in physiological function.

Genetic Polymorphisms. Numerous genetic polymorphisms that may alter susceptibility to Pb through altered toxicokinetics (i.e., absorption, distribution, and retention of Pb) or toxicodynamics (e.g., effects) have been identified. The most well-studied polymorphisms are δ -ALAD and the VDR. Several other polymorphisms that may alter susceptibility to Pb have been identified, although little data are available. In addition to the references listed below, information also was obtained from a recent review by Broberg et al. 2015.

ALAD. As reviewed in Section 2.8 (Health Effects, Hematological), Pb binds to and inhibits δ -ALAD, causing decreased hemoglobin formation, measurable decreases in blood hemoglobin concentration, and anemia. δ -ALAD is the major binding site for Pb in the blood (see Section 3.1.2). As such, polymorphisms of ALAD have the potential to alter Pb toxicokinetics, and thereby alter health effects. Many studies have evaluated the potential effects of ALAD polymorphisms on Pb distribution and toxicity. Information reviewed below was obtained from the following publications: Åkesson et al. (2000); Alexander et al. (1998); Astrin et al. (1987); Battistuzzi et al. (1981); Bellinger et al. (1994); Bergdahl et al. (1997a, 1997b); Chia et al. (2005); Chiu et al. (2013); Fang et al. (2010); Fleming et al. (1998a); Gao et al. (2010); Hsieh et al. (2000); Hu et al. (2001); Huo et al. (2014); Jaffe et al. (2000, 2001); Kim et al. (2004); Krieg et al. (2009); Lee et al. (2001); Ong et al. (1990); Pagliuca et al. (1990); Pawlas et al. (2012); Petrucci et al. (1982); Sakai et al. (2000); Schwartz (1995); Schwartz et al. (1995, 1997a, 1997b, 2000a, 2000b); Scinicariello et al. (2007, 2010); Shen et al. (2001); Sithisarankul et al. (1997); Smith (1995); Suzen et al. (2003); Szymanska-Chaowska et al. (2015); Tasmin et al. (2015); Warrington et al. (2015); Weaver et al. (2008); Wetmur et al. (1991a, 1991b); Wu et al. (2003a); and Zheng et al. (2011).

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

The ALAD gene encodes for the heme metabolism enzyme δ -ALAD. ALAD is a polymorphic enzyme with two alleles (ALAD-1 and ALAD-2) and three genotypes (ALAD 1,1; ALAD 1,2; and ALAD 2,2). The ALAD 2,2 genotype is rare, and is found in 1% of Caucasians; in contrast, the ALAD 1,1 and ALAD 1,2 genotypes occur in 80 and 19%, respectively, of Caucasians. The ALAD 2,2 genotype occurs in <1% of Asian and African populations. A study using NHANES III data (1988–1994) reported that 15.6% of non-Hispanic whites, 2.6% non-Hispanic blacks, and 8.8% Mexican Americans carried the ALAD-2 allele (Scinicariello et al. 2010). The ALAD-2 protein has a higher binding affinity than the ALAD-1 protein for Pb. Due to this higher binding affinity, it has been proposed that ALAD-2 sequesters Pb in erythrocytes, limiting distribution of Pb to other tissues. Numerous studies have shown that ALAD-2 carriers have higher PbB than ALAD-1 carriers. Although it has been demonstrated that ALAD genotype affects the toxicokinetics of Pb, the association between adverse effects of Pb and ALAD genotype have not been definitively established.

VDR. Several studies have evaluated the potential effects of VDR polymorphisms on Pb uptake and distribution. Information reviewed below was obtained from the following publications: Ames et al. (1999); Cooper and Umbach (1996); Gundacker et al. (2009, 2010); Haynes et al. (2003); Krieg et al. (2010); Morrison et al. (1992); Onalaja and Claudio (2000); Rezende et al. (2008); Schwartz et al. (2000a, 2000b); Szymanska-Chaowska et al. (2015); Theppeang et al. (2004); and Weaver et al. (2003b).

The VDR is located in the nucleus of intestinal, renal, and bone cells. It is involved in maintaining calcium and phosphate homeostasis and regulating bone metabolism. Binding of vitamin D3 (the active form of vitamin D) to the VDR activates genes that encode for various calcium-binding proteins involved in intestinal absorption and accumulation of calcium in bone. The VDR regulates the production of calcium-binding proteins, and accounts for up to 75% of the total genetic effect on bone density. Because Pb can replace and mimic calcium, the VDR plays a critical role in the accumulation of Pb in bone. The VDR has several polymorphic forms that are defined based on restriction enzyme digestion; these include FokI with three genotypes (FF, Ff, and ff) and BsmI with three genotypes (BB, Bb, bb). The FF genotype has been associated with higher PbB and increased bone mineral density and calcium uptake. The BB genotype has been associated with higher PbB and bone Pb. However, the role of VDR polymorphisms in the Pb uptake into bone remains to be fully elucidated.

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

Hemochromatosis gene (HFE). Information on HFE polymorphisms was taken from the following publications: Åkesson et al. (2000); Barton et al. (1994); Fan et al. (2014); Hopkins et al. (2008); Onalaja and Claudio (2000); Park et al. (2009a); Wang et al. (2007); Wright et al. (2004); and Zhang et al. (2010).

Hemochromatosis is an autosomal, recessive disease characterized by the excessive accumulation of iron in the body. In individuals with hemochromatosis, excess iron accumulates in various organs of the body and causes damage to the liver and compromises cardiovascular function. Hemochromatosis is caused by mutations of the HFE gene, which result in defects to the HFE protein. In individuals with normal HFE, HFE binds to transferrin, decreasing the gastrointestinal absorption of iron; however, in individuals with hemochromatosis, the HFE protein is not functional, leading to an increased accumulation of iron. The absorption of Pb is linked to iron status such that Pb absorption increases when iron is limited. HFE polymorphisms have been shown to enhance Pb-induced cognitive impairment (Wang et al. 2007) and the HFE H63D polymorphism appears to enhance positive associations between bone Pb and pulse pressure (Zhang et al. 2010). However, the influence of HFE variants on absorption and health effects of Pb is still being defined.

Other polymorphisms. Several other polymorphisms have been examined to evaluate potential alterations in susceptibility to adverse effects of Pb; however, little data are available. These include:

- *Apoprotein E (APOE).* APOE is an intracellular transporter of cholesterol and fatty acids that is synthesized by astrocytes in the brain and plays a key role in the structure of cell membranes and myelin. There are three alleles of the APOE gene: E2, E3, and E4. It has been proposed that APOE gene variants may alter susceptibility to Pb-induced changes in neurodevelopment and neurological deficits (Stewart et al. 2002; Wright et al. 2003a).
- *Dopamine receptor D4 (DRD4), Dopamine Receptor D2 (DRD2), and Dopamine Transporter (DAT1).* Pb is associated with alterations in the dopaminergic system, which is involved in cognition and behavior. Thus, polymorphisms of DRD4, DRD2, and DAT1 may alter susceptibility to Pb-induced neurocognitive impairment (Froehlich et al. 2007; Kordas et al. 2011; Roy et al. 2011).
- *Glutathione S-transferase mu 1 (GSTM1).* Glutathione is an intracellular scavenger of oxidants and electrophiles. It is encoded by the polymorphic gene GSTM1. Genetic alterations causing a decrease in functional glutathione could result in increased oxidative damage or inflammation (Kim et al. 2007).

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

- *Endothelial nitric oxide synthase (eNOS)*. Nitric oxide, an endogenous signaling molecule involved in vasodilation, is produced by a family of nitric oxide synthase enzymes, including eNOS. Polymorphisms of eNOS could increase susceptibility to Pb (Barbosa et al. 2006b).
- *Metallothionein (MT)*. MT binds to and sequesters Pb. It has been proposed that polymorphisms of MT (MT1 and MT2) may affect binding of Pb to MT and lead to an increased PbB (Chen et al. 2010; Fernandes et al. 2016; Yang et al. 2013b).
- *Peptide transporter 2 (PEPT2)*. Polymorphisms of PEPT2 have been associated with increased PbB in children (Sobin et al. 2009).
- *Tumor necrosis factor-alpha (TNF- α)*: TNF- α is a cell signaling protein involved in the development of inflammation. Genetic variants in TNF- α have the potential to alter susceptibility to Pb (Kim et al. 2007).

3.3 BIOMARKERS OF EXPOSURE AND EFFECT

Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have been classified as biomarkers of exposure, biomarkers of effect, and biomarkers of susceptibility (NAS/NRC 1989).

A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally the substance itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta. Biomarkers of exposure to Pb are discussed in Section 3.3.1. The National Report on Human Exposure to Environmental Chemicals provides an ongoing assessment of the exposure of a generalizable sample of the U.S. population to environmental chemicals using biomonitoring (see <http://www.cdc.gov/exposurereport/>). If available, biomonitoring data for Pb from this report are discussed in Section 5.6, General Population Exposure.

Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an organism that (depending on magnitude) can be recognized as an established or potential health impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung capacity. Note that these markers are not often substance specific. They also may not be directly

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

adverse, but can indicate potential health impairment (e.g., DNA adducts). Biomarkers of effect caused by Pb are discussed in Section 3.3.2.

A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability to respond to the challenge of exposure to a specific xenobiotic substance. It can be an intrinsic genetic or other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are discussed in Section 3.2, Children and Other Populations that are Unusually Susceptible.

3.3.1 Biomarkers of Exposure

Biomarkers of exposure in practical use today are measurements of total Pb levels in body fluids or tissues, such as blood, bone, or urine. Tetraalkyl Pb compounds may also be measured in the breath. Of these, PbB is the most widely used and is considered to be the most reliable biomarker for general clinical use and public health surveillance. Currently, PbB measurement is the screening test of choice to identify children with elevated PbBs (CDC 2012d). Venous sampling of blood is preferable to finger prick sampling, which has a considerable risk of surface Pb contamination from the finger if proper finger cleaning is not carried out. In children, PbBs greater than the blood lead reference value identify high-risk childhood populations and geographic areas most in need of primary prevention (CDC 2012d). In 2012, the reference value was defined as 5 µg/dL (CDC 2012d).

PbB. Measurement of PbB is the most widely used biomarker of Pb exposure. CDC considers PbB to be elevated in children when it exceeds a reference value defined as the 97.5th percentile for the U.S. population. The current CDC reference value, based on data from NHANES 2007–2009 and 2009–2010, is 5 µg/dL (CDC 2012d). Elevated PbB (e.g., >5 µg/dL) is an indication of excessive exposure in infants and children. The biological exposure index (BEI) for Pb in blood of exposed workers is 20 µg/dL (ACGIH 2018). The BEI also notes to advise “female workers of child-bearing age about the risk of delivering a child with a PbB over the current CDC reference value.” The Occupational Safety and Health Administration’s (OSHA) permissible exposure limit (PEL) for lead (50 µg/m³ air, 8-hour time-weighted average [TWA]) was established to keep a majority of worker PbBs below 40 µg/dL (OSHA 2016a). The National Institute for Occupational Safety and Health (NIOSH) recommended exposure limit (REL) for workers (50 µg/m³ air, 8-hour TWA) is established to ensure that the PbB does not exceed 60 µg/dL (NIOSH 2016b).

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

The extensive use of PbB as a dose metric reflects mainly the greater feasibility of incorporating PbB measurements into clinical or epidemiological studies, compared to other potential dose indicators, such as Pb in kidney, plasma, or bone. PbB measurements have several limitations as measures of total Pb body burden. Blood comprises <2% of the total Pb burden; most of the Pb burden resides in bone (Barry 1975). Pb is eliminated from blood more rapidly than from bone (Behinaein et al. 2014; Brito et al. 2005; Chamberlain et al. 1978; Griffin et al. 1975; Manton et al. 2001; Nie et al. 2005; Nilsson et al. 1991; Rabinowitz et al. 1976; Rentschler et al. 2012); therefore, the Pb concentration in blood reflects mainly the exposure history of the previous few months and does not necessarily reflect the larger burden and much slower elimination kinetics of Pb in bone (Graziano 1994; Lyngbye et al. 1990b). Slow release of Pb from bone can contribute to blood Pb levels long after external exposure has ceased (Fleming et al. 1997; Inskip et al. 1996; Kehoe 1987; McNeill et al. 2000; O'Flaherty et al. 1982; Smith et al. 1996). The relationship between Pb intake and PbB is curvilinear; the increment in PbB per unit of intake decreases with increasing PbB (Ryu et al. 1983; Sherlock and Quinn 1986; Sherlock et al. 1982, 1984). Pb intake-PbB relationships also vary with age as a result of age-dependency of gastrointestinal absorption of Pb, and vary with diet and nutritional status (Mushak 1991). A practical outcome of the above characteristics of PbB is that PbB can change relatively rapidly (e.g., days to weeks) in response to changes in exposure; thus, PbB can be influenced by short-term variability in exposure that may have only minor effects on total Pb body burden. A single PbB determination cannot distinguish between lower-level intermediate or chronic exposure and higher-level acute exposure. Similarly, a single measurement may fail to detect a higher exposure that occurred (or ended) several months earlier. Time-integrated measurements of PbB (CBLI) may provide a means for accounting for some of these factors and thereby provide a better measure of long-term exposure (Armstrong et al. 1992; Behinaein et al. 2014; Chuang et al. 2000; Fleming et al. 1997; Gerhardsson et al. 1993; Healey et al. 2008; Hu et al. 2007; McNeill et al. 2000; Nie et al. 2011a; Roels et al. 1995). The correlation observed between CBLI and tibia bone Pb concentrations provides supporting evidence for this (Hu et al. 2007).

Bone and Tooth Pb Measurements. The development of noninvasive XRF techniques for measuring Pb concentrations in bone has enabled the exploration of bone Pb as a biomarker of Pb exposure in children and in adults (Behinaein et al. 2011; Chettle et al. 2003; Hu et al. 2007; Ji et al. 2014; Nie et al. 2011b; Specht et al. 2016; Todd et al. 2000). Pb in bone is considered a biomarker of cumulative exposure to Pb because Pb accumulates in bone over the lifetime and most of the Pb body burden resides in bone. Pb is not distributed uniformly in bone. Pb will accumulate in those regions of bone undergoing the most active calcification at the time of exposure. During infancy and childhood, bone calcification is most active in trabecular bone, whereas in adulthood, calcification occurs at sites of remodeling in both cortical

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

and trabecular bone. This suggests that Pb accumulation will occur predominantly in trabecular bone during childhood, and in both cortical and trabecular bone in adulthood (Aufderheide and Wittmers 1992). Patella, calcaneus, and sternum XRF measurements primarily reflect Pb in trabecular bone, whereas XRF measurements of midtibia, phalanx, or ulna primarily reflect primarily Pb in cortical bone. Pb levels in cortical bone may be a better indicator of long-term cumulative exposure than Pb in trabecular bone, possibly because Pb in trabecular bone may exchange more actively with Pb in blood than does cortical bone. This is consistent with estimates of a longer elimination half-time of Pb in cortical bone, compared to trabecular bone (Behinaein et al. 2014; Borjesson et al. 1997; Brito et al. 2005; Nie et al. 2005; Nilsson et al. 1991; Schutz et al. 1987). Longitudinal studies that have repeatedly measured bone Pb (by XRF) over many years have shown more rapid declines in trabecular bone compared to cortical bone (Kim et al. 1997; Wilker et al. 2011). Estimates of cortical bone Pb elimination half-times (5–50 years) show a dependence on Pb burden, with longer half-times in people who have higher total body burdens (estimated from CBLI) and bone Pb burdens (Behinaein et al. 2014; Brito et al. 2005; Nie et al. 2005). Further evidence that cortical bone Pb measurements may provide a better reflection of long-term exposure than do measurements of trabecular bone comes from studies in which cortical and trabecular bone Pb measurements have been compared to PbB. Pb levels in trabecular bone (in adults) correlate more highly with contemporary PbB than do levels of Pb in cortical bone (Erkkila et al. 1992; Hernandez-Avila et al. 1996; Hu et al. 1996b, 1998; Watanabe et al. 1994). Cortical bone Pb measurements correlate well with time-integrated PbB measurements, which would be expected to be a better reflection of cumulative exposure than contemporary PbB measurements (Behinaein et al. 2012; Borjesson et al. 1997; Hu et al. 2007; Roels et al. 1994). Bone Pb levels tend to increase with age (Hu et al. 1996b; Kosnett et al. 1994; Roy et al. 1997), although the relationship between age and bone Pb may be stronger after adolescence (Hoppin et al. 1997). These observations are consistent with cortical bone reflecting cumulative exposures over the lifetime.

Standard methods for bone Pb XRF measurements have not been universally accepted, in part, because the technology continues to be improved, and this needs to be considered in comparisons of measurements reported by different laboratories and at different times in development of the methodology used. Historically, two XRF methods have seen the most use in bone Pb epidemiology: K-shell and L-shell methods. The K-shell method is the more widely used, although, improvements in L-shell technology continue to be reported (Nie et al. 2011a). One study reported a correlation of 0.65 between bone Pb measurements made with a portable L-shell device and a K-shell method (Nie et al. 2011a). In general, recent advances in K-shell technology have yielded higher sensitivities (approximately 3 µg/g tibia mineral; Behinaein et al. 2011) than L-shell technology (approximately 8 µg/g tibia bone mineral;

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

Nie et al. 2011a). Precision of K-shell XRF bone Pb measurements have been extensively discussed (Aro et al. 2000; Behinaein et al. 2014; Todd et al. 2000, 2001, 2002). Methodological factors can contribute substantially to observed variability in bone Pb measurements in populations (Behinaein et al. 2014). These factors include bone Pb target, radioactive source, measurement time, and data reduction methods (e.g., approach to handling negative values). Measurement uncertainty also appears to contribute by biological factors, such as BMI and bone mineral content (Behinaein et al. 2014; Berkowitz et al. 2004; Hu et al. 2007; Theppeang et al. 2008). The association between BMI and measurement uncertainty may reflect the effect attenuation of the XRF signal by tissue overlaying the target bone site (Behinaein et al. 2014). Bone mineral can be a factor because XRF measures bone Pb fluorescence in relation to fluorescence from bone calcium and the result is expressed in units of $\mu\text{g Pb per g bone mineral}$. As a result, variability in bone mineral content can contribute to variability in measured bone Pb. Typically, potential associations between bone density and bone Pb concentration are not evaluated in epidemiologic studies (Berkowitz et al. 2004; Hu et al. 2007; Theppeang et al. 2008). An important consequence of expressing bone Pb measures relative to bone mineral content is that lower bone mineral density is associated with greater measurement uncertainty in bone Pb. This uncertainty can have important implications for studies in older women for whom low bone mineral density is more common than in other populations including men and younger adults.

Tooth Pb has been considered a potential biomarker for measuring long-term exposure to Pb (e.g., years) because Pb that accumulates in tooth dentin and enamel appears to be retained until the tooth is shed or extracted (Costa de Almeida et al. 2007; Ericson 2001; Fosse et al. 1995; Gomes et al. 2004; Gulson and Wilson 1994; Gulson et al. 1996; Omar et al. 2001; Rabinowitz 1995; Rabinowitz et al. 1989, 1993; Robbins et al. 2010; Steenhout and Pourtois 1987; Tvinnereim et al. 1997). Formation of enamel and primary dentin of deciduous teeth begins *in utero* and is complete prior to the time children begin to crawl. Formation of secondary dentin begins after completion of the tooth root and continues through childhood until the tooth is lost, or otherwise loses vitality. Pb in shed deciduous teeth is not uniformly distributed. Differences in Pb levels and stable isotope signatures of the enamel and dentin suggest that Pb uptake occurs differentially in enamel and dentin (Gulson 1996; Gulson and Wilson 1994). Pb in enamel is thought to reflect primarily Pb exposure that occurs *in utero* and early infancy, prior to tooth eruption. Dentin appears to continue to accumulate Pb after eruption of the tooth; therefore, dentin Pb is thought to reflect exposure that occurs up to the time the teeth are shed or extracted (Gulson 1996; Gulson and Wilson 1994; Rabinowitz 1995; Rabinowitz et al. 1993). The technique of laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS) allows measurement of Pb levels in regions of dentin formed at various times during deciduous tooth formation *in utero* and after birth (Arora et al. 2014;

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

Shepherd et al. 2016). Accumulation of Pb in dentin of permanent teeth may continue for the life of the tooth (Steenhout 1982; Steenhout and Pourtois 1981). Because enamel is in direct contact with the external environment, enamel Pb levels may be more influenced than dentin Pb by external Pb levels and tooth wear (Purchase and Fergusson 1986).

An analysis of eight cross-sectional and/or prospective studies that reported tooth Pb and PbBs of the same children found considerable consistency among the studies (Rabinowitz 1995). The mean tooth Pb levels ranged from <3 to >12 µg/g. Dentin Pb was found to be predictive of Pb in tibia, patella, and mean bone Pb in 32 of 63 subjects at follow-up of ≤13 years (Kim et al. 1996b). The authors estimated that a 10 µg/g increase in dentin Pb levels in childhood was predictive of a 1 µg/g increase in tibia Pb levels, a 5 µg/g in patella Pb levels, and a 3 µg/g increase in mean bone Pb among the young adults. Arora et al. (2014) found that Pb levels in primary (prenatal) dentin were more strongly correlated with PbBs at birth (correlation coefficient, $r=0.69$, $n=27$), whereas Pb levels in secondary (postnatal) dentin were more strongly correlated with CBLI ($r=0.38$, $n=75$). Shepherd et al. (2016) combined LA-ICP-MS with histological determinations of dentin age to reconstruct the history of incorporation of environmental Pb from various sources.

Plasma Pb Concentration. The concentration of Pb in plasma is extremely difficult to measure accurately because levels in plasma are near the quantitation limits of most analytical techniques (e.g., approximately 0.04 µg/dL at PbB of 10 µg/dL) (Bergdahl and Skerfving 1997; Bergdahl et al. 1997a) and because hemolysis that occurs with typical analytical practices can contribute to substantial measurement error (Bergdahl et al. 1998, 2006; Cavalleri et al. 1978; Smith et al. 1998a). ICP-MS offers sensitivity sufficient for measurements of Pb in plasma (Schütz et al. 1996). The technique has been applied to assessing Pb exposures in adults (Barbosa et al. 2006a; Cake et al. 1996; Hernandez-Avila et al. 1998; Manton et al. 2001; Smith et al. 2002; Tellez-Rojo et al. 2004; Tian et al. 2013). A direct comparison of Pb concentrations in plasma and serum yielded similar results (Bergdahl et al. 2006); however, the interchangeability of plasma and serum Pb measurements for biomonitoring of Pb exposure or body burden had not been thoroughly evaluated in large numbers of subjects (Bergdahl et al. 2006; Manton et al. 2001; Smith et al. 2002).

Urinary Pb. Measurements of urinary Pb levels have been used to assess Pb exposure (e.g., Chiang et al. 2008; Fels et al. 1998; Fukui et al. 1999; Gerhardsson et al. 1992; Lilis et al. 1968; Lin et al. 2001; Mendy et al. 2012; Mortada et al. 2001; Navas-Acien et al. 2005; Rentschler et al. 2012; Roels et al. 1994; Sun et al. 2008b). However, like PbB, urinary Pb excretion mainly reflects recent exposure and thus shares

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

many of the same limitations for assessing Pb body burden or long-term exposure (Sakai 2000; Skerfving 1988). Although collection of urine is noninvasive, urine Pb levels exhibit variability with PbB, and interpretation of urine Pb levels requires estimates of GFR and measurement of urine volume (NTP 2012). A significant, but relatively weak correlation between urinary Pb levels ($\mu\text{g}/\text{dg}$ creatinine) and individual Pb intakes ($\mu\text{g}/\text{day}$) was observed in a study of 10–12-year-old children (β : 0.053, $R=0.320$, $p=0.02$, $N=57$; Chiang et al. 2008). In this study, urine sampling and measurements used to estimate intake were separated by as long as 6 months for some children, which may have contributed to the relatively weak correlation. The measurement is further complicated by variability in urine volume, which can affect concentrations independent of excretion rate (Diamond 1988) and the potential effects of decrements in kidney function on excretion, in association with high, nephrotoxic Pb exposures or kidney disease (Lilis et al. 1968; Wedeen et al. 1975). Urinary Pb concentration increases exponentially with PbB and can exhibit relatively high intra-individual variability, even at similar PbBs (Gulson et al. 1998a; Skerfving et al. 1985). However, the relationship between plasma Pb and urinary Pb (μg Pb/g creatinine) was linear in a small group of children (Rentschler et al. 2012). The linear relationship between plasma and urinary Pb may reflect the importance of plasma Pb in determining the rate of glomerular filtration and renal tubular transport of Pb (see Section 3.1.4). Urinary diethyl Pb has been proposed as a qualitative marker of exposure to tetraethyl Pb (Turlakiewicz and Chmielnicka 1985; Vural and Duydu 1995; Zhang et al. 1994).

The measurement of Pb excreted in urine following an injection (intravenous or intramuscular) of the chelating agent, calcium disodium EDTA (*EDTA provocation*), or oral dosing with dimercaptosuccinic acid (DMSA) has been used to detect elevated body burden of Pb in adults (Biagini et al. 1977; Lee et al. 2009; Lilis et al. 1968; Lin et al. 2003, 2006a, 2006b; Schwartz et al. 2000a, 2000c; Wedeen 1992; Wedeen et al. 1975) and children (Chisolm et al. 1976; Markowitz and Rosen 1981). However, the American College of Medical Toxicology (ACMT 2010) position statement on post-chelator challenge urinary metal testing states that “post-challenge urinary metal testing has not been scientifically validated, has no demonstrated benefit, and may be harmful when applied in the assessment and treatment of patients in whom there is concern for metal poisoning.” The assay is not a substitute for PbB measurements in the clinical setting. Note that children whose PbBs are ≥ 45 $\mu\text{g}/\text{dL}$ should not receive a provocative chelation test; they should be immediately referred for appropriate chelation therapy (CDC 2002a, 2012f). For additional information on recommended actions based on PbB level in children and adults, see Section 3.5 (Methods for Reducing Toxic Effects). Further limitations for routine use of the test are that EDTA must be given parenterally and requires timed urine collections. A study conducted in rats found that intraperitoneal administration of a single dose of EDTA following 3–4-month exposures to

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

Pb in drinking water increased levels of Pb in the liver and brain (Cory-Slechta et al. 1987) raising concern for similar effects in humans who undergo the EDTA provocation test. The use of EDTA to assess bone stores of Pb (Wedeen 1992) is largely being supplanted by more direct, noninvasive procedures for measuring Pb in bone. DMSA is a Pb chelating agent that can be administered orally. DMSA-chelatable Pb has been used as marker of Pb body burden in adults (Schwartz et al. 1997, 2000a, 2000c; Scinicariello et al. 2007; Weaver et al. 2003a, 2003b).

Pb in Saliva and Sweat. Pb is excreted in human saliva and sweat (Genuis et al. 2011; Lilley et al. 1988; Omokhodion and Crockford 1991; Rabinowitz et al. 1976; Stauber and Florence 1988; Sears et al. 2012; Stauber et al. 1994). Sweat has not been widely adopted for monitoring Pb exposures. Lilley et al. (1988) found that Pb concentrations in sweat were elevated in Pb workers; however, sweat and PbBs were poorly correlated. This may reflect excretion of Pb in or on the skin that had not been absorbed into blood. Studies conducted in rats have found relatively strong correlations between Pb concentrations in plasma and saliva (e.g., $r^2 > 0.9$), compared to blood Pb and saliva; therefore, saliva may serve as a better predictor of plasma Pb than PbB (Timchalk et al. 2006). However, studies of saliva Pb conducted in humans have had mixed results, with some studies showing relatively strong correlations between salivary Pb concentration and PbB (Brodeur et al. 1983; Omokhodion and Crockford 1991; P'an 1981), and other studies showing weak or inconsistent relationships (Barbosa et al. 2006c; Costa de Almeida et al. 2009, 2010, 2011; Nriagu et al. 2006). Variable outcomes from these studies may reflect differences in PbBs, exposure history and/or dental health (i.e., transfer of Pb between dentin and saliva), and methods used for determining Pb in saliva. Other complicating factors reported in the literature include uncontrolled variation in salivary flow rates (Barbosa et al. 2005; Esteban and Castano 2009) and potential blood contamination of saliva (Koh and Koh 2007).

Hair and Nail Pb. Pb is incorporated into human hair and hair roots (Bos et al. 1985; Rabinowitz et al. 1976) and has been explored as a possibly noninvasive approach for estimating Pb body burden (Gerhardsson et al. 1995b; Wilhelm et al. 1989). The method is subject to error from contamination of the surface with environmental Pb and contaminants in artificial hair treatments (i.e., dyeing, bleaching, permanents) and is a relatively poor predictor of PbB, particularly at low concentrations ($< 12 \mu\text{g/dL}$) (Campbell and Toribara 2001; Drasch et al. 1997; Esteban et al. 1999; Rodrigues et al. 2008). Nevertheless, levels of Pb in hair were positively correlated with children's classroom attention deficit behavior in a study (Tuthill 1996). Pb in hair was correlated with liver and kidney Pb in a study of deceased smelter workers (Gerhardsson et al. 1995b). Correlations between maternal and infant hair Pb concentrations have been observed (Kordas et al. 2010). Although hair Pb measurements have been used

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

in some epidemiologic studies (Bao et al. 2009; Huel et al. 2008; Marcus et al. 2010; Shah et al. 2011), an empirical basis for interpreting hair Pb measurements in terms of body burden or exposure has not been firmly established. Nail Pb has also been utilized as a marker of Pb exposure, although nails may be contaminated with Pb from external sources (Barbosa et al. 2005; Gerhardsson et al. 1995b).

Semen Pb. Pb concentrations in semen have been explored as an internal exposure biomarker for adverse effects of Pb on the testes (Hernandez-Ochoa et al. 2005; Kasperczyk et al. 2015; Slivkova et al. 2009; Taha et al. 2013; Wu et al. 2012). Correlations between concentrations of Pb in semen and blood have been reported and vary in strength across studies (Alexander et al. 1998a, 1998b; Farias et al. 2005; Hernandez-Ochoa et al. 2005; Mendiola et al. 2011; Telisman et al. 2000). This variation may relate, in part, to analytical challenges in the measurement of the relatively low concentrations of Pb in semen. Using ICP-MS and rigorous collection methods to avoid contamination, Farias et al. (2005) reported a detection limit of 0.2 µg/L semen. Mean semen Pb concentration in a group of 160 men (age range 19–48 years) who were not exposed to Pb occupationally was 2.66 µg/L (range 0.08–19.42) and was significantly correlated with PbB (mean 10.8 µg/dL, range 4.5–40.2) and tibia bone Pb (mean 14.51 µg/g, range not-detected–44.71 µg/g).

Stable Pb Isotopes. Analysis of the relative abundance of stable isotopes of Pb in blood and other accessible body fluids (e.g., breast milk, urine) has been used to differentiate exposures from multiple sources (Flegal and Smith 1995). Relative abundances of stable isotopes of Pb (²⁰⁴Pb, ²⁰⁶Pb, ²⁰⁷Pb, and ²⁰⁸Pb) in Pb ores vary with the age of the ore (which determines the extent to which the parent isotopes have undergone radioactive decay to stable Pb). Humans have Pb isotope abundance profiles that reflect the profiles of Pb deposits to which they have been exposed. Pb isotope studies can be used to identify sources of Pb contributing to exposure. Similarly, if exposure abruptly changes to a Pb source having a different isotope abundance profile, the kinetics of the change in profile in the person can be measured, reflecting the kinetics of uptake and distribution of Pb from the new source (Gulson et al. 2003; Maddaloni et al. 1998; Manton et al. 2003). Numerous examples of the application of stable isotope abundance measurements for studying sources of Pb exposures have been reported (Angle et al. 1995; Graziano et al. 1996; Gulson and Wilson 1994; Gulson et al. 1996, 1997b, 1999c, 2016; Manton 1977, 1998).

Effect Biomarkers Used to Assess Exposure to Pb. Certain physiological changes that are associated with Pb exposure have been used as biomarkers of exposure (see Section 3.3.2). These include measurements of biomarkers of impaired heme biosynthesis (blood zinc protoporphyrin, urinary

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

coproporphyrin, erythrocyte ALAD activity, serum ALA). These types of measurements have largely been supplanted with measurement of PbB for the purpose of assessing Pb exposure due to the higher sensitivity of PbB measurements in quantifying lower level Pb exposures.

3.3.2 Biomarkers of Effect

Certain effects of Pb have been used in diagnosing Pb poisoning to support measurements of PbB; however, none of these diagnostic aids are considered preferable to measurement of PbB. A multisite study of populations living near four NPL sites was conducted to assess the relationship between exposure (PbB and area of residence) and biomarkers of four organ systems: immune system dysfunction, kidney dysfunction, liver dysfunction, and hematopoietic dysfunction (ATSDR 1995). The geometric mean PbB in those living in the target areas was 4.26 $\mu\text{g}/\text{dL}$ ($n=1,645$) compared with 3.45 $\mu\text{g}/\text{dL}$ for a group living in comparison areas ($n=493$). In children <6 years old, the corresponding means were 5.37 versus 3.96 $\mu\text{g}/\text{dL}$. In subjects ≥ 15 years old, the target and comparison values were 3.06 and 3.63 $\mu\text{g}/\text{dL}$, respectively. Ninety percent of target and 93% of comparison area participants had PbBs <10 $\mu\text{g}/\text{dL}$. Pb in soil and water was found to be higher in comparison areas than in the target areas, but Pb in house dust and in interior paint was higher in the target areas. PbB correlated with Pb in soil and dust, but not with Pb in paint and water. Multivariate regression analyses showed that of all the biomarkers analyzed, PbB was significantly associated with, and predictive of, hematocrit in adults ≥ 15 years of age and with increased mean serum IgA in children 6–71 months of age. The biological significance of these associations is unclear since both hematocrit and IgA levels were well within normal ranges and were hardly different than levels in subjects from the comparison areas.

Pb inhibits heme biosynthesis, which is necessary for production of red blood cells. Hematologic tests such as hemoglobin concentration may suggest toxicity, but this is not specific for Pb (Bernard and Becker 1988). However, inhibition of ferrochelatase in the heme pathway causes accumulation of protoporphyrin in erythrocytes (CDC 1985). Most protoporphyrin in erythrocytes (about 90%) exists as zinc-protoporphyrin (ZPP). This fraction is preferentially measured by hematofluorometers. Extraction methods measure all of the protoporphyrin present, but strip the zinc from the ZPP during the extraction process. For this reason, extraction results are sometimes referred to as (zinc) free erythrocyte protoporphyrin (FEP). Although the chemical forms measured by the two methods differ slightly, on a weight basis, they are roughly equivalent; thus, results reported as EP, ZPP, or FEP all reflect essentially the same analyte. An elevated EP level is one of the earliest and most reliable indicators of impairment of heme biosynthesis and reflects average Pb levels at the site of erythropoiesis over the previous 4 months

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

(Janin et al. 1985). The concentration of EP rises above background at PbBs of 25–30 µg/dL, above which, there is a positive correlation between PbB and EP (CDC 1985; Gennart et al. 1992a; Roels and Lauwerys 1987; Soldin et al. 2003; Wildt et al. 1987). Pb toxicity is generally considered to be present when a PbB ≥ 10 µg/dL is associated with an EP level ≥ 35 µg/dL (CDC 1991; Somashekaraiah et al. 1990). This effect is detectable in circulating erythrocytes only after a lag time reflecting maturation in which the entire population of red blood cells has turned over (i.e., 120 days) (EPA 1986; Moore and Goldberg 1985). Similarly, elevated EP can reflect iron deficiency, sickle cell anemia, and hyperbilirubinemia (jaundice). Therefore, reliance on EP levels alone for initial screening could result in an appreciable number of false positive cases (CDC 1985; Mahaffey and Annett 1986; Marcus and Schwartz 1987). Conversely, since EP does not go up until the PbB exceeds 25 µg/dL, and the reference value is 5 µg/dL, relying on EP measures would result in many false negative cases. Some have estimated that relying only on ZPP screening to predict future Pb toxicity would miss approximately three cases with toxic PbBs in every 200 workers at risk (Froom et al. 1998). A limitation of measuring porphyrin accumulation is that porphyrin is labile because of photochemical decomposition; thus, assay samples must be protected from light. However, other diseases or conditions such as porphyria, liver cirrhosis, iron deficiency, age, and alcoholism may also produce similar effects on heme synthesis (Somashekaraiah et al. 1990).

ALAD, an enzyme occurring early in the heme pathway, is also considered a sensitive indicator of Pb effect (Graziano 1994; Hernberg et al. 1970; Morris et al. 1988; Somashekaraiah et al. 1990; Tola et al. 1973). ALAD activity is negatively correlated with PbBs of 5–95 µg/dL, with >50% inhibition occurring at PbBs >20 µg/dL (Hernberg et al. 1970; Morita et al. 1997; Roels and Lauwerys 1987). However, ALAD activity may also be decreased with other diseases or conditions such as porphyria, liver cirrhosis, and alcoholism (Somashekaraiah et al. 1990). ALAD was found to be a more sensitive biomarker than urinary ALA and ZPP at PbBs between 21 and 30 µg/dL (Schuhmacher et al. 1997). A marked increase in urinary excretion of ALA, the intermediate that accumulates from decreased ALAD, can be detected when PbB exceeds 35 µg/dL in adults and 25–75 µg/dL in children (NAS 1972b; Roels and Lauwerys 1987; Sakai and Morita 1996; Schuhmacher et al. 1997).

Another potential biomarker for hematologic effects of Pb is the observation of basophilic stippling and premature erythrocyte hemolysis (Paglia et al. 1975, 1977). Pb can impair the activity of pyrimidine 5'-nucleotidase, resulting in a corresponding increase in pyrimidine nucleotides in red blood cells, which leads to a deficiency in maturing erythroid elements and thus, decreased red blood cells. However, this effect is nonspecific; it is encountered with benzene and arsenic poisoning (Smith et al. 1938) and in a

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

genetically-induced enzyme-deficiency syndrome (Paglia et al. 1975, 1977). Furthermore, since basophilic stippling is not universally found in chronic Pb poisoning, it is relatively insensitive to lesser degrees of Pb toxicity (CDC 1985). The activity of adenine dinucleotide synthetase (NADS) in erythrocytes has also been explored as a biomarker for predicting PbBs >40 µg/dL; NADS activity is negatively correlated with PbB over the range 5–80 µg/dL (Morita et al. 1997).

Reduction in the serum 1,25-dihydroxyvitamin D concentration has been reported as an indicator of increased Pb absorption or Pb concentrations in the blood (Rosen et al. 1980). Pb inhibits the formation of this active metabolite of vitamin D, which occurs in bone mineral metabolism (EPA 1986; Landrigan 1989). Children with PbBs of 12–120 µg/dL showed decreased serum 1,25-dihydroxyvitamin D concentrations comparable to those found in patients with hypoparathyroidism, uremia, and metabolic bone disease (Mahaffey et al. 1982; Rosen et al. 1980). This biomarker is clearly not specific for Pb exposure and several diseases can influence this measurement.

One of the most sensitive systems affected by Pb exposure is the nervous system. Encephalopathy is characterized by symptoms such as coma, seizures, ataxia, apathy, bizarre behavior, and incoordination (CDC 1985). Children are more sensitive to neurological changes than adults. In children, encephalopathy has been associated with PbBs as low as 70 µg/dL (CDC 1985). An early sign of peripheral manifestations of neurotoxicity is gastrointestinal colic, which can occur with PbBs above 50 µg/dL. The most sensitive peripheral index of neurotoxicity of Pb is reported to be slowed conduction velocity in small motor fibers of the ulnar nerve in workers with PbBs of 30–40 µg/dL (Landrigan 1989). Other potential biomarkers of Pb suggested for neurotoxicity in workers are neurological and behavioral tests, as well as cognitive and visual sensory function tests (Williamson and Teo 1986). However, these tests are not specific to elevated Pb exposure.

Functional deficits associated with Pb-induced nephrotoxicity increase in severity with increasing PbB. Effects include decreased glomerular filtration, enzymuria and proteinuria, and impaired transport function. Biomarkers for these changes include elevation of serum creatinine, urinary enzymes (e.g., NAG), or protein (albumin, β₂µ-globulin, α₁µ-globulin, retinol binding protein). However, none of these markers are specific for Pb-induced nephrotoxicity. A characteristic histologic feature of Pb nephrotoxicity is the formation of intranuclear inclusion bodies in the renal proximal tubule (Choi and Richter 1972; Goyer et al. 1970a, 1970b).

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

3.4 INTERACTIONS WITH OTHER CHEMICALS

Interactions between Pb and other chemicals can be classified into two categories: interactions with contaminants that are commonly found together with Pb at hazardous waste sites, and interactions with essential elements (ATSDR 2004a, 2004b, 2006; EPA 2014c).

Interactions with Other Contaminants. Several metals and metalloids frequently are found together with Pb at hazardous waste sites, including arsenic (As), cadmium (Cd), manganese (Mn), zinc (Zn), copper (Cu), and inorganic mercury (Hg). ATSDR (2004a, 2004b, 2006) has conducted assessments to predict interactions of these chemicals with Pb; conclusions are presented in Table 3-3. For each co-contaminant, interactions were classified as less than additive (indicating an antagonistic effect with Pb), additive (indicating no effect of combined exposure), or greater than additive (indicating a synergistic effect with Pb). Greater-than-additive effects were observed for neurological effects for As and Cd, male reproductive effects for Cd, and renal effects for Hg. Interactions for other metals were either less than additive or additive for cardiovascular (Cd, Zn), developmental (Zn), hematological (As, Cd, Mn, Zn, Cu), immunological (Cd), neurological effects (Zn), renal (As, Cd, Mn, Zn, Cu), and male reproductive (Zn) effects. Other metals that may interact with Pb include selenium and chromium(VI) (Nordberg et al. 2015). Observed interactions of metals and metalloids with Pb could be the results of alterations to Pb toxicokinetics, toxicodynamics, or a combination of both.

Table 3-3. Influence of Other Metals and Metalloids on Lead (Pb) Toxicity

Organ system	Metal					
	Arsenic ^a	Cadmium ^a	Manganese ^b	Zinc ^b	Copper ^b	Inorganic mercury ^c
Cardiovascular	–	< or 0	–	<	–	–
Developmental	–	–	–	<	–	–
Hematological	< or 0	< or 0	0	< or 0	<	–
Immunological	–	<	–	–	–	–
Neurological	>	>	–	< or 0	<	–
Renal	0	< or 0	0	<	–	>
Male reproductive	–	>	–	<	–	–

^aATSDR 2004a.

^bATSDR 2004b.

^cATSDR 2006.

< = less than additive; 0 = additive (no effect); > = greater than additive; – = not assessed

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

Interactions with Essential Elements. In physiological systems, Pb mimics divalent cations (calcium, iron, zinc). Substitution of Pb for essential elements in membrane transport systems is the mechanism by which Pb is absorbed from the intestine and crosses cell membranes throughout the body. Thus, numerous interactions between Pb and essential elements have been observed, including the following (additional details on these findings are provided in Section 3.1, Toxicokinetics):

- Dietary calcium intake appears to affect Pb absorption. An inverse relationship has been observed between dietary calcium intake and PbBs in children (Elias et al. 2007; Mahaffey et al. 1986; Schell et al. 2004; Ziegler et al. 1978).
- Nutritional iron status may affect Pb absorption in children. Higher PbBs have been observed in iron-deficient children compared to children who are iron replete. This observation suggests that iron deficiency may result in higher absorption of Pb or, possibly, other changes in Pb biokinetics that would contribute to higher PbBs (Mahaffey and Annett 1986; Marcus and Schwartz 1987).
- In young children (ages 6–12 months), PbB increased in association with lower dietary Zn levels (Schell et al. 2004). It is not clear, however, if these associations were caused by changes in Pb absorption.

3.5 METHODS FOR REDUCING TOXIC EFFECTS

This section will describe clinical practice and research concerning methods for reducing toxic effects of exposure to lead. However, because some of the treatments discussed may be experimental and unproven, this section should not be used as a guide for treatment of exposures to lead. When specific exposures have occurred, poison control centers, medical toxicologists, or other clinicians with expertise and experience treating and managing lead exposed adults and/or children should be consulted. The following resources provide specific information about treatment and management of patients following exposure to lead:

AAP. 2005. Lead exposure in children: Prevention, detection, and management. *Pediatrics* 116(4):1036-1046. 10.1542/peds.2005-1947.

AAP. 2016. Council on Environmental Health. Prevention of childhood lead toxicity. *Pediatrics* 38(1):e20161493

ATSDR. 2017. Case studies in environmental medicine (CSEM). Lead toxicity. https://www.atsdr.cdc.gov/csem/lead/docs/csem-lead_toxicity_508.pdf. August 30, 2018.

Calello DP, Henretig FM. 2014. Lead. In: Goldfrank's toxicologic emergencies. Tenth ed. New York, NY: McGraw-Hill, 1219-1234.

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

Holland MG, Cawthon D. 2016. ACOEM Position Statement. Workplace lead exposure. *J Occup Environ Med* 58(12):e371-e374.

Leikin JB, Paloucek FP. 2008. Lead. In: *Poisoning and toxicology handbook*. Fourth ed. Boca Raton, FL: CRC Press, 807-811.

CDC. 2002a. Managing elevated blood levels among young children. Recommendations from the Advisory Committee on Childhood Lead Poisoning. Centers for Disease Control and Prevention. <https://www.cdc.gov/nceh/lead/casemanagement/managingEBLLs.pdf>. July 18, 2018.

Kosnett MJ. 2001. Lead. In: Ford M, Delaney KA, Ling L, et al., eds. *Clinical toxicology*. St. Louis: WB Saunders, 723-736.

Kosnett MJ. 2005. Lead. In: Brent J, Wallace KL, Burkhart KK, et al., eds. *Critical care toxicology*. Philadelphia, PA: Elsevier Mosby, 821-836.

PEHSU. 2013. Recommendations on medical management of childhood lead exposure and poisoning. *Pediatric Environmental Health Specialty Units*.

Additional publicly available clinical resources for the health care professional can be found in Appendix D.

3.5.1 Reducing Absorption Following Exposure

No treatment modalities to reduce lead absorption have been developed. Therefore, the most important intervention is to identify and remove the source of exposure (AAP 2005, 2016; ATSDR 2017; CDC 2012f). Lead absorption from the gastrointestinal tract is influenced by nutrition, especially calcium, iron, and vitamin C (AAP 2005; CDC 2012f). It is recommended that a child's diet contain ample amounts of iron and calcium to reduce the likelihood of increased absorption of lead and that children eat regular meals since more lead is absorbed on an empty stomach (AAP 2005; CDC 2002a, 2012f). Good sources of iron include liver, fortified cereal, cooked legumes, and spinach, whereas milk, yogurt, cheese, and cooked greens are good sources of calcium (CDC 1991).

General recommendations to reduce absorption of lead following acute exposure include the following (AAP 2016; ATSDR 2017; Calello and Henretig 2014; Kosnett et al. 2007):

- remove the individual from the source of exposure;
- mitigate source of exposure;
- if suspected that elevated PbB is due to ingestion of a foreign object (e.g., Pb paint chips, toys or jewelry containing Pb, Pb ammunition), radiographic imaging is suggested;
- if elevated PbB is due to ingestion of a foreign object, decontamination of the bowel (surgical or gastric lavage) is indicated; and

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

- ensure that diet is adequate in calcium, iron, and vitamin C.

For children, specific recommended actions based on PbB levels are summarized in Table 3-4. CDC considers PbB to be elevated in children when it exceeds a reference value defined as the 97.5th percentile for the U.S. population. The current CDC reference value, based on data from NHANES 2007–2009 and 2009–2010, is 5 µg/dL (CDC 2016). Recent NHANES surveys show that the 97.5th percentile PbB in the U.S. population continues to decline (CDC 2018a).

Table 3-4. Recommended Actions Based on Child Blood Lead Level (PbB)

PbB (µg/dL)	Recommended actions
<Reference value ^a	<ul style="list-style-type: none"> • Education on environmental sources of Pb and sufficient dietary nutrition • Follow-up PbB monitoring
≥Reference value and ≤45	<ul style="list-style-type: none"> • Follow recommendations for <Reference value • Complete history and physical examination • Laboratory analysis <ul style="list-style-type: none"> ○ Monitor iron status ○ Consider measurement of hemoglobin or hematocrit • Neurodevelopmental monitoring • Abdominal radiography and bowel decontamination if ingestion of Pb particulate is suspected • Conduct environmental investigation and Pb hazard reduction
≥45 and ≤69	<ul style="list-style-type: none"> • Follow recommendations for ≥Reference value and ≤45 • Laboratory analyses <ul style="list-style-type: none"> ○ Hemoglobin or hematocrit ○ Iron status ○ Zinc protoporphyrin • Oral chelation therapy • Consider hospitalization if cannot assure mitigation of Pb source
≥70	<ul style="list-style-type: none"> • Hospitalize • Initiate chelation therapy with consultation with a medical toxicologist or pediatric environmental health expert or unit • Follow recommendations for ≥45 and ≤69

^a5 µg/dL (CDC 2012d).

Source: CDC 2012f

For occupational exposures, OSHA and NIOSH have developed recommendations to reduce Pb exposure through procedures and surveillance. In 1987, NIOSH created the Adult Blood Lead Epidemiology and Surveillance (ABLES) program to monitor adult PbBs through coordinated efforts with state agencies (NIOSH 2017a). This program was designed to decrease the rate of adults with PbBs ≥10 µg/dL as a result of work-related lead exposure. In 2015, NIOSH designated PbB of 5 µg/dL as the PbB reference value and defined elevated PbB as PbB ≥5 µg/dL (NIOSH 2017a). Several federal and state agencies

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

work together to reduce the rate of elevated PbBs among workers. The OSHA (1995) mandated rule on lead provides recommendations to reduce occupational Pb exposure for general industry, shipyard employment, and construction through use of respirators, protective clothing, routine biological monitoring of PbB and zinc protoporphyrin, and medical assessments for workers with elevated PbB. More recently, Holland and Cawthon (2016) suggested the actions based on PbB levels, with a baseline PbB <5 µg/dL (Table 3-5).

Table 3-5. Recommended Actions for Workers Based on Blood Lead Level (PbB)

PbB (µg/dL)	Recommended actions
All workers	<ul style="list-style-type: none"> PbB monitoring at initial employment Monitor PbB every 6 months after initial employment monitoring PbB goal is <5 µg/dL for pregnant workers
≥5–9	<ul style="list-style-type: none"> Increase monitoring if indicated Recommend removal for pregnant workers or workers who are trying to become pregnant; return to work may be considered if two consecutive PbB measurements are <5 µg/dL Continue PbB monitoring as noted above
10–19	<ul style="list-style-type: none"> Monitor PbB every 2 months until two consecutive PbB measurements are <10 µg/dL Mandatory medical removal for pregnant workers or workers who are trying to become pregnant; return to work may be considered if two consecutive PbB measurements are <5 µg/dL Continue PbB monitoring as noted above Evaluate exposure, controls, and work practices
≥20	<ul style="list-style-type: none"> Remove from work if repeat PbB measurement in 4 weeks is ≥20 µg/dL or if single PbB measurement is ≥30 µg/dL Monitor PbB monthly; return to work after two consecutive monthly PbB measurements are <15 µg/dL Continue PbB monitoring as noted above Evaluate exposure, controls, and work practices
≥30	<ul style="list-style-type: none"> Removed from exposure immediately Monitor PbB monthly; return to work after two consecutive monthly PbB measurements are <15 µg/dL Continue PbB monitoring as noted above Evaluate exposure, controls, and work practices

^aSource: Holland and Cawthon (2016)

3.5.2 Reducing Body Burden

Lead is initially distributed throughout the body and then redistributed to soft tissues and bone. In human adults and children, approximately 94 and 73% of the total body burden of lead is found in bones,

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

respectively. Lead may be stored in bone for long periods of time, but may be mobilized, thus achieving a steady state of intercompartmental distribution (see Section 3.3.2).

Currently available methods to obviate the toxic effects of lead are based on their ability to reduce the body burden of lead by chelation. All of the chelating agents bind inorganic lead, enhance its excretion, and facilitate the transfer of lead from soft tissues to the circulation where it can be excreted. Since the success of chelation therapy depends on excretion of chelated lead via the kidney, caution should be used when treating a patient with renal failure. For all cases where chelation therapy is considered or implemented, medical providers should consult with a medical toxicologist or an expert in the medical management of lead toxicity (CDC 2002a, 2012f). Chelation treatment should be administered in conjunction with meticulous supportive therapy (Calello and Henretig 2014). Most of the information below regarding chelators was obtained from Calello and Henretig (2014) and Kosnett (2005, 2007).

Several pharmacological substances are available for chelation therapy for Pb intoxication. Chelating agents currently in use are dimercaprol (British Anti-Lewisite, or BAL), $\text{CaNa}_2\text{-EDTA}$ (or EDTA), and 2,3-dimercaptosuccinic acid (DMSA; Succimer[®]). Dosages and administration protocols for these agents vary with patient age, PbB level, and symptom types and severity. Specific treatment protocols should be developed in consultation with clinical experts in the management of lead toxicity for the most current chelation therapy procedures for children and adults (CDC 2002a, 2012f).

Dimercaprol (BAL). The mechanism of action of BAL is through formation of stable chelate-metal compounds intra- and extracellularly. BAL is administered parenterally. The onset of action for BAL is 30 minutes. BAL increases fecal excretion of lead as chelated lead is excreted predominantly in bile within 4–6 hours; BAL also increases urinary excretion of chelated lead. A number of adverse reactions have been associated with BAL, including nausea, vomiting, hypertension, tachycardia, headache, increased secretions, anxiety, abdominal pain, and fever.

CaNa₂-EDTA (or EDTA). EDTA works by forming a stable metal-chelate complex that is excreted by the kidney. It increases renal excretion of lead 20–50 times. EDTA is administered parenterally. Numerous adverse effects have been described due to treatment with EDTA including rash, fever, fatigue, thirst, myalgias, chills, and cardiac dysrhythmias. Since EDTA chelates zinc, patients with low zinc stores may be adversely affected by EDTA. Since EDTA also chelates other metals, administration of EDTA (or BAL) to persons occupationally exposed to cadmium may result in increased renal excretion of cadmium and renal damage.

3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

2,3-Dimercaptosuccinic acid (DMSA; Succimer®). The mechanism of action of DMSA is similar to BAL. DMSA is administered orally. DMSA has been shown to be as effective as EDTA in increasing the urinary excretion of lead. Minimal adverse effects that have been reported include anorexia, nausea, vomiting, and rashes. DMSA increases the excretion of zinc, but to a much lesser extent than other chelators, and has minimal effects on calcium, iron, magnesium, and copper.

CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION

4.1 CHEMICAL IDENTITY

Pb is a naturally occurring element with an abundance of 0.0016% in the earth's crust (Davidson et al. 2014). It is a member of Group 14 (IVA) of the periodic table. Natural Pb is a mixture of four stable isotopes: ^{204}Pb (1.4%), ^{206}Pb (24.1%), ^{207}Pb (22.1%), and ^{208}Pb (52.4%). The Pb isotopes ^{206}Pb , ^{207}Pb , and ^{208}Pb are the stable decay product of the naturally occurring decay series of uranium, actinium, and thorium, respectively (Haynes 2014).

Pb is found in concentrated and easily accessible Pb ore deposits that are widely distributed throughout the world (King et al. 2014). Its properties, such as corrosion resistance, density, and low melting point, make it a familiar metal in pipes, solder, weights, and storage batteries. The chemical identities of Pb and several of its compounds are provided in Table 4-1.

Table 4-1. Chemical Identity of Lead and Compounds

Characteristic	Lead	Lead(II) acetate	Lead(II) azide	Lead(II) bromide
Synonym(s) and registered trade name(s)	C.I. 77575; C.I. Pigment metal 4; Glover; Lead flake; Lead S2; Omaha; Omaha & Grant; SI; SO ^a	Acetic acid lead(2+) salt (2:1); neutral lead acetate; plumbous acetate; normal lead acetate; sugar of lead; salt of Saturn ^b	Lead azide ^b	Lead bromide (PbBr ₂); plumbous bromide ^b
Chemical formula	Pb ^b	Pb(CH ₃ CO ₂) ₂ ^b	Pb(N ₃) ₂ ^b	PbBr ₂ ^b
Chemical structure	Not applicable	Not applicable	Not applicable	Not applicable
CAS Registry Number	7439-92-1 ^b	301-04-2 ^b	13424-46-9 ^b	10031-22-8 ^b


4. CHEMICAL AND PHYSICAL INFORMATION

Table 4-1. Chemical Identity of Lead and Compounds

Characteristic	Lead(II) chloride	Lead(II) chromate	Lead(II) tetrafluoroborate ^c	Lead(II) iodide
Synonym(s) and registered trade name(s)	Lead chloride (PbCl ₂); Lead(2+) chloride; Plumbous chloride ^b	Chromic acid (H ₂ CrO ₄ lead(2+) salt (1:1); Chrome yellow; Cologne yellow; King's yellow; Leipzig yellow; Paris yellow; C.I. Pigment Yellow 34; lead chromium oxide (PbCrO ₄); plumbous chromate; C.I. 77600 ^b	Tetrafluoro borate(1-) Lead(2+) ^a	Lead iodide (PbI ₂); Plumbous iodide ^b
Chemical formula	PbCl ₂ ^b	PbCrO ₄ ^b	Pb(BF ₄) ₂ ^a	PbI ₂ ^b
Chemical structure	Not applicable	Not applicable	Not applicable	Not applicable
CAS Registry Number	7758-95-4 ^b	7758-97-6 ^b	13814-96-5 ^a	10101-63-0 ^b


4. CHEMICAL AND PHYSICAL INFORMATION

Table 4-1. Chemical Identity of Lead and Compounds

Characteristic	Lead molybdenum chromate	Lead(II) nitrate	Lead(II) oxide	Lead(II,II,IV) oxide
Synonym(s) and registered trade name(s)	Chromic acid, lead and molybdenum salt; chromic acid lead salt with lead molybdate; C.I. Pigment Red 104; Lead chromate, Molybdenum-Lead chromate; Molybdenum Orange ^a	Nitric acid lead(2+) salt (2:1); Plumbous nitrate ^b	C.I. 77577; C.I. Pigment Yellow 46; Lead oxide; Lead oxide yellow; Lead protoxide; Litharge; Litharge Yellow L-28; Massicot; Massicotite; Plumbous oxide; Yellow lead ocher ^a	Lead tetraoxide; Lead tetroxide; Lead oxide red; C.I. Pigment Red 105; C.I. 77578; Gold satinobre; Lead orthoplumbate; Lead oxide (3:4); Mineral Orange; Mineral Red; Paris Red; Saturn Red; Minium; Plumboplumbic oxide; Red Lead; Red Lead oxide; Trilead tetraoxide ^{d,e}
Chemical formula	No data	Pb(NO ₃) ₂ ^b	PbO ^a	Pb ₃ O ₄ ^e
Chemical structure	Not applicable	Not applicable	Not applicable	
CAS Registry Number	12709-98-7 ^a	10099-74-8 ^b	1317-36-8 ^a	1314-41-6 ^d
Characteristic	Lead(II) phosphate	Lead(II) styphnate	Lead(II) sulfate	
Synonym(s) and registered trade name(s)	C.I. 77622; Lead orthophosphate; Lead phosphate (3:2); Lead(2+) phosphate; normal lead orthophosphate; Phosphoric acid, lead(2+) salt (2:3); Plumbous phosphate; Trilead phosphate ^a	Lead trinitroresorcinat ^f	Anglesite; C.I. 77630; C.I. Pigment White 3; Fast White; Freemans White Lead; Lead bottoms; Milk white; Mulhouse White; Sulfuric acid, lead(2+) salt (1:1) ^a	
Chemical formula	Pb ₃ (PO ₄) ₂ ^a	Pb(C ₆ H ₃ N ₃ O ₈) ₂ ^f	PbSO ₄ ^b	
Chemical structure	Not applicable	Not applicable	Not applicable	
CAS Registry Number	7446-27-7 ^a	15245-44-0 ^f	7446-14-2 ^b	

4. CHEMICAL AND PHYSICAL INFORMATION

Table 4-1. Chemical Identity of Lead and Compounds

Characteristic	Lead(II) sulfide	Tetraethyl lead	Lead(II) carbonate
Synonym(s) and registered trade name(s)	C.I. 77640; Galena; Natural lead sulfide; Plumbous sulfide ^a	Tetraethylplumbane; Lead tetraethyl; TEL ^b	Carbonic acid, lead(2+) salt (1:1); Cerussite; Dibasic lead carbonate; Lead(2+) carbonate; White lead ^a
Chemical formula	PbS ^a	Pb(C ₂ H ₅) ₄ ^a	PbCO ₃ ^a
Chemical structure	Not applicable		Not applicable
CAS Registry Number	1314-87-0 ^a	78-00-2 ^b	598-63-0 ^a

^aLewis 2012.^bO'Neil et al. 2015 2013.^cStable only in aqueous solution (Haynes 2014).^dCHEMIDplus 2018.^eHaynes 2014.^fBoileau et al. 2012.

CAS = Chemical Abstracts Services

4.2 PHYSICAL AND CHEMICAL PROPERTIES

Pb, a blueish-white metal with bright luster, is very soft, highly malleable, ductile, a poor conductor of electricity, and is very resistant to corrosion (Haynes 2014). A clean lead surface will not be attacked by dry air; however, in moist air, the surface will react and become coated with a layer of lead(II) oxide (PbO). This coating may be hydrated and combine with carbon dioxide to form lead(II) carbonate (PbCO₃) (Carr et al. 2004). This protective coating of insoluble Pb compounds slows or halts corrosion of the underlying metal. Pb is rarely found in its metallic form in nature and commonly occurs as a mineral with sulfur or oxygen. The most important lead mineral is galena (PbS). Other common Pb-containing minerals include anglesite (PbSO₄), cerussite (PbCO₃), and minium (Pb₃O₄) (Carr et al. 2004; Davidson et al. 2014; Haynes 2014).

Pb can exist in the 0 oxidation state in metallic Pb and in compounds as the +2 or +4 oxidation states. In the environment, Pb is primarily found in the +2 state in inorganic compounds. The chemistry of inorganic Pb compounds is generally similar to that of the Group 2(II) or alkaline earth metals. There are three common oxides of Pb: lead(II) oxide (PbO); lead(II,IV) oxide or lead tetroxide (Pb₃O₄); and lead(IV) oxide or lead dioxide (PbO₂). The +4 state is only formed under strongly oxidizing conditions. Inorganic Pb(+4) compounds are relatively unstable and would not be expected to be found under

4. CHEMICAL AND PHYSICAL INFORMATION

ordinary environmental conditions. Pb is amphoteric, meaning that it can react with acids and bases. In acid, Pb forms Pb(+2) (plumbous) and Pb(+4) (plumbic) salts and in basic solution, it forms plumbites (PbO_2^{2-}) and plumbates (Pb(OH)_6^{2-}) (Carr et al. 2004). In organolead compounds, Pb is typically in the tetravalent (+4) oxidation state (Carr et al. 2004; Haynes 2014).

Data on the physical and chemical properties of lead and several of its compounds are provided in Table 4-2.

4. CHEMICAL AND PHYSICAL INFORMATION

Table 4-2. Physical and Chemical Properties of Lead and Compounds

Property	Lead	Lead(II) acetate	Lead(II) azide	Lead(II) bromide
Molecular weight	207.2 ^a	325.3 ^b	291.24 ^a	367.0 ^b
Color	Bluish-white, silvery, gray metal ^a	White crystals ^b	Needles or white powder ^a	White orthorhombic crystals ^b
Physical state	Solid	Solid	Solid	Solid
Melting point	327.4°C ^a	280°C ^b	Decomposes at 190°C ^c	371°C ^b
Boiling point	1,740°C ^a	Decomposes ^b	No data	892°C ^b
Density	11.34 g/cm ³ at 20°C ^a	3.25 g/cm ^{3b}	4.17 g/cm ³ at 20°C ^c	6.69 g/cm ^{3b}
Odor	No data	Slightly acetic odor (trihydrate) ^a	No data	No data
Odor threshold:				
Water	No data	No data	No data	No data
Air	No data	No data	No data	No data
Solubility:				
Water	Insoluble ^d	443,000 mg/L at 20°C ^b	230 mg/L at 18°C ^a	9,750 mg/L at 25°C ^b
Acids	Soluble in dilute nitric acid ^d ; reacts with sulfuric acid ^a	Soluble in acid ^e	Freely soluble in acetic acid ^a	No data
Bases	No data	Soluble in alkali ^e	No data	No data
Organic solvents	Soluble in glycerin; slightly soluble in alcohol ^e	Slightly soluble in alcohol; freely soluble in glycerol ^d	No data	Insoluble in alcohol ^b
Partition coefficients:				
Log K _{ow}	No data	No data	No data	No data
Log K _{oc}	No data	No data	No data	No data
Vapor pressure	1.77 mmHg at 1,000°C ^a	No data	No data	0.0075 mmHg at 374°C ^b
Henry's law constant	No data	No data	No data	No data
Autoignition temperature	No data	No data	No data	No data
Flashpoint	No data	No data	No data	No data
Flammability limits	No data	No data	No data	No data
Conversion factors	Not relevant ^f	Not relevant ^f	Not relevant ^f	Not relevant ^f
Explosive limits	No data	No data	Explodes at 350°C ^a	No data
Valence state	0	+2	+2	+2

4. CHEMICAL AND PHYSICAL INFORMATION

Table 4-2. Physical and Chemical Properties of Lead and Compounds

Property	Lead(II) chloride	Lead(II) chromate	Lead(II) tetrafluoroborate	Lead iodide
Molecular weight	278.1 ^g	323.19 ^a	380.8 ^b	461.05 ^g
Color	White, orthorhombic needles ^g	Yellow or orange-yellow powder ^a	No data	Yellow hexagonal crystals ^g
Physical state	Solid	Solid	Stable only in aqueous solution ^b	Solid
Melting point	501°C ^g	844°C ^a	No data	402°C ^g
Boiling point	950°C ^g	No data	No data	954°C ^g
Density	5.85 g/cm ^{3g}	6.12 g/cm ^{3b}	No data	6.16 g/cm ^{3g}
Odor	No data	No data	No data	No data
Odor threshold	No data	No data	No data	No data
Solubility:				
Water	9,900 mg/L at 20°C ^g	0.2 mg/L ^a	Soluble ^b	630 mg/L at 20°C ^g
Acids	Slightly soluble in dilute hydrochloric acid ^g	Soluble in dilute nitric acid; insoluble in acetic acid ^a	No data	No data
Bases	Slightly soluble in dilute ammonia ^g	No data	No data	No data
Organic solvents	Insoluble in alcohol ^g	No data	No data	Insoluble in alcohol ^g
Partition coefficients:				
Log K _{ow}	No data	No data	No data	No data
Log K _{oc}	No data	No data	No data	No data
Vapor pressure	7.5 mmHg at 637°C ^b	No data	No data	0.75 mmHg at 470°C ^b
Henry's law constant	No data	No data	No data	No data
Autoignition temperature	No data	No data	No data	No data
Flashpoint	No data	No data	No data	No data
Flammability limits	No data	No data	No data	No data
Conversion factors	Not relevant ^f	Not relevant ^f	Not relevant ^f	Not relevant ^f
Explosive limits	No data	No data	No data	No data
Valence state	+2	+2	+2	+2

4. CHEMICAL AND PHYSICAL INFORMATION

Table 4-2. Physical and Chemical Properties of Lead and Compounds

Property	Lead molybdenum chromate	Lead(II) nitrate	Lead(II) oxide	Lead(II,II,IV) oxide
Molecular weight	No data	331.23 ^g	223.21 ^g	685.57 ^e
Color	No data	Cubic or monoclinic colorless crystals ^g	Reddish-yellow; yellow (above 489°C) ^g	Bright red heavy powder ^a ; red tetrahedral crystals ^b
Physical state	No data	Solid	Solid	Solid
Melting point	No data	Begins to decompose above 205°C ^g	897°C (begins to sublime before melting) ^g	830°C ^b ; 500°C ^e
Boiling point	No data	No data	Decomposes at 1,472°C ^g	Decomposes between 500-530°C ^d
Density	No data	4.53 g/cm ^{3g}	9.53 g/cm ³ (Litharge) ^g ; 9.6 g/cm ³ (Massicot) ^g	8.92 g/cm ^{3b} ; 9.1 g/cm ^{3e}
Odor	No data	No data	No data	No data
Odor threshold:	No data	No data	No data	No data
Solubility:				
Water	No data	56:5 g/100 mL at 20°C ^g	50.4 mg/L at 25°C (Litharge) ^g ; 106.5 mg/L at 25°C (Massicot) ^g	Insoluble in water ^d
Acid	No data	Insoluble in concentrated nitric acid ^a	Soluble ^g	Dissolves in acetic acid or hot hydrochloric acid ^{b,g}
Base	No data	Soluble in alkali and ammonia ^g	Soluble ^g	No data
Organic solvents	No data	87.7 mg/L (43% aqueous ethanol) at 22°C ^g	Insoluble in alcohol ^a	Insoluble in alcohol ^g
Partition coefficients:				
Log K _{ow}	No data	No data	No data	No data
Log K _{oc}	No data	No data	No data	No data
Vapor pressure	No data	No data	0.0075 mmHg at 724°C ^b	No data
Henry's law constant	No data	No data	No data	No data
Autoignition temperature	No data	No data	No data	No data
Flashpoint	No data	No data	No data	No data
Flammability limits	No data	No data	No data	No data
Conversion factors	Not relevant ^f	Not relevant ^f	Not relevant ^f	Not relevant ^f
Explosive limits	No data	No data	No data	No data
Valence state	+2	+2	+2	+2, +2, +4

4. CHEMICAL AND PHYSICAL INFORMATION

Table 4-2. Physical and Chemical Properties of Lead and Compounds

Property	Lead(II) phosphate	Lead(II) styphnate	Lead(II) sulfate
Molecular weight	811.54 ^a	450.29 ^h	303.25 ^g
Color	White powder ^a	Monoclinic orange-yellow crystal (monohydrate) ^b	White, heavy, crystalline powder ^a
Physical state	Solid	Solid	Solid
Melting point	1,014°C ^a	No data	1,170°C ^g
Boiling point	No data	No data	No data
Density	6.9 g/cm ^{3a}	3.1 g/cm ³ (monohydrate); 2.9 g/cm ³ (anhydrous) ^b	6.2 g/cm ^{3g}
Odor	No data	No data	No data
Odor threshold:	No data	No data	No data
Solubility:			
Water	Insoluble ^b	Insoluble ^b	42.5 mg/L at 25°C ^g
Acid	Soluble in nitric acid ^a	No data	Soluble in concentrated acids ^g
Base	Soluble in fixed alkali hydroxides ^a	No data	Soluble in alkalies ^g
Organic solvents	Insoluble in alcohol ^a	No data	Insoluble in alcohol ^a
Partition coefficients:			
Log K _{ow}	No data	No data	No data
Log K _{oc}	No data	No data	No data
Vapor pressure	No data	No data	No data
Henry's law constant	No data	No data	No data
Autoignition temperature	No data	No data	No data
Flashpoint	No data	No data	No data
Flammability limits	No data	No data	No data
Conversion factors	Not relevant ^f	Not relevant ^f	Not relevant ^f
Explosive limits	No data	Detonates at 260°C ^b	No data
Valence state	+2	+2	+2

4. CHEMICAL AND PHYSICAL INFORMATION

Table 4-2. Physical and Chemical Properties of Lead and Compounds

Property	Lead(II) sulfide	Tetraethyl lead	Lead(II) carbonate
Molecular weight	239.25 ^g	323.45 ^a	267.22 ^g
Color	Metallic black cubic crystals ^g	Colorless ^a	Colorless rhombic crystals ^g
Physical state	Solid	Liquid ^a	Solid
Melting point	1,114°C ^d	No data	315°C (decomposes) ^g
Boiling point	Sublimes at 1,281°C ^d	200 °C; 227.7°C (with decomposition) ^a	No data
Density	7.57–7.59 g/cm ^{3g}	1.653 g/cm ^{3a}	6.6 g/cm ^{3g}
Odor	No data	No data	No data
Odor threshold:	No data	No data	No data
Solubility:			
Water	124.4 mg/L 20°C ^g	0.29 mg/L ⁱ	1.1 mg/L at 20°C ^g
Acid	Soluble in nitric acid ^g	No data	Soluble ^g
Base	Insoluble in alkalis ^d	No data	Soluble in alkalis; insoluble in ammonia ^g
Organic solvents	Insoluble in alcohol ^a	Soluble in benzene, petroleum ether, gasoline; slightly soluble in alcohol ^a	Insoluble in alcohol ^g
Partition coefficients:			
Log K _{ow}	No data	4.15 ^j	No data
Log K _{oc}	No data	No data	No data
Vapor pressure	0.0075 mmHg at 705°C ^b	0.26 mmHg at 25°C ^j	No data
Henry's law constant	No data	No data	No data
Autoignition temperature	No data	No data	No data
Flashpoint	No data	200°F (93°C) (closed cup) ^k	No data
Flammability limits	No data	Lower flammable limit: 1.8% by volume ^k	No data
Conversion factors	Not relevant ^f	No data	Not relevant ^f
Explosive limits	No data	No data	No data
Valence state	+2	+4	+2

^aO'Neil et al. 2013.

^bHaynes 2014.

^cAkvavan 2004.

^dLarrañaga et al. 2016.

^eJacob 2012.

^fSince these compounds exist in the atmosphere in the particulate state, their concentrations are expressed as µg/m³ only.

^gCarr et al. 2004.

^hMolecular weight calculated from atomic weights.

ⁱFeldhake and Stevens 1963.

^jWang et al. 1996.


^kNFPA 2002.

CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE


5.1 OVERVIEW

Pb and Pb compounds have been identified in at least 1,274 and 47 sites, respectively, of the 1,832 hazardous waste sites that have been proposed for inclusion on the EPA National Priorities List (NPL) (ATSDR 2015). However, the number of sites evaluated for Pb is not known. The number of sites in each state is shown in Figures 5-1 and 5-2, respectively. Of these 1,274 sites for Pb, 1,261 are located within the United States, 2 are located in the Virgin Islands, 2 are located in Guam, and 9 are located in Puerto Rico (not shown). All the sites for Pb compounds are only in the United States.


Figure 5-1. Number of NPL Sites with Lead Contamination




Source: ATSDR 2015



5. POTENTIAL FOR HUMAN EXPOSURE

Figure 5-2. Number of NPL Sites with Lead Compound Contamination

Source: ATSDR 2015



- Pb is an element found in concentrated and easily accessible Pb ore deposits that are widely distributed throughout the world.
- The general population may be exposed to Pb in ambient air, foods, drinking water, soil, and dust. For adults, exposure to levels of Pb beyond background are usually associated with occupational exposures.
- For children, exposure to high levels of Pb are associated with living in areas contaminated by Pb (e.g., soil or indoor dust in older homes with Pb paint). Exposure usually occurs by hand-to-mouth activities.
- As an element, Pb does not degrade. However, particulate matter contaminated with Pb can move through air, water, and soil.
- Atmospheric deposition is the largest source of Pb found in soils. Pb is transferred continuously between air, water, and soil by natural chemical and physical processes such as weathering, runoff, precipitation, dry deposition of dust, and stream/river flow; however, soil and sediments appear to be important sinks for Pb.
- Pb adsorbs strongly to most soils, which limits the rate of leaching of Pb from soil. Soil acidity (pH) is the most important factor affecting solubility, mobility, and phytoavailability of Pb in soil.

5. POTENTIAL FOR HUMAN EXPOSURE

Other conditions that increase Pb mobility in soils are reducing conditions (low redox potential; for example, anoxia) and high chloride content.

Pb is dispersed throughout the environment primarily as the result of anthropogenic activities. In the air, Pb is in the form of particles and is removed by rain or gravitational settling. The solubility of Pb compounds in water is a function of pH, ionic strength, and the presence of humic material. Solubility is highest in acidic water. Soil and sediment are an important sink for Pb. Because Pb is strongly adsorbed to soil, very little is transported through runoff to surface water or leached to groundwater except under acidic conditions. Anthropogenic sources of Pb include the mining and smelting of ore, manufacture and use of Pb-containing products, combustion of coal and oil, and waste incineration. Many anthropogenic sources of Pb, most notably leaded gasoline, Pb-based paint, Pb solder in food cans, Pb-arsenate pesticides, and shot and sinkers, have been eliminated or are regulated. Pb compounds released to the environment may be transformed to other Pb compounds; however, Pb is an element and cannot be destroyed or degraded. Because Pb does not degrade over time, deposits of Pb in the environment by current and former uses leave their legacy as higher concentrations of Pb in the environment. These deposits can continue to be a source for potential Pb exposure (e.g., soil particles containing Pb also may be resuspended and redeposited). Plants and animals may bioconcentrate Pb, but Pb is not biomagnified in the aquatic or terrestrial food chain.

The general population may be exposed to Pb in ambient air, foods, drinking water, soil, and dust. Segments of the general population at highest risk of health effects from Pb exposure are preschool-age children and pregnant women and their fetuses. Other segments of the general population with an increased exposure include individuals living near sites where Pb was produced or disposed. Some of the more important Pb exposures have occurred as a result of living in urban environments, particularly in areas near stationary emission sources (e.g., smelters); renovation of homes containing Pb-based paint; pica (the compulsive, habitual consumption of nonfood items); contact with interior Pb paint dust; occupational exposure; and secondary occupational exposure (e.g., families of workers in Pb industries). Higher exposures may also occur to residents living in close proximity to NPL sites that contain elevated levels of Pb.

The primary source of Pb in the environment has historically been anthropogenic emissions to the atmosphere. In 1984, combustion of leaded gasoline was responsible for approximately 90% of all anthropogenic Pb emissions. The United States gradually phased out the use of Pb alkyls in gasoline, and by 1990, auto emissions accounted for only 33% of the annual Pb emissions (EPA 1996b). Use of Pb

5. POTENTIAL FOR HUMAN EXPOSURE

additives in most motor fuels was totally banned after December 31, 1995 (EPA 1996a). The ban went into effect on February 2, 1996. The ban did not include off-road vehicles, including aircraft, racing cars, farm equipment, and marine engines. Pb additives are still used in fuels for piston driven airplane engines and it continues to be commercially available for other off-road uses. Atmospheric deposition is the largest source of Pb found in soils. Pb is transferred continuously between air, water, and soil by natural chemical and physical processes such as weathering, runoff, precipitation, dry deposition of dust, and stream/river flow; however, soil and sediments appear to be important sinks for Pb. Pb particles are removed from the atmosphere primarily by wet and dry deposition. The average residence time in the atmosphere is 10 days. Over this time, long-distance transport, up to thousands of kilometers, may take place. The speciation of Pb in these media varies widely depending upon such factors as temperature, pH, and the presence of humic materials. Pb is largely associated with suspended solids and sediments in aquatic systems, and it occurs in relatively immobile forms in soil.

5.2 PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL

5.2.1 Production

The most important mineable Pb ore is galena (PbS), which is commonly associated with other minerals, typically zinc ores. Anglesite (PbSO₄) and cerussite (PbCO₃), formed by the weathering of galena, are two other important Pb minerals. Pb is processed from ore to refined metal in four steps: ore dressing; smelting; drossing; and refining. Ore dressing involves crushing, grinding, and beneficiation (concentration) (King et al. 2014).

Since 1998, U.S. production of Pb has shifted to the domestic secondary Pb industry (USGS 2014). Since 2014, primary Pb metal has not been produced in the United States (USGS 2016). The Doe Run Resources Corporation operated the last domestic primary Pb smelter-refinery facility in the United States at Herculaneum, Missouri and it was closed at the end of 2013. Pb-acid batteries are the dominant source of recoverable Pb scrap, accounting for 98% of all secondary Pb (USGS 2016).

Domestic mines produced 368,000 metric tons of recoverable Pb in 2014, a more than 11% increase from 2013. Nearly all of the secondary Pb produced in 2014 was by 7 companies operating 12 plants in Alabama, California, Florida, Indiana, Minnesota, Missouri, New York, Pennsylvania, Tennessee, and Texas (USGS 2016). Secondary (recycled) Pb, derived from mainly scrapped Pb-acid batteries, accounted for all of the domestic refined Pb production in 2014. Due to plant closings, U.S. production

5. POTENTIAL FOR HUMAN EXPOSURE

of secondary refined Pb decreased in 2014 by 11% to 1.02 metric tons, from 1.5 metric tons in 2013 (USGS 2016).

World mine production of Pb was 4.91 million metric tons in 2014, a decrease of 9% from 2013. The United States accounted for approximately 8% of global mine production in 2014. The United States ranked third in global mine production behind China and Australia, which accounted for 49 and 15%, respectively. World production of refined Pb (primary and secondary) was 10.6 million metric tons in 2014. China produced about 45% of global refined Pb in 2014 with the United States as the second leading world producer of refined Pb, accounting for 10% (USGS 2016).

Manufacturers and importers of Pb metal and selected Pb compounds are listed in Table 5-1. These data are from EPA's Chemical Data Access Tool, which provides information on chemicals submitted to the EPA under the Toxic Substance Control Act that are manufactured or imported into the United States. Table 5-2 shows the U.S. production volumes for Pb for 2010 through 2013.

Table 5-1. Current U.S. Manufacturers of Lead Metal and Selected Lead Compounds

Company	Location	Domestic manufacturing (pounds/year)
Lead		
5n Plus Inc.	Fairfield, Connecticut	36,671
Colfin Specialty Steel Corp.	New Brighton, Pennsylvania	2,552
Compliance Administrators & Project Services Inc.	Bloomington, California	848,008
Concorde/Interspace Battery	West Covina, California	348,998
Doe Run Co.	Herculaneum, Missouri	280,000,000
East Penn Manufacturing Co. Inc.	Lyon Station, Pennsylvania	194,537,569
Exide Technologies	Bristol, Tennessee	150,000
	Columbus, Georgia	4,200,000
	Forest City, Missouri	84,000,000
	Fort Smith, Arkansas	3,600,000
	Frisco, Texas	140,000,000
	Kansas City, Kansas	9,100,000
	Los Angeles, California	230,000,000
	Manchester, Iowa	16,000,000
Muncie, Indiana	160,000,000	
Reading, Pennsylvania	130,000,000	

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-1. Current U.S. Manufacturers of Lead Metal and Selected Lead Compounds

Company	Location	Domestic manufacturing (pounds/year)
	Salina, Kansas	990,000
Gopher Resource	Eagan, Minnesota	310,000,000
	Tampa, Florida	38,000,000
Horsehead Holding Corp.	Chicago, Illinois	2,444,492
	Palmerton, Pennsylvania	3,867,016
	Rockwood, Tennessee	1,872,054
	Snelling, South Carolina	2,012,236
Johnson Controls	Canby, Oregon	36,832,250
	Geneva, Illinois	47,025,828
	Holland, Ohio	82,721,150
	Kernersville, North Carolina	204,679,893
	Middletown, Delaware	86,732,852
	Tampa, Florida	3,069,380
	Yuma, Arizona	359,977,380
Johnson Controls Distribution Center	Saint Joseph, Missouri	2,550,177
	St. Joseph, Missouri	266,151,342
Renco Group Inc.	Boss, Missouri	310,000,000
Sanders Lead Co., Inc.	Troy, Alabama	471,954,520
Stemar Investments Inc.	Butler, Pennsylvania	40,506
Yuasa Battery Inc.	Laureldale, Pennsylvania	1,492,754
Lead(II) nitrate		
American Pacific Corp.	Cedar City, Utah	42,500
Lead(II) oxide		
C&D Technologies Inc.	Attica, Indiana	18,657,255
	Leola, Pennsylvania	1,348,311
	Milwaukee, Wisconsin	48,491,557
Crown Battery Manufacturing Co.	Fremont, Ohio	25,600,000
Fiamm Energy LLC	Waynesboro, Georgia	4,700,000
Hammond Group Inc.	Hammond, Indiana	3,585,529
	Pottstown, Pennsylvania	8,287,521
Renco Group Inc.	Boss, Missouri	7,700,000
Steel Dust Recycling	Millport, Alabama	2,000,000
Superior Battery Manufacturing	Russell Springs, Kentucky	16,866,793
Trojan Battery Co.	Lithonia, Georgia	38,540,700
	Santa Fe Springs, California	35,241,500

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-1. Current U.S. Manufacturers of Lead Metal and Selected Lead Compounds

Company	Location	Domestic manufacturing (pounds/year)
Lead(II) styphnate		
Alliant Techsystems Inc.	Lewiston, Idaho	78,767
Alliant Techsystems Operations LLC	Independence, Missouri	43,489
Lead(II) sulfate		
Crown Battery Manufacturing Co.	Fremont, Ohio	768,000
East Penn Manufacturing Co., Inc.	Corydon, Iowa	17,006,710
	Lyon Station, Pennsylvania	220,436,420
Johnson Controls	Canby, Oregon	6,098,880
	Geneva, Illinois	11,340,306
	Holland, Ohio	10,714,048
	Middletown, Delaware	5,749,910
	Tampa, Florida	5,506,240
	Yuma, Arizona	86,756
Johnson Controls Distribution Center	Saint Joseph, Missouri	306,021
	St. Joseph, Missouri	29,577,055
Palos Verdes Bldg Corp.	Augusta, Georgia	6,904,629
Superior Battery Manufacturing	Russell Springs, Kentucky	22,905,105
Trojan Battery Co.	Lithonia, Georgia	58,127,100
	Santa Fe Springs, California	53,083,500
Lead(II) chloride		
Horsehead Holding Corp.	Monaca, Pennsylvania	1,891,700
	Palmerton, Pennsylvania	11,484,955

Source: EPA 2014d.

Table 5-2. U.S. Lead Production 2010–2013

Production volumes in metric tons			
2010	2011	2012	2013
356,000	334,000	336,000	331,000
115,000	118,000	111,000	114,000
1,140,000	1,130,000	1,110,000	1,150,000

Source: USGS 2016

5. POTENTIAL FOR HUMAN EXPOSURE

Tables 5-3 (Pb) and 5-4 (Pb compounds) list the facilities in each state that manufacture or process Pb or Pb compounds, the intended use, and the range of maximum amounts of Pb that are stored on site. The data listed in Tables 5-3 and 5-4 are derived from the Toxics Release Inventory (TRI) (TRI15 2017). The data presented in Table 5-3 are for Pb metal and the data from Table 5-4 are for all Pb compounds. Facilities with ≥ 10 full-time employees in certain TRI-covered industry sectors (e.g., manufacturing) must submit data on releases and other waste management for TRI-listed chemicals (Pb and Pb compounds are TRI listed). Therefore, there are sources for Pb and Pb compounds not contained in the TRI database. In comparing TRI data with that of previous years, it is important to note that starting in 2001, the threshold for reporting Pb and all Pb compounds was reduced to 100 pounds, except for lead contained in a stainless steel, brass, or bronze alloy. Previously, reporting was only required of facilities that manufactured or processed $>25,000$ pounds annually or that used $>10,000$ pounds annually. Beginning in 1998, additional industries were required to report, including metal mining, coal mining, electrical utilities, and Resource Conservation and Recovery Act (RCRA)/Solvent Recovery. Table 5-1 lists the producers of primary Pb metal and selected Pb compounds. Companies listed are those producing Pb compounds in commercial quantities $>5,000$ pounds or \$10,000 in value annually. Table 5-2 shows the U.S. production volumes for Pb for 2010 through 2013. During this time, the primary Pb production declined, while secondary Pb production was relatively constant.

Table 5-3. Facilities that Produce, Process, or Use Lead

State ^a	Number of facilities	Minimum amount on site in pounds ^b	Maximum amount on site in pounds ^b	Activities and uses ^c
AK	5	100	99,999	12
AL	105	0	499,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
AR	66	0	999,999	1,2,3,4,6,7,8,9,11,12,13,14
AZ	63	0	9,999,999	1,2,3,5,7,8,9,10,11,12,13,14
CA	214	0	9,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
CO	33	0	99,999	1,2,5,7,8,9,11,12,13,14
CT	53	0	99,999	1,2,3,5,6,7,8,9,10,11,12,13,14
DC	5	0	9,999	1,8,11,12,13,14
DE	5	0	99,999	12,14
FL	188	0	999,999	1,2,3,5,6,7,8,9,10,11,12,13,14
GA	114	0	999,999	1,2,3,5,6,7,8,9,10,11,12,13,14
GU	2	100	9,999	12
HI	4	10,000	999,999	12
IA	108	0	9,999,999	1,2,4,5,7,8,9,10,11,12,13,14
ID	30	0	9,999,999	1,2,3,4,5,8,9,11,12,13,14
IL	242	0	999,999	1,2,3,4,5,7,8,9,11,12,13,14

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-3. Facilities that Produce, Process, or Use Lead

State ^a	Number of facilities	Minimum amount on site in pounds ^b	Maximum amount on site in pounds ^b	Activities and uses ^c
IN	169	0	999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
KS	64	0	49,999,999	1,3,5,7,8,9,10,11,12,13,14
KY	83	0	999,999	1,2,3,4,5,6,7,8,9,11,12,13,14
LA	56	0	999,999	1,2,3,5,6,8,9,10,11,12,13,14
MA	62	0	999,999	1,2,3,4,5,7,8,9,11,12,14
MD	35	0	49,999,999	1,5,7,8,9,11,12,14
ME	22	0	999,999	1,2,3,4,5,8,9,11,12,13,14
MI	155	0	999,999	1,2,3,4,5,7,8,9,10,11,12,13,14
MN	140	0	99,999	1,2,3,5,7,8,9,10,11,12,13,14
MO	95	0	499,999,999	2,3,5,6,7,8,9,10,11,12,13,14
MS	46	0	999,999	1,2,3,5,8,9,11,12,13,14
MT	13	0	99,999	1,2,5,12,13,14
NC	167	0	49,999,999	1,2,3,5,6,7,8,9,10,11,12,13,14
ND	19	0	9,999	1,5,8,9,11,12,14
NE	69	0	999,999	1,2,3,5,7,8,9,11,12,13,14
NH	36	0	99,999	1,2,3,4,5,7,8,9,11,12,14
NJ	48	0	99,999	1,2,3,5,7,8,9,11,12,13,14
NM	18	0	999,999	8,11,12
NV	25	0	999,999	1,2,4,5,8,9,11,12,13,14
NY	149	0	9,999,999	1,2,3,5,7,8,9,10,11,12,13,14
OH	266	0	9,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
OK	56	0	99,999,999	1,2,3,5,6,7,8,9,11,12,13,14
OR	54	0	9,999,999	1,2,3,4,5,7,8,10,11,12,13,14
PA	193	0	99,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
PR	8	0	9,999	1,5,7,8,9,11,12
RI	16	0	999,999	1,5,6,7,8,9,10,11,12,13,14
SC	90	0	999,999	1,2,3,4,5,7,8,9,10,11,12,13,14
SD	19	0	99,999	1,5,8,9,12,14
TN	107	0	999,999	1,2,3,4,5,6,7,8,9,11,12,13,14
TX	335	0	9,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
UT	35	0	99,999	1,5,7,8,9,11,12,13,14
VA	114	0	999,999	1,2,3,4,5,7,8,9,10,11,12,13,14
VT	10	0	99,999	1,2,3,5,7,8,9,11,12,13,14
WA	69	0	9,999,999	1,2,3,4,5,7,8,9,10,11,12,13,14
WI	170	0	999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
WV	34	0	999,999	1,2,3,5,7,8,9,11,12,13,14

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-3. Facilities that Produce, Process, or Use Lead

State ^a	Number of facilities	Minimum amount on site in pounds ^b	Maximum amount on site in pounds ^b	Activities and uses ^c
WY	15	0	99,999	1,2,4,5,6,8,9,10,12,14

^aPost office state abbreviations used.

^bMinimum and maximum amounts on site reported for the compilation of all facilities in each state.

^cActivities/Uses:

- | | | |
|--------------------------|--------------------------|-----------------------------|
| 1. Produce | 6. Impurity | 11. Chemical Processing Aid |
| 2. Import | 7. Reactant | 12. Manufacturing Aid |
| 3. Onsite use/processing | 8. Formulation Component | 13. Ancillary/Other Uses |
| 4. Sale/Distribution | 9. Article Component | 14. Process Impurity |
| 5. Byproduct | 10. Repackaging | |

Source: TRI15 2017 (Data are from 2015)

Table 5-4. Facilities that Produce, Process, or Use Lead Compounds

State ^a	Number of facilities	Minimum amount on site in pounds ^b	Maximum amount on site in pounds ^b	Activities and uses ^c
AK	19	0	499,999,999	1,5,7,9,12,13,14
AL	129	0	499,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
AR	65	0	49,999,999	1,2,3,4,5,6,7,8,9,11,12,13,14
AZ	60	0	9,999,999	1,2,3,4,5,7,8,9,10,11,12,13,14
CA	301	0	49,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
CO	63	0	9,999,999	1,2,3,4,5,7,8,9,11,12,13,14
CT	37	0	49,999,999	1,3,5,6,7,8,9,10,11,12,13,14
DC	1	100,000,000	499,999,999	12
DE	8	100	49,999,999	1,2,3,4,5,7,8,9,12,13,14
FL	157	0	499,999,999	1,2,3,4,5,7,8,9,10,11,12,13,14
GA	100	0	9,999,999	1,2,3,4,5,6,7,8,9,11,12,13,14
GU	3	0	99	1,5,7,9,12,13,14
HI	12	0	99,999	1,2,5,7,9,12,13,14
IA	58	0	49,999,999	1,2,3,4,5,7,8,9,12,13,14
ID	28	0	499,999,999	1,2,3,4,5,7,8,9,11,12,13,14
IL	170	0	49,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
IN	163	0	99,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
KS	38	0	49,999,999	1,2,3,4,5,6,7,8,9,11,12,13,14
KY	74	0	9,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
LA	86	0	99,999,999	1,2,3,4,5,7,8,9,10,11,12,13,14
MA	60	0	49,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
MD	34	0	99,999,999	1,2,3,4,5,7,8,9,11,12,13,14
ME	12	0	999,999	1,5,8,9,12,13,14
MI	121	0	999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-4. Facilities that Produce, Process, or Use Lead Compounds

State ^a	Number of facilities	Minimum amount on site in pounds ^b	Maximum amount on site in pounds ^b	Activities and uses ^c
MN	56	0	49,999,999	1,2,3,4,5,6,7,8,9,10,12,13,14
MO	73	0	10,000,000,000	1,2,3,4,5,6,7,8,9,11,12,13,14
MP	1	0	99	1,5,12,13,14
MS	72	0	9,999,999	1,2,3,4,5,6,7,8,9,12,13,14
MT	23	0	10,000,000,000	1,2,3,5,6,7,9,12,13,14
NC	130	0	49,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
ND	23	0	99,999	1,2,3,4,5,7,9,10,12,13,14
NE	23	0	999,999	1,3,4,5,6,7,8,9,12,13,14
NH	18	0	999,999	1,2,5,7,8,9,11,12,13,14
NJ	56	0	999,999	1,2,3,4,5,7,8,9,11,12,13,14
NM	16	0	9,999,999	1,2,3,4,5,7,8,9,10,11,12,13,14
NV	52	0	499,999,999	1,2,3,5,6,7,8,9,10,11,12,13,14
NY	84	0	49,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
OH	201	0	49,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
OK	94	0	9,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
OR	50	0	9,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
PA	215	0	99,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
PR	12	0	99,999	1,2,3,4,5,7,8,9,12,13
RI	19	0	99,999	1,2,3,4,5,7,8,9,10,11,12,13,14
SC	99	0	49,999,999	1,2,3,4,5,6,7,8,9,11,12,13,14
SD	13	0	9,999,999	1,3,4,5,6,7,8,9,12,13,14
TN	92	0	9,999,999	1,2,3,4,5,6,7,8,9,11,12,13,14
TX	322	0	499,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
UT	40	0	499,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
VA	82	0	49,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
VI	1	0	99	1,5
VT	5	0	9,999	7,8,14
WA	79	0	9,999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
WI	106	0	999,999	1,2,3,4,5,6,7,8,9,10,11,12,13,14
WV	48	0	999,999	1,2,3,4,5,7,8,9,11,12,13,14
WY	13	0	999,999	1,2,3,4,5,8,9,12,13,14

^aPost office state abbreviations used.

^bMinimum and maximum amounts on site reported for the compilation of all facilities in each state.

^cActivities/Uses:

- | | | |
|--------------------------|--------------------------|-----------------------------|
| 1. Produce | 6. Impurity | 11. Chemical Processing Aid |
| 2. Import | 7. Reactant | 12. Manufacturing Aid |
| 3. Onsite use/processing | 8. Formulation Component | 13. Ancillary/Other Uses |
| 4. Sale/Distribution | 9. Article Component | 14. Process Impurity |
| 5. Byproduct | 10. Repackaging | |

Source: TRI15 2017 (Data are from 2015)

5. POTENTIAL FOR HUMAN EXPOSURE

5.2.2 Import/Export

In 2014, 1,080 and 593,000 metric tons of Pb as base bullion and pigs and bars, respectively, were imported into the United States. Imports have increased since 2010 when 602 and 271,000 metric tons of Pb as base bullion and pigs and bars, respectively, were imported. In 2014, 65,100 metric tons, Pb content of Pb pigments and compounds were imported in the United States (USGS 2016).

Exports of Pb in ore and concentrates and Pb materials, excluding scrap were 299,000 and 83,500 metric tons, respectively, in 2010 as compared to 365,000 and 61,300 metric tons, respectively, in 2014. In 2013 and 2014, 34,900 and 36,400 metric tons of Pb scrap were exported, respectively (USGS 2016).

5.2.3 Use

Pb may be used in the form of metal, either pure or alloyed with other metals, or as chemical compounds. The main uses of Pb and its compounds are in Pb-acid batteries, with most other applications using Pb alloys. The commercial importance of Pb is based on its physical properties, including its low melting point, ease of casting, high density, softness, malleability, low strength, ease of fabrication, acid resistance, electrochemical reaction with sulfuric acid, and chemical stability in air, water, and soil (King et al. 2014).

In the United States in 2014, Pb was consumed by over 70 companies to manufacture products such as ammunition; building-construction materials; covering for power and communication cable; Pb-acid storage batteries; Pb oxides for ceramics, chemicals, glass, and pigments; Pb sheet; and solder for construction, electronic components and accessories, metal containers, and motor vehicles (USGS 2016). The majority of U.S. Pb consumption (88%) was in the Pb-acid battery industry. Pb-acid batteries were primarily used as starting-lighting-ignition (SLI) batteries for automobiles and trucks and as industrial-type batteries for standby power for computer and telecommunications networks and for motive power. Global consumption of refined Pb was 10.9 million metric tons in 2014, with leading consumers: China (43%); United States (15%); India (5%); Republic of Korea (5%); and Germany (3%) (USGS 2016).

Prior to the EPA beginning to regulate the Pb content in gasoline during the early 1970s, approximately 250,000 tons of organic Pb (e.g., tetraethyl Pb) were added to gasoline on an annual basis in the United States (Giddings 1973). These Pb-based “anti-knock” additives increased the octane rating of the gasoline and, as a result, increased engine efficiency (Giddings 1973). In 1971, the average Pb content

5. POTENTIAL FOR HUMAN EXPOSURE

for a gallon of gasoline purchased in the United States was 2.2 g/gallon (Giddings 1973). After determining that Pb additives would impair the performance of emission control systems installed on motor vehicles, and that Pb particle emission from motor vehicles presented a significant health risk to urban populations, EPA, in 1973, initiated a phase-down program designed to minimize the amount of Pb in gasoline over time. By 1988, the phase-down program had reduced the total Pb usage in gasoline to <1% of the amount of Pb used in the peak year of 1970 (EPA 1996a).

In 1990, a Congressional amendment to the Clean Air Act (CAA) banned the use of gasoline containing Pb or Pb additives as fuel in most motor vehicles. On February 2, 1996, the EPA incorporated the statutory ban in a direct final rule, which defined unleaded gasoline as gasoline containing trace amounts of Pb up to 0.05 g/gallon (EPA 1996a). The definition still allowed trace amounts of Pb, but expressly prohibited the use of any Pb additive in the production of unleaded gasoline. The term “lead additive” was defined to include pure Pb as well as Pb compounds (EPA 1996a). Although the regulatory action of Congress banned the use of leaded gasoline as fuel in motor vehicles, it did not restrict other potential uses of gasoline containing Pb or Pb additives (EPA 1996a). Gasoline produced with Pb additives continues to be made and marketed for use as fuels in aircraft, race cars, and non-road engines such as farm equipment engines and marine engines to the extent allowed by law (EPA 1996a), but tetraethyl Pb has not been produced in the United States since March 1991. All gasoline sold for motor vehicle use since January 1, 1996 has been unleaded (EPA 1997a).

Table 5-5 lists the uses of the specific Pb compounds identified in Chapter 4.

Table 5-5. Current and Former Uses of Selected Lead Compounds

Compound	Uses
Lead(II) acetate	Dyeing of textiles, waterproofing, varnishes, lead driers, chrome pigments, gold cyanidation process, insecticide, anti-fouling paints, analytical reagent, hair dye
Lead(II) azide	Primary detonating compound for high explosives, firing of Pb-based ammunition
Lead(II) bromide	Photopolymerization catalyst, inorganic filler in fire-retardant plastics, general purpose welding flux
Lead(II) carbonate	Polymerization catalyst, component of high pressure lubricating greases, coating on vinyl chloride polymers
Lead(II) chloride	Preparation of lead salts, lead chromate pigments, analytical reagent
Lead(II) chromate	Pigment in industrial paints, rubber, plastics, ceramic coatings; organic analysis

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-5. Current and Former Uses of Selected Lead Compounds

Compound	Uses
Lead(II) tetrafluoroborate	Salt for electroplating lead; can be mixed with stannous fluoborate to electroplate any composition of tin and lead as an alloy
Lead(II) iodide	Bronzing, printing, photography, cloud seeding
Lead molybdenum chromate	Analytical chemistry, pigments
Lead(II) nitrate	Lead salts, mordant in dyeing and printing calico, matches, mordant for staining mother of pearl, oxidizer in the dye industry, sensitizer in photography, explosives, tanning, process engraving, and lithography
Lead(II) oxide	Storage batteries, ceramic cements and fluxes, pottery and glazes, glass, chromium pigments, oil refining, varnishes, paints, enamels, assay of precious metal ores, manufacture of red lead, cement (with glycerol), acid-resisting compositions, match-head compositions, other lead compounds, rubber accelerator
Lead(II) phosphate	Stabilizing agent in plastics
Lead(II) styphnate	Primary explosive, firing of Pb-based ammunition
Lead(II) sulfate	Storage batteries, paints, ceramics, pigments, electrical and other vinyl compounds requiring high heat stability
Lead(II) sulfide	Ceramics, infrared radiation detector, semi-conductor, ceramic glaze, source of lead
Tetraethyl lead	Anti-knock agent in aviation gasoline

Sources: Boileau et al. 1987; Carr 1995; Carr et al. 2004; Davidson et al. 2014

Pb arsenate, basic Pb arsenate, and Pb arsenite were formerly used as herbicides, insecticides, or rodenticides. Until the 1960s, they were widely used to control pests in fruit orchards, especially apple orchards (EPA 2002c; PAN Pesticides Database 2004; Peryea 1998; Wisconsin Department of Health and Family Services 2002). All insecticidal use of Pb arsenate was officially banned on August 1, 1988. However, all registrations for its insecticidal use had lapsed before that time.

5.2.4 Disposal

Secondary (recycled) Pb, derived mainly from scrapped Pb-acid batteries, accounted for 100% of refined Pb production in the United States in 2014. Almost all of the Pb recycled in 2014 was recovered by 7 companies operating 12 plants in Alabama, California, Florida, Indiana, Minnesota, Missouri, New York, Pennsylvania, Tennessee, and Texas (USGS 2016). More than 99% of all battery Pb is recycled and new batteries contain between 60 and 80% recycled Pb and plastic, respectively (Battery Council International 2016a). Scrap Pb is also recovered from dross, dust, residue, and sludge generated by smelting of metals, Pb pipe and sheet, printing materials, sheaths from power and telephone cable, and vehicle wheel weights (USGS 2014).

5. POTENTIAL FOR HUMAN EXPOSURE

Disposal of wastes containing Pb or Pb compounds is controlled by several federal regulations (see Chapter 7). Pb is listed as a toxic substance under Section 313 of the Emergency Planning and Community Right to Know Act (EPCRA) under Title III of the Superfund Amendments and Reauthorization Act (SARA) (EPA 1988). Pb-containing waste products include storage batteries, ammunition waste, ordnance, sheet Pb, solder, pipes, traps, and other metal products; solid waste and tailings from Pb mining; items covered with Pb-based paint; and solid wastes created by mineral ore processing, iron and steel production, copper and zinc smelting, and the production and use of various Pb-containing products (EPA 1982a).

There is currently no federal regulation for battery recycling in the United States (Gies 2015). However, 38 states have adopted battery recycling laws and 5 others have disposal bans (Battery Council International 2016b). The Mercury-Containing and Rechargeable Battery Management Act (the Battery Act) of 1996 removed certain barriers to the recycling of batteries including small, sealed lead acid (SSLA) batteries (EPA 2002b). The intent was to provide the efficient and cost-effective collection and recycling or proper disposal of batteries to keep them out of the waste stream. The Act established uniform national labeling requirements, mandated that batteries under the Act be “easily removable” from consumer products where possible, made the Universal Waste Rule effective in all 50 states for the collection, storage, and transportation of batteries covered by the Battery Act, and required EPA to establish a public education program on battery recycling and the proper handling and disposal of used batteries (EPA 1997a).

According to data from the TRI, total disposal of Pb and Pb compounds varied during the period of 2005–2015 from 387 million pounds in 2009 to 832 million pounds in 2013, with an overall increase of 20% during this time period. The metal mining sector contributes most to the disposal of Pb and Pb compounds, with metal mines reporting 85% of total Pb and Pb compound releases in 2015.

5.3 RELEASES TO THE ENVIRONMENT

Facilities with ≥ 10 full-time employees in certain industry sectors (e.g., manufacturing) covered by the TRI (e.g., manufacturing) must submit data to TRI on releases and other waste management for TRI-listed chemicals (Pb and Pb compounds are TRI listed). Therefore, TRI data do not reflect all sources of Pb releases (EPA 2005a). TRI-covered facilities are required to report information to the TRI only if they employ the equivalent of ≥ 10 full-time employees; if their facility is included in Standard Industrial

5. POTENTIAL FOR HUMAN EXPOSURE

Classification (SIC) Codes 10 (except 1011, 1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to facilities that combust coal and/or oil for the purpose of generating electricity for distribution in commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, imports, or processes >25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI chemical in a calendar year (EPA 2005a).

Starting in 2001, the threshold to trigger reporting of Pb in most Pb compounds was reduced to 100 pounds. The higher threshold still applies to Pb contained in stainless steel, brass, or bronze alloys. The threshold for Pb is determined using the weight of the metal, whereas the threshold for Pb compounds is determined by the weight of the entire compound. Prior to 1998, only facilities classified within the SIC codes 20–39 (Manufacturing Industries) were required to report. After 1998, the industries required to report were enlarged to include other industrial sectors, such as metal mining, coal mining, electrical utilities, and hazardous waste treatment (EPA 2001).

Pb is a naturally-occurring element that is typically found combined in various minerals. It occurs in the Earth's crust primarily as the mineral galena (PbS), and to a lesser extent as anglesite (PbSO₄) and cerussite (PbCO₃) (Carr et al. 2004; Davidson et al. 2014; Haynes 2014). Pb minerals are found in association with zinc, copper, and iron sulfides as well as gold, silver, bismuth, and antimony minerals. It also occurs as a trace element in coal, oil, and wood. Typical Pb concentrations in some ores and fuels are: copper ores, 11,000 ppm; Pb and zinc ores, 24,000 ppm; gold ores, 6.60 ppm; bituminous coal, 3–111 ppm; crude oil, 0.31 ppm; No. 6 fuel oil, 1 ppm; and wood, 20 ppm (EPA 2001).

Leaded gasoline remains commercially available for off-road uses, including aircraft, racing cars, farm equipment, and marine engines. Currently, the largest contributor to atmospheric Pb emissions in the United States is piston-engine aircraft emissions (NEI data 2014). Industrial sources of Pb can result from the mining and smelting of Pb ores, as well as other ores in which Pb is a byproduct or contaminant. Fuel combustion also contributes to releases of Pb to the environment. As a result of these processes, Pb may be released to land, water, and air. Many of the anthropogenic sources of Pb have been eliminated or phased out because of Pb's persistence, bioaccumulative nature, and toxicity. These include Pb-based paint in 1978, Pb-containing pesticides in 1988, and Pb in gasoline for use in on-road vehicles in 1996. In

5. POTENTIAL FOR HUMAN EXPOSURE

early 2017, the use of Pb ammunition and Pb sinkers was banned on most federal lands; however, this ban was temporarily halted soon after. Because Pb does not degrade and remains in the environment long after its release, these former uses continue to be a potential source for Pb exposure.

5.3.1 Air

According to the TRI, in 2015, a total of 99,738 pounds of Pb were released to air from 4,252 reporting facilities (TRI15 2017). In addition, a total of 290,444 pounds of Pb compounds were released to air from 3,873 reporting facilities (TRI15 2017). Tables 5-6 and 5-7 list amounts of Pb and Pb compounds released from these facilities grouped by state, respectively.

Table 5-6. Releases to the Environment from Facilities that Produce, Process, or Use Lead^a

Reported amounts released in pounds per year ^b									
State ^c	RF ^d	Air ^e	Water ^f	UI ^g	Land ^h	Other ⁱ	Total release		
							On-site ^j	Off-site ^k	On- and off-site
AK	5	0	0	0	20,505	0	20,505	0	20,505
AL	105	2,504	908	1	2,014,146	8,978	2,015,775	10,761	2,026,537
AR	66	1,355	120	0	90,130	3,264	91,143	3,726	94,869
AZ	63	307	626	0	116,359	92	94,025	23,359	117,384
CA	204	523	2,044	0	527,218	47,338	523,315	53,808	577,122
CO	33	40	14	0	118,225	2,856	118,057	3,078	121,135
CT	53	86	412	0	2,240	10,650	2,253	11,136	13,389
DC	5	349	1	0	124	300	349	424	774
DE	5	8	3	196	16,110	39	16,121	235	16,356
FL	186	344	161	5	91,265	10,371	53,596	48,549	102,145
GA	114	381	1,139	1	78,152	11,450	77,789	13,333	91,123
GU	2	1	0	0	7,679	0	7,680	No data	7,680
HI	4	0	0	0	104,522	0	104,522	No data	104,522
IA	108	586	75	49	6,405	18,008	4,695	20,428	25,123
ID	30	191	3	0	618,847	15,330	618,421	15,951	634,372
IL	242	2,272	753	0	788,245	33,476	761,987	62,759	824,746
IN	167	2,113	356	102	382,724	1,258,386	5,208	1,638,473	1,643,681
KS	64	785	35	0	48,740	4,208	30,304	23,463	53,768
KY	83	1,974	626	0	29,619	2,654	25,655	9,219	34,873
LA	56	391	719	0	37,749	481	35,790	3,550	39,340
MA	62	54	1,554	73	76,950	23,321	42,215	59,738	101,953
MD	34	44,602	7	0	21,258	314	63,754	2,426	66,181

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-6. Releases to the Environment from Facilities that Produce, Process, or Use Lead^a

Reported amounts released in pounds per year ^b									
State ^c	RF ^d	Air ^e	Water ^f	UI ^g	Land ^h	Other ⁱ	Total release		On- and off-site
							On-site ^j	Off-site ^k	
ME	21	5	45	0	8,597	80,670	29	89,288	89,317
MI	152	5,740	641	50	52,619	8,731	34,680	33,102	67,781
MN	140	505	225	22	5,893	2,747	966	8,426	9,392
MO	95	504	65	3	144,956	926	128,775	17,679	146,454
MS	45	1,327	50	0	66,575	1,096	67,096	1,952	69,048
MT	12	19	1	0	49,209	5	48,823	411	49,234
NC	167	409	708	336	113,962	28,503	21,458	122,459	143,917
ND	18	3	66	0	1,370	55	1,412	82	1,494
NE	67	3,805	104	0	150,180	15,920	84,281	85,728	170,009
NH	36	29	11	0	1,649	514	1,136	1,068	2,203
NJ	48	202	31	110	2,706	3,393	1,437	5,004	6,441
NM	18	13	59	0	18,016	1,068	16,735	2,422	19,157
NV	23	257	0	0	743,402	1,263	743,652	1,271	744,922
NY	148	1,168	539	0	38,390	36,515	30,029	46,584	76,613
OH	265	7,419	1,192	1,556	257,007	87,544	230,813	123,905	354,718
OK	56	735	599	2	62,170	2,274	62,818	2,962	65,780
OR	54	95	54	0	1,095,773	1,217	1,093,593	3,545	1,097,138
PA	193	6,806	2,002	246	18,659	533,974	16,014	545,673	561,687
PR	8	4	0	0	5,223	513	5,227	514	5,741
RI	15	7	2	0	10	2,686	7	2,699	2,706
SC	89	1,057	443	838	165,256	2,991	153,116	17,468	170,585
SD	19	6	3	0	3	406	6	412	417
TN	106	1,311	559	1	40,231	5,135	26,058	21,179	47,238
TX	334	2,266	689	69,633	354,930	18,646	401,712	44,452	446,164
UT	34	165	9	0	82,700	47,137	81,008	49,003	130,011
VA	107	1,783	555	76	166,683	38,940	114,534	93,503	208,037
VT	10	1	5	0	12,135	886	12,116	911	13,027
WA	66	117	63	0	3,273,169	137,911	3,246,153	165,107	3,411,260
WI	169	4,756	294	0	42,076	14,652	4,876	56,901	61,777
WV	33	272	2	125	151,600	2,049	147,302	6,745	154,047

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-6. Releases to the Environment from Facilities that Produce, Process, or Use Lead^a

Reported amounts released in pounds per year ^b									
State ^c	RF ^d	Air ^e	Water ^f	UI ^g	Land ^h	Other ⁱ	Total release		
							On-site ^j	Off-site ^k	On- and off-site
WY	13	86	78	0	42,417	0	39,607	2,974	42,581
Total	4,252	99,738	18,648	73,425	12,364,781	2,529,881	11,528,626	3,557,847	15,086,473

^aThere are sources for release other than those reported to TRI. This chart reflects information provided to TRI. Data are rounded to nearest whole number.

^bData in TRI are total amounts released by each facility.

^cPost office state abbreviations are used.

^dNumber of reporting facilities.

^eThe sum of fugitive and point source releases are included in releases to air by a given facility.

^fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal and metal compounds).

^gUnderground injection Class I wells and Class II-V wells.

^hResource Conservation and Recovery Act (RCRA) Subtitle C landfills; other onsite landfills, land treatment, surface impoundments, other land disposal, other landfills.

ⁱStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for disposal, unknown

^jThe sum of all releases of the chemical to air, land, water, and underground injection wells.

^kTotal amount of chemical transferred off-site, including to POTWs.

RF = reporting facilities; UI = underground injection

Source: TRI15 2017 (Data are from 2015)

Table 5-7. Releases to the Environment from Facilities that Produce, Process, or Use Lead Compounds^a

Reported amounts released in pounds per year ^b									
State ^c	RF ^d	Air ^e	Water ^f	UI ^g	Land ^h	Other ⁱ	Total release		
							On-site ^j	Off-site ^k	On- and off-site
AK	17	10,328	209	0	223,161,561	5	223,165,066	7,037	223,172,103
AL	129	9,457	4,547	0	1,038,358	12,293	922,926	141,730	1,064,656
AR	63	7,901	1,206	0	48,454	71,513	54,177	74,897	129,074
AZ	59	18,709	99	0	20,469,170	2,795	20,482,921	7,852	20,490,773
CA	291	7,559	716	5	4,373,766	14,153	3,879,798	516,401	4,396,199
CO	63	3,278	38	0	8,313,098	8,025	8,294,566	29,874	8,324,440
CT	37	178	722	0	11,910	12,569	201	25,179	25,379
DC	1	0	0	0	23	0	24	0	24
DE	8	218	107	0	18,899	12,731	1,141	30,814	31,955
FL	157	5,896	1,987	0	993,233	12,076	944,643	68,549	1,013,192
GA	100	6,269	2,258	0	388,326	1,066	333,881	64,039	397,920

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-7. Releases to the Environment from Facilities that Produce, Process, or Use Lead Compounds^a

Reported amounts released in pounds per year ^b									
State ^c	RF ^d	Air ^e	Water ^f	UI ^g	Land ^h	Other ⁱ	Total release		On- and off-site
							On-site ^j	Off-site ^k	
GU	3	36	2	0	13	0	50	0	50
HI	12	975	23	14	4,664	212	2,237	3,650	5,888
IA	58	7,365	998	11	189,469	31,847	73,657	156,034	229,691
ID	28	1,847	212	0	2,987,992	1,168	2,989,477	1,743	2,991,220
IL	170	13,784	10,450	11,476	1,114,360	583,163	311,897	1,421,336	1,733,233
IN	159	24,115	39,916	1,256	3,998,658	694,360	949,772	3,808,534	4,758,306
KS	38	2,809	244	38	30,739	32,818	30,542	36,106	66,648
KY	73	14,518	574	3,903	889,194	131,680	882,701	157,168	1,039,869
LA	84	5,940	4,456	589	757,684	5,872	595,908	178,633	774,541
MA	60	1,199	270	0	5,266	44,975	2,661	49,049	51,710
MD	34	1,062	326	6	34,647	155,509	14,410	177,140	191,550
ME	12	784	586	0	30,452	4	4,750	27,075	31,825
MI	120	5,708	3,991	59	741,434	107,685	437,412	421,465	858,877
MN	56	2,650	415	0	1,031,992	3,124	113,673	924,508	1,038,182
MO	72	15,169	21,933	2,075	24,880,815	208,477	24,725,309	403,158	25,128,468
MP	1	2	0	0	1	No data	2	No data	2
MS	72	2,050	2,445	309,122	66,528	3,350	338,514	44,980	383,494
MT	23	2,225	2	5,557	6,576,730	1,996	6,578,917	7,592	6,586,510
NC	126	6,064	785	0	713,311	80,430	611,373	189,216	800,589
ND	21	3,836	40	0	113,296	5,254	84,928	37,498	122,425
NE	23	951	108	0	62,568	6,743	56,177	14,193	70,370
NH	18	64	13	0	1,531	5,968	299	7,278	7,576
NJ	55	1,295	1,480,932	0	22,073,190	1,092,177	47,828	24,599,766	24,647,594
NM	16	1,351	103	1	7,619,073	113,027	7,591,784	141,772	7,733,556
NV	51	5,670	0	0	71,295,426	209	71,297,978	3,327	71,301,305
NY	84	2,791	4,992	0	651,466	23,267	74,757	607,759	682,516
OH	200	11,150	3,223	24,123	1,078,489	320,175	457,177	979,985	1,437,161
OK	93	6,165	278	0	485,889	463	401,246	91,549	492,795
OR	50	1,325	2,141	0	44,379	233	12,427	35,650	48,077
PA	215	15,389	8,771	7	1,182,089	288,391	530,697	963,950	1,494,648
PR	12	916	287	6	1,183	2,456	1,207	3,641	4,848
RI	19	54	10	0	989	137	54	1,137	1,191
SC	98	4,238	499	0	2,383,853	32,870	121,907	2,299,555	2,421,462
SD	13	101	2	0	840,669	124	839,746	1,149	840,895
TN	92	4,985	2,886	84	1,301,596	251,629	1,230,147	331,032	1,561,180
TX	317	15,182	4,166	937	2,657,771	14,300	2,381,651	310,704	2,692,356
UT	40	10,399	261	0	126,927,346	3,486	126,882,715	58,778	126,941,493

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-7. Releases to the Environment from Facilities that Produce, Process, or Use Lead Compounds^a

Reported amounts released in pounds per year ^b									
State ^c	RF ^d	Air ^e	Water ^f	UI ^g	Land ^h	Other ⁱ	Total release		On- and off-site
							On-site ^j	Off-site ^k	
VA	80	12,727	7,938	0	297,037	14,306	219,221	112,787	332,008
VI	1	11	0	0	0	No data	11	No data	11
VT	5	10	0	0	81	0	10	81	91
WA	79	5,094	1,243	0	254,154	19,721	212,365	67,847	280,212
WI	104	4,410	1,539	4	247,231	34,846	81,033	206,996	288,029
WV	48	3,448	1,171	0	509,721	3,604	371,742	146,202	517,944
WY	13	786	11	0	78,585	320	69,971	9,730	79,701
Total	3,873	290,444	1,620,131	359,275	542,978,361	4,467,601	509,709,687	40,006,124	549,715,811

^aThere are sources for release other than those reported to TRI. This chart reflects information provided to TRI. Data are rounded to nearest whole number.

^bData in TRI are total amounts released by each facility.

^cPost office state abbreviations are used.

^dNumber of reporting facilities.

^eThe sum of fugitive and point source releases are included in releases to air by a given facility.

^fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal and metal compounds).

^gUnderground injection Class I wells and Class II-V wells.

^hResource Conservation and Recovery Act (RCRA) Subtitle C landfills; other onsite landfills, land treatment, surface impoundments, other land disposal, other landfills.

ⁱStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for disposal, unknown

^jThe sum of all releases of the chemical to air, land, water, and underground injection wells.

^kTotal amount of chemical transferred off-site, including to POTWs.

RF = reporting facilities; UI = underground injection

Source: TRI15 2017 (Data are from 2015)

The decrease in national Pb emissions between 1970 to 2011 is estimated to be 99.6% (220,000 tons), which is mostly attributed to the elimination of leaded gasoline for on-road vehicles. Since 2000, nonroad engines and metals industrial processing have accounted for most of the anthropogenic Pb emissions in the United States (EPA 2015). Based on data from the National Emissions Inventory (NEI 2014), the following sectors contribute the largest portions of total Pb emissions in the United States: mobile-aircraft (63%), industrial processes—not elsewhere classified (6.8%), industrial processes—ferrous metals (6.8%), fuel combustion—electric generation—coal (5.5%), and industrial processes—non-ferrous metals (4.1%) (EPA 2016c). Historical trends of Pb emissions in the United States are provided in Table 5-8 (EPA 2015).

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-8. Historic Levels of Lead Emissions to the Atmosphere in the United States (in Thousand Metric Tons)

	1970	1975	1980	1985	1990	1995	1999	2002	2005	2008	2011
On-road vehicles	172	130.2	60.5	18.1	2.17	2.05	1	0	0	0	0
Metals industrial processing	24.22	9.923	3.03	2.1	0.5	0.49	0.96	0.4	0.3	0.16	0.14
Fuel combustion	10.62	10.35	4.3	0.52	0.42	0.02	0	0.39	0.14	0.12	0.09
Nonroad engines	9.737	6.13	4.2	0.92	0.78	0.54	0.55	0.45	0.66	0.56	0.49
Other sources	4.331	3.053	2.12	1.31	1.11	0.83	0.84	0.43	0.25	0.11	0.1

Source: EPA 2015

According to the data from the NEI, the largest portions of total Pb emissions are in the U.S. mobile-aircraft sector. Murphy et al. (2008) studied weekly patterns of metals and other aerosol components using data collected from 2000 to 2006 at Interagency Monitoring of Protected Visual Environments (IMPROVE) sites, and these data suggested that Pb concentrations were impacted by piston aircraft emissions.

As indicated in Table 5-6, by the early 2000s, transportation (i.e., automotive) emissions were no longer the dominant source of Pb emitted to the atmosphere. When such emissions were prevalent, >90% (mass basis) of automotive Pb emissions from leaded gasoline were in the form of inorganic particulate matter (e.g., Pb bromochloride [PbBrCl]) and <10% (mass basis) were in the form of organolead vapors (e.g., Pb alkyls). In 1984, the average Pb content of gasoline was 0.44 g Pb/gallon (EPA 1986); however, as of January 1986, the allowable Pb content of leaded gasoline dropped to 0.1 g Pb/gallon (EPA 1985d). Between January and June of 1990, the actual average Pb concentration in leaded gasoline was 0.085 g Pb/gallon, indicating consumption of approximately 230,000 kg of Pb for the production of 2.74 billion gallons of leaded gasoline. In the early 1980s, EPA allowed up to 0.05 g of Pb in a gallon of unleaded gasoline (EPA 1982b).

According to data from TRI, on-site air releases of Pb and Pb compounds varied over the same period from 431,311 pounds in 2014 to 1,037,265 pounds in 2006, with an overall decrease of 40%. The electric utility and primary metals industry sectors contributed to this overall decrease; both sectors have decreased air Pb and Pb compounds releases by approximately 70% from 2005 to 2015. The primary metal sector, which includes iron and steel manufacturers and smelting operations, contributes the greatest quantity of Pb and Pb compounds to air releases (EPA 2017a, 2017b).

5. POTENTIAL FOR HUMAN EXPOSURE

While Pb levels in paints for interior use have been restricted since the 1950s, older houses and furniture may still be covered with leaded paint. Releases from Pb-based paints are frequently confined to the area in the immediate vicinity of painted surfaces, and deterioration or removal of the paint by sanding or sandblasting can result in high localized concentrations of Pb dust in both indoor and outdoor air.

The largest volume of organolead vapors released to the atmosphere results from industrial processes; prior to its phaseout and ban, leaded gasoline containing tetraethyl Pb as an anti-knock additive was also a major contributor. Tetraalkyl Pb vapors are photoreactive, and their presence in local atmospheres is transitory. Halogenated Pb compounds are formed during combustion by reaction of the tetraalkyl Pb compounds with halogenated Pb scavenger compounds. These halogenated Pb compounds ultimately give rise to Pb oxides and carbonates in the environment (EPA 1985b). Tetraalkyl Pb compounds once contributed 5–10% of the total particulate Pb present in the atmosphere. Organolead vapors were most likely to occur in occupational settings (e.g., gasoline transport and handling operations, gas stations, and parking garages) and high-traffic areas (Nielsen 1984).

5.3.2 Water

According to the TRI, in 2015, a total of 18,648 pounds of Pb were released to water from 4,252 reporting facilities (TRI15 2017). In addition, a total of 620,131 pounds of Pb compounds were released to water from, 3,873 reporting facilities (TRI15 2017). Tables 5-6 and 5-7 list amounts of Pb and Pb compounds released from these facilities grouped by state, respectively.

The following industry sectors accounted for the majority of release of Pb to surface water in 2015: chemicals (27%); paper (25%); primary metals (18%); transportation equipment (12%); fabricated metals (7%); and electrical utilities (3%). The following industry sectors accounted for the majority of release of Pb compounds to surface water in 2015: metal mining (32%); paper (31%); electric utilities (15%); primary metals (9%); chemicals (5%); fabricated metals (4%); and petroleum (3%) (TRI15 2017). The trends in discharges of Pb and Pb compounds to surface water from 2001 to 2015 are presented in Table 5-9.

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-9. U.S. Surface Water Discharges of Lead and Lead Compounds (Pounds/Year)

Year	Lead	Lead compounds
2001	45,871	97,479
2002	20,694	92,366
2003	21,314	109,299
2004	14,564	107,386
2005	15,883	100,778
2006	22,985	86,772
2007	16,745	82,815
2008	11,404	153,681
2009	9,886	73,683
2010	7,263	72,556
2011	7,086	77,568
2012	7,307	60,656
2013	6,327	76,053
2014	8,836	79,344
2015	5,264	70,981

Source: EPA 2017c; TRI15 2017

Data reported by Environment and Climate Change Canada (2016) show that other industries, which include the iron and steel industry, oil and gas industry, and cement and concrete industry, contributed 136.9 tonnes of the total Pb released to water in 2014. This release includes 134.1 tonnes of Pb that were released when a dam securing a tailings pond from the Mount Polley mine in central British Columbia breached on August 4, 2014, spilling mining waste into Polley Lake and surrounding waters. Waste, pulp, paper, and paperboard industry, and non-ferrous smelting and refining were the next largest contributors (Table 5-10). In 2013, Pb releases to water were similar for other industries and waste.

Table 5-10. Canada Surface Water Discharges of Lead and Lead Compounds (Tonnes)

Year	Other industries	Waste	Pulp, paper, and paperboard industry	Non-ferrous smelting and refining	Other sources
2003	4.38	15.49	2.55	1.74	0.18
2004	3.97	11.53	2.84	2.26	0.26
2005	6.11	9.47	3.29	1.82	0.58
2006	5	9.9	2.35	1.65	0.24
2007	3.63	6.42	2.37	1.64	0.19
2008	4.76	11.58	2.42	2.04	0.16

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-10. Canada Surface Water Discharges of Lead and Lead Compounds (Tonnes)

Year	Other industries	Waste	Pulp, paper, and paperboard industry	Non-ferrous smelting and refining	Other sources
2009	3.39	8.49	2.25	2.13	0.19
2010	3.21	11.97	2.12	1.45	0.14
2011	3.65	8.97	2.91	1.5	0.16
2012	4.66	4.69	2.8	1.75	0.12
2013	4.17	4.66	2.42	1.48	0.13
2014	136.92	5.11	1.85	1.77	0.13

Source: Environment and Climate Change Canada (2016)

Urban runoff and atmospheric deposition are significant indirect sources of Pb found in the aquatic environment. Pb reaching surface waters is sorbed to suspended solids and sediments (EPA 1982a; EPA 2006, 2014c).

Pb is released into surface water from Pb shot and Pb sinkers. A study of a shooting range in Southwestern Virginia found that the dissolved Pb content of surface water ranged up to 473 ppb, with the highest concentrations closest to the backstop (Craig et al. 1999). Upstream from the site, the Pb concentration was 0.5 ppb. In 1991, the U.S. Fish and Wildlife Service banned the use of Pb shot when hunting waterfowl, such as geese or ducks, in order to avoid releasing Pb directly to surface water.

5.3.3 Soil

According to the TRI, in 2015, a total of 12,364,781 pounds of Pb were released to the land, both on-site and off-site, by 4,252 reporting facilities (TRI15 2017). Table 5-6 lists amounts of Pb released from these facilities grouped by state. In addition, a total of 542,978,361 pounds of Pb compounds were released to land, both on-site and off-site, by 3,873 reporting facilities (TRI15 2017). Table 5-7 lists amounts of Pb compounds released from these facilities grouped by state. In addition, 73,425 and 359,275 pounds of Pb and Pb compounds, respectively, were injected underground. Ninety-five percent of Pb injected underground were by two facilities in Texas. Eighty-six percent of Pb compounds injected underground was by one facility in Mississippi. Facilities with ≥ 10 full-time employees in certain TRI-covered industry sectors (e.g., manufacturing) must submit data on releases and other waste management for TRI-listed chemicals (Pb and Pb compounds are TRI listed).

5. POTENTIAL FOR HUMAN EXPOSURE

Pb-containing material from home and commercial use may be sent to municipal landfills. It is important to note that land is the ultimate repository for Pb, and Pb released to air and water ultimately is deposited in soil or sediment. For example, Pb released to the air from leaded gasoline or in stack gas from smelters and power plants will settle on soil, sediment, foliage, or other surfaces. The heaviest contamination occurs near the highway, in the case of leaded gasoline, or near the facility, in the case of a power plant or smelter. Road dust contributes to Pb in soil. Pb concentrations were higher in surface soils within 1,000 m of roadways (134 kg/ha) as compared to outside the 1,000-m region (38.7 kg/ha) (Yesilonis et al. 2008). Wheel weights can contribute to releases of Pb along roadways. Aucott and Caldarelli (2012) estimated that approximately 12 tons of Pb as wheel weights are deposited on New Jersey roadways; however, they estimated that only a small amount enters the environment as small particulate from grinding. Root (2000) also estimated a rate of Pb deposition in Albuquerque, New Mexico as 50–70 kg/km/year. However, use of Pb wheel weights are on the decline due to legislation, voluntary phase-out, and new wheel technology (Aucott and Caldarelli 2012).

5.3.4 Paint

Although the sale of residential Pb-based paint was banned in the United States in 1978, flaking paint, paint chips, and weathered powdered paint, which are most commonly associated with deteriorated housing stock in urban areas, remain major sources of Pb exposure for young children residing in these houses, particularly for children afflicted with pica (the compulsive, habitual consumption of nonfood items) (Bornschein et al. 1986; EPA 1986). Pb concentrations of 1–5 mg/cm² have been found in chips of Pb-based paint (Billick and Gray 1978), suggesting that consumption of a single chip of paint would provide greater short-term exposure than any other source of Pb (EPA 1986). An estimated 40–50% of occupied housing in the United States may contain Pb-based paint on exposed surfaces (Chisolm 1986).

In the late 1980s, the U.S. Department of Housing and Urban Development (HUD) conducted a national survey of Pb-based paint in housing. The EPA subsequently sponsored a comprehensive technical report on the HUD-sponsored survey to provide estimates of the extent of Pb-based paint in housing. In the EPA report, a home is considered to have Pb-based paint if the measured Pb concentration on any painted surface is ≥ 1.0 mg/cm². The EPA report estimates that 64 million (± 7 million) homes, or 83% ($\pm 9\%$) of privately-owned housing units built before 1980, have Pb-based paint somewhere in the building. Approximately 12 million (± 5 million) of these homes are occupied by families with children under the age of 7 years. Approximately 49 million (± 7 million) privately owned homes have Pb-based paint in

5. POTENTIAL FOR HUMAN EXPOSURE

their interiors. By contrast, approximately 86% ($\pm 8\%$) of all pre-1980 public housing family units have Pb-based paint somewhere in the building (EPA 1995b).

Damaged Pb-based paint is associated with excessive dust Pb levels. Approximately 14 million homes (19% of pre-1980 housing) have >5 square feet of damaged Pb-based paint, and nearly half (47%) of those homes have excessive dust Pb levels (EPA 1995b).

In the Cincinnati prospective Pb study of public and private low- and moderate-income housing, the Pb concentration ranges were: painted interior walls, 0.1–35 mg/cm²; interior home surface dust, 0.04–39 mg/m² and 72–16,200 µg/g; interior home dustfall, 0.0040–60 mg/m²/30 days; exterior dust scrapings, 20–108,000 µg/g; and dust on children's hands, 1–191 µg. The Pb levels in older private deteriorating or dilapidated housing were higher than the levels in newer public and rehabilitated housing (Clark et al. 1985).

Releases from Pb-based paints are frequently confined to the area in the immediate vicinity of painted surfaces, and deterioration or removal of the paint can result in high localized concentrations of Pb in dust in air (from sanding and sandblasting) and on exposed surfaces. A study was conducted in New Orleans where power sanding is a common practice during repainting old houses; median, 90th percentile, and maximum Pb concentrations in 31 study houses were 35, 126, and 257 mg/g, respectively (Mielke et al. 2001). Pb concentrations in dust and soil samples from one study of a house where the paint chips contained about 90 mg Pb/g were very high. If the house had been sanded down to bare wood, 7.4 kg of Pb would have been released to the environment. Disturbance of older structures containing Pb-based paints is now a significant contributor to total Pb releases.

The authors of a report of findings from NHANES III, conducted in 1988–1991, commented that of the multiple sources of exposure, Pb-based paint is the principal high-dose source of Pb. Exposure occurs not only through the direct ingestion of flaking and chalking paint, but also through the inhalation of dust and soil contaminated with paint (Brody et al. 1994). According to a study by the New York State Department of Health, renovation and remodeling activities that disturb Pb-based paints in homes can produce significant amounts of Pb dust, which can be inhaled or ingested (CDC 1997a).

5. POTENTIAL FOR HUMAN EXPOSURE

5.4 ENVIRONMENTAL FATE

The atmosphere is the main environmental transport media for Pb that is deposited onto surface water and soils (EPA 2006, 2014c). Upon release to the atmosphere, Pb particles are dispersed and ultimately removed from the atmosphere by wet or dry deposition. Pb deposition is typically greatest closer to Pb emission sources. An important factor in determining the atmospheric transport of Pb is particle size distribution. Large particles settle out of the atmosphere more rapidly and are deposited relatively close to emission sources and smaller particles may be transported much farther distances. After deposition, particles may be resuspended and redeposited. The cycling of Pb in aquatic environments is governed by chemical, biological, and mechanical processes. The exchange between sediment and surface water will be affected by pH, ionic strength, formation of organic complexes with Pb ions, and oxidation-reduction potential of the environment (EPA 2006, 2014c).

5.4.1 Transport and Partitioning

Transport and partitioning of Pb in the environment is an interplay of various processes (EPA 2014c). Global atmospheric deposition of Pb peaked in the 1970s and has declined since then; however, these deposits are still in the environment and can be transported and partitioned between environmental compartments. Past and current releases of Pb to the air result in the deposition of Pb on land and in surface water. While soil is a repository for Pb, it is not a passive repository, and resuspension of Pb contaminated soil-derived dust particulates can contribute to Pb exposure (Laidlaw and Filippelli 2008; Laidlaw et al. 2012). Pb in soil can be washed off surfaces into waters, and within water, it can partition between water and sediments (EPA 2006, 2014c).

Air. EPA (2006) summarized that the major pathway for the transport of Pb in the environment is the atmosphere and that airborne Pb tends to be in the form of submicron aerosols, which can travel large distances. After release to the atmosphere, Pb particles are dispersed and ultimately removed from the atmosphere by wet or dry deposition. Dry deposition was the major removal process for Pb in coarse particulate matter and wet deposition was the most important removal process for fine particulate matter. Soil-bound Pb and contaminated road dust can be resuspended and can be a significant source of airborne Pb in areas near major sources of Pb emissions (EPA 2006, 2014c).

In the atmosphere, non-organic compounds of Pb exist primarily in the particulate form. The median particle distribution for Pb emissions from smelters is 1.5 μm , with 86% of the particle sizes under 10 μm (Corrin and Natusch 1977). The smallest Pb-containing particulate matter (<1 μm) is associated with

5. POTENTIAL FOR HUMAN EXPOSURE

high-temperature combustion processes. Upon release to the atmosphere, Pb particles are dispersed and ultimately removed from the atmosphere by wet or dry deposition. Approximately 40–70% of the deposition of Pb is by wet fallout; 20–60% of particulate Pb once emitted from automobiles is deposited near the source. An important factor in determining the atmospheric transport of Pb is particle size distribution. Large particles, particularly those with aerodynamic diameters of $>2 \mu\text{m}$, settle out of the atmosphere more rapidly and are deposited relatively close to emission sources (e.g., 25 m from the roadway for those size particles emitted in motor vehicle exhaust in the past); smaller particles may be transported thousands of kilometers away from the emission source.

The amount of Pb scavenged from the atmosphere by wet deposition varies widely; wet deposition can account for 40–70% of Pb deposition depending on such factors as geographic location and amount of emissions in the area (Nielsen 1984). An annual scavenging ratio (concentration in precipitation, mg/L, to concentration in air, $\mu\text{g}/\text{m}^3$) of 0.18×10^{-6} has been calculated for Pb, making it the lowest value among seven trace metals studied (iron, aluminum, manganese, copper, zinc, cadmium); this indicates that Pb (which initially exists as fine particles in the atmosphere) is removed from the atmosphere by wet deposition relatively inefficiently.

While Pb particles from automobile emissions are quite relatively small ($<0.1 \mu\text{m}$ in diameter), they may coagulate to form larger particulates (Chamberlain et al. 1979). Pb has been found in sediment cores of lakes in Ontario and Quebec, Canada far from any point sources of Pb releases, suggesting that long-range atmospheric transport was occurring (Evans and Rigler 1985). Sabin and Schiff (2008) reported that median dry deposition fluxes along a coastal transect in southern California ranged from 0.52 to $14 \mu\text{g}/\text{m}^2\text{-day}$ in 2006. Pb fluxes ranged from 20 to $330 \mu\text{g}/\text{m}^2\text{-day}$ in 1975. Osterberg et al. (2008) reported elevated concentrations of Pb in a 1970–1998 ice core from the summit of Mt. Logan, Canada, and indicated that elevated levels correspond to increased industrial activity in Asia over the same time period. Mean Pb concentrations in the 1970–1998 portion were 68.9 ng/L, more than 10-fold above the natural background (5.6 ng/L).

Pb in soil in urban areas of older cities may be a source of airborne Pb (Laidlaw and Filippelli 2008). Studies of the Pb species found in airborne particulate matter collected in El Paso, Texas found that Pb-humate was the dominant form of Pb in air samples. Pb-humate, a stable, sorbed complex formed in the humus fraction of Pb contaminated soil, is the major Pb species in soils in El Paso (Pingitore et al. 2009). In a review, Cho et al. (2011) noted that studies over the past 40 years have shown that there has been a shift of airborne particle bound Pb to larger sizes of particulate as concentrations of Pb in urban areas

5. POTENTIAL FOR HUMAN EXPOSURE

have decreased. They note that this shift has occurred as the use of leaded gasoline was phased-out and that industrial emissions and resuspension of road dust became more important sources of Pb. In addition to soil-derived dust, re-entrainment of dusts near highways and deteriorating Pb-based paint from elevated steel structures can contribute to airborne Pb (Sabi et al. 2006; Weis et al. 2006). Studies suggest that there is long-range transport of Pb bound to particulate matter from industrial emissions. Dust samples from surface glaciers and in dust traps in remote areas on the west coast of New Zealand's South Island were identified as being both Australian and New Zealand in origin. Samples were enriched in metals, including Pb, and the degree of metal enrichment indicated that they were transported from eastern Australia (Marx et al. 2008).

Water. The amount of soluble Pb in surface waters depends upon the pH and the ionic strength of the water. Equilibrium calculations show that at $\text{pH} > 5.4$, the total solubility of Pb is approximately $30 \mu\text{g/L}$ in hard water and approximately $500 \mu\text{g/L}$ in soft water. Sulfate ions, if present in soft water, limit the Pb concentration in solution through the formation of Pb sulfate. Above $\text{pH} 5.4$, the Pb carbonates, PbCO_3 and $\text{Pb}_2(\text{OH})_2\text{CO}_3$, limit the amount of soluble Pb. The carbonate concentration is in turn dependent upon the partial pressure of carbon dioxide, pH, and temperature (EPA 1986).

A significant fraction of Pb carried by river water is expected to be in an undissolved form, which can consist of colloidal particles or larger undissolved particles of Pb carbonate, Pb oxide, Pb hydroxide, or other Pb compounds incorporated in other components of surface particulate matters from runoff. Pb may occur either as sorbed ions or surface coatings on sediment mineral particles, or it may be carried as a part of suspended living or nonliving organic matter in water.

Sediment and Soil. EPA (2006, 2014c) reviewed and summarized the factors affecting the behavior of Pb in soil. While Pb is relatively immobile in soil and has a long retention time in most soils, it has some capacity to leach through the soil column and potentially contaminate groundwater. Pb sorbs strongly to soil components and is only weakly soluble in pore water, making the leaching of Pb in soil a slower process as compared to other contaminants. Various soil conditions and characteristics affect the sorbing capacity of the soil and the solubility of contaminants including hydraulic conductivity of the soils, composition of the soil solution, organic matter, clay mineral content of the soil, pH, and microbial activity (EPA 2006). In soil, Pb can be partitioned between the soil water, precipitate forms, secondary iron and manganese oxides, carbonates, organic matter, sulfides, or the surfaces of clay, humus, or silicate particles. Pb adsorbed to the surfaces of colloid soil particles (e.g., organic matter, clay, oxides, and carbonates) are the most labile fraction. High chloride content in soil also enhances Pb solubility. At low

5. POTENTIAL FOR HUMAN EXPOSURE

pH, metal species bound to carbonates, hydroxides, and other soil components are more likely to dissolve into solution, increasing rates of Pb migration through the soil. EPA (2014c) reported that soil pH is the most important factor affecting solubility, mobility, and phytoavailability of Pb in soil; however, reducing conditions (e.g., anoxia) in soil also increase Pb mobility. In addition, dissolved organic matter is more important than iron oxyhydroxides in Pb mobility in soil.

The fate of Pb in soil is affected by the adsorption at mineral interfaces, precipitation of sparingly soluble solid forms of the compound, and formation of relatively stable organic-metal complexes or chelates with soil organic matter. These processes are dependent on such factors as soil pH, soil type, particle size, organic matter content of soil, presence of inorganic colloids and iron oxides, cation exchange capacity (CEC), and amount of Pb in soil (NSF 1977; Reddy et al. 1995). Soil samples were extracted from the Powder River Basin in Wyoming to determine the relative distribution and speciation of Pb and other metals in acidic environments (Reddy et al. 1995). At near neutral pH, organic carbon-Pb complexes were the predominant species in the soil water extracts. At low pH, dissolved Pb in ionic form (Pb^{2+}) and ion pairs (e.g., PbSO_4) were the predominant species. It was concluded that the mobility of Pb will increase in environments having low pH due to the enhanced solubility of Pb under acidic conditions. The accumulation of Pb in most soils is primarily a function of the rate of deposition from the atmosphere. Most Pb is retained strongly in soil, and very little is transported through runoff to surface water or leached to groundwater except under acidic conditions (EPA 1986; NSF 1977). Clays, silts, iron and manganese oxides, and soil organic matter can bind metals electrostatically (cation exchange) as well as chemically (specific adsorption) (Reed et al. 1995). Although sorption to organic matter in soil limits the rate and extent of leaching, Pb may enter surface waters as a result of erosion of Pb-containing soil particulates. Pb bromochloride, the primary form of Pb emitted from motor vehicles, which once burned leaded gasoline in the presence of organohalogen scavenger compounds, is converted to the less-soluble Pb sulfate either by reactions in the atmosphere or by reactions at the soil surface, thus limiting its mobility in soil. It has been determined that Pb oxides, carbonates, oxycarbonates, sulfates, and oxysulfates become the most prominent constituents of aged automobile exhaust particles (i.e., those collected at locations more remote from traffic sources) (Ter Haar and Bayard 1971). Pb may also be immobilized by ion exchange with hydrous oxides or clays or by chelation with humic or fulvic acids in the soil (Olson and Skogerboe 1975). In soils with $\text{pH} \geq 5$ and with at least 5% organic matter content, atmospheric Pb is retained in the upper 2–5 cm of undisturbed soil. Inorganic Pb may be bound into crystalline matrices of rocks and remain essentially immobile; it can also occur in water entrapped in soil macro- and micropores (Reed et al. 1995). In soil with high organic matter content and a pH of 6–8, Pb may form insoluble organic Pb complexes; if the soil has less organic matter at the same pH, hydrous Pb

5. POTENTIAL FOR HUMAN EXPOSURE

oxide complexes may form or Pb may precipitate out with carbonate or phosphate ions. At a pH of 4–6, the organic Pb complexes become soluble and leach out or may be taken up by plants (EPA 1986). Entrainment or suspension of soil particles in moving air is another route of Pb transport (EPA 1982c). This process may be important in contributing to the atmospheric burden of Pb around some Pb smelting facilities and NPL sites that contain elevated levels of Pb in soil.

The downward movement of elemental Pb and inorganic Pb compounds from soil to groundwater by leaching is very slow under most natural conditions except for highly acidic situations (NSF 1977). The conditions that induce leaching are the presence of Pb in soil at concentrations that either approach or exceed the CEC of the soil, the presence of materials in soil that are capable of forming soluble chelates with Pb, and a decrease in the pH of the leaching solution (e.g., acid rain) (NSF 1977). Favorable conditions for leaching may be present in some soils near Pb smelting and NPL sites. Tetraalkyl Pb compounds, such as tetraethyl Pb, are insoluble in water and would not be expected to leach in soil. However, they can be transported through a soil column when it is present in a migrating plume of gasoline (USAF 1995). In aqueous media, tetraalkyl Pb compounds are first degraded to their respective ionic trialkyl Pb species and are eventually mineralized to inorganic Pb (Pb^{2+}) by biological and chemical degradation processes (Ou et al. 1995).

In a study of Pb migration in forest soils in Vermont, Miller and Friedland (1994) used Pb deposition time series and measurements of organic soil horizon Pb content made in 1966, 1980, and 1990 to compute dynamic response times for Pb storage in several types of soil. The authors concluded that maximum Pb concentrations in organic soil occurred around 1980, with concentrations of about 85 $\mu\text{g/g}$ in soils of the northern hardwood forests of the study area and about 200 $\mu\text{g/g}$ in soils of the spruce-fir forests. The large surge of atmospheric Pb deposited in these forests during the time when leaded gasoline was routinely used in motor vehicles is being redistributed in the soil profile rather than being retained in the organic horizon. Based on an analysis of Pb transit times through mineral soil horizons, the pulse of Pb may begin to be released to upland streams sometime in the middle of the next century (Miller and Friedland 1994). However, Wang et al. (1995) observed that Pb migration in forest soils is slowed considerably due to a decrease in solubility when Pb moves from the soil surface horizon to streams. Their results suggest that Pb is effectively trapped in the subsurface soil horizons, which may greatly reduce its release to streams.

Lewis et al. (2010) studied the distribution, chemical speciation, and mobility of Pb and antimony from small arms ammunition in a coarse-grained surface sand and reported that the transport of Pb was small in

5. POTENTIAL FOR HUMAN EXPOSURE

this soil type. Ninety-three percent of the mass of the bullets was found in the top 30 cm of the sand. Pb was mostly associated with the following grain sizes in decreasing order >5.0 mm (~3.3 g/kg), 1.2–5.0 mm (~1.5 g/kg), and <0.06 mm (~0.25 mg/kg). In the 0.06–0.6 mm fractions, Pb concentrations were just above background levels (0.0004 g/kg). Declining concentrations with depth has also been observed in clay/loam shooting range soils (Vantelon et al. 2005). Pb in the fine fraction (<2 mm) shooting range soils also showed a depth distribution, with the highest concentrations in the top 10 cm (Cao et al. 2003a, 2003b; Hui et al. 2002; Lin et al. 1995; Perroy et al. 2014; Selonen et al. 2012). In a study of various contaminant levels in soil at a major training facility used for testing military tanks and munitions, Pb concentrations in the 0–15 cm soil depth ranged from 249.2 to 1,963.7 mg/kg (Berthelot et al. 2008).

Flooding events can change the spatial distribution of Pb in soil and sediments (Lead ISA 2013). Zahran et al. (2010) and Presley et al. (2010) reported variations in Pb concentrations in soil samples from schoolyards in New Orleans, Louisiana before and after Hurricanes Katrina and Rita in 2005, with some sites increasing and others decreasing in Pb concentrations. Forty-six census tracts in New Orleans were sampled before and after Hurricanes Katrina and Rita; 29 of these showed a decline in Pb concentrations, with 6 samples >400 mg/kg. Prior to these hurricanes, 15 of 46 samples had Pb concentrations >400 mg/kg. Across the tracts, the average median Pb concentration decreased from 328.5 to 203.33 mg/kg (Zahran et al. 2010). Presley et al. (2010) reported similar trends. Of the 17 schoolyard sites that were sampled, 7 sites had concentrations exceeding Pb concentrations of 400 mg/kg in June 2005, and in January 2006, Pb concentrations at 3 sites exceeded this concentration. The geometric mean concentration of the sites decreased from 290.0 to 207.4 mg/kg; however, at two sites, Pb concentrations increased from 804.0 to 1,740.0 mg/kg and from 1,090.0 to 2,500.0 mg/kg. During a 4-day storm event, 2,400 tonnes of suspended particulate matter were transported in a historical mining, ore processing, and smelting region in the Czech Republic that contained various metals including 2,954 kg of Pb (Žak et al. 2009).

Other Media. Plants and animals may bioconcentrate Pb, but biomagnification is not expected. In general, the highest Pb concentrations are found in aquatic and terrestrial organisms with habitats near Pb mining, smelting, and refining facilities; storage battery recycling plants; areas affected by high automobile and truck traffic; sewage sludge and spoil disposal areas; sites where dredging has occurred; areas of heavy hunting and fishing (Pb from spent shot or sinkers); and urban and industrialized areas. Pb may be present on plant surfaces as a result of atmospheric deposition; its presence in internal plant tissues indicates biological uptake from the soil and leaf surfaces. Although the bioavailability of Pb in soil to plants is limited because of the strong adsorption of Pb to soil organic matter, bioavailability

5. POTENTIAL FOR HUMAN EXPOSURE

increases with increased soil organic matter content and with decreased soil pH (more acidic). Plants grown in Pb-contaminated soils were shown to accumulate low levels of Pb in the edible portions of the plant from adherence of dusts and translocation into the tissues (Finster et al. 2004). Thirty-two different types of fruits or vegetables were grown in urban gardens with soils containing high Pb levels (27–4,580 mg/kg). Samples were harvested and washed with either water or detergents and analyzed for Pb content. Only one fruiting vegetable among 52 samples contained Pb levels greater than the detection limit of 10 µg/g in the edible portion. However, 39% of the leafy vegetables and herbs had Pb levels >10 µg/g in the edible shoot portion following washing of the vegetables with detergent and water (Finster et al. 2004).

Pb may be taken up in edible plants from the soil via the root system, by direct foliar uptake and translocation within the plant, and by surface deposition of particulate matter. The amount of Pb in soil that is bioavailable to a vegetable plant depends on factors such as cation exchange capacity, pH, amount of organic matter present, soil moisture content, and type of amendments added to the soil. Background agricultural soil Pb concentrations for major growing areas of the United States have been determined (Holmgren et al. 1993).

The influence of various combinations of soil amendments on Pb uptake by soybeans was studied for a metal-contaminated alluvial soil (Pierzynski and Schwab 1993). Addition of limestone was found to be most effective in reducing the bioavailability of metals (including Pb) as indicated by the reduction in labile soil metals, increased yields, and decreased soybean tissue metal content. Uptake of metals by lettuce and radishes grown in a loam soil spiked with cadmium chloride and Pb nitrate (from 100 to 1,000 mg/kg) was also studied (Nwosu et al. 1995). Results indicated that the mean uptake of Pb by lettuce increased as the concentration of Pb rose in the soil mixture. However, the uptake was low and this finding is inconsistent with other reports. Pb was not bioaccumulated by either plant regardless of soil Pb concentrations. The response of kidney bean growth to the concentration and chemical form of Pb in soils obtained near a zinc smelter in Japan has been studied (Xian 1989). It was found that the amount of Pb in the total plant (approximately 35–80 µg) correlated strongly with the concentration of Pb in the soil (0–240 mg/kg). The best relationship was found between the amount of metal uptake and the concentration of exchangeable and carbonate forms of Pb in the soil.

Uptake of Pb in animals may occur as a result of inhalation of contaminated ambient air or ingestion of contaminated plants. However, Pb is not biomagnified in aquatic or terrestrial food chains. Older organisms tend to contain the greatest body burdens of Pb. In aquatic organisms, Pb concentrations are

5. POTENTIAL FOR HUMAN EXPOSURE

usually highest in benthic organisms and algae, and lowest in upper trophic level predators (e.g., carnivorous fish). Exposure of a fresh water fish to several sublethal concentrations of Pb for a period of 30 days showed significant accumulation of Pb in the blood and tissues. The Pb accumulation in tissues was found to increase with Pb in water up to a concentration of 5 mg/L ($\mu\text{g}/\text{mL}$); at concentrations of 10 and 20 mg/L, the Pb accumulation in the tissues, although indicating an increase, was not proportional to the Pb concentration in water (Tulasi et al. 1992). High bioconcentration factors (BCFs) were determined in studies using oysters (6,600 for *Crassostrea virginica*), fresh water algae (92,000 for *Senenastrium capricornutum*), and rainbow trout (726 for *Salmo gairdneri*). However, most median BCF values for aquatic biota were significantly lower: 42 for fish, 536 for oysters, 500 for insects, 725 for algae, and 2,570 for mussels (Eisler 1988). Pb is toxic to all aquatic biota, and organisms higher up in the food chain may experience Pb poisoning as a result of eating Pb-contaminated food. Organolead compounds, such as trialkyl and tetraalkyl Pb compounds, are more toxic than inorganic forms and have been shown to bioconcentrate in aquatic organisms.

Biomagnification of organolead compounds has not been found to occur. Depuration is relatively rapid, with half-life values of 30–45 hours for rainbow trout exposed to tetramethyl Pb. Tetraalkyl Pb compounds are more toxic than trialkyl Pb compounds, and ethyl forms are more toxic than methyl forms (Eisler 1988). Isolation of a *Pseudomonas aeruginosa* strain designated CHL004, which is able to remove Pb from solidified media and soil, has been reported (Vesper et al. 1996). The rate of uptake of Pb nitrate by CHL004 was very rapid initially and then decreased greatly.

5.4.2 Transformation and Degradation

As an element, Pb cannot be degraded in the environment, but may undergo various precipitation or ligand exchange reactions. Pb will typically be found in compounds with oxygen and sulfur, and may undergo oxidation-reduction reactions under different environmental conditions. Under most environmental conditions, Pb will most likely exist in its Pb(II) oxidation state. Pb can be complexed by various ligands present in the environment (e.g., fulvic and humic acids). Despite forming complexes with organic matter, it is unlikely that it would be incorporated into organic compounds under environmental conditions. Transformations of Pb compounds that occur during their movement through the environment will be between various inorganic compounds.

Air. According to EPA (2014c), Pb accumulated on airborne mineral dusts can be transformed into different compounds during transport. It was also noted that Pb can accumulate on coarse particulate

5. POTENTIAL FOR HUMAN EXPOSURE

matter during transport in air and undergo chemical transformations. For example, Pb sulfate (PbSO_4), one of the main components of Pb-containing aerosols from coal combustion, can react with calcite (CaCO_3) in particulate matter to form various Pb carbonate compounds on the calcite surface. Another study included in the discussion noted that Pb levels in the PM_{10} fraction from dust storms collected in Israel were enriched with Pb at levels higher than those found in their source in the Sahara desert, suggesting that the dust samples accumulated Pb during transit between the Sahara desert and Israel (EPA 2014c).

Before the ban on sales of leaded gasoline, Pb particles were emitted to the atmosphere from automobile exhaust as Pb halides (mostly PbBrCl) and as double salts with ammonium halides (e.g., $2\text{PbBrCl}\cdot\text{NH}_4\text{Cl}$, $\text{Pb}_3[\text{PO}_4]_2$, and PbSO_4) (Biggins and Harrison 1979; Ter Haar and Bayard 1971). After 18 hours, approximately 75% of the bromine and 30–40% of the chlorine was released, and Pb carbonates, oxycarbonates, and oxides were produced. These Pb oxides are subject to further weathering to form additional carbonates and sulfates (Olson and Skogerboe 1975). Pb particles are emitted from mines and smelters primarily in the form of elemental Pb and Pb-sulfur compounds, PbSO_4 , $\text{PbO}\cdot\text{PbSO}_4$, and PbS (Corrin and Natusch 1977; EPA 1986; Spear et al. 1998). The Pb emitted from the combustion of waste oil was found to be in the form of PbCl_2 , PbO , and elemental Pb (Pb^0) (Nerin et al. 1999). In the atmosphere, Pb exists primarily in the form of PbSO_4 and PbCO_3 (EPA 1986).

While Pb is no longer added to gasoline for on-road use, the inorganic Pb degradation products of these organolead compounds may still be present in the environment. Based on the vapor pressure of tetraethyl Pb (0.26 mmHg at 25 °C) and tetramethyl Pb (26.0 mmHg at 20 °C), these two compounds exist almost entirely in the vapor phase in the atmosphere (Eisenreich et al. 1981). When exposed to sunlight, they decompose rapidly to trialkyl and dialkyl Pb compounds, and eventually to inorganic Pb oxides by a combination of direct photolysis, reaction with hydroxyl radicals, and reaction with ozone. The half-life of tetraethyl Pb in reactions with hydroxyl radicals during summer is approximately 5.7 hours, based on a rate constant of $6.8 \times 10^{-11} \text{ cm}^3/\text{molecule}\cdot\text{second}$ (Nielsen et al. 1991). The half-life for tetramethyl Pb is about 65 hours, based on a rate constant of $5.9 \times 10^{-12} \text{ cm}^3/\text{molecule}\cdot\text{second}$. In the winter, both compounds have half-lives of up to several days since the concentration of atmospheric hydroxyl radicals is lower than in summer months (DeJonghe and Adams 1986).

Water. The fate of Pb in water will be determined by the conditions of the water, including acidity (pH), ionic strength, oxidation-reductions potential, flow rate, and amount and composition of suspended materials (EPA 2014c). The pH of water is an important factor in determining the fate of Pb in water. At

5. POTENTIAL FOR HUMAN EXPOSURE

neutral to more basic pH, Pb will tend to be complexed, precipitated, or sorbed to suspended sediments in water (EPA 2014c). Pb will form compounds of low solubility with the major anions found in natural waters. The maximum solubility of Pb in hard water is about 30 µg/L at pH>5.4 and the maximum solubility of Pb in soft water is approximately 500 µg/L at pH>5.4 (EPA 1977). In the environment, the divalent form (Pb²⁺) is the stable ionic species of Pb. Hydroxide, carbonate, sulfide, and, more rarely, sulfate may act as solubility controls in precipitating Pb from water. At pH<5.4, the formation of Pb sulfate limits the concentration of soluble Pb in water, while at pH>5.4, the formation of Pb carbonates limits the amount of soluble Pb (EPA 1979). The relatively volatile organolead compound, tetramethyl Pb, may form as a result of biological alkylation of organic and inorganic Pb compounds by microorganisms in anaerobic lake sediments; however, if the water over the sediments is aerobic, volatilization of tetramethyl Pb from the sediments is not considered to be important because the tetramethyl Pb will be oxidized (EPA 1979).

The speciation of Pb was found to differ in fresh water and seawater. In fresh water, Pb may partially exist as the divalent cation (Pb²⁺) at pHs below 7.5, but complexes with dissolved carbonate to form insoluble PbCO₃ under alkaline conditions (Long and Angino 1977). Even small amounts of carbonate ions formed in the dissolution of atmospheric CO₂ are sufficient to keep Pb concentrations in rivers at the 500 µg/L solubility limit (EPA 1979). Pb chloride and Pb carbonate are the primary compounds formed in seawater (Long and Angino 1977). The speciation of Pb in water is also dependent on the presence of other ligands in water. Pb is known to form strong complexes with humic acid and other organic matter (Denaix et al. 2001; Gao et al. 1999; Guibaud et al. 2003). Pb-organic matter complexes are stable to a pH of 3 with the affinity increasing with increasing pH, but decreasing with increased water hardness (EPA 1979). In seawater, there is the presence of Pb complexed to Fe-Mn oxides, which is due to the content of these oxides in seawater (Elbaz-Poulichet et al. 1984). Sorption of Pb to polar particulate matter in fresh water and estuarine environments is an important process for the removal of Pb from these surface waters. The adsorption of Pb to organic matter, clay, and mineral surfaces, and coprecipitation and/or sorption by hydrous iron and manganese oxides increases with increasing pH (EPA 1979).

Sediment and Soil. Pb in its naturally-occurring mineral forms is a component of many soils in the United States. The speciation of Pb in soils is dependent upon the properties of the soil. In a calcareous soil, PbSO₄ and PbCO₃ were shown to account for <5% of the total Pb content, whereas in roadside dust, PbSO₄, elemental Pb, Pb₃O₄, PbO·PbSO₄, and 2PbCO₃·Pb(OH)₂ were present in significant quantities (Chaney et al. 1988). It was also reported that after adding 3,000–4,000 mg/kg of Pb in the form of

5. POTENTIAL FOR HUMAN EXPOSURE

PbSO₄, subsequent extractions revealed that the Pb sulfate was rapidly transformed to other Pb compounds in the soil (Chaney et al. 1988).

Nearly all forms of Pb that are released to soil from anthropogenic sources, such as elemental Pb, PbSO₄, PbCO₃, PbS, Pb(OH)₂, PbCrO₄, and PbClBr, are transformed by chemical and biotic processes to adsorbed forms in soil (Chaney et al. 1988). The transformation process involves the formation of Pb complexes with binding sites on clay minerals, humic acid and other organic matter, and hydrous iron oxides (Chaney et al. 1988; Chuan et al. 1996; Sauve et al. 1997). The ability of soils to bind Pb is dependent on soil pH and the cation exchange capacity of the soil components (e.g., hydrous iron oxides on clay and organic matter) (Chaney et al. 1988; EPA 1986). Only a small fraction (0.1–1%) of Pb appears to remain water-soluble in soil (Khan and Frankland 1983). The solubility of Pb in soil is dependent on pH, being sparingly soluble at pH 8 and becoming more soluble as the pH approaches 5 (Chuan et al. 1996). Between pH 5 and 3.3, large increases in Pb solubility in soil are observed. These changes in Pb solubility appear to correlate with the pH-dependent adsorption and dissolution of Fe-Mn oxyhydroxides. In addition to pH, other factors that influence Pb solubility in soil are total Pb content and the concentrations of phosphate and carbonate in soils (Bradley and Cox 1988; Ge et al. 2000; Pardo et al. 1990; Sauve et al. 1997).

Large particles of elemental Pb (e.g., shot and bullet fragments) degrade from weathering processes (Cao et al. 2003a, 2003b). Weathering includes physical transformation of larger particles to smaller particles (particle dissolution), as well as oxidation of the particle surface (coating) to PbO₂, with subsequent further oxidation to carbonates, phosphates, and sulfates (Cao et al. 2003a, 2003b; Hardison et al. 2004; Hashimoto 2013; Lewis et al. 2010; Lin et al. 1995; Rooney et al. 2007; Vantenlon et al. 2005). Particle dissolution rates for shotgun pellets in soils have been estimated to range from 1 to 20 mg/g pellet/year, depending on soil type, precipitation, and vegetation cover (Jorgenson and Willems 1987; Takamatsu et al. 2010).

Since the ban on the use of leaded gasoline, atmospheric Pb deposition to soil has decreased considerably. However, the deposited organolead compounds and their transformation products remain in the soil. Limited data indicate that tetraethyl and tetramethyl Pb are converted into water-soluble Pb compounds in soil through microbial metabolism (Ou et al. 1994). Using an Arredondo fine sand from Florida (92% sand, 7% silt, 1% clay, 11.8 g/kg organic carbon, pH 5.5), tetraethyl Pb was shown to degrade sequentially to monoionic triethyl Pb, diionic diethyl Pb, and eventually Pb⁺² (Ou et al. 1994). Experiments were conducted using non-sterilized and autoclaved soil samples. The presence of

5. POTENTIAL FOR HUMAN EXPOSURE

monoionic triethyl Pb and diionic diethyl Pb was generally lower in the autoclaved samples, suggesting that both abiotic and biotic mechanisms are responsible for the degradation of tetraethyl Pb. At the end of a 28-day incubation period, no tetraethyl Pb was present in the soil; however, there were significant quantities of monoionic triethyl Pb and diionic diethyl Pb, which suggest that the degradation products are more persistent than the original species. Although tetraethyl and tetramethyl Pb are not expected to leach significantly through soil, their more water-soluble metabolites may be subject to leaching (EPA 1985a).

Pb content in plants is largely the result of atmospheric deposition. This is due to the strong retention of particulate matter on plant surfaces that is difficult to remove through washing (EPA 1977). Uptake of Pb into plant tissue appears to involve a combination of uptake from the leaf surface and uptake from roots, with the relative contribution of each pathway dependent on species and soil characteristics (Angelova et al. 2010; Bindler et al. 2008; Chrastny et al. 2010; Cui et al. 2007; Guyette et al. 1991; Hu and Ding 2009; Nwosu et al. 1995). Pb taken up by the root systems remains largely associated with root tissues (Comino et al. 2011; Businelli et al. 2011; Deng et al. 2004; Mellem et al. 2009; Murray et al. 2009; Nan and Cheng 2001; Sonmez et al. 2008; Wang et al. 2011). Translocation from roots to stem and leaf tissue has been shown to occur in some species (Peralta-Videa et al. 2009; Shaheen and Tsadilas 2009; Tamura et al. 2005; Wang et al. 2006; Zaprjanova et al. 2010). Eventually, the Pb will be returned to soil when these plants decay unless they are harvested (to possibly enter the food chain) or removed.

5.5 LEVELS IN THE ENVIRONMENT

Reliable evaluation of the potential for human exposure to Pb depends, in part, on the reliability of supporting analytical data from environmental samples and biological specimens. Concentrations of Pb in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits of current analytical methods. In reviewing data on Pb levels monitored or estimated in the environment, it should also be noted that the amount of chemical identified analytically is not necessarily equivalent to the amount that is bioavailable.

Table 5-11 shows the lowest limit of detections that are achieved by analytical analysis in environmental media. An overview summary of the range of concentrations detected in environmental media is presented in Table 5-12.

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-11. Lowest Limit of Detection Based on Standards^a

Media	Detection limit	Reference
Air	1.5 ng/cm ² (XRF)	EPA, 1999, Method IO-3.3
	2.6 µg/sample	NIOSH 2017b, Method 7082
	6 µg/sample	NIOSH 1998, Method 7702
	0.02 µg/sample	NIOSH 1994c, Method 7105
	0.05 µg/sample	NIOSH 2016a, Method 7701
	0.062 µg/filter	NIOSH 2003c, Method 7300
	0.062 µg/filter	NIOSH 2003a, Method 7301
	0.023 µg/mL	NIOSH 2003b, Method 7303
	0.6 µg/sample	NIOSH 2014a, Method 7302
	1 µg/sample	NIOSH 2014b, Method 7304
	0.062 µg/sample	NIOSH 2015, Method 7306
	0.03 µg/mL	OSHA 2002, Method ID-121
	2.1 µg/sample	OSHA 2002, Method ID-125G
Drinking water	1.1 µg/L (ICP-AES)	EPA 2003 Method 200.5
	0.02 µg/L (ICP-MS)	EPA 1994 Method 200.8
Surface water and groundwater	0.07 µg/L	EPA 1997b
	2.4 µg/L (GFAA)	EPA 1997b
	0.28 µg/L (GFAA with preconcentration)	
	0.07 µg/L (ICP-MS)	
	0.05 µg/L (ICP-MS)	USGS 1998
	60 µg/L (ICP-OES)	
	1 µg/L (GFAA)	USGS 1993
	1.1 µg/L (AVICP-AES)	
	10 µg/L (ICP)	USGS 1989
	100 µg/L (total recoverable, FLAA)	
	1 µg/L (whole water recoverable, GFAA)	
	0.5 µg/L (dissolved in water by GFAA)	
	100µg/L (suspended recoverable, FLAA)	
100 µg/L (dissolved, FLAA)		
0.6 µg/L (ICP-MS)	EPA 1994d	
0.7 µg/L (GFAA)		
10 µg/L (ICP-AES)		
Soil/sediment	0.15 µg/g (ICP-MS)	NOAA 1998
	0.2 µg/g (XRF)	
	0.2 µg/g (GF-AAS)	
	10 µg/g (FLAA)	USGS 1989

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-11. Lowest Limit of Detection Based on Standards^a

Media	Detection limit	Reference
Wipes	0.042 µg/wipe	NIOSH 2003d, Method 9102
	0.02 µg/cm ² for 100-cm ² area (FLAA or ICP);	NIOSH 1996a, Method 9100
	0.001 µg/cm ² for 100-cm ² area (GF-AAS)	
	Range: 5–15 µg/wipe sample	NIOSH 2003e, Method 9105

^aDetection limits based on using appropriate preparation and analytics. These limits may not be possible in all situations.

AES = atomic emission spectroscopy; AVICP = axially viewed inductively coupled plasma; FLAA = flame atomic absorption; GFAA = graphite furnace atomic absorption; GF-AAS = graphite furnace-atomic absorption spectrometer; GRAV = gravimetry; ICP = inductively coupled plasma; MS = mass spectrometry; OES = optical emission spectrometry; Pb = lead; XRF = x-ray fluorescence

Table 5-12. Lead Levels in Water, Soil, and Air of National Priorities List (NPL) Sites

Medium	Median ^a	Geometric mean ^a	Geometric standard deviation ^a	Number of quantitative measurements	NPL sites
Water (ppb)	0.118	0.0075	13.8	1,451	657
Soil (ppb)	1,110	878	19.8	1,443	655
Air (ppbv)	0.00165	0.0025	32.6	84	50

^aConcentrations found in ATSDR site documents from 1981 to 2015 for 1,832 NPL sites (ATSDR 2015). Maximum concentrations were abstracted for types of environmental media for which exposure is likely. Pathways do not necessarily involve exposure or levels of concern.

5.5.1 Air

Four national monitoring networks collect data on Pb concentrations in ambient air to report to the Air Quality System (AQS). State and local agencies carry out monitoring at state and local monitoring stations (SLAMS). These data are primarily used to evaluate compliance with the National Ambient Air Quality Standard (NAAQS) for Pb. Pb levels are also monitored in the Chemical Speciation Network (CSN), Interagency Monitoring of Protected Visual Environments (IMPROVE), and National Air Toxics Trends Station (NATTS) networks. Pb concentrations in air are measured in three particulate matter (PM) size fractions: total suspended particles (TSP), PM₁₀, and PM_{2.5}. The CNS and IMPROVE networks monitor Pb in PM_{2.5} and the NATTS network monitors Pb in PM₁₀. These networks are designed to meet different objectives than those of the Pb NAAQS monitoring network (EPA 2006, 2014c). EPA (2014c) analyzed data from these monitoring systems and presented data summaries for

5. POTENTIAL FOR HUMAN EXPOSURE

source-oriented (defined as near point sources and exceeded a defined emission threshold) and non-source-oriented Pb monitors across the United States for 2008–2010 (EPA 2014c). Maximum 3-month daily average Pb concentrations were calculated for non-source-oriented Pb-TSP monitors for 47 counties across the United States (1.5% of U.S. counties) and for source-oriented Pb-TSP monitors for 50 counties across the United States (1.6% of U.S. counties) during the period 2008–2010. Summaries of these analyses are presented in Table 5-13.


Table 5-13. Summary Data for Lead Monitors Across the United States, 2008–2010 ($\mu\text{g}/\text{m}^3$)

	Mean	Median	95 th %	99 th %	Maximum
Monthly (source-oriented)	0.20	0.063	0.86	1.6	4.4
Monthly (nonsource-oriented)	0.012	0.010	0.040	0.052	0.14

Source: EPA 2014c

Pb levels have been declining in the ambient air of the United States for several decades and according to the EPA, there has been approximately a 94% decrease since 2000 (EPA 2018a). Figure 5-3 shows the annual maximum 3-month average Pb level in the United States based upon data at 24 monitoring sites.

Figure 5-3. Annual Maximum 3-Month Average Representing the National Trend



5. POTENTIAL FOR HUMAN EXPOSURE

Data compiled from the EPA AQS database from 2015 to 2018 were used to calculate the percentile distribution of arithmetic mean 3-month averages at locations across the United States. These data are summarized in Table 5-14.

Table 5-14. Percentile Distribution of Mean Lead (TSP) Concentrations ($\mu\text{g}/\text{m}^3$) Measured in Ambient Air at Locations Across the United States

Year	Percentile				Maximum
	25th	50th	75th	95th	
2015	0.0036	0.0090	0.0216	0.0753	0.1942
2016	0.0038	0.0093	0.0220	0.0782	0.1466
2017	0.0039	0.0080	0.0190	0.0756	0.2087
2018	0.0035	0.0090	0.0313	0.1248	0.5574

TSP = total suspended particles

Source: EPA 2018b

Pb in indoor air is related to Pb in housedust, and predominant sources are outdoor air and degraded Pb-based paint (EPA 2006). Smoking can also contribute to higher concentrations of Pb in indoor air. Pb concentrations in air and dust in the indoor environment were measured in residential homes as part of the National Human Exposure Assessment Survey (NHEXAS) in EPA Region V (Indiana, Illinois, Michigan, Minnesota, Ohio, and Wisconsin). Mean (± 1 SD) and median concentrations of Pb in indoor air from 213 residences were $15.2 \text{ ng}/\text{m}^3$ ($37.6 \text{ ng}/\text{m}^3$) and $6.17 \text{ ng}/\text{m}^3$, respectively, with a maximum value of $293.5 \text{ ng}/\text{m}^3$ (Bonanno et al. 2001). The median Pb concentration in outdoor air was $8.84 \text{ ng}/\text{m}^3$ (Clayton et al. 2002). Pb concentrations were higher in households where one or more residents smoked indoors (mean concentration of $21.8 \text{ ng}/\text{m}^3$) as compared to households with nonsmoking residents (mean concentration of $7.79 \text{ ng}/\text{m}^3$) (Bonanno et al. 2001). In dust collected from the living areas of 238 residences, the mean (± 1 SD) and median Pb concentrations were $467.4 \mu\text{g}/\text{g}$ ($2,100 \mu\text{g}/\text{g}$) and $131.6 \mu\text{g}/\text{g}$, respectively, with a maximum value of $30,578 \mu\text{g}/\text{g}$. Dust samples collected from window sills had mean (± 1 SD) and median Pb concentrations of $987 \mu\text{g}/\text{g}$ ($2,723 \mu\text{g}/\text{g}$) and $207.5 \mu\text{g}/\text{g}$, respectively, with a maximum value of $21,120 \mu\text{g}/\text{g}$. For both indoor air and dust measurements, higher concentrations of Pb were correlated with dilapidated and suburban homes. Dixon et al. (2009) analyzed children's exposures to residential dust Pb using data from the NHANES survey and associated demographics as well as smoking status to exposure levels. Children who resided in homes in which smoking occurred indoors had significantly ($p=0.015$) higher PbB levels than children who lived in homes of nonsmokers.

5. POTENTIAL FOR HUMAN EXPOSURE

In another analysis of the NHEXAS EPA Region V data, Pellizzari et al. (1999) looked at potential differences in Pb concentrations in indoor air and personal air exposures between minorities (e.g., Hispanics and African-Americans) and nonminorities (e.g., Caucasian). Some differences were noted in the mean (± 1 SD) Pb concentrations between minorities of 57 ng/m^3 ($\pm 24 \text{ ng/m}^3$) and nonminorities of 22 ng/m^3 ($\pm 3.4 \text{ ng/m}^3$) in personal air exposures, although the differences were not significant ($p=0.147$). Similarly, differences were noted between minorities ($26 \pm 12 \text{ ng/m}^3$) and nonminorities ($13 \pm 2.6 \text{ ng/m}^3$) in indoor air, although these were also not significantly different ($p=0.266$). When the age of the home was considered in the analysis, it was found that Pb concentrations were significantly ($p=0.036$) higher in homes built before 1940 than in homes built between 1960 and 1979, with mean (± 1 SD) values of 46 ng/m^3 ($\pm 1.6 \text{ ng/m}^3$) and 13 ng/m^3 ($\pm 2.1 \text{ ng/m}^3$), respectively. The Pb concentrations measured in indoor air in homes built before 1940 were not significantly different from mean (± 1 SD) Pb concentrations of 22 ng/m^3 ($\pm 5.1 \text{ ng/m}^3$) and 23 ng/m^3 ($\pm 5.1 \text{ ng/m}^3$) measured in indoor air in homes built between 1940 and 1959 and between 1980 and 1995, respectively.

5.5.2 Water

Pb has been monitored in surface water, groundwater, and drinking water throughout the United States and other countries. The concentration of Pb in surface water is highly variable depending upon sources of pollution, Pb content of sediments, and characteristics of the system (pH, temperature, etc.). Pb concentrations in surface water are generally higher in urban areas than in rural areas (EPA 1982c), and Pb measured in natural or “pristine” surface waters may be due to anthropogenic input. Western Airborne Contaminants Assessment Project (WACAP) data collected at five U.S. National Parks showed median Pb levels in surface waters ranging from 0.006 to 0.075 $\mu\text{g/L}$ (EPA 2014c). The median Pb level in natural river water was 5 $\mu\text{g/L}$, with a range of 0.6–120 $\mu\text{g/L}$; however, lower Pb levels are to be expected after leaded gasoline was banned in 1985, which resulted in decreased rates of atmospheric deposition (Bown et al. 1966; King et al. 2014). The National Academies of Science reported Pb concentration levels in surface water and groundwater (EPA 1986). The mean Pb concentration level in surface water was 4 $\mu\text{g/L}$ with a range from below the detection limit to 890 $\mu\text{g/L}$ (EPA 2014c); concentrations $>100 \mu\text{g/L}$ were observed near sources of urban runoff or industrial discharge. Mean levels of Pb in surface water measured at 50,000 surface water stations throughout the United States were 3.9 $\mu\text{g/L}$ (based on 39,490 occurrences) (Eckel and Jacob 1988). Using the EPA Storage and Retrieval (STORET) database, from January 1, 2005 to May 16, 2005, Pb had been detected in surface water in Washington, Utah at concentrations of 20.5 and 142 $\mu\text{g/L}$ and surface water from Salt Lake City, Utah at 7.75 $\mu\text{g/L}$ (EPA 2005b). Pb was not detected above the detection limits in 224 other surface water samples obtained

5. POTENTIAL FOR HUMAN EXPOSURE

from various locations in Utah and Iowa over the sampling period (EPA 2005b). Pb content in groundwater is driven largely by the surrounding bedrock geochemistry; Pb concentrations are generally low in groundwater and natural springs ranging from below the detection limit to 100 µg/L (EPA 2014c). Pb levels in seawater are estimated as 0.005 µg/L (EPA 1982c).

Urban storm water runoff is an important source of Pb entering receiving waterways. Sources of Pb in runoff can be contributed to substantial direct atmospheric deposition, as well as indirect release from building materials, soil, and road dust, and industrial discharge. Pb is found in building material (brick, concrete, painted and unpainted wood, roofing, and vinyl), and automotive sources (brakes, used oil), which contribute to runoff (Davis et al. 2001). The largest contributing sources were siding and roofing. Soto-Jiménez-Flegal (2009) evaluated the sources of Pb pollution in the Gulf of California, northwest Mexico by sampling urban and rural areas for Pb levels and isotope ratios. Urban street dust (157 µg/g), agricultural soils (29.0 µg/g), and surface estuary sediments (35.6 µg/g) were all higher than natural bedrock (16.0 µg/g). Isotopic ratios in rural and soil runoff samples were comparable to natural Pb containing bedrock. Pb concentrations in the suspended particulate matter were measured in sewage effluent (132 µg/g), agricultural effluent (29.3 µg/g), river runoff (7.3 µg/g), and estuary water (68.3 µg/g). Urban, street dust, and sewage showed contributions from automotive emissions from past leaded gasoline combustion.

Pb in drinking water can derive from source water contamination as described above, but the more common source of Pb in drinking water is from internal corrosion of water distribution system piping and plumbing. Internal corrosion of Pb service lines, Pb-based pipe solder, brass meters and plumbing fixtures, and dissolution of existing protective scales contribute directly to Pb levels in drinking water. The Lead and Copper Rule (LCR) was promulgated in 1991 with the purpose of protecting public health by minimizing Pb and copper levels in drinking water, primarily by reducing water corrosivity (EPA 2004). The LCR established a Pb action level (AL) of 15 µg/L and a maximum contaminant level goal (MCLG) of zero. The Pb action level is based on feasibility of public water systems to control corrosion in their distribution systems and is not a health benchmark for Pb in drinking water. The Pb action level is exceeded if the concentration of the 90th percentile first draw tap sample (collected after a minimum stagnation period of 6 hours from high risk sites) exceeds 15 µg/L (EPA 2016g). If the Pb AL is exceeded, the LCR can require public water systems to take steps to minimize the risk of Pb exposure that may include source water monitoring/treatment, public education, water quality monitoring, implementing corrosion control treatment, and Pb service line replacement.

5. POTENTIAL FOR HUMAN EXPOSURE

The amount of Pb contained in pipes and plumbing fittings has been strictly regulated since 1986. Section 1417 of the Safe Drinking Water Act (SDWA) was amended to ban the use of service lines, pipe fittings, pipe solder, and fixtures that are not “Pb free” (not more than 0.2% Pb for pipe solder and flux, and not more than 8% Pb for pipe fittings and service lines) and are connected to a public water system and intended to provide water for human consumption. The 1996 Amendment broadened this ban by limiting the amount of leaching of Pb from new plumbing, and an industry standard was established. In 2011, the Reduction of Lead in Drinking Water Act amended Section 1417, revising the existing SDWA definition of “Pb free” and getting rid of the leaching certification requirement. Implemented in 2014, the act reduced the allowable level of Pb by “not more than a weighted average of 0.25 percent Pb when used with respect to the wetted surfaces of pipes, pipe fittings, plumbing fittings and fixtures.”

Analyses done in support of the short-term revisions to the LCR suggest that in 2003, <2% of public water systems serving >3,300 people exceeded the Pb action level of 15 µg/L (EPA 2007a). Additionally, a 2004 study conducted by the EPA on LCR compliance monitoring for public water systems serving >3,300 people indicated that <4% of those systems exceeded the Pb action level (Hill 2011). It is important to note that states were not required until 2002 to report 90th percentile Pb concentrations to the EPA unless those samples exceeded the Pb AL; therefore, it is difficult to accurately compare differences between tap water Pb levels prior to LCR implementation and immediately following LCR implementation with current nationwide Pb concentration levels (Hill 2011). Nevertheless, the EPA evaluated water sample data from 166 large public water systems (systems serving >50,000 people) that exceeded the Pb AL in 1992 and 1993 (Hill 2011). Of the large systems that exceeded the Pb AL in 1992–1993, only 15 of those systems continued to exceed the Pb AL between 2000 and 2004, and their associated average 90th percentile Pb concentration levels significantly decreased from 32 to 8.2 µg/L.

According to EPA's National Public Water Systems Compliance Report for calendar year 2013 (EPA 2013), 73% of public water systems in the United States, serving approximately 77% of the population, had no significant reported violations of any type. Significant violations include all violations of health-based standards, including violations of the maximum contaminant levels, treatment technique requirements, and significant monitoring and reporting requirements. In 2013, 7% of public water systems had no reported violations of health-based standards, and 5% of all health-based standard violations were LCR violations.

5. POTENTIAL FOR HUMAN EXPOSURE

5.5.3 Sediment and Soil

Pb is a naturally occurring metal found in the earth's crust at about 15–20 mg/kg (Goyer 2001). However, the concentration of Pb in the top layers of soil varies widely due to deposition and accumulation of atmospheric particulates from anthropogenic sources. The concentration of soil Pb generally decreases as distance from contaminating sources increases. The estimated Pb levels in the upper layer of soil beside roadways are typically 30–2,000 µg/g higher than natural levels, although these levels drop exponentially up to 25 m from the roadway (EPA 1986). Soil adjacent to a smelter in Missouri had Pb levels in excess of 60,000 µg/g (Palmer and Kucera 1980). Soils adjacent to houses with exterior Pb-based paints have reported Pb levels >10,000 µg/g (EPA 1986). As a result of Pb reactions with the soil, extractable Pb in surface soil samples (0–5 cm depth) from an agricultural area near a car battery manufacturing plant (taken at 0.3 km from the source) decreased from 117 to 1 µg/g within 1 year after the plant stopped operating (Schalscha et al. 1987). Soil collected by scraping the top 2.5 cm of soil surface near homes and streetside in Louisiana and Minnesota contained median Pb concentrations of >840 µg/g in New Orleans and 265 µg/g in Minneapolis. In contrast, the small towns of Natchitoches, Louisiana, and Rochester, Minnesota had soil Pb concentrations of <50 and 58 µg/g, respectively. These data suggest that Pb-contaminated soil is a major source of Pb exposure in urban areas (Mielke 1993). As would be expected, soils in elementary school properties were also found to have the same pattern of Pb levels as the soils in the surrounding residences. Pb concentrations in soils collected from inner-city schools in New Orleans were higher (median concentration of 96.5 µg/g) than soils collected from mid-city (30.0 µg/g) and outer-city (16.4 µg/g) elementary schools (Higgs et al. 1999).

The former use of Pb in paints, particularly in older structures, is also a source of Pb in soil and within homes. Meilke and Gonzales (2008) reported median Pb concentrations of 76,603 mg/kg (464–317,151 mg/kg) and 416 mg/kg (24–63,313 mg/kg) for exterior and interior paints, respectively, in 40 paint chip samples collected from homes in metropolitan New Orleans. The authors noted that the age of the house is often used as a surrogate for the amount of Pb in paints; the mid-1920s being the peak use of leaded paint with declines until 1978. Demolition and renovation of buildings where leaded paint was used can result in transport of Pb to soil surrounding the building as well as indoor dust that contains Pb.

Pb concentrations were measured in residential transects through Lubbock, Texas. Pb concentrations through the city showed a trend of decreasing Pb concentrations with increasing distance from the city center, which also paralleled a decrease in the property age. The highest Pb concentration in the city center were 90.0–174.0 mg/kg, with a median of 35.4 mg/kg, and decreased out to the farther part of the

5. POTENTIAL FOR HUMAN EXPOSURE

residential transect to 6.0–9.0 mg/kg. The highest concentrations outside city development were 4.9 mg/kg (Brown et al. 2008).

Studies conducted in Maryland and Minnesota indicate that within large, light-industrial, urban settings such as Baltimore, the highest soil Pb levels generally occur near inner-city areas, especially where high traffic flows have long prevailed (Mielke et al. 1983, 1984, 1989) and that the amount of Pb in the soil is correlated with the size of the city (Mielke 1991). In 1981, soil Pb levels in the Minneapolis/St. Paul inner-city area were 60 times higher (423 µg/g) than levels found in rural Minnesota (6.7 µg/g), with almost all the increase (95%) resulting from the combustion of leaded gasoline. A study conducted in Minneapolis, Minnesota, after the Pb content of gasoline had been significantly reduced, found that median soil Pb levels taken from the foundations of homes, in yards, and adjacent to the street were 700, 210, and 160 µg/g, respectively; median soil Pb concentrations in comparable samples from the smaller city of Rochester, Minnesota, did not exceed 100 µg/g at any location tested (Mielke et al. 1989). The Minneapolis data suggested that average Pb levels were elevated in soil samples taken from the foundations of homes, but that Pb levels were low (<50 µg/g) in areas where children could be expected to play, such as parks that were located away from traffic, but were higher in play areas around private residences. Soil samples taken from around the foundations of homes with painted exteriors had the highest Pb levels (mean concentrations of 522 µg/g), but levels around homes composed of brick or stucco were significantly lower (mean concentration 158 µg/g) (Schmitt et al. 1988). Severely contaminated soils (levels as high as 20,136 µg/g) were located near house foundations adjacent to private dwellings with exterior Pb-based paint. Elevated soil Pb concentrations were found in larger urban areas, with 27, 26, 32, and 42% of the soil samples exceeding 300 µg/g Pb in Duluth, inner-city North Minneapolis, inner-city St. Paul, and inner-city South Minneapolis, respectively. Only 5% of the soil samples taken from the smaller urban areas of Rochester and St. Cloud, Minnesota, had Pb levels >150 µg/g. It has been suggested that the higher Pb levels associated with soils taken from around painted homes in the inner city are the result of greater atmospheric Pb content, resulting from the burning of leaded gasoline in cars and the washdown of building surfaces to which the small Pb particles adhere by rain (Mielke et al. 1989). A state-wide Minnesota study concluded that exterior Pb-based paint was the major source of contamination in severely contaminated soils located near the foundations of private residences and that aerosol Pb accounted for virtually all of the contamination found in soils removed from the influence of Pb-based paint. Contamination due to Pb-based paint was found to be “highly concentrated over a limited area, while contamination due to aerosol Pb was found to be less concentrated, but more widespread” (Schmitt et al. 1988).

5. POTENTIAL FOR HUMAN EXPOSURE

Pb was analyzed in dust wipes and soil samples from 67 public housing projects containing 487 dwelling units across the United States (Succop et al. 2001). A total of 5,906 dust wipes and 1,222 soil samples were included in the data set. The median soil levels were 194 ppm near the foundation, 177 ppm near the walkways, and 145 ppm elsewhere in the yard. The maximum level, 3,900 ppm, was found in a foundation sample. Median dust Pb loading ($\mu\text{g m}^{-2}$) from kitchens, living rooms, and two children's bedrooms were 151 (5th–95th percentile range: 22, 674), 936 (86, 10,190), and 8,560 (818, 313,000) for floor window sills and window troughs, respectively. Thirteen percent of the floor samples and 30% of the window sill samples from the rooms exceeded the HUD Interim Dust Lead Standards of 431 and 2,690 $\mu\text{g m}^{-2}$ for floor and window sill samples, respectively.

5.5.4 Paint

Weathering and deterioration of Pb-based paint can contribute to the Pb content of dust and soil (Clark et al. 2004; Hunt et al. 1992; Jaeger et al. 1998; Lucas et al. 2013; Marcus and Elias 1995 <in Beard and Iske 1995>; MPCA 1987). A state-wide Minnesota study concluded that exterior Pb-based paint was the major source of contamination in severely contaminated soils located near the foundations of private residences (MPCA 1987). A soil Pb study in Minneapolis, Minnesota, found that soil samples taken from around the foundations of homes with painted exteriors had a mean concentration of 522 $\mu\text{g/g}$, while soil samples taken from around the foundations of brick or stucco had a mean concentration of 158 $\mu\text{g/g}$ (Schmitt et al. 1988). Pb-based paint, removed from surfaces by burning (gas torch or hot air gun), scraping, or sanding have been found to result, at least temporarily, in higher levels of exposure for families residing in these homes. A 2006 survey of U.S. housing stock estimated that 35% of 106 million housing units contained Pb-based paint and that approximately 20% of houses contained deteriorating Pb-based pant (HUD 2011).

5.5.5 Other Media

Pb has been detected in a variety of foods and spices (Lin et al. 2010). Pb may be introduced into food through uptake from soil into plants or atmospheric deposition onto plant surfaces, during transport to market, processing, and kitchen preparation (EPA 1986). The ban on leaded gasoline as well as the use of welded (non-soldered) food cans during the 1980s are largely responsible for the decreases in levels of Pb in the U.S. diet beginning in the 1980s (FDA 2006). The FDA analyzed samples of foods commonly eaten by toddlers and infants for Pb and noted that levels of Pb in infant and toddler foods, on average, are relatively low (FDA 2016a). These results are summarized in Table 5-15. Selected data from the 2006–2011 FDA Total Diet Study Market Baskets are presented in Table 5-16 (FDA 2016b). Mean Pb levels in

5. POTENTIAL FOR HUMAN EXPOSURE

dairy products (e.g., milk, cheese, ice cream, cream, yogurt) were generally low or below the detection limit. The dairy product category with the highest Pb level was for low-fat fruit-flavored yogurt, with a mean concentration of 0.002 mg/kg for 24 analyses. Mean concentrations of Pb in fruits and vegetable were also generally low, with the highest concentrations in raisins (0.005 mg/kg), spinach (0.004 mg/kg), and lettuce (0.004 mg/kg). Mean concentration of Pb in baby foods ranged from not detected to 0.013 mg/kg. The highest levels reported were found in sweet potatoes (0.013 mg/kg), arrowroot cookies (0.012 mg/kg), grape juice (0.011 mg/kg), teething biscuits (0.008 mg/kg), and apple-cherry juice (0.008 mg/kg). Based on a multimedia Pb exposure modeling analysis for children 1–5 years old, below the 70th percentile of PbB in the general U.S. population, dietary intake was a major background exposure pathway (Zartarian et al. 2017)

Table 5-15. Lead Levels in Foods Commonly Eaten by Toddlers and Infants

Product category	Average ^a (range) (µg/kg)	Number of samples
Cereal, infant/toddler (rice)	15.6 (5.0–82.0)	76
Cereal, infant/toddler (multigrain)	7.2 (6.0–8.0)	6
Cereal, infant/toddler (non-rice)	4.8 (0.4–17.0)	30
Apples ^b	3.3	10
Cereal, oat ring	7.8 (3.3–16.4)	30
Grapes	3.7 (3.3–7.6)	10
Juice, grape	5.6 (0.3–41.3)	30
Juice boxes and pouches	3.3 (0.3–17.0)	40
Peanut butter	5.3 (3.3–45.2)	29
Quinoa	22.2 (0.4–98.0)	30
Raisins	18.1 (1.8–151)	23
Stage 2 toddler foods	5.2 (1.0–22.2)	35
Teething biscuits	12.0 (2.0–131)	27
Toddler puffs	19.1 (3.3–91.0)	31

^aThe average concentration reported for each product category was calculated using all values. For those samples with results below the detection limit, half of the detection limit was used to calculate the average.

^bAll of the apple samples were below the limit of detection.

Source: FDA 2016a

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-16. Selected Mean Lead Concentrations in Food from the FDA Total Diet Study

Food	Mean (range) (mg/kg) ^a	Number of analyses	Number <LOD	LOD (mg/kg)
Syrup, chocolate	0.016 (0–0.027)	24	1	0.007
Apricots, canned in heavy/light syrup	0.015 (0–0.036)	24	1	0.007
Baby food, sweet potatoes	0.013 (0–0.034)	24	5	0.007
Peach, canned in light/medium syrup	0.013 (0–0.038)	24	2	0.007
Candy bar, milk chocolate, plain	0.013 (0–0.027)	24	5	0.01
Baby food, arrowroot cookies	0.012 (0–0.031)	24	9	0.01
Sweet potatoes, canned	0.012 (0–0.018)	24	2	0.007
Shrimp, boiled	0.012 (0–0.18)	24	18	0.01
Baby food, juice, grape	0.011 (0–0.02)	24	1	0.004
Fruit cocktail, canned in light syrup	0.011 (0–0.025)	24	4	0.007
Brownie	0.01 (0–0.032)	24	5	0.007

^aNote: 1 mg/kg = 1,000 µg/kg.

FDA = U.S. Food and Drug Administration; LOD = limit of detection

Source: FDA 2016b

The U.S. Fish and Wildlife Service reported the concentrations of metals in a total of 315 composite samples of whole fish sampled from 109 stations nationwide from late 1994 to early 1995. For Pb, the geometric mean, maximum, and 85th percentile concentrations (µg/g wet weight) were 0.11, 4.88, and 0.22, respectively. The mean concentration of Pb was significantly lower than in the 1980–1981 survey. Pb concentrations in fish have declined steadily from 1976 to 1984, suggesting that reductions of leaded gasoline and controls on mining and industrial discharges have reduced Pb in the aquatic environment (Schmitt and Brumbaugh 1990).

In order to reduce Pb exposure from consumption of Pb-contaminated fish and shellfish, consumption advisories are issued by states recommending that individuals restrict their consumption of specific fish and shellfish species from certain water bodies where Pb concentrations in fish and shellfish tissues exceed the human health level of concern. This level of concern is set by individual state agencies and used to issue advisories recommending no consumption, or restricted consumption, of contaminated fish and shellfish from certain waterbody types (e.g., lakes and/or rivers). In 1995, the EPA Office of Water issued guidance to states on sampling and analysis procedures to use in assessing the health risks from consuming locally caught fish and shellfish. The risk assessment method proposed by EPA was specifically designed to assist states in developing fish consumption advisories for recreational and

5. POTENTIAL FOR HUMAN EXPOSURE

subsistence fishers (EPA 1995a). These two groups within the general population consume larger quantities of fish and shellfish than the general population and frequently fish the same water bodies routinely. Because of this, these populations are at greater risk of exposure to Pb and other chemical contaminants if the waters they fish are contaminated. In 2007, eight advisories restricting the consumption of Pb-contaminated fish and shellfish were in effect in five states (Hawaii, Idaho, Washington, Kansas, and Missouri) and one territory (American Samoa) (EPA 2007b).

Elevated levels of Pb in the blood of cattle grazing near a Pb smelter have been reported, although no implications regarding Pb in beef were made. The mean Pb levels for the herd were highest near the smelter and decreased with distance. Ingestion of soil along with the forage was thought to be a large source of additional metal (Neuman and Dollhopf 1992). Evidence has also been shown for transfer of Pb to milk and edible tissue in cattle poisoned by licking the remains of storage batteries burned and left in a pasture (Oskarsson et al. 1992). Levels of Pb in muscle of acutely sick cows that were slaughtered ranged from 0.23 to 0.5 mg/kg (wet weight basis). Normal Pb levels in bovine meat from Swedish farms are <0.005 mg/kg. For eight cows that were less exposed, levels of Pb in milk taken 2 weeks after the exposure were 0.08 ± 0.04 mg/kg. The highest Pb level found in the milk of eight cows studied for 18 weeks was 0.22 mg/kg. Pb in most milk samples decreased to values <0.03 mg/kg 6 weeks after exposure. Two affected cows delivered a calf at 35 and 38 weeks after the exposure. There was a high Pb level in the blood of the cows at the time of delivery, which suggests mobilization of Pb in connection with the latter stages of gestation and delivery. Pb levels in colostrum were increased as compared to mature milk samples taken 18 weeks after exposure. The concentration of Pb in milk produced after delivery decreased rapidly with time and was almost down to the limit of detection in mature milk.

In a survey, 324 multivitamin-mineral products were analyzed for Pb content (Mindak et al. 2008). Estimates of Pb exposure from these products were derived for four groups summarized in Table 5-17. The overall median value for Pb exposure was 0.576 $\mu\text{g}/\text{day}$. Five samples would have provided exposures that exceeded 4 $\mu\text{g}/\text{day}$. The authors reported that the estimates of Pb exposures were below the provisional total tolerable intake levels for the four population groups (Mindak et al. 2008). Twenty-one elements, including Pb, were analyzed in various botanical and dietary supplements; Pb concentrations ranged from not detected to 4.21 $\mu\text{g}/\text{g}$. None of the products analyzed would result in a maximum exposure that exceeds a tolerable level of exposure (Avula et al. 2010).

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-17. Estimated Median and Maximum Lead Exposures

Population group	Median ($\mu\text{g}/\text{day}$)	Maximum ($\mu\text{g}/\text{day}$)
Young children (0–6 years)	0.123	2.88
Older children (7+ years)	0.356	1.78
Pregnant or lactating women	0.845	8.97
Adult women	0.842	4.92

Source: Adapted with permission from Mindak et al. (2008), American Chemical Society.

Many non-Western folk remedies used to treat diarrhea or other ailments may contain substantial amounts of Pb. Examples of these include: Alarcon, Ghasard, Alkohl, Greta, Azarcon, Liga, Bali Goli, Pay-loo-ah, Coral, and Rueda. In addition, an adult case of Pb poisoning was attributed to an Asian remedy for menstrual cramps known as Koo Sar. The pills contained Pb at levels as high as 12 ppm (CDC 1998). The source of the Pb was thought to be in the red dye used to color the pills. Pb was the most common heavy metal contaminant/adulterant found in samples (n=54) of Asian traditional remedies available at health food stores and Asian groceries in Florida, New York, and New Jersey (Garvey et al. 2001). Sixty percent of the remedies tested would give a daily dose of Pb in excess of 300 mg when taken according to labeling instructions. Pb poisoning has been caused by ingestion of a Chinese herbal medicine to which metallic Pb was added to increase its weight and sales price (Wu et al. 1996). Ayurveda is a traditional form of medicine practiced in India and other South Asian countries; the medications used often contain herbs, minerals, metals, or animal products and are made in standardized and nonstandardized formulations (CDC 2004). CDC (1998, 2002b) reported cases of elevated PbBs in children after consuming candy from Mexico or using various folk remedies. Elevated PbBs were reported in two 7-year-old children in Rhode Island. A sample of litargirio, which was used as an antiperspirant/deodorant, found in the home contained 79% Pb (CDC 2005).

During 2011–2012, six cases of Pb poisoning were associated with the use of 10 oral Ayurvedic medications made in India. Pb concentrations in these medications were as high as 2.4%. Blood Pb levels of these women ranged from 16 to 64 $\mu\text{g}/\text{dL}$ (CDC 2012c). In 2004–2012, the New York City Department of Health and Mental Hygiene identified 22 oral medications, supplements, or remedies containing high levels of heavy metals, including Pb (Table 5-18).

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-18. Lead Content in Ayurvedic Medications and Other Health Remedies

Product	Country where manufactured	Country where purchased	Lead content (ppm)
Calabash Chalk (Nzu)	Unknown	United States	6.6
Emperor's Tea Pill (concentrated)	China	United States	5,400
Garbha Chintamani Ras (Vrihat) (Swarna Yukt)	India	India	120
Garbha Dharak Yog	India	India	110
Garbhupal Ras	India	India	22,000
Garbhupal Ras	India	United States	15,000
Hepatico Extract (concentrated)	China	United States	5,900
Jambrulin	India	United States	243,000
Kankayan Bati (Gulma)	India	United States	12
Lakshmivilash Ras (Nardiya)	India	United States	260
Laxmana Louh	India	India	180
Maha Sudarshan	India	United States	41
Mahashakti Rasayan	India	India	9,400
Mahayogaraj Guggulu (enriched with silver)	India	United States	47,000
Ovarin	India	India	24,000
Pigmento	India	India	7.3
Pregnita	India	India	12,000
Sorin	India	India	46,707
Tierra Santa	Mexico	United States	13
Vasant Kusumakar Ras (with Gold and Pearl)	India	India	29
Vatvidhwansan Ras	India	United States	20,000
Vita Breath	United States	United States	1,100

Source: CDC 2012c

A study was conducted in an urban neighborhood in Chicago in order to gauge the levels of Pb in an array of fruits, vegetables, and herbs (Finster et al. 2004). The soil Pb concentrations where the plants were sampled varied from 27 to 4,580 ppm (median 800 ppm, geometric mean 639 ppm). Detectable Pb levels in the edible fruit, vegetables, and herbs sampled ranged from 11 to 81 ppm. Only one fruiting vegetable (cucumber 81 ppm) among the 52 sampled had detectable levels of Pb in the edible portion. However, 12 of the 31 leafy vegetables and herbs sampled contained Pb in the edible shoot part of the plant (range, 11–60 ppm). The Pb concentrations in the four samples of root vegetables ranged from 10 to 21 ppm. No significant correlation was found between the Pb concentrations in the edible portion of plant and the soil Pb level.

5. POTENTIAL FOR HUMAN EXPOSURE

Pb may leach from Pb crystal decanters and glasses into the liquids they contain. Port wine that contained an initial concentration of 89 µg/L Pb was stored for 4 months in crystal decanters containing up to 32% Pb oxide. At the end of 4 months, Pb concentrations in the port were 5,331, 3,061, and 2,162 µg/L in decanters containing 32, 32, and 24% Pb oxide, respectively. Pb was also found to elute from Pb crystal wine glasses within minutes. Mean Pb concentrations in wine contained in 12 glasses rose from 33 µg/L initially to 68, 81, 92, and 99 µg/L after 1, 2, 3, and 4 hours, respectively (Graziano and Blum 1991).

Hair dyes and some cosmetics may contain Pb compounds (Cohen and Roe 1991). Hair dyes formulated with Pb acetate may have Pb concentrations 3–10 times the allowable concentration in paint. Measured Pb concentrations of 2,300–6,000 µg of Pb/gram of product have been reported (Mielke et al. 1997). Pb acetate is soluble in water and easily transferred to hands and other surfaces during and following application of a hair dye product. Measurements of 150–700 µg of Pb on each hand following application have been reported (Mielke et al. 1997). In addition to transfer of Pb to the hand-to-mouth pathway of the person applying the product, Pb can be transferred to any other surface (comb, hair dryer, outside of product container, counter top, etc.) that comes into contact with the product. It is also on the hair that it is applied to and the hands applying it. Objects coming into contact with hair dyed with a Pb-containing product also become contaminated. A dry hand passed through dry hair dyed with a Pb-containing product in cream form was shown to pick up about 786 µg of Pb. A dry hand passed through dry hair dyed using foam or liquid Pb-containing hair dye products picked up less Pb: 69 µg/hand for foam products and 73 µg/hand for liquid products (Mielke et al. 1997). An elevated PbB (12 µg/dL) in an infant was observed after the use of tiro, a Nigerian eye cosmetic applied to the infant's eyes (CDC 2012a). Elevated PbBs (27.0 and 33.5 µg/dL) were reported in two young children in New Mexico after the use of kajal, a cosmetic imported from Afghanistan, that was applied to the children's eyelids. The kajal was reported to contain 54% Pb (CDC 2013). Sindoor, a cosmetic and cultural/religious powder used Hindu cultures, has been found to contain very high amounts of Pb (Lin et al. 2010).

Cases of Pb poisoning have been related to less common sources of exposure. Illicit "moonshine" whiskey made in stills composed of Pb-soldered parts (e.g., truck radiators) may contain high levels of Pb. Detectable levels of Pb with a maximum concentration of 5.3 mg/L were found in 7 of 12 samples of Georgia moonshine whiskey (Gerhardt et al. 1980). Of the 115 suspected moonshine samples seized by local law enforcement between 1995 and 2001 and analyzed by the Bureau of Alcohol, Tobacco, and Firearms, 33 samples (28.7%) contained Pb levels >300 µg/dL. The median and maximum levels were 44.0 and 53,200 µg/dL, respectively (Parramore et al. 2001).

5. POTENTIAL FOR HUMAN EXPOSURE

Firing of Pb ammunition may result in exposure to Pb aerosols and dusts generated during gun or rifle discharge at levels up to 1,000 $\mu\text{g}/\text{m}^3$ (EPA 1985c), from Pb pellets ingested by or imbedded in animals that are used as food sources, and from Pb pellets or fragments imbedded in humans from shooting incidents (see Appendix C, Ingestion of Lead Debris). Exposures to airborne Pb dust from firearm discharge in indoor shooting ranges has been shown to result in increases in PbBs that are 1.5–2 times higher than preexposure concentrations (Greenberg and Hamilton 1999; Gulson et al. 2002). However, the use of copper-jacketed bullets, nonlead primers, and well-ventilated indoor firing ranges lessen the impact of airborne Pb on blood Pb levels (Gulson et al. 2002).

A Pb poisoning hazard for young children exists in imported vinyl miniblinds that had Pb added to stabilize the plastic. Over time, the plastic deteriorates to produce Pb dust that can be ingested when the blinds are touched by children, who then put their hands in their mouths (CPSC 1996). The U.S. Consumer Product Safety Commission (CPSC) has requested that manufacturers change the manufacturing process to eliminate the Pb. As a consequence, vinyl miniblinds should now be Pb-free. The CPSC recommends that consumers with young children remove old vinyl miniblinds from their homes and replace them with new miniblinds made without added Pb or with alternative window coverings.

Inexpensive metallic jewelry items specifically intended for children and teenagers have been shown to contain varying levels of Pb (Maas et al. 2005). A total of 311 chemical assays conducted using 285 jewelry items purchased in 20 different stores in California revealed that a considerable amount of Pb was added to the items, presumably to increase their weight or to impart some type of metallic coating to the surface of the item. The mean weight percentage of Pb for all 311 assays was 30.6%. Of the 311 samples tested, 169 contained at least 3% Pb by weight in at least one portion of the jewelry piece and 123 of the samples were found to contain >50% Pb by weight (Maas et al. 2005). In addition, 62 pieces of the purchased jewelry were tested for surface levels of Pb that could potentially be transferred dermally through the routine handling of these pieces. Using standard laboratory wipes, the surface of the jewelry pieces were wiped for a total of 20 seconds and subsequently analyzed for Pb content. Mean Pb levels in the wipes ranged from 0.06 to 541.97 μg . The authors characterized the potential Pb exposure from these dermal transfer experiments as either low exposure (<1 μg of Pb transferred to the laboratory wipe), moderate exposure (1–10 μg of Pb transferred to the laboratory wipe), high exposure (10–50 μg of Pb transferred to the laboratory wipe), and very high exposure (>50 μg of Pb transferred to the laboratory wipe). Approximately 35% of the 62 pieces tested were characterized as

5. POTENTIAL FOR HUMAN EXPOSURE

having low exposure, 48% were characterized as moderate exposure, 11% were characterized as high exposure, and 5% were characterized as very high exposure (Maas et al. 2005).

5.6 GENERAL POPULATION EXPOSURE

Measurements of Pb in blood, urine, and tissues (postmortem) have been used to assess exposures of individuals to Pb. Table 5-19 shows the lowest limit of detections that are achieved by analytical analysis of blood, urine and tissues.

Table 5-19. Lowest Limit of Detection Based on Standards^a

Media	Detection limit	Reference
Whole blood/urine/tissue	0.05 µg Pb/g blood or mL urine	NIOSH 1994b, Method 8003
	1 µg/100 g blood; 0.2 µg/g tissue	NIOSH 1994a, Method 8005
Animal tissue	0.1 µg/g (ICP-MS or GFAA)	NOAA 1998

^aDetection limits based on using appropriate preparation and analytics. These limits may not be possible in all situations.

GFAA = graphite furnace atomic absorption; ICP-MS = inductively coupled plasma-mass spectrometry

Prior to the 1980s, aerolized Pb emissions from the use of leaded gasoline was the main source of Pb exposure for the general U.S. population. Aerolized Pb can be either inhaled or ingested after deposition on surfaces and food crops. Adult Pb exposures tend to be limited to occupational or recreational sources. For children, the primary source of Pb exposure is from surface dusts (on the ground or entrained) that contain Pb from a variety of sources including deteriorated Pb-based paint (Bornschein et al. 1986; CDC 2009; Dixon et al. 2009; Egeghy et al. 2005; EPA 1996c; Garavan et al. 2008; Gulson et al. 2009; Lanphear and Roghmann 1997; Lanphear et al. 1998a; Lewin et al. 1999; Malcoe et al. 2002; Mielke et al. 2007; Succop et al. 1998; Von Lindern et al. 2003, 2016; Zahran et al. 2013). Young children are particularly vulnerable to Pb exposure because of hand-to-mouth activity, which contributes to ingestion of Pb in surface dusts. Pb in the fine particle fraction of surface dusts (<150 µm) readily adheres to the skin surface, from which it can be inadvertently ingested from hand-to-mouth activity (Choate et al. 2006a, 2006b; Clausung et al. 1987; Davis and Mirick 2006; Davis et al. 1990; Siciliano et al. 2009; Yamamoto et al. 2006). Several studies have attempted to quantify soil and dust ingestion in children (Chien et al. 2017; Ozkaynak et al. 2011; Sedman et al. 1994; Stanek et al. 2012; Von Lindern et al. 2016; Wilson et al. 2013) and adults (Calabrese et al. 1990; Doyle et al. 2012; Irvine et al. 2014; Stanek et al. 1997).

5. POTENTIAL FOR HUMAN EXPOSURE

Although air Pb can be a direct pathway of exposure in children, it can also be an indirect pathway from its effect on Pb concentration in surface dusts (Brunekreef 1984; Hayes et al. 1994; Hiltz 2003; Rabinowitz et al. 1985; Schnaas et al. 2004; Schwartz and Pitcher 1989; Tripanthi et al. 2001). Second-hand smoke may also contribute to increased Pb exposure (Apostolou et al. 2012; Mannino et al. 2003; Richter et al. 2013). Dietary sources of Pb can originate from direct or indirect transfer of atmospheric Pb emissions to secondary media such as water, food crops, game, and fish. Pb in the maternal system can also be transferred to the fetus during gestation and to the nursing infant (EPA 2014c).

Several studies provided data with which dietary intakes of Pb for the general population in the United States have been estimated (FDA 2016 <TDS 2006–2011>; FDA 2016 -< Combination Metals Testing>; FDA 2016 <TDS 2006–2011>). An analysis of individual food intakes and PbB from NHANES (2006–2008) estimated that diet explained approximately 2.9% of the variations of PbB in children and 1.6% in adults (Davis et al. 2014). A randomized survey of 250 individuals (adults and children) from the Midwest United States conducted over the period 1995–1997 estimated average dietary Pb intake to be approximately 10 µg/day (Clayton et al. 1999). The EPA has estimated mean dietary Pb intakes in children ages 6–84 months to be approximately 2 µg/day (EPA 2014c). The ban on the use of welded (non-soldered) food cans during the 1980s has resulted in a decrease in Pb exposure from foods (FDA 2006). In recent surveys, the mean Pb levels in dairy products (e.g., milk, cheese, ice cream, cream, yogurt) were generally low or below the detection limit. Mean concentrations of Pb in fruits and vegetable were also generally low. Mean concentration of Pb in baby foods ranged from not detected to 0.013 mg/kg. Possible sources of Pb in food samples include introduction during processing or preparation with drinking water contaminated with Pb, deposition of Pb onto raw materials for each food, and Pb exposure in livestock that produce dairy or meat ingredients (EPA 2014c). Pb has also been reported in home-prepared reconstituted infant formula. Although, at one time, use of Pb solder in formula containers contributed to PbB from formula consumption (Ryu et al. 1983), this practice was phased out after 1970 in the United States and subsequently banned (FDA 1995). However, tap water remains a potential source of Pb in home-prepared formula at locations where tap water Pb concentrations are elevated. In a study conducted in the Boston area in 1997, 2 of 40 samples of home-prepared formula had Pb concentrations >15 µg/L. In both cases, the reconstituted formula had been prepared using cold tap water run for 5–30 seconds, drawn from the plumbing of houses >20 years old. Pb-containing ceramic ware used in food preparation has also been associated with childhood Pb exposure in children of Hispanic ethnicity in San Diego County, California. One study (Gersberg et al. 1997) used the IEUBK

5. POTENTIAL FOR HUMAN EXPOSURE

Model to determine that dietary Pb exposure from beans prepared in Mexican ceramic bean pots may account for a major fraction of blood Pb burden in children whose families use such ceramic ware.

Generally, Pb is unlikely to be found in source water used for drinking water unless there is a specific source of contamination. The main source of Pb in drinking water is from the corrosion of Pb service lines, which are pipes constructed of pure Pb that connect the water distribution main to a building's internal plumbing. Other common sources of Pb in drinking water are exposed leaded solder or corroded fixtures containing Pb (EPA 2016). While Pb was restricted to no more than 8% in plumbing materials in 1986, older homes and neighborhoods may still contain Pb service lines, Pb connections, Pb solder, or other Pb-based plumbing materials that may contaminate drinking water during its delivery from its source to homes. Corrosion of these older plumbing materials can result in leaching of Pb into drinking water (CDC 2012b; Hanna-Attisha et al. 2016). Flint, Michigan is an example of how a water system with Pb sources in drinking water infrastructure resulted in elevated Pb levels in drinking water. For decades, the drinking water for the City of Flint was purchased from the Detroit Water and Sewer Department. This water had optimized corrosion control and was treated with orthophosphate, a corrosion inhibitor that reduces Pb solubility and leaching from leaded plumbing materials by the formation of protective scales on the pipe's interior surface. When the water source was changed to the Flint River in 2014, corrosion control was not implemented, which allowed Pb to leach into the drinking water (EPA 2017). Pb concentration in first-draw tap water tends to be higher than after the plumbing system has been flushed, although with Pb service lines, it is possible to see higher Pb concentrations in flushed water, if flushing is sufficient draw stagnant water from the service line to the tap. Gulson et al. (1997a) measured Pb in household water throughout the day when the plumbing system of an unoccupied test house was not flushed. Water concentration data ranged from 119 µg/L for the initial (first-draw) sample to 35–52 µg/L for hourly samples to 1.7 µg/L for a fully flushed sample. The 1991 LCR was implemented to protect public health by minimizing Pb and copper levels in drinking water, by primarily reducing water corrosivity (EPA 2010). The rule set a Pb action level of 15 µg/L based on 90th percentile levels of tap water samples. The LCR established tap sampling monitoring requirements for public water systems. One-liter samples are taken at the tap where water has stood in the pipes for at least 6 hours (first-draw) in homes and buildings that are considered high-risk of Pb and copper contamination, and the number of samples are based on the system size. Pb action level exceedances can trigger a number of steps that a water system can take to reduce Pb exposure. These requirements include implementing a corrosion control treatment program, monitoring and/or treating source water, public education, and Pb service line replacement (EPA 2004).

5. POTENTIAL FOR HUMAN EXPOSURE

Other less common sources of Pb exposure also exist. Exposure may also result from engaging in hobbies that use Pb (e.g., leaded solder is used in making stained glass, molten Pb used in casting, leaded glazes and frits are used in making pottery, and Pb compounds as coloring agents in glassblowing) (Grabo 1997). The use of inadequately glazed or heavily worn earthenware vessels for food storage and cooking may result in Pb exposure (CDC 1985; EPA 1986). Various folk remedies and Ayurvedic medication (CDC 1998, 2004, 2012c; Garvey et al. 2001; Wu et al. 1996) and some cosmetics (Mielke et al. 1997) may also be sources of Pb exposure. Moonshine consumption was strongly associated with elevated PbBs (Morgan and Parramore 2001). A 2000 study found a median PbB of 11 µg/dL among 35 moonshine consumers versus 2.5 µg/dL in 68 randomly-selected nonmoonshine consumers (Parramore et al. 2001). Exposure to infants and children can occur from mouthing of leaded jewelry and toys containing Pb or painted with leaded paint (CDC 2018c).

Plastic food wrappers may be printed with pigments that contain Pb chromates. Plastic wrappers used for 14 different national brands of bread collected in New Jersey contained a mean concentration of 26 mg of Pb for a bag size of 2,000 cm². A survey of 106 homemakers who buy such breads indicated that 39% of them reused the bags and 16% of the respondents turned the bags inside out to reuse them, suggesting that the potential exists for Pb leaching from the paint into the stored food (Weisel et al. 1991).

Blood Pb levels measured as a part of the NHANES revealed that between 1976 and 1991, the mean PbBs of the U.S. population aged 1–74 years old dropped 78%, from 12.8 to 2.8 µg/dL. The prevalence of PbBs ≥10 µg/dL also decreased sharply from 77.8 to 4.3%. The major cause of the observed decline in PbBs is most likely the removal of 99.8% of Pb from gasoline and the removal of Pb from soldered cans (Pirkle et al. 1994). Data from the Fourth National Report on Human Exposure to Environmental Chemical are summarized in Tables 5-20 and 5-21, which provide geometric means of Pb levels in the blood and urine in segments of the U.S. population.

Table 5-20. Geometric Mean Blood Lead Levels (µg/dL) and the 95th Percentile Confidence Interval, by Race/Ethnicity, Sex, and Age for the Years for 2011–2016

	Survey years	Geometric mean (95% confidence interval)	Sample size
Total	11–12	0.973 (0.916–1.04)	7,920
	13–14	0.858 (0.813–0.906)	5,215
	15–16	0.820 (0.772–0.872)	4,988
Age group			
1–5 years	11–12	0.970 (0.877–1.07)	713
	13–14	0.782 (0.705–0.869)	818
	15–16	0.758 (0.675–0.850)	790

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-20. Geometric Mean Blood Lead Levels ($\mu\text{g}/\text{dL}$) and the 95th Percentile Confidence Interval, by Race/Ethnicity, Sex, and Age for the Years for 2011–2016

	Survey years	Geometric mean (95% confidence interval)	Sample size
6–11 years	11–12	0.681 (0.623–0.744)	1,048
	13–14	0.567 (0.529–0.607)	1,075
	15–16	0.571 (0.523–0.623)	565
12–19 years	11–12	0.554 (0.511–0.601)	1,129
	13–14	0.506 (0.464–0.551)	627
	15–16	0.467 (0.433–0.504)	1,023
20 years and older	11–12	1.09 (1.03–1.16)	5,030
	13–14	0.967 (0.921–1.02)	2,695
	15–16	0.920 (0.862–0.982)	2,610
Gender			
Males	11–12	1.13 (1.06–1.21)	3,968
	13–14	0.994 (0.919–1.08)	2,587
	15–16	1.13 (1.06–1.21)	3,968
Females	11–12	0.842 (0.796–0.890)	3,952
	13–14	0.746 (0.715–0.777)	2,628
	15–16	0.735 (0.679–0.795)	2,500
Race/ethnicity			
Mexican Americans	11–12	0.838 (0.767–0.916)	1,077
	13–14	0.746 (0.685–0.813)	969
	15–16	0.704 (0.659–0.759)	994
Non-Hispanic blacks	11–12	0.998 (0.947–1.05)	2,195
	13–14	0.871 (0.787–0.963)	1,119
	15–16	0.856 (0.763–0.962)	1,070
Non-Hispanic whites	11–12	0.993 (0.914–1.08)	2,493
	13–14	0.882 (0.820–0.950)	1,848
	15–16	0.835 (0.774–0.900)	1,511
All Hispanics	11–12	0.855 (0.793–0.922)	1,931
	13–14	0.742 (0.695–0.793)	1,481
	15–16	0.703 (0.658–0.750)	1,664
Asians	11–12	1.15 (1.06–1.24)	1,005
	13–14	1.01 (0.923–1.11)	510
	15–16	1.07 (0.976–1.18)	479

Source: CDC 2018a

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-21. Geometric Mean Urine Lead Levels ($\mu\text{g}/\text{dL}$) and the 95th Percentile Confidence Interval, by Race/Ethnicity, Sex, and Age

	Survey years	Geometric mean (95% confidence interval)	Sample size
Total	11–12	0.360 (0.328–0.396)	2,504
	13–14	0.277 (0.257–0.298)	2,664
Age group			
6–11 years	11–12	0.346 (0.292–0.410)	399
	13–14	0.222 (0.192–0.258)	402
12–19 years	11–12	0.259 (0.219–0.305)	390
	13–14	0.201 (0.166–0.245)	451
20 years and older	11–12	0.381 (0.348–0.416)	1,715
	13–14	0.297 (0.280–0.315)	1,811
Gender			
Males	11–12	0.414 (0.367–0.466)	1,262
	13–14	0.315 (0.295–0.337)	1,318
Females	11–12	0.316 (0.282–0.355)	1,242
	13–14	0.245 (0.222–0.269)	1,346
Race/ethnicity			
Mexican Americans	11–12	0.372 (0.320–0.431)	317
	13–14	0.277 (0.240–0.319)	453
Non-Hispanic blacks	11–12	0.431 (0.385–0.483)	669
	13–14	0.371 (0.320–0.429)	581
Non-Hispanic whites	11–12	0.346 (0.311–0.385)	820
	13–14	0.267 (0.245–0.290)	985
All Hispanics	11–12	0.372 (0.327–0.423)	573
	13–14	0.270 (0.239–0.305)	701
Asians	11–12	0.383 (0.341–0.429)	353
	13–14	0.257 (0.230–0.287)	292

Source: CDC 2018a

The Adult Blood Lead Epidemiology and Surveillance (ABLES) program tracks adult (aged ≥ 16 years) cases with elevated PbBs from workplace exposure. In 2016, 26 states submitted PbB data on 18,093 adults with PbBs $\geq 10 \mu\text{g}/\text{dL}$. PbBs $\geq 10 \mu\text{g}/\text{dL}$ declined from 26.6 adults per 100,000 employed in 2010 to 15.8 per 100,000 employed in 2016 (results for data submitted as of December 2018). In 2016, among adults with known exposures, 90.3% had occupational exposure. The majority of these adults were employed in manufacturing, construction, mining, and services. Table 5-22 presents industries within each sector with the most workers with occupational exposures resulting in PbB $\geq 25 \mu\text{g}/\text{dL}$ during 2010–2016 (NIOSH 2017a).

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-22. Industries by Sector with Most Workers having Blood Lead Concentrations (PbBs) ≥ 25 $\mu\text{g}/\text{dL}$, 2010–2016

NORA Sector	Industry NAICS Code
Manufacturing	Storage battery manufacturing (33591)
	Nonferrous metal (except copper and aluminum) rolling, drawing, extruding, and alloying (33149)
	Alumina and aluminum production and processing (33131)
	Nonferrous metal foundries (33152)
	Nonferrous metal (except aluminum) smelting and refining (33141)
	Other basic inorganic chemical manufacturing (32518)
	Motor vehicle electrical and electronic equipment manufacturing (33632)
Construction	Painting and wall covering contractors (23832)
	Highway, street, and bridge construction (23731)
	Residential building construction (23611)
	Plumbing, heating, and air-conditioning contractors (23822)
	Site preparation contractors (23891)
	Commercial and institutional building construction (23622)
Services (except public safety)	All other amusement and recreation industries (71399)
	Remediation services (56291)
	Automotive mechanical and electrical repair and maintenance (81111)
	Other services (except public safety industries) (71394)
Mining	Copper, nickel, lead, and zinc mining (21223)

NAICS = North American Industry Classification System; NORA = National Occupational Research Agenda

Source: NIOSH 2017a

Raymond and Brown (2015a, 2015b, 2017) and analyzed the 2007–2012 and 2009–2014 datasets from the Childhood Blood Lead Surveillance (CBLS) system. In 2007, a total of 38 states identified and reported 37,289 children (<6 years) with PbB ≥ 10 $\mu\text{g}/\text{dL}$. In 2012, a total of 30 jurisdictions identified and reported approximately 138,000 children (<6 years) with PbB ≥ 5 $\mu\text{g}/\text{dL}$. In 2012, federal funding ended and several states lost their state-wide Pb poisoning prevention programs and in 2013, the number of states reporting data declined, as did the number of children reported to the CDC with PbB ≥ 5 $\mu\text{g}/\text{dL}$. In October 2013, federal funding resumed and in 2013, 27 states, the District of Columbia, and New York City reported data. In 2014, 30 states, the District of Columbia, and New York City reported data. Table 5-23 summarizes the number and rate per 100,000 children aged <5 years with blood Pb levels 5–9 $\mu\text{g}/\text{dL}$ reported in the 2010–2014 CBLS system. PbBs ≥ 10 $\mu\text{g}/\text{dL}$ continue to be more prevalent among children with known risk factors, such as minority race or ethnicity, urban residence, residing in homes built prior to the 1950s, and low family income (CDC 2009).

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-23. Number and Rate per 100,000 Children Aged <5 Years with Blood Lead Levels 5–9 µg/dL in the Childhood Blood Lead Surveillance System, United States, 2010–2014

Year	<1 Year		1–4 Years	
	Number	Rate	Number	Rate
2010 ^a	18,598	448.48	137,887	805.62
2011 ^b	13,981	352.69	130,838	810.56
2012 ^c	7,876	199.74	95,854	596.58
2013 ^d	5,494	138.26	57,293	360.46
2014 ^e	5,904	148.51	70,680	444.49

^a37 jurisdictions reporting.

^b36 jurisdictions reporting.

^c30 jurisdictions reporting.

^d29 jurisdictions reporting.

^e32 jurisdictions reporting.

Source: Raymond and Brown 2017

Various studies suggest that ingestion of game hunted with Pb shot is associated with increased PbBs. Johansen et al. (2006) collected blood samples from 50 men in Nuuk, Greenland to study the relationship between the consumption of birds hunted with Pb shot and PbBs. Men who regularly ate hunted birds killed with Pb shot had mean PbB ranging from 6.2 µg/dL in the group eating 0.1–5 bird equivalents per month to 12.8 µg/dL in those eating >30 bird equivalents per month. In addition, levels were highest in mid-winter when consumption of hunted birds was highest. Those who did not consume hunted birds had a mean PbB of 1.5 µg/dL. These results are consistent with earlier surveys of Arctic hunting communities. A 1992 survey of 492 Inuit adults from the Arctic region of Quebec, Canada showed that consumption of waterfowl, along with age and smoking, were associated with elevated PbB (Dewailly et al. 2001). The geometric mean PbB was 0.42 µmol/L (8.7 µg/dL), with a range of 0.04–2.28 µmol/L (0.8–47 µg/dL). In a cohort of Inuit newborns from northern Quebec, where the population consumed game killed with Pb shot, the geometric umbilical cord PbB was 3.9 µg/dL (range 0.2–27 µg/dL); 7% of Inuit newborns had cord PbBs >10 µg/dL as compared to 0.16% of the non-Inuit population in southern Quebec (Lévesque et al. 2003).

Second-hand smoke may also contribute to increased Pb exposure (Apostolou et al. 2012; Mannino et al. 2003; Richter et al. 2013). Pb is a component of tobacco and tobacco smoke, and smokers often have higher Pb blood levels than nonsmokers (Bonanno et al. 2001; Mannino et al. 2003). Using data from the NHEXAS EPA Region V study, PbB levels in smokers and nonsmokers were analyzed and a correlation between tobacco smoke and exposure levels was observed (Bonanno et al. 2001). The mean PbBs in

5. POTENTIAL FOR HUMAN EXPOSURE

smokers, nonsmokers exposed to environmental tobacco smoke (ETS), and nonsmokers without ETS were 2.85, 2.06, and 1.81 $\mu\text{g}/\text{dL}$, respectively (Bonanno et al. 2001). Recent Pb urine concentrations for the U.S. adult population from the NHANES by smoking status are presented in Table 5-24.

Table 5-24. Geometric Mean Urine Lead Levels ($\mu\text{g}/\text{dL}$) and the 95th Percentile Confidence Interval by Smoking Status

	Survey years	Geometric mean (95% confidence interval)	Sample size
Cigarette smokers			
Total	11–12	2.36 (1.71–4.62)	876
	13–14	1.51 (1.30–1.91)	957
Age group			
20–49 years	11–12	1.78 (1.41–3.07)	522
18–49 years	13–14	1.34 (1.13–1.92)	583
50 years and older	11–12	3.35 (1.62–6.83)	354
	13–14	1.72 (1.40–2.03)	374
Gender			
Males	11–12	3.07 (1.73–5.03)	527
	13–14	1.91 (1.48–2.14)	512
Females	11–12	1.58 (1.14–3.45)	349
	13–14	1.30 (1.12–1.41)	445
Nonsmokers^a			
Total	11–12	1.38 (1.25–1.58)	1,343
	13–14	1.16 (0.950–1.51)	1,487
Age group			
20–49 years	11–12	1.26 (1.02–1.38)	671
18–49 years	13–14	0.880 (0.720–1.04)	778
50 years and older	11–12	1.63 (1.29–2.16)	672
	13–14	1.48 (1.12–2.52)	709
Gender			
Males	11–12	1.61 (1.18–2.13)	635
	13–14	1.51 (1.04–2.68)	663
Females	11–12	1.32 (1.06–1.38)	708
	13–14	0.238 (0.219–0.258)	824

^aCigarette nonsmokers who used other tobacco products were excluded.

Source: CDC 2018a

Studies have been conducted to determine exposure of firearm instructors to Pb at outdoor firing ranges when either nonjacketed (pure Pb) or jacketed (copper-coated) bullets were used. Instructors are likely to have higher exposure than shooters because they spend more time at the range. In studies at an outdoor

5. POTENTIAL FOR HUMAN EXPOSURE

range in Virginia, the mean breathing zone Pb level when nonjacketed bullets were fired was $67.1 \mu\text{g}/\text{m}^3$ for one instructor and $211.1 \mu\text{g}/\text{m}^3$ for another (Tripathi and Llewellyn 1990). When jacketed bullets were used, breathing zone levels decreased to $\leq 8.7 \mu\text{g}/\text{m}^3$. PbBs of the instructors did not exceed the OSHA Pb standard's medical removal level of $2.4 \mu\text{mol}/\text{L}$ ($60 \mu\text{g}/\text{dL}$) in either case (OSHA 2016a). When shooters fired conventional Pb bullets, their mean exposures to airborne Pb were $128 \mu\text{g}/\text{m}^3$ in the personal breathing zone and $68 \mu\text{g}/\text{m}^3$ in the general area. When totally copper-jacketed Pb bullets were fired, the mean breathing zone and general area air sample concentrations were 9.53 and $5.80 \mu\text{g}/\text{m}^3$, respectively (Tripathi and Llewellyn 1990). At an outdoor uncovered range in Los Angeles, instructors who spent an average of 15–20 hours/week behind the firing line were found to be exposed to breathing zone Pb concentrations of 460 and $510 \mu\text{g}/\text{m}^3$ measured as 3-hour, time-weighted averages. The PbB of one instructor reached $3.38 \mu\text{mol}/\text{L}$ ($70 \mu\text{g}/\text{dL}$). After reassignment to other duties, repeat testing indicated his PbB had dropped to $1.35 \mu\text{mol}/\text{L}$ ($28 \mu\text{g}/\text{dL}$) (Goldberg et al. 1991).

In 1991, NIOSH conducted a survey of the Federal Bureau of Investigations (FBI) Firearms Training Unit firing ranges and related facilities to determine occupational Pb exposures among FBI and Drug Enforcement Agency (DEA) firing range personnel (NIOSH 1996b). Sixty-one personal breathing-zone and 30 area samples for airborne Pb were collected. Exposures ranged up to $51.7 \mu\text{g}/\text{m}^3$ (mean, $12.4 \mu\text{g}/\text{m}^3$), $2.7 \mu\text{g}/\text{m}^3$ (mean, $0.6 \mu\text{g}/\text{m}^3$), and $4.5 \mu\text{g}/\text{m}^3$ (mean, $0.6 \mu\text{g}/\text{m}^3$) for range instructors, technicians, and gunsmiths, respectively. Exposure of custodians ranged from nondetectable to $220 \mu\text{g}/\text{m}^3$ during short-term cleaning of a large indoor range. Carpet dust sampling of dormitory rooms of students who practiced at the firing ranges revealed higher ($p < 0.0005$) dust-Pb concentrations when compared to nonstudent dormitories (dust-Pb concentration range of 116 – $546 \mu\text{g}/\text{g}$ with a geometric mean of $214 \mu\text{g}/\text{g}$ in the student's rooms versus a dust-Pb concentration range of 50 – $188 \mu\text{g}/\text{g}$ with a geometric mean of $65 \mu\text{g}/\text{g}$ for the nonstudent rooms). This suggested that the students were contaminating their living quarters with Pb.

The American Academy of Pediatrics (AAP) (1998, 2005) concluded that although monitoring data demonstrate a decline in PbBs, Pb remains a common, preventable, environmental health threat. Most Pb poisoning in children is the result of dust and chips from deteriorating Pb paint on interior surfaces (AAP 2005, 2016; ATSDR 2017). The AAP supported the CDC guidelines endorsing universal screening in certain areas and targeted screening for children at high risk (CDC 1997b, 2005). Many children continue to be at risk for ingestion of Pb-based paint and of soil and dust contaminated through the deterioration of Pb-based paint and the residues from combustion of leaded gasoline. A 1974 study indicated that elevated PbBs in children were most likely a result of ingesting Pb-contaminated soil, and that the most

5. POTENTIAL FOR HUMAN EXPOSURE

likely source was Pb-based paint rather than Pb from automotive exhaust (Ter Haar and Aronow 1974). However, more recent studies have shown that children with the highest PbBs live in areas with high traffic flow where Pb particles in the air may fall directly to the soil or adhere to the outer surfaces of building and wash to the soil with rain (Mielke et al. 1989, 2008, 2010). The CDC concluded that a common source of Pb exposure for children who have elevated PbB is Pb-based paint that has deteriorated into paint chips and Pb dusts (CDC 1997c, 2012d).

Pb can readily cross the placenta; therefore, exposure of women to Pb during pregnancy results in uptake by the fetus. Furthermore, since the physiological stress of pregnancy may result in mobilization of Pb from maternal bone, fetal uptake of Pb can occur from a mother who was exposed to Pb before pregnancy, even if no Pb exposure occurs during pregnancy. Maternal Pb can also be transferred to breastfeeding infants.

Malcoe et al. (2002) assessed Pb sources and their effect on blood Pb in rural Native American and white children living in a former mining region. Blood samples, residential environmental samples (soil, dust, paint, water), and caregiver interviews (hand-mouth behaviors, socioeconomic conditions) were obtained from a representative sample of 245 children ages 1–6 years. There were no ethnic differences in the results. However, poor children were especially vulnerable. Regression analysis showed that mean floor dust Pb loading $>10.1 \mu\text{g}/\text{ft}^2$ and yard soil Pb $>165.3 \text{ mg}/\text{kg}$ were independently associated with blood Pb levels $\geq 10 \mu\text{g}/\text{dL}$.

The Pb content of dusts can be a significant source of exposure, especially for young children. Baseline estimates of potential human exposure to dusts, including intake due to normal hand-to-mouth activity, are 0.2 g/day for children 1–6 years old versus 0.1 g/day for adults when both indoor and outdoor ingestion of soil including dust is considered (EPA 1989c). For children who engage in pica behavior (the compulsive, habitual consumption of nonfood items), the ingestion rate of soil can be as high as 5 g/day. Although ingestion of Pb-containing paint may lead to elevated PbBs in young children, a major source of elevated PbBs ($>10 \mu\text{g}/\text{dL}$) in children is often contaminated household dust and subsequent hand contamination and repetitive mouthing (Bornschein et al. 1986; Charney et al. 1980; Dixon et al. 2009; Lanphear and Roghmann 1997; Lanphear et al. 1998a; Succop et al. 1998). Weathering of Pb-based paint can contribute to the Pb content of dust and soil. Pb levels of indoor dust and outdoor soil were found to be strongly predictive of PbBs in over 200 urban and suburban infants followed from birth to 2 years of age; however, PbBs were not correlated with indoor air or tap water Pb levels, nor the size of nearby roadways. Indoor dust Pb levels and soil Pb levels in the homes of children with high PbBs

5. POTENTIAL FOR HUMAN EXPOSURE

(>8.8 µg/dL) were 72 µg/wipe (window sill dust) and 1,011 µg/g, respectively; children with low PbBs (<3.7 µg/dL) were exposed to 22 µg/wipe and 380 µg/g, respectively. In addition, 79% of the homes of children with high PbBs had been renovated, while only 56% of the homes of children with low PbBs had been renovated, suggesting that renovating the interior of homes previously painted with leaded paint may increase, at least temporarily, a child's exposure to Pb dust (Rabinowitz et al. 1985). Regular use of dust control methods (e.g., wet mopping of floors, damp-sponging of horizontal surfaces, high-efficiency vacuum cleaner) has been shown in some, although not all, cases to reduce indoor dust, Pb dust, and blood Pb levels in some, although not all, older homes containing leaded paints (Lanphear et al. 2000b; Rhoads et al. 1999). Decreases of between 17 and 43% in blood Pb concentrations were observed in children where regular dust control methods had been used to reduce indoor levels of Pb (Rhoads et al. 1999). EPA (2014c) summarized concentrations of Pb in house dust in the United States from 2006 to 2011; these data are presented in Table 5-25.

Table 5-25. Measurements of Lead in Indoor Dust in the United States from 2006 to 2011

Location	Sample site	Value reported
New York City, New York	Glass plate next to open window of academic building	Median weekly dust loading: 52 µg/m ²
Eureka, Utah near Eureka Mills Superfund Site	Indoor home site (not specified)	Dust concentrations, range: 160–2,000 mg/kg
Denver, Colorado, near Vasquez Blvd and I-70 Superfund Site	Indoor home site (not specified)	Dust concentrations, range: 11–660 mg/kg
East Helena, Montana, near East Helena Superfund Site	Indoor home site (not specified)	Dust concentrations, range: 68–1,000 mg/kg
Syracuse, New York	Floor	Dust concentrations, range: 209–1,770 mg/kg
United States (nationwide)	Smooth floor	Median dust loading: 1.7 µg/m ² Average dust loading: 4.4 µg/m ²
	Rough floor	Median dust loading: 5.6 µg/m ² Average dust loading: 16 µg/m ²
	Smooth windowsill	Median dust loading: 2.5 µg/m ² Average dust loading: 190 µg/m ²
	Rough windowsill	Median dust loading: 55 µg/m ² Average dust loading: 480 µg/m ²
Milwaukee, Wisconsin	Central perimeter	Average dust concentration: 107 µg/m ²
	Entry	Average dust concentration: 140 µg/m ²
	Window	Average dust concentration: 151 µg/m ²

5. POTENTIAL FOR HUMAN EXPOSURE

Table 5-25. Measurements of Lead in Indoor Dust in the United States from 2006 to 2011

Location	Sample site	Value reported
Rural towns, Idaho	Vacuum	Dust concentration Median: 120 mg/kg Maximum: 830 mg/kg
	Floor	Median dust concentration: 95 mg/kg Maximum dust concentration: 1,300 mg/kg
Bunker Hill, Idaho Superfund Site	Vacuum	Median dust concentration: 470 mg/kg Maximum dust concentration: 2,000 mg/kg
	Floor	Median dust concentration: 290 mg/kg Maximum dust concentration: 4,600 mg/kg

Source: EPA 2014c

Lanphear and Roghmann (1997) and Lanphear et al. (1996a, 1996b, 1998b) studied factors affecting PbBs in urban children and found the following independent predictors of children's PbBs: dust Pb loading in homes (carpets, uncarpeted floors, window sills, and troughs), African-American race/ethnicity, foundation perimeter soil Pb levels, ingestion of soil or dirt, Pb content and condition of interior painted surfaces, and first-flush kitchen drinking water Pb levels (Lanphear et al. 1996a, 1996b). Differences in housing conditions and exposures to Pb-containing house dust appear to contribute to the racial differences in urban children's PbBs. In addition, white children were more likely to put soil in their mouths (outdoor exposure) and suck their fingers, and African-American children were more likely to put their mouths on window sills (indoor exposure) and to use a bottle. Interior Pb exposures were more significant for African American children and exterior Pb exposures were more significant for white children (Lanphear et al. 1996a, 1996b). Mouthing behaviors are an important mechanism of Pb exposure among urban children (Lanphear and Roghmann 1997). Community characteristics such as residence within a city, proportion of African Americans, lower housing value, housing built before 1950, higher population density, higher rates of poverty, lower percent of high school graduates, and lower rates of owner-occupied housing have been used to identify children with elevated blood levels (Lanphear et al. 1998b). An analysis of children's PbBs and multiple measures of Pb concentrations in household dust, tap water, foundation perimeter soil, and interior house paint has been used to predict the effect of changing concentrations of Pb in environmental media on children's PbBs. An increase in dust Pb loading from background to 200 $\mu\text{g}/\text{ft}^2$ was estimated to produce an increase of 23.3% in the percentage of children estimated to have a PbB >10 $\mu\text{g}/\text{dL}$; an increase in tap water Pb concentration from background to 15 $\mu\text{g}/\text{L}$ was estimated to produce an increase of 13.7% in the percentage of children estimated to have a PbB level >10 $\mu\text{g}/\text{dL}$; and an increase in soil Pb concentration from background to

5. POTENTIAL FOR HUMAN EXPOSURE

400 µg/g was estimated to produce an increase of 11.6% in the percentage of children estimated to have a PbB level >10 µg/dL (Lanphear et al. 1998a).

Outdoor Pb dust was found to be a more potent contaminant of children's hands than indoor dust at daycare centers in New Orleans; boys, in general, had higher hand Pb levels than girls. The conclusions were based on Pb analysis of hand wipe samples taken before and after children played outdoors at four different daycare centers (a private inner-city site, a private outer-city site, a public inner-city site, and a public outer-city site). The private inner-city site had a severely contaminated outdoor play area with measured soil Pb concentrations ranging from 287 to 1,878 mg/kg. The outdoor play area at the public inner-city site, where children exhibited the lowest hand Pb measurements of any site in the study, had been completely paved over with concrete or rubberized asphalt and had well-maintained equipment (Viverette et al. 1996).

EPA conducted the Urban Soil Lead Abatement Demonstration Project (USLADP), also known as the "Three City Lead Study," in Boston, Baltimore, and Cincinnati (EPA 1996c). The purpose was to determine whether abatement of Pb in soil could reduce PbBs of inner-city children. No significant evidence was found that soil abatement had any direct impact on children's PbBs in either the Baltimore or Cincinnati studies. In the Boston study, however, a mean soil Pb reduction of 1,856 ppm resulted in a mean decline of 1.28 µg/dL PbB at 11 months postabatement (Weitzman et al. 1993). Phase II extended the study to 2 years and included soil abatement of the two comparison areas from Phase I (Aschengrau et al. 1994). Combined results from Phase I and II suggested a higher impact of soil remediation on PbBs (2.2–2.7 µg/dL). EPA reanalyzed the data from the USLADP in an integrated report (EPA 1996c). They concluded that when soil is a significant source of Pb in the child's environment, under certain conditions, the abatement of that soil will result in a reduction in exposure and consequently, PbB level. The results of the USLADP suggest that a number of factors are important in determining the influence of soil remediation on PbBs in children. These include the site-specific exposure scenario, the magnitude of the remediation, and the magnitude of additional sources of Pb exposure.

Authors of a study of PbBs in children in Toronto, Canada, before and after abatement of Pb-contaminated soil and house dust found that they could neither strongly support nor refute beneficial effects of abatement. The failure to reach a definite conclusion from the results of the study, which included data from 12 cross-sectional blood-screening surveys that were conducted over an 8-year period, was due, in part, to a low response rate (32–75%) to questionnaires used to determine behavioral,

5. POTENTIAL FOR HUMAN EXPOSURE

household, lifestyle, neighborhood, and environmental factors relating to study participants (Langlois et al. 1996).

Seasonal variations in PbBs in children have been observed in a number of studies (Gulson et al. 2008; Haley and Talbot 2004; Havlena et al. 2009; Kemp et al. 2007; Johnson and Bretsch 2002; Johnson et al. 1996; Laidlaw et al. 2005; Yiin et al. 2000). These studies suggest a general trend of increasing PbB during late summer and early fall. In addition to seasonal patterns in behavior (e.g., outdoor activities), seasonal patterns in weather (humidity and wind velocity) that promote re-entrainment and transport of dust Pb may contribute to the observed seasonal patterns in PbB (Laidlaw et al. 2005, 2012).

In addition to the ingestion of hand soil/dust through normal hand-to-mouth activity, some children engage in pica behavior (consumption of nonfood items), which can put them at increased risk through ingestion of large amounts of soil contaminated with Pb. It has been estimated that an average child may ingest between 20 and 50 mg of soil/day and that a pica child may ingest $\geq 5,000$ mg of soil/day (LaGoy 1987; Mielke et al. 1989). If the soil contains 100 $\mu\text{g/g}$ of Pb, an average child may be exposed to 5 μg Pb/day from this source alone (Mielke et al. 1989), and a pica child may be exposed to >100 times that amount.

Improper removal of Pb from housing known to contain Pb-based paint can significantly increase Pb levels in dust, thus causing Pb toxicity in children living in the home during the Pb-removal process. Four such cases have been documented (Amitai et al. 1987). In January 1995, the New York State Department of Health identified 320 children in 258 households in New York State (excluding New York City) with PbBs ≥ 20 $\mu\text{g/dL}$ that were considered to be attributable to residential renovation and remodeling (CDC 1997a).

Workers occupationally exposed to Pb can carry Pb home on clothing, bodies, or tools (take home exposure). PbBs of children in households of occupationally exposed workers were almost twice those of children in neighboring homes whose parents were not occupationally exposed to Pb (median ranges were 10–14 and 5–8 $\mu\text{g/dL}$, respectively) (Grandjean and Bach 1986). Young children (<6 years old) of workers exposed to high levels of Pb in workplace air at an electronic components plant (61–1,700 $\mu\text{g Pb/m}^3$ ambient concentrations) had significantly elevated PbBs (13.4 $\mu\text{g/dL}$) compared with children from the same locale whose parents did not work in the electronics plant (7.1 $\mu\text{g/dL}$) (Kaye et al. 1987). Based upon data collected from 1987 to 1994, children aged 1–5 years ($n=139$) of workers whose occupation resulted in Pb exposure had a geometric mean PbB of 9.3 $\mu\text{g/dL}$ as compared to a U.S. population

5. POTENTIAL FOR HUMAN EXPOSURE

geometric mean of 3.6 µg/dL (Roscoe et al. 1999). Of this group, 52% of the children had PbBs ≥ 10 µg/dL compared to 8.9% of the U.S. population and 21% had PbBs ≥ 20 µg/dL compared to 1.1% of the U.S. population (Roscoe et al. 1999). Exposures of Pb workers' families have been identified in nearly 30 different industries and occupations. Industries in which exposure of family members has been reported most often include Pb smelting, battery manufacturing and recycling, radiator repair, electrical components manufacturing, pottery and ceramics, and stained glass making (NIOSH 1995). Children of Pb-exposed construction workers may also be at increased risk (Whelan et al. 1997).

Children may be exposed to Pb because of activities associated with certain hobbies and artistic activities practiced by adults in the home. Some of the more obvious hobbies and activities involving use of Pb-containing materials include casting, stained glass, pottery, painting, glassblowing, and screenprinting. Activities involving use of Pb-containing materials should always be done in an area well-ventilated with outdoor air and should never be done with children in the same room or in close proximity. Maas et al. (2005) indicated that high levels of Pb are prevalent in inexpensive cosmetic jewelry that is sold to the general public at retail stores.

Accidental or intentional ingestion of folk remedies (e.g., Chinese herbal medicines and Ayurvedic medicines containing Pb) or use of the Pb containing eye cosmetic tiro in children (discussed in Section 5.5.5) represents another source for potential Pb-poisoning in children. Sindoor, a cosmetic and cultural/religious powder used Hindu cultures, has been found to contain very high amounts of Pb (Lin et al. 2010). Hair dyes formulated with Pb acetate represent a potential source for Pb-poisoning both by accidental ingestion and by hand-to-mouth activity following contact with Pb-contaminated surfaces, including dyed hair of adults (Mielke et al. 1997).

Children may be exposed to Pb through the inhalation of second-hand smoke. Mannino et al. (2003) employed data from the NHANES III and analyzed PbBs of children aged 4–16 years who were exposed to high, low, and intermediate levels of second-hand smoke. Serum levels of the nicotine biomarker cotinine were used to classify the children into one of the three second-hand smoke exposure categories. The geometric mean PbBs were 1.5, 1.9, and 2.6 µg/dL for children with low (≤ 0.050 – 0.104 ng/mL), intermediate (0.105 – 0.562 ng/mL), and high (0.563 – 14.9 ng/mL) serum cotinine levels, respectively (Mannino et al. 2003).

5. POTENTIAL FOR HUMAN EXPOSURE

5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES

In addition to workers exposed to Pb in the workplace and family members of workers exposed via take home exposure, other population groups are at risk for potential exposure to high levels of Pb. These include populations residing in older housing or buildings that contain deteriorating leaded paint or that have galvanized pipes, Pb service lines, or scales that contain Pb within a distribution public water system; in high-traffic areas with legacies from leaded gasoline; near sites where Pb was produced or disposed; or near one of the NPL hazardous waste sites where Pb has been detected in some environmental media (ATSDR 2015; EPA 2014c, 2016g). Since Pb is often detected in tobacco and tobacco smoke, persons who use chewing tobacco or smoke or are exposed to second-hand smoke, may have higher PbB levels than persons that do not use these products (Apostolou et al. 2012; Bonanno et al. 2001; Richter et al. 2013). Recent studies have also found e-cigarettes to be a potential source of Pb exposure (Olmedo et al. 2018). Other Pb sources that can contribute to elevated exposures to individual children include mouthing or ingestion of toys containing Pb and consumption of candy and folk remedies that contain Pb (CDC 2002b, 2018c).

General population exposure is most likely to occur through the ingestion of food and water contaminated with Pb. Based on a multimedia Pb exposure modeling analysis for children 1–5 years old at upper percentiles of PbB in the U.S. population, soil and dust ingestion are dominant exposure pathways, but for lower percentiles, other age groups (e.g., younger children), or specific local U.S. locations, the main exposure source/pathway could be different (Zartarian et al. 2017). However, some individuals and families may be exposed to additional sources of Pb in their homes. This is particularly true of older homes that may contain Pb-based paint. In an attempt to reduce the amount of exposure due to deteriorating leaded paint, the paint is commonly removed from homes by burning (gas torch or hot air gun), scraping, or sanding. These activities have been found to result, at least temporarily, in higher levels of exposure for families residing in these homes. In addition, those individuals involved in the paint removal process (i.e., do-it-yourself renovators and professionals who remove Pb) can be exposed to such excessive levels that Pb poisoning may occur (Chisolm 1986; Fischbein et al. 1981; Rabinowitz et al. 1985). Special populations at risk of high exposure to tetraethyl Pb include workers at hazardous waste sites and those involved in the manufacture and dispensing of tetraethyl Pb (Bress and Bidanset 1991).

CHAPTER 6. ADEQUACY OF THE DATABASE

Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate information on the health effects of Pb is available. Where adequate information is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research designed to determine the adverse health effects (and techniques for developing methods to determine such health effects) of Pb.

Data needs are defined as substance-specific informational needs that, if met, would reduce the uncertainties of human health risk assessment. This definition should not be interpreted to mean that all data needs discussed in this section must be filled. In the future, the identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be proposed.

6.1 Information on Health Effects

Studies evaluating the health effects of exposure of humans Pb that are discussed in Chapter 2 are summarized in Figure 2-1. The purpose of this figure is to illustrate the information concerning the health effects of Pb. The number of human studies included in the profile for each endpoint is indicated regardless of whether an effect was found.

The health effects of Pb have been extensively studied in humans, including numerous studies in children. Due to the extent of the database in humans, a comprehensive review of the complete epidemiological database is not feasible. Epidemiological studies included in Chapter 2 were selected to identify the major lines of evidence regarding health effects in humans. Because the database of epidemiological studies is so large, animal studies were not included in the profile. Due to the increasing awareness that low-level environmental exposure resulting in blood Pb concentrations (PbB) $<10 \mu\text{g/dL}$ is associated with adverse effects, particularly in children, the primary objective of current research is focused on health effects associated with $\text{PbB} \leq 10 \mu\text{g/dL}$. Additional details on studies with $\text{PbB} \leq 10 \mu\text{g/dL}$, including statistical analyses and assessment of confounding factors, are provided in the *Supporting Document for Epidemiological Studies for Lead*.

Health effects of Pb in humans are not defined in terms of route or duration of exposure. Epidemiological studies on Pb toxicity rely on internal exposure metrics (e.g., PbB), rather than measurements of external

6. ADEQUACY OF THE DATABASE

exposures (e.g., concentration of Pb in water or air) or ingested dose. Furthermore, once absorbed into the body, the health effects of Pb are the same, regardless of the route of exposure. Environmental exposure to Pb occurs continuously over a lifetime and Pb can be retained in the body for decades; therefore, health effects of Pb in humans are considered to be associated with chronic exposure, rather than to shorter exposures.

6.2 Identification of Data Needs

A data need, as defined in ATSDR's *Decision Guide for Identifying Substance-Specific Data Needs Related to Toxicological Profiles* (ATSDR 1989), is substance-specific information necessary to conduct comprehensive public health assessments. Generally, ATSDR defines a data gap more broadly as any substance-specific information missing from the scientific literature.

Increased awareness of the potential adverse consequences of low environmental exposures to Pb has led to changes in U.S. public health policy, with a focus on lowering PbB levels to well below 10 µg/dL (CDC 2012d; EPA 2016b). In 2012, the CDC concluded that the 97.5th percentile of the U.S. PbB distribution (based on NHANES data) should be considered a reference value for identifying children who have "elevated" PbB (CDC 2012d). At that time, the reference was approximately 5 µg/dL, and the value continues to decline (NHANES 2011–2012; CDC 2018a). Therefore, additional epidemiological studies for all health outcomes are needed. The objective of these additional studies would be to define the low end of the dose-response curve (e.g., at PbB ≤5 µg/dL) and to identify threshold levels for health outcomes.

MRLs. Epidemiological studies have identified health effects of Pb in all organ systems. However, exposure thresholds for effects have not been identified, and it is not possible to determine from the epidemiological data which organ system are the most sensitive (i.e., primary) targets for Pb toxicity. Because clear thresholds for these effects have not been identified, MRLs for Pb have not been derived. Additional epidemiological studies would provide more data to further characterize effects; however, as PbBs continue to decline and effects are observed at the lowest PbB examined, identification of control groups has become increasingly difficult. Thus, it is not anticipated that additional epidemiological studies would identify threshold values for Pb-induced toxicity endpoints.

Health Effects. As noted above, epidemiological studies have identified health effects of Pb in every organ system at the lowest PbB evaluated. Additional prospective studies on all health outcomes would

6. ADEQUACY OF THE DATABASE

provide important information to further characterize the effects of Pb and evaluate potential implications for long-term effects. However, as noted above, it is not anticipated that additional epidemiological studies would identify threshold values for health effects.

Epidemiology and Human Dosimetry Studies. Several models of the Pb exposure-biokinetics toxicokinetics in humans have been developed and used in dosimetry studies. Additional studies would be helpful for addressing major uncertainties in these models, including: (1) absence of calibration data for the kinetics of Pb in blood and bone in children in association with exposures that have been quantified with high certainty; (2) absence of calibration data on bone Pb concentrations in adolescents and adults in association with exposures that have been quantified with high certainty; (3) absence of data on the absolute bioavailability of ingested Pb in older children and adolescents; (4) incomplete understanding of Pb kinetics during periods of changing bone metabolism, including adolescence, pregnancy, and menopause; and (5) incomplete understanding of inter- and intra-individual variability in model parameters values in humans. In addition, there is a need for studies that can evaluate or validate model predictions of concentrations of Pb in blood and other tissues in populations in which PbBs are typical of the U.S. population ($\leq 5 \mu\text{g/dL}$).

Biomarkers of Exposure and Effect. Measurement of blood Pb concentration is the most widely used biomarker of Pb exposure and is used to identify children who have elevated exposures. Measurement of bone Pb by XRF has been used to estimate Pb body burden in adults, which is a more accurate biomarker of long-term exposure than PbB. Additional studies that could improve and evaluate the validity of non-invasive biomarkers (e.g., hair, saliva, sweat, deciduous teeth, urine) for quantifying exposure would be helpful for population monitoring of Pb exposures and for epidemiology of Pb health effects.

Absorption, Distribution, Metabolism, and Excretion. Studies of Pb absorption are limited to studies in infants and adults. No data are available on the absorption of Pb in older children and adolescents. Additional studies of Pb absorption in this age category would be useful for improving exposure-biokinetic models.

A variety of factors are known to influence the absorption of ingested Pb, including the chemical form of the ingested Pb, the presence of food in the gastrointestinal tract, diet, and nutritional status with respect to calcium, vitamin D, and iron; however, for the most part, the mechanisms by which these interactions occur are not fully understood. This reflects, in part, a lack of understanding of the mechanisms by which

6. ADEQUACY OF THE DATABASE

Pb is absorbed in the gastrointestinal tract, and studies aimed at elucidating such mechanisms would be helpful for developing PBPK models that accurately simulate relationships between Pb exposure and Pb in blood and other target and biomarker tissue.

The quantitative significance of the dermal absorption pathway as a contributor to Pb body burden remains an uncertainty. Few studies are available on Pb absorption after dermal exposure of inorganic Pb compounds in humans. Children may experience extensive dermal contact with Pb in soil, sand, or surface water and suspended sediment (e.g., beach or shoreline exposure scenario), even a low percent absorption across the skin may represent a significant internal dose. Therefore, additional studies designed to quantify dermal absorption of inorganic Pb compounds from both aqueous media and from soil would be helpful for improving PBPK models, in particular, studies that enable measurements to be extrapolated to children.

Comparative Toxicokinetics. Animal models (e.g., swine, mouse) have been used extensively as a model for assessing relative bioavailability of Pb in ingested soil in humans and for evaluating *in vitro* approaches to assessing bioaccessibility of Pb. However, no studies are available in which the absolute or relative bioavailability of ingested Pb has been quantitatively compared in animal models and humans. Such studies would be useful for validating both the *in vivo* swine model and the *in vitro* bioaccessibility model.

Children's Susceptibility. Children are likely to have increased susceptibility to Pb compared to adults for several reasons: increased susceptibility of developing physiological systems compared to mature systems; increased absorption of Pb in children compared to adults; and common childhood behaviors (e.g., hand-to-mouth activity, pica behavior [the compulsive, habitual consumption of nonfood items], proximity of breathing zone to entrained surface dust). In addition, several other factors may affect children's susceptibility to Pb, including (but not limited to) family socio-economic status, parent education, parent alcohol, tobacco, and drug use, allergen exposure, and family history of disease, although these factors may not be unique to children. Additional studies evaluating these factors would provide an increased understanding of relative contributions of these factors to child PbB and associated health effects.

Physical and Chemical Properties. No data needs were identified regarding physical and chemical properties of Pb.

6. ADEQUACY OF THE DATABASE

Production, Import/Export, Use, Release, and Disposal. Continued monitoring of Pb production, import/export, use, release, and disposal would be helpful for identifying sources of potential human exposure. In particular, additional data on releases of Pb from leaded gasoline used in piston-driven engines would be helpful for determining potential contributions of this source to human exposure. Industrial wastes, as well as consumer products, containing Pb are disposed of in municipal and hazardous waste landfills. Current information on the amounts being disposed would be helpful for evaluating potential for exposures to Pb from these sources.

Environmental Fate. Additional information on the atmospheric transformations of organic and inorganic Pb compounds in the atmosphere would be helpful for identifying Pb compounds to which humans are most likely to be exposed by inhalation. Additional data regarding the chemical speciation and the transformation pathways of Pb in soils and water with varying properties such as pH, oxygen content, and salinity would be helpful for improving understanding of the environmental fate of Pb in soils and water.

Bioavailability from Environmental Media. Studies conducted in animal models show that oral RBA of soil Pb varies depending upon the Pb mineralogy and physical characteristics of the Pb in the soil. There is only one published study that assessed the bioavailability of Pb in humans (adults) who ingested hazardous waste site soil. Additional studies of this type would provide an improved basis for estimating Pb uptake in people who are exposed to Pb in soil. No studies have measured oral RBA of surface dusts. Since this is an important exposure pathway, especially in urban environments, studies of oral Pb RBA of surface dusts collected from various types of indoor and outdoor surfaces, including those impacted by paint Pb, would be helpful.

Recent interest in the use of soil-amending agents (e.g., phosphate) to reduce soil Pb bioavailability, would be served by additional studies directed at developing methods for monitoring the magnitude and persistence of the effect of amending agents on Pb bioavailability and for predicting the magnitude of the effect for improved design of amending projects.

Food Chain Bioaccumulation. No data needs were identified regarding food chain bioaccumulation.

Exposure Levels in Environmental Media. Reliable monitoring data for the levels of Pb in contaminated media at hazardous waste sites are needed so that the information obtained on levels of Pb in the environment can be used in combination with the known body burden of Pb to assess the potential

6. ADEQUACY OF THE DATABASE

risk of adverse health effects in populations living in the vicinity of hazardous waste sites. Continued monitoring of Pb levels in air, drinking water, and diet (e.g., food and bottled water) would be helpful for evaluating potential for exposures to Pb from these sources. Continued testing of consumer products would be helpful for identifying potential localized sources of human exposure (e.g., ceramics, cosmetics, jewelry, toys).

Exposure Levels in Humans. Continued updating of national (e.g., NHANES) and regional surveys of Pb biomarkers (e.g., PbB) would be helpful for assessing temporal and demographic trends in Pb exposure in the U.S. population as well as for evaluating associations between Pb exposure and health metrics (e.g., those included in the NHANES), and for evaluating models that relate exposure to PbB.

Exposures of Children. Since an important variable in estimating Pb intakes from measurements of surface dust Pb levels is the rate of surface dust ingestion, improved estimates of soil ingestion would increase confidence in predictions of Pb intakes associated with exposures to Pb in surface dusts. In some contexts, exposure to surface dust Pb is measured in terms of Pb loading ($\mu\text{g}/\text{Pb}/\text{cm}^2$ of surface area available for contact); however, Pb loading measurements do not provide a direct way of estimating Pb ingestion without corresponding estimates of dust loading and surface dust ingestion rates. Improved methods for translating measurements of Pb loading into estimates of surface dust Pb concentration or surface dust Pb intake would be helpful for improving models for predicting exposure-Pb relationships in children.

6.3 Ongoing Studies

Ongoing studies on Pb are outlined in Table 6-1. Note that the studies listed below are funded by the National Institute of Health (NIH) and do not include ongoing studies that are funded by other sources.

Table 6-1. Ongoing Studies on Lead (Pb)

Investigator	Affiliation	Research description	Sponsor
D'Sa, VA	Memorial Hospital of Rhode Island	Longitudinal study on the relationship between PbB and myelination and neurite density in children ages 12–24 months	NICHHD
Guilarte, TR	Florida International University	Mechanism of action study in rats to evaluate the role the NMDA receptor in Pb-induced neurotoxicity	NIEHS

6. ADEQUACY OF THE DATABASE

Table 6-1. Ongoing Studies on Lead (Pb)

Investigator	Affiliation	Research description	Sponsor
Guilarte, TR	Florida International University	Study in rats to evaluate presynaptic mechanisms of Pb-induced neurotoxicity	NIEHS
Murphy, MP	University of Kentucky	Study in rats to evaluate mechanism of Pb-induced neurotoxicity	NIEHS
Sandler, DP	NIEHS	Epidemiological study examining Pb and other neurotoxins as risk factors for amyotrophic lateral sclerosis	NIEHS
Steenland, NK	Emory University	Epidemiological study examining mortality and renal disease in Pb-exposed workers	NIOSH
Bhattacharya, A	University of Cincinnati	Epidemiological study on the effects of early exposure to Pb as a risk for bone health later in life in African-American women	NIEHS
Wright, RO	Icahn School of Medicine Mount Sinai	Epidemiological study in children on the link between Pb exposure, stress, and neurological development	NIEHS

NICHD = National Institute of Child Health and Human Development; NIEHS = National Institute of Environmental Health Sciences; NIOSH = National Institute of Occupational Safety and Health; NMDA = N-methyl-D-aspartate; PbB = blood lead concentration

Source: NIH Reporter 2017

CHAPTER 7. REGULATIONS AND GUIDELINES

Pertinent international and national regulations, advisories, and guidelines regarding Pb in air, water, and other media are summarized in Table 7-1. This table is not an exhaustive list, and current regulations should be verified by the appropriate regulatory agency.

ATSDR develops MRLs, which are substance specific guidelines intended to serve as screening levels by ATSDR health assessors and other responders to identify contaminants and potential health effects that may be of concern at hazardous waste sites. See Section 1.3 and Appendix A for information on procedures for deriving MRLs, as well as the deliberations and conclusions regarding derivation of MRLs for Pb.

Table 7-1. Regulations and Guidelines Applicable to Lead (Pb)

Agency	Description	Information	Reference
Air			
EPA	RfC	No data	IRIS 2002 , 2004
EPA	NAAQS	0.15 µg/m ³ ^a	EPA 2016e
WHO	Air quality guidelines	No data	WHO 2010
Water & Food			
EPA	Drinking water standards and health advisories	No data	EPA 2018c
	National primary drinking water regulations for inorganic lead		EPA 2009
	TT	TT5	
	Action level	0.015 mg/L ^b	
	Public health goal	zero	
	RfD		
	Tetraethyl lead	1 x10 ⁻⁷ mg/kg/day ^c	IRIS 2002
WHO	Drinking water quality guidelines		WHO 2017
	Provisional guideline value, lead	0.01 mg/L (10 µg/L) ^d	
FDA	EAFUS ^e	No data	FDA 2013
Cancer			
ACGIH	Carcinogenicity classification		
	Lead (inorganic compounds as Pb)	A3 ^{f,g}	ACGIH 2001a, 2018
	Lead chromate (as Pb or chromium)	A2 ^{h,i}	ACGIH 2001b, 2018
	Tetraethyl lead	A4 ^{i,k}	ACGIH 2001c, 2018
HHS	Carcinogenicity classification		NTP 2016
	Lead and lead compounds	Reasonably anticipated to be human carcinogens ^l	

7. REGULATIONS AND GUIDELINES

Table 7-1. Regulations and Guidelines Applicable to Lead (Pb)

Agency	Description	Information	Reference
EPA	Carcinogenicity classification Lead and compounds (inorganic)	B2 ^{m,n}	IRIS 2004
IARC	Carcinogenicity classification Lead Lead compounds, inorganic Lead compounds, organic	Group 2B ^{o,p} Group 2A ^{q,r} Group 3 ^{s,t}	IARC 1987 , 2017 IARC 2006 , 2017 IARC 2006 , 2017
Occupational			
ACGIH	TLV Lead Lead chromate (as Pb) Lead chromate (as chromium) Tetraethyl lead BEI Lead in blood	0.05 mg/m ³ 0.05 mg/m ³ 0.012 mg/m ³ 0.1 mg/m ³ 20 µg/100 mL ^u	ACGIH 2018
OSHA	PEL (8-hour TWA) for general industry Lead (elemental, inorganic and organic soaps) Tetraethyl lead and tetramethyl lead PEL (8-hour TWA) for construction and shipyards Lead (elemental, inorganic and organic soaps) Tetraethyl lead Tetramethyl lead Action level (8-hour TWA) for general industry, construction Lead (elemental, inorganic and organic soaps) Medical removal protection for general industry Temporary removal blood lead level Return to work blood lead level Medical removal protection for construction and shipyards Temporary removal blood lead level Return to work blood lead level	0.5 mg/m ³ 0.075 mg/m ^{3v} 50 µg/m ³ 0.1 mg/m ^{3v} 0.15 mg/m ^{3v} 30 µg/m ³ ≥60 µg/dL <40 µg/dL ≥50 µg/dL <40 µg/dL	OSHA 2016a OSHA 2016b OSHA 2016c , 2016d OSHA 2016e , 2016f OSHA 2016e , 2016f OSHA 2016a , 2016c OSHA 2016a OSHA 2016c
NIOSH	REL (8-hour TWA) Lead and compounds (as Pb) Tetraethyl lead (as Pb) IDLH Lead and compounds (as Pb) Tetraethyl lead (as Pb)	0.05 mg/m ³ 0.075 mg/m ^{3v} 100 mg/m ³ 40 mg/m ³	NIOSH 2016b NIOSH 2016c NIOSH 2016b NIOSH 2016c

7. REGULATIONS AND GUIDELINES

Table 7-1. Regulations and Guidelines Applicable to Lead (Pb)

Agency	Description	Information	Reference
Emergency Criteria			
EPA	AEGLs-air	No data	EPA 2016d
DOE	PACs-air		DOE 2016
	Lead		
	PAC-1	0.15 mg/m ³	
	PAC-2	120 mg/m ³	
	PAC-3	700 mg/m ³	
	Tetraethyl lead		
	PAC-1	0.5 mg/m ³	
	PAC-2	5.5 mg/m ³	
	PAC-3	33 mg/m ³	
	Lead acetate		
	PAC-1	5 mg/m ³	
	PAC-2	55 mg/m ³	
	PAC-3	330 mg/m ³	
	Lead carbonate		
	PAC-1	0.19 mg/m ³	
	PAC-2	24 mg/m ³	
	PAC-3	900 mg/m ³	
	Lead dioxide and lead sulfide		
	PAC-1	0.17 mg/m ³	
	PAC-2	140 mg/m ³	
	PAC-3	810 mg/m ³	
	Lead tetroxide		
	PAC-1	0.17 mg/m ³	
	PAC-2	130 mg/m ³	
	PAC-3	770 mg/m ³	
	Lead oxide		
	PAC-1	0.16 mg/m ³	
	PAC-2	130 mg/m ³	
	PAC-3	750 mg/m ³	
	Lead sulfate		
	PAC-1	0.22 mg/m ³	
	PAC-2	170 mg/m ³	
	PAC-3	1,000 mg/m ³	

7. REGULATIONS AND GUIDELINES

Table 7-1. Regulations and Guidelines Applicable to Lead (Pb)

Agency	Description	Information	Reference
	Lead phosphate		
	PAC-1	0.2 mg/m ³	
	PAC-2	150 mg/m ³	
	PAC-3	910 mg/m ³	
	Lead chloride		
	PAC-1	0.2 mg/m ³	
	PAC-2	160 mg/m ³	
	PAC-3	940 mg/m ³	
	Lead chromate		
	PAC-1	0.036 mg/m ³	
	PAC-2	16 mg/m ³	
	PAC-3	97 mg/m ³	
	Lead bromide		
	PAC-1	0.27 mg/m ³	
	PAC-2	200 mg/m ³	
	PAC-3	1,200 mg/m ³	
	Lead nitrate		
	PAC-1	0.24 mg/m ³	
	PAC-2	180 mg/m ³	
	PAC-3	1,100 mg/m ³	
	Lead iodide		
	PAC-1	0.33 mg/m ³	
	PAC-2	270 mg/m ³	
	PAC-3	1,600 mg/m ³	
	Lead fluoroborate		
	PAC-1	0.28 mg/m ³	
	PAC-2	220 mg/m ³	
	PAC-3	1,300 mg/m ³	
Miscellaneous Federal Guidance			
CDC	PbB reference value	5 µg/dL ^w	CDC 2012d , 2012f
EPA	Soil screening level	400 ppm ^x	EPA 1994e, 1998 ; 2016f

7. REGULATIONS AND GUIDELINES

Table 7-1. Regulations and Guidelines Applicable to Lead (Pb)

Agency	Description	Information	Reference
HUD	Dust lead hazard action levels ^y		HUD 2017
	Floors	≥10 µg/ft ²	
	Window sills	≥100 µg/ft ²	
	Dust lead clearance action levels ^y		
	Interior floors	<10 µg/ft ²	
	Porch floors	<40 µg/ft ²	
	Window sills	<100 µg/ft ²	
	Window troughs	<100 µg/ft ²	

^aNot-to-exceed air Pb concentration of 0.15 µg/m³ in total suspended solids for a 3-month rolling average, evaluated over a 3-year period (i.e., the 3-month rolling average cannot exceed 0.15 µg/m³ over a 3-year period). Based on a variety of lines of evidence including human epidemiological evidence for a variety of adverse health effects in children and other at-risk populations, most notably effects on the developing nervous system.

^bPotential health effects from long-term exposure above the MCL include delays in physical or mental development in infants and children (children could show slight deficits in attention span and learning abilities) and kidney problems and high blood pressure in adults.

^cBased on histopathology of liver and thymus; POD = LOAEL: 1.2x10⁻³ mg/kg/day; composite uncertainty factor=10,000; confidence=medium.

^dThe guideline value is designated as provisional on the basis of treatment performance and analytical achievability because it is extremely difficult to achieve a lower concentration by central conditioning, such as phosphate dosing.

^eThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food additives or listed or affirmed as GRAS.

^fA3: confirmed animal carcinogen with unknown relevance to humans.

^gBased on demonstrated carcinogenicity of soluble lead compounds in animals.

^hA2: Suspected human carcinogen.

ⁱBased on experimental animal and epidemiological studies that demonstrated a low degree of carcinogenicity.

^jA4: not classifiable as a human carcinogen.

^kBased on inconclusive evidence of carcinogenicity in rodent bioassays.

^lBased on sufficient evidence of carcinogenicity in experimental animals.

^mGroup B2: probable human carcinogen.

ⁿBased on sufficient evidence of carcinogenicity in animals.

^oGroup 2B: possibly carcinogenic to humans.

^pBased on inadequate evidence for carcinogenicity to humans and sufficient evidence for carcinogenicity of inorganic lead compounds in animals.

^qGroup 2A: probably carcinogenic to humans.

^rBased on limited evidence of carcinogenicity of inorganic lead in humans and sufficient evidence of carcinogenicity in experimental animals. Also based on sufficient evidence of carcinogenicity of inorganic compounds in experimental animals, sufficient evidence of carcinogenicity of Pb acetate, Pb subacetate, Pb chromate, and Pb phosphate in experimental animals, and based on inadequate evidence of carcinogenicity of Pb oxide, Pb arsenate, tetraethyl Pb, and Pb powder in experimental animals.

^sGroup 3: not classifiable as to carcinogenicity to humans.

^tBased on inadequate evidence of carcinogenicity in humans and inadequate evidence of carcinogenicity in experimental animals.

^u2016 Notice of Intended Change for BEI: 200 µg/L.

^vSkin designation.

^wBased on 97.5th percentile of NHANES PbB distribution in children 1–5 years of age.

^xBased on evidence for adverse effects on the developing nervous system in association with PbB in the 2–8 µg/dL range.

^yBased on evidence for adverse effects on the developing nervous system in association with PbB <5 µg/dL.

ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels; AIHA = American Industrial Hygiene Association; BEI = biological exposure index; CDC = Centers for Disease Control and Prevention; DOE = Department of Energy; EAFUS = Everything Added to Food in the United States; EPA = Environmental Protection Agency; ERPG = emergency response planning guidelines; FDA = Food and Drug Administration; GRAS = generally recognized as safe; HHS = Department of Health and Human Services; HUD = Housing and Urban Development; IARC = International Agency for Research on Cancer;

7. REGULATIONS AND GUIDELINES

Table 7-1. Regulations and Guidelines Applicable to Lead (Pb)

Agency	Description	Information	Reference
<p>IDLH = immediately dangerous to life or health concentration; IRIS = Integrated Risk Information System; LOAEL = lowest-observed-adverse-effect level; MCL = maximum contaminant level; NAAQS = National Ambient Air Quality Standard; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health Administration; PAC = Protective Action Criteria; PEL = permissible exposure limit; POD = point of departure; REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose; TLV = threshold limit values; TT = treatment technique; TWA = time-weighted average; WHO = World Health Organization</p>			

CHAPTER 8. REFERENCES

- AAP. 1998. Screening for elevated blood lead levels. *Pediatrics* 101(6):1072-1078.
- AAP. 2005. Lead exposure in children: Prevention, detection, and management. *Pediatrics* 116(4):1036-1046. 10.1542/peds.2005-1947.
- AAP. 2016. Council on Environmental Health. Prevention of childhood lead toxicity. *Pediatrics* 38(1):e20161493.
- Abam E, Okediran BS, Odukoya OO, et al. 2008. Reversal of ionoregulatory disruptions in occupational lead exposure by vitamin C. *Environ Toxicol Pharmacol* 26(3):297-304. 10.1016/j.etap.2008.05.008.
- Abadin HG, Wheeler JS, Jones DE, et al. 1997. A framework to guide public health assessment decisions at lead sites. *J Clean Technol Environ Toxicol Occup Med* 6(3):225-237.
- Abdelouahab N, Mergler D, Takser L, et al. 2008. Gender differences in the effects of organochlorines, mercury, and lead on thyroid hormone levels in lakeside communities of Quebec (Canada). *Environ Res* 107(3):380-392. 10.1016/j.envres.2008.01.006.
- ACGIH. 2001a. Lead and inorganic compounds. Documentation of the TLVs and BEIs for chemical substances and physical agents and biological exposure indices. Cincinnati, OH: American Conference of Governmental Industrial Hygienists. May 3, 2017.
- ACGIH. 2001b. Lead chromate. Documentation of the TLVs and BEIs for chemical substances and physical agents and biological exposure indices. Cincinnati, OH: American Conference of Governmental Industrial Hygienists, May 3, 2017.
- ACGIH. 2001c. Tetraethyl lead. Documentation of the TLVs and BEIs for chemical substances and physical agents and biological exposure indices. Cincinnati, OH: American Conference of Governmental Industrial Hygienists. May 3, 2017.
- ACGIH. 2018. TLVs and BEIs based on the documentation of the threshold limit values for chemical substances and physical agents and biological exposure indices. Cincinnati, OH: American Conference of Governmental Industrial Hygienists.
- ACMT. 2010. American College of Medical Toxicology. Position statement on post-chelator challenge urinary metal testing. *J Med Toxicol* 6:74-75.
- Adebonojo FO. 1974. Hematologic status of urban black children in Philadelphia. *Clin Pediatr (Phila)* 13(10):874-888.
- Ademuyiwa O, Ugbaja RN, Idumebor F, et al. 2005. Plasma lipid profiles and risk of cardiovascular disease in occupational lead exposure in Abeokuta, Nigeria. *Lipids Health Dis* 4:19. 10.1186/1476-511X-4-19.
- Afeiche M, Peterson KE, Sánchez BN, et al. 2011. Prenatal lead exposure and weight of 0 to 5 year-old children in Mexico City. *Environ Health Perspect* 119(10):1436-1441. 10.1289/ehp.1003184.
- Ahamed M, Siddiqui MK. 2007. Low level lead exposure and oxidative stress: Current opinions. *Clin Chim Acta* 383(1-2):57-64. 10.1016/j.cca.2007.04.024.
- Ahamed M, Singh S, Behari JR, et al. 2007. Interaction of lead with some essential trace metals in the blood of anemic children from Lucknow, India. *Clin Chim Acta* 377(1-2):92-97. 10.1016/j.cca.2006.08.032.
- Ahamed M, Verma S, Kumar A, et al. 2005. Environmental exposure to lead and its correlation with biochemical indices in children. *Sci Total Environ* 346(1-3):48-55. 10.1016/j.scitotenv.2004.12.019.
- Ahamed M, Verma S, Kumar A, et al. 2006. δ -Aminolevulinic acid dehydratase inhibition and oxidative stress in relation to blood lead among urban adolescents. *Hum Exp Toxicol* 25(9):547-553. 10.1191/0960327106het657oa.
- Aiba Y, Ohshiba S, Horiguchi S, et al. 1999. Peripheral hemodynamics evaluated by acceleration plethysmography in workers exposed to lead. *Ind Health* 37:3-8.

8. REFERENCES

- AIHA. 2015. Current ERPG Values (2015). Fairfax, VA: American Industrial Hygiene Association. <https://www.aiha.org/get-involved/AIHAGuidelineFoundation/EmergencyResponsePlanningGuidelines/Documents/2015%20ERPG%20Levels.pdf>. March 22, 2016.
- Akesson A, Lundh T, Vahter M, et al. 2005. Tubular and glomerular kidney effects in Swedish women with low environmental cadmium exposure. *Environ Health Perspect* 113(11):1627-1631. 10.1289/ehp.8033.
- Akesson A, Stal P, Vahter M. 2000. Phlebotomy increases cadmium uptake in hemochromatosis. *Environ Health Perspect* 108:289-291.
- Akhavan J. 2004. Explosives and propellants. In: Kirk-Othmer encyclopedia of chemical technology. Vol. 10. 719-744. <http://onlinelibrary.wiley.com/doi/10.1002/0471238961.0524161212091404.a01.pub2/pdf>. March 30, 2017.
- Al Bakheet SA, Attafi IM, Maayah ZH, et al. 2013. Effect of long-term human exposure to environmental heavy metals on the expression of detoxification and DNA repair genes. *Environ Pollut* 181:226-232.
- Alarcon WA. 2015. Summary of notifiable noninfectious conditions and disease outbreaks: Elevated blood lead levels among employed adults - United States, 1994-2012. *MMWR Morb Mortal Wkly Rep* 62(54):52-75. 10.15585/mmwr.mm6254a4.
- Alessio L. 1988. Relationship between "chelatable lead" and the indicators of exposure and effect in current and past occupational life. *Sci Total Environ* 71:293-299.
- Alessio L, Bertazzi PA, Monelli O, et al. 1976. Free erythrocyte protoporphyrin as an indicator of the biological effect of lead in adult males. *Int Arch Occup Environ Health* 37:89-105.
- Alexander BH, Checkoway H, Costa-Mallen P, et al. 1998b. Interaction of blood lead and δ -aminolevulinic acid dehydratase genotype on markers of heme synthesis and sperm production in lead smelter workers. *Environ Health Perspect* 106:213-216.
- Alexander BH, Checkoway H, Faustman EM, et al. 1998a. Contrasting associations of blood and semen lead concentrations with semen quality among lead smelter workers. *Am J Ind Med* 34:464-469.
- Alexander FW, Clayton BE, Delves HT. 1974. Mineral and trace-metal balances in children receiving normal and synthetic diets. *Q J Med* 169:89-111.
- Al-Hakkak ZS, Hamamy HA, Murad AM, et al. 1986. Chromosome aberrations in workers at a storage battery plant in Iraq. *Mutat Res Genet Toxicol* 171(1):53-60.
- Ali Z, Ulrik CS. 2013. Obesity and asthma: A coincidence or a causal relationship? A systematic review. *Respir Med* 107:1287-1300.
- Aligne CA, Auinger P, Byrd RS, et al. 2000. Risk factors for pediatric asthma: Contributions of poverty, race, and urban residence. *Am J Respir Crit Care Med* 162(3 Pt. 1):873-877.
- Al-Modhefer AJ, Bradbury MWB, Simons TJB. 1991. Observations on the chemical nature of lead in human blood serum. *Clin Sci* 81:823-829.
- Al-Neamy FR, Almehdi AM, Alwash R, et al. 2001. Occupational lead exposure and amino acid profiles and liver function tests in industrial workers. *Int J Environ Health Res* 11(2):181-188.
- Alomran AH, Shleamoon MN. 1988. The influence of chronic lead exposure on lymphocyte proliferative response and immunoglobulin levels in storage battery workers. *J Biol Sci* 19(3):575-585.
- Al-Saleh I, Shinwari N, Mashhour A, et al. 2005. Is lead considered as a risk factor for high blood pressure during menopause period among Saudi women? *Int J Hyg Environ Health* 208(5):341-356.
- Al-Saleh I, Shinwari N, Mashhour A, et al. 2014. Birth outcome measures and maternal exposure to heavy metals (lead, cadmium and mercury) in Saudi Arabian population. *Int J Hyg Environ Health* 217(2-3):205-218. 10.1016/j.ijheh.2013.04.009.
- Amaral JH, Rezende VB, Quintana SM, et al. 2010. The relationship between blood and serum lead levels in peripartum women and their respective umbilical cords. *Basic Clin Pharmacol Toxicol* 107(6):971-975. 10.1111/j.1742-7843.2010.00616.x.

8. REFERENCES

- Amato MS, Magzamen S, Imm P, et al. 2013. Early lead exposure (<3 years old) prospectively predicts fourth grade school suspension in Milwaukee, Wisconsin (USA). *Environ Res* 126:60-65. 10.1016/j.envres.2013.07.008.
- Ames SK, Ellis KJ, Gunn SK, et al. 1999. Vitamin D receptor gene Fok1 polymorphism predicts calcium absorption and bone mineral density in children. *J Bone Miner Res* 14(5):740-746.
- Amitai Y, Graef JW, Brown MJ, et al. 1987. Hazards of 'deleading' homes of children with lead poisoning. *Am J Dis Child* 141:758-760.
- Anetor J, Adeniyi F. 1997. Decreased immune status in Nigerian workers occupationally exposed to lead. *Afr J Med Sci* 27(3-4):169-172.
- Angelova VR, Ivanova RV, Todorov JM, et al. 2010. Lead, cadmium, zinc, and copper bioavailability in the soil-plant-animal system in a polluted area. *Sci World J* 10:273-285. 10.1100/tsw.2010.33.
- Angle CR, Manton WI, Stanek KL. 1995. Stable isotope identification of lead sources in preschool children - The Omaha Study. *Clin Toxicol* 33(6):657-662.
- Angle CR, McIntire MS, Swanson MS, et al. 1982. Erythrocyte nucleotides in children -- Increased blood lead and cytidine triphosphate. *Pediatr Res* 16:331-334.
- Annesi-Maesano I, Pollitt R, King G, et al. 2003. *In utero* exposure to lead and cord blood total IgE. Is there a connection? *Allergy* 58(7):589-594.
- Anttila A, Heikkila P, Nykyri E, et al. 1996. Risk of nervous system cancer among workers exposed to lead. *J Occup Environ Med* 38(2):131-136.
- Anttila A, Heikkila P, Pukkala E, et al. 1995. Excess lung cancer among workers exposed to lead. *Scand J Work Environ Health* 21:460-469.
- Anwar WA, Kamal AA. 1988. Cytogenetic effects in a group of traffic policemen in Cairo. *Mutat Res* 208(3-4):225-231.
- Aoki Y, Brody DJ, Flegal KM, et al. 2016. Blood lead and other metal biomarkers as risk factors for cardiovascular disease mortality. *Medicine* 95(1):e2223. 10.1097/md.0000000000002223.
- Apostoli P, Maranelli G, Cas LD, et al. 1990. Blood lead and blood pressure: A cross sectional study in a general population group. *Cardiologia* 35(7):597-603.
- Apostolou A, Garcia-Esquinas E, Fadrowski JJ, et al. 2012. Secondhand tobacco smoke: A source of lead exposure in US children and adolescents. *Am J Public Health* 102(20):12. 10.2105/AJPH.2011.300161.
- Araki S, Aono H, Yokoyama K, et al. 1986. Filterable plasma concentration, glomerular filtration, tubular balance, and renal clearance of heavy metals and organic substances in metal workers. *Arch Environ Health* 41(4):216-221.
- Araki S, Honma T, Yanagihara S, et al. 1980. Recovery of slowed nerve conduction velocity in lead-exposed workers. *Int Arch Occup Environ Health* 46:151-157.
- Araki S, Murata K, Aono H. 1987. Central and peripheral nervous system dysfunction in workers exposed to lead, zinc and copper. *Int Arch Occup Environ Health* 59:177-187.
- Araki S, Sata F, Murata K. 1990. Adjustment for urinary flow rate: An improved approach to biological monitoring. *Int Arch Occup Environ Health* 62(6):471-477.
- Araki S, Sato H, Yokoyama K, et al. 2000. Subclinical neurophysiological effects of lead: A review on peripheral, central, and autonomic nervous system effects in lead workers. *Am J Ind Med* 37:193-204.
- Ari E, Kaya Y, Demir H, et al. 2011. The correlation of serum trace elements and heavy metals with carotid artery atherosclerosis in maintenance hemodialysis patients. *Biol Trace Elem Res* 144(1-3):351-359. 10.1007/s12011-011-9103-0.
- Armstrong R, Chettle DR, Scott MC, et al. 1992. Repeated measurements of tibia lead concentrations by *in vivo* x ray fluorescence in occupational exposure. *Br J Ind Med* 49(1):14-16.
- Arnvig E, Grandjean P, Beckmann J. 1980. Neurotoxic effects of heavy lead exposure determined with psychological tests. *Toxicol Lett* 5:399-404.

8. REFERENCES

- Aro A, Amarasiriwardena C, Lee ML, et al. 2000. Validation of K x-ray fluorescence bone lead measurements by inductively coupled plasma mass spectrometry in cadaver legs. *Med Phys* 27(1):119-123.
- Arora M, Ettinger AS, Peterson KE, et al. 2008. Maternal dietary intake of polyunsaturated fatty acids modifies the relationship between lead levels in bone and breast milk. *J Nutr* 138:73-79.
- Arora M, Weuve J, Weisskopf MG, et al. 2009. Cumulative lead exposure and tooth loss in men: The Normative Aging Study. *Environ Health Perspect* 117(10):1531-1534.
- Aschengrau A, Beiser A, Bellinger D, et al. 1994. The impact of soil lead abatement on urban children's blood lead levels: Phase II results from Boston Lead-in-Soil Demonstration Project. *Environ Res* 67:125-148.
- Assennato G, Paci C, Baser ME, et al. 1987. Sperm count suppression without endocrine dysfunction in lead-exposed men. *Arch Environ Health* 42:124-127.
- Astrin KH, Bishop DF, Wetmur JG, et al. 1987. δ -Aminolevulinic acid dehydratase isozymes and lead toxicity. *Ann NY Acad Sci* 514:23-39.
- ATSDR. 1989. Decision guide for identifying substance-specific data needs related to toxicological profiles; Notice. *Fed Regist* 54(174):37618-37634.
- ATSDR. 1995. Multisite lead and cadmium exposure study with biological markers incorporated. Atlanta, GA: Agency for Toxic Substances and Disease Registry, U.S. Department of Health and Human Services.
- ATSDR. 2004a. Interaction profile for arsenic, cadmium, chromium, and lead. Atlanta, GA: Agency for Toxic Substances and Disease Registry. <http://www.atsdr.cdc.gov/interactionprofiles/ip04.html>. July 3, 2017.
- ATSDR. 2004b. Interaction profile for lead, manganese, zinc, and copper. Atlanta, GA: Agency for Toxic Substances and Disease Registry. <http://www.atsdr.cdc.gov/interactionprofiles/ip06.html>. July 3, 2017.
- ATSDR. 2006. Interaction profile for chlorpyrifos, lead, mercury, and methylmercury. Atlanta, GA: Agency for Toxic Substances and Disease Registry. <http://www.atsdr.cdc.gov/interactionprofiles/IP-11/ip11.pdf>. July 3, 2017.
- ATSDR. 2007. Toxicological profile for lead. Agency for Toxic Substances and Disease Registry. <https://www.atsdr.cdc.gov/toxprofiles/tp13.pdf>. June 20, 2017.
- ATSDR. 2015. Lead. Full SPL data. Substance priority list (SPL) resource page. Agency for Toxic Substances and Disease Registry, Centers for Disease Control and Prevention. <http://www.atsdr.cdc.gov/SPL/resources/index.html>. February 28, 2017.
- ATSDR. 2017. Case studies in environmental medicine (CSEM). Lead toxicity. https://www.atsdr.cdc.gov/csem/lead/docs/csem-lead_toxicity_508.pdf. August 30, 2018.
- Aucott M, Caldarelli A. 2012. Quantity of lead released to the environment in New Jersey in the form of motor vehicle wheel weights. *Water Air Soil Pollut* 223(4):1743-1752. 10.1007/s11270-011-0979-2.
- Aufderheide AC, Wittmers LE, Jr. 1992. Selected aspects of the spatial distribution of lead in bone. *Neurotoxicology* 13:809-820.
- Aungst BJ, Fung HL. 1981. Kinetic characterization of *in vitro* lead transport across the rat small intestine. *Toxicol Appl Pharmacol* 61:39-47.
- Aungst BJ, Dolce JA, Fung HL. 1981. The effect of dose on the disposition of lead in rats after intravenous and oral administration. *Toxicol Appl Pharmacol* 61:48-57.
- Avula B, Wang YH, Smillie TJ, et al. 2010. Quantitative determination of multiple elements in botanicals and dietary supplements using ICP-MS. *J Agric Food Chem* 58:8887-8894.
- Awad el Karin, Hamed AS, Elhaimi YA, et al. 1986. Effects of exposure to lead among lead-acid battery factory workers in Sudan. *Arch Environ Health* 41(4):261-265.
- Azar A, Trochimowica HJ, Maxfield ME. 1973. Review of lead studies in animals carried out at Haskell Laboratory: Two year feeding study and response to hemorrhage study. *Environmental Health* 5004:199-210. Aspects of Lead, Proceedings of the International Symposium, October, 1972.

8. REFERENCES

- Baeyens W, Vrijens J, Gao Y, et al. 2014. Trace metals in blood and urine of newborn/mother pairs, adolescents and adults of the Flemish population (2007-2011). *Int J Hyg Environ Health* 217(8):878-890.
- Bagci C, Bozkurt A, Cakmak E, et al. 2004. Blood lead levels of the battery and exhaust workers and their pulmonary function tests. *Int J Clin Pract* 58(6):568-572.
- Baghurst PA, McMichael AJ, Tong S, et al. 1995. Exposure to environmental lead and visual-motor integration at age 7 years: The Port Pirie cohort study. *Epidemiology* 6(2):104-109.
- Baghurst PA, McMichael AJ, Wigg NR, et al. 1992. Environmental exposure to lead and children's intelligence at the age of seven years. *N Engl J Med* 327(18):1279-1284.
- Baghurst PA, Robertson EF, McMichael AJ, et al. 1987. The Port Pirie cohort study: Lead effects on pregnancy outcome and early childhood development. *Neurotoxicology* 8(3):395-402.
- Bailey MR, Roy M. 1994. Clearance of particles from the respiratory tract. In: *Human respiratory tract model for radiological protection: A report of a task group of the International Commission on Radiological Protection*. Oxford, UK: Pergamon Press, 301-413.
- Baker EL, Feldman RG, White RF, et al. 1983. The role of occupational lead exposure in the genesis of psychiatric and behavioral disturbances. *Acta Psychiatr Scand* 67:38-48.
- Baker EL, Landrigan PJ, Barbour AG, et al. 1979. Occupational lead poisoning in the United States: Clinical and biochemical findings related to blood lead levels. *Br J Ind Med* 36:314-322.
- Bakulski KM, Rozek LS, Dolinoy DC, et al. 2012. Alzheimer's disease and environmental exposure to lead: The epidemiologic evidence and potential role of epigenetics. *Curr Alzheimer Res* 9(5):563-573.
- Balo J, Attila B, Bela S. 1965. [Experimental adenomas of the kidney produced by chronic administration of lead phosphate] *Magy Onkol* 9:141-151 (Hungarian)
- Bandeem-Roche K, Glass TA, Bolla KI, et al. 2009. Cumulative lead dose and cognitive function in older adults. *Epidemiology* 20(6):831-839. 10.1097/EDE.0b013e3181b5f100.
- Bannon DI, Williams MA. 2017. Matching target dose to target organ. *F1000 Research* 5:2785.
- Bannon DI, Abounader R, Lees PSJ, et al. 2003. Effect of DMT1 knockdown on iron, cadmium, and lead uptake in Caco-2 cells. *Am J Physiol Cell Physiol* 284:C44-C50.
- Bannon DI, Drexler JW, Fent GM, et al. 2009. Evaluation of small arms range soils for metal contamination and lead bioavailability. *Environ Sci Technol* 43(24):9071-9076. 10.1021/es901834h.
- Bannon DI, Olivi L, Bressler J. 2000. The role of anion exchange in the uptake of Pb by human erythrocytes and Madin-Darby canine kidney cells. *Toxicology* 147:101-107.
- Bannon DI, Portnoy ME, Olivi L, et al. 2002. Uptake of lead and iron by divalent metal transporter 1 in yeast and mammalian cells. *Biochem Biophys Res Commun* 295(4):978-984.
- Bao QS, Lu CY, Song H, et al. 2009. Behavioural development of school-aged children who live around a multi-metal sulphide mine in Guangdong province, China: A cross-sectional study. *BMC Public Health* 9(1):217. 10.1186/1471-2458-9-217.
- Baranowska-Bosiacka I, Kosinska I, Jamiol D, et al. 2016. Environmental lead (Pb) exposure versus fatty acid content in blood and milk of the mother and in the blood of newborn children. *Biol Trace Elem Res* 170:279-287. 10.1007/s12011-015-0482-5.
- Barbosa F, Correa Rodrigues MH, Buzalaf MR, et al. 2006c. Evaluation of the use of salivary lead levels as a surrogate of blood lead or plasma lead levels in lead exposed subjects. *Arch Toxicol* 80(10):633-637. 10.1007/s00204-006-0096-y.
- Barbosa F, Ramires I, Rodrigues MHC, et al. 2006a. Contrasting effects of age on the plasma/whole blood lead ratio in men and women with a history of lead exposure. *Environ Res* 102(1):90-95. 10.1016/j.envres.2006.03.007.
- Barbosa F, Sandrim VC, Uzuelli JA, et al. 2006b. eNOS genotype-dependent correlation between whole blood lead and plasma nitric oxide products concentrations. *Nitric Oxide* 14(1):58-64.

8. REFERENCES

- Barbosa F, Tanus-Santos JE, Gerlach RQ, et al. 2005. A critical review of biomarkers used for monitoring human exposure to lead: Advantages, limitations, and future needs. *Environ Health Perspect* 113(12):1669-1674.
- Barltrop D, Meek F. 1979. Effect of particle size on lead absorption from the gut. *Arch Environ Health* 34(4):280-285.
- Barman T, Kalahasthi R, Rajmohan HR. 2014. Effects of lead exposure on the status of platelet indices in workers involved in a lead-acid battery manufacturing plant. *J Expo Sci Environ Epidemiol* 24(6):629-633. 10.1038/jes.2014.4.
- Barregård L, Svalander C, Schütz A, et al. 1999. Cadmium, mercury, and lead in kidney cortex of the general Swedish population: A study of biopsies from living kidney donors. *Environ Health Perspect* 107(11):867-871.
- Barry PSI. 1975. A comparison of concentrations of lead in human tissues. *Br J Ind Med* 32:119-139.
- Barry PSI. 1981. Concentrations of lead in the tissues of children. *Br J Ind Med* 38:61-71.
- Barth A, Schaffer AW, Osterode W, et al. 2002. Reduced cognitive abilities in lead-exposed men. *Int Arch Occup Environ Health* 75:394-398.
- Barton JC. 1984. Active transport of lead-210 by everted segments of rat duodenum. *Am J Physiol* 247:G193-G198.
- Barton JC, Conrad ME, Harrison L, et al. 1978a. Effects of calcium on the absorption and retention of lead. *J Lab Clin Med* 91(3):366-376.
- Barton JC, Conrad ME, Nuby S, et al. 1978b. Effects of iron on the absorption and retention of lead. *J Lab Clin Med* 92(4):536-547.
- Barton JC, Patton MA, Edwards CQ, et al. 1994. Blood lead concentrations in hereditary hemochromatosis. *J Lab Clin Med* 124(2):193-198.
- Basaran N, Undeger U. 2000. Effects of lead on immune parameters in occupationally exposed workers. *Am J Ind Med* 38:349-354.
- Battistuzzi G, Petrucci R, Silvagni L, et al. 1981. δ -Aminolevulinic acid dehydratase: A new genetic polymorphism in man. *Ann Hum Genet* 45(3):223-229.
- Bauchinger M, Dresch J, Schmid E, et al. 1977. Chromosome analyses of children after ecological lead exposure. *Mutat Res* 56:75-80.
- Beck BD, Mattuck RL, Bowers TS, et al. 2001. The development of a stochastic physiologically-based pharmacokinetic model for lead. *Sci Total Environ* 274:15-19.
- Bekley AL, Caspi A, Broadbent J, et al. 2018. Association of childhood blood lead levels with criminal offending. *JAMA Pediatrics* 172(2):166-173. <http://doi.org/10.1001/jamapediatrics.2017.4005>.
- Beers MH, Berkow R, eds. 1999. Injuries, poisoning, and cardiopulmonary resuscitation. In: *The Merck manual of diagnosis and therapy*. Whitehouse Station, NJ: Merck Research Laboratories, 2264-2300.
- Behinaein S, Chettle DR, Atanackovic J, et al. 2011. *In vivo* measurement of lead in the bones of smelter workers using the four-element 'clover-leaf' geometry detector system. *Phys Med Biol* 56(3):653-665. 10.1088/0031-9155/56/3/008.
- Behinaein S, Chettle DR, Egden LM, et al. 2012. Nonlinearity in the relationship between bone lead concentrations and CBLI for lead smelter employees. *J Environ Monit* 14(12):3267-3275. 10.1039/c2em30652b.
- Behinaein S, Chettle DR, Egden LM, et al. 2014. The estimation of the rates of lead exchange between body compartments of smelter employees. *Environ Sci Process Impacts* 16(7):1705-1715. 10.1039/c4em00032c.
- Bellinger DC. 2004. Assessing environmental neurotoxicant exposures and child neurobehavior: Confounded by confounding? *Epidemiology* 15(4):383-384.
- Bellinger DC. 2011. The protean toxicities of lead: New chapters in a familiar story. *Int J Environ Res Public Health* 8(7):2593-2628. 10.3390/ijerph8072593.
- Bellinger DC, Needleman HL. 2003. Intellectual impairment and blood lead levels. *N Engl J Med* 349(5):500. 10.1056/NEJM200307313490515.

8. REFERENCES

- Bellinger DC, Hu H, Titlebaum L, et al. 1994. Attentional correlates of dentin and bone lead levels in adolescents. *Arch Environ Health* 49(2):98-105.
- Bellinger DC, Leviton A, Sloman J. 1990. Antecedents and correlates of improved cognitive performance of children exposed *in utero* to low levels of lead. *Environ Health Perspect* 89:5-11.
- Bellinger DC, Leviton A, Waternaux C, et al. 1987. Longitudinal analyses of prenatal and postnatal lead exposure and early cognitive development. *N Engl J Med* 316:1037-1043.
- Bellinger DC, Sloman J, Leviton A, et al. 1991. Low-level lead exposure and children's cognitive function in the preschool years. *Pediatrics* 87(2):219-227.
- Bellinger DC, Stiles KM, Needleman HL. 1992. Low-level lead exposure, intelligence and academic achievement: A long-term follow-up study. *Pediatrics* 90(6):855-861.
- Bener A, Almehdi AM, Alwash R, et al. 2001. A pilot survey of blood lead levels in various types of workers in the United Arab Emirates. *Environ Int* 27(4):311-314. 10.1016/S0160-4120(01)00061-7.
- Bergdahl IA, Skerfving S. 1997. Partition of circulating lead between plasma and red cells does not seem to be different for internal and external sources of lead. Letter to the editor. *Am J Ind Med* 32:317-318.
- Bergdahl IA, Gerhardsson L, Liljelind IE, et al. 2006. Plasma-lead concentration: Investigations into its usefulness for biological monitoring of occupational lead exposure. *Am J Ind Med* 49(2):93-101.
- Bergdahl IA, Gerhardsson L, Schütz A, et al. 1997b. δ -Aminolevulinic acid dehydratase polymorphism: Influence on lead levels and kidney function in humans. *Arch Environ Health* 52(2):91-96.
- Bergdahl IA, Grubb A, Schütz A, et al. 1997a. Lead binding to δ -aminolevulinic acid dehydratase (ALAD) in human erythrocytes. *Basic Clin Pharmacol Toxicol* 81(4):153-158.
- Bergdahl IA, Schutz A, Gerhardsson L, et al. 1997c. Lead concentrations in human plasma, urine and whole blood. *Scand J Work Environ Health* 23(5):359-363.
- Bergdahl IA, Sheveleva M, Schutz A, et al. 1998. Plasma and blood lead in humans: Capacity-limited binding to δ -aminolevulinic acid dehydratase and other lead-binding components. *Toxicol Sci* 46:247-253.
- Bergdahl IA, Vahter M, Counter SA, et al. 1999. Lead in plasma and whole blood from lead-exposed children. *Environ Res* 80:25-33.
- Bergeret A, Pouget E, Tedone R, et al. 1990. Neutrophil functions in lead-exposed workers. *Hum Exp Toxicol* 9(4):231-233. 10.1177/096032719000900405.
- Berkowitz GS, Wolff MS, Lapinski RH, et al. 2004. Prospective study of blood and tibia lead in women undergoing surgical menopause. *Environ Health Perspect* 112(17):1673-1678.
- Berlin CM, Gorman RL, May DG, et al. 1995. Treatment guidelines for lead exposure in children. *Pediatrics* 96(1):155-160.
- Bernard BP, Becker CE. 1988. Environmental lead exposure and the kidney. *Clin Toxicol* 26(1&2):1-34.
- Bernard AM, Vyskocil A, Roels H, et al. 1995. Renal effects in children living in the vicinity of a lead smelter. *Environ Res* 68:91-95.
- Bert JL, Van DLJ, Grace JR. 1989. A generalized model for the prediction of lead body burdens. *Environ Res* 48:117-127.
- Bertazzi PA, Zocchetti C. 1980. A mortality study of newspaper printing workers. *Am J Ind Med* 1:85-97.
- Berthelot Y, Valton E, Auroy A, et al. 2008. Integration of toxicological and chemical tools to assess the bioavailability of metals and energetic compounds in contaminated soils. *Chemosphere* 74:166-177.
- Bhattacharya A, Shukla R, Dietrich KN, et al. 2006. Effect of early lead exposure on the maturation of children's postural balance: A longitudinal study. *Neurotoxicol Teratol* 28(3):376-385. 10.1016/j.ntt.2006.02.003.
- Bhatti P, Stewart PA, Hutchinson A, et al. 2009. Lead exposure, polymorphisms in genes related to oxidative stress, and risk of adult brain tumors. *Cancer Epidemiol Biomarkers Prev* 18(6):1841-1848. 10.1158/1055-9965.EPI-09-0197.

8. REFERENCES

- Biagini G, Caudarella R, Vangelista A. 1977. Renal morphological and functional modification in chronic lead poisoning. In: Brown, SS, ed. *Clinical Chemistry and Chemical Toxicology of Metals*. Elsevier/North-Holland Biomedical Press, 123-126.
- Biggins PDE, Harrison RM. 1979. Atmospheric chemistry of automotive lead. *Environ Sci Technol* 13:558-565.
- Billick IH, Gray VE. 1978. Lead based paint poisoning research: Review and evaluation, 1971-1977. Washington, DC: Department of Housing and Urban Development, Office of Policy Development and Research.
- Bindler R, Renberg I, Klaminder J. 2008. Bridging the gap between ancient metal pollution and contemporary biogeochemistry. *J Paleolimnol* 40(3):755-770.
- Blake K, Mann M. 1983. Effect of calcium and phosphorus on the gastrointestinal absorption of ^{203}Pb in man. *Environ Res* 30(1):188-194.
- Blake KC, Barbezat H, Mann M. 1983. Effect of dietary constituents on the gastrointestinal absorption of ^{203}Pb in man. *Environ Res* 30:182-187.
- Bloom MS, Buck Louis GM, Sundaram R, et al. 2011. Associations between blood metals and fecundity among women residing in New York State. *Reprod Toxicol* 31(2):158-163. 10.1016/j.reprotox.2010.09.013.
- Bloom MS, Buck Louis GM, Sundaram R, et al. 2015. Birth outcomes and background exposures to select elements, the Longitudinal Investigation of Fertility and the Environment (LIFE). *Environ Res* 138:118-129. 10.1016/j.envres.2015.01.008.
- Bloom MS, Parsons PJ, Steuerwald AJ, et al. 2010. Toxic trace metals and human oocytes during *in vitro* fertilization (IVF). *Reprod Toxicol* 29(3):298-305. 10.1016/j.reprotox.2010.01.003.
- Bockelmann I, Pfister EA, McGauran N, et al. 2002. Assessing the suitability of cross-sectional and longitudinal cardiac rhythm tests with regard to identifying effects of occupational chronic lead exposure. *J Occup Environ Med* 44:59-65.
- Boileau J, Fauguignon C, Hlueber B, et al. 2012. Explosives. In: *Ullman's encyclopedia of industrial chemistry*. http://onlinelibrary.wiley.com/doi/10.1002/14356007.a10_143.pub2/pdf. March 30, 2017.
- Boileau J, Fauquignon C, Napoly C. 1987. Explosives. In: *Ullman's encyclopedia of industrial chemistry* A10:143-172.
- Bolanowska W, Piotrowski J, Garczynski H. 1967. Triethyl lead in the biological material in cases of acute tetraethyl lead poisoning. *Arch Toxicol* 22:278-282.
- Bonanno LJ, Freeman NCG, Greenburg M, et al. 2001. Multivariate analysis on levels of selected metals, particulate matter, VOC, and household characteristics and activities from the Midwestern states NHEXAS. *Appl Occup Environ Hyg* 16(9):859-874.
- Bonde JP, Joffe M, Apostoli P, et al. 2002. Sperm count and chromatin structure in men exposed to inorganic lead: Lowest adverse effect levels. *Occup Environ Med* 59(4):234-242.
- Borja-Aburto VH, Hertz-Picciotto I, Lopez MR, et al. 1999. Blood lead levels measured prospectively and risk of spontaneous abortion. *Am J Epidemiol* 150:590-597.
- Borjesson J, Gerhardsson L, Schutz A, et al. 1997. *In vivo* measurements of lead in fingerbone in active and retired lead smelters. *Int Arch Occup Environ Health* 69:97-105.
- Bornschein RL, Grote J, Mitchell T, et al. 1989. Effects of prenatal lead exposure on infant size at birth In: *Lead exposure and child development. An international assessment*. Workshop organized by the Commission of the European Communities and the U.S. Environmental Protection Agency. September 1986. Edinburgh, United Kingdom, 307-319.
- Bornschein RL, Succop PA, Krafft KM, et al. 1986. Exterior surface dust lead, interior house dust lead and childhood lead exposure in an urban environment. *Trace Subst Environ Health* 20:322-332.
- Bos AJJ, van der Strap, Valkovic V, et al. 1985. Incorporation routes of elements into human hair: Implications for hair analysis used for monitoring. *Sci Total Environ* 42:157-169.

8. REFERENCES

- Boscolo P, Di Gioacchino M, Sabbioni E, et al. 1999. Expression of lymphocyte subpopulations, cytokine serum levels, and blood and urinary trace elements in asymptomatic atopic men exposed to an urban environment. *Int Arch Occup Environ Health* 72(1):26-32. 10.1007/s004200050330.
- Boscolo P, Di Gioacchino M, Sabbioni E, et al. 2000. Lymphocyte subpopulations, cytokines and trace elements in asymptomatic atopic women exposed to an urban environment. *Life Sci* 67(10):1119-1126. 10.1016/S0024-3205(00)00712-8.
- Bost L, Primatesta P, Dong W, et al. 1999. Blood lead and blood pressure: Evidence from the health survey for England 1995. *J Hum Hypertens* 13(2; 2):123-128.
- Bouchard MF, Bellinger DC, Weuve J, et al. 2009. Blood lead levels and major depressive disorder, panic disorder, and generalized anxiety disorder in US young adults. *Arch Gen Psychiatry* 66(12):1313-1319. 10.1001/archgenpsychiatry.2009.164.
- Boucher O, Jacobson SW, Plusquellec P, et al. 2012. Prenatal methylmercury, postnatal lead exposure, and evidence of attention deficit/hyperactivity disorder among Inuit children in Arctic Quebec. *Environ Health Perspect* 120(10):1456-1461. 10.1289/ehp.1204976.
- Boucher O, Muckle G, Jacobson JL, et al. 2014. Domain-specific effects of prenatal exposure to PCBs, mercury, and lead on infant cognition: Results from the Environmental Contaminants and Child Development Study in Nunavik. *Environ Health Perspect* 122(3):310-316. 10.1289/ehp.1206323.
- Boudene C, Despaux-Pages N, Comoy E, et al. 1984. Immunological and enzymatic studies of erythrocytic δ -aminolevulinic acid dehydratase. *Int Arch Occup Environ Health* 55(1):87-96.
- Boudene C, Malet D, Masse R. 1977. Fate of Pb inhaled by rats. *Toxicol Appl Pharmacol* 41:271-276.
- Bound JP, Harvey PW, Francis BJ, et al. 1997. Involvement of deprivation and environmental lead in neural tube defects: A matched case-control study. *Arch Dis Child* 76(2):107-112.
- Bouton C, Pevsner J. 2000. Effects of lead on gene expression. *Neurotoxicology* 21(6):1045-1056.
- Bowen HJM. 1966. Trace elements in biochemistry. New York, NY: Academic Press, 31-32.
- Bowers TS, Mattuck RL. 2001. Further comparisons of empirical and epidemiological data with predictions of the Integrated Exposure Uptake Biokinetic Model for lead in children. *Hum Ecol Risk Assess* 7:1699-1713.
- Bowers TS, Beck BD, Karam HS. 1994. Assessing the relationship between environmental lead concentrations and adult blood lead levels. *Risk Anal* 14(2):183-189.
- Bradham KD, Green W, Hayes H, et al. 2016. Estimating relative bioavailability of soil lead in the mouse. *J Toxicol Environ Health A* 79(24):1179-1182. 10.1080/15287394.2016.1221789.
- Bradley SB, Cox JJ. 1988. The potential availability of cadmium, copper, iron, lead, manganese, nickel and zinc in standard river sediment (NBS 1645). *Environ Technol Lett* 9:733-739.
- Braun JM, Froehlich TE, Daniels JL, et al. 2008. Association of environmental toxicants and conduct disorder in U.S. children: NHANES 2001-2004. *Environ Health Perspect* 116(7):956-962. 10.1289/ehp.11177.
- Braun JM, Hoffman E, Schwartz J, et al. 2012. Assessing windows of susceptibility to lead-induced cognitive deficits in Mexican children. *Neurotoxicology* 33(5):1040-1047. 10.1016/j.neuro.2012.04.022.
- Braun JM, Kahn RS, Froehlich T, et al. 2006. Exposures to environmental toxicants and attention deficit hyperactivity disorder in US children. *Environ Health Perspect* 114(12):1904-1909. 10.1289/ehp.9478.
- Braun JM, Wright RJ, Just AC, et al. 2014. Relationships between lead biomarkers and diurnal salivary cortisol indices in pregnant women from Mexico City: A cross-sectional study. *Environ Health* 13(1):50. 10.1186/1476-069x-13-50.
- Braunstein GD, Dahlgren J, Loriaux DL. 1978. Hypogonadism in chronically lead-poisoned men. *Infertility* 1(1):33-51.
- Brender JD, Suarez L, Felkner M, et al. 2006. Maternal exposure to arsenic, cadmium, lead, and mercury and neural tube defects in offspring. *Environ Res* 101(1):132-139. 10.1016/j.envres.2005.08.003.

8. REFERENCES

- Bres EF, Voegel JC, Barry JC, et al. 1986. Feasibility study for the detection of lead substitution sites in the hydroxyapatite crystal structure using high resolution electron microscopy (HREM) at optimum focus. *J Appl Crystallogr* 19:168-173.
- Bress WC, Bidanset JH. 1991. Percutaneous *in vivo* and *in vitro* absorption of lead. *Vet Hum Toxicol* 33(3):212-214.
- Bressler J, Kim K, Chakraborti T, et al. 1999. Molecular mechanisms of lead neurotoxicity. *Neurochem Res* 24(4):595-600.
- Bressler JP, Olivi L, Kim Y-B, et al. 2005. Plasma membrane transporters for lead and cadmium. *Biomol Ther* 13(1):1-6.
- Brito JA, McNeill FE, Webber CE, et al. 2005. Grid search: An innovative method for the estimation of the rates of lead exchange between body compartments. *J Environ Monit* 7(3):241-247.
- Brodeur J, Lacasse Y, Talbot D. 1983. Influence of removal from occupational lead exposure on blood and saliva lead concentrations. *Toxicol Lett* 19(1-2):195-199.
- Brody DJ, Pirkle JL, Kramer RA, et al. 1994. Blood lead levels in the US population: Phase I of the third National Health and Nutritional Examination Survey (NHANES III, 1968-1991). *J Am Med Assoc* 272(4):277-283.
- Broberg K, Engstrom K, Ameer S. 2015. Gene-environment interactions for metals. In: Nordberg GF, Fowler BA, Nordberg M, eds. *Handbook on the toxicology of metals*. Chapter 12. Fourth ed. Elsevier, 239-264.
- Bronner F, Pansu D, Stein WD. 1986. An analysis of intestinal calcium transport across the rat intestine. *Am J Physiol* 250(13):G561-G569.
- Brown RW, Gonzales C, Hooper MJ, et al. 2008. Soil lead (Pb) in residential transects through Lubbock, Texas: A preliminary assessment. *Environ Geochem Health* 30(6):541-547. 10.1007/s10653-008-9180-y.
- Brown S, Chaney RL, Hallfrisch J, et al. 2004. In situ soil treatments to reduce the phyto and bioavailability of lead, zinc and cadmium. *J Environ Qual* 33:522-531.
- Brubaker CJ, Dietrich KN, Lanphear BP, et al. 2010. The influence of age of lead exposure on adult gray matter volume. *Neurotoxicology* 31(3):259-266. 10.1016/j.neuro.2010.03.004.
- Brunekreef B. 1984. The relationship between air lead and blood lead in children: A critical review. *Sci Total Environ* 38:79-123.
- Buc H, Kaplan J. 1978. Red-cell pyrimidine 5'-nucleotidase and lead poisoning. *Clin Chim Acta* 87(1):49-55.
- Buchet J, Roels H, Bernard Jr A, et al. 1980. Assessment of renal function of workers exposed to inorganic lead, cadmium or mercury vapor. *J Occup Environ Med* 22(11):741-750.
- Budtz-Jorgensen E, Bellinger D, Lanphear B, et al. 2013. An international pooled analysis for obtaining a benchmark dose for environmental lead exposure in children. *Risk Anal* 33(3):450-461. 10.1111/j.1539-6924.2012.01882.x.
- Bulsma JB, De FHF. 1976. Cytogenetic investigations in volunteers ingesting inorganic lead. *Int Arch Occup Environ Health* 38:145-148.
- Burns JS, Williams PL, Lee ML, et al. 2017. Peripubertal blood lead levels and growth among Russian boys. *Environ Int* 106:53-59. 10.1016/j.envint.2017.05.023.
- Buser MC, Scinicariello F. 2017. Cadmium, lead, and depressive symptoms: Analysis of National Health and Nutrition Examination Survey 2011-2012. *J Clin Psychiatry* 78(5):e515-e521. 10.4088/JCP.15m10383.
- Bushnik T, Levallois P, D'Amour M, et al. 2014. Association between blood lead and blood pressure: Results from the Canadian Health Measures Survey (2007 to 2011). *Health Rep* 25(7):12-22.
- Businelli D, Onofri A, Massacesi L. 2011. Factors involved in uptake of lead by some edible crops grown in agricultural soils of Central Italy. *Soil Sci* 176(9):472-478.
- Butterweck G, Schuler C, Vezzù G, et al. 2002. Experimental determination of the absorption rate of unattached radon progeny from respiratory tract to blood. *Radiat Prot Dosimetry* 102(4):343-348.

8. REFERENCES

- Cabral M, Dieme D, Verdin A, et al. 2012. Low-level environmental exposure to lead and renal adverse effects: A cross-sectional study in the population of children bordering the Mbeubeuss landfill near Dakar, Senegal. *Hum Exp Toxicol* 31(12):1280-1291. 10.1177/0960327112446815.
- Cake K, Bowins R, Vaillancourt C, et al. 1996. Partition of circulating lead between serum and red cells is different for internal and external sources of lead. *Am J Ind Med* 29(5):440-445.
- Calabrese EJ, Stanek EJ, Gilbert CE, et al. 1990. Preliminary adult soil ingestion estimates: Results of a pilot study. *Regul Toxicol Pharmacol* 12(1):88-95.
- Calderon-Salinas JV, Quintanar-Escorcia MA, Gonzalez-Martinez MT, et al. 1999. Lead and calcium transport in human erythrocyte. *Hum Exp Toxicol* 18:327-332.
- Calello DP, Henretig FM. 2014. Lead. In: Goldfrank's toxicologic emergencies. Tenth ed. New York, NY: McGraw-Hill, 1219-1234.
- Cal EPA. 2013. Estimating workplace air and worker blood lead concentration using an updated physiologically-based pharmacokinetic (PBPB) model. California Environmental Protection Agency.
- Cal EPA. 2017. User's guide to LeadSpread 8 and recommendations for evaluation of lead exposures in adults. California Department of Toxic Substances Control. Human and Ecological Risk Office, California Environmental Protection Agency. http://www.dtsc.ca.gov/AssessingRisk/upload/LeadSpread8_UserGuide.pdf. September 1, 2017.
- Campara P, D'Andrea F, Micciolo R, et al. 1984. Psychological performance of workers with blood-lead concentration below the current threshold limit value. *Int Arch Occup Environ Health* 53:233-246.
- Campbell JR, Auinger P. 2007. The association between blood lead levels and osteoporosis among adults--results from the Third National Health and Nutrition Examination Survey (NHANES III). *Environ Health Perspect* 115(7):1018-1022. 10.1289/ehp.9716.
- Campbell JR, Toribara TY. 2001. Hair-root lead to screen for lead toxicity. *J Trace Elem Exp Med* 14:69-72.
- Campbell JR, Moss ME, Raubertas RF. 2000a. The association between caries and childhood lead exposure. *Environ Health Perspect* 108(11):1099-1102.
- Campbell JR, Rosier RN, Novotny L, et al. 2004. The association between environmental lead exposure and bone density in children. *Environ Health Perspect*:1200-1203.
- Campbell TF, Needleman HL, Riess JA, et al. 2000b. Bone lead levels and language processing performance. *Dev Neuropsychol* 18(2):171-186.
- Can S, Bağcı C, Ozaslan M, et al. 2008. Occupational lead exposure effect on liver functions and biochemical parameters. *Acta Physiol Hung* 95(4):395-403. 10.1556/APhysiol.95.2008.4.6.
- Canfield RL, Henderson CR, Jr., Cory-Slechta DA, et al. 2003. Intellectual impairment in children with blood lead concentrations below 10 micrograms per deciliter. *N Engl J Med* 348(16):1517-1526. 10.1056/NEJMoa022848.
- Canonne-Hergaux F, Gruenheid S, Ponka P, et al. 1999. Cellular and subcellular localization of the Nramp2 iron transporter in the intestinal brush border and regulation by dietary iron. *Blood* 93(12):4406-4417.
- Cantonwine D, Hu H, Sánchez BN, et al. 2010a. Critical windows of fetal lead exposure: Adverse impacts on length of gestation and risk of premature delivery. *J Occup Environ Med* 52(11):1106-1111. 10.1097/JOM.0b013e3181f86fee.
- Cantonwine D, Hu H, Tellez-Rojo MM, et al. 2010b. HFE gene variants modify the association between maternal lead burden and infant birthweight: A prospective birth cohort study in Mexico City, Mexico. *Environmental Health: A Global Access Science Source* 9:43. 10.1186/1476-069X-9-43.
- Cao X, Ma LQ, Chen M, et al. 2003a. Lead transformation and distribution in the soils of shooting ranges in Florida, USA. *Sci Total Environ* 307:179-189.
- Cao X, Ma LQ, Chen M, et al. 2003b. Weathering of lead bullets and their environmental effects at outdoor shooting ranges. *J Environ Qual* 32:526-534.
- Carbone R, Laforgia N, Crollo E, et al. 1998. Maternal and neonatal lead exposure in southern Italy. *Biol Neonate* 73:362-366.

8. REFERENCES

- Cardenas A, Roels H, Bernard A, et al. 1993. Markers of early renal changes induced by industrial pollutants. II. Application to workers exposed to lead. *Br J Ind Med* 50(1):28-36.
- Cardozo dos Santos A, Colacciopo S, Dal Bó CM, et al. 1994. Occupational exposure to lead, kidney function tests, and blood pressure. *Am J Ind Med* 26(5):635-643.
- Carlisle JC, Wade MJ. 1992. Predicting blood lead concentrations from environmental concentrations. *Regul Toxicol Pharmacol* 16(3):280-289.
- Carr DS. 1995. Lead compounds: Lead salts. In: Kirk-Othmer encyclopedia of chemical technology, New York, NY: John Wiley & Sons, 132-152.
- Carr DS, Spangenberg WC, Chronley K, et al. 2004. Lead compounds. In: Kirk-Othmer encyclopedia of chemical technology.
- Cassidy-Bushrow AE, Havstad S, Basu N, et al. 2016. Detectable blood lead level and body size in early childhood. *Biol Trace Elem Res* 171(1):41-47. 10.1007/s12011-015-0500-7.
- Casteel SW, Cowart RP, Weis CP, et al. 1997. Bioavailability of lead to juvenile swine dosed with soil from the Smuggler Mountain NPL site of Aspen, Colorado. *Toxicol Sci* 36(2):177-187.
- Casteel SW, Weis CP, Henningsen GM, et al. 2006. Estimation of relative bioavailability of lead in soil and soil-like materials using young swine. *Environ Health Perspect* 114(8):1162-1171.
- Cavalleri A, Minoia C, Pozzoli L, et al. 1978. Determination of plasma lead levels in normal subjects and lead-exposed workers. *Br J Ind Med* 35:21-26.
- CDC. 1985. Preventing lead poisoning in young children. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control. Publication No. 99-2230.
- CDC. 1991. Preventing lead poisoning in young children. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control. <http://aepo-xdv-www.epo.cdc.gov/wonder/prevguid/p0000029/p0000029.asp>.
- CDC. 1997a. Children with elevated blood lead levels attributed to home renovation and remodeling activities – New York, 1993-1994. *MMWR Morb Mortal Wkly Rep* 45:1120-1123.
- CDC. 1997b. Screening young children for lead poisoning: Guidance for state and local public health officials. Atlanta, GA: Centers for Disease Control and Prevention. <http://www.cdc.gov/nceh/lead/guide/guide97.htm>.
- CDC. 1997c. Update: Blood lead levels – United States, 1991-1994. *MMWR Morb Mortal Wkly Rep* 46(7):141-146.
- CDC. 1998. Lead poisoning associated with imported candy and powdered food coloring - California and Michigan. *MMWR Morb Mortal Wkly Rep* 47(48):1041-1043.
- CDC. 2002a. Managing elevated blood levels among young children. Recommendations from the Advisory Committee on Childhood Lead Poisoning. Centers for Disease Control and Prevention. <https://www.cdc.gov/nceh/lead/casemanagement/managingEBLLs.pdf>. July 18, 2018.
- CDC. 2002b. Childhood lead poisoning associated with tamarind candy and fold remedies-California, 1999-2000. *MMWR Morb Mortal Wkly Rep* 51:684-686. <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5131a3.htm>. June 28, 2017.
- CDC. 2004. Lead poisoning associated with Ayurveda medications - five states, 2000-2003. *MMWR Morb Mortal Wkly Rep* 53(26):582-584.
- CDC. 2005. Lead poisoning associated with use of litargirio-Rhode Island, 2003. Centers for Disease Control and Prevention. *MMWR Morb Mortal Wkly Rep* 54(09):227-229. <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5409a5.htm>. June 28, 2017.
- CDC. 2006. Brief report: Death of a child after ingestion of a metallic charm- Minnesota 2006. *MMWR Morb Mortal Wkly Rep* 55(12):340-341.
- CDC. 2009. Fourth national report on human exposure to environmental chemicals. Atlanta, GA: Centers for Disease Control and Prevention, Department of Health and Human Services. <http://www.cdc.gov/exposurereport>. April 20, 2014.
- CDC. 2011. State-based prevalence data of ADHD diagnosis. Atlanta, GA: Centers for Disease Control and Prevention, Department of Health and Human Services.

8. REFERENCES

- CDC. 2012a. Infant lead poisoning associated with use of tiro, an eye cosmetic from Nigeria-Boston, Massachusetts, 2011. *MMWR Morb Mortal Wkly Rep* 61(30):574-576.
- CDC. 2012b. Lead in drinking water and human blood lead levels in the United States. *MMWR*. Centers for Disease Control and Prevention. *MMWR Morb Mortal Wkly Rep* 61(Suppl). August 10, 2012. <https://www.cdc.gov/mmwr/pdf/other/su6104.pdf>. June 29, 2017.
- CDC. 2012c. Lead poisoning in pregnant women who used Ayurvedic medications from India-New York City, 2011-2012. *MMWR Morb Mortal Wkly Rep* 61(33):641-646.
- CDC. 2012d. CDC response to Advisory Committee on Childhood Lead Poisoning Prevention. Recommendations in “Low level lead exposure harms children: A renewed call for primary prevention.” Atlanta, GA: Centers for Disease Control and Prevention, Department of Health and Human Services. https://www.cdc.gov/nceh/lead/acclpp/cdc_response_lead_exposure_recs.pdf. December 8, 2017.
- CDC. 2012e. Tested and confirmed elevated blood lead levels by state, year and blood lead level group for children <72 months. Atlanta, GA: Centers for Disease Control and Prevention, Department of Health and Human Services. <http://www.cdc.gov/nceh/lead/data/national.htm>. June 29, 2017.
- CDC. 2012f. Lead level lead exposure harms children: A renewed call for primary prevention. Atlanta, GA: Centers for Disease Control and Prevention, Department of Health and Human Services. https://www.cdc.gov/nceh/lead/acclpp/final_document_030712.pdf. August 25, 2017.
- CDC. 2013. Childhood lead exposure associated with the use of kajal, an eye cosmetic from Afghanistan — Albuquerque, New Mexico, 2013. *MMWR Morb Mortal Wkly Rep* 62(46):917-919.
- CDC. 2016. Standard surveillance definitions and classifications. Center for Disease Control and Prevention. <https://www.cdc.gov/nceh/lead/data/definitions.htm>. February 6, 2019.
- CDC. 2018a. Fourth national report on human exposure to environmental chemicals. Updated tables, March 2018, Volumes 1& 2. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. <https://www.cdc.gov/exposurereport/>. May 1, 2018.
- CDC. 2018b. Lead. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. <https://www.cdc.gov/nceh/lead/default.htm>. February 5, 2019.
- CDC. 2018c. Lead hazards in some holiday toys and toy jewelry. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. <https://www.cdc.gov/features/leadintoys/index.html>. March 08, 2018.
- Cecil KM, Brubaker CJ, Adler CM, et al. 2008. Decreased brain volume in adults with childhood lead exposure. *PLoS Med* 5(5):e112. 10.1371/journal.pmed.0050112.
- Cecil KM, Dietrich KN, Altaye M, et al. 2011. Proton magnetic resonance spectroscopy in adults with childhood lead exposure. *Environ Health Perspect* 119(3):403-408. 10.1289/ehp.1002176.
- Chamberlain AC. 1983. Effect of airborne lead on blood lead. *Atmos Environ* 17:677-692.
- Chamberlain AC, Heard MJ, Little P, et al. 1978. Investigations into lead from motor vehicles. United Kingdom Atomic Energy Authority. AERE-R9188.
- Chamberlain AC, Heard MJ, Little P, et al. 1979. The dispersion of lead from motor exhausts. *Philosophical Transactions of the Royal Society of London, Series A Mathematical and Physical Sciences* 290:577-589.
- Chandramouli K, Steer CD, Ellis M, et al. 2009. Effects of early childhood lead exposure on academic performance and behaviour of school age children. *Arch Dis Child* 94(11):844-848. 10.1136/adc.2008.149955.
- Chaney RL, Mielke HW, Sterrett SB. 1988. Speciation, mobility and bioavailability of soil lead. *Lead in Soil: Issues and Guidelines*. *Environ Geochem Health Monographs Series* 4, 105-130.
- Chang SH, Cheng BH, Lee SL, et al. 2006. Low blood lead concentration in association with infertility in women. *Environ Res* 101(3):380-386. 10.1016/j.envres.2005.10.004.
- Chao K, Hutton H, Levin A. 2015. Laboratory assessment of kidney disease. Glomerular filtration rate, urinalysis and proteinuria. In: Shorecki K, Chertow GM, Mardsen PA, et al., eds. *Brenner and Rector's The Kidney*. Elsevier, 780-803.

8. REFERENCES

- Charney E, Sayre J, Coulter M. 1980. Increased lead absorption in inner city children: Where does the lead come from? *Pediatrics* 65(2):226-231.
- Chen A, Cai B, Dietrich KN, et al. 2007. Lead exposure, IQ, and behavior in urban 5- to 7-year-olds: Does lead affect behavior only by lowering IQ? *Pediatrics* 119(3):e650-e658. 10.1542/peds.2006-1973.
- Chen A, Dietrich KN, Ware JH, et al. 2005. IQ and blood lead from 2 to 7 years of age: Are the effects in older children the residual of high blood lead concentrations in 2-year-olds? *Environ Health Perspect* 113(5):597-601. 10.1289/ehp.7625.
- Chen CC, Yen HW, Lo YH, et al. 2013. The association of prolonged QT interval on electrocardiography and chronic lead exposure. *J Occup Environ Med* 55(6):614-619. 10.1097/JOM.0b013e318291787a.
- Chen HI, Chiu YW, Hsu YK, et al. 2010. The association of metallothionein-4 gene polymorphism and renal function in long-term lead-exposed workers. *Biol Trace Elem Res* 137:55-62.
- Chen PC, Pan IJ, Wang JD. 2006. Parental exposure to lead and small for gestational age births. *Am J Ind Med* 49(6):417-422. 10.1002/ajim.20313.
- Chen Z, Myers R, Wei T, et al. 2014. Placental transfer and concentrations of cadmium, mercury, lead, and selenium in mothers, newborns, and young children. *J Expo Sci Environ Epidemiol* 24(5):537-544. 10.1038/jes.2014.26.
- Cheng Y, Schwartz J, Sparrow D, et al. 2001. Bone lead and blood lead levels in relation to baseline blood pressure and the prospective development of hypertension: The Normative Aging Study. *Am J Epidemiol* 153(2):164-171. 10.1093/aje/153.2.164.
- Cheng Y, Schwartz J, Vokonas PS, et al. 1998. Electrocardiographic conduction disturbances in association with low-level lead exposure (the Normative Aging Study). *Am J Cardiol* 82:594-599.
- Chettle DR, Arnold ML, Aro ACA, et al. 2003. An agreed statement on calculating lead concentration and uncertainty in XRF *in vivo* bone lead analysis. *Appl Radiat Isot* 58:603-605.
- Chettle DR, Scott MC, Somerville LJ. 1991. Lead in bone: Sampling and quantitation using K X-rays excited by ¹⁰⁹Cd. *Environ Health Perspect* 91:49-55.
- Cheung MR. 2013. Blood lead concentration correlates with all cause, all cancer and lung cancer mortality in adults: A population based study. *Asian Pac J Cancer Prev* 14(5):3105-3108.
- Chia KS, Jeyaratnam J, Lee J, et al. 1995b. Lead-induced nephropathy: Relationship between various biological exposure indices and early markers of nephrotoxicity. *Am J Ind Med* 27(6):883-895.
- Chia KS, Jeyaratnam J, Tan C, et al. 1995a. Glomerular function of lead-exposed workers. *Toxicol Lett* 77(1-3):319-328.
- Chia KS, Mutti A, Tan C, et al. 1994. Urinary N-acetyl- β -D-glucosaminidase activity in workers exposed to inorganic lead. *Occup Environ Med* 51:125-129.
- Chia SE, Chia HP, Ong CN, et al. 1996. Cumulative concentrations of blood lead and postural stability. *Occup Environ Med* 53:264-268.
- Chia SE, Zhou H, Tham MT, et al. 2005. Possible influence of δ -aminolevulinic acid dehydratase polymorphism and susceptibility to renal toxicity of lead: A study of a Vietnamese population. *Environ Health Perspect* 113(10):1313-1317. 10.1289/ehp.7904.
- Chiang WF, Yang HJ, Lung SC, et al. 2008. A comparison of elementary schoolchildren's exposure to arsenic and lead. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev* 26(3):237-255. 10.1080/10590500802343958.
- Chinde S, Kumari M, Devi KR, et al. 2014. Assessment of genotoxic effects of lead in occupationally exposed workers. *Environ Sci Pollut Res Int* 21(19):11469-11480. 10.1007/s11356-014-3128-9.
- Chiodo LM, Jacobson SW, Jacobson JL. 2004. Neurodevelopmental effects of postnatal lead exposure at very low levels. *Neurotoxicol Teratol* 26(3):359-371. 10.1016/j.ntt.2004.01.010.
- Chisolm JJ, Jr. 1986. Editorial. Removal of lead paint from old housing: The need for a new approach. *Am J Public Health* 76(3):236-237.

8. REFERENCES

- Chisolm JJ, Mellits ED, Barrett MB. 1976. Interrelationships among blood lead concentration, quantitative daily ALA-U and urinary lead output following calcium EDTA. In: Nordberg GF, ed. Effects and dose relationships of toxic metals. Amsterdam, The Netherlands: Elsevier Scientific Publishing Company, 416-433.
- Cho SH, Richmond-Bryant J, Thornburg J, et al. 2011. A literature review of concentrations and size distributions of ambient airborne Pb-containing particulate matter. *Atmos Environ* 45(28):5005-5015. 10.1016/j.atmosenv.2011.05.009.
- Choate LM, Ranville JF, Bunge AL, et al. 2006a. Dermal adhered soil: 1. Amount and particle-size distribution. *Integr Environ Assess Manag* 2(4):375-384.
- Choate LM, Ranville JF, Bunge AL, et al. 2006b. Dermal adhered soil: 2. Reconstruction of dry-sieve particle-size distributions from wet-sieve data. *Integr Environ Assess Manag* 2(4):385-390.
- Choi WJ, Kwon HJ, Lim MH, et al. 2016. Blood lead, parental marital status and the risk of attention-deficit/hyperactivity disorder in elementary school children: A longitudinal study. *Psychiatry Res* 236:42-46. 10.1016/j.psychres.2016.01.002.
- Choi YH, Hu H, Mukherjee B, et al. 2012. Environmental cadmium and lead exposures and hearing loss in U.S. adults: The National Health and Nutrition Examination Survey, 1999 to 2004. *Environ Health Perspect* 120(11):1544-1550. 10.1289/ehp.1104863.
- Choi DD, Richter GW. 1972. Lead poisoning: Rapid formation of intranuclear inclusions. *Science* 177:1194-1195.
- Chowdhury R, Sarnat SE, Darrow L, et al. 2014. Mortality among participants in a lead surveillance program. *Environ Res* 132:100-104. 10.1016/j.envres.2014.03.008.
- Chrastny V, Komarek M, Hajek T. 2010. Lead contamination of an agricultural soil in the vicinity of a shooting range. *Environ Monit Assess* 162:37-46. 10.1007/s10661-009-0774-3.
- Chu NF, Liou SH, Wu TN, et al. 1999. Reappraisal of the relation between blood lead concentration and blood pressure among the general population in Taiwan. *Occup Environ Med* 56:30-33.
- Chuan MC, Shu GY, Liu JC. 1996. Solubility of heavy metals in a contaminated soil: Effects of redox potential and pH. *Water Air Soil Pollut* 90:543-556.
- Chuang HY, Kuo CH, Chiu YW, et al. 2007. A case-control study on the relationship of hearing function and blood concentrations of lead, manganese, arsenic, and selenium. *Sci Total Environ* 387(1-3):79-85. 10.1016/j.scitotenv.2007.07.032.
- Chuang HY, Schwartz J, Tsai SY, et al. 2000. Vibration perception thresholds in workers with long term exposure to lead. *Occup Environ Med* 57(9):588-594.
- Chung HK, Chang YS, Ahn CW. 2015. Effects of blood lead levels on airflow limitations in Korean adults: Findings from the 5th KNHNES 2011. *Environ Res* 136:274-279. 10.1016/j.envres.2014.10.027.
- Clark C, Bornschein R, Succop P, et al. 1985. Condition and type of housing as an indicator of potential environmental lead exposure and pediatric blood lead levels. *Environ Res* 38(1):46-53.
- Clark S, Menrath W, Chen M, et al. 2004. The influence of exterior dust and soil lead on interior dust lead levels in housing that had undergone lead-based paint hazard control. *J Occup Environ Hyg* 1(5):273-282. 10.1080/15459620490439036.
- Clausing P, Brunekreef B, van Wijnen JH. 1987. A method for estimating soil ingestion by children. *Int Arch Occup Environ Health* 59(1):73-82.
- Clayton CA, Pellizzari ED, Quackenboss JJ. 2002. National Human Exposure Assessment Survey: Analysis of exposure pathways and routes for arsenic and lead in EPA Region 5. *J Expo Anal Environ Epidemiol* 12:29-43.
- Clayton CA, Pellizzari ED, Whitmore RW, et al. 1999. National Human Exposure Assessment Survey (NHEXAS): Distributions and associations of lead, arsenic and volatile organic compounds in EPA Region 5. *J Expo Anal Environ Epidemiol* 9(5):381-392.
- Clewell HJ, Andersen ME. 1985. Risk assessment extrapolations and physiological modeling. *Toxicol Ind Health* 1(4):111-131.

8. REFERENCES

- Coate D, Fowles R. 1989. Is there statistical evidence for a blood lead-blood pressure relationship? *J Health Econ* 8:173-184.
- Cocco P, Dosemeci M, Heineman EF. 1998a. Brain cancer and occupational exposure to lead. *J Occup Environ Med* 40(11):937-942.
- Cocco P, Heineman EF, Dosemeci M. 1999a. Occupational risk factors for cancer of the central nervous system (CNS) among US women. *Am J Ind Med* 36:70-74.
- Cocco P, Hua F, Boffetta P, et al. 1997. Mortality of Italian lead smelter workers. *Scand J Work Environ Health* 23:15-23.
- Cocco P, Ward MH, Dosemeci M. 1998b. Occupational risk factors for cancer of the gastric cardia. *J Occup Environ Med* 40(10):855-861.
- Cocco P, Ward MH, Dosemeci M. 1999b. Risk of stomach cancer associated with 12 workplace hazards: Analysis of death certificates from 24 states of the United States with the aid of job exposure matrices. *Occup Environ Med* 56:781-787.
- Cocco PL, Carta P, Belli S, et al. 1994. Mortality of Sardinian lead and zinc miners: 1960-1968. *Occup Environ Med* 51:674-682.
- Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. *Nephron* 16:31-41.
- Cohen AJ, Roe FJC. 1991. Review of lead toxicology relevant to the safety assessment of lead acetate as a hair colouring. *Food Chem Toxicol* 29(7):485-507.
- Cohen N, Modai D, Golik A, et al. 1989. Increased concanavalin A-induced suppressor cell activity in humans with occupational lead exposure. *Environ Res* 48(1):1-6.
- Comino E, Menegatti S, Fiorucci A, et al. 2011. Accumulation and translocation capacity of As, Co, Cr and Pb by forage plants. *Agrochimica* 55:105-115.
- Conterato GM, Bulcao RP, Sobieski R, et al. 2013. Blood thioredoxin reductase activity, oxidative stress and hematological parameters in painters and battery workers: Relationship with lead and cadmium levels in blood. *J Appl Toxicol* 33(2):142-150. 10.1002/jat.1731.
- Cools A, Salle HJA, Verberk MM, et al. 1976. Short Communications. Biochemical response of male volunteers ingesting inorganic lead for 49 days. *Int Arch Occup Environ Health* 38:129-139.
- Coon S, Stark A, Peterson E, et al. 2006. Whole-body lifetime occupational lead exposure and risk of Parkinson's disease. *Environ Health Perspect* 114(12):1872-1876. 10.1289/ehp.9102.
- Cooper WC. 1988. Deaths from chronic renal disease in US battery and lead production workers. *Environ Health Perspect* 78:61-63.
- Cooper GS, Umbach DM. 1996. Are Vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis. *J Bone Miner Res* 11(12):1841-1849.
- Cooper WC, Wong O, Kheifets L. 1985. Mortality among employees of lead battery plants and lead-producing plants, 1947-1980. *Scand J Work Environ Health* 11:331-345.
- Corrin ML, Natusch DF. 1977. Physical and chemical characteristics of environmental lead. In: *Lead in the environment*. Washington, DC: National Science Foundation, 7-31.
- Cory-Slechta DA. 1995. Relationships between lead-induced learning impairments and changes in dopaminergic, cholinergic, and glutamatergic neurotransmitter system functions. *Ann Rev Pharmacol Toxicol* 35:391-415.
- Cory-Slechta DA. 2003. Lead-induced impairments in complex cognitive function: Offerings from experimental studies. *Child Neuropsychol* 9(1):54-75.
- Cory-Slechta DA, Weiss B, Cox C. 1987. Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetraacetate chelation therapy. *J Pharmacol Exp Ther* 243(3):804-813.
- Costa de Almeida GR, de Freitas Tavares CF, de Souza AM, et al. 2010. Whole blood, serum, and saliva lead concentrations in 6- to 8-year-old children. *Sci Total Environ* 408(7):1551-1556. 10.1016/j.scitotenv.2009.12.034.

8. REFERENCES

- Costa de Almeida GR, de Sousa Guerra C, de Angelo Souza Leite G, et al. 2011. Lead contents in the surface enamel of primary and permanent teeth, whole blood, serum, and saliva of 6- to 8-year-old children. *Sci Total Environ* 409(10):1799-1805. 10.1016/j.scitotenv.2011.01.004.
- Costa de Almeida GR, Umbelino de Freitas C, Barbosa F, Jr., et al. 2009. Lead in saliva from lead-exposed and unexposed children. *Sci Total Environ* 407(5):1547-1550. 10.1016/j.scitotenv.2008.10.058.
- Coste J, Mandereau L, Pessione F, et al. 1991. Lead-exposed workmen and fertility: A cohort study on 354 subjects. *Eur J Epidemiol* 7(2):154-158.
- Counter SA, Buchanan LH, Ortega F. 2008. Zinc protoporphyrin levels, blood lead levels and neurocognitive deficits in Andean children with chronic lead exposure. *Clin Biochem* 41(1-2):41-47. 10.1016/j.clinbiochem.2007.10.002.
- Counter SA, Buchanan LH, Ortega F. 2009. Neurocognitive screening of lead-exposed Andean adolescents and young adults. *J Toxicol Environ Health, Part A* 72(10):625-632. 10.1080/15287390902769410.
- Counter SA, Buchanan LH, Ortega F, et al. 2014. Lead levels in the breast milk of nursing Andean mothers living in a lead-contaminated environment. *J Toxicol Environ Health A* 77(17):993-1003. 10.1080/15287394.2014.897281.
- Cox WM, Pesola GR. 2005. Buckshot ingestion. *N Engl J Med* 353(26):e23.
- CPSC. 1996. CPSC finds lead poisoning hazard for young children in imported vinyl miniblinds. U.S. Consumer Product Safety Commission. <http://www.cpsc.gov/cpscpub/prerel/prhtml/96150.html>.
- Craig JR, Rimstidt JD, Bonnaffon CA, et al. 1999. Surface water transport of lead at a shooting range. *Bull Environ Contam Toxicol* 63:312-319.
- Cramer K, Goyer RA, Jagenburg R, et al. 1974. Renal ultrastructure, renal function, and parameters of lead toxicity in workers with different periods of lead exposure. *Br J Ind Med* 31:113-127.
- Crump KS, Van Landingham C, Bowers TS, et al. 2013. A statistical reevaluation of the data used in the Lanphear et al. (2005) pooled-analysis that related low levels of blood lead to intellectual deficits in children. *Crit Rev Toxicol* 43(9):785-799. <http://doi.org/10.3109/10408444.2013.832726>.
- Cui S, Zhou Q, Chao L. 2007. Potential hyperaccumulation of Pb, Zn, Cu and Cd in enduring plants distributed in an old smeltery, northeast China. *Environ Geol* 51(6):1043-1048.
- Cullen MR, Kayne RD, Robins JM. 1984. Endocrine and reproductive dysfunction in men associated with occupational inorganic lead intoxication. *Arch Environ Health* 39(6):431-440.
- Dallaire R, Dewailly E, Ayotte P, et al. 2014. Growth in Inuit children exposed to polychlorinated biphenyls and lead during fetal development and childhood. *Environ Res* 134:17-23. 10.1016/j.envres.2014.06.023.
- Dalpra L, Tibiletti MG, Nocera G, et al. 1983. SCE analysis in children exposed to lead emission from a smelting plant. *Mutat Res* 120:249-256.
- Danadevi K, Rozati R, Banu BS, et al. 2003. DNA damage in workers exposed to lead using comet assay. *Toxicology* 187(2):183-193.
- Davidson A, Ryman J, Sutherland CA, et al. 2014. Lead. In: Ullmann's encyclopedia of industrial chemistry. 10.1002/14356007.a15_193.pub3.
- Davies JM. 1984a. Lung cancer mortality among workers making lead chromate and zinc chromate pigments at three English factories. *Br J Ind Med* 41:158-169.
- Davies JM. 1984b. Long term mortality study of chromate pigment workers who suffered lead poisoning. *Br J Ind Med* 41:170-178.
- Davis AP, Shokouhian M, Ni S. 2001. Loading estimates of lead, copper, cadmium, and zinc in urban runoff from specific sources. *Chemosphere* 44:997-1009.
- Davis JM, Svendsgaard DJ. 1990. Nerve conduction velocity and lead: A critical review and meta-analysis. *Advances in neurobehavioral toxicology: Appl Environ Occup Health* 353-376.
- Davis S, Mirick DK. 2006. Soil ingestion in children and adults in the same family. *J Expo Sci Environ Epidemiol* 16(1):63-75. 10.1038/sj.jea.7500438.

8. REFERENCES

- Davis A, Ruby MV, Bergstrom PD. 1994. Factors controlling lead bioavailability in the Butte mining district, Montana, USA. *Environ Geochem Health* 16(3/4; 3/4):147-157.
- Davis MA, Gilbert-Diamond D, Karagas MR, et al. 2014. A dietary-wide association study (DWAS) of environmental metal exposure in US children and adults. *PLoS ONE* 9(9):e104768. 10.1371/journal.pone.0104768.
- de Burbure C, Buchet JP, Leroyer A, et al. 2006. Renal and neurologic effects of cadmium, lead, mercury, and arsenic in children: Evidence of early effects and multiple interactions at environmental exposure levels. *Environ Health Perspect* 114(4):584-590. 10.1289/ehp.8202.
- De Kort W, Zwennis W. 1988. Blood lead and blood pressure: Some implications for the situation in The Netherlands. *Environ Health Perspect* 78:67-70.
- De Kort WLAM, Verschoor MA, Wibowo AAE, et al. 1987. Occupational exposure to lead and blood pressure: A study in 105 workers. *Am J Ind Med* 11:145-156.
- de Restrepo HG, Sicard D, Torres MM. 2000. DNA damage and repair in cells of lead exposed people. *Am J Ind Med* 38(3):330-334.
- DeJonghe W, Adams F. 1986. Biogeochemical cycling of organic lead compounds. *Adv Environ Sci Technol* 17:561-594.
- Denaix L, Semlali RM, Douay F. 2001. Dissolved and colloidal transport of Cd, Pb, and Zn in a silt loam soil affected by atmospheric industrial deposition. *Environ Pollut* 113:29-38.
- Deng H, Ye Z, Wong M. 2004. Accumulation of lead, zinc, copper and cadmium by 12 wetland plant species thriving in metal-contaminated sites in China. *Environ Pollut* 132(1):29-40.
- Denham M, Schell LM, Deane G, et al. 2005. Relationship of lead, mercury, mirex, dichlorodiphenyldichloroethylene, hexachlorobenzene, and polychlorinated biphenyls to timing of menarche among Akwesasne Mohawk girls. *Pediatrics* 115(2):e127-e134. 10.1542/peds.2004-1161.
- Den Hond E, Dhooge W, Bruckers L, et al. 2011. Internal exposure to pollutants and sexual maturation in Flemish adolescents. *J Expo Sci Environ Epidemiol* 21(3):224-233. 10.1038/jes.2010.2.
- Den Hond E, Nawrot T, Staessen JA. 2001. Relationship between blood pressure and blood lead in NHANES III. *J Hypertens* 19(2):S57.
- Den Hond E, Nawrot T, Staessen JA. 2002. The relationship between blood pressure and blood lead in NHANES III. *J Hum Hypertens* 16:563-568.
- Desilva PE. 1981. Determination of lead in plasma and studies on its relationship to lead in erythrocytes. *Br J Ind Med* 38:209-217.
- Dewailly E, Ayotte P, Bruneau S, et al. 2001. Exposure of the Inuit population of Nunavik (Arctic Quebec) to lead and mercury. *Arch Environ Health* 56(4):350-357.
- Di Lorenzo L, Silvestroni A, Martino MG, et al. 2006. Evaluation of peripheral blood neutrophil leucocytes in lead-exposed workers. *Int Arch Occup Environ Health* 79(6):491-498. 10.1007/s00420-005-0073-4.
- Diamond GL. 1988. Biological monitoring of urine for exposure to toxic metals. In: Clarkson TW, Friberg L, Nordberg GF, et al., eds. *Biological monitoring of toxic metals*. Plenum Publishing Corp., 515-529.
- Diamond GL. 2005. Risk assessment of nephrotoxic metals. In: Tarloff J, Lash L, eds. *The toxicology of the kidney*. London: CRC Press, 1099-1132.
- Dietrich KN, Berger OG, Succop PA. 1993b. Lead exposure and the motor developmental status of urban six-year-old children in the Cincinnati prospective study. *Pediatrics* 91(2):301-307.
- Dietrich KN, Berger OG, Succop PA, et al. 1993a. The developmental consequences of low to moderate prenatal and postnatal lead exposure: Intellectual attainment in the Cincinnati Lead Study cohort following school entry. *Neurotoxicol Teratol* 15(1):37-44.
- Dietrich KN, Douglas RM, Succop PA, et al. 2001. Early exposure to lead and juvenile delinquency. *Neurotoxicol Teratol* 23(6):511-518.

8. REFERENCES

- Dietrich KN, Krafft KM, Bier M, et al. 1989. Neurobehavioral effects of foetal lead exposure: The first year of life. In: Smith M, Grant LD, Sors A, eds. Lead exposure and child development: An international assessment. Lancaster, UK: Kluwer Academic Publishers, 320-331.
- Dietrich KN, Krafft KM, Bier M, et al. 1986. Early effects of fetal lead exposure: Neurobehavioral findings at 6 months. *Int J Biosoc Res* 8(2):151-168.
- Dietrich KN, Krafft KM, Shukla R, et al. 1987. The neurobehavioral effects of early lead exposure. In: Schroeder SR, ed. Toxic substances and mental retardation: Neurobehavioral toxicology and teratology. Washington, DC: American Association on Mental Deficiency, 71-95.
- Dietrich KN, Succop PA, Berger OG, et al. 1991. Lead exposure and the cognitive development of urban preschool children: The Cincinnati Lead Study cohort at age 4 years. *Neurotoxicol Teratol* 13(2):203-211.
- Dietrich KN, Succop PA, Berger OG, et al. 1992. Lead exposure and the central auditory processing abilities and cognitive development of urban children: The Cincinnati Lead Study cohort at age 5 years. *Neurotoxicol Teratol* 14(1):51-56.
- Dingwall-Fordyce I, Lane RE. 1963. A follow-up study of lead workers. *Br J Ind Med* 20:313-315.
- Dixon SL, Gaitens JM, Jacobs DE, et al. 2009. Exposure of U.S. children to residential dust lead, 1999-2004: II. The contribution of lead-contaminated dust to children's blood lead levels. *Environ Health Perspect* 117(3):468-474. 10.1289/ehp.11918.
- DOE. 2016. Table 3: Protective Action Criteria (PAC) Rev. 29 based on applicable 60-minute AEGLs, ERPGs, or TEELs. The chemicals are listed by CASRN. May 2016. Oak Ridge, TN: U.S. Department of Energy. https://sp.eota.energy.gov/pac/teel/Revision_29_Table3.pdf. February 28, 2017.
- Dong Z, Yan K, Liu Y, et al. 2016. A meta-analysis to correlate lead bioavailability and bioaccessibility and predict lead bioavailability. *Environ Int* 92-93:139-145. <http://doi.org/10.1016/j.envint.2016.04.009>.
- Dongre NN, Suryakar AN, Patil AJ, et al. 2013. Biochemical effects of lead exposure on battery manufacture workers with reference to blood pressure, calcium metabolism and bone mineral density. *Indian J Clin Biochem* 28(1):65-70. 10.1007/s12291-012-0241-8.
- do Nascimento SN, Charao MF, Moro AM, et al. 2014. Evaluation of toxic metals and essential elements in children with learning disabilities from a rural area of southern Brazil. *Int J Environ Res Public Health* 11(10):10806-10823. 10.3390/ijerph111010806.
- Dorsey CD, Lee B, Bolla KI, et al. 2006. Comparison of patella lead with blood lead and tibia lead and their associations with neurobehavioral test scores. *J Occup Environ Med* 48(5):489-496.
- Doyle JR, Blais JM, Holmes RD, et al. 2012. A soil ingestion pilot study of a population following a traditional lifestyle typical of rural or wilderness areas. *Sci Total Environ* 424:110-120. 10.1016/j.scitotenv.2012.02.043.
- Drasch G, Wanghofer E, Roider G. 1997. Are blood, urine, hair, and muscle valid biomarkers for the internal burden of men with the heavy metals mercury, lead and cadmium? An investigation on 150 deceased. *Trace Elem Electrolytes* 14(3):116-123.
- Drasch GA, Bohm J, Baur C. 1987. Lead in human bones. Investigations on an occupationally non-exposed population in southern Bavaria (F.R.G.) I. Adults. *Sci Total Environ* 64:303-315.
- Drexler JW, Brattin WJ. 2007. An *in vitro* procedure for estimation of lead relative bioavailability: With validation. *Hum Ecol Risk Assess* 13(2):383-401. 10.1080/10807030701226350.
- Dundar B, Öktem F, Arslan MK, et al. 2006. The effect of long-term low-dose lead exposure on thyroid function in adolescents. *Environ Res* 101(1):140-145. 10.1016/j.envres.2005.10.002.
- DuVal GE, Fowler BA. 1989. Preliminary purification and characterization studies of a low molecular weight, high affinity cytosolic lead-binding protein in rat brain. *Biochem Biophys Res Commun* 159:177-184.
- Duydu Y, Dur A, Süzen HS. 2005. Evaluation of increased proportion of cells with unusually high sister chromatid exchange counts as a cytogenetic biomarker for lead exposure. *Biol Trace Elem Res* 104(2):121-129. 10.1385/BTER:104:2:121.

8. REFERENCES

- Duydu Y, Süzen H, Aydin A, et al. 2001. Correlation between lead exposure indicators and sister chromatid exchange (SCE) frequencies in lymphocytes from inorganic lead exposed workers. *Arch Environ Contam Toxicol* 41(2):241-246.
- Dye BA, Hirsch R, Brody DJ. 2002. The relationship between blood lead levels and periodontal bone loss in the United States, 1988-1994. *Environ Health Perspect* 110(10):997-1002.
- Eaton DL, Stacey NH, Wong KL, et al. 1980. Dose response effects of various metal ions on rat liver metallothionein, glutathione, heme oxygenase, and cytochrome P-450. *Toxicol Appl Pharmacol* 55:393-402.
- Eckel WP, Jacob TA. 1988. Ambient levels of 24 dissolved metals in U.S. surface and ground waters. *Prepr Pap Natl Meet Am Chem Soc Div Environ Chem* 28:371-372.
- Egeghy PP, Quackenboss JJ, Catlin S, et al. 2005. Determinants of temporal variability in NHEXAS-Maryland environmental concentrations, exposures, and biomarkers. *J Expo Anal Environ Epidemiol* 15(5):388-397. 10.1038/sj.jea.7500415.
- Ehrlich R, Robins T, Jordaan E, et al. 1998. Lead absorption and renal dysfunction in a South African battery factory. *Occup Environ Med* 55:453-460.
- Eisenreich SJ, Looney BB, Thornton JD. 1981. Airborne organic contaminants in the Great Lakes ecosystem. *Environ Sci Technol* 15(1):30-38.
- Eisler R. 1988. Lead hazards to fish, wildlife, and invertebrates: A synoptic review. U.S. Department of the Interior, Fish and Wildlife Service.
- Elbaz-Poulichet F, Holliger P, Huang WW, et al. 1984. Lead cycling in estuaries, illustrated by the Gironde estuary, France. *Nature* 308:409-414.
- Elias SM, Hashim Z, Marjam ZM, et al. 2007. Relationship between blood lead concentration and nutritional status among Malay primary school children in Kuala Lumpur, Malaysia. *Asia Pac J Public Health* 19:29-37.
- Ellenhorn MJ. 1997. Lead. In: *Ellenhorn's medical toxicology: Diagnosis and treatment of human poisoning*. Second ed. Baltimore, MD: Williams & Wilkins, 1563-1579.
- Elmarsafawy SF, Jain NB, Schwartz J, et al. 2006. Dietary calcium as a potential modifier of the relationship of lead burden to blood pressure. *Epidemiology* 17(5):531-537.
- Elwood PC, Davey-Smith G, Oldham PD, et al. 1988a. Two Welsh surveys of blood lead and blood pressure. *Environ Health Perspect* 78:119-121.
- Elwood PC, Yarnell JWG, Oldham PD, et al. 1988b. Blood pressure and blood lead in surveys in Wales. *Am J Epidemiol* 127(5):942-945.
- Emory E, Ansari Z, Pattillo R, et al. 2003. Maternal blood lead effects on infant intelligence at age 7 months. *Am J Obstet Gynecol* 188(4):S26-S32.
- Englyst V, Lundstrom NG, Gerhardsson L, et al. 2001. Lung cancer risks among lead smelter workers also exposed to arsenic. *Sci Total Environ* 273:77-82.
- Environment and Climate Change Canada. 2016. Canadian environmental sustainability indicators: Releases of harmful substances to the environment. Minister of Environment and Climate Change. http://www.ec.gc.ca/indicateurs-indicators/3C4C1124-63E6-40BB-941A-EB87E1A23387/Releases%20of%20Harmful%20Substances_EN.pdf. June 26, 2017.
- EPA. 1977. 40 CFR 60; Subpart L. Code of Federal Regulations. U.S. Environmental Protection Agency.
- EPA. 1979. Lead water-related environmental fate of 129 priority pollutants. 13-11 - 13-19.
- EPA. 1982a. 40 CFR 60; Subpart KK. Code of Federal Regulations. U.S. Environmental Protection Agency.
- EPA. 1982b. 40 CFR 80.3. Code of Federal Regulations. U.S. Environmental Protection Agency.
- EPA. 1982c. An exposure and risk assessment for lead. Washington, DC: U.S. Environmental Protection Agency, Office of Water Regulations and Standards, Monitoring and Data Support Division. EPA440485010. PB85220606.
- EPA. 1985a. 40 CFR 80.20. Code of Federal Regulations. Washington, DC: U.S. Environmental Protection Agency.

8. REFERENCES

- EPA. 1985b. Determination of reportable quantities. Fed Regist 40 CFR, 117.3
- EPA. 1985c. Lead exposures in the human environment. Research Triangle Park, NC: U.S. Environmental Protection Agency, Environmental Criteria and Assessment Office. EPA600D86185. PB86241007.
- EPA. 1985d. Regulation of fuels and fuel additives; gasoline lead content. Fed Regist 50(45):9386-9399.
- EPA. 1986. Air quality criteria for lead. Research Triangle Park, NC: U.S. Environmental Protection Agency, Office of Research and Development, Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office. EPA600883028F.
- EPA. 1988. Specific toxic chemical listings. Code of Federal Regulations. Washington, DC: U.S. Environmental Protection Agency. Vol. 40 CFR 372.65
- EPA. 1989c. Exposure factors handbook. Washington, DC: U.S. Environmental Protection Agency, Office of Health and Environmental Assessment. EPA600889043.
- EPA. 1989d. National primary drinking water regulations. Code of Federal Regulations. U.S. Environmental Protection Agency. 40 CFR 141,142
- EPA. 1991. Reference air concentrations. Health based limits for exclusion of waste-derived residues. Code of Federal Regulations. 40 CFR 266, Appendices IV and VII.
- EPA. 1994a. Guidance manual for the integrated exposure uptake biokinetic model for lead in children. U.S. Environmental Protection. EPA540R93081. PB93963510.
- EPA. 1994b. Technical support document: Parameters and equations used in integrated exposure uptake biokinetic model for lead in children (v0.99d). Washington, DC: U.S. Environmental Protection Agency, Office of Solid Waste and Emergency Response. EPA540R94040. PB94963505.
- EPA. 1994c. Validation strategy for the integrated exposure uptake biokinetic model for lead in children. Washington, DC: U.S. Environmental Protection Agency, Office of Solid Waste and Emergency Response. EPA540R94039. PB94963504.
- EPA. 1994d. Methods for the determination of metals in environmental samples. Supplement 1. Cincinnati, OH: U.S. Environmental Protection Agency, Office of Research and Development, Environmental Monitoring Systems Laboratory. EPA600R94111. <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=300036HL.txt>. March 30, 2017.
- EPA, 1994e. Revised interim soil lead guidance for CERCLA sites and RCRA corrective action facilities. Washington, DC: U.S. Environmental Protection Agency, Office of Solid Waste and Emergency Response.
- EPA. 1994f. Method 200.8, revision 5.4: Determination of trace elements in waters and wastes by inductively coupled plasma-mass spectrometry. Cincinnati, OH: U.S. Environmental Protection Agency. https://www.epa.gov/sites/production/files/2015-08/documents/method_200-8_rev_5-4_1994.pdf. December 8, 2017.
- EPA. 1995a. Guidance for assessing chemical contaminant data for use in fish advisories. Volume 1: Fish sampling and analysis.
- EPA. 1995b. Report on the national survey of lead based paint in housing - base report. U.S. Environmental Protection Agency.
- EPA. 1996a. Prohibition on gasoline containing lead or lead additives for highway use. U.S. Environmental Protection Agency. Fed Regist 61(23):3832.
- EPA. 1996b. National air quality and emissions trends report 1995. U.S. Environment Protection Agency.
- EPA. 1996c. Urban Soil Lead Abatement Demonstration Project. Volume I: EPA Integrated Report.
- EPA. 1997. Methods for the determination of chemical substances in marine and estuarine environmental matrices- 2nd edition. Washington, DC: U.S. Environmental Protection Agency, Office of Research and Development. EPA600R97072. https://cfpub.epa.gov/si/si_public_record_report.cfm?dirEntryId=309412. March 30, 2017.
- EPA. 1997. Implementation of the mercury-containing and rechargeable battery management act. U.S. Environmental Protection Agency. <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=10000MXZ.txt>.

8. REFERENCES

- EPA. 1998. Clarification to the 1994 revised interim soil lead guidance for CERCLA sites and RCRA corrective action facilities. U.S. Environmental Protection Agency, Office of Solid Waste and Emergency Response. EPA540F98030. <https://www.epa.gov/superfund/lead-superfund-sites-guidance>. August 25, 2017.
- EPA. 1999. Determination of metals in ambient particulate matter using X-ray fluorescence (XRF) spectroscopy. Compendium Method 10-3.3. Cincinnati, OH: U.S. Environmental Protection Agency, Office of Research and Development, Center for Environmental Research Information. EPA625R96010a. <https://www3.epa.gov/ttnamti1/files/ambient/inorganic/mthd-3-3.pdf>. March 30, 2017.
- EPA. 2001. Lead and lead compounds. Guidance for reporting releases and other waste management quantities of toxic chemicals. Washington, DC: U.S. Environmental Protection Agency.
- EPA. 2002a. Reference manual for the Integrated Exposure Uptake Biokinetic Model for lead in children (IEUBK) Windows 32 bit version. U.S. Environmental Protection Agency. EPA9285744 <https://www.epa.gov/superfund/lead-superfund-sites-software-and-users-manuals#technical>.
- EPA. 2002b. The "battery act". Enforcement alert. U.S. Environmental Protection Agency. EPA300N02002.
- EPA. 2002c. National primary drinking water regulations. Washington, DC: U.S. Environmental Protection Agency, Office of Ground Water and Drinking Water. EPA816F02013. <http://www.epa.gov/safewater/mcl.html>.
- EPA. 2003. Method 200.5: Determination of trace elements in drinking water by axially viewed inductively coupled plasma- atomic emission spectrometry. Cincinnati, OH: U.S. Environmental Protection Agency, Office of Research and Development, National Exposure Research Laboratory. EPA600R06115. https://www.epa.gov/sites/production/files/2015-08/documents/method_200-5_rev_4-2_2003.pdf. March 30, 2017.
- EPA. 2004. Lead and copper rule: A quick reference guide. U.S. Environmental Protection Agency. EPA816F04009. <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=30006646.txt>. February 5, 2019.
- EPA. 2005a. Toxic chemical release inventory reporting forms and instructions: Revised 2004 version. Section 313 of the Emergency Planning and Community Right-to-Know Act (Title III of the Superfund Amendments and Reauthorization Act of 1986). U.S. Environmental Protection Agency, Office of Environmental Information. EPA260B05001.
- EPA. 2005b. STORET database access. U.S. Environmental Protection Agency. <http://www.epa.gov/storet/dbtop.html>. May 20, 2005.
- EPA. 2006. Air quality criteria for lead. Volume 1 of II. U.S. Environmental Protection Agency. EPA600R5144aF. http://ofmpub.epa.gov/eims/eimscomm.getfile?p_download_id=459555. June 27, 2017.
- EPA. 2007a. National primary drinking water regulations for lead and copper: Short-term regulatory revisions and clarifications. Fed Regist 72(195):57782-57820. <https://www.gpo.gov/fdsys/pkg/FR-2007-10-10/pdf/E7-19432.pdf>. June 28, 2017.
- EPA. 2007b. The national listing of fish advisories. Advisory report output. U.S. Environmental Protection Agency. <http://map1.epa.gov/>.
- EPA. 2009. National primary drinking water regulations. Washington, DC: Office of Ground Water and Drinking Water, U.S. Environmental Protection Agency. EPA 816-F-09-0004. https://www.epa.gov/sites/production/files/2016-06/documents/npwdr_complete_table.pdf. February 28, 2017.
- EPA. 2010. Lead and copper rule monitoring and reporting guidance for public water systems. U.S. Environmental Protection Agency. EPA816R10004. <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100DP2P.txt>. February 5, 2019.
- EPA. 2013. Providing safe drinking water in America: 2013 National Public Water Systems compliance report. U.S. Environmental Protection Agency. <https://www.epa.gov/sites/production/files/2015-06/documents/sdwacom2013.pdf>. February 6, 2019.

8. REFERENCES

- EPA. 2014a. Development and evaluation of the all ages lead model (AALM). U.S. Environmental Protection Agency.
- EPA. 2014b. Approach for estimating exposures and incremental health effects from lead due to renovation, repair, and painting activities in public and commercial buildings. U.S. Environmental Protection Agency. https://www.epa.gov/sites/production/files/2014-08/documents/approachdocument_0.pdf. April 3, 2017.
- EPA. 2014c. Integrated science assessment for lead. Contains errata sheet created 5/12/2014. EPA600R10075F. <https://cfpub.epa.gov/ncea/isa/recordisplay.cfm?deid=255721>. October 21, 2016.
- EPA. 2014d. Lead and lead compounds. Chemical data access tool (CDAT). [2012 Chemical Data Reporting (CDR)]. U.S. Environmental Protection Agency. https://java.epa.gov/oppt_chemical_search/. June 26, 2017.
- EPA. 2014e. Identification and consideration of errors in Lanphear et al. (2005), “Low-Level Environmental Lead Exposure and Children’s Intellectual Function: An International Pooled Analysis”. Memorandum to Integrated Science Assessment for Lead Docket (EPA-HQ-ORD-2011-0051). Research Triangle Park, NC: U.S. Environmental Protection Agency. https://ofmpub.epa.gov/eims/eimscomm.getfile?p_download_id=518543. February 5, 2019.
- EPA. 2015. Report on the environment. Lead emissions. <https://cfpub.epa.gov/roe/>. June 27, 2017.
- EPA. 2016a. Hazardous wastes from non-specific sources, Subpart D-Lists of hazardous waste. Code of Federal Regulations. U.S. Environmental Protection Agency. 40 CFR 261.31 <https://www.gpo.gov/fdsys/pkg/CFR-2016-title40-vol28/pdf/CFR-2016-title40-vol28-part261-subpartD.pdf>. June 26, 2017.
- EPA. 2016b. Memorandum. Updated scientific considerations for lead in soil cleanups. U.S. Environmental Protection Agency. <https://assets.documentcloud.org/documents/3525442/EPA-Memo-Updated-Scientific-Considerations-for.pdf>. June 28, 2017.
- EPA. 2016c. 2014 National Emissions Inventory, version 1. Technical support document. Research Triangle Park, NC: U.S. Environmental Protection Agency.
- EPA. 2016d. Acute Exposure Guideline Levels (AEGLS) Values. U.S. Environmental Protection Agency. <https://www.epa.gov/aegl/access-acute-exposure-guideline-levels-aegls-values#chemicals>. February 28, 2017.
- EPA. 2016e. Review of the National Ambient Air Quality Standards for lead. U.S. Environmental Protection Agency. Fed Regist 81(201):71906-71043. <https://www.gpo.gov/fdsys/pkg/FR-2016-10-18/pdf/2016-23153.pdf>. August 25, 2017.
- EPA. 2016f. Updated scientific considerations for lead in soil cleanups. U.S. Environmental Protection Agency, Office of Land and Emergency Management. <https://quicksilver.epa.gov/work/08/1884174.pdf>. August 25, 2017.
- EPA. 2016g. Optimal corrosion control treatment evaluation technical recommendations for primacy agencies and public water systems. U.S. Environmental Protection Agency. EPA816B16003. <https://www.epa.gov/dwreginfo/optimal-corrosion-control-treatment-evaluation-technical-recommendations>. February 6, 2019.
- EPA. 2017a. Lead air releases trend in the 2015 TRI national analysis. U.S. Environmental Protection Agency.
- EPA. 2017b. Supporting data files for the 2015 TRI national analysis: 2015 Toxics Release Inventory national analysis: Releases of chemicals: Lead air releases trend. U.S. Environmental Protection Agency.
- EPA. 2017c. TRI basic data files: Calendar years 1987-2015 [US data from 2015]. U.S. Environmental Protection Agency.
- EPA. 2017d. Transmittal of update to the adult lead methodology's default baseline blood lead concentration and geometric standard deviation parameters. OLEM Directive 9285-56. Washington, DC: U.S. Environmental Protection Agency. <https://semspub.epa.gov/work/HQ/196766.pdf>. August 25, 2017.

8. REFERENCES

- EPA. 2017e. Review of Michigan's lead and copper rule. Review of the Michigan Department of Environmental Quality Drinking Water Program 2016. U.S. Environmental Protection Agency. 16-29.
- EPA. 2018a. Lead trends: National trends in lead levels. U.S. Environmental Protection Agency. <https://www.epa.gov/air-trends/lead-trends>. February 6, 2019.
- EPA. 2018b. Air quality system: Lead. U.S. Environmental Protection Agency. <https://www.epa.gov/aqs>. February 6, 2019.
- EPA. 2018c. 2018 Edition of the drinking water standards and health advisories tables. Washington, DC: Office of Water, U.S. Environmental Protection Agency. EPA822F18001. <https://www.epa.gov/sites/production/files/2018-03/documents/dwtable2018.pdf>. May 4, 2017.
- Erenberg G, Rinsler SS, Fish BG. 1974. Lead neuropathy and sickle cell disease. *Pediatrics* 54:438-441.
- Erfurth EM, Gerhardsson L, Nilsson A, et al. 2001. Effects of lead on the endocrine system in lead smelter workers. *Arch Environ Health* 56(5):449-455.
- Ergurhan-Ilhan I, Cadir B, Koyuncu-Arslan M, et al. 2008. Level of oxidative stress and damage in erythrocytes in apprentices indirectly exposed to lead. *Pediatr Int* 50(1):45-50. 10.1111/j.1442-200X.2007.02442.x.
- Erie JC, Good JA, Butz JA. 2009. Excess lead in the neural retina in age-related macular degeneration. *Am J Ophthalmol* 148(6):890-894. 10.1016/j.ajo.2009.07.001.
- Erkkila J, Armstrong R, Riihimaki V, et al. 1992. *In vivo* measurements of lead in bone at four anatomical sites: Long term occupational and consequent endogenous exposure. *Br J Ind Med* 49:631-644.
- Ernhart CB, Morrow-Tlucak M, Wolf AW, et al. 1989. Low level lead exposure in the prenatal and early preschool periods: Intelligence prior to school entry. *Neurotoxicol Teratol* 11(2):161-170.
- Esteban M, Castano A. 2009. Non-invasive matrices in human biomonitoring: A review. *Environ Int* 35:438-449.
- Esteban E, Rubin CH, Jones RL, et al. 1999. Hair and blood as substrates for screening children for lead poisoning. *Arch Environ Health* 54(6):436-440.
- Esteban-Vasallo MD, Aragonés N, Pollán M, et al. 2012. Mercury, cadmium, and lead levels in human placenta: A systematic review. *Environ Health Perspect* 120(10):1369-1377. 10.1289/ehp.1204952.
- Ethier AA, Muckle G, Bastien C, et al. 2012. Effects of environmental contaminant exposure on visual brain development: A prospective electrophysiological study in school-aged children. *Neurotoxicology* 33(5):1075-1085. 10.1016/j.neuro.2012.05.010.
- Ettinger AS, Lamadrid-Figueroa H, Tellez-Rojo MM, et al. 2009. Effect of calcium supplementation on blood lead levels in pregnancy: A randomized placebo-controlled trial. *Environ Health Perspect* 117(1):26-31.
- Ettinger AS, Roy A, Amarasiriwardena CJ, et al. 2014. Maternal blood, plasma, and breast milk lead: Lactational transfer and contribution to infant exposure. *Environ Health Perspect* 122(1):87-92. 10.1289/ehp.1307187.
- Ettinger AS, Tellez-Rojo MM, Amarasiriwardena C, et al. 2004. Levels of lead in breast milk and their relation to maternal blood and bone lead levels at one month postpartum. *Environ Health Perspect* 112:926-931.
- Ettinger AS, Tellez-Rojo MM, Amarasiriwardena C, et al. 2006. Influence of maternal bone lead burden and calcium intake on levels of lead in breast milk over the course of lactation. *Am J Epidemiol* 163(1):48-56.
- Eum KD, Nie LH, Schwartz J, et al. 2011. Prospective cohort study of lead exposure and electrocardiographic conduction disturbances in the Department of Veterans Affairs Normative Aging Study. *Environ Health Perspect* 119(7):490-494. 10.1289/ehp.1003279.
- Eum KD, Seals RM, Taylor KM, et al. 2015. Modification of the association between lead exposure and amyotrophic lateral sclerosis by iron and oxidative stress related gene polymorphisms. *Amyotroph Lateral SclerFrontotemporal Degener* 16(1-2):72-79. 10.3109/21678421.2014.964259.

8. REFERENCES

- Eum KD, Wang FT, Schwartz J, et al. 2013. Modifying roles of glutathione S-transferase polymorphisms on the association between cumulative lead exposure and cognitive function. *Neurotoxicology* 39:65-71. 10.1016/j.neuro.2013.08.002.
- Eum KD, Weisskopf MG, Nie LH, et al. 2014. Cumulative lead exposure and age at menopause in the Nurses' Health Study cohort. *Environ Health Perspect* 122(3):229-234. 10.1289/ehp.1206399.
- Evans M, Elinder CG. 2011. Chronic renal failure from lead: Myth or evidence-based fact? *Kidney Int* 79(3):272-279. 10.1038/ki.2010.394.
- Evans RD, Rigler FH. 1985. Long distance transport of anthropogenic lead as measured by lake sediments. *Water Air Soil Pollut* 24:141-151.
- Evens A, Hryhorczuk D, Lanphear BP, et al. 2015. The impact of low-level lead toxicity on school performance among children in the Chicago public schools: A population-based retrospective cohort study. *Environ Health* 14:21. 10.1186/s12940-015-0008-9.
- Ewers U, Stiller-Winkler R, Idel H. 1982. Serum immunoglobulin, complement C3, and salivary IgA levels in lead workers. *Environ Res* 29(2):351-357. 10.1016/0013-9351(82)90036-6.
- Factor-Litvak P, Graziano JH, Kline JK, et al. 1991. A prospective study of birthweight and length of gestation in a population surrounding a lead smelter in Kosovo, Yugoslavia. *Int J Epidemiol* 20:722-728.
- Factor-Litvak P, Kline JK, Popovac D, et al. 1996. Blood lead and blood pressure in young children. *Epidemiology* 7(6):633-637. 10.1097/00001648-199611000-00012.
- Factor-Litvak P, Slavkovich V, Liu X, et al. 1998. Hyperproduction of erythropoietin in nonanemic lead-exposed children. *Environ Health Perspect* 106(6):361-364.
- Factor-Litvak P, Wasserman G, Kline JK, et al. 1999. The Yugoslavia prospective study of environmental lead exposure. *Environ Health Perspect* 107(1):9-15.
- Fadowski JJ, Navas-Acien A, Tellez-Plaza M, et al. 2010. Blood lead level and kidney function in US adolescents: The Third National Health and Nutrition Examination Survey. *Arch Intern Med* 170(1):75-82. 10.1001/archinternmed.2009.417.
- Fan G, Du G, Li H, et al. 2014. The effect of the hemochromatosis (HFE) genotype on lead load and iron metabolism among lead smelter workers. *PLoS ONE* 9(7):e101537. 10.1371/journal.pone.0101537.
- Fang F, Kwee LC, Allen KD, et al. 2010. Association between blood lead and the risk of amyotrophic lateral sclerosis. *Am J Epidemiol* 171(10):1126-1133. 10.1093/aje/kwq06.
- Fanning D. 1988. A mortality study of lead workers, 1926-1985. *Arch Environ Health* 43(3):247-251.
- Faramawi MF, DeLongchamp R, Lin YS, et al. 2015. Environmental lead exposure is associated with visit-to-visit systolic blood pressure variability in the US adults. *Int Arch Occup Environ Health* 88(3):381-388. 10.1007/s00420-014-0970-5.
- Farhat A, Mohammadzadeh A, Balali-Mood M, et al. 2013. Correlation of blood lead level in mothers and exclusively breastfed infants: A study on infants aged less than six months. *Asia Pac J Med Toxicol* 2:150-152.
- Farias P, Echavarria M, Hernandez-Avila M, et al. 2005. Bone, blood and semen lead in men with environmental and moderate occupational exposure. *Int J Environ Health Res* 15(1):21-31.
- Fayerweather WE, Karns ME, Nuwayhid IA, et al. 1997. Case-control study of cancer risk in tetraethyl lead manufacturing. *Am J Ind Med* 31:28-35.
- Fazli D, Malekirad AA, Mirzaee M, et al. 2014. Study on the link between lead exposure and hematological, psychological, and memorial parameters in automobile repair workers. *Sci Res* 6:712-719.
- FDA. 2006. Supporting document for recommended maximum level for lead in candy likely to be consumed frequently by small children. U.S. Food and Drug Administration. <https://www.fda.gov/food/foodborneillnesscontaminants/metals/ucm172050.htm>. June 28, 2017.
- FDA. 2013. Everything added to food in the United States (EAFUS). Washington, DC: U.S. Food and Drug Administration. <http://www.accessdata.fda.gov/scripts/fcn/fcnavigation.cfm?rpt=eafuslisting>. February 28, 2017.

8. REFERENCES

- FDA. 2016a. Lead and cadmium in foods. Combination metals testing. U.S. Food and Drug Administration. <https://www.fda.gov/Food/FoodborneIllnessContaminants/Metals/ucm521427.htm>. March 23, 2017.
- FDA. 2016b. Total diet study elements results- summary statistics. Market baskets 2006 through 2011. U.S. Food and Drug Administration. March 23, 2017.
- Fears TR, Elashoff RM, Schneiderman MA. 1989. The statistical analysis of a carcinogen mixture experiment. III. Carcinogens with different target systems, aflatoxin B1, n-butyl-N(4-hydroxybutyl)nitrosamine, lead acetate, and thiouracil. *Toxicol Ind Health* 5(1):1-23.
- Feldhake CJ, Stevens CD. 1963. The solubility of tetraethyllead in water. *J Chem Eng Data* 8(2):196-197. 10.1021/je60017a016.
- Fels LM, Wunsch M, Baranowski J, et al. 1998. Adverse effects of chronic low level lead exposure on kidney function - a risk group study in children. *Nephrol Dial Transplant* 13:2248-2256.
- Fergusson DM, Horwood LJ, Lynskey MT. 1993. Early dentine lead levels and subsequent cognitive and behavioural development. *J Child Psychol Psychiatry* 34(2):215-227. 10.1111/j.1469-7610.1993.tb00980.x.
- Fernandes KC, Martins AC, Jr., Oliveira AA, et al. 2016. Polymorphism of metallothionein 2A modifies lead body burden in workers chronically exposed to the metal. *Publ Health Genom* 19(1):47-52. 10.1159/000441713.
- Finster ME, Gray KA, Binns HJ. 2004. Lead levels of edibles grown in contaminated residential soils: A field survey. *Sci Total Environ* 320(2):245-257.
- Fischbein A, Anderson KE, Sassa S, et al. 1981. Lead poisoning from "Do-It-Yourself" heat guns for removing lead-based paint: Report of two cases. *Environ Res* 24:425-431.
- Fischbein A, Tsang P, Luo JCJ, et al. 1993. Phenotypic aberrations of CD3+ and CD4+ cells and functional impairments of lymphocytes at low-level occupational exposure to lead. *Clin Immunol Immunopathol* 66(2):163-168.
- Flanagan PR, Hamilton DL, Haist J, et al. 1979. Interrelationships between iron and lead absorption in iron-deficient mice. *Gastroenterology* 77:1074-1081.
- Flegal AR, Smith DR. 1995. Measurements of environmental lead contamination and human exposure. *Rev Environ Contam Toxicol* 143:1-45.
- Fleisch AF, Burns JS, Williams PL, et al. 2013. Blood lead levels and serum insulin-like growth factor 1 concentrations in peripubertal boys. *Environ Health Perspect* 121(7):854-858. 10.1289/ehp.1206105.
- Fleming D, Boulay D, Richard NS, et al. 1997. Accumulated body burden and endogenous release of lead in employees of a lead smelter. *Environ Health Perspect* 105(2):224-233.
- Fleming DEB, Chettle DR, Wetmur JG, et al. 1998b. Effect of the δ -aminolevulinic acid dehydratase polymorphism on the accumulation of lead in bone and blood in lead smelter workers. *Environ Res* 77:49-61.
- Fleming MD, Romano MA, Su MA, et al. 1998a. Nramp2 is mutated in the anemic Belgrade (b) rat: Evidence of a role for Nramp2 in endosomal iron transport. *Proc Natl Acad Sci* 95(3):1148-1153.
- Flora G, Gupta D, Tiwari A. 2012. Toxicity of lead: A review with recent updates. *Interdiscip Toxicol* 5(2):47-58. 10.2478/v10102-012-0009-2.
- Forbes GB, Reina JC. 1972. Effect of age on gastrointestinal absorption (Fe, Sr, Pb) in the rat. *J Nutr* 102:647-652.
- Forni A, Cambiaghi G, Secchi GC. 1976. Initial occupational exposure to lead. Chromosome and biochemical findings. *Arch Environ Health* 31:73-78.
- Foster P, Gray LE. Chapter 20. Toxic responses of the reproductive system. In: Klaassen CD, ed. Casarett and Doull's toxicology. The basic science of poisons. New York, NY: The McGraw-Hill Companies, Inc., 761-806.
- Fowler B. 1989. Biological roles of high affinity metal-binding proteins in mediating cell injury. *Comm Toxicol* 3:27-46.

8. REFERENCES

- Fowler BA, DuVal G. 1991. Effects of lead on the kidney: Roles of high-affinity lead-binding proteins. *Environ Health Perspect* 91:77-80.
- Fracasso ME, Perbellini L, Soldà S, et al. 2002. Lead induced DNA strand breaks in lymphocytes of exposed workers: Role of reactive oxygen species and protein kinase C. *Mutat Res Genet Toxicol Environ Mutagen* 515(1):159-169.
- Franklin CA, Inskip MJ, Baccanale CL, et al. 1997. Use of sequentially administered stable lead isotopes to investigate changes in blood lead during pregnancy in a nonhuman primate (*Macaca fascicularis*). *Fundam Appl Toxicol* 39:109-119.
- Fraser S, Muckle G, Despres C. 2006. The relationship between lead exposure, motor function and behaviour in Inuit preschool children. *Neurotoxicol Teratol* 28(1):18-27. 10.1016/j.ntt.2005.10.008.
- Freeman GB, Dill JA, Johnson JD, et al. 1996. Comparative absorption of lead from contaminated soil and lead salts by weanling Fischer 344 rats. *Fundam Appl Toxicol* 33:109-119.
- Freeman GB, Johnson JD, Killinger JM, et al. 1992. Relative bioavailability of lead from mining waste soil in rats. *Fundam Appl Toxicol* 19(3):388-398.
- Freeman GB, Johnson JD, Liao SC, et al. 1994. Absolute bioavailability of lead acetate and mining waste lead in rats. *Toxicology* 91:151-163.
- Frisancho AR, Ryan AS. 1991. Decreased stature associated with moderate blood lead concentrations in Mexican-American children. *Am J Clin Nutr* 54:516-519.
- Froehlich TE, Lanphear BP, Auinger P, et al. 2009. Association of tobacco and lead exposures with attention-deficit/hyperactivity disorder. *Pediatrics* 124(6):E1054-E1063. 10.1542/peds.2009-0738.
- Froehlich TE, Lanphear BP, Dietrich KN, et al. 2007. Interactive effects of a DRD4 polymorphism, lead and sex on executive functions in children. *Biol Psychiatry* 62(3):243-249. 10.1016/j.biopsycho.2006.09.039.
- Froom P, Kristal-Boneh E, Benbassat J, et al. 1998. Predictive value of determinations of zinc protoporphyrin for increased blood lead concentrations. *Clin Chem* 44(6):1283-1288.
- Fujita H, Sato K, Sano S. 1982. Increase in the amount of erythrocyte δ -aminolevulinic acid dehydratase in workers with moderate lead exposure. *Int Arch Occup Environ Health* 50:287-297.
- Fukui Y, Miki M, Ukai H, et al. 1999. Urinary lead as a possible surrogate of blood lead among workers occupationally exposed to lead. *Int Arch Occup Environ Health* 72(8):516-520.
- Fukumoto K, Karai I, Horiguchi S. 1983. Effect of lead on erythrocyte membranes. *Br J Ind Med* 40:220-223.
- Fullmer CS, Rosen JF. 1990. Effect of dietary calcium and lead status on intestinal calcium absorption. *Environ Res* 51:91-99.
- Gao A, Lu XT, Li QY, et al. 2010. Effect of the δ -aminolevulinic acid dehydratase gene polymorphism on renal and neurobehavioral function in workers exposed to lead in China. *Sci Total Environ* 408(19):4052-4055. 10.1016/j.scitotenv.2010.04.024.
- Gao K, Pearce J, Jones J, et al. 1999. Interaction between peat, humic acid and aqueous metal ions. *Environ Geochem Health* 21(1):13-26.
- Garavan C, Breen J, Moles R, et al. 2008. A case study of the health impacts in an abandoned lead mining area, using children's blood lead levels. *Int J Min Reclam Environ* 22(4):265-284.
- Garcia-Esquinas E, Aragonés N, Fernandez MA, et al. 2014. Newborns and low to moderate prenatal environmental lead exposure: Might fathers be the key? *Environ Sci Pollut Res Int* 21(13):7886-7898. 10.1007/s11356-014-2738-6.
- Garcia-Leston J, Mendez J, Pasaro E, et al. 2010. Genotoxic effects of lead: An updated review. *Environ Int* 36(6):623-636. 10.1016/j.envint.2010.04.011.
- García-Lestón J, Roma-Torres J, Vilares M, et al. 2011. Biomonitoring of a population of Portuguese workers exposed to lead. *Mutat Res* 721(1):81-88. 10.1016/j.mrgentox.2011.01.001.
- Garçon G, Leleu B, Marez T, et al. 2007. Biomonitoring of the adverse effects induced by the chronic exposure to lead and cadmium on kidney function: Usefulness of α -glutathione S-transferase. *Sci Total Environ* 377(2-3):165-172. 10.1016/j.scitotenv.2007.02.002.

8. REFERENCES

- Garrido Latorre F, Hernandez-Avila M, Orozco JT, et al. 2003. Relationship of blood and bone lead to menopause and bone mineral density among middle-age women in Mexico City. *Environ Health Perspect* 111(4):631-636.
- Gartside PS. 1988. The relationship of blood lead levels and blood pressure in NHANES II: Additional calculations. *Environ Health Perspect* 78:31-34.
- Garvey GJ, Hahn G, Lee RV, et al. 2001. Heavy metal hazards of Asian traditional remedies. *Int J Environ Health Res* 11(1):63-71.
- Ge Y, Murray P, Hendershot W. 2000. Trace metal speciation and bioavailability in urban soils. *Environ Pollut* 107(1):137-144.
- Gemmel A, Tavares M, Alperin S, et al. 2002. Blood lead level and dental caries in school-age children. *Environ Health Perspect* 110(10):A625-A630.
- Gennart JP, Bernard A, Lauwerys R. 1992a. Assessment of thyroid, testes, kidney and autonomic nervous system function in lead-exposed workers. *Int Arch Occup Environ Health* 64:49-57.
- Genus SJ, Birkholz D, Rodushkin I, et al. 2011. Blood, urine, and sweat (BUS) study: Monitoring and elimination of bioaccumulated toxic elements. *Arch Environ Contam Toxicol* 61(2):344-357. 10.1007/s00244-010-9611-5.
- Gercken B, Barnes RM. 1991. Determination of lead and other trace element species in blood by size exclusion chromatography and inductively coupled plasma/mass spectrometry. *Anal Chem* 63:283-287.
- Gerhardsson L, Attewell R, Chettle DR, et al. 1993. *In vivo* measurements of lead in bone in long-term exposed lead smelter workers. *Arch Environ Health* 48(3):147-156. 10.1080/00039896.1993.9940813.
- Gerhardsson L, Brune D, Nordberg GF, et al. 1986a. Distribution of cadmium, lead and zinc in lung, liver and kidney in long-term exposed smelter workers. *Sci Total Environ* 50:65-85.
- Gerhardsson L, Chettle D, Englyst V, et al. 1992. Kidney effects in long term exposed lead smelter workers. *Br J Ind Med* 49(3):186-192.
- Gerhardsson L, Englyst V, Lundstrom NG, et al. 1995b. Lead in tissues of deceased lead smelter worker. *J Trace Elem Med Biol* 9:136-143.
- Gerhardsson L, Hagmar L, Rylander L, et al. 1995a. Mortality and cancer incidence among secondary lead smelter workers. *Occup Environ Med* 52:667-672.
- Gerhardt RE, Crecelius EA, Hudson JB. 1980. Trace element content of moonshine. *Arch Environ Health* 35:332-334.
- Gerr F, Letz R, Stokes L, et al. 2002. Association between bone lead concentration and blood pressure among young adults. *Am J Ind Med* 42:98-106.
- Gersberg RM, Gaynor K, Tenczar D, et al. 1997. Quantitative modeling of lead exposure from glazed ceramic pottery in childhood lead poisoning cases. *Int J Environ Health Res* 7:193-202.
- Ghiasvand M, Aghakhani K, Salimi A, et al. 2013. Ischemic heart disease risk factors in lead exposed workers: Research study. *J Occup Med Toxicol* 8:11. 10.1186/1745-6673-8-11.
- Gibbs PNB, Gore MG, Jordan PM. 1985. Investigation of the effect of metal ions on the reactivity of thiol groups in human 5-aminolaevulinic acid dehydratase. *Biochem J* 225:573-580.
- Giddings JC. 1973. Chemistry, man, and environmental change. An integrated approach. New York, NY: Canfield Press, 351-353.
- Gilbert M, Lasley SM. 2002. Long-term consequences of developmental exposure to lead or polychlorinated biphenyls: Synaptic transmission and plasticity in the rodent CNS. *Environ Toxicol Pharmacol* 12(2):105-117.
- Glass TA, Bandeen-Roche K, McAtee M, et al. 2009. Neighborhood psychosocial hazards and the association of cumulative lead dose with cognitive function in older adults. *Am J Epidemiol* 169(6):683-692. 10.1093/aje/kwn390.
- Glenn BS, Bandeen-Roche K, Lee BK, et al. 2006. Changes in systolic blood pressure associated with lead in blood and bone. *Epidemiology* 17(5):538-544. 10.1097/01.ede.0000231284.19078.4b.

8. REFERENCES

- Glenn BS, Stewart WF, Links JM, et al. 2003. The longitudinal association of lead with blood pressure. *Epidemiology* 14(1):30-36.
- Goering PL, Fowler BA. 1987. Metal constitution of metallothionein influences inhibition of δ -aminolaevulinic acid dehydratase (porphobilinogen synthase) by lead. *Biochem J* 245(2):339-345.
- Goldberg RL, Hicks AM, O'Leary LM, et al. 1991. Lead exposure at uncovered outdoor firing ranges. *J Occup Med* 33(6):718-719.
- Gollenberg AL, Hediger ML, Lee PA, et al. 2010. Association between lead and cadmium and reproductive hormones in peripubertal U.S. girls. *Environ Health Perspect* 118(12):1782-1787. 10.1289/ehp.1001943.
- Golub NI, Winters PC, van Wijngaarden E. 2010. A population-based study of blood lead levels in relation to depression in the United States. *Int Arch Occup Environ Health* 83(7):771-777.
- Gomaa A, Howard H, Bellinger D, et al. 2002. Maternal bone lead as an independent risk factor for fetal neurotoxicity: A prospective study. *Pediatrics* 110(1):110-118.
- Gonick HC. 2011. Lead-binding proteins: A review. *J Toxicol* 2011:686050. 10.1155/2011/686050.
- Gonzalez-Cossio T, Peterson KE, Sanin L, et al. 1997. Decrease in birth weight in relation to maternal bone-lead burden. *Pediatrics* 100(5):856-862.
- Goodman M, LaVerda N, Clarke C, et al. 2002. Neurobehavioural testing in workers occupationally exposed to lead: Systematic review and meta-analysis of publications. *Occup Environ Med* 59(4):217-223.
- Goodrum PE, Diamond GL, Hassett JM, et al. 1996. Monte Carlo modeling of childhood lead exposure: Development of a probabilistic methodology for use with the USEPA IEUBK model for lead in children. *Hum Ecol Risk Assess* 2(4):681-708.
- Goyer RA. 1989. Mechanisms of lead and cadmium nephrotoxicity. *Toxicol Lett* 46:153-162.
- Goyer RA. 1990. Transplacental transport of lead. *Environ Health Perspect* 89:101-105.
- Goyer RA. 2001. Lead. In: Bingham E, Cohn B, Powell CH, eds. *Patty's toxicology*. Vol. 2. 5th ed. New York, NY: John Wiley & Sons, Inc., 611-675.
- Goyer RA, Leonard DL, Moore JF, et al. 1970a. Lead dosage and the role of the intranuclear inclusion body: An experimental study. *Arch Environ Health* 20:705-711.
- Goyer RA, May P, Cates MM, et al. 1970b. Lead and protein content of isolated intranuclear inclusion bodies from kidneys of lead-poisoned rats. *Lab Invest* 22(3):245-251.
- Grabo TN. 1997. Unknown toxic exposures: Arts and crafts materials. *AAOHN J* 45(3):124-130.
- Grandjean P. 1979. Occupational lead exposure in Denmark: Screening with the haematofluorometer. *Br J Ind Med* 36:52-58.
- Grandjean P, Bach E. 1986. Indirect exposures: The significance of bystanders at work and at home. *Am Ind Hyg Assoc J* 47(12):819-824.
- Grandjean P, Lintrup J. 1978. Erythrocyte-Zn-protoporphyrin as an indicator of lead exposure. *Scand J Clin Lab Invest* 38:669-675.
- Grandjean P, Hollnagel H, Hedegaard L, et al. 1989. Blood lead-blood pressure relations: Alcohol intake and hemoglobin as confounders. *Am J Epidemiol* 129(4):732-739.
- Grandjean P, Jorgensen PJ, Viskum S. 1991. Temporal and interindividual variation in erythrocyte-zinc-protoporphyrin in lead exposed workers. *Br J Ind Med* 48:254-257.
- Grandjean P, Wulf HC, Niebuhr E. 1983. Sister chromatid exchange in response to variations in occupational lead exposure. *Environ Res* 32(1):199-204.
- Grashow R, Miller MW, McKinney A, et al. 2013a. Lead exposure and fear-potentiated startle in the VA Normative Aging Study: A pilot study of a novel physiological approach to investigating neurotoxicant effects. *Neurotoxicol Teratol* 38:21-28. 10.1016/j.ntt.2013.04.003.
- Grashow R, Sparrow D, Hu H, et al. 2015. Cumulative lead exposure is associated with reduced olfactory recognition performance in elderly men: The Normative Aging Study. *Neurotoxicology* 49:158-164. 10.1016/j.neuro.2015.06.006.

8. REFERENCES

- Grashow R, Spiro A, Taylor KM, et al. 2013b. Cumulative lead exposure in community-dwelling adults and fine motor function: Comparing standard and novel tasks in the VA Normative Aging Study. *Neurotoxicology* 35:154-161. 10.1016/j.neuro.2013.01.005.
- Graziano JH. 1994. Validity of lead exposure markers in diagnosis and surveillance. *Clin Chem* 40(7):1387-1390.
- Graziano JH, Blum C. 1991. Lead exposure from lead crystal. *Lancet* 337:141-142.
- Graziano J, Slavkovich V, Liu X, et al. 2004. A prospective study of prenatal and childhood lead exposure and erythropoietin production. *J Occup Environ Med* 46(9):924-929.
- Graziano JH, Popovac D, Factor-Litvak P, et al. 1990. Determinants of elevated blood lead during pregnancy in a population surrounding a lead smelter in Kosovo, Yugoslavia. *Environ Health Perspect* 89:95-100.
- Greenberg M, Hamilton R. 1999. Lack of blood lead elevations in police officers following small arms qualification on an indoor range. *J Toxicol Clin Toxicol* 37(5):627.
- Griffin S, Goodrum PE, Diamond GL, et al. 1999. Application of a probabilistic risk assessment methodology to a lead smelter site. *Hum Ecol Risk Assess* 5(4):845-868.
- Griffin TB, Coulston F, Wills H. 1975. Biological and clinical effects of continuous exposure to airborne particulate lead. *Arh Hig Rada Toksikol* 26:191-208.
- Gross M, Kumar R. 1990. Physiology and biochemistry of vitamin D-dependent calcium binding proteins. *Am J Physiol* 259:F195-F209.
- Gross SB, Pfitzer EA, Yeager DW, et al. 1975. Lead in human tissues. *Toxicol Appl Pharmacol* 32:638-651.
- Grover P, Rekhadevi PV, Danadevi K, et al. 2010. Genotoxicity evaluation in workers occupationally exposed to lead. *Int J Hyg Environ Health* 213(2):99-106. 10.1016/j.ijheh.2010.01.005.
- Guibaud G, Tixier N, Bouju A, et al. 2003. Relation between extracellular polymers' composition and its ability to complex Cd, Cu and Pb. *Chemosphere* 52(10):1701-1710.
- Gulson B, Korsch M, Matison M, et al. 2009. Windblown lead carbonate as the main source of lead in blood of children from a seaside community: An example of local birds as "canaries in the mine". *Environ Health Perspect* 117(1):148-154. 10.1289/ehp.11577.
- Gulson B, Mizon K, Korsch M, et al. 2016. Revisiting mobilisation of skeletal lead during pregnancy based on monthly sampling and cord/maternal blood lead relationships confirm placental transfer of lead. *Arch Toxicol* 90(4):805-816. 10.1007/s00204-015-1515-8.
- Gulson B, Mizon K, Taylor A, et al. 2008. Longitudinal monitoring of selected elements in blood of healthy young children. *J Trace Elem Med Biol* 22(3):206-214. 10.1016/j.jtemb.2008.04.001.
- Gulson BL, Gray B, Mahaffey KR, et al. 1999a. Comparison of the rates of exchange of lead in the blood of newly born infants and their mothers with lead from their current environment. *J Lab Clin Med* 133(2):171-178.
- Gulson BL, James M, Giblin AM, et al. 1997a. Maintenance of elevated lead levels in drinking water from occasional use and potential impact on blood leads in children. *Sci Total Environ* 205:271-275.
- Gulson BL, Jameson CW, Mahaffey KR, et al. 1997b. Pregnancy increases mobilization of lead from maternal skeleton. *J Lab Clin Med* 130:51-62.
- Gulson BL, Jameson CW, Mahaffey KR, et al. 1998a. Relationships of lead in breast milk to lead in blood, urine, and diet of the infant and mother. *Environ Health Perspect* 106(10):667-674.
- Gulson BL, Mahaffey KR, Jameson CW, et al. 1998b. Mobilization of lead from the skeleton during the postnatal period is larger than during pregnancy. *J Lab Clin Med* 131:324-329.
- Gulson BL, Mahaffey KR, Jameson CW, et al. 1999c. Impact of diet on lead in blood and urine in female adults and relevance to mobilization of lead from bone stores. *Environ Health Perspect* 107(4):257-263.
- Gulson BL, Mizon KJ, Korsch MJ, et al. 2003. Mobilization of lead from human bone tissue during pregnancy and lactation - a summary of long-term research. *Sci Total Environ* 303:79-104.

8. REFERENCES

- Gulson BL, Mizon KJ, Palmer JM, et al. 2004. Blood lead changes during pregnancy and postpartum with calcium supplementation. *Environ Health Perspect* 12(15):1499-1507.
- Gulson BL, Palmer JM, Bryce A. 2002. Changes in blood lead of a recreational shooter. *Sci Total Environ* 293(1):143-150.
- Gulson BL, Pounds JG, Mushak P, et al. 1999b. Estimation of cumulative lead releases (lead flux) from the maternal skeleton during pregnancy and lactation. *J Lab Clin Med* 134(6):631-640.
- Gump BB, Mackenzie JA, Bendinskas K, et al. 2011. Low-level Pb and cardiovascular responses to acute stress in children: The role of cardiac autonomic regulation. *Neurotoxicol Teratol* 33(2):212-219. 10.1016/j.ntt.2010.10.001.
- Gump BB, Stewart P, Reihman J, et al. 2005. Prenatal and early childhood blood lead levels and cardiovascular functioning in 9 1/2 year old children. *Neurotoxicol Teratol* 27(4):655-665. 10.1016/j.ntt.2005.04.002.
- Gump BB, Stewart P, Reihman J, et al. 2008. Low-level prenatal and postnatal blood lead exposure and adrenocortical responses to acute stress in children. *Environ Health Perspect* 116(2):249-255. 10.1289/ehp.10391.
- Gundacker C, Fröhlich S, Graf-Rohrmeister K, et al. 2010. Perinatal lead and mercury exposure in Austria. *Sci Total Environ* 408(23):5744-5749. 10.1016/j.scitotenv.2010.07.079.
- Gundacker C, Wittmann KJ, Kukuckova M, et al. 2009. Genetic background of lead and mercury metabolism in a group of medical students in Austria. *Environ Res* 109:786-796.
- Guo M, He L, Strong PJ, et al. 2014. Binding between lead ions and the high-abundance serum proteins. *Chemosphere* 112:472-480. 10.1016/j.chemosphere.2014.05.018.
- Gurer-Orhan H, Sabır HU, Özgüneş H. 2004. Correlation between clinical indicators of lead poisoning and oxidative stress parameters in controls and lead-exposed workers. *Toxicology* 195(2):147-154.
- Gustafson A, Hedner P, Schutz A, et al. 1989. Occupational lead exposure and pituitary function. *Int Arch Occup Environ Health* 61:277-281.
- Guyette RP, Cutter BE, Henderson GS. 1991. Long-term correlations between mining activity and levels of lead and cadmium in tree-rings of eastern red-cedar. *J Environ Qual* 20(1):146-150.
- Haenninen H, Hernberg S, Mantere P, et al. 1978. Psychological performance of subjects with low exposure to lead. *J Occup Med* 20(10):683-689.
- Haley VB, Talbot TO. 2004. Seasonality and trend in blood lead levels of New York State children. *BMC pediatrics* 4(1):8.
- Hamurcu Z, Donmez H, Saraymen R, et al. 2001. Micronucleus frequency in human lymphocyte exposed to occupational lead, zinc, and cadmium. *Biol Trace Elem Res* 83(2):97-102.
- Hanna CW, Bloom MS, Robinson WP, et al. 2012. DNA methylation changes in whole blood is associated with exposure to the environmental contaminants, mercury, lead, cadmium and bisphenol A, in women undergoing ovarian stimulation for IVF. *Hum Reprod* 27(5):1401-1410. 10.1093/humrep/des038.
- Hanna-Attisha M, LaChance J, Sadler RC, et al. 2016. Elevated blood lead levels in children associated with the Flint drinking water crisis: A spatial analysis of risk and public health response. *Am J Public Health* 106(2):283-290. 10.2105/ajph.2015.303003.
- Hanninen H, Aitio A, Kovala T, et al. 1998. Occupational exposure to lead and neuropsychological dysfunction. *Occup Environ Med* 55:202-209.
- Hansen S, Nieboer E, Sandanger TM, et al. 2011. Changes in maternal blood concentrations of selected essential and toxic elements during and after pregnancy. *J Environ Monit* 13(8):2143-2152. 10.1039/c1em10051c.
- Hardison DWJ, Ma LQ, Luongo T, et al. 2004. Lead contamination in shooting range soils from abrasion of lead bullets and subsequent weathering. *Sci Total Environ* 328:175-183. 10.1016/j.scitotenv.2003.12.013.
- Harlan WR. 1988. The relationship of blood lead levels to blood pressure in the U.S. population. *Environ Health Perspect* 78:9-13.

8. REFERENCES

- Harlan WR, Landis JR, Schmouder RL, et al. 1985. Blood lead and blood pressure. Relationship in the adolescent and adult US population. *J Am Med Assoc* 253:530-534.
- Harville EW, Hertz-Picciotto I, Schramm M, et al. 2005. Factors influencing the difference between maternal and cord blood lead. *Occup Environ Med* 62(4):263-269.
- Hashimoto Y. 2013. Field and laboratory assessments on dissolution and fractionation of Pb from spent and unspent shots in the rhizosphere soil. *Chemosphere* 93(11):2894-2900. 10.1016/j.chemosphere.2013.08.095.
- Hauser R, Sergeev O, Korrick S, et al. 2008. Association of blood lead levels with onset of puberty in Russian boys. *Environ Health Perspect* 116(7):976-980. 10.1289/ehp.10516.
- Havlena J, Kanarek MS, Coons M. 2009. Factors associated with the seasonality of blood lead levels among preschool Wisconsin children. *WMJ* 108(3):151-155.
- Hayes EB, McElvaine MD, Orbach HG, et al. 1994. Long-term trends in blood lead levels among children in Chicago: Relationship to air lead levels. *Pediatrics* 93(2):195-200.
- Haynes EN, Kalkwarf HJ, Hornung R, et al. 2003. Vitamin D receptor *FokI* polymorphism and blood lead concentration in children. *Environ Health Perspect* 111:1665-1669.
- Haynes WM. 2014. Lead. In: *CRC handbook of chemistry and physics*. Ninety-fifth ed. Boca Raton, FL: CRC Press, 4-20.
- Healey N, Chettle DR, McNeill FE, et al. 2008. Uncertainties in the relationship between tibia lead and cumulative blood lead index. *Environ Health Perspect* 116(3):A109; author reply A109-110. 10.1289/ehp.10778.
- Healy MA, Harrison PG, Aslam M, et al. 1982. Lead sulphide and traditional preparations: Routes for ingestion, and solubility and reactions in gastric fluid. *J Clin Hosp Pharm* 7:169-173.
- Heard MJ, Chamberlain AC. 1982. Effect of minerals and food on uptake of lead from the gastrointestinal tract in humans. *Hum Toxicol* 1:411-415.
- Heard MJ, Wells AC, Newton D, et al. 1979. Human uptake and metabolism of tetra ethyl and tetra methyl lead vapour labelled with 203Pb. *International Conference on Management and Control of Heavy Metals in the Environment*, 103-108.
- Hengstler JG, Bolm-Audorff U, Faldum A, et al. 2003. Occupational exposure to heavy metals: DNA damage induction and DNA repair inhibition prove co-exposures to cadmium, cobalt and lead as more dangerous than hitherto expected. *Carcinogenesis* 24(1):63-73.
- Hense HW, Filipiak B, Keil U. 1993. The association of blood lead and blood pressure in population surveys. *Epidemiology* 4:173-179.
- Heo Y, Lee BK, Ahn KD, et al. 2004. Serum IgE elevation correlates with blood lead levels in battery manufacturing workers. *Hum Exp Toxicol* 23(5):209-213. 10.1191/0960327104ht4420a.
- Hernandez-Avila M, Gonzalez-Cossio T, Palazuelos E, et al. 1996. Dietary and environmental determinants of blood and bone lead levels in lactating postpartum women living in Mexico City. *Environ Health Perspect* 104(10):1076-1082.
- Hernandez-Avila M, Peterson KE, Gonzalez-Cossio T, et al. 2002. Effect of maternal bone lead on length and head circumference of newborns and 1-month-old infants. *Arch Environ Health* 57(5):482-488.
- Hernandez-Avila M, Smith D, Meneses F, et al. 1998. The influence of bone and blood lead on plasma lead levels in environmentally exposed adults. *Environ Health Perspect* 106(8):473-477.
- Hernandez-Avila M, Villalpano CG, Palazuelos E, et al. 2000. Determinants of blood lead levels across the menopausal transition. *Arch Environ Health* 53:355-360.
- Hernández-Ochoa I, García-Vargas G, López-Carrillo L, et al. 2005. Low lead environmental exposure alters semen quality and sperm chromatin condensation in northern Mexico. *Reprod Toxicol* 20(2):221-228. 10.1016/j.reprotox.2005.01.007.
- Hernberg S, Nikkanen J, Mellin G, et al. 1970. δ -Aminolevulinic acid dehydrase as a measure of lead exposure. *Arch Environ Health* 21:140-145.
- Hertz-Picciotto I, Croft J. 1993. Review of the relation between blood lead and blood pressure. *Epidemiol Rev* 15(2):352-373.

8. REFERENCES

- Hertz-Picciotto I, Schramm M, Watt-Morse M, et al. 2000. Patterns and determinants of blood lead during pregnancy. *Am J Epidemiol* 152:829-837.
- Hettiarachchi GM, Pierzynski GM, Oehme FW, et al. 2003. Treatment of contaminated soil with phosphorus and manganese oxide reduces lead absorption by Sprague-Dawley rats. *J Environ Qual* 32:1335-1345.
- Higgs FJ, Mielke HW, Brisco M. 1999. Soil lead at elementary public schools: Comparison between school properties and residential neighbourhoods of New Orleans. *Environ Geochem Health* 21(1):27-36.
- Hill CP. 2011. Overview of internal corrosion impacts in drinking water distribution systems. In: *Internal corrosion control in water distribution systems*. 1st ed. American Water Works Association, 1-11.
- Hilts SR. 2003. Effect of smelter emission reductions on children's blood lead levels. *Sci Total Environ* 303(1-2):51-58.
- Hirata M, Kosaka H. 1993. Effects of lead exposure on neurophysiological parameters. *Environ Res* 63:60-69.
- Hogan K, Marcus A, Smith R, et al. 1998. Integrated exposure uptake biokinetic model for lead in children: Empirical comparisons with epidemiologic data. *Environ Health Perspect* 106(Suppl 6):1557-1567.
- Hogstedt C, Hane M, Agrell A, et al. 1983. Neuropsychological test results and symptoms among workers with well-defined long-term exposure to lead. *Br J Ind Med* 40:99-105.
- Holland MG, Cawthon D. 2016. ACOEM Position Statement. Workplace lead exposure. *J Occup Environ Med* 58(12):e371-e374.
- Holmgren GGS, Meyer MW, Chaney RL, et al. 1993. Cadmium, lead, zinc, copper, and nickel in agricultural soils of the United States of America. *J Environ Qual* 22:335-348.
- Homan CS, Brogan GX, Orava RS. 1998. Lead toxicity. In: *Viccellio P, ed. Emergency toxicology*. Second ed. Philadelphia, PA: Lippincott-Raven, 363-378.
- Hon KL, Ching GK, Hung EC, et al. 2009. Serum lead levels in childhood eczema. *Clin Exp Dermatol* 34(7):e508-e509. 10.1111/j.1365-2230.2009.03596.x.
- Hon KL, Wang SS, Hung ECW, et al. 2010. Serum levels of heavy metals in childhood eczema and skin diseases: Friends or foes. *Pediatric Allerg Immunol* 21(5):831-836. 10.1111/j.1399-3038.2010.01022.x.
- Hong CD, Hanenson IB, Lerner S, et al. 1980. Occupational exposure to lead: Effects on renal function. *Kidney Int* 18:489-494.
- Hong SB, Im MH, Kim JW, et al. 2015. Environmental lead exposure and attention deficit/hyperactivity disorder symptom domains in a community sample of South Korean school-age children. *Environ Health Perspect* 123(3):271-276. 10.1289/ehp.1307420.
- Hong YC, Kulkarni SS, Lim YH, et al. 2014. Postnatal growth following prenatal lead exposure and calcium intake. *Pediatrics* 134(6):1151-1159. 10.1542/peds.2014-1658.
- Hopkins MR, Ettinger AS, Hernández-Avila M, et al. 2008. Variants in iron metabolism genes predict higher blood lead levels in young children. *Environ Health Perspect* 116(9):1261-1266. 10.1289/ehp.11233.
- Hornung RW, Lanphear BP, Dietrich KN. 2009. Age of greatest susceptibility to childhood lead exposure: A new statistical approach. *Environ Health Perspect* 117(8):1309-1312. 10.1289/ehp.0800426.
- Hou S, Yuan L, Jin P, et al. 2013. A clinical study of the effects of lead poisoning on the intelligence and neurobehavioral abilities of children. *Theor Biol Medl Model* 10:13. 10.1186/1742-4682-10-13.
- Hsiao CL, Wu KH, Wan KS. 2011. Effects of environmental lead exposure on T-helper cell-specific cytokines in children. *J Immunotoxicol* 8(4):284-287. 10.3109/1547691X.2011.592162.
- Hsiao C-Y, Wu H-DI, Lai J-S, et al. 2001. A longitudinal study of the effects of long-term exposure to lead among lead battery factory workers in Taiwan (1989–1999). *Sci Total Environ* 279(1):151-158.

8. REFERENCES

- Hsieh L-L, Liou S-H, Chen Y-H, et al. 2000. Association between aminolevulinic acid dehydratase genotype and blood lead levels in Taiwan. *J Occup Environ Med* 42(2):151-155.
- Hsieh TJ, Chen YC, Li CW, et al. 2009. A proton magnetic resonance spectroscopy study of the chronic lead effect on the basal ganglion and frontal and occipital lobes in middle-age adults. *Environ Health Perspect* 117(6):941-945. 10.1289/ehp.0800187.
- Hu X, Ding Z. 2009. Lead/cadmium contamination and lead isotopic ratios in vegetables grown in peri-urban and mining/smelting contaminated sites in Nanjing, China. *Bull Environ Contam Toxicol* 82(1):80-84. 10.1007/s00128-008-9562-y.
- Hu H, Aro A, Payton M, et al. 1996a. The relationship of bone and blood lead to hypertension. The Normative Aging Study. *J Am Med Assoc* 275(15):1171-1176.
- Hu H, Hashimoto D, Besser M. 1996b. Levels of lead in blood and bone of women giving birth in a Boston hospital. *Arch Environ Health* 51(1):52-58.
- Hu H, Shih R, Rothenberg S, et al. 2007. The epidemiology of lead toxicity in adults: Measuring dose and consideration of other methodologic issues. *Environ Health Perspect* 115(3):455-462. 10.1289/ehp.9783.
- Hu H, Tellez-Rojo MM, Bellinger D, et al. 2006. Fetal lead exposure at each stage of pregnancy as a predictor of infant mental development. *Environ Health Perspect* 114(11):1730-1735. 10.1289/ehp.9067.
- Hu H, Wu MT, Cheng Y, et al. 2001. The α -aminolevulinic acid dehydratase (ALAD) polymorphism and bone and blood lead levels in community-exposed men: The Normative Aging Study. *Environ Health Perspect* 109:827-832.
- Hu J, Little J, Xu T, et al. 1999. Risk factors for meningioma in adults: A case-control study in northeast China. *Int J Cancer* 83:299-304.
- Huang J, Wu J, Li T, et al. 2011. Effect of exposure to trace elements in the soil on the prevalence of neural tube defects in a high-risk area of China. *Biomed Environ Sci* 24(2):94-101. 10.3967/0895-3988.2011.02.002.
- Huang WH, Lin JL, Lin-Tan DT, et al. 2013. Environmental lead exposure accelerates progressive diabetic nephropathy in type II diabetic patients. *BioMed Res Int* 2013:742545. 10.1155/2013/742545.
- Huang XP, Feng ZY, Zhai WL, et al. 1988. Chromosomal aberrations and sister chromatid exchanges in workers exposed to lead. *Biomed Environ Sci* 1:382-387.
- HUD. 2011. American Health Homes Survey. Lead and arsenic findings.
- HUD. 2017. Revised dust-lead action levels for risk assessment and clearance; clearance of porch floors. Washington, DC: U.S. Department of Housing and Urban Development. <https://portal.hud.gov/hudportal/documents/huddoc?id=leaddustclearance.pdf>. August 25, 2017.
- Huel G, Sahuquillo J, Debotte G, et al. 2008. Hair mercury negatively correlates with calcium pump activity in human term newborns and their mothers at delivery. *Environ Health Perspect* 116(2):263-267. 10.1289/ehp.10381.
- Hui CA. 2002. Lead distribution throughout soil, flora, and an invertebrate at a wetland skeet range. *J Toxicol Environ Health Part A* 65:1093-1107. 10.1080/00984100290071289.
- Hunt A, Johnson DL, Thornton I, et al. 1993. Apportioning the sources of lead in house dusts in the London borough of Richmond, England. *Sci Total Environ* 138(1-3):183-206.
- Huo X, Peng L, Qiu B, et al. 2014. ALAD genotypes and blood lead levels of neonates and children from e-waste exposure in Guiyu, China. *Environ Sci Pollut Res Int* 21(10):6744-6750. 10.1007/s11356-014-2596-2.
- Hursh J, Mercer T. 1970. Measurement of ^{212}Pb loss rate from human lungs. *J Appl Physiol* 28(3):268-274.
- Hursh JB, Suomela J. 1968. Absorption of ^{212}Pb from the gastrointestinal tract of man. *Acta Radiol* 7(2):108-120.
- Hursh JB, Clarkson TW, Miles EF, et al. 1989. Percutaneous absorption of mercury vapor by man. *Arch Environ Health* 44(2):120-127.

8. REFERENCES

- Hursh JB, Schraub A, Sattler EL, et al. 1969. Fate of ^{212}Pb inhaled by human subjects. *Health Phys* 16:257-267.
- Hwang YH, Chiang HY, Yen-Jean MC, et al. 2009. The association between low levels of lead in blood and occupational noise-induced hearing loss in steel workers. *Sci Total Environ* 408(1):43-49. 10.1016/j.scitotenv.2009.09.016.
- Hytten F. 1985. Blood volume changes in normal pregnancy. *Clin Haematol* 14(3):601-612.
- IARC. 1987. Lead and lead compounds. IARC Monographs on the evaluation of carcinogenic risks to humans. Supplement 7. Overall evaluations of carcinogenicity: An updating of IARC monographs. Volumes 1 to 42. Lyon, France: International Agency for Research on Cancer. <http://monographs.iarc.fr/ENG/Monographs/suppl7/Suppl7-95.pdf>. May 4, 2017.
- IARC. 2006. IARC Monographs on the evaluation of carcinogenic risks to humans. Volume 87. Inorganic and organic lead compounds. Lyon, France: International Agency for Research on Cancer. <http://monographs.iarc.fr/ENG/Monographs/vol87/mono87.pdf>. May 4, 2017.
- IARC. 2017. Agents classified by the IARC Monographs, Volumes 1–118. Lyon, France: International Agency for Research on Cancer. http://monographs.iarc.fr/ENG/Classification/List_of_Classifications.pdf. May 3, 2017.
- ICRP. 1994. Human respiratory tract model for radiological protection. International Commission on Radiological Protection. 36-53; 72-77; Annex F 415-432.
- Ignasiak Z, Slawinska T, Rozek K, et al. 2006. Lead and growth status of schoolchildren living in the copper basin of south-western Poland: Differential effects on bone growth. *Ann Hum Biol* 33(4):401-414. 10.1080/03014460600730752.
- Iijima K, Otake T, Yoshinaga J, et al. 2007. Cadmium, lead, and selenium in cord blood and thyroid hormone status of newborns. *Biol Trace Elem Res* 119(1):10-18. 10.1007/s12011-007-0057-1.
- Inskip MJ, Franklin CA, Baccanale CL, et al. 1996. Measurement of the flux of lead from bone to blood in a nonhuman primate (*Macaca fascicularis*) by sequential administration of stable lead isotopes. *Fundam Appl Toxicol* 33:235-245.
- Ionescu JG, Novotny J, Stejskal V, et al. 2007. Breast tumours strongly accumulate transition metals. *Maedica* 2(1):5-9.
- Irgens A, Kruger K, Skorve AH, et al. 1998. Reproductive outcome in offspring of parents occupationally exposed to lead in Norway. *Am J Ind Med* 34(5):431-437.
- IRIS. 2002. Tetraethyl lead; CASRN 78-00-2. Integrated Risk Information System. Washington, DC: U.S. Environmental Protection Agency. https://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/0109_summary.pdf. May 4, 2017.
- IRIS. 2004. Lead and compounds (inorganic); CASRN 7439-92-1. Integrated Risk Information System. Washington, DC: U.S. Environmental Protection Agency. https://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/0277_summary.pdf. May 4, 2017.
- Irvine G, Doyle JR, White PA, et al. 2014. Soil ingestion rate determination in a rural population of Alberta, Canada practicing a wilderness lifestyle. *Sci Total Environ* 470-471:138-146. 10.1016/j.scitotenv.2013.09.037.
- Iwata T, Yano E, Karita K, et al. 2005. Critical dose of lead affecting postural balance in workers. *Am J Ind Med* 48(5):319-325. 10.1002/ajim.20220.
- Jackson LW, Cromer BA, Panneerselvamm A. 2010. Association between bone turnover, micronutrient intake, and blood lead levels in pre- and postmenopausal women, NHANES 1999-2002. *Environ Health Perspect* 118(11):1590-1596.
- Jackson LW, Howards PP, Wactawski-Wende J, et al. 2011. The association between cadmium, lead and mercury blood levels and reproductive hormones among healthy, premenopausal women. *Hum Reprod* 26(10):2887-2895. 10.1093/humrep/der250.
- Jacobs DE. 2012. Lead. In: *Patty's toxicology*. 10.1002/0471435139.tox034.pub2.
- Jaeger RJ, Weiss AL, Manton WI. 1998. Isotopic ratio analysis in residential lead-based paint and associated surficial dust. *J Toxicol Clin Toxicol* 36(7):691-703.

8. REFERENCES

- Jaffe EK, Martins J, Li J, et al. 2001. The molecular mechanism of lead inhibition of human porphobilinogen synthase. *J Biol Chem* 276(2):1531-1537. 10.1074/jbc.M007663200.
- Jaffe EK, Volin M, Bronson-Mullins CR, et al. 2000. An artificial gene for human porphobilinogen synthase allows comparison of an allelic variation implicated in susceptibility to lead poisoning. *J Biol Chem* 275(4):2619-2626.
- Jain RB. 2013a. Effect of pregnancy on the levels of blood cadmium, lead, and mercury for females aged 17-39 years old: Data from National Health and Nutrition Examination Survey 2003-2010. *J Toxicol Environ Health A* 76(1):58-69. 10.1080/15287394.2012.722524.
- Jain RB. 2013b. Effect of pregnancy on the levels of urinary metals for females aged 17-39 years old: Data from National Health and Nutrition Examination Survey 2003-2010. *J Toxicol Environ Health Part A* 76(2):86-97.
- Jain NB, Potula V, Schwartz J, et al. 2007. Lead levels and ischemic heart disease in a prospective study of middle-aged and elderly men: The VA Normative Aging Study. *Environ Health Perspect* 115(6):871-875. 10.1289/ehp.9629.
- James AC, Stahlhofen W, Rudolf G, et al. 1994. Deposition of inhaled particles. *Ann ICRP* 24(1-3):231-299.
- James HM, Hilburn ME, Blair JA. 1985. Effects of meals and meal times on uptake of lead from the gastrointestinal tract in humans. *Hum Toxicol* 4:401-407.
- Janakiraman V, Ettinger A, Mercado-Garcia A, et al. 2003. Calcium supplements and bone resorption in pregnancy: A randomized crossover trial. *Am J Prev Med* 24(3):260-264.
- Janin Y, Couinaud C, Stone A, et al. 1985. The "lead-induced colic" syndrome in lead intoxication. *Surg Annu* 17:287-307.
- Jannuzzi AT, Alpertunga B. 2016. Evaluation of DNA damage and DNA repair capacity in occupationally lead-exposed workers. *Toxicol Ind Health* 32(11):1859-1865. 10.1177/0748233715590919.
- Jasso-Pineda Y, Diaz-Barriga F, Calderon J, et al. 2012. DNA damage and decreased DNA repair in individuals exposed to arsenic and lead in a mining site. *Biol Trace Elem Res* 146(2):141-149.
- Jedrychowski W, Perera F, Maugeri U, et al. 2011. Intrauterine exposure to lead may enhance sensitization to common inhalant allergens in early childhood: A prospective prebirth cohort study. *Environ Res* 111(1):119-124. 10.1016/j.envres.2010.11.002.
- Jedrychowski W, Perera FP, Jankowski J, et al. 2009. Very low prenatal exposure to lead and mental development of children in infancy and early childhood: Krakow prospective cohort study. *Neuroepidemiology* 32(4):270-278. 10.1159/000203075.
- Jelliffe-Pawlowski LL, Miles SQ, Courtney JG, et al. 2006. Effect of magnitude and timing of maternal pregnancy blood lead (Pb) levels on birth outcomes. *J Perinatol* 26(3):154-162.
- Jemal A, Graubard BI, Devesa SS, et al. 2002. The association of blood lead level and cancer mortality among whites in the United States. *Environ Health Perspect* 110(4):325-329.
- Jhun MA, Hu H, Schwartz J, et al. 2015. Effect modification by vitamin D receptor genetic polymorphisms in the association between cumulative lead exposure and pulse pressure: A longitudinal study. *Environ Health* 14:5. 10.1186/1476-069x-14-5.
- Ji JS, Elbaz A, Weisskopf MG. 2013. Association between blood lead and walking speed in the National Health and Nutrition Examination Survey (NHANES 1999-2002). *Environ Health Perspect* 121(6):711-716. 10.1289/ehp.1205918.
- Ji JS, Power MC, Sparrow D, et al. 2015. Lead exposure and tremor among older men: The VA Normative Aging Study. *Environ Health Perspect* 123(5):445-450. 10.1289/ehp.1408535.
- Ji JS, Schwartz J, Sparrow D, et al. 2014. Occupational determinants of cumulative lead exposure: Analysis of bone lead among men in the VA Normative Aging Study. *J Occup Environ Med* 56(4):435-440. 10.1097/jom.000000000000127.
- Jiang YM, Long LL, Zhu XY, et al. 2008. Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: A study by magnetic resonance imaging and 1H magnetic resonance spectroscopy. *Toxicol Lett* 181(2):118-125. 10.1016/j.toxlet.2008.07.009.

8. REFERENCES

- Jin C, Li Y, Li YL, et al. 2008. Blood lead: Its effect on trace element levels and iron structure in hemoglobin. *Nucl Instrum Methods Phys Res B*: 266(16):3607-3613. 10.1016/j.nimb.2008.05.087.
- Jin CW, Zhang SJ, He YF, et al. 2005. Lead contamination in tea garden soils and factors affecting its bioavailability. *Chemosphere* 59:1151-1159. 10.1016/j.chemosphere.2004.11.058.
- Jin YP, Liao YJ, Lu CW, et al. 2006. Health effects in children aged 3-6 years induced by environmental lead exposure. *Ecotoxicol Environ Saf* 63(2):313-317. 10.1016/j.ecoenv.2005.05.011.
- Johansen P, Pedersen HS, Asmund G, et al. 2006. Lead shot from hunting as a source of lead in human blood. *Environ Pollut* 142:93-97.
- Johnson DL, Bretsch JK. 2002. Soil lead and children's blood lead levels in Syracuse, NY, USA. *Environ Geochem Health* 24:375-385.
- Johnson DL, McDade K, Griffith D. 1996. Seasonal variation in paediatric blood lead levels in Syracuse, NY, USA. *Environ Geochem Health* 18(2):81-88. 10.1007/bf01771136.
- Jones SR, Atkin P, Holroyd C, et al. 2007. Lung cancer mortality at a UK tin smelter. *Occup Med* 57(4):238-245. 10.1093/occmed/kql153.
- Jørgensen SS, Willems M. 1987. The fate of lead in soils: The transformation of lead pellets in shooting-range soils. *Ambio*:11-15.
- Joseph CLM, Havstad S, Ownby DR, et al. 2005. Blood lead level and risk of asthma. *Environ Health Perspect* 113(7):900-904. 10.1289/ehp.7453.
- Juhasz AL, Scheckel KG, Betts AR, et al. 2016. Predictive capabilities of *in vitro* assays for estimating Pb relative bioavailability in phosphate amended soils. *Environ Sci Technol* 50(23):13086-13094. 10.1021/acs.est.6b04059.
- Juhasz AL, Weber J, Smith E, et al. 2009. Evaluation of SBRC-gastric and SBRC-intestinal methods for the prediction of *in vivo* relative lead bioavailability in contaminated soils. *Environ Sci Technol* 43(12):4503-4509. 10.1021/es803238u.
- Juhasz AL, Weber J, Smith E. 2011. Impact of soil particle size and bioaccessibility on children and adult lead exposure in peri-urban contaminated soil. *J Hazard Mater* 186(2-3):1870-1879. 10.1016/j.jhazmat.2010.12.095.
- Jusko TA, Henderson CR, Lanphear BP, et al. 2008. Blood lead concentrations < 10 microg/dL and child intelligence at 6 years of age. *Environ Health Perspect* 116(2):243-248. 10.1289/ehp.10424.
- Kahn LG, Liu X, Rajovic B, et al. 2014. Blood lead concentration and thyroid function during pregnancy: Results from the Yugoslavia Prospective Study of Environmental Lead Exposure. *Environ Health Perspect* 122(10):1134-1140. 10.1289/ehp.1307669.
- Kamel F, Umbach DM, Munsat TL, et al. 2002. Lead exposure and amyotrophic lateral sclerosis. *Epidemiology* 13:311-319.
- Kang HG, Jeong SH, Cho MR, et al. 2009. Time-dependent changes in lead and δ -aminolevulinic acid after subchronic lead exposure in rats. *Hum Exp Toxicol* 28(10):647-654. 10.1177/0960327109107046.
- Kapuku GK, Harshfield GA, Davis HC, et al. 2006. Early markers of cardiovascular disease. *Vascul Pharmacol* 45(5):277-280. 10.1016/j.vph.2006.08.009.
- Karimooy HN, Mood MB, Hosseini M, et al. 2010. Effects of occupational lead exposure on renal and nervous system of workers of traditional tile factories in Mashhad (northeast of Iran). *Toxicol Ind Health* 26(9):633-638. 10.1177/0748233710377774.
- Karita K, Yano E, Dakeishi M, et al. 2005. Benchmark dose of lead inducing anemia at the workplace. *Risk Anal* 25(4):957-962. 10.1111/j.1539-6924.2005.00652.x.
- Karmaus W, Brooks KR, Nebe T, et al. 2005. Immune function biomarkers in children exposed to lead and organochlorine compounds: A cross-sectional study. *Environ Health* 4(1):5. 10.1186/1476-069X-4-5.

8. REFERENCES

- Kasperczyk A, Dobrakowski M, Czuba ZP, et al. 2015. Environmental exposure to lead induces oxidative stress and modulates the function of the antioxidant defense system and the immune system in the semen of males with normal semen profile. *Toxicol Appl Pharmacol* 284(3):339-344. 10.1016/j.taap.2015.03.001.
- Kasperczyk A, Kasperczyk S, Horak S, et al. 2008. Assessment of semen function and lipid peroxidation among lead exposed men. *Toxicol Appl Pharmacol* 228(3):378-384. 10.1016/j.taap.2007.12.024.
- Kasperczyk S, Blaszczyk I, Dobrakowski M, et al. 2013. Exposure to lead affects male biothiols metabolism. *Ann Agric Environ Med* 20(4):721-725.
- Kasprzak KS, Hoover KL, Poirier LA. 1985. Effects of dietary calcium acetate on lead subacetate carcinogenicity in kidneys of male Sprague-Dawley rats. *Carcinogenesis* 6(2):279-282.
- Kasuba V, Rozgaj R, Milic M, et al. 2012. Evaluation of genotoxic effects of lead in pottery-glaze workers using micronucleus assay, alkaline comet assay and DNA diffusion assay. *Int Arch Occup Environ Health* 85(7):807-818. 10.1007/s00420-011-0726-4.
- Kauppinen T, Riala R, Seitsamo J, et al. 1992. Primary liver cancer and occupational exposure. *Scand J Work Environ Health* 18(1):18-25.
- Kayaalti Z, Kaya-Akyuzlu D, Soylemez E, et al. 2015b. Maternal hemochromatosis gene H63D single-nucleotide polymorphism and placental lead levels. *Environ Res* 140:456-461.
- Kayaalti Z, Sert S, Kaya-Akyuzlu D, et al. 2016. Association between δ -aminolevulinic acid dehydratase polymorphism and placental lead levels. *Environ Toxicol Pharmacol* 41:147-151. 10.1016/j.etap.2015.11.017.
- Kaye WE, Novotny TE, Tucker M. 1987. New ceramics-related industry implicated in elevated blood lead levels in children. *Arch Environ Health* 42(2):161-164.
- Kazi TG, Shah F, Shaikh HR, et al. 2014. Exposure of lead to mothers and their new born infants, residents of industrial and domestic areas of Pakistan. *Environ Sci Pollut Res Int* 21(4):3021-3030. 10.1007/s11356-013-2223-7.
- Kehoe RA. 1987. Studies of lead administration and elimination in adult volunteers under natural and experimentally induced condition over extended periods of time. *Food Chem Toxicol* 25(6):425-494.
- Kehoe RA, Thamann F. 1931. The behavior of lead in the animal organism, II. Tetraethyl lead. *Am J Hyg* 13:478-498.
- Kelly RS, Lundh T, Porta M, et al. 2013. Blood erythrocyte concentrations of cadmium and lead and the risk of B-cell non-Hodgkin's lymphoma and multiple myeloma: A nested case-control study. *PLoS ONE* 8(11):e81892. 10.1371/journal.pone.0081892.
- Kemp FW, Neti PVS, Howell RW, et al. 2007. Elevated blood lead concentrations and vitamin D deficiency in winter and summer in young urban children. *Environ Health Perspect* 115(4):630-635. 10.1289/ehp.9389.
- Kerper LE, Hinkle PM. 1997a. Lead uptake in brain capillary endothelial cells: Activation by calcium store depletion. *Toxicol Appl Pharmacol* 146(1):127-133.
- Kerper LE, Hinkle PM. 1997b. Cellular uptake of lead is activated by depletion of intracellular calcium stores. *J Biol Chem* 272(13):8346-8352.
- Khalil N, Cauley JA, Wilson JW, et al. 2008. Relationship of blood lead levels to incident nonspine fractures and falls in older women: The study of osteoporotic fractures. *J Bone Miner Res* 23(9):1417-1425. 10.1359/jbmr.080404.
- Khalil N, Wilson JW, Talbott EO, et al. 2009. Association of blood lead concentrations with mortality in older women: A prospective cohort study. *Environ* 8:15. 10.1186/1476-069x-8-15.
- Khan DA, Qayyum S, Saleem S, et al. 2008. Lead-induced oxidative stress adversely affects health of the occupational workers. *Toxicol Ind Health* 24(9):611-618. 10.1177/0748233708098127.
- Khan DA, Qayyum S, Saleem S, et al. 2010a. Lead exposure and its adverse health effects among occupational worker's children. *Toxicol Ind Health* 26(8):497. 10.1177/0748233710373085.

8. REFERENCES

- Khan DH, Frankland B. 1983. Chemical forms of cadmium and lead in some contaminated soils. *Environ Pollut* 6:15-31.
- Khan MI, Ahmad I, Mahdi AA, et al. 2010b. Elevated blood lead levels and cytogenetic markers in buccal epithelial cells of painters in India: Genotoxicity in painters exposed to lead containing paints. *Environ Sci Pollut Res Int* 17(7):1347-1354. 10.1007/s11356-010-0319-x.
- Kim Y, Lee BK. 2013. Association between blood lead and mercury levels and periodontitis in the Korean general population: Analysis of the 2008-2009 Korean National Health and Nutrition Examination Survey data. *Int Arch Occup Environ Health* 86(5):607-613. 10.1007/s00420-012-0796-y.
- Kim HS, Lee SS, Lee GS, et al. 2004. The protective effect of δ -aminolevulinic acid dehydratase 1-2 and 2-2 isozymes against blood lead with higher hematologic parameters. *Environ Health Perspect* 112:538-541.
- Kim JH, Lee KH, Yoo DH, et al. 2007. GSTM1 and TNF- α gene polymorphisms and relations between blood lead and inflammatory markers in a non-occupational population. *Mutat Res* 629(1):32-39. 10.1016/j.mrgentox.2007.01.004.
- Kim KN, Kwon HJ, Hong YC. 2016. Low-level lead exposure and autistic behaviors in school-age children. *Neurotoxicology* 53:193-200. 10.1016/j.neuro.2016.02.004.
- Kim MG, Ryoo JH, Chang SJ, et al. 2015. Blood Lead levels and cause-specific mortality of inorganic lead-exposed workers in South Korea. *PLoS ONE* 10(10):e0140360. 10.1371/journal.pone.0140360.
- Kim R, Hu H, Rotnitzky A, et al. 1995. A longitudinal study of chronic lead exposure and physical growth in Boston children. *Environ Health Perspect* 103(10):952-957.
- Kim R, Hu H, Rotnitzky A, et al. 1996b. Longitudinal relationship between dentin lead levels in childhood and bone lead levels in young adulthood. *Arch Environ Health* 51(5):375-382.
- Kim R, Landrigan C, Mossman P, et al. 1997. Age and secular trends in bone lead levels in middle-aged and elderly men: Three-year longitudinal follow-up in the Normative Aging Study. *Am J Epidemiol* 146(4):586-591.
- Kim R, Rotnitzky A, Sparrow D, et al. 1996a. A longitudinal study of low-level lead exposure and impairment of renal function: The Normative Aging Study. *J Am Med Assoc* 275(15):1177-1181.
- Kim S, Arora M, Fernandez C, et al. 2013a. Lead, mercury, and cadmium exposure and attention deficit hyperactivity disorder in children. *Environ Res* 126:105-110.
- Kim Y, Ha EH, Park H, et al. 2013b. Prenatal lead and cadmium co-exposure and infant neurodevelopment at 6 months of age: The Mothers and Children's Environmental Health (MOCEH) study. *Neurotoxicology* 35:15-22. 10.1016/j.neuro.2012.11.006.
- Kimber I, Stonard MD, Gidlow DA, et al. 1986. Influence of chronic low-level exposure to lead on plasma immunoglobulin concentration and cellular immune function in man. *Int Arch Occup Environ Health* 57:117-125.
- King M, Ramachandran V, Prengaman RD, et al. 2014. Lead and lead alloys. In: Kirk-Othmer encyclopedia of chemical technology. 10.1002/0471238961.1205010411091407.a01.pub3.
- Kirkby H, Gyntelberg F. 1985. Blood pressure and other cardiovascular risk factors of long-term exposure to lead. *Scand J Work Environ Health* 11:15-19.
- Klaassen C. 2001. Heavy metals and heavy metal antagonists. In: Hardman JG, Limbard LE, eds. Goodman and Gilman's the pharmacological basis of therapeutics. Tenth ed. McGraw-Hill Companies, Medical Publishing Division, 1851-1875.
- Klaassen CD, Shoeman DW. 1974. Biliary excretion of lead in rats, rabbits and dogs. *Toxicol Appl Pharmacol* 29:434-446.
- Koh DS, Koh GC. 2007. The use of salivary biomarkers in occupational and environmental medicine. *Occup Environ Med* 64:202-210. 10.1136/oem.2006.026567.
- Koller LD, Kerkvliet NI, Exon JH. 1985. Neoplasia induced in male rats fed lead acetate, ethyl urea, and sodium nitrite. *Toxicol Pathol* 13(1):50-57.

8. REFERENCES

- Kordas K, Ettinger AS, Bellinger DC, et al. 2011. A dopamine receptor (DRD2) but not dopamine transporter (DAT1) gene polymorphism is associated with neurocognitive development of Mexican preschool children with lead exposure. *J Pediatr* 159(4):638-643. 10.1016/j.jpeds.2011.03.043.
- Kordas K, Ettinger AS, Lamadrid-Figueroa H, et al. 2009. Methylene tetrahydrofolate reductase (MTHFR) C677T, A1298C and G1793A genotypes, and the relationship between maternal folate intake, tibia lead and infant size at birth. *Br J Nutr* 102(6):907-914. 10.1017/s0007114509318280.
- Kordas K, Queirolo EL, Ettinger AS, et al. 2010. Prevalence and predictors of exposure to multiple metals in preschool children from Montevideo, Uruguay. *Sci Total Environ* 408:4488-4494.
- Korrick SA, Hunter DJ, Rotnitzky A, et al. 1999. Lead and hypertension in a sample of middle-aged women. *Am J Public Health* 89(3):330-335.
- Korrick SA, Schwartz J, Tsaih SW, et al. 2002. Correlates of bone and blood lead levels among middle-aged and elderly women. *Am J Epidemiol* 156(4):335-343.
- Kosnett MJ. 2001. Lead. In: Ford M, Delaney KA, Ling L, et al., eds. *Clinical toxicology*. St. Louis, MO: WB Saunders, 723-736.
- Kosnett MJ. 2004. Lead. In: *Poisoning and drug overdose*. Fourth ed. New York, NY: McGraw-Hill, 238-242.
- Kosnett MJ. 2005. Lead. In: Brent J, Wallace KL, Burkhart KK, et al., eds. *Critical care toxicology*. Philadelphia, PA: Elsevier Mosby, 821-836.
- Kosnett MJ, Becker CE, Osterloh JD, et al. 1994. Factors influencing bone lead concentration in a suburban community assessed by noninvasive K X-ray fluorescence. *J Am Med Assoc* 271(3):197-203.
- Kosnett MJ, Wedeen RP, Rothenberg SJ, et al. 2007. Recommendations for medical management of adult lead exposure. *Environ Health Perspect* 115(3):463-471. <http://doi.org/10.1289/ehp.9784>. <http://dx.doi.org/10.1289/ehp.9784>.
- Kostial K, Kello D, Jugo S, et al. 1978. Influence of age on metal metabolism and toxicity. *Environ Health Perspect* 25:81-86.
- Koyashiki GAK, Paoliello MMB, Matsuo T, et al. 2010. Lead levels in milk and blood from donors to the breast milk bank in southern Brazil. *Environ Res* 110:265-271.
- Kresovich JK, Argos M, Turyk ME. 2015. Associations of lead and cadmium with sex hormones in adult males. *Environ Res* 142:25-33. 10.1016/j.envres.2015.05.026.
- Krieg EF, Jr. 2007. The relationships between blood lead levels and serum follicle stimulating hormone and luteinizing hormone in the Third National Health and Nutrition Examination Survey. *Environ Res* 104(3):374-382. 10.1016/j.envres.2006.09.009.
- Krieg EF, Jr., Butler MA, Chang MH, et al. 2009. Lead and cognitive function in ALAD genotypes in the Third National Health and Nutrition Examination Survey. *Neurotoxicol Teratol* 31(6):364-371. 10.1016/j.ntt.2009.08.003.
- Krieg EF, Jr., Butler MA, Chang MH, et al. 2010. Lead and cognitive function in VDR genotypes in the Third National Health and Nutrition Examination Survey. *Neurotoxicol Teratol* 32(2):262-272. 10.1016/j.ntt.2009.12.004.
- Krieg EF, Jr., Chrislip DW, Crespo CJ, et al. 2005. The relationship between blood lead levels and neurobehavioral test performance in NHANES III and related occupational studies. *Public Health Rep* 120(3):240-251.
- Krishnan K, Anderson ME, Clewell HJ, et al. 1994. Physiologically based pharmacokinetic modeling of chemical mixtures. In: Yang RSH, ed. *Toxicology of chemical mixtures. Case studies, mechanisms, and novel approaches*. San Diego, CA: Academic Press, 399-437.
- Kristal-Boneh E, Collier D, Froom P, et al. 1999. The association between occupational lead exposure and serum cholesterol and lipoprotein levels. *Am J Public Health* 89(7):1083-1087.
- Kromhout D. 1988. Blood lead and coronary heart disease risk among elderly men in Zutphen, The Netherlands. *Environ Health Perspect* 78:43-46.
- Kromhout D, Wibowo A, Herber R, et al. 1985. Trace metals and coronary heart disease risk indicators in 152 elderly men (the Zutphen Study). *Am J Epidemiol* 122(3):378-385.

8. REFERENCES

- Krueger WS, Wade TJ. 2016. Elevated blood lead and cadmium levels associated with chronic infections among non-smokers in a cross-sectional analysis of NHANES data. *Environ Health* 15(1):16. 10.1186/s12940-016-0113-4.
- Kumar BD, Krishnaswamy K. 1995. Detection of occupational lead nephropathy using early renal markers. *J Toxicol Clin Toxicol* 33(4):331-335.
- Kuruvilla A, Pillay VV, Adhikari P, et al. 2006. Clinical manifestations of lead workers of Mangalore, India. *Toxicol Ind Health* 22(9):405-413.
- Lagerkvist BJ, Ekesrydh S, Englyst V, et al. 1996. Increased blood lead and decreased calcium levels during pregnancy: A prospective study of Swedish women living near a smelter. *Am J Public Health* 86(9):1247-1252.
- LaGoy PK. 1987. Estimated soil ingestion rates for use in risk assessment. *Risk Anal* 7(3):355-359.
- Laidlaw MAS, Filippelli GM. 2008. Resuspension of urban soils as a persistent source of lead poisoning in children: A review and new directions. *Appl Geochem* 23(8):2021-2039. 10.1016/j.apgeochem.2008.05.009.
- Laidlaw MAS, Mielke HW, Filippelli GM, et al. 2005. Seasonality and children's blood lead levels: Developing a predictive model using climatic variables and blood lead data from Indianapolis, Indiana, Syracuse, New York, and New Orleans, Louisiana (USA). *Environ Health Perspect* 113(6):793-800.
- Laidlaw MAS, Zahran S, Mielke HW, et al. 2012. Re-suspension of lead contaminated urban soil as a dominant source of atmospheric lead in Birmingham, Chicago, Detroit and Pittsburgh, USA. *Atmos Environ* 49:302-310. 10.1016/j.atmosenv.2011.11.030.
- Lamadrid-Figueroa H, Téllez-Rojo MM, Hernández-Cadena L, et al. 2006. Biological markers of fetal lead exposure at each stage of pregnancy. *J Toxicol Environ Health* 69(19):1781-1796. 10.1080/15287390600630195.
- Lamadrid-Figueroa H, Téllez-Rojo MM, Hernández-Avila M, et al. 2007. Association between the plasma/whole blood lead ratio and history of spontaneous abortion: A nested cross-sectional study. *BMC Pregnancy and Childbirth* 7:22. 10.1186/1471-2393-7-22.
- Lamb MR, Janevic T, Liu X, et al. 2008. Environmental lead exposure, maternal thyroid function, and childhood growth. *Environ Res* 106(2):195-202. 10.1016/j.envres.2007.09.012.
- Lancranjan I, Popescu HI, Gavanescu O, et al. 1975. Reproductive ability of workmen occupationally exposed to lead. *Arch Environ Health* 30:396-401.
- Landrigan PJ. 1989. Toxicity of lead at low dose - Editorial. *Br J Ind Med* 46:593-596.
- Landrigan PJ, Baker EL, Feldman RG, et al. 1976. Increased lead absorption with anemia and slowed nerve conduction in children near a lead smelter. *J Pediatr* 89(6; 6):904-910.
- Langlois P, Smith L, Fleming S, et al. 1996. Blood lead levels in Toronto children and abatement of lead-contaminated soil and house dust. *Arch Environ Health* 51(1):59-67.
- Lanphear BP, Roghmann KJ. 1997. Pathways of lead exposure in urban children. *Environ Res* 74:67-73.
- Lanphear BP, Burgoon DA, Rust SW, et al. 1998a. Environmental exposures to lead and urban children's blood lead levels. *Environ Res Section A* 76:120-130.
- Lanphear BP, Byrd RS, Auinger P, et al. 1998b. Community characteristics associated with elevated blood lead levels in children. *Pediatrics* 101(2):264-271.
- Lanphear BP, Dietrich K, Auinger P, et al. 2000a. Cognitive deficits associated with blood lead concentrations <10 microg/dL in US children and adolescents. *Public Health Rep* 115(6):521-529.
- Lanphear BP, Eberly S, Howard CR. 2000b. Long-term effect of dust control on blood lead concentrations. *Pediatrics* 106(4):1-4.
- Lanphear BP, Hornung R, Khoury J, et al. 2005. Low-level environmental lead exposure and children's intellectual function: An international pooled analysis. *Environ Health Perspect* 113(7):894-899.
- Lanphear BP, Rauch S, Auinger P, et al. 2018. Low-level lead exposure and mortality in US adults: A population-based cohort study. *Lancet Public Health* 3(4):e177-e184. [http://doi.org/10.1016/S2468-2667\(18\)30025-2](http://doi.org/10.1016/S2468-2667(18)30025-2). February 6, 2019.

8. REFERENCES

- Lanphear BP, Weitzman M, Eberly S. 1996a. Racial differences in urban children's environmental exposures to lead. *Am J Public Health* 86:1460-1463.
- Lanphear BP, Weitzman M, Winter NL, et al. 1996b. Lead-contaminated house dust and urban children's blood lead levels. *Am J Public Health* 86:1416-1421.
- Larranaga MD, Lewis RJ, Sr., Lewis RA, eds. 2016. Lead and lead compounds. In: *Hawley's condensed chemical dictionary*. Sixteenth ed. Hoboken, NJ: John Wiley & Sons, Inc., 817-824.
- Lasley SM, Gilbert ME. 2000. Glutamatergic components underlying lead-induced impairments in hippocampal synaptic plasticity. *Neurotoxicology* 21(6):1057-1068.
- Laug EP, Kunze FM. 1948. The penetration of lead through the skin. *J Ind Hyg Toxicol* 30(4; 4):256-259.
- Lauwerys R, Buchet JP, Roels H, et al. 1978. Placental transfer of lead, mercury, cadmium, and carbon monoxide in women. I. Comparison of the frequency distributions of the biological indices in maternal and umbilical cord blood. *Environ Res* 15:278-289.
- Lee B-K, Lee G-S, Stewart WF, et al. 2001. Associations of blood pressure and hypertension with lead dose measures and polymorphisms in the vitamin D receptor and δ -aminolevulinic acid dehydratase genes. *Environ Health Perspect* 109(4):383-389.
- Lee TH, Tseng MC, Chen CJ, et al. 2009. Association of high body lead store with severe intracranial carotid atherosclerosis. *Neurotoxicology* 30(6):876-880. 10.1016/j.neuro.2009.07.004.
- Legare ME, Barhoumi R, Hebert E, et al. 1998. Analysis of Pb+2 entry into cultured astroglia. *Toxicol Sci* 46:90-100.
- Leggett RW. 1993. An age-specific kinetic model of lead metabolism in humans. *Environ Health Perspect* 101(7):598-616.
- Leikin JB, Paloucek FP. 2008. Lead. In: *Poisoning and toxicology handbook*. Fourth ed. Boca Raton, FL: CRC Press, 807-811.
- Lerda D. 1992. Study of sperm characteristics in persons occupationally exposed to lead. *Am J Ind Med* 22:567-571.
- Levesque B, Duchesne JF, Garipey C, et al. 2003. Monitoring of umbilical cord blood lead levels and sources assessment among the Inuit. *Occup Environ Med* 60(9):693-695.
- Levey AS, Bosch JP, Lewis JB, et al. 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. *Ann Intern Med* 130(6):461-479.
- Levey AS, Stevens LA, Schmid CH, et al. 2009. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 150:604-612.
- Lewin MD, Sarasua S, Jones PA. 1999. A multivariate linear regression model for predicting children's blood lead levels based on soil lead levels: A study at four Superfund sites. *Environ Res* 81(Section A):52-61.
- Lewis RJ, Sr. 2012. Lead and lead compounds. In: *Sax's dangerous properties of industrial materials*. Vol. 4. Twelfth ed. John Wiley & Sons, Inc., 2711-2725.
- Lewis RC, Meeker JD. 2015. Biomarkers of exposure to molybdenum and other metals in relations to testosterone among men from the United States National Health and Nutrition Examination Survey 2011-2012. *Fertil Steril* 103:172-178.
- Lewis J, Sjoström J, Skyllberg U, et al. 2010. Distribution, chemical speciation, and mobility of lead and antimony originating from small arms ammunition in a coarse-grained unsaturated surface sand. *J Environ Qual* 39:863-870.
- Li CJ, Yeh CY, Chen RY, et al. 2015. Biomonitoring of blood heavy metals and reproductive hormone level related to low semen quality. *J Hazard Mater* 300:815-822. 10.1016/j.hazmat.2015.08.027.
- Li W, Han S, Gregg TR, et al. 2003. Lead exposure potentiates predatory attack behavior in the cat. *Environ Res* 92(3):197-206.
- Li Y, Hu J, Wu W, et al. 2016. Application of IEUBK model in lead risk assessment of children aged 61-84 months old in central China. *Sci Total Environ* 541:673-682. 10.1016/j.scitotenv.2015.09.103.

8. REFERENCES

- Liebelt EL, Schonfeld DJ, Gallagher P. 1999. Elevated blood lead levels in children are associated with lower erythropoietin concentrations. *J Pediatr* 134:107-109.
- Lilis R, Eisinger J, Blumberg W, et al. 1978. Hemoglobin, serum iron, and zinc protoporphyrin in lead-exposed workers. *Environ Health Perspect* 25:97-102.
- Lilis R, Fischbein A, Valciukas JA, et al. 1980. Kidney function and lead: Relationships in several occupational groups with different levels of exposure. *Am J Ind Med* 1(3-4):405-412.
- Lilis R, Gavrilescu N, Nestorescu B, et al. 1968. Nephropathy in chronic lead poisoning. *Br J Ind Med* 25:196-202.
- Lilley SG, Florence TM, Stauber JL. 1988. The use of sweat to monitor lead absorption through the skin. *Sci Total Environ* 76:267-278.
- Lin TA, Tai-Yi J. 2007. Benchmark dose approach for renal dysfunction in workers exposed to lead. *Environ Toxicol* 22(3):229-233. 10.1002/tox.20260.
- Lin CC, Chen YC, Su FC, et al. 2013. *In utero* exposure to environmental lead and manganese and neurodevelopment at 2 years of age. *Environ Res* 123:52-57. 10.1016/j.envres.2013.03.003.
- Lin CG, Schaidler LA, Brabander DJ, et al. 2010. Pediatric lead exposure from imported Indian spice and cultural powders. *Pediatrics* 125(4):e828-e835. <http://doi.org/10.1542/peds.2009-1396>.
- Lin CN, Wang LH, Shen KH. 2009. Determining urinary trace elements (Cu, Zn, Pb, As, and Se) in patients with bladder cancer. *J Clin Lab Anal* 23(3):192-195. 10.1002/jcla.20318.
- Lin JL, Lin-Tan DT, Hsu KH, et al. 2003. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. *N Engl J Med* 348(4):277-286.
- Lin JL, Lin-Tan DT, Li YJ, et al. 2006a. Low-level environmental exposure to lead and progressive chronic kidney diseases. *Am J Med* 119(8):1-9. 10.1016/j.amjmed.2006.01.005.
- Lin JL, Lin-Tan DT, Yu CC, et al. 2006b. Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes. *Kidney Int* 69(11):2049-2056.
- Lin JL, Tan DT, Hsu KH, et al. 2001. Environmental lead exposure and progressive renal insufficiency. *Arch Intern Med* 161:264-271.
- Lin Z, Comet B, Qvarfort U, et al. 1995. The chemical and mineralogical behaviour of Pb in shooting range soils from central Sweden. *Environ Pollut* 89(3):303-309.
- Lin-Tan DT, Lin JL, Yen TH, et al. 2007. Long-term outcome of repeated lead chelation therapy in progressive non-diabetic chronic kidney diseases. *Nephrol Dial Transplant* 22(10):2924-2931. 10.1093/ndt/gfm342.
- Little BB, Spalding S, Walsh B, et al. 2009. Blood lead levels and growth status among African-American and Hispanic children in Dallas, Texas-1980 and 2002: Dallas Lead Project II. *Ann Hum Biol* 36(3):331-341. 10.1080/03014460902806615.
- Liu C, Huo X, Lin P, et al. 2015a. Association between blood erythrocyte lead concentrations and hemoglobin levels in preschool children. *Environ Sci Pollut Res Int* 22(12):9233-9240. 10.1007/s11356-014-3992-3.
- Liu J, Chen Y, Gao D, et al. 2014b. Prenatal and postnatal lead exposure and cognitive development of infants followed over the first three years of life: A prospective birth study in the Pearl River Delta region, China. *Neurotoxicology* 44:326-334. 10.1016/j.neuro.2014.07.001.
- Liu J, Gao D, Chen Y, et al. 2014a. Lead exposure at each stage of pregnancy and neurobehavioral development of neonates. *Neurotoxicology* 44:1-7. 10.1016/j.neuro.2014.03.003.
- Liu J, Liu X, Pak V, et al. 2015b. Early blood lead levels and sleep disturbance in preadolescence. *Sleep* 38(12):1869-1874. 10.5665/sleep.5230.
- Liu J, Xu X, Wu K, et al. 2011. Association between lead exposure from electronic waste recycling and child temperament alterations. *Neurotoxicology* 32(4):458-464. 10.1016/j.neuro.2011.03.012.
- Liu R, Gress J, Gao J, et al. 2013. Impacts of two best management practices on Pb weathering and leachability in shooting range soils. *Environ Monit Assess* 185:6477-6484. 10.1007/s10661-012-3039-5.
- Lloyd RD, Mays CW, Atherton DR, et al. 1975. ²¹⁰Pb studies in beagles. *Health Phys* 28:575-583.

8. REFERENCES

- Lockett CJ, Arbuckle D. 1987. Lead, ferritin, zinc, and hypertension. *Bull Environ Contam Toxicol* 38:975-980.
- Loghman-Adham M. 1997. Renal effects of environmental and occupational lead exposure. *Environ Health Perspect* 105(9):928-939.
- Long DT, Angino EE. 1977. Chemical speciation of Cd, Cu, Pb, and Zn in mixed freshwater, seawater, and brine solutions. *Geochim Cosmochim Acta* 41:1183-1191.
- Lopez CM, Pineiro AE, Nunez N, et al. 2000. Thyroid hormone changes in males exposed to lead in the Buenos Aires area (Argentina). *Pharmacol Res Commun* 42(6):599-602.
- Lu Y, Yin W, Huang L, et al. 2011. Assessment of bioaccessibility and exposure risk of arsenic and lead in urban soils of Guangzhou City, China. *Environ Geochem Health* 33(2):93-102. 10.1007/s10653-010-9324-8.
- Lucas JP, Bellanger L, Le Strat Y, et al. 2014. Source contributions of lead in residential floor dust and within-home variability of dust lead loading. *Sci Total Environ* 470-471:768-779. 10.1016/j.scitotenv.2013.10.028.
- Lucchini R, Albini E, Cortesi I, et al. 2000. Assessment of neurobehavioral performance as a function of current and cumulative occupational lead exposure. *Neurotoxicology* 21(5):805-812.
- Lundstrom NG, Englyst V, Gerhardsson L, et al. 2006. Lung cancer development in primary smelter workers: A nested case-referent study. *J Occup Environ Med* 48(4):376-380. 10.1097/01.jom.0000201556.95982.95.
- Lundstrom NG, Nordberg G, Englyst V, et al. 1997. Cumulative lead exposure in relation to mortality and lung cancer morbidity in a cohort of primary smelter workers. *Scand J Work Environ Health* 23:24-30.
- Luo J, Hendryx M. 2014. Relationship between blood cadmium, lead, and serum thyroid measures in US adults - the National Health and Nutrition Examination Survey (NHANES) 2007-2010. *Int J Environ Health Res* 24(2):125-136. 10.1080/09603123.2013.800962.
- Lustberg M, Silbergeld E. 2002. Blood lead levels and mortality. *Arch Intern Med* 162(21):2443-2449.
- Lutz PM, Wilson TJ, Ireland J, et al. 1999. Elevated immunoglobulin E (IgE) levels in children with exposure to environmental lead. *Toxicology* 134(1):63-78. 10.1016/S0300-483X(99)00036-0.
- Lyngbye T, Jorgensen J, Grandjean P, et al. 1990. Validity and interpretation of blood lead levels: A study on Danish school children. *Scand J Clin Lab Invest* 50:441-449.
- Maas RP, Patch SC, Pandolfo TJ, et al. 2005. Lead content and exposure from children's and adult's jewelry products. *Bull Environ Contam Toxicol* 74:437-444.
- Machida M, Sun SJ, Oguma E, et al. 2009. High bone matrix turnover predicts blood levels of lead among perimenopausal women. *Environ Res* 109(7):880-886. 10.1016/j.envres.2009.06.005.
- MacMillan JW, Behinaein S, Chettle DR, et al. 2015. Physiologically based modeling of lead kinetics: A pilot study using data from a Canadian population. *Environ Sci Process Impacts* 17(12):2122-2133. 10.1039/c5em00517e.
- Maddaloni M, Ballew M, Diamond G, et al. 2005. Assessing lead risks at non-residential hazardous waste sites. *Hum Ecol Risk Assess* 11:967-1003.
- Maddaloni M, Lolocono N, Manton W, et al. 1998. Bioavailability of soilborne lead in adults, by stable isotope dilution. *Environ Health Perspect* 106(Suppl 6):1589-1594.
- Maenhaut W, Zoller WH, Duce RA, et al. 1979. Concentration and size distribution of particulate trace elements in the south polar atmosphere. *J Geophys Res* 84(C5):2421-2431.
- Magzamen S, Amato MS, Imm P, et al. 2015. Quantile regression in environmental health: Early life lead exposure and end-of-grade exams. *Environ Res* 137:108-119. 10.1016/j.envres.2014.12.004.
- Magzamen S, Imm P, Amato MS, et al. 2013. Moderate lead exposure and elementary school end-of-grade examination performance. *Ann Epidemiol* 23(11):700-707. 10.1016/j.annepidem.2013.08.007.
- Mahaffey KR, Annett JL. 1986. Association of erythrocyte protoporphyrin with blood lead level and iron status in the second National Health and Nutrition Examination Survey, 1976-1980. *Environ Res* 41(1):327-338.

8. REFERENCES

- Mahaffey KR, Gartside PS, Glueck CJ. 1986. Blood lead levels and dietary calcium intake in 1-to 11-year-old children: The Second National Health and Nutrition Examination Survey, 1976 to 1980. *Pediatrics* 78(2):257-262.
- Mahaffey KR, Rosen JF, Chesney RW, et al. 1982. Association between age, blood lead concentration, and serum 1,25-dihydroxycholecalciferol levels in children. *Am J Clin Nutr* 35:1327-1331.
- Maheswaran R, Gill JS, Beevers DG. 1993. Blood pressure and industrial lead exposure. *Am J Epidemiol* 137(6):645-653.
- Maizlish NA, Parra G, Feo O. 1995. Neurobehavioural evaluation of Venezuelan workers exposed to inorganic lead. *Occup Environ Med* 52:408-414.
- Maki-Paakkanen J, Sorsa M, Vainio H. 1981. Chromosome aberrations and sister chromatid exchanges in lead-exposed workers. *Hereditas* 94:269-275.
- Malcoe LH, Lynch RA, Keger MC, et al. 2002. Lead sources, behaviors, and socioeconomic factors in relation to blood lead in native and white children: A community-based assessment of a former mining area. *Environ Health Perspect* 110(Suppl 2):221-231.
- Malcolm D, Barnett HAR. 1982. A mortality study of lead workers 1925-76. *Br J Ind Med* 39:404-410.
- Maldonado-Vega M, Cerbon-Solorzano J, Albores-Medina A, et al. 1996. Lead: Intestinal absorption and bone mobilization during lactation. *Hum Exp Toxicol* 15(11):872-877.
- Malekirad AA, Kalantari-Dehaghi R, Abdollahi M. 2013. Clinical, haematological, and neurocognitive findings in lead-exposed workers of a battery plant in Iran. *Arh Hig Rada Toksikol* 64(4):497-503. 10.2478/10004-1254-64-2013-2385.
- Mannino DM, Albalak R, Grosse S, et al. 2003. Second-hand smoke exposure and blood lead levels in U.S. children. *Epidemiology* 14(6):719-727.
- Mantere P, Hänninen H, Hernberg S. 1982. Subclinical neurotoxic lead effects: Two-year follow-up studies with psychological test methods. *Neurobehav Toxicol Teratol* 4:725-727.
- Manton WI, Cook JD. 1984. High accuracy (stable isotope dilution) measurements of lead in serum and cerebrospinal fluid. *Br J Ind Med* 41:313-319.
- Manton WI, Malloy CR. 1983. Distribution of lead in body fluids after ingestion of soft solder. *Br J Ind Med* 40(1):51-57.
- Manton WI, Angle CR, Stanek KL, et al. 2000. Acquisition and retention of lead by young children. *Environmental Research Section A* 82:60-80.
- Manton WI, Angle CR, Stanek KL, et al. 2003. Release of lead from bone in pregnancy and lactation. *Environ Res* 92(2):139-151.
- Manton WI, Rothenberg SJ, Manalo M. 2001. The lead content of blood serum. *Environ Res* 86(Section A):263-273.
- Marcus AH. 1985a. Multicompartment kinetic model for lead. I. Bone diffusion models for long-term retention. *Environ Res* 36:441-458.
- Marcus AH. 1985b. Multicompartment kinetic model for lead. II. Linear kinetics and variable absorption in humans without excessive lead exposure. *Environ Res* 36:459-472.
- Marcus AH. 1985c. Multicompartment kinetic model for lead. III. Lead in blood plasma and erythrocytes. *Environ Res* 36:473-489.
- Marcus AH, Elias RW. 1995. Estimating the contribution of lead-based paint to soil lead, dust lead, and childhood blood lead. In: *Lead in paint, soil and dust: Health risks, exposure studies, control measures, measurement methods, and quality assurance*. ASTM International, 12-23.
- Marcus AH, Schwartz J. 1987. Dose-response curves for erythrocyte protoporphyrin vs blood lead: Effects of iron status. *Environ Res* 44(2):221-227.
- Marcus DK, Fulton JJ, Clarke EJ. 2010. Lead and conduct problems: A meta-analysis. *J Clin Child Adolesc Psychol* 39(2):234-241. 10.1080/15374411003591455.
- Mari M, Nadal M, Schuhmacher M, et al. 2014. Human exposure to metals: Levels in autopsy tissues of individuals living near a hazardous waste incinerator. *Biol Trace Elem Res* 159(1-3):15-21.
- Markowitz ME, Rosen JF. 1981. Zinc (Zn) and copper (Cu) metabolism in CaNa-2 EDTA-treated children with plumbism. *Pediatr Res* 15:635.

8. REFERENCES

- Markowitz ME, Weinberger HL. 1990. Immobilization-related lead toxicity in previously lead-poisoned children. *Pediatrics* 86:455-457.
- Marques RC, Bernardi JV, Dorea JG, et al. 2014. Perinatal multiple exposure to neurotoxic (lead, methylmercury, ethylmercury, and aluminum) substances and neurodevelopment at six and 24 months of age. *Environ Pollut* 187:130-135. 10.1016/j.envpol.2014.01.004.
- Marsden PA. 2003. Increased body lead burden--cause or consequence of chronic renal insufficiency? *N Engl J Med* 348(4):345-347. 10.1056/NEJMe020164.
- Marsh J, Birchall A. 1999. Determination of lung-to-blood absorption rates for lead and bismuth which are appropriate for radon progeny. *Radiat Prot Dosimetry* 83(4):331-337.
- Martin D, Glass TA, Bandeen-Roche K, et al. 2006. Association of blood lead and tibia lead with blood pressure and hypertension in a community sample of older adults. *Am J Epidemiol* 163(5):467-478. 10.1093/aje/kwj060.
- Marx SK, Kamber BS, McGowan HA. 2008. Scavenging of atmospheric trace metal pollutants by mineral dusts: Inter-regional transport of Australian trace metal pollution to New Zealand. *Atmos Environ* 42(10):2460-2478. 10.1016/j.atmosenv.2007.12.014.
- Matte TD, Figueroa JP, Burr G, et al. 1989. Lead exposure among lead-acid battery workers in Jamaica. *Am J Ind Med* 16:167-177.
- Mazumdar M, Bellinger DC, Gregas M, et al. 2011. Low-level environmental lead exposure in childhood and adult intellectual function: A follow-up study. *Environ Health* 10(1):24. 10.1186/1476-069X-10-24.
- McDonald JA, Potter NU. 1996. Lead's legacy? Early and late mortality of 454 lead-poisoned children. *Arch Environ Health* 51(2):116-121.
- McElroy JA, Shafer MM, Gangnon RE, et al. 2008. Urinary lead exposure and breast cancer risk in a population-based case-control study. *Cancer Epidemiol Biomarkers Prev* 17(9):2311-2317. 10.1158/1055-9965.epi-08-0263.
- McElvenny DM, Miller BG, MacCalman LA, et al. 2015. Mortality of a cohort of workers in Great Britain with blood lead measurements. *Occup Environ Med* 72(9):625-632. 10.1136/oemed-2014-102637.
- McFarlane AC, Searle AK, Van Hooff M, et al. 2013. Prospective associations between childhood low-level lead exposure and adult mental health problems: The Port Pirie cohort study. *Neurotoxicology* 39:11-17. 10.1016/j.neuro.2013.08.003.
- McGregor AJ, Mason HJ. 1990. Chronic occupational lead exposure and testicular endocrine function. *Hum Exp Toxicol* 9:371-376.
- McLaine P, Navas-Acien A, Lee R, et al. 2013. Elevated blood lead levels and reading readiness at the start of kindergarten. *Pediatrics* 131(6):1081-1089. 10.1542/peds.2012-2277.
- McMichael AJ, Baghurst PA, Wigg NR, et al. 1988. Port Pirie cohort study: Environmental exposure to lead and children's abilities at the age of four years. *N Engl J Med* 319(8):468-475.
- McMichael AJ, Vimpani GV, Robertson EF, et al. 1986. The Port Pirie cohort study: Maternal blood lead and pregnancy outcome. *J Epidemiol Community Health* 40(1):18-25.
- McNeill FE, Stokes L, Brito JA, et al. 2000. ¹⁰⁹Cd K x-ray fluorescence measurements of tibial lead content in young adults exposed to lead in early childhood. *Occup Environ Med* 57(7):465-471. 10.1136/oem.57.7.465.
- Meeker JD, Rossano MG, Protas B, et al. 2008. Cadmium, lead, and other metals in relation to semen quality: Human evidence for molybdenum as a male reproductive toxicant. *Environ Health Perspect* 116(11):1473-1479. 10.1289/ehp.11490.
- Meeker JD, Rossano MG, Protas B, et al. 2010. Environmental exposure to metals and male reproductive hormones: Circulating testosterone is inversely associated with blood molybdenum. *Fertil Steril* 93(1):130-140. 10.1016/j.fertnstert.2008.09.044.
- Meirer F, Pemmer B, Pepponi G, et al. 2011. Assessment of chemical species of lead accumulated in tidemarks of human articular cartilage by X-ray absorption near-edge structure analysis. *J Synchrotron Radiat* 18(Pt 2):238-244. 10.1107/S0909049510052040.

8. REFERENCES

- Mellem JJ, Baijnath H, Odhav B. 2009. Translocation and accumulation of Cr, Hg, As, Pb, Cu and Ni by *Amaranthus dubius* (Amaranthaceae) from contaminated sites. *J Environ Sci Health A Tox Hazard Subst Environ Eng* 44(6):568-575. 10.1080/10934520902784583.
- Méndez-Gómez J, García-Vargas GG, López-Carrillo L, et al. 2008. Genotoxic effects of environmental exposure to arsenic and lead on children in region Lagunera, Mexico. *Ann NY Acad Sci* 1140:358-367. 10.1196/annals.1454.027.
- Mendiola J, Moreno JM, Roca M, et al. 2011. Relationships between heavy metal concentrations in three different body fluids and male reproductive parameters: A pilot study. *Environ Health* 10(1):6. 10.1186/1476-069X-10-6.
- Menditto A, Morisi G, Spagnolo A, et al. 1994. Association of blood lead to blood pressure in men aged 55 to 75 years: Effect of selected social and biochemical confounders. NFR Study Group. *Environ Health Perspect* 102 Suppl 9:107-111.
- Mendola P, Brett K, Dibari JN, et al. 2013. Menopause and lead body burden among US women aged 45-55, NHANES 1999-2010. *Environ Res* 121:110-113. 10.1016/j.envres.2012.12.009.
- Mendy A, Gasana J, Vieira ER. 2012. Urinary heavy metals and associated medical conditions in the US adult population. *Int J Environ Health Res* 22(2):105-118. 10.1080/09603123.2011.605877.
- Mendy A, Gasana J, Vieira ER. 2013. Low blood lead concentrations and thyroid function of American adults. *Int J Environ Health Res* 23(6):461-473. 10.1080/09603123.2012.755155.
- Menke A, Muntner P, Batuman V, et al. 2006. Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. *Circulation* 114(13):1388-1394. 10.1161/circulationaha.106.628321.
- Meredith PA, Moore MR, Campbell BC, et al. 1978. δ -Aminolaevulinic acid metabolism in normal and lead-exposed humans. *Toxicology* 9:1-9.
- Meyer-Baron M, Seeber A. 2000. A meta-analysis for neurobehavioural results due to occupational lead exposure with blood lead concentrations <70 μ g/100 ml. *Arch Toxicol* 73:510-518.
- Michaels D, Zoloth SR, Stern FB. 1991. Does low-level lead exposure increase risk of death? A mortality study of newspaper printers. *Int J Epidemiol* 20(4):978-983.
- Mielke HW. 1991. Lead in residential soils: Background and preliminary results of New Orleans. *Water Air Soil Pollut* 57(1):111-119.
- Mielke HW. 1993. Lead dust contaminated USA communities: Comparison of Louisiana and Minnesota. *Appl Geochem Suppl*:(2):257-261.
- Mielke HW, Gonzales C. 2008. Mercury (Hg) and lead (Pb) in interior and exterior New Orleans house paint films. *Chemosphere* 72(6):882-885. 10.1016/j.chemosphere.2008.03.061.
- Mielke HW, Adams JL, Reagan PL, et al. 1989. Soil-dust lead and childhood lead exposure as a function of city size and community traffic flow: The case for lead abatement in Minnesota. *Lead in soil: Issues and guidelines*, 253-271.
- Mielke HW, Anderson JC, Berry KJ, et al. 1983. Lead concentrations in inner-city soils as a factor in the child lead problem. *Am J Public Health* 73(12; 12):1366-1369.
- Mielke HW, Burroughs S, Wade R, et al. 1984. Urban lead in Minnesota: Soil transect results of four cities. *J Minn Acad Sci* 50(1):19-24.
- Mielke HW, Dugas D, Mielke PW, Jr., et al. 1997. Associations between soil lead and childhood blood lead in urban New Orleans and rural Lafourche Parish of Louisiana. *Environ Health Perspect* 105:950-954.
- Mielke HW, Gonzales CR, Powell E, et al. 2007. Nonlinear association between soil lead and blood lead of children in metropolitan New Orleans, Louisiana: 2000-2005. *Sci Total Environ* 388(1-3):43-53. 10.1016/j.scitotenv.2007.08.012.
- Mielke HW, Gonzales C, Powell E, et al. 2008. Urban soil-lead (Pb) footprint: Retrospective comparison of public and private properties in New Orleans. *Environ Geochem Health* 30(3):231-242. 10.1007/s10653-007-9111-3.
- Mielke HW, Laidlaw MA, Gonzales C. 2010. Lead (Pb) legacy from vehicle traffic in eight California urbanized areas: Continuing influence of lead dust on children's health. *Sci Total Environ* 408(19):3965-3975. 10.1016/j.scitotenv.2010.05.017.

8. REFERENCES

- Mielke HW, Powell ET, Shah A, et al. 2001. Multiple metal contamination from house paints: Consequences of power sanding and paint scraping in New Orleans. *Environ Health Perspect* 109(9):973-978.
- Mielżyńska D, Siwińska E, Kapka L, et al. 2006. The influence of environmental exposure to complex mixtures including PAHs and lead on genotoxic effects in children living in Upper Silesia, Poland. *Mutagenesis* 21(5):295-304. 10.1093/mutage/ge1037.
- Miller EK, Friedland AJ. 1994. Lead migration in forest soils: Response to changing atmospheric inputs. *Environ Sci Technol* 28(4):662-669.
- Min KB, Min JY. 2015. Environmental lead exposure and increased risk for total and allergen-specific IgE in US adults. *J Allergy Clin Immunol* 135(1):275-277. 10.1016/j.jaci.2014.08.052.
- Min JY, Min KB, Kim R, et al. 2008a. Blood lead levels and increased bronchial responsiveness. *Biol Trace Elem Res* 123(1-3):41-46. 10.1007/s12011-008-8099-6.
- Min KB, Min JY, Cho SI, et al. 2008b. Relationship between low blood lead levels and growth in children of white-collar civil servants in Korea. *Int J Hyg Environ Health* 211(1-2):82-87. 10.1016/j.ijheh.2007.03.003.
- Min MYO, Singer LT, Kirchner HL, et al. 2009. Cognitive development and low-level lead exposure in poly-drug exposed children. *Neurotoxicol Teratol* 31(4):225-231. 10.1016/j.ntt.2009.03.002.
- Mindak WR, Cheng J, Canas BJ, et al. 2008. Lead in women's and children's vitamins. *J Agric Food Chem* 56:6892-6896.
- Minozzo R, Deimling LI, Gigante LP, et al. 2004. Micronuclei in peripheral blood lymphocytes of workers exposed to lead. *Mutat Res* 565(1):53-60. 10.1016/j.mrgentox.2004.09.003.
- Miranda ML, Edwards SE, Swamy GK, et al. 2010. Blood lead levels among pregnant women: Historical versus contemporaneous exposures. *Int J Environ Res Public Health* 7(4):1508-1519. 10.3390/ijerph7041508.
- Miranda ML, Kim D, Reiter J, et al. 2009. Environmental contributors to the achievement gap. *Neurotoxicology* 30(6):1019-1024. 10.1016/j.neuro.2009.07.012.
- Mishra KP. 2009. Lead exposure and its impact on immune system: A review. *Toxicol in Vitro* 23(6):969-972. 10.1016/j.tiv.2009.06.014.
- Mishra KP, Rani R, Yadav VS, et al. 2010. Effect of lead exposure on lymphocyte subsets and activation markers. *Immunopharmacol Immunotoxicol* 32(3):446-449. 10.3109/08923970903503668.
- Mistry P, Lucier GW, Fowler BA. 1985. High affinity lead binding proteins from rat kidney cytosol mediate cell-free nuclear translocation of lead. *J Pharmacol Exp Ther* 232:462-469.
- Mistry P, Mastro C, Fowler BA. 1986. Influence of metal ions on renal cytosolic lead-binding proteins and nuclear uptake of lead in the kidney. *Biochem Pharmacol* 35:711-713.
- Miyake M. 1986. Structure refinements of Pb²⁺ ion-exchanged apatites by x-ray powder pattern-fitting. *J Solid State Chem* 61(2):230-235. 10.1016/0022-4596(86)90026-5.
- Mohammad IK, Mahdi AA, Raviraja A, et al. 2008. Oxidative stress in painters exposed to low lead levels. *Arh Hig Rada Toksikol* 59(3):161-169. 10.2478/10004-1254-59-2008-1883.
- Møller L, Kristensen TS. 1992. Blood lead as a cardiovascular risk factor. *Am J Epidemiol* 136(9):1091-1100.
- Montenegro MF, Barbosa F, Jr., Tanus-Santos JE. 2008. Assessment of how pregnancy modifies plasma lead and plasma/whole blood lead ratio in ALAD 1-1 genotype women. *Basic Clin Pharmacol Toxicol* 102(4):347-351. 10.1111/j.1742-7843.2007.00205.x.
- Moon SS. 2013. Association of lead, mercury and cadmium with diabetes in the Korean population: The Korea National Health and Nutrition Examination Survey (KNHANES) 2009-2010. *Diabetic Med* 30(4):e143-148. 10.1111/dme.12103.
- Moore MR, Goldberg A. 1985. Health implications of the hematopoietic effects of lead Dietary and Environmental Lead: *Human Health Effects*, 261-314.

8. REFERENCES

- Moore MR, Meredith PA, Watson WS, et al. 1980. The percutaneous absorption of lead-203 in humans from cosmetic preparations containing lead acetate, as assessed by whole-body counting and other techniques. *Food Chem Toxicol* 18:399-405.
- Moran-Martinez J, Carranza-Rosales P, Morales-Vallarta M, et al. 2013. Chronic environmental exposure to lead affects semen quality in a Mexican men population. *Iran J Reprod Med* 11(4):267-274.
- Moreau T, Hannaert P, Orssaud G, et al. 1988. Influence of membrane sodium transport upon the relation between blood lead and blood pressure in a general male population. *Environ Health Perspect* 78:47-51.
- Moreau T, Orssaud G, Juguet B, et al. 1982. [Blood lead levels and arterial pressure. Initial results of a cross sectional study of 431 male subjects]. *Rev Epidemiol Sante Publique* 30(3):395-397. (French)
- Morgan A, Holmes A. 1978. The fate of lead in petrol-engine exhaust particulates inhaled by the rat. *Environ Res* 15:44-56.
- Morgan B, Parramore C. 2001. Elevated blood lead levels associated with the consumption of illicitly distilled moonshine. *J Toxicol Clin Toxicol* 39(5):551.
- Morita Y, Sakai T, Araki S, et al. 1997. Nicotinamide adenine dinucleotide synthetase activity in erythrocytes as a tool for the biological monitoring of lead exposure. *Int Arch Occup Environ Health* 70:195-198.
- Morris C, McCarron DA, Bennett WM. 1990. Low-level lead exposure, blood pressure, and calcium metabolism. *Am J Kidney Dis* 15:568-574.
- Morris V, Markowitz ME, Rosen JF. 1988. Serial measurements of aminolevulinic acid dehydratase in children with lead toxicity. *J Pediatr* 112(6):916-919.
- Morrison JN, Quarterman J. 1987. The relationship between iron status and lead absorption in rats. *Biol Trace Elem Res* 14(1-2):115-126. 10.1007/bf02795602.
- Morrison NA, Yeoman R, Kelly PJ, et al. 1992. Contribution of trans-acting factor alleles to normal physiological variability: Vitamin D receptor gene polymorphism and circulating osteocalcin. *Proc Natl Acad Sci* 89(15):6665-6669.
- Morrow P, Beiter H, Amato F, et al. 1980. Pulmonary retention of lead: An experimental study in man. *Environ Res* 21(2):373-384.
- Mortada WI, Sobh MA, El-Defrawy MM, et al. 2001. Study of lead exposure from automobile exhaust as a risk for nephrotoxicity among traffic policemen. *Am J Nephrol* 21:274-279.
- Moss ME, Lanphear BP, Auinger P. 1999. Association of dental caries and blood lead levels. *JAMA* 281(24):2294-2298.
- Muldoon SB, Cauley JA, Kuller LH, et al. 1996. Effects of blood lead levels on cognitive function of older women. *Neuroepidemiology* 15:62-72.
- Muntner P, He J, Vupputuri S, et al. 2003. Blood lead and chronic kidney disease in the general United States population: Results from NHANES III. *Kidney Int* 63(3):1044-1050.
- Muntner P, Menke A, Batuman V, et al. 2007. Association of tibia lead and blood lead with end-stage renal disease: A pilot study of African-Americans. *Environ Res* 104(3):396-401. 10.1016/j.envres.2007.04.001.
- Muntner P, Menke A, DeSalvo KB, et al. 2005. Continued decline in blood lead levels among adults in the United States - The National Health and Nutrition Examination Surveys. *Arch Intern Med* 165(18):2155-2161. 10.1001/archinte.165.18.2155.
- Murata K, Iwata T, Dakeishi M, et al. 2009. Lead toxicity: Does the critical level of lead resulting in adverse effects differ between adults and children? *J Occup Health* 51(1):1-12. 10.1539/joh.K8003.
- Murphy DM, Capps SL, Daniel JS, et al. 2008. Weekly patterns of aerosol in the United States. *Atmos Chem Phys* 8(10):2729-2739. 10.5194/acp-8-2729-2008.
- Murphy MJ, Graziano JH, Popovac D, et al. 1990. Past pregnancy outcomes among women living in the vicinity of a lead smelter in Kosova, Yugoslavia. *Am J Public Health* 80:33-35.
- Murray H, Thompson K, Macfie SM. 2009. Site-and species-specific patterns of metal bioavailability in edible plants. *Botany* 87(7):702-711.

8. REFERENCES

- Mushak P. 1991. Gastro-intestinal absorption of lead in children and adults: Overview of biological and biophysico-chemical aspects. *Chem Spec Bioavail* 3(3-4):87-104.
- Mykkanen HM, Wasserman RH. 1981. Gastrointestinal absorption of lead (^{203}Pb) in chicks: Influence of lead, calcium, and age. *J Nutr* 111:1757-1765.
- Mykkanen HM, Wasserman RH. 1982. Effect of vitamin D on the intestinal absorption of ^{203}Pb and ^{47}Ca in chicks. *J Nutr* 112:520-527.
- Naha N, Chowdhury AR. 2006. Inorganic lead exposure in battery and paint factory: Effect on human sperm structure and functional activity. *J UOEH* 28(2):157-171.
- Naicker N, Norris SA, Mathee A, et al. 2010. Lead exposure is associated with a delay in the onset of puberty in South African adolescent females: Findings from the birth to twenty cohort. *Sci Total Environ* 408(21):4949-4954. 10.1016/j.scitotenv.2010.07.037.
- Nan Z, Cheng G. 2001. Accumulation of Cd and Pb in spring wheat (*Triticum aestivum L.*) grown in calcareous soil irrigated with wastewater. *Bull Environ Contam Toxicol* 66(6):748-754.
- NAS. 1972a. Biological effects of lead in man. Relation between symptoms of acute lead poisoning and lead content of blood. *Lead: Airborne lead in perspective*. Washington, DC: National Academy of Sciences, National Research Council, 91-117.
- NAS. 1972b. *Lead: Airborne lead in perspective: Biological effects of atmospheric pollutants*. Washington, DC: National Academy of Sciences, 71-177, 281-313.
- NAS/NRC. 1989. Report of the oversight committee. *Biologic markers in reproductive toxicology*. Washington, DC: 15-35.
- Nash D, Magder L, Lustberg M, et al. 2003. Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women. *JAMA* 289(12):1523-1532.
- Nash D, Magder LS, Sherwin R, et al. 2004. Bone density-related predictors of blood lead level among peri- and postmenopausal women in the United States. The Third National Health and Nutrition Examination Survey, 1988–1994. *Am J Epidemiol* 160(9):901-911.
- Navas-Acien A, Guallar E, Silbergeld EK, et al. 2007. Lead exposure and cardiovascular disease- A systematic review. *Environ Health Perspect* 115:472-482. 10.1289/ehp.9785.
- Navas-Acien A, Schwartz BS, Rothenberg SJ, et al. 2008. Bone lead levels and blood pressure endpoints: A meta-analysis. *Epidemiology* 19(3):496-504. 10.1097/EDE.0b013e31816a2400.
- Navas-Acien A, Selvin E, Sharrett AR, et al. 2004. Lead, cadmium, smoking, and increased risk of peripheral arterial disease. *Circulation* 109:3196-3201.
- Navas-Acien A, Silbergeld EK, Sharrett AR, et al. 2005. Metals in urine and peripheral arterial disease. *Environ Health Perspect* 113(2):164-169. 10.1289/ehp.7329.
- Navas-Acien A, Tellez-Plaza M, Guallar E, et al. 2009. Blood cadmium and lead and chronic kidney disease in US adults: A joint analysis. *Am J Epidemiol* 170(9):1156-1164. 10.1093/aje/kwp248.
- Nawrot TS, Thijs L, Hond EMD, et al. 2002. An epidemiological re-appraisal of the association between blood pressure and blood lead: A meta-analysis. *J Hum Hypertens* 16:123-131.
- Needleman H. 2004. Lead poisoning. *Ann Rev Med* 55:209-222.
- Needleman HL, Gunnoe C, Leviton A, et al. 1979. Deficits in psychologic and classroom performance of children with elevated dentine lead levels. *N Engl J Med* 300(13):689-695.
- Needleman HL, McFarland C, Ness RB, et al. 2002. Bone lead levels in adjudicated delinquents. A case control study. *Neurotoxicol Teratol* 24:711-717.
- Needleman HL, Rabinowitz M, Leviton A, et al. 1984. The relationship between prenatal exposure to lead and congenital anomalies. *J Am Med Assoc* 251(22):2956-2959.
- Needleman HL, Riess JA, Tobin MJ, et al. 1996. Bone lead levels and delinquent behavior. *J Am Med Assoc* 275:363-369.
- Needleman HL, Schell A, Bellinger D, et al. 1990. The long-term effects of exposure to low doses of lead in childhood: An 11-year follow-up report. *N Engl J Med* 322(2):83-88.

8. REFERENCES

- Nelson AE, Chaudhary S, Kraus VB, et al. 2011. Whole blood lead levels are associated with biomarkers of joint tissue metabolism in African American and white men and women: The Johnston County Osteoarthritis Project. *Environ Res* 111(8):1208-1214. 10.1016/j.envres.2011.08.002.
- Neri LC, Hewitt D, Orser B. 1988. Blood lead and blood pressure: Analysis of cross-sectional and longitudinal data from Canada. *Environ Health Perspect* 78:123-126.
- Nerin C, Domeno C, Garcia JI, et al. 1999. Distribution of Pb, V, Cr, Ni, Cd, Cu and Fe in particles formed from the combustion of waste oils. *Chemosphere* 38(7):1533-1540.
- Neuberger JS, Hu SC, Drake KD, et al. 2009. Potential health impacts of heavy-metal exposure at the Tar Creek Superfund site, Ottawa County, Oklahoma. *Environ Geochem Health* 31(1):47-59. 10.1007/s10653-008-9154-0.
- Neugebauer J, Wittsiepe J, Kasper-Sonnenberg M, et al. 2015. The influence of low level pre- and perinatal exposure to PCDD/Fs, PCBs, and lead on attention performance and attention-related behavior among German school-aged children: Results from the Duisburg Birth Cohort Study. *Int J Hyg Environ Health* 218(1):153-162. 10.1016/j.ijheh.2014.09.005.
- Neuman DR, Dollhopf DJ. 1992. Lead levels in blood from cattle residing near a lead smelter. *J Environ Qual* 21:181-184.
- NFPA. 2002. Tetraethyl lead. In: Spencer AB, Colonna GR, eds. *Fire protection guide to hazardous materials*. National Fire Protection Association, 325-106.
- Ng TP, Goh HH, Ng YL, et al. 1991. Male endocrine functions in workers with moderate exposure to lead. *Br J Ind Med* 48:485-491.
- Nie H, Chettle DR, Webber CE, et al. 2005. The study of age influence on human bone lead metabolism by using a simplified model and X-ray fluorescence data. *J Environ Monit* 7(11):1069-1073. 10.1039/b507749d.
- Nie H, Sanchez BN, Wilker E, et al. 2009. Bone lead and endogenous exposure in an environmentally exposed elderly population: The Normative Aging Study. *J Occup Environ Med* 51:848-857.
- Nie LH, Sanchez S, Newton K, et al. 2011b. *In vivo* quantification of lead in bone with a portable x-ray fluorescence system--methodology and feasibility. *Phys Med Biol* 56(3):N39-N51. 10.1088/0031-9155/56/3/n01.
- Nie LH, Wright RO, Bellinger DC, et al. 2011a. Blood lead levels and cumulative blood lead index (CBLI) as predictors of late neurodevelopment in lead poisoned children. *Biomarkers* 16(6):517-524. 10.3109/1354750x.2011.604133.
- Nielsen T. 1984. Atmospheric occurrence of organolead compounds. *Biological Effects of Organolead Compound*, 44-62.
- Nielsen OJ, O'Farrell DJ, Treacy JJ, et al. 1991. Rate constants for the gas-phase reactions of hydroxyl radicals with tetramethyllead and tetraethyllead. *Environ Sci Technol* 25(6):1098-1103.
- Nielsen T, Jensen KA, Grandjean P. 1978. Organic lead in normal human brains. *Nature* 274:602-603.
- Nielson KB, Atkin CL, Winge DR. 1985. Distinct metal-binding configurations in metallothionein. *J Biol Chem* 260:5342-5350.
- Nihei MK, Guilarte TR. 1999. NMDAR-2A subunit protein expression is reduced in the hippocampus of rats exposed to Pb 2+ during development. *Brain Res Mol Brain Res* 66(1):42-49.
- Nilsson U, Attewell R, Christofferson JO, et al. 1991. Kinetics of lead in bone and blood after end of occupational exposure. *Pharmacol Toxicol* 69:477-484.
- NIOSH. 1994a. Elements in blood or tissue: Method 8005, Issue 2. NIOSH Manual of Analytical Methods (NMAM), Fourth ed. National Institute for Occupational Safety and Health. <https://www.cdc.gov/niosh/docs/2003-154/pdfs/8005.pdf>. March 30, 2017.
- NIOSH. 1994b. Lead in blood and urine. NIOSH manual of analytical methods (NMAM), Method 8003. Cincinnati, OH: National Institute for Occupational Safety and Health.
- NIOSH. 1994c. Lead by GFAAS: Method 7105, Issue 2. NIOSH Manual of Analytical Methods (NMAM), Fourth ed. National Institute for Occupational Safety and Health. <https://www.cdc.gov/niosh/docs/2003-154/pdfs/7105>. March 29, 2017.

8. REFERENCES

- NIOSH. 1995. Report to Congress on Workers' Home Contamination Study Conducted Under The Worker's Family Protection Act (29 U.S.C. 671a). Cincinnati, OH: National Institute for Occupational Safety and Health, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. DHHS (NIOSH) Publication No. 95-123. PB96192000HEF.
- NIOSH. 1996b. NIOSH health hazard evaluation report: HETA 91-0346-2572 FBI Academy Quantico, Virginia. Cincinnati, OH: National Institute for Occupational Safety and Health, U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention.
- NIOSH. 1996a. Lead in surface wipe samples: Method 9100, Issue 2. NIOSH Manual of Analytical Methods (NMAM), Fourth ed. National Institute for Occupational Safety and Health. <https://www.cdc.gov/niosh/docs/2003-154/pdfs/9100.pdf>. March 30, 2017.
- NIOSH. 1998. Lead by field portable XRF: Method 7702, Issue 1. NIOSH Manual of Analytical Methods (NMAM), Fourth ed. National Institute for Occupational Safety and Health. <http://www.cdc.gov/niosh/docs/2003-154/pdfs/7702.pdf>. March 29, 2017.
- NIOSH. 2003a. Elements by ICP (Aqua Regia Ashing): Method 7301, Issue 1. NIOSH Manual of Analytical Methods (NMAM), Fourth ed. National Institute for Occupational Safety and Health. <https://www.cdc.gov/niosh/docs/2003-154/pdfs/7301.pdf>. March 29, 2017.
- NIOSH. 2003b. Elements by ICP (Hot Block/HCl/HNO₃ Ashing): Method 7303, Issue 1. NIOSH Manual of Analytical Methods (NMAM), Fourth ed. National Institute for Occupational Safety and Health. <https://www.cdc.gov/niosh/docs/2003-154/pdfs/7303.pdf>.
- NIOSH. 2003c. Elements by (ICP): Method 7300, Issue 3. NIOSH Manual of Analytical Methods (NMAM), Fourth ed. National Institute for Occupational Safety and Health. <https://www.cdc.gov/niosh/docs/2003-154/pdfs/7300.pdf>. March 29, 2017.
- NIOSH. 2003d. Elements on wipes methods: Method 9102, Issue 1. NIOSH Manual of Analytical Methods (NMAM), Fourth ed. National Institute for Occupational Safety and Health. <https://www.cdc.gov/niosh/docs/2003-154/pdfs/9102.pdf>. March 30, 2017.
- NIOSH. 2003e. Lead in dust wipes: Method 9105, Issue 1. NIOSH Manual of Analytical Methods (NMAM), Fourth ed. National Institute for Occupational Safety and Health. <https://www.cdc.gov/niosh/docs/2003-154/pdfs/9105.pdf>. March 30, 2017.
- NIOSH. 2005. Lead. NIOSH pocket guide to chemical hazards. Atlanta, GA: National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. <http://www.cdc.gov/niosh/npg/npgdname.html>.
- NIOSH. 2014a. Elements by ICP (Microwave Digestion): Method 7302, Issue 1. NIOSH Manual of Analytical Methods (NMAM), Fifth ed. National Institute for Occupational Safety and Health. <https://www.cdc.gov/niosh/docs/2014-151/pdfs/methods/7302.pdf>. March 29, 2017.
- NIOSH. 2014b. Elements by ICP (Microwave Digestion): Method 7304, Issue 1. NIOSH Manual of Analytical Methods (NMAM), Fifth ed. National Institute for Occupational Safety and Health. <https://www.cdc.gov/niosh/docs/2014-151/pdfs/methods/7304.pdf>. March 29, 2017.
- NIOSH. 2015. Elements by cellulosic internal capsule sampler: Method 7306, Issue 1. NIOSH Manual of Analytical Methods (NMAM), Fifth ed. National Institute for Occupational Safety and Health. <https://www.cdc.gov/niosh/docs/2014-151/pdfs/methods/7306.pdf>. March 29, 2017.
- NIOSH. 2016a. Lead by portable ultrasonic extraction/ASV: Method 7701, Issue 3. NIOSH Manual of Analytical Methods (NMAM), Fifth ed. National Institute for Occupational Safety and Health. <https://www.cdc.gov/niosh/docs/2014-151/pdfs/methods/7701.pdf>. March 29, 2017.
- NIOSH. 2016b. Lead. NIOSH pocket guide to chemical hazards. Atlanta, GA: National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. <https://www.cdc.gov/niosh/npg/npgd0368.html>. May 10, 2017.
- NIOSH. 2016c. Tetraethyl lead. NIOSH pocket guide to chemical hazards. Atlanta, GA: National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. <https://www.cdc.gov/niosh/npg/npgd0601.html>. May 10, 2017.
- NIOSH. 2017a. Elevated blood lead levels among employed adults — United States, 2014 Adult Blood Lead Epidemiology and Surveillance (ABLES).

8. REFERENCES

- NIOSH. 2017b. Lead by Flame AAS: Method 7082, Issue 2. NIOSH Manual of Analytical Methods (NMAM), Fifth edition. National Institute for Occupational Safety and Health. <https://www.cdc.gov/niosh/docs/2014-151/pdfs/methods/7082.pdf>. March 13, 2019.
- Nishioka E, Yokoyama K, Matsukawa T, et al. 2014. Evidence that birth weight is decreased by maternal lead levels below 5 µg/dl in male newborns. *Reprod Toxicol* 47:21-26. 10.1016/j.reprotox.2014.05.007.
- Niu Y, Yu W, Fang S, et al. 2015. Lead poisoning influences TCR-related gene expression patterns in peripheral blood T-lymphocytes of exposed workers. *J Immunotoxicol* 12(1):92-97. 10.3109/1547691x.2014.899412.
- NOAA. 1998. Sampling and analytical methods of the National Status and Trends Program Mussel Watch Project: 1993-1996 Update. Silver Spring, MD: National Oceanic and Atmospheric Administration. NOAA Technical Memorandum NOS ORCA 130. <http://aquaticcommons.org/2201/>. March 30, 2017.
- Nordberg GF, Gerhardsson L, Mumtaz MM, et al. 2015. Interactions and mixtures in metal toxicology. In: Nordberg GF, Fowler BA, Nordberg M, eds. *Handbook on the toxicology of metals*. Chapter 11. Fourth ed. Elsevier, 213-238.
- Nordenson I, Beckman G, Beckman L, et al. 1978. Occupational and environmental risks in and around a smelter in northern Sweden. IV. Chromosomal aberrations in workers exposed to lead. *Hereditas* 88:263-267.
- NRC. 2005. Superfund and mining megasites. Lessons from Coeur d'Alene River Basin. National Research Council. <http://dels.nas.edu/Report/Superfund-Mining-Megasites-Lessons-from/11359>. December 5, 2017
- Nriagu J, Burt B, Linder A, et al. 2006. Lead levels in blood and saliva in a low-income population of Detroit, Michigan. *Int J Hyg Environ Health* 209(2):109-121. 10.1016/j.ijheh.2005.11.005.
- NSF. 1977. Lead in the Environment. Washington, DC: National Science Foundation, 105-133. Report No NSF/RA-770214.
- NTP. 2012. NTP monograph on health effects of low-level lead. National Toxicology Program. https://ntp.niehs.nih.gov/ntp/ohat/lead/final/monographtheeffectslowlevellead_newissn_508.pdf. May 31, 2017.
- NTP. 2016. Lead and lead compounds, CAS No. 7439-92-1 (lead). Report on carcinogens, Fourteenth ed. Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program. <https://ntp.niehs.nih.gov/ntp/roc/content/profiles/lead.pdf>. May 4, 2017.
- Nwosu JU, Harding AK, Linder G. 1995. Cadmium and lead uptake by edible crops grown in a silt loam soil. *Bull Environ Contam Toxicol* 54:570-578.
- Odland JO, Nieboer E, Romanova N, et al. 1999. Blood lead and cadmium and birth weight among sub-arctic and arctic populations of Norway and Russia. *Acta Obstet Gynecol Scand* 78:852-860.
- O'Flaherty EJ. 1987. Modeling: An introduction. In: *Pharmacokinetics in risk assessment: Drinking water and health*. Vol. 8. Washington, DC: National Academy Press, National Academy of Sciences, 27-33.
- O'Flaherty EJ. 1991a. Physiologically based models for bone-seeking elements. II. Kinetics of lead disposition in rats. *Toxicol Appl Pharmacol* 111:313-331.
- O'Flaherty EJ. 1991b. Physiologically based models for bone-seeking elements: III. Human skeletal and bone growth. *Toxicol Appl Pharmacol* 111(2):332-341.
- O'Flaherty EJ. 1993. Physiologically based models for bone-seeking elements. IV. Kinetics of lead disposition in humans. *Toxicol Appl Pharmacol* 118(1):16-29.
- O'Flaherty EJ. 1995a. Physiologically based models for bone-seeking elements. V. Lead absorption and disposition in childhood. *Toxicol Appl Pharmacol* 131:297-308.
- O'Flaherty EJ. 1995b. PBK modeling for metals. Examples with lead, uranium, and chromium. *Toxicol Lett* 82/83:367-372.

8. REFERENCES

- O'Flaherty EJ. 1998. A physiologically based kinetic model for lead in children and adults. *Environ Health Perspect* 106(Suppl 6):1495-1503.
- O'Flaherty EJ. 2000. Modeling normal aging bone loss, with consideration of bone loss in osteoporosis. *Toxicol Sci* 55:171-188.
- O'Flaherty EJ, Hammond PB, Lerner SI. 1982. Dependence of apparent blood lead half-life on the length of previous lead exposure in humans. *Fundam Appl Toxicol* 2:49-55.
- Oldereid NB, Thomassen Y, Attramadal A, et al. 1993. Concentrations of lead, cadmium and zinc in the tissues of reproductive organs of men. *J Reprod Fertil* 99:421-425.
- Olivero-Verbel J, Duarte D, Echenique M, et al. 2007. Blood lead levels in children aged 5-9 years living in Cartagena, Colombia. *Sci Total Environ* 372(2-3):707-716. 10.1016/j.scitotenv.2006.10.025.
- Olmedo P, Goessler W, Tanda S, et al. 2018. Metal concentrations in e-cigarette liquid and aerosol samples: The contribution of metallic coils. *Environ Health Perspect* 126(2):027010. <http://doi.org/https://doi.org/10.1289/EHP2175>.
- Olson KW, Skogerboe RK. 1975. Identification of soil lead compounds from automobile sources. *Environ Sci Technol* 9:227-230.
- Omae K, Sakurai H, Higashi T, et al. 1990. No adverse effects of lead on renal function in lead-exposed workers. *Ind Health* 28(2):77-83.
- Omokhodion FO, Crockford GW. 1991. Lead in sweat and its relationship to salivary and urinary levels in normal healthy subjects. *Sci Total Environ* 103(2-3):113-122.
- Onalaja AO, Claudio L. 2000. Genetic susceptibility to lead poisoning. *Environ Health Perspect* 108(Suppl 1):23-28.
- O'Neil MJ, Heckelman PE, Dobbelaar PH, et al. 2013. Lead and lead compounds. In: *The Merck index*. The Royal Society of Chemistry, 1004-1007, 1706.
- Ong C, Kong Y, Ong H, et al. 1990. The *in vitro* and *in vivo* effects of lead on δ -aminolevulinic acid dehydratase and pyrimidine 5'-nucleotidase. *Basic Clin Pharmacol Toxicol* 66(1):23-26.
- Ong CN, Lee WR. 1980. Distribution of lead-203 in human peripheral blood *in vitro*. *Br J Ind Med* 37:78-84.
- Onuegbu AJ, Olisekodiaka MJ, Nwaba EI, et al. 2011. Assessment of some renal indices in people occupationally exposed to lead. *Toxicol Ind Health* 27(5):475-479. 10.1177/0748233710390020.
- Oomen AG, Rempelberg CJ, Bruil MA, et al. 2003b. Development of an *in vitro* digestion model for estimating the bioaccessibility of soil contaminants. *Arch Environ Contam Toxicol* 44(3):281-287.
- Oomen AG, Tolls J, Sips AJAM, et al. 2003a. Lead speciation in artificial human digestive fluid. *Arch Environ Contam Toxicol* 44:107-115.
- Opler MGA, Brown AS, Graziano J, et al. 2004. Prenatal lead exposure, δ -aminolevulinic acid, and schizophrenia. *Environ Health Perspect* 112(5):548-552. 10.1289/ehp.10464.
- Opler MGA, Buka SL, Groeger J, et al. 2008. Prenatal exposure to lead, δ -aminolevulinic acid, and schizophrenia: Further evidence. *Environ Health Perspect* 116(11):1586-1590. 10.1289/ehp.10464.
- Orisakwe O, Nwachukwu E, Osadolor H, et al. 2007. Liver and kidney function tests amongst paint factory workers in Nkpor, Nigeria. *Toxicol Ind Health* 23(3):161-165.
- Orssaud G, Claude JR, Moreau T, et al. 1985. Blood lead concentration and blood pressure. *Br Med J* 290:244.
- OSHA. 1995. Subpart Z - Toxic and hazardous substances. Lead-general. Code of Federal Regulations. 29 CFR 1910.1025. Occupational Safety and Health Administration.
- OSHA. 2016a. Subpart Z - Toxic and hazardous substances. Lead - general. Code of Federal Regulations. 29 CFR 1910.1025. <https://www.gpo.gov/fdsys/pkg/CFR-2016-title29-vol6/pdf/CFR-2016-title29-vol6-sec1910-1025.pdf>. May 4, 2017.
- OSHA. 2016b. Subpart Z - Toxic and hazardous substances. Air contaminants - general industry. Code of Federal Regulations. 29 CFR 1910.1000. <https://www.gpo.gov/fdsys/pkg/CFR-2016-title29-vol6/pdf/CFR-2016-title29-vol6-sec1910-1000.pdf>. March 6, 2017.

8. REFERENCES

- OSHA. 2016c. Subpart D - Occupational health and environment controls. Section 1926.62 - Lead - construction. Code of Federal Regulations. 29 CFR 1926.62. <https://www.gpo.gov/fdsys/pkg/CFR-2016-title29-vol8/pdf/CFR-2016-title29-vol8-sec1926-62.pdf>. May 4, 2017.
- OSHA. 2016d. Subpart Z - Toxic and hazardous substances. Lead - shipyards. Code of Federal Regulations. 29 CFR 1915.1025. <https://www.gpo.gov/fdsys/pkg/CFR-2016-title29-vol7/pdf/CFR-2016-title29-vol7-sec1915-1025.pdf>. March 6, 2017.
- OSHA. 2016e. Subpart D - Occupational health and environment controls. Section 1926.55 - Gases, vapors, fumes, dusts, and mists. Appendix A to Part 1926.55 - threshold limit values of airborne contaminants for construction. Code of Federal Regulations. 29 CFR 1926.55. <https://www.gpo.gov/fdsys/pkg/CFR-2016-title29-vol8/pdf/CFR-2016-title29-vol8-sec1926-55.pdf>. March 6, 2017.
- OSHA. 2016f. Subpart Z - Toxic and hazardous substances. Air contaminants. Table Z - Shipyards. Code of Federal Regulations. 29 CFR 1915.1000. <https://www.gpo.gov/fdsys/pkg/CFR-2016-title29-vol7/pdf/CFR-2016-title29-vol7-sec1915-1000.pdf>. March 6, 2017.
- Oskarsson A, Jorhem L, Sundberg J, et al. 1992. Lead poisoning in cattle - transfer of lead to milk. *Sci Total Environ* 111:83-94.
- Osman K, Pawlas K, Schutz A, et al. 1999. Lead exposure and hearing effects in children in Katowice, Poland. *Environ Res* 80 Section A:1-8.
- Osterberg E, Mayewski P, Kreutz K, et al. 2008. Ice core record of rising lead pollution in the North Pacific atmosphere. *Geophys Res Lett* 35(5):L05810. 10.1029/2007gl032680.
- Osterode W, Barnas U, Geissler K. 1999. Dose dependent reduction of erythroid progenitor cells and inappropriate erythropoietin response in exposure to lead: New aspects of anaemia induced by lead. *Occup Environ Med* 56:106-109.
- Otto D, Robinson G, Baumann S, et al. 1985. 5-year follow-up study of children with low-to-moderate lead absorption: Electrophysiological evaluation. *Environ Res* 38(1):168-186.
- Ou LT, Jing W, Thomas JE. 1995. Biological and chemical degradation of ionic ethyllead compounds in soil. *Environ Toxicol Chem* 14(4):545-551.
- Ou LT, Thomas JE, Jing W. 1994. Biological and chemical degradation of tetraethyl lead in soil. *Bull Environ Contam Toxicol* 52:238-245.
- Ozkaynak H, Xue J, Zartarian VG, et al. 2011. Modeled estimates of soil and dust ingestion rates for children. *Risk Anal* 31(4):592-608. 10.1111/j.1539-6924.2010.01524.x.
- Padilla MA, Elobeid M, Ruden DM, et al. 2010. An examination of the association of selected toxic metals with total and central obesity indices: NHANES 99-02. *Int J Environ Res Public Health* 7:3332-3347. 10.3390/ijerph7093332.
- Paglia DE, Valentine WN, Dahlgren JG. 1975. Effects of low-level lead exposure on pyrimidine 5'-nucleotidase and other erythrocyte enzymes. Possible role of pyrimidine 5'-nucleotidase in the pathogenesis of lead-induced anemia. *J Clin Invest* 56:1164-1169.
- Paglia DE, Valentine WN, Fink K. 1977. Lead poisoning. Further observations on erythrocyte pyrimidine-nucleotidase deficiency and intracellular accumulation of pyrimidine nucleotides. *J Clin Invest* 60(6):1362-1366.
- Pagliuca A, Mufti GJ, Baldwin D, et al. 1990. Lead poisoning: Clinical, biochemical, and haematological aspects of a recent outbreak. *J Clin Pathol* 43:277-281.
- Palaniappan K, Roy A, Balakrishnan K, et al. 2011. Lead exposure and visual-motor abilities in children from Chennai, India. *Neurotoxicology* 32(4):465-470. 10.1016/j.neuro.2011.03.011.
- Palmer KT, Kucera CL. 1980. Lead contamination of sycamore and soil from lead mining and smelting operations in eastern Missouri. *J Environ Qual* 9(1):106-111.
- P'An AY. 1981. Lead levels in saliva and in blood. *J Toxicol Environ Health* 7(2):273-280. 10.1080/15287398109529978.
- PAN Pesticides Database. 2004. PAN Pesticides Database-Chemicals.

8. REFERENCES

- Pan SY, Morrison H, Gibbons L, et al. 2011. Breast cancer risk associated with residential proximity to industrial plants in Canada. *J Occup Environ Med* 53(5):522-529. 10.1097/JOM.0b013e318216d0b3.
- Parajuli RP, Fujiwara T, Umezaki M, et al. 2013. Association of cord blood levels of lead, arsenic, and zinc with neurodevelopmental indicators in newborns: A birth cohort study in Chitwan Valley, Nepal. *Environ Res* 121:45-51. 10.1016/j.envres.2012.10.010.
- Pardo R, Barrado E, Perez L, et al. 1990. Determination and speciation of heavy metals in sediments of the Pisuerga River. *Water Res* 24(3):373-379.
- Park SJ, Lee JH, Woo SJ, et al. 2015. Five heavy metallic elements and age-related macular degeneration: Korean National Health and Nutrition Examination Survey, 2008-2011. *Ophthalmology* 122(1):129-137. 10.1016/j.ophtha.2014.07.039.
- Park SK, Elmarsafawy S, Mukherjee B, et al. 2010. Cumulative lead exposure and age-related hearing loss: The VA Normative Aging Study. *Hear Res* 269(1-2):48-55. 10.1016/j.heares.2010.07.004.
- Park SK, Hu H, Wright RO, et al. 2009a. Iron metabolism genes, low-level lead exposure, and QT interval. *Environ Health Perspect* 117(1):80-85.
- Park SK, Mukherjee B, Xia X, et al. 2009b. Bone lead level prediction models and their application to examine the relationship of lead exposure and hypertension in the third National Health and Nutrition Examination Survey. *J Occup Environ Med* 51(12):1422-1436. 10.1097/JOM.0b013e3181bf6c8d.
- Park SK, Schwartz J, Weisskopf M, et al. 2006. Low-level lead exposure, metabolic syndrome, and heart rate variability: The VA Normative Aging Study. *Environ Health Perspect* 114:1718-1724.
- Parkinson DK, Hodgson MJ, Bromet EJ, et al. 1987. Occupational lead exposure and blood pressure. *Br J Ind Med* 44(11):744-748.
- Parkinson DK, Ryan C, Bromet EJ, et al. 1986. A psychiatric epidemiologic study of occupational lead exposure. *Am J Epidemiol* 123(2):261-269.
- Parramore CS, Morgan BW, Ethridge MW. 2001. Lead contaminated moonshine: A report of ATF analyzed samples. *J Toxicol Clin Toxicol* 39(5):520.
- Partanen T, Heikkila P, Hernberg S, et al. 1991. Renal cell cancer and occupational exposure to chemical agents. *Scand J Work Environ Health* 17(4):231-239.
- Pasternak MD, Becker CE, Lash A, et al. 1989. Cross-sectional neurotoxicology study of lead-exposed cohort. *Clin Toxicol* 27(1 and 2):37-51.
- Patel AB, Prabhu AS. 2009. Determinants of lead level in umbilical cord blood. *Indian Pediatr* 46(9):791-793.
- Patil AJ, Bhagwat VR, Patil JA, et al. 2006. Effect of lead (Pb) exposure on the activity of superoxide dismutase and catalase in battery manufacturing workers (BMW) of Western Maharashtra (India) with reference to heme biosynthesis. *Int J Environ Res Public Health* 3(4):329-337.
- Patil AJ, Bhagwat VR, Patil JA, et al. 2007. Occupational lead exposure in battery manufacturing workers, silver jewelry workers, and spray painters in western Maharashtra (India): Effect on liver and kidney function. *J Basic Clin Physiol Pharmacol* 18(2):87-100. 10.1515/JBCPP.2007.18.2.87.
- Pawlas N, Broberg K, Olewinska E, et al. 2012. Modification by the genes ALAD and VDR of lead-induced cognitive effects in children. *Neurotoxicology* 33:37-43.
- Pawlas N, Broberg K, Skerfving S, et al. 2014. Disturbance of posture in children with very low lead exposure, and modification by VDR FokI genotype. *Ann Agric Environ Med* 21(4):739-744. 10.5604/12321966.1129926.
- Pawlas N, Plachetka A, Kozłowska A, et al. 2015. Telomere length in children environmentally exposed to low-to-moderate levels of lead. *Toxicol Appl Pharmacol* 287(2):111-118. 10.1016/j.taap.2015.05.005.
- Pawlas N, Plachetka A, Kozłowska A, et al. 2016. Telomere length, telomerase expression, and oxidative stress in lead smelters. *Toxicol Ind Health* 32(12):1961-1970. 10.1177/0748233715601758.

8. REFERENCES

- Payton M, Hu H, Sparrow D, et al. 1994. Low-level lead exposure and renal function in the Normative Aging Study. *Am J Epidemiol* 140(9):821-829.
- Payton M, Riggs KM, Sprio A, et al. 1998. Relations of bone and blood lead to cognitive function: The VA Normative Aging Study. *Neurotoxicol Teratol* 20(1):19-27.
- PEHSU. 2013. Recommendations on medical management of childhood lead exposure and poisoning. Pediatric Environmental Health Specialty Units.
- Pekcici R, Kavlakoglu B, Yilmaz S, et al. 2010. Effects of lead on thyroid functions in lead-exposed workers. *Cent Eur J Med* 5(2):215-218. 10.2478/s11536-009-0092-8.
- Pellizzari ED, Perritt RL, Clayton CA. 1999. National Human Exposure Assessment Survey (NHEXAS): Exploratory survey of exposure among population subgroups in EPA region V. *J Expo Anal Environ Epidemiol* 9:49-55.
- Peralta-Videa JR, Lopez ML, Narayan M, et al. 2009. The biochemistry of environmental heavy metal uptake by plants: Implications for the food chain. *Int J Biochem Cell Biol* 41(8-9):1665-1677. 10.1016/j.biocel.2009.03.005.
- Pergande M, Jung K, Precht S, et al. 1994. Changed excretion of urinary proteins and enzymes by chronic exposure to lead. *Nephrol Dial Transplant* 9:613-618.
- Perkins M, Wright RO, Amarasiwardena CJ, et al. 2014. Very low maternal lead level in pregnancy and birth outcomes in an eastern Massachusetts population. *Ann Epidemiol* 24(12):915-919. 10.1016/j.annepidem.2014.09.007.
- Perlstein T, Weuve J, Schwartz J, et al. 2007. Cumulative community-level lead exposure and pulse pressure: The Normative Aging Study. *Environ Health Perspect* 115(12):1696-1700. 10.1289/ehp.10350.
- Perneger TV, Nieto FJ, Whelton PK, et al. 1993. A prospective study of blood pressure and serum creatinine: Results from the 'Clue' Study and the ARIC Study. *J Am Med Assoc* 269:488-493.
- Perroy RL, Belby CS, Mertens CJ. 2014. Mapping and modeling three dimensional lead contamination in the wetland sediments of a former trap-shooting range. *Sci Total Environ* 487:72-81. 10.1016/j.scitotenv.2014.03.102.
- Peryea FJ. 1998. Historical use of lead arsenate insecticides, resulting soil contamination and implications for soil remediation. Proceedings of the 16th World Congress of Soil Science, Montpellier, France, 20-26 August 1998.
- Pesch B, Haerting J, Ranft U, et al. 2000. Occupational risk factors for renal cell carcinoma: Agent-specific results from a case-control study in Germany. *Int J Epidemiol* 29:1014-1024.
- Peters JL, Kubzansky L, McNeely E, et al. 2007. Stress as a potential modifier of the impact of lead levels on blood pressure: The Normative Aging Study. *Environ Health Perspect* 115(8):1154-1159. 10.1289/ehp.10002.
- Petrucci R, Leonardi A, Battistuzzi G. 1982. The genetic polymorphism of δ -aminolevulinic acid dehydratase in Italy. *Hum Genet* 60(3):289-290.
- Pierzynski GM, Schwab AP. 1993. Heavy metals in the environment. Bioavailability of zinc, cadmium, and lead in a metal-contaminated alluvial soil. *J Environ Qual* 22:247-254.
- Pilsner JR, Hu H, Ettinger A, et al. 2009. Influence of prenatal lead exposure on genomic methylation of cord blood DNA. *Environ Health Perspect* 117(9):1466-1471. 10.1289/ehp.0800497.
- Pineda-Zavaleta AP, García-Vargas G, Borja-Aburto VH, et al. 2004. Nitric oxide and superoxide anion production in monocytes from children exposed to arsenic and lead in region Lagunera, Mexico. *Toxicol Appl Pharmacol* 198(3):283-290. 10.1016/j.taap.2003.10.034.
- Pingitore NE, Jr., Clague JW, Amaya MA, et al. 2009. Urban airborne lead: X-ray absorption spectroscopy establishes soil as dominant source. *PLoS ONE* 4(4):e5019. 10.1371/journal.pone.0005019.
- Pinkerton LE, Biagini RE, Ward EM, et al. 1998. Immunologic findings among lead-exposed workers. *Am J Ind Med* 33(4):400-408. 10.1002/(SICI)1097-0274(199804)33:4<400::AID-AJIM11>3.0.CO;2-2.

8. REFERENCES

- Pinto D, Ceballos JM, García G, et al. 2000. Increased cytogenetic damage in outdoor painters. *Mutat Res* 467(2):105-111. 10.1016/S1383-5718(00)00024-3.
- Pinto de Almeida AR, Carvalho FM, Spinola AG, et al. 1987. Renal dysfunction in Brazilian lead workers. *Am J Nephrol* 7(6):455-458.
- Piomelli S, Seaman C, Zullo D, et al. 1982. Threshold for lead damage to heme synthesis in urban children. *Proc Natl Acad Sci USA* 79:3335-3339.
- Pirkle JL, Brody DJ, Gunter EW, et al. 1994. The decline in blood lead levels in the United States. The National Health and Nutrition Examination Surveys (NHANES). *J Am Med Assoc* 272(4):284-291.
- Pirkle JL, Kaufmann RB, Brody DJ, et al. 1998. Exposure of the U.S. population to lead, 1991-1994. *Environ Health Perspect* 106(11):745-750.
- Pirkle JL, Schwartz J, Landis JR, et al. 1985. The relationship between blood lead levels and blood pressure and its cardiovascular risk implications. *Am J Epidemiol* 121(2):246-258.
- Pizent A, Macan J, Jurasović J, et al. 2008. Association of toxic and essential metals with atopy markers and ventilatory lung function in women and men. *Sci Total Environ* 390(2-3):369-376. 10.1016/j.scitotenv.2007.10.049.
- Pocock SJ, Shaper AG, Ashby D, et al. 1984. Blood lead concentration, blood pressure, and renal function. *Br Med J* 289:872-874.
- Pocock SJ, Shaper AG, Ashby D, et al. 1988. The relationship between blood lead, blood pressure, stroke, and heart attacks in middle-aged British men. *Environ Health Perspect* 78:23-30.
- Pocock SJ, Shaper AG, Walker M, et al. 1983. Effects of tap water lead, water hardness, alcohol, and cigarettes on blood lead concentrations. *J Epidemiol Community Health* 37:1-7.
- Pollack AZ, Mumford SL, Mendola P, et al. 2015. Kidney biomarkers associated with blood lead, mercury, and cadmium in premenopausal women: A prospective cohort study. *J Toxicol Environ Health A* 78(2):119-131. 10.1080/15287394.2014.944680.
- Pollack AZ, Mumford SL, Wactawski-Wende J, et al. 2013. Bone mineral density and blood metals in premenopausal women. *Environ Res* 120:76-81.
- Pollack AZ, Schisterman EF, Goldman LR, et al. 2011. Cadmium, lead, and mercury in relation to reproductive hormones and anovulation in premenopausal women. *Environ Health Perspect* 119(8):1156-1161. 10.1289/ehp.1003284.
- Popovic M, McNeill FE, Chettle DR, et al. 2005. Impact of occupational exposure on lead levels in women. *Environ Health Perspect* 113(4):478-484.
- Poreba R, Gac P, Poreba M, et al. 2012. Assessment of cardiovascular risk in workers occupationally exposed to lead without clinical presentation of cardiac involvement. *Environ Toxicol Pharmacol* 34(2):351-357. 10.1016/j.etap.2012.05.008.
- Poreba R, Gac P, Poreba M, et al. 2013. Echocardiographic assessment of myocardial function in workers occupationally exposed to lead without clinically evident heart disease. *Environ Toxicol Pharmacol* 36(2):522-528. 10.1016/j.etap.2013.05.010.
- Poreba R, Poreba M, Gać P, et al. 2011. Ambulatory blood pressure monitoring and structural changes in carotid arteries in normotensive workers occupationally exposed to lead. *Hum Exp Toxicol* 30(9):1174-1180. 10.1177/09603271110391383.
- Pounds JG, Leggett RW. 1998. The ICRP age-specific biokinetic model for lead: Validations, empirical comparisons, and explorations. *Environ Health Perspect* 106(Suppl 6):1505-1511.
- Pounds JG, Marlar RJ, Allen JR. 1978. Metabolism of lead-210 in juvenile and adult Rhesus monkeys (*Macaca mulatta*). *Bull Environ Contam Toxicol* 19(1):684-691.
- Power MC, Korrick S, Tchetchen EJ, et al. 2014. Lead exposure and rate of change in cognitive function in older women. *Environ Res* 129:69-75. 10.1016/j.envres.2013.12.010.
- Presley SM, Abel MT, Austin GP, et al. 2010. Metal concentrations in schoolyard soils from New Orleans, Louisiana before and after hurricanes Katrina and Rita. *Chemosphere* 80(1):67-73. 10.1016/j.chemosphere.2010.03.031.
- Proctor SP, Rotnitzky A, Sparrow D, et al. 1996. The relationship of blood lead and dietary calcium to blood pressure in the Normative Aging Study. *Int J Epidemiol* 25(3):528-536.

8. REFERENCES

- Pugh Smith P, Nriagu JO. 2011. Lead poisoning and asthma among low-income and African American children in Saginaw, Michigan. *Environ Res* 111(1):81-86. 10.1016/j.envres.2010.11.007.
- Queirolo EI, Ettinger AS, Stoltzfus RJ, et al. 2010. Association of anemia, child and family characteristics with elevated blood lead concentrations in preschool children from Montevideo, Uruguay. *Arch Environ Occup Health* 65(2):94-100. 10.1080/19338240903390313.
- Queiroz MLS, Almeida M, Gallão MI, et al. 1993. Defective neutrophil function in workers occupationally exposed to lead. *Pharmacol Toxicol* 72(2):73-77. 10.1111/j.1600-0773.1993.tb00293.x.
- Queiroz MLS, Costa FF, Bincoletto C, et al. 1994a. Engulfment and killing capabilities of neutrophils and phagocytic splenic function in persons occupationally exposed to lead. *Int J Immunopharmacol* 16(3):239-244. 10.1016/0192-0561(94)90018-3.
- Queiroz MLS, Perlingeiro RCR, Bincoletto C, et al. 1994b. Immunoglobulin levels and cellular immune function in lead exposed workers. *Immunopharmacol Immunotoxicol* 16(1):115-128. 10.3109/08923979409029904.
- Rabinowitz MB. 1995. Relating tooth and blood lead levels in children. *Bull Environ Contam Toxicol* 55:853-857.
- Rabinowitz M, Bellinger D, Leviton A, et al. 1987. Pregnancy hypertension, blood pressure during labor, and blood lead levels. *Hypertension* 10:447-451.
- Rabinowitz M, Leviton A, Bellinger D. 1985. Home refinishing, lead paint and infant blood lead levels. *Am J Public Health* 75(4):403-404.
- Rabinowitz MB, Allred EN, Bellinger DC, et al. 1990. Lead and childhood propensity to infectious and allergic disorders: Is there an association? *Bull Environ Contam Toxicol* 44(5):657-660. 10.1007/BF01701784.
- Rabinowitz MB, Kopple JD, Wetherill GW. 1980. Effect of food intake and fasting on gastrointestinal lead absorption in humans. *Am J Clin Nutr* 33:1784-1788.
- Rabinowitz MB, Wetherill GW, Kopple JD. 1976. Kinetic analysis of lead metabolism in healthy humans. *J Clin Invest* 58:260-270.
- Rabito FA, Kocak M, Werthmann DW, et al. 2014. Changes in low levels of lead over the course of pregnancy and the association with birth outcomes. *Reprod Toxicol* 50:138-144. 10.1016/j.reprotox.2014.10.006.
- Rajan P, Kelsey KT, Schwartz JD, et al. 2007. Lead burden and psychiatric symptoms and the modifying influence of the δ -aminolevulinic acid dehydratase (ALAD) polymorphism: The VA Normative Aging Study. *Am J Epidemiol* 166(12):1400-1408. 10.1093/aje/kwm220.
- Rajan P, Kelsey KT, Schwartz JD, et al. 2008. Interaction of the δ -aminolevulinic acid dehydratase polymorphism and lead burden on cognitive function: The VA Normative Aging Study. *J Occup Environ Med* 50(9):1053-1061. 10.1097/JOM.0b013e3181792463.
- Rajaraman P, Stewart PA, Samet JM, et al. 2006. Lead, genetic susceptibility, and risk of adult brain tumors. *Cancer Epidemiol Biomarkers Prev* 15(12):2514-2520. 10.1158/1055-9965.EPI-06-0482.
- Rapisarda V, Ledda C, Ferrante M, et al. 2016. Blood pressure and occupational exposure to noise and lead (Pb): A cross-sectional study. *Toxicol Ind Health* 32(10):1729-1736. 10.1177/0748233715576616.
- Ravnskov U. 1992. Cholesterol lowering trials in coronary heart disease: Frequency of citation and outcome. *Br Med J* 305:15-19.
- Raymond J, Brown MJ. 2015a. Childhood blood lead levels - United States, 2007-2012 [Erratum: *MMWR* 64(45):1277]. *MMWR Morb Mortal Wkly Rep* 62(54):76-80. 10.15585/mmwr.mm6254a5.
- Raymond J, Brown MJ. 2015b. Childhood blood lead levels - United States, 2007-2012 [Erratum to: *MMWR* 62(54):76-80]. *MMWR Morb Mortal Wkly Rep* 64(45):1277.
- Raymond J, Brown MJ. 2017. Childhood blood lead levels in children aged <5 years - United States, 2009-2014. *MMWR Morb Mortal Wkly Rep* 66(3):1-7.

8. REFERENCES

- Reddy KJ, Wang L, Gloss SP. 1995. Solubility and mobility of copper, zinc, and lead in acidic environments. *Plant Soil* 171:53-58.
- Reddy YS, Yamarthi A, Ramalaksmi BA, et al. 2014. Lead and trace element levels in placenta, maternal and cord blood: A cross-sectional pilot study. *J Obstet Gynaecol Res* 40(12):2184-2190. 10.1111/jog.12469.
- Reed BE, Moore RE, Cline SR. 1995. Soil flushing of a sandy loam contaminated with Pb(II), PbSO₄ (s), PbCO₃ (3) or Pb-naphthalene: Column results. *J Soil Contam* 4(3):243-267.
- Rees DC, Duley JA, Marinaki AM. 2003. Pyrimidine 5' nucleotidase deficiency. *Br J Haematol* 120(3):375-383.
- Reimer W, Tittelbach U. 1989. Verhalten von Herzfrequenz, Blutdruck und systolischen Zeitintervallen in Ruhe und während einhandarbeit bei bleiexponierten und kontrollpersonen. *Z Gesamte Hyg* 35:491-492. (German)
- Rentschler G, Broberg K, Lundh T, et al. 2012. Long-term lead elimination from plasma and whole blood after poisoning. *Int Arch Occup Environ Health* 85(3):311-316. 10.1007/s00420-011-0673-0.
- Rezende VB, Barbosa F, Montenegro MF, et al. 2008. Haplotypes of vitamin D receptor modulate the circulating levels of lead in exposed subjects. *Arch Toxicol* 82:29-36.
- Reuben A, Caspi A, Belsky DW, et al. 2017. Association of childhood blood lead levels with cognitive function and socioeconomic status at age 38 years and with IQ change and socioeconomic mobility between childhood and adulthood. *JAMA* 317(12):1244-1251. <http://doi.org/10.1001/jama.2017.1712>.
- Rhoads GG, Ettinger AS, Weisel CP, et al. 1999. The effect of dust lead control on blood lead in toddlers: A randomized trial. *Pediatrics* 103(3):551-555.
- Rhodes D, Spiro III A, Aro A, et al. 2003. Relationship of bone and blood lead levels to psychiatric symptoms: The Normative Aging Study. *J Occup Environ Med* 45(11):1144-1151.
- Richter PA, Bishop EE, Wang J, et al. 2013. Trends in tobacco smoke exposure and blood lead levels among youths and adults in the United States: The National Health and Nutrition Examination Survey, 1999-2008. *Prev Chronic Dis* 10 10.588/pcd10.130056.
- Riddell TJ, Solon O, Quimbo SA, et al. 2007. Elevated blood-lead levels among children living in the rural Philippines. *Bull World Health Org* 85(9):674-680.
- Riedt CS, Buckley BT, Brolin RE, et al. 2009. Blood lead levels and bone turnover with weight reduction in women. *J Expo Sci Environ Epidemiol* 19:90-96.
- Ris MD, Dietrich KN, Succop PA, et al. 2004. Early exposure to lead and neuropsychological outcome in adolescence. *J Int Neuropsychol Soc* 10(2):261-270. 10.1017/S1355617704102154.
- Risch HA, Burch JD, Miller AB, et al. 1988. Occupational factors and the incidence of cancer of the bladder in Canada. *Br J Ind Med* 45:361-367.
- Robins JM, Cullen MR, Connors BB, et al. 1983. Depressed thyroid indexes associated with occupational exposure to inorganic lead. *Arch Intern Med* 143:220-224.
- Robinson G, Baumann S, Kleinbaum D, et al. 1985. Effects of low to moderate lead exposure on brainstem auditory evoked potentials in children. *Neurobehavioural methods in occupational and environmental health: Extended Abstracts from the Second International Symposium, Copenhagen, 6-9 August 1985*, 3:177-182.
- Rodamilans M, Osaba MJ, To-Figueras J, et al. 1988. Lead toxicity on endocrine testicular function in an occupationally exposed population. *Hum Toxicol* 7:125-128.
- Rodrigues JL, Batista BL, Nunes JA, et al. 2008. Evaluation of the use of human hair for biomonitoring the deficiency of essential and exposure to toxic elements. *Sci Total Environ* 405(1-3):370-376. 10.1016/j.scitotenv.2008.06.002.
- Roels H, Lauwerys R. 1987. Evaluation of dose-effect and dose-response relationships for lead exposure in different Belgian population groups (fetus, child, adult men and women). *Trace Elem Med* 4(2):80-87.
- Roels H, Buchet JP, Lauwerys R, et al. 1976. Impact of air pollution by lead on the heme biosynthetic pathway in school-age children. *Arch Environ Health* Nov/Dec:310-315.

8. REFERENCES

- Roels H, Konings J, Green S, et al. 1995. Time-integrated blood lead concentration is a valid surrogate for estimating the cumulative lead dose assessed by tibial lead measurement. *Environ Res* 69(2):75-82.
- Roels H, Lauwerys R, Buchet J, et al. 1975. Response of free erythrocyte porphyrin and urinary δ -aminolevulinic acid in men and women moderately exposed to lead. *Int Arch Occup Environ Health* 34(2):97-108.
- Roels H, Lauwerys R, Konings J, et al. 1994. Renal function and hyperfiltration capacity in lead smelter workers with high bone lead. *Occup Environ Med* 51:505-512.
- Roels HA, Balis-Jacques MN, Buchet J-P, et al. 1979. The influence of sex and of chelation therapy on erythrocyte protoporphyrin and urinary δ -aminolevulinic acid in lead-exposed workers. *J Occup Environ Med* 21(8):527-539.
- Rokadia H, Agarwal S. 2013. Serum heavy metals and obstructive lung disease: Results from the National Health and Nutrition Examination Survey. *Chest* 143(2):388-397. 10.1378/chest.12-0595.
- Romeo R, Aprea C, Boccalon P, et al. 1996. Serum erythropoietin and blood lead concentrations. *Int Arch Occup Environ Health* 69:73-75.
- Ronco AM, Gutierrez Y, Gras N, et al. 2010. Lead and arsenic levels in women with different body mass composition. *Biol Trace Elem Res* 136:269-278. 10.1007/s12011-009-8546-z.
- Rooney CP, McLaren RG, Condrion LM. 2007. Control of lead solubility in soil contaminated with lead shot: Effect of soil pH. *Environ Pollut* 149:149-157. 10.1016/j.envpol.2007.01.009.
- Root RA. 2000. Lead loading of urban streets by motor vehicle wheel weights. *Environ Health Perspect* 108(10):937-940.
- Roscoe RJ, Gittleman JL, Deddens JA, et al. 1999. Blood lead levels among children of lead-exposed workers: A meta-analysis. *Am J Med* 36(4):475-481.
- Rosen JF, Chesney RW, Hamstra A, et al. 1980. Reduction in 1,25-dihydroxyvitamin D in children with increased lead absorption. *N Engl J Med* 302(20):1128-1131.
- Rosenman KD, Sims A, Luo Z, et al. 2003. Occurrence of lead-related symptoms below the current occupational safety and health act allowable blood lead levels. *J Occup Environ Med* 45(5):546-555.
- Rothenberg SJ, Kondrashov V, Manalo M, et al. 2002b. Increases in hypertension and blood pressure during pregnancy with increased bone lead levels. *Am J Epidemiol* 156(12):1079-1087.
- Rothenberg SJ, Schnaas L, Cansino-Ortiz S, et al. 1989. Neurobehavioral deficits after low level lead exposure in neonates: The Mexico City pilot study. *Neurotoxicol Teratol* 11:85-93.
- Rothenberg SJ, Schnaas L, Salgado-Valladares M, et al. 2002a. Increased ERG a- and b-wave amplitudes in 7- to 10-year-old children resulting from prenatal lead exposure. *Invest Ophthalmol Visual Sci* 43(6):2036-2044.
- Rousseau MC, Parent ME, Nadon L, et al. 2007. Occupational exposure to lead compounds and risk of cancer among men: A population-based case-control study. *Am J Epidemiol* 166(9):1005-1014. 10.1093/aje/kwm183.
- Roussel H, Waterlot C, Pelfrene A, et al. 2010. Cd, Pb and Zn oral bioaccessibility of urban soils contaminated in the past by atmospheric emissions from two lead and zinc smelters. *Arch Environ Contam Toxicol* 58(4):945-954. 10.1007/s00244-009-9425-5.
- Roy A, Bellinger D, Hu H, et al. 2009. Lead exposure and behavior among young children in Chennai, India. *Environ Health Perspect* 117(10):1607-1611. 10.1289/ehp.0900625.
- Roy A, Ettinger AS, Hu H, et al. 2013. Effect modification by transferrin C2 polymorphism on lead exposure, hemoglobin levels, and IQ. *Neurotoxicology* 38:17-22. 10.1016/j.neuro.2013.05.005.
- Roy A, Hu H, Bellinger DC, et al. 2011. Hemoglobin, lead exposure, and intelligence quotient: Effect modification by the DRD2 Taq IA polymorphism. *Environ Health Perspect* 119(1):144-149. 10.1289/ehp.0901878.
- RTECS. 2015. Lead and lead compounds. Registry of Toxic Effects on Chemical Substances. National Institute for Occupational Safety and Health. MDL Information Systems, Inc. <http://ccinfoweb.ccohs.ca/rtecs/search.html>. April 06, 2016.

8. REFERENCES

- Ruby MV, Schoof R, Brattin W, et al. 1999. Advances in evaluating the oral bioavailability of inorganics in soil for use in human health risk assessment. *Environ Sci Technol* 33(21):3697-3705.
- Ryan JA, Scheckel KG, Berti WR, et al. 2004. Reducing children's risk from lead in soil. *Environ Sci Technol* 38:19A-24A.
- Ryu JE, Ziegler EE, Nelson SE, et al. 1983. Dietary intake of lead and blood lead concentration in early infancy. *Am J Dis Child* 137:886-891.
- Sabin LD, Schiff KC. 2008. Dry atmospheric deposition rates of metals along a coastal transect in southern California. *Atmos Environ* 42(27):6606-6613. 10.1016/j.atmosenv.2008.04.042.
- Sabin LD, Lim JH, Stolzenbach KD, et al. 2006. Atmospheric dry deposition of trace metals in the coastal region of Los Angeles, California, USA. *Environ Toxicol Chem* 25(9):2334-2341. 10.1897/05-300r.1.
- Sadeghniaat-Haghighi K, Saraie M, Ghasemi M, et al. 2013. Assessment of peripheral neuropathy in male hospitalized patients with lead toxicity in Iran. *J Res Med Sci* 18(1):6-9.
- Saikat S, Barnes B, Westwood D. 2007. A review of laboratory results for bioaccessibility values of arsenic, lead and nickel in contaminated UK soils. *J Environ Sci Health, Part A* 42(9):1213-1221. 10.1080/10934520701435486.
- Sakai T. 2000. Biomarkers of lead exposure. *Ind Health* 38:127-142.
- Sakai T, Morita Y. 1996. δ -Aminolevulinic acid in plasma or whole blood as a sensitive indicator of lead effects, and its relation to the other heme-related parameters. *Int Arch Occup Environ Health* 68:126-132.
- Sakai T, Morita Y, Araki T, et al. 2000. Relationship between δ -aminolevulinic acid dehydratase genotypes and heme precursors in lead workers. *Am J Ind Med* 38:355-360.
- Sakai T, Yanagihara S, Kunugi Y, et al. 1982. Relationships between distribution of lead in erythrocytes *in vivo* and *in vitro* and inhibition of ALA-D. *Br J Ind Med* 39:382-387.
- Sakai T, Yanagihara S, Kunugi Y, et al. 1983. Mechanisms of ALA-D inhibition by lead and of its restoration by zinc and dithiothreitol. *Br J Ind Med* 40:61-66.
- Sakata S, Shimizu S, Ogoshi K, et al. 2007. Inverse relationship between serum erythropoietin and blood lead concentrations in Kathmandu tricycle taxi drivers. *Int Arch Occup Environ Health* 80(4):342-345. 10.1007/s00420-006-0125-4.
- Sallmen M, Anttila A, Lindbohm ML, et al. 1995. Time to pregnancy among women occupationally exposed to lead. *J Occup Environ Med* 37(8):931-934.
- Sallmén M, Lindbohm M-L, Nurminen M. 2000. Paternal exposure to lead and infertility. *Epidemiology* 11(2):148-152.
- Sanin LH, Gonzalez-Cossio T, Romieu I, et al. 2001. Effect of maternal lead burden on infant weight and weight gain at one month of age among breastfed infants. *Pediatrics* 107(5):1016-1023.
- Sankila R, Karjalainen A, Pukkala E, et al. 1990. Cancer risk among glass factory workers: An excess of lung cancer? *Br J Ind Med* 47:815-818.
- Sanna E, Vallascas E. 2011. Hair lead levels to evaluate the subclinical impact of lead on growth in Sardinian children (Italy). *Am J Hum Biol* 23(6):740-746. 10.1002/ajhb.21203.
- Santibanez M, Vioque J, Alguacil J, et al. 2008. Occupational exposures and risk of oesophageal cancer by histological type: A case-control study in eastern Spain. *Occup Environ Med* 65(11):774-781. 10.1136/oem.2007.037929.
- Sarasua SM, Vogt RF, Henderson LO, et al. 2000. Serum immunoglobulins and lymphocyte subset distributions in children and adults living in communities assessed for lead and cadmium exposure. *J Toxicol Environ Health Part A* 60(1):1-15. 10.1080/009841000156556.
- Sata F, Araki S, Tanigawa T, et al. 1998. Changes in T cell subpopulations in lead workers. *Environ Res* 76(1):61-64.
- Sauve S, McBride MB, Hendershot WH. 1997. Speciation of lead in contaminated soils. *Environ Pollut* 98(2):149-155.
- Schalscha EB, Morales M, Pratt PF. 1987. Lead and molybdenum in soils and forage near an atmospheric source. *J Environ Qual* 16(4):313-315.

8. REFERENCES

- Schaumberg DA, Mendes F, Balaram M, et al. 2004. Accumulated lead exposure and risk of age-related cataract in men. *JAMA* 292(22):2750-2754.
- Schell LM, Denham M, Stark AD, et al. 2004. Relationship between blood lead concentration and dietary intakes of infants from 3 to 12 months of age. *Environ Res* 96(3):264-273. 10.1016/j.envres.2004.02.008.
- Schell LM, Denham M, Stark AD, et al. 2009. Growth of infants' length, weight, head and arm circumferences in relation to low levels of blood lead measured serially. *Am J Hum Biol* 21(2):180-187. 10.1002/ajhb.20842.
- Schmitt CJ, Brumbaugh WG. 1990. National contaminant biomonitoring program: Concentrations of arsenic, cadmium, copper, lead, mercury, selenium, and zinc in U.S. freshwater fish, 1976-1984. *Arch Environ Contam Toxicol* 19:731-747.
- Schmitt MDC, Trippler DJ. 1988. Soil lead concentrations in residential Minnesota as measured by ICP-AES. *Water Air Soil Pollut* 39:157-168.
- Schnaas L, Rothenberg SJ, Flores MF, et al. 2004. Blood lead secular trend in a cohort of children in Mexico City (1987-2002). *Environ Health Perspect* 112(10):1110-1115.
- Schnaas L, Rothenberg SJ, Flores MF, et al. 2006. Reduced intellectual development in children with prenatal lead exposure. *Environ Health Perspect* 114(5):791-797. 10.1289/ehp.8552.
- Schnaas L, Rothenberg SJ, Perroni E, et al. 2000. Temporal pattern in the effect of postnatal blood lead level on intellectual development of young children. *Neurotoxicol Teratol* 22:805-810.
- Schober SE, Mirel LB, Graubard BI, et al. 2006. Blood lead levels and death from all causes, cardiovascular disease, and cancer: Results from the NHANES III Mortality Study. *Environ Health Perspect* 114(10):1538-1541.
- Schroeder HA, Tipton IH. 1968. The human body burden of lead. *Arch Environ Health* 17(6):965-978.
- Schuhmacher M, Paternain JL, Domingo JL, et al. 1997. An assessment of some biomonitors indicative of occupational exposure to lead. *Trace Elem Electrolytes* 14(3):145-149.
- Schumacher C, Brodtkin CA, Alexander B, et al. 1998. Thyroid function in lead smelter workers: Absence of subacute or cumulative effects with moderate lead burdens. *Int Arch Occup Environ Health* 71(7):453-458.
- Schutz A, Bergdahl IA, Ekholm A, et al. 1996. Measurement by ICP-MS of lead in plasma and whole blood of lead workers and controls. *Occup Environ Med* 53:736-740.
- Schutz A, Skerfving S, Ranstam J, et al. 1987. Kinetics of lead in blood after the end of occupational exposure. *Scand J Work Environ Health* 13:221-231.
- Schwartz G, Gebhart E, Rott H-D, et al. 1975. Chromosomenuntersuchungen bei Personen mit beruflicher Bleiexposition. *DMW-Deutsche Medizinische Wochenschrift* 100(18):1007-1011.
- Schwartz G, Leinert G, Gebhart E. 1970. Chromosome damage after occupational exposure to lead. *Dtsch Med Wochenschr* 95(32):1636-1641.
- Schwartz J. 1995. Lead, blood pressure, and cardiovascular disease in men. *Arch Environ Health* 50(1):31-37.
- Schwartz J, Otto D. 1987. Blood lead, hearing threshold, and neurobehavioral development in children and youth. *Arch Environ Health* 42(2; 2):153-160.
- Schwartz J, Otto D. 1991. Lead and minor hearing impairment. *Arch Environ Health* 46(5):300-305.
- Schwartz J, Pitcher H. 1989. The relationship between gasoline lead and blood lead in the United States. *J Off Stat* 5:421-431.
- Schwartz BS, Lee BK, Bandeen-Roche K, et al. 2005. Occupational lead exposure and longitudinal decline in neurobehavioral test scores. *Epidemiology* 16(1):106-113. 10.1097/01.ede.0000147109.62324.51.
- Schwartz BS, Lee BK, Lee GS, et al. 2000a. Associations of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with polymorphisms in the vitamin D receptor and δ -aminolevulinic acid dehydratase genes. *Environ Health Perspect* 108(10):949-954.

8. REFERENCES

- Schwartz BS, Lee BK, Lee GS, et al. 2001. Associations of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with neurobehavioral test scores in South Korean lead workers. *Am J Epidemiol* 153(5):453-464.
- Schwartz BS, Lee BK, Stewart W, et al. 1995. Associations of δ -aminolevulinic acid dehydratase genotype with plant, exposure duration, and blood lead and zinc protoporphyrin levels in Korean lead workers. *Am J Epidemiol* 142(7):738-745.
- Schwartz BS, Lee BK, Stewart W, et al. 1997a. Associations of subtypes of hemoglobin with δ -aminolevulinic acid dehydratase genotype and dimercaptosuccinic acid-chelatable lead levels. *Arch Environ Health* 52(2):97-103.
- Schwartz BS, Lee BK, Stewart W, et al. 1997b. δ -Aminolevulinic acid dehydratase genotype modifies four hour urinary lead excretion after oral administration of dimercaptosuccinic acid. *Occup Environ Med* 54(4):241-246.
- Schwartz BS, Stewart W, Bolla K, et al. 2000b. Past adult lead exposure is associated with longitudinal decline in cognitive function. *Neurology* 55(8):1144-1150.
- Schwartz BS, Stewart WF, Todd AC, et al. 2000c. Different associations of blood lead, meso 2,3-dimercaptosuccinic acid (DMSA)-chelatable lead, and tibial lead levels with blood pressure in 543 organolead manufacturing workers. *Arch Environ Health* 55:85-92.
- Schwartz J, Landrigan PJ, Baker EL, et al. 1990. Lead-induced anemia: Dose-response relationships and evidence for a threshold. *Am J Public Health* 80(2):165-168.
- Schwartz J, Landrigan PJ, Feldman RG, et al. 1988. Threshold effect in lead-induced peripheral neuropathy. *J Pediatr* 112:12-17.
- Scinicariello F, Abadin HG, Murray HE. 2011. Association of blood lead and blood pressure in the NHANES 1999-2006. *Environ Res* 111(8):1249-1257.
- Scinicariello F, Buser MC. 2015. Blood cadmium and depressive symptoms in young adults (aged 20-39 years). *Psychol Med* 45(4):807-815.
- Scinicariello F, Buser MC, Mevissen M, et al. 2013. Blood lead level association with lower body weight in NHANES 1999-2006. *Toxicol Appl Pharmacol* 273(3):516-523. 10.1016/j.taap.2013.09.022.
- Scinicariello F, Murray HE, Moffett DB, et al. 2007. Lead and δ -aminolevulinic acid dehydratase polymorphism: Where does it lead? A meta-analysis. *Environ Health Perspect* 115(1):35-41. 10.1289/ehp.9448.
- Scinicariello F, Yesupriya A, Chang MH, et al. 2010. Modification by ALAD of the association between blood lead and blood pressure in the U.S. population: Results from the Third National Health and Nutrition Examination Survey. *Environ Health Perspect* 118(2):259-264. 10.1289/ehp.0900866.
- Sears ME, Kerr KJ, Bray RI. 2012. Arsenic, cadmium, lead, and mercury in sweat: A systematic review. *J Environ Public Health* 2012:184745. 10.1155/2012/184745.
- Secchi GC, Erba L, Cambiaghi G. 1974. δ -Aminolevulinic dehydratase activity of erythrocytes and liver tissue in man. Relationship to lead exposure. *Arch Environ Health* 28:130-132.
- Sedman RM, Mahmood RJ. 1994. Soil ingestion by children and adults reconsidered using the results of recent tracer studies. *Air Waste* 44(2):141-144.
- Seegal RF, Fitzgerald EF, McCaffrey RJ, et al. 2013. Tibial bone lead, but not serum polychlorinated biphenyl, concentrations are associated with neurocognitive deficits in former capacitor workers. *J Occup Environ Med* 55(5):552-562. 10.1097/JOM.0b013e318285f3fd.
- Selevan SG, Landrigan PJ, Stern FB, et al. 1985. Mortality of lead smelter workers. *Am J Epidemiol* 122:673-683.
- Selevan SG, Rice DC, Hogan KA, et al. 2003. Blood lead concentration and delayed puberty in girls. *N Engl J Med* 348(16):1527-1536. 10.1056/NEJMoa020880.
- Selonen S, Liiri M, Strommer R, et al. 2012. The fate of lead at abandoned and active shooting ranges in a boreal pine forest. *Environ Toxicol Chem* 31(12):2771-2779. 10.1002/etc.1998.
- Seo J, Lee BK, Jin SU, et al. 2014. Lead-induced impairments in the neural processes related to working memory function. *PLoS ONE* 9(8):e105308. 10.1371/journal.pone.0105308.

8. REFERENCES

- Seto DSY, Freeman JM. 1964. Lead neuropathy in childhood. *Am J Dis Child* 107:337-342.
- Shah F, Kazi TG, Afridi HI, et al. 2010. Environmental exposure of lead and iron deficit anemia in children age ranged 1-5 years: A cross sectional study. *Sci Total Environ* 408(22):5325-5330. 10.1016/j.scitotenv.2010.07.091.
- Shah F, Kazi TG, Afridi HI, et al. 2011. The influence of environmental exposure on lead concentrations in scalp hair of children in Pakistan. *Ecotoxicol Environ Saf* 74(4):727-732. 10.1016/j.ecoenv.2010.10.036.
- Shaheen SM, Tsadilas CD. 2009. Concentration of lead in soils and some vegetable plants in north Nile Delta as affected by soil type and irrigation water. *Commun Soil Sci Plant Anal* 40(1-6):327-344.
- Shaik AP, Jamil K. 2009. Individual susceptibility and genotoxicity in workers exposed to hazardous materials like lead. *J Hazard Mater* 168(2-3):918-924. 10.1016/j.jhazmat.2009.02.129.
- Shao W, Liu Q, He X, et al. 2017. Association between level of urinary trace heavy metals and obesity among children aged 6-19 years: NHANES 1999-2011. *Environ Sci Pollut Res Int* 24:11573-11581. 10.1007/s11356-017-8803-1.
- Shaper AG, Pocock SJ, Walker M, et al. 1981. British regional heart study: Cardiovascular risk factors in middle-aged men in 24 towns. *Br Med J* 283:179-186.
- Sharp DS, Benowitz NL, Osterloh JD, et al. 1990. Influence of race, tobacco use, and caffeine use on the relation between blood pressure and blood lead concentration. *Am J Epidemiol* 131(5):845-854.
- Sharp DS, Osterloh J, Becker CE, et al. 1988. Blood pressure and blood lead concentration in bus drivers. *Environ Health Perspect* 78:131-137.
- Sharp DS, Smith AH, Holman BL, et al. 1989. Elevated blood pressure in treated hypertensives with low-level lead accumulation. *Arch Environ Health* 44:18-22.
- Sheffet A, Thind I, Miller AM, et al. 1982. Cancer mortality in a pigment plant utilizing lead and zinc chromates. *Arch Environ Health* 37(1):44-52.
- Shen XM, Wu SH, Yan C-H, et al. 2001. δ -Aminolevulinatase polymorphism and blood lead levels in Chinese children. *Environ Res* 85(3):185-190.
- Shen XM, Yan CH, Guo D, et al. 1998. Low-level prenatal lead exposure and neurobehavioral development of children in the first year of life: A prospective study in Shanghai. *Environ Res* 79:1-8.
- Sherlock J, Quinn M. 1986. Relationship between blood lead concentrations and dietary lead intake in infants: The Glasgow Duplicate Diet Study 1979-1980. *Food Addit Contam* 3(2):167-176.
- Sherlock J, Smart G, Forbes GI, et al. 1982. Assessment of lead intakes and dose-response for a population in Ayr exposed to a plumbosolvent water supply. *Hum Toxicol* 1:115-122.
- Sherlock JC, Ashby D, Delves HT, et al. 1984. Reduction in exposure to lead from drinking water and its effect on blood lead concentrations. *Hum Toxicol* 3:383-392.
- Shiau C, Wang J, Chen P. 2004. Decreased fecundity among male lead workers. *Occup Environ Med* 61(11):915-923.
- Shih RA, Glass TA, Bandeen-Roche K, et al. 2006. Environmental lead exposure and cognitive function in community-dwelling older adults. *Neurology* 67(9):1556-1562. 10.1212/01.wnl.0000239836.26142.c5.
- Shih RA, Hu H, Weisskopf MG, et al. 2007. Cumulative lead dose and cognitive function in adults: A review of studies that measured both blood lead and bone lead. *Environ Health Perspect* 115:483-492. 10.1289/ehp.9786.
- Shiue I. 2014. Higher urinary heavy metal, phthalate, and arsenic but not parabens concentrations in people with high blood pressure, U.S. NHANES, 2011-2012. *Int J Environ Res Public Health* 11:5989-5999. 10.3390/ijerph110605989.
- Siciliano SD, James K, Zhang G, et al. 2009. Adhesion and enrichment of metals on human hands from contaminated soil at an Arctic urban brownfield. *Environ Sci Technol* 43(16):6385-6390.
- Siegel M, Forsyth B, Siegel L, et al. 1989. The effect of lead on thyroid function in children. *Environ Res* 49:190-196.
- Siemiatycki J. 1991. Risk factors for cancer in the workplace. Boca Raton, FL: CRC Press.

8. REFERENCES

- Silbergeld EK, Schwartz J, Mahaffey K. 1988. Lead and osteoporosis: Mobilization of lead from bone in postmenopausal women. *Environ Res* 47(1):79-94.
- Silberstein T, Saphier O, Paz-Tal O, et al. 2006. Lead concentrates in ovarian follicle compromises pregnancy. *J Trace Elem Med Biol* 20(3):205-207. 10.1016/j.jtemb.2006.05.001.
- Simon DL, Maynard EJ, Thomas KD. 2007. Living in a sea of lead — changes in blood- and hand-lead of infants living near a smelter. *J Expo Sci Environ Epidemiol* 17(3):248-259. 10.1038/sj.jes.7500512.
- Simons TJB. 1985. Influence of lead ions on cation permeability in human red cell ghosts. *J Membr Biol* 84:61-71.
- Simons TJB. 1986a. The role of anion transport in the passive movement of lead across the human red cell membrane. *J Physiol* 378:287-312.
- Simons TJB. 1986b. Passive transport and binding of lead by human red blood cells. *J Physiol* 378:267-286.
- Simons TJB. 1988. Active transport of lead by the calcium pump in human red cell ghosts. *J Physiol* 405:105-113.
- Simons TJB. 1993. Lead transport and binding by human erythrocytes *in vitro*. *Pflugers Arch* 423:307-313.
- Simons TJB, Pocock G. 1987. Lead enters bovine adrenal medullary cells through calcium channels. *J Neurochem* 48:383-389.
- Singh B, Chandran V, Bandhu HK, et al. 2000. Impact of lead exposure on pituitary-thyroid axis in humans. *Biomaterials* 13:187-192.
- Singh Z, Chadha P, Sharma S. 2013. Evaluation of oxidative stress and genotoxicity in battery manufacturing workers occupationally exposed to lead. *Toxicol Int* 20(1):95-100. 10.4103/0971-6580.111550.
- Sioen I, Den Hond E, Nelen V, et al. 2013. Prenatal exposure to environmental contaminants and behavioural problems at age 7-8 years. *Environ Int* 59:225-231. 10.1016/j.envint.2013.06.014.
- Sirivarasai J, Wananukul W, Kaojarern S, et al. 2013. Association between inflammatory marker, environmental lead exposure, and glutathione S-transferase gene. *BioMed Res Int* 2013:474963. 10.1155/2013/474963.
- Sithisarankul P, Schwartz BS, Lee BK, et al. 1997. Aminolevulinic acid dehydratase genotype mediates plasma levels of the neurotoxin, 5-aminolevulinic acid, in lead-exposed workers. *Am J Ind Med* 32(1):15-20.
- Skerfving S. 1988. Biological monitoring of exposure to inorganic lead. *Biological Monitoring of Toxic Metals*, 169-197.
- Skerfving S, Bergdahl IA. 2015. Lead. Specific metals, Volume II. In: Nordberg GF, Fowler BA, eds. *Handbook of toxicology of metals*. Fourth ed. Academic Press, 911-967.
- Skerfving S, Ahlgren L, Christoffersson JO, et al. 1985. Metabolism of inorganic lead in man. *Nutr Res Suppl* 1:601-607.
- Slivkova J, Popelkova M, Massanyi P, et al. 2009. Concentration of trace elements in human semen and relation to spermatozoa quality. *J Environ Sci Health Part A* 44(4):370-375. 10.1080/10934520802659729.
- Smith GR. 1995. Lead. *Minerals yearbook: Volume I. Metals and minerals*.
- Smith D, Hernandez-Avila M, Tellez-Rojo MM, et al. 2002. The relationship between lead in plasma and whole blood in women. *Environ Health Perspect* 110(3):263-268.
- Smith DR, Ilustre RP, Osterloh JD. 1998a. Methodological considerations for the accurate determination of lead in human plasma and serum. *Am J Ind Med* 33:430-438.
- Smith DR, Kahng MW, Quintanilla-Vega B, et al. 1998b. High-affinity renal lead-binding proteins in environmentally-exposed humans. *Toxicol Appl Pharmacol* 115:39-52.
- Smith DR, Osterloh JD, Flegal AR. 1996. Use of endogenous, stable lead isotopes to determine release of lead from the skeleton. *Environ Health Perspect* 104(1):60-66.

8. REFERENCES

- Smith E, Weber J, Naidu R, et al. 2011. Assessment of lead bioaccessibility in peri-urban contaminated soil. *J Hazard Mater* 186(1):300-305. 10.1016/j.jhazmat.2010.10.111.
- Smith FL, Rathmell TK, Marcil GE. 1938. The early diagnosis of acute and latent plumbism. *Am J Clin Pathol* 8:471-508.
- Sobin C, Flores-Montoya MG, Gutierrez M, et al. 2015. δ -Aminolevulinic acid dehydratase single nucleotide polymorphism 2 (ALAD2) and peptide transporter 2 haplotype (hPEPT2) differently influence neurobehavior in low-level lead exposed children. *Neurotoxicol Teratol* 47:137-145. 10.1016/j.ntt.2014.12.001.
- Sobin C, Gutierrez M, Alterio H. 2009. Polymorphisms of δ -aminolevulinic acid dehydratase (ALAD) and peptide transporter 2 (PEPT2) genes in children with low-level lead exposure. *Neurotoxicology* 30(6):881-887. 10.1016/j.neuro.2009.08.006.
- Sokas RK, Simmens S, Sophar K, et al. 1997. Lead levels in Maryland construction workers. *Am J Ind Med* 31:188-194.
- Soldin OP, Pezzullo JC, Hanak B, et al. 2003. Changing trends in the epidemiology of pediatric lead exposure: Interrelationship of blood lead and ZPP concentrations and a comparison to the US population. *Ther Drug Monit* 25(4):415-420.
- Solliway BM, Schaffer A, Pratt H, et al. 1996. Effects of exposure to lead on selected biochemical and haematological variables. *Pharmacol Toxicol* 78:18-22.
- Somashekaraiah BV, Venkaiah B, Prasad ARK. 1990. Biochemical diagnosis of occupational exposure to lead toxicity. *Bull Environ Contam Toxicol* 44:268-275.
- Songdej N, Winters PC, McCabe MJ, Jr., et al. 2010. A population-based assessment of blood lead levels in relation to inflammation. *Environ Res* 110(3):272-277. 10.1016/j.envres.2009.12.008.
- Sönmez F, Dönmez O, Keskinöglu A, et al. 2002. Lead exposure and urinary N-acetyl β D glucosaminidase activity in adolescent workers in auto repair workshops. *J Adolesc Health* 30(3):213-216.
- Sonmez O, Bukun B, Kaya C, et al. 2008. The assessment of tolerance to heavy metals (Cd, Pb and Zn) and their accumulation in three weed species. *Pak J Bot* 40(2):747-754.
- Soto-Jiménez MF, Flegal AR. 2009. Origin of lead in the Gulf of California ecoregion using stable isotope analysis. *J Geochem Explor* 101(3):209-217. 10.1016/j.gexplo.2008.07.003.
- Spear TM, Svee W, Vincent JH, et al. 1998. Chemical speciation of lead dust associated with primary lead smelting. *Environ Health Perspect* 106(9):565-571.
- Specht AJ, Lin Y, Weisskopf M, et al. 2016. XRF-measured bone lead (Pb) as a biomarker for Pb exposure and toxicity among children diagnosed with Pb poisoning. *Biomarkers* 21(4):347-352. 10.3109/1354750x.2016.1139183.
- Specht AJ, Weisskopf M, Nie LH. 2018. Childhood lead biokinetics and associations with age among a group of lead-poisoned children in China. *J Expo Sci Environ Epidemiol* <http://doi.org/10.1038/s41370-018-0036-y>.
- Spector JT, Navas-Acien A, Fadrowski J, et al. 2011. Associations of blood lead with estimated glomerular filtration rate using MDRD, CKD-EPI and serum cystatin C-based equations. *Nephrol Dial Transplant* 26(9):2786-2792. 10.1093/ndt/gfq773.
- Staessen J, Bulpitt C, Roels H, et al. 1984. Urinary cadmium and lead concentrations and their relation to blood pressure in a population with low exposure. *Br J Ind Med* 41(2):241-248.
- Staessen J, Yeoman WB, Fletcher AE, et al. 1990. Blood lead concentration, renal function, and blood pressure in London civil servants. *Br J Ind Med* 47:442-447.
- Staessen JA, Buchet J-P, Ginocchio G, et al. 1996a. Public health implications of environmental exposure to cadmium and lead: An overview of epidemiological studies in Belgium. *J Cardiovasc Risk* 3(1):26-41.
- Staessen JA, Lauwerys RR, Buchet JP, et al. 1992. Impairment of renal function with increasing blood lead concentrations in the general population. *N Engl J Med* 327:151-156.
- Staessen JA, Lauwerys RR, Bulpitt CJ, et al. 1994. Is a positive association between lead exposure and blood pressure supported by animal experiments? *Curr Opin Nephrol Hypertens* 3(3):257-263.

8. REFERENCES

- Staessen JA, Nawrot T, Den Hond E, et al. 2001. Renal function, cytogenetic measurements, and sexual development in adolescents in relation to environmental pollutants: A feasibility study of biomarkers. *The Lancet* 357(9269):1660-1669.
- Staessen JA, O'Brien ET, Thijs L, et al. 2000. Modern approaches to blood pressure measurement. *Occup Environ Med* 57(8):510-520.
- Staessen JA, Roels H, Fagard R. 1996b. Lead exposure and conventional and ambulatory blood pressure. A prospective population study. *J Am Med Assoc* 275(20):1563-1570.
- Stanek EJ, Calabrese EJ, Barnes R, et al. 1997. Soil ingestion in adults--results of a second pilot study. *Ecotoxicol Environ Saf* 36(3):249-257. 10.1006/eesa.1996.1510.
- Stanek EJ, Calabrese EJ, Xu B. 2012. Meta-analysis of mass-balance studies of soil ingestion in children. *Risk Anal* 32(3):433-447. 10.1111/j.1539-6924.2011.01673.x.
- Stauber JL, Florence TM. 1988. A comparative study of copper, lead, cadmium and zinc in human sweat and blood. *Sci Total Environ* 74:235-247.
- Stauber JL, Florence TM, Gulson BL, et al. 1994. Percutaneous absorption of inorganic lead compounds. *Sci Total Environ* 145:55-70.
- Steenland K, Boffetta P. 2000. Lead and cancer in humans: Where are we now? *Am J Ind Med* 38:295-299.
- Steenland K, Selevan S, Landrigan P. 1992. The mortality of lead smelter workers: An update. *Am J Public Health* 82(12):1641-1644.
- Stern AH. 1994. Derivation of a target level of lead in soil at residential sites corresponding to a *de minimis* contribution to blood lead concentration. *Risk Anal* 14(6):1049-1056.
- Stern AH. 1996. Derivation of a target concentration of Pb in soil based on elevation of adult blood pressure. *Risk Anal* 16(2):201-210.
- Stewart WF, Schwartz BS, Simon D, et al. 2002. ApoE genotype, past adult lead exposure, and neurobehavioral function. *Environ Health Perspect* 110(5):501-505.
- Stollery BT, Banks HA, Broadbent DE, et al. 1989. Cognitive functioning in lead workers. *Br J Ind Med* 46:698-707.
- Stollery BT, Broadbent DE, Banks HA, et al. 1991. Short term prospective study of cognitive functioning in lead workers. *Br J Ind Med* 48:739-749.
- Stuik EJ. 1974. Biological response of male and female volunteers to inorganic lead. *Int Arch Arbeitsmed* 33:83-97.
- Stutz DR, Janusz SJ. 1988. Protocol 57. Toxicity level 3, protection level B. In: *Hazardous materials injuries. A handbook for pre-hospital care*. Second ed. Beltsville, MD: Bradford Communications Corporation, 314-315.
- Succop P, Bornschein R, Brown K, et al. 1998. An empirical comparison of lead exposure pathway models. *Environ Health Perspect* 106 Suppl 6:1577-1583.
- Succop P, Clark S, Tseng CY, et al. 2001. Evaluation of public housing lead risk assessment data. *Environ Geochem Health* 23:1-15.
- Sun CC, Wong TT, Hwang YH, et al. 2002. Percutaneous absorption of inorganic lead compounds. *Am Ind Hyg Assoc J* 63:641-646.
- Sun L, Hu J, Zhao Z, et al. 2003. Influence of exposure to environmental lead on serum immunoglobulin in preschool children. *Environ Res* 92(2):124-128. 10.1016/S0013-9351(02)00090-7.
- Sun Y, Sun D, Zhou Z, et al. 2008a. Osteoporosis in a Chinese population due to occupational exposure to lead. *Am J Ind Med* 51(6):436-442. 10.1002/ajim.20567.
- Sun Y, Sun DH, Zhou ZJ, et al. 2008b. Estimation of benchmark dose for bone damage and renal dysfunction in a Chinese male population occupationally exposed to lead. *Ann Occup Hyg* 52(6):527-533. 10.1093/annhyg/men031.
- Suszkiw JB. 2004. Presynaptic disruption of transmitter release by lead. *Neurotoxicology* 25(4):599-604.

8. REFERENCES

- Süzen HS, Duydu Y, Aydın A, et al. 2003. Influence of the δ -aminolevulinic acid dehydratase (ALAD) polymorphism on biomarkers of lead exposure in Turkish storage battery manufacturing workers. *Am J Ind Med* 43(2):165-171.
- Sweeney MH, Beaumont JJ, Waxweiler RJ, et al. 1986. An investigation of mortality from cancer and other causes of death among workers employed at an east Texas chemical plant. *Arch Environ Health* 41(1):23-28.
- Swenberg JA, Short B, Borghoff S, et al. 1989. The comparative pathobiology of α 2u-globulin nephropathy. *Toxicol Appl Pharmacol* 97(1):35-46.
- Symanski E, Hertz-Picciotto I. 1995. Blood lead levels in relation to menopause, smoking, and pregnancy history. *Am J Epidemiol* 141(11):1047-1058.
- Szymanska-Chabowska A, Laczmanski L, Jedrychowska I, et al. 2015. The relationship between selected VDR, HFE and ALAD gene polymorphisms and several basic toxicological parameters among persons occupationally exposed to lead. *Toxicology* 334:12-21. 10.1016/j.tox.2015.05.002.
- Taha EA, Sayed SK, Ghandour NM, et al. 2013. Correlation between seminal lead and cadmium and seminal parameters in idiopathic oligoasthenozoospermic males. *Cent Eur J Urol* 66(1):84-92. 10.5173/cej.2013.01.art28.
- Takematsu T, Murata T, Koshikawa MK, et al. 2010. Weathering and dissolution rates among Pb shot pellets at differing elemental compositions exposed to various aqueous and soil conditions. *Arch Environ Contam Toxicol* 59:91-99. 10.1007/s00244-009-9449-x.
- Tamura H, Honda M, Sato T, et al. 2005. Pb hyperaccumulation and tolerance in common buckwheat (*Fagopyrum esculentum Moench*). *J Plant Res* 118(5):355-359. 10.1007/s10265-005-0229-z.
- Tasmin S, Furusawa H, Ahmad SA, et al. 2015. δ -Aminolevulinic acid dehydratase (ALAD) polymorphism in lead exposed Bangladeshi children and its effect on urinary aminolevulinic acid (ALA). *Environ Res* 136:318-323. 10.1016/j.envres.2014.08.045.
- Taylor CM, Humphriss R, Hall A, et al. 2015. Balance ability in 7- and 10-year-old children: Associations with prenatal lead and cadmium exposure and with blood lead levels in childhood in a prospective birth cohort study. *BMJ open* 5(12):e009635. 10.1136/bmjopen-2015-009635.
- Taylor MP, Camenzuli D, Kristensen LJ, et al. 2013. Environmental lead exposure risks associated with children's outdoor playgrounds. *Environ Pollut* 178:447-454. 10.1016/j.envpol.2013.03.054.
- Teichmann R, Stremmel W. 1990. Iron uptake by human upper small intestine microvillous membrane vesicles. Indication for a facilitated transport mechanism mediated by a membrane iron-binding protein. *J Clin Invest* 86(6):2145-2153.
- Telisman S, Colak B, Pizent A, et al. 2007. Reproductive toxicity of low-level lead exposure in men. *Environ Res* 105(2):256-266. 10.1016/j.envres.2007.05.011.
- Telisman S, Cvitkovic P, Jurasovic J, et al. 2000. Semen quality and reproductive endocrine function in relation to biomarkers of lead, cadmium, zinc, and copper in men. *Environ Health Perspect* 108(1):45-53.
- Téllez-Rojo MM, Bellinger DC, Arroyo-Quiroz C, et al. 2006. Longitudinal associations between blood lead concentrations lower than 10 microg/dL and neurobehavioral development in environmentally exposed children in Mexico City. *Pediatrics* 118(2):e323-e330. 10.1542/peds.2005-3123.
- Téllez-Rojo MM, Hernandez-Avila M, Gonzalez-Cossio T, et al. 2002. Impact of breastfeeding on the mobilization of lead from bone. *Am J Epidemiol* 155(5):420-428.
- Téllez-Rojo MM, Hernandez-Avila M, Lamadrid-Figueroa H, et al. 2004. Impact of bone lead and bone resorption on plasma and whole blood lead levels during pregnancy. *Am J Epidemiol* 160(7):668-678.
- Ter Haar G, Aronow R. 1974. New information on lead in dirt and dust as related to the childhood lead problem. *Environ Health Perspect* 7:83-89.
- Ter Haar GL, Bayard MA. 1971. Composition of airborne lead particles. *Nature* 232:553-554.
- Theppeang K, Glass TA, Bandeen-Roche K, et al. 2008. Associations of bone mineral density and lead levels in blood, tibia, and patella in urban-dwelling women. *Environ Health Perspect* 116:784-790. 10.1289/ehp.10877.

8. REFERENCES

- Theppeang K, Schwartz BS, Lee B-K, et al. 2004. Associations of patella lead with polymorphisms in the vitamin D receptor, δ -aminolevulinic acid dehydratase and endothelial nitric oxide synthase genes. *J Occup Environ Med* 46(6):528-537.
- Thomas KW, Pellizzari ED, Berry MR. 1999. Population-based dietary intakes and tap water concentrations for selected elements in the EPA region V National Human Exposure Assessment Survey (NHEXAS). *J Expo Anal Environ Epidemiol* 9(5):402-413.
- Thomas S, Arbuckle TE, Fisher M, et al. 2015. Metals exposure and risk of small-for-gestational age birth in a Canadian birth cohort: The MIREC study. *Environ Res* 140:430-439. 10.1016/envres.2015.04.018.
- Thompson GN, Robertson EF, Fitzgerald S. 1985. Lead mobilization during pregnancy. *Med J Aust* 143:131.
- Tian L, Zheng G, Sommar JN, et al. 2013. Lead concentration in plasma as a biomarker of exposure and risk, and modification of toxicity by δ -aminolevulinic acid dehydratase gene polymorphism. *Toxicol Lett* 221(2):102-109. 10.1016/j.toxlet.2013.06.214.
- Timchalk C, Lin Y, Weitz KK, et al. 2006. Disposition of lead (Pb) in saliva and blood of Sprague-Dawley rats following a single or repeated oral exposure to Pb-acetate. *Toxicology* 222(1):86-94.
- Todd AC, Buchanan R, Carroll S, et al. 2001. Tibia lead levels and methodological uncertainty in 12-year-old children. *Environ Res* 86:60-65.
- Todd AC, Carroll S, Geraghty C, et al. 2002. L-shell x-ray fluorescence measurements of lead in bone: Accuracy and precision. *Phys Med Biol* 47:1399-1419.
- Todd AC, Carroll S, Godbold JH, et al. 2000. Variability in XRF-measured tibia lead levels. *Phys Med Biol* 45(12):3737-3748.
- Tola S, Hernberg S, Asp S, et al. 1973. Parameters indicative of absorption and biological effect in new lead exposure: A prospective study. *Br J Ind Med* 30(2):134-141.
- Tomoum HY, Mostafa GA, Ismail NA, et al. 2010. Lead exposure and its association with pubertal development in school-age Egyptian children: Pilot study. *Pediatr Int* 52(1):89-93. 10.1111/j.1442-200X.2009.02893.x.
- Tomsig J, Suszkiw JB. 1991. Permeation of Pb²⁺ through calcium channels: Fura-2 measurements of voltage- and dihydropyridine-sensitive Pb²⁺ entry in isolated bovine chromaffin cells. *Biochim Biophys Acta* 1069(2):197-200.
- Tong S, Baghurst P, McMichael A, et al. 1996. Lifetime exposure to environmental lead and children's intelligence at 11-13 years: The Port Pirie cohort study. *BMJ* 312(7046):1569-1575.
- Tong S, McMichael AJ, Baghurst PA. 2000. Interactions between environmental lead exposure and sociodemographic factors on cognitive development. *Arch Environ Health* 55(5):330-335. 10.1080/00039890009604025.
- Toscano CD, Guilarte TR. 2005. Lead neurotoxicity: From exposure to molecular effects. *Brain Res Brain Res Rev* 49(3):529-554. 10.1016/j.brainresrev.2005.02.004.
- Treble RG, Thompson RS. 1997. Preliminary results of a survey of lead levels in human liver tissue. *Bull Environ Contam Toxicol* 59:688-695.
- TRI15. 2017. TRI explorer: Providing access to EPA's toxics release inventory data. Washington, DC: Office of Information Analysis and Access. Office of Environmental Information. U.S. Environmental Protection Agency. Toxics Release Inventory. <http://www.epa.gov/triexplorer/>. May 11, 2017.
- Triebig G, Weltle D, Valentin H. 1984. Investigations on neurotoxicity of chemical substances at the workplace. *Int Arch Occup Environ Health* 53:189-204.
- Tripathi RK, Llewellyn GC. 1990. Deterioration of air quality in firing ranges: A review of airborne lead exposures. Mycotoxins, biotoxins, wood decay, air quality, cultural properties, general biodeterioration, and degradation. *Biodeterioration Res* 3:445-457.
- Tripathi R, Raghunath R, Kumar AV, et al. 2001. Atmospheric and children's blood lead as indicators of vehicular traffic and other emission sources in Mumbai, India. *Sci Total Environ* 267(1):101-108.

8. REFERENCES

- Tsaih S-W, Korrick S, Schwartz J, et al. 2004. Lead, diabetes, hypertension, and renal function: The Normative Aging Study. *Environ Health Perspect*:1178-1182.
- Tulasi SJ, Reddy PUM, Rao JVR. 1992. Accumulation of lead and effects on total lipids and lipid derivatives in the freshwater fish *Anabas testudineus*. *Ecotoxicol Environ Saf* 23(1):33-38.
- Tuppurainen M, Wagar G, Kurppa K, et al. 1988. Thyroid function as assessed by routine laboratory tests of workers with long-term lead exposure. *Scand J Work Environ Health* 14:175-180.
- Turlakiewicz Z, Chmielnicka J. 1985. Diethyllead as a specific indicator of occupational exposure to tetraethyllead. *Br J Ind Med* 42:682-685.
- Tuthill RW. 1996. Hair lead levels related to children's classroom attention-deficit behavior. *Arch Environ Health* 51(3):214-220.
- Ukajeifo E, Thomas N, Ike S. 2009. Haematological assessment of occupational exposure to lead handlers in Enugu urban, Enugu State, Nigeria. *Niger J Clin Prac* 12(1).
- Ulmer DD, Vallee BL. 1969. Effects of lead on biochemical systems. In: Hemphill DD, ed. *Trace substances in environmental health*. University of Missouri Press, 7-27.
- Undeger U, Basaran N, Canpinar H, et al. 1996. Immune alterations in lead-exposed workers. *Toxicology* 109:167-172.
- United Nations. 2017. European Agreement concerning the international carriage of dangerous goods by road. ADR applicable as from 1 January 2017. United Nations. http://www.unece.org/fileadmin/DAM/trans/danger/publi/adr/adr2017/ADR2017e_web.pdf. June 26, 2017.
- USAF. 1995. The fate and behavior of lead alkyls in the subsurface environment. Tyndall Air Force Base, FL: U.S. Air Force. AL/EQ-TR-1994-0026.
- USGS. 1989. Methods for the determination of inorganic substances in water and fluvial sediments. Techniques of water-resources investigations of the United States Geological Survey, Book 5, Chapter A1. U.S. Geological Survey, U.S. Department of the Interior. <https://pubs.er.usgs.gov/publication/twri05A1>. March 30, 2017.
- USGS. 1993. Methods of analysis by the U.S. Geological Survey National Water Quality Laboratory. Determination of inorganic and organic constituents in water and fluvial sediments. Denver, CO: U.S. Geological Survey, U.S. Department of the Interior. Open-File Report 93-125. <https://pubs.usgs.gov/of/1993/0125/report.pdf>. March 30, 2017.
- USGS. 2014. Comparison of the U.S. lead recycling industry in 1998 and 2011. U.S. Geological Survey. Scientific Investigations Report 2014-5086. <https://pubs.usgs.gov/sir/2014/5086/pdf/sir2014-5086.pdf>. June 26, 2017.
- USGS. 2016. 2014 Mineral yearbook. Lead [advance release]. U.S. Geological Survey. <https://minerals.usgs.gov/minerals/pubs/commodity/lead/myb1-2014-lead.pdf>. June 26, 2017.
- Vaglenov A, Carbonell E, Marcos R. 1998. Biomonitoring of workers exposed to lead. Genotoxic effects, its modulation by polyvitamin treatment and evaluation of induced radioresistance. *Mutat Res* 418:79-92.
- Vaglenov A, Creus A, Laltchev S, et al. 2001. Occupational exposure to lead and induction of genetic damage. *Environ Health Perspect* 109(3):295-298.
- Valciukas JA, Lilis R, Eisinger J, et al. 1978. Behavioral indicators of lead neurotoxicity: Results of a clinical field survey. *Int Arch Occup Environ Health* 41(4):217-236.
- Valentino M, Governa M, Marchiseppe I, et al. 1991. Effects of lead on polymorphonuclear leukocyte (PMN) functions in occupationally exposed workers. *Arch Toxicol* 65(8):685-688.
- Valentino M, Rapisarda V, Santarelli L, et al. 2007. Effect of lead on the levels of some immunoregulatory cytokines in occupationally exposed workers. *Hum Exp Toxicol* 26(7):551-556. 10.1177/0960327107073817.
- Vander AJ, Taylor DL, Kalitis K, et al. 1977. Renal handling of lead in dogs: Clearance studies. *Am J Physiol* 233(6):F532-F538.

8. REFERENCES

- Van de Wiele TR, Oomen AG, Wragg J, et al. 2007. Comparison of five *in vitro* digestion models to *in vivo* experimental results: Lead bioaccessibility in the human gastrointestinal tract. *J Environ Sci Health Part A* 42(9):1203-1211. 10.1080/10934520701434919.
- Van Esch GJ, Kroes R. 1969. The induction of renal tumours by feeding basic lead acetate to mice and hamsters. *Br J Cancer* 23(4):765-771.
- Van Larebeke N, Koppen G, Nelen V, et al. 2004. Differences in HPRT mutant frequency among middle-aged Flemish women in association with area of residence and blood lead levels. *Biomarkers* 9(1):71-84. 10.1080/13547500310001652160.
- Vantelon D, Lanzirotti A, Scheinost AC, et al. 2005. Spatial distribution and speciation of lead around corroding bullets in a shooting range soil studies by micro-x-ray fluorescence and absorption spectroscopy. *Environ Sci Technol* 39(13):4808-4815.
- van Wijngaarden E, Dosemeci M. 2006. Brain cancer mortality and potential occupational exposure to lead: Findings from the National Longitudinal Mortality Study, 1979-1989. *Int J Cancer* 119(5):1136-1144. 10.1002/ijc.21947.
- van Wijngaarden E, Campbell JR, Cory-Slechta DA. 2009. Bone lead levels are associated with measures of memory impairment in older adults. *Neurotoxicology* 30(4):572-580. 10.1016/j.neuro.2009.05.007.
- Verbeeck RMH, Lassuyt CJ, Heijligers HJM, et al. 1981. Lattice parameters and cation distribution of solid solutions of calcium and lead hydroxyapatite. *Calcif Tissue Int* 33(1):243-247. 10.1007/BF02409444.
- Verberk MM, Willems TEP, Verplanke AJW, et al. 1996. Environmental lead and renal effects in children. *Arch Environ Health* 51(1):83-87.
- Verschoor M, Wibowo A, Herber R, et al. 1987. Influence of occupational low-level lead exposure on renal parameters. *Am J Ind Med* 12(4):341-351.
- Vesper SJ, Donovan-Brand R, Paris KP, et al. 1996. Microbial removal of lead from solid media and soil. *Water Air Soil Pollut* 86:207-219.
- Victory W, Vander AJ, Mouw DR. 1979. Effect of acid-base status on renal excretion and accumulation of lead in dogs and rats. *Am J Physiol* 237(5):F398-F407.
- Vigeh M, Yokoyama K, Kitamura F, et al. 2010. Early pregnancy blood lead and spontaneous abortion. *Women Health* 50:756-766.
- Vigeh M, Yokoyama K, Matsukawa T, et al. 2014. Low level prenatal blood lead adversely affects early childhood mental development. *J Child Neurol* 29(10):1305-1311. 10.1177/0883073813516999.
- Vigeh M, Yokoyama K, Seyedaghamiri Z, et al. 2011. Blood lead at currently acceptable levels may cause preterm labour. *Occup Environ Med* 68(3):231-234. 10.1136/oem.2009.050419.
- Viverette L, Mielke HW, Brisco M, et al. 1996. Environmental health in minority and other underserved populations: Benign methods for identifying lead hazards at day care centres of New Orleans. *Environ Geochem Health* 18(1):41-45. 10.1007/bf01757218.
- von Lindern I, Spalinger S, Petroysan V, et al. 2003. Assessing remedial effectiveness through the blood lead:soil/dust lead relationship at the Bunker Hill Superfund Site in the Silver Valley of Idaho. *Sci Total Environ* 303(1-2):139-170.
- von Lindern I, Spalinger S, Stifelman ML, et al. 2016. Estimating children's soil/dust ingestion rates through retrospective analyses of blood lead biomonitoring from the Bunker Hill Superfund Site in Idaho. *Environ Health Perspect* 124:1462-1470. 10.1289/ehp.1510144.
- Vupputuri S, He J, Muntner P, et al. 2003. Blood lead level is associated with elevated blood pressure in blacks. *Hypertension* 41(3):463-468.
- Vural N, Duydu Y. 1995. Biological monitoring of lead in workers exposed to tetraethyllead. *Sci Total Environ* 171:183-187.
- Waalkes MP, Klaassen CD. 1985. Concentration of metallothionein in major organs of rats after administration of various metals. *Fundam Appl Toxicol* 5:473-477.
- Waalkes MP, Diwan BA, Ward JM, et al. 1995. Renal tubular tumors and atypical hyperplasias in B6C3F1. *Cancer Res* 55:5265-5271.

8. REFERENCES

- Waalkes MP, Harvey MJ, Klaassen CD. 1984. Relative *in vitro* affinity of hepatic metallothionein for metals. *Toxicol Lett* 20:33-39.
- Wang EX, Bormann FH, Benoit G. 1995. Evidence of complete retention of atmospheric lead in the soils of northern hardwood forested ecosystems. *Environ Sci Technol* 29:735-739.
- Wang FT, Hu H, Schwartz J, et al. 2007. Modifying effects of the HFE polymorphisms on the association between lead burden and cognitive decline. *Environ Health Perspect* 115(8):1210-1215. 10.1289/ehp.9855.
- Wang G, Su MY, Chen YH, et al. 2006. Transfer characteristics of cadmium and lead from soil to the edible parts of six vegetable species in southeastern China. *Environ Pollut* 144(1):127-135. 10.1016/j.envpol.2005.12.023.
- Wang HL, Chen XT, Yang B, et al. 2008. Case-control study of blood lead levels and attention deficit hyperactivity disorder in Chinese children. *Environ Health Perspect* 116(10):1401-1406. 10.1289/ehp.11400.
- Wang N, Chen C, Nie X, et al. 2015. Blood lead level and its association with body mass index and obesity in China - Results from SPECT-China study. *Sci Rep* 5:18299. 10.1038/srep18299.
- Wang Q, Zhao HH, Chen JW, et al. 2010. δ -Aminolevulinic acid dehydratase activity, urinary δ -aminolevulinic acid concentration and zinc protoporphyrin level among people with low level of lead exposure. *Int J Hyg Environ Health* 213(1):52-58. 10.1016/j.ijheh.2009.08.003.
- Wang Y, Allen AG, Harrison RM. 1996. Determination of octanol-water partition coefficients, water solubility and vapour pressures of alkyl-lead compounds. *Appl Organomet Chem* 10(10):773-778.
- Wang ZW, Nan ZR, Wang SL, et al. 2011. Accumulation and distribution of cadmium and lead in wheat (*Triticum aestivum* L.) grown in contaminated soils from the oasis, north-west China. *J Sci Food Agric* 91(2):377-384. 10.1002/jsfa.4196.
- Warrington NM, Zhu G, Dy V, et al. 2015. Genome-wide association study of blood lead shows multiple associations near ALAD. *Hum Mol Genet* 24(13):3871-3879. 10.1093/hmg/ddv112.
- Wasserman GA, Factor-Litvak P, Liu X, et al. 2003. The relationship between blood lead, bone lead and child intelligence. *Child Neuropsychol* 9(1):22-34.
- Wasserman GA, Graziano JH, Factor-Litvak P, et al. 1994. Consequences of lead exposure and iron supplementation on childhood development at age 4 years. *Neurotoxicol Teratol* 16(3):233-240.
- Wasserman GA, Liu X, Lolocono NJ, et al. 1997. Lead exposure and intelligence in 7-year-old children: The Yugoslavia Prospective Study. *Environ Health Perspect* 105(9):956-962.
- Wasserman GA, Liu X, Popovac D, et al. 2000. The Yugoslavia prospective lead study: Contributions of prenatal and postnatal lead exposure to early intelligence. *Neurotoxicol Teratol* 22:811-818.
- Watson WS, Morrison J, Bethel MIF, et al. 1986. Food iron and lead absorption in humans. *Am J Clin Nutr* 44:248-256.
- Weaver VM, Ellis LR, Lee BK, et al. 2008. Associations between patella lead and blood pressure in lead workers. *Am J Ind Med* 51(5):336-343. 10.1002/ajim.20573.
- Weaver VM, Griswold M, Todd AC, et al. 2009. Longitudinal associations between lead dose and renal function in lead workers. *Environ Res* 109(1):101-107. 10.1016/j.envres.2008.09.005.
- Weaver VM, Jaar BG, Schwartz BS, et al. 2005a. Associations among lead dose biomarkers, uric acid, and renal function in Korean lead workers. *Environ Health Perspect*:36-42.
- Weaver VM, Lee BK, Ahn KD, et al. 2003a. Associations of lead biomarkers with renal function in Korean lead workers. *Occup Environ Med* 60(8):551-562.
- Weaver VM, Lee BK, Todd AC, et al. 2005b. Associations of patella lead and other lead biomarkers with renal function in lead workers. *J Occup Environ Med* 47(3):235-243.
- Weaver VM, Lee BK, Todd AC, et al. 2006. Effect modification by δ -aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase gene polymorphisms on associations between patella lead and renal function in lead workers. *Environ Res* 102(1):61-69. 10.1016/j.envres.2006.01.001.
- Weaver VM, Schwartz BS, Ahn KD, et al. 2003b. Associations of renal function with polymorphisms in the δ -aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase genes in Korean lead workers. *Environ Health Perspect* 111(13):1613-1619.

8. REFERENCES

- Weaver VM, Schwartz BS, Jaar BG, et al. 2005c. Associations of uric acid with polymorphisms in the δ -aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase genes in Korean lead workers. *Environ Health Perspect* 113(11):1509-1515. 10.1289/ehp.7927.
- Wedeen RP. 1992. Removing lead from bone: Clinical implications of bone lead stores. *Neurotoxicology* 13:843-852.
- Wedeen RP, Maesaka JK, Weiner B, et al. 1975. Occupational lead nephropathy. *Am J Med* 59:630-641.
- Wedeen RP, Mallik DK, Batuman V. 1979. Detection and treatment of occupational lead nephropathy. *Arch Intern Med* 139:53-57.
- Weis CP, LaVelle JM. 1991. Characteristics to consider when choosing an animal model for the study of lead bioavailability. *Chemical Speciation & Bioavailability* 3(3-4):113-119.
- Weisel C, Demak M, Marcus S, et al. 1991. Soft plastic bread packaging: Lead content and reuse by families. *Am J Public Health* 81(6):756-758.
- Weiss AL, Caravanos J, Blaise MJ, et al. 2006. Distribution of lead in urban roadway grit and its association with elevated steel structures. *Chemosphere* 65(10):1762-1771.
- Weiss ST, Munoz A, Stein A, et al. 1986. The relationship of blood lead to blood pressure in a longitudinal study of working men. *Am J Epidemiol* 123(5):800-808.
- Weiss ST, Munoz A, Stein A, et al. 1988. The relationship of blood lead to systolic blood pressure in a longitudinal study of policemen. *Environ Health Perspect* 78:53-56.
- Weisskopf MG, Nitin J, Nie H, et al. 2009. A prospective study of bone lead concentration and death from all causes, cardiovascular diseases, and cancer in the Department of Veterans Affairs Normative Aging Study. *Circulation* 120(12):1056-1064. 10.1161/CIRCULATIONAHA.108.827121.
- Weisskopf MG, Proctor SP, Wright RO, et al. 2007. Cumulative lead exposure and cognitive performance among elderly men. *Epidemiology* 18(1):59-66. 10.1097/01.ede.0000248237.35363.29.
- Weisskopf MG, Weuve J, Nie H, et al. 2010. Association of cumulative lead exposure with Parkinson's disease. *Environ Health Perspect* 118(11):1609-1613. 10.1289/ehp.1002339.
- Weisskopf MG, Wright RO, Schwartz J, et al. 2004. Cumulative lead exposure and prospective change in cognition among elderly men. The VA Normative Aging Study. *Am J Epidemiol* 160(12):1184-1193. 10.1093/aje/kwh333.
- Weitzman M, Aschengrau A, Bellinger D, et al. 1993. Lead-contaminated soil abatement and urban children's blood lead levels. *J Am Med Assoc* 269(13):1647-1654.
- Wells A, Venn J, Heard M. 1975. Deposition in the lung and uptake to blood of motor exhaust labelled with ^{203}Pb . In: *Inhaled particles IV. Proceedings of the Symposium of the British Occupational Hygiene Society*. Oxford: Pergamon Press, 175-189.
- Wells EM, Bonfield TL, Dearborn DG, et al. 2014. The relationship of blood lead with immunoglobulin E, eosinophils, and asthma among children: NHANES 2005-2006. *Int J Hyg Environ Health* 217(2-3):196-204. 10.1016/j.ijheh.2013.04.010.
- Wells EM, Navas-Acien A, Herbstman JB, et al. 2011. Low-level lead exposure and elevations in blood pressure during pregnancy. *Environ Health Perspect* 119:664-669.
- Were FH, Moturi MC, Gottesfeld P, et al. 2014. Lead exposure and blood pressure among workers in diverse industrial plants in Kenya. *J Occup Environ Hyg* 11(11):706-715. 10.1080/15459624.2014.908258.
- Wetmur JG, Kaya AH, Plewiska M, et al. 1991a. Molecular characterization of the human δ -aminolevulinic acid dehydratase 2 (ALAD2) allele: Implications for molecular screening of individuals for genetic susceptibility to lead poisoning. *Am J Hum Genet* 49(4):757-763.
- Wetmur JG, Lehnert G, Desnick RJ. 1991b. The δ -aminolevulinic acid dehydratase polymorphism: Higher blood lead levels in lead workers and environmentally exposed children with 1-2 and 2-2 isozymes. *Environ Res* 56:109-119.

8. REFERENCES

- Weuve J, Kelsey KT, Schwartz J, et al. 2006. δ -Aminolevulinic acid dehydratase polymorphism and the relation between low level lead exposure and the Mini-Mental Status Examination in older men: The Normative Aging Study. *Occup Environ Med* 63(11):746-753. 10.1136/oem.2006.027417.
- Weuve J, Korrick SA, Weisskopf MA, et al. 2009. Cumulative exposure to lead in relation to cognitive function in older women. *Environ Health Perspect* 117(4):574-580. 10.1289/ehp.11846.
- Weuve J, Press DZ, Grodstein F, et al. 2013. Cumulative exposure to lead and cognition in persons with Parkinson's disease. *Mov Disord* 28(2):176-182. 10.1002/mds.25247.
- Whelan EA, Piacitelli GM, Gerwel B, et al. 1997. Elevated blood lead levels in children of construction workers. *Am J Public Health* 87(8):1352-1355.
- White PD, Van LP, Davis BD, et al. 1998. The conceptual structure of the integrated exposure uptake biokinetic model for lead in children. *Environ Health Perspect* 106(Suppl 6):1513-1530.
- WHO. 1995. Environmental transport, distribution and transformation. In: *Environmental Health Criteria* 165. Inorganic lead. Vol. 165. Geneva, Switzerland: World Health Organization, 60-65.
- WHO. 2010. Guidelines for indoor air quality: Selected pollutants. Geneva, Switzerland: World Health Organization. http://www.euro.who.int/__data/assets/pdf_file/0009/128169/e94535.pdf. January 08, 2014.
- WHO. 2017. Guidelines for drinking-water quality. Fourth edition incorporating the first addendum. Geneva, Switzerland: World Health Organization. <http://apps.who.int/iris/bitstream/10665/254637/1/9789241549950-eng.pdf?ua=1>. February 28, 2017.
- Wildt K, Berlin M, Isberg PE. 1987. Monitoring of zinc protoporphyrin levels in blood following occupational lead exposure. *Am J Ind Med* 12(4):385-398.
- Wildt K, Eliasson R, Berlin M. 1983. Effects of occupational exposure to lead on sperm and semen. Reproductive and developmental toxicity of metals. *Proceedings of a Joint Meeting*. May 1982, 279-300.
- Wilhelm M, Lombeck I, Hafner D, et al. 1989. Hair lead levels in young children from the FRG. *J Trace Elem Electrolytes Health Dis* 3:165-170.
- Wilker E, Korrick S, Nie LH, et al. 2011. Longitudinal changes in bone lead levels: The VA Normative Aging Study. *J Occup Environ Med* 53(8):850-855. 10.1097/JOM.0b013e31822589a9.
- Williams PL, Sergeev O, Lee MM, et al. 2010. Blood lead levels and delayed onset of puberty in a longitudinal study of Russian boys. *Pediatrics* 125(5):1088-1096. 10.1542/peds.2009-2575.
- Williamson AM, Teo RKC. 1986. Neurobehavioral and memory of occupational lead workers. *Br J Ind Med* 43:373-380.
- Wilson R, Jones-Otazo H, Petrovic S, et al. 2013. Revisiting dust and soil ingestion rates based on hand-to-mouth transfer. *Hum Ecol Risk Assess* 19(1):158-188.
- Wingren G, Englander V. 1990. Mortality and cancer morbidity in a cohort of Swedish glassworkers. *Int Arch Occup Environ Health* 62:253-257.
- Wisconsin Department of Health and Family Services. 2002. Lead arsenate pesticides. <http://www.dhfs.state.wi.us/eh/HlthHaz/fs/LeadArPest.htm>. February 22, 2005.
- Wiwanitkit V, Suwansaksri J, Soogarun S. 2008. White blood cell sister chromatid exchange among a sample of Thai subjects exposed to lead: Lead-induced genotoxicity. *Toxicol Environ Chem* 90(4):765-768. 10.1080/02772240701712758.
- Wolf C, Wallnofer A, Waldhor T, et al. 1995. Effect of lead on blood pressure in occupationally nonexposed men. *Am J Ind Med* 27(6):897-903.
- Wolff MS, Britton JA, Boguski L, et al. 2008. Environmental exposures and puberty in inner-city girls. *Environ Res* 107(3):393-400. 10.1016/j.envres.2008.03.006.
- Wong O, Harris F. 2000. Cancer mortality study of employees at lead battery plants and lead smelters, 1947-1995. *Am J Ind Med* 38:255-270.
- Wright RO, Hu H, Silverman EK, et al. 2003a. Apolipoprotein E genotype predicts 24-month Bayley scales infant development score. *Pediatr Res* 54(6):819-825.

8. REFERENCES

- Wright RO, Silverman EK, Schwartz J, et al. 2004. Association between hemochromatosis genotype and lead exposure among elderly men: The Normative Aging Study. *Environ Health Perspect* 112(6):746-750.
- Wright RO, Tsaih SW, Schwartz J, et al. 2003b. Lead exposure biomarkers and mini-mental status exam scores in older men. *Epidemiology* 14(6):713-718.
- Wu F-Y, Chang P-W, Wu C-C, et al. 2002. Correlations of blood lead with DNA-protein cross-links and sister chromatid exchanges in lead workers. *Cancer Epidemiol Prev Biomarkers* 11(3):287-290.
- Wu HM, Lin-Tan DT, Wang ML, et al. 2012. Lead level in seminal plasma may affect semen quality for men without occupational exposure to lead. *Reprod Biol Endocrinol* 10:91.
- Wu M-T, Kelsey K, Schwartz J, et al. 2003a. A δ -aminolevulinic acid dehydratase (ALAD) polymorphism may modify the relationship of low-level lead exposure to uricemia and renal function: The Normative Aging Study. *Environ Health Perspect* 111(3):335-340.
- Wu T, Buck GM, Mendola P. 2003b. Blood lead levels and sexual maturation in U.S. girls: The Third National Health and Nutrition Examination Survey, 1988-1994. *Environ Health Perspect* 111(5):737-741. 10.1289/ehp.6008.
- Wu TN, Yang KC, Wang CM, et al. 1996. Lead poisoning caused by contaminated Cordyceps, a Chinese herbal medicine: Two case reports. *Sci Total Environ* 182:193-195.
- Xian X. 1989. Response of kidney bean to concentration and chemical form of cadmium, zinc, and lead in polluted soils. *Environ Pollut* 57:127-137.
- Xie X, Ding G, Cui C, et al. 2013. The effects of low-level prenatal lead exposure on birth outcomes. *Environ Pollut* 175:30-34. 10.1016/j.envpol.2012.12.013.
- Xie Y, Chiba M, Shinohara A, et al. 1998. Studies on lead-binding protein and interaction between lead and selenium in the human erythrocytes. *Ind Health* 36:234-239.
- Xu X, Chen X, Zhang J, et al. 2015. Decreased blood hepatitis B surface antibody levels linked to e-waste lead exposure in preschool children. *J Hazard Mater* 298:122-128. 10.1016/j.jhazmat.2015.05.020.
- Yamamoto N, Takahashi Y, Yoshinaga J, et al. 2006. Size distributions of soil particles adhered to children's hands. *Arch Environ Contam Toxicol* 51(2):157-163. 10.1007/s00244-005-7012-y.
- Yang CC, Chen HI, Chiu YW, et al. 2013b. Metallothionein 1A polymorphisms may influence urine, uric acid and N-acetyl-beta-D-glucosaminidase (NAG) excretion in chronic lead-exposed workers. *Toxicology* 306:68-73. 10.1016/j.tox.2013.02.007.
- Yang H, Huo X, Yekeen TA, et al. 2013a. Effects of lead and cadmium exposure from electronic waste on child physical growth. *Environ Sci Pollut Res Int* 20(7):4441-4447. 10.1007/s11356-012-1366-2.
- Yazbeck C, Thiebaugeorges O, Moreau T, et al. 2009. Maternal blood lead levels and the risk of pregnancy-induced hypertension: The EDEN cohort study. *Environ Health Perspect* 117(10):1526-1530. 10.1289/ehp.0800488.
- Yesilonis ID, Pouyat RV, Neerchal NK. 2008. Spatial distribution of metals in soils in Baltimore, Maryland: Role of native parent material, proximity to major roads, housing age and screening guidelines. *Environ Pollut* 156(3):723-731. 10.1016/j.envpol.2008.06.010.
- Yiin LM, Rhoads GG, Lioy PJ. 2000. Seasonal influences on childhood lead exposure. *Environ Health Perspect* 108(2):177-182.
- Yin Y, Zhang T, Dai Y, et al. 2008. The effect of plasma lead on anembryonic pregnancy. *Ann N Y Acad Sci* 1140:184-189. 10.1196/annals.1454.042.
- Yokoyama K, Araki S, Murata K, et al. 1997. Subclinical vestibulo-cerebellar, anterior cerebellar lobe and spinocerebellar effects in lead workers in relation to concurrent and past exposure. *Neurotoxicology* 18(2):371-380.
- Yoon JH, Ahn YS. 2016. The association between blood lead level and clinical mental disorders in fifty thousand lead-exposed male workers. *J Affect Disord* 190:41-46. 10.1016/j.jad.2015.09.030.
- Yorita Christensen KL. 2013. Metals in blood and urine, and thyroid function among adults in the United States 2007-2008. *Int J Hyg Environ Health* 216(6):624-632.

8. REFERENCES

- Youravong N, Teanpaisan R. 2015. The periodontal health of lead-exposed children living in a shipyard industrial area. *Toxicol Ind Health* 31(5):459-466. 10.1177/0748233712472529.
- Yu CC, Lin JL, Lin-Tan DT. 2004. Environmental exposure to lead and progression of chronic renal diseases: A four-year prospective longitudinal study. *J Am Soc Nephrol* 15(4):1016-1022.
- Yücesoy B, Turhan A, Üre M, et al. 1997. Simultaneous effects of lead and cadmium on NK cell activity and some phenotypic parameters. *Immunopharmacol Immunotoxicol* 19(3):339-348. 10.3109/08923979709046980.
- Zahran S, Laidlaw MA, McElmurry SP, et al. 2013. Linking source and effect: Resuspended soil lead, air lead, and children's blood lead levels in Detroit, Michigan. *Environ Sci Technol* 47(6):2839-2845. 10.1021/es303854c.
- Zahran S, Mielke HW, Gonzales CR, et al. 2010. New Orleans before and after hurricanes Katrina/Rita: A quasi-experiment of the association between soil lead and children's blood lead. *Environ Sci Technol* 44(12):4433-4440. 10.1021/es100572s.
- Zak K, Rohovec J, Navratil T. 2009. Fluxes of heavy metals from a highly polluted watershed during flood events: A case study of the Litavka River, Czech Republic. *Water Air Soil Pollut* 203(1-4):343-358. 10.1007/s11270-009-0017-9.
- Zaprijanova P, Dospatliev L, Angelova V, et al. 2010. Correlation between soil characteristics and lead and cadmium content in the aboveground biomass of Virginia tobacco. *Environ Monit Assess* 163(1-4):253-261. 10.1007/s10661-009-0831-y.
- Zaragoza L, Hogan K. 1998. The integrated exposure uptake biokinetic model for lead in children: Independent validation and verification. *Environ Health Perspect* 106(Suppl 6):1551-1556.
- Zartarian V, Xue J, Tornero-Velez R, et al. 2017. Children's lead exposure: A multimedia modeling analysis to guide public health decision-making. *Environ Health Perspect* 125(9):e97009. <http://doi.org/10.1289/EHP1605>.
- Zawia NH, Crumpton T, Brydie M, et al. 2000. Disruption of the zinc finger domain: A common target that underlies many of the effects of lead. *Neurotoxicology* 21(6):1069-1080.
- Zawirska B. 1981. The role of the kidneys in disorders of porphyrin metabolism during carcinogenesis induced with lead acetate. *Environ Res* 24:391-408.
- Zawirska B, Medraś K. 1971. The role of the kidneys in disorders of porphyrin metabolism during carcinogenesis induced with lead acetate. *Arch Immunol Ther Exp (Warsz)* 20(2):257-272.
- Zentner LE, Rondó PH, Mastroeni SS. 2006. Lead contamination and anthropometry of the newborn baby. *J Trop Pediatr* 52(5):369-371. 10.1093/tropej/fml009.
- Zeyrek D, Soran M, Cakmak A, et al. 2009. Serum copper and zinc levels in mothers and cord blood of their newborn infants with neural tube defects: A case-control study. *Indian Pediatr* 46(8):675-680.
- Zhang A, Hu H, Sánchez BN, et al. 2011. Association between prenatal lead exposure and blood pressure in female offspring. *Environ Health Perspect* 120(3):445-450. 10.1289/ehp.1103736.
- Zhang A, Park SK, Wright RO, et al. 2010. HFE H63D polymorphism as a modifier of the effect of cumulative lead exposure on pulse pressure: The Normative Aging Study. *Environ Health Perspect* 118(9):1261-1266. 10.1289/ehp.1002251.
- Zhang N, Baker HW, Tufts M, et al. 2013. Early childhood lead exposure and academic achievement: Evidence from Detroit public schools, 2008-2010. *Am J Public Health* 103(3):e72-77. 10.2105/ajph.2012.301164.
- Zhang W, Zhang GG, He HZ, et al. 1994. Early health effects and biological monitoring in persons occupationally exposed to tetraethyl lead. *Int Arch Occup Environ Health* 65:395-399.
- Zhang XL, Guariglia SR, McGothan JL, et al. 2015. Presynaptic mechanisms of lead neurotoxicity: Effects on vesicular release, vesicle clustering and mitochondria number. *PLoS ONE* 10(5):e01274.
- Zhao ZY, Li R, Sun L, et al. 2004. Effect of lead exposure on the immune function of lymphocytes and erythrocytes in preschool children. *Journal of Zhejiang University- Science* 5(8):1001-1004. 10.1007/BF02947614.
- Zheng G, Tian L, Liang Y, et al. 2011. δ -Aminolevulinic acid dehydratase genotype predicts toxic effects of lead on workers' peripheral nervous system. *Neurotoxicology* 32:374-382.

8. REFERENCES

- Zhu M, Fitzgerald EF, Gelberg KH, et al. 2010. Maternal low-level lead exposure and fetal growth. *Environ Health Perspect* 118(10):1471-1475. 10.1289/ehp.0901561.
- Ziegler EE, Edwards BB, Jensen RL, et al. 1978. Absorption and retention of lead by infants. *Pediatr Res* 12(1):29-34.
- Zimmermann-Tansella C, Campara P, Andrea FD, et al. 1983. Psychological and physical complaints of subjects with low exposure to lead. *Hum Toxicol* 2:615-623.
- Zollinger HU. 1953. Durch chronische bleivergiftung erzeugte nierenadenome und-carcinome bei ratten und ihre beziehungen zu den entsprechenden Neubildungen menschen. *Virchows Archiv A Pathologische Anatomie* 323:694-710.
- Zota AR, Needham BL, Blackburn EH, et al. 2015. Associations of cadmium and lead exposure with leukocyte telomere length: Findings from National Health and Nutrition Examination Survey, 1999-2002. *Am J Epidemiol* 181(2):127-136. 10.1093/aje/kwu293.
- Zota AR, Shenassa ED, Morello-Frosch R. 2013. Allostatic load amplifies the effect of blood lead levels on elevated blood pressure among middle-aged U.S. adults: A cross-sectional study. *Environ Health* 12(1):64. 10.1186/1476-069x-12-64.

APPENDIX A. ATSDR MINIMAL RISK LEVEL WORKSHEETS

MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance that is likely to be without appreciable risk of adverse noncancer health effects over a specified route and duration of exposure. MRLs are based on noncancer health effects only; cancer effects are not considered. These substance-specific estimates, which are intended to serve as screening levels, are used by ATSDR health assessors to identify contaminants and potential health effects that may be of concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or action levels.

MRLs are derived for hazardous substances using the NOAEL/uncertainty factor approach. They are below levels that might cause adverse health effects in the people most sensitive to such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and chronic (≥ 365 days) durations and for the oral and inhalation routes of exposure. Currently, MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method suitable for this route of exposure. MRLs are generally based on the most sensitive substance-induced endpoint considered to be of relevance to humans. Serious health effects (such as irreparable damage to the liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level above the MRL does not mean that adverse health effects will occur.

MRLs are intended only to serve as a screening tool to help public health professionals decide where to look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, elderly, nutritionally or immunologically compromised) to the effects of hazardous substances. ATSDR uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health principle of prevention. Although human data are preferred, MRLs often must be based on animal studies because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes that humans are more sensitive to the effects of hazardous substance than animals and that certain persons may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that have been shown to be nontoxic in laboratory animals.

APPENDIX A

Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the Division of Toxicology and Human Health Sciences, expert panel peer reviews, and agency-wide MRL Workgroup reviews, with participation from other federal agencies and comments from the public. They are subject to change as new information becomes available concomitant with updating the toxicological profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published MRLs. For additional information regarding MRLs, please contact the Division of Toxicology and Human Health Sciences, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop S102-1, Atlanta, Georgia 30329-4027.

The literature evaluating the health effects of Pb is enormous, and includes an extensive database in humans, including children. Effects are diverse and exposure to Pb is associated with toxicity to every organ system. For the most studied endpoints (neurological, renal, cardiovascular, hematological, immunological, reproductive, and developmental), effects occur at the lowest PbBs studied ($\leq 5 \mu\text{g/dL}$). Exposure thresholds for effects on specific organ systems have not been identified (i.e., no safe level has been identified). Cognitive deficits in children occurring at the lowest PbB concentrations ($\leq 5 \mu\text{g/dL}$) are the best substantiated effects. However, because the lowest PbBs are associated with serious adverse effects (e.g., declining cognitive function in children), MRLs for Pb have not been derived.

APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR LEAD

The objective of the toxicological profile is to evaluate the potential for human exposure and the potential health hazards associated with exposure to Pb.

B.1 LITERATURE SEARCH AND SCREEN

A literature search and screen was conducted to identify studies examining health effects, toxicokinetics, mechanisms of action, susceptible populations, biomarkers, chemical interactions, physical and chemical properties, production, use, environmental fate, environmental releases, and environmental and biological monitoring data for Pb. ATSDR primarily focused on peer-reviewed articles without publication date or language restrictions. The inclusion criteria used to identify relevant studies examining the health effects of Pb are presented in Table B-1.

The literature on health effects of Pb in humans is enormous, with countless epidemiological studies in workers and the general population, including children. Due to the extent of the Pb database in humans, it is impossible to cite all, or even most, of the studies on health effects of Pb. Thus, no attempt was made to conduct a comprehensive review of the epidemiological literature. Epidemiological studies were selected to identify the major lines of evidence regarding health effects in humans. The literature database on adverse effects of Pb in laboratory animals also is extensive. Although the literature on adverse effects of Pb in laboratory animals also is extensive, due to the large number of available epidemiological studies, results of animal studies were not considered for the identification of health effects associated with Pb. This potentially leaves out discussion of effects that may have been observed in animal models that have not been studied in humans and that may be future targets of human epidemiology and clinical toxicology studies. Animal studies were included in discussion of mechanisms of toxicity of Pb and toxicokinetics.

Table B-1. Inclusion Criteria for the Literature Search and Screen

Health Effects
Species
Human
Internal Exposure Metric
Blood Pb Concentration (PbB)
Health outcome
Death
Systemic effects
Body weight effects
Respiratory effects
Cardiovascular effects
Gastrointestinal effects
Hematological effects
Musculoskeletal effects
Hepatic effects
Renal effects
Dermal effects
Ocular effects
Endocrine effects

Table B-1. Inclusion Criteria for the Literature Search and Screen

Immunological effects
Neurological effects
Reproductive effects
Developmental effects
Other noncancer effects
Cancer
Toxicokinetics
Absorption
Distribution
Metabolism
Excretion
PBPK models
Biomarkers
Biomarkers of exposure
Biomarkers of effect
Interactions with other chemicals
Potential for human exposure
Releases to the environment
Air
Water
Soil
Environmental fate
Transport and partitioning
Transformation and degradation
Environmental monitoring
Air
Water
Sediment and soil
Other media
Biomonitoring
General populations
Occupation populations

APPENDIX B

B.1.1 Literature Search

The current literature search was intended to update the existing toxicological profile for Pb (ATSDR 2007). To avoid interagency redundancy, ATSDR reviewed the EPA (2014c) *Integrated Science Assessment (ISA) for Lead* to identify studies relevant to the toxicological profile. Thus, the literature search was restricted to studies published between 2013 and February 2016. The following main databases were searched in February 2016:

- PubMed
- National Library of Medicine's TOXLINE
- Scientific and Technical Information Network's TOXCENTER

The search strategy used the chemical names, Chemical Abstracts Service (CAS) numbers, synonyms, and Medical Subject Headings (MeSH) terms for Pb. The query strings used for the literature search are presented in Table B-2.

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
PubMed	
2/2016	((("Lead/toxicity"[mh] OR "Lead/adverse effects"[mh] OR "Lead/poisoning"[mh] OR "Lead/pharmacokinetics"[mh] OR "Lead/blood"[mh] OR "Lead/cerebrospinal fluid"[mh] OR "Lead/urine"[mh] OR "Lead/antagonists and inhibitors"[mh] OR ("Lead/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh]))) OR ("Lead"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "toxicokinetics"[mh:noexp] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh])) OR ("Lead"[mh] AND ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("Lead"[majr] AND cancer[sb]) OR ("Lead/pharmacology"[majr]) OR ("Lead"[mh] AND ((population health[tw] AND ("public health"[MeSH Major Topic] OR "public health administration"[MeSH Terms] OR "public health/education"[Mesh Terms] OR "public health practice"[MeSH Terms] OR "public policy"[MeSH Terms])) OR (population[tw] AND "health care quality, access, and evaluation"[MeSH Major Topic] AND "demography"[MeSH Major Topic] AND "health services"[MeSH Major Topic] OR ("health status indicators"[MeSH Major Topic] AND "population characteristics"[MeSH Major Topic] AND "social environment"[MeSH Major Topic]) OR ("health services accessibility"[MeSH Terms] AND "demography"[MeSH Terms] AND disparities[tw]) OR (population health[ti] AND ("health care quality, access, and evaluation"[MeSH Terms] OR "preventive health services"[MeSH Terms] OR "health planning"[MeSH Terms] OR "health policy"[MeSH Terms] OR "demography"[MeSH Terms] OR "health expenditures"[MeSH Terms] OR "income"[MeSH Terms] OR "population dynamics"[MeSH Terms] OR "social determinants of health"[MeSH Terms] OR

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
	<p>"socioeconomic factors"[MeSH Terms] OR "population characteristics"[MeSH Terms] OR "health promotion"[MeSH Terms] OR "public health/education"[Mesh Terms] OR "public health/methods"[Mesh Terms])) OR (population health[tw] AND ("community health services"[MeSH Major Topic] OR "health services"[MeSH Major Topic] OR "health services research"[MeSH Major Topic] OR "delivery of health care"[MeSH Major Topic] OR "health planning"[MeSH Major Topic] OR "health policy"[MeSH Major Topic] OR "preventive health services"[MeSH Major Topic] OR "health care evaluation mechanisms"[MeSH Major Topic] OR "public health administration"[MeSH Major Topic] OR "public health/education"[MAJR] OR "public policy"[MeSH Major Topic] OR "quality of life"[MeSH Major Topic] OR "health surveys"[MeSH Major Topic] OR "public health administration"[MeSH Major Topic] OR "demography"[MeSH Major Topic] OR "socioeconomic factors"[MeSH Major Topic] OR "health behavior"[MeSH Major Topic] OR "attitude to health"[MeSH Major Topic] OR "social environment"[MeSH Major Topic] OR "social welfare"[MeSH Major Topic] OR "population characteristics"[MeSH Major Topic] OR "vulnerable populations"[MeSH Major Topic] OR "residence characteristics"[MeSH Terms] OR "poverty"[MeSH Major Topic] OR "healthcare disparities"[MeSH Major Topic])) OR ("health status indicators"[MeSH Terms] AND "mass screening/methods"[MAJR] AND "morbidity"[MeSH Major Topic]) OR ("health status indicators"[MeSH Major Topic] AND "public health practice"[MeSH Major Topic] AND "outcome assessment (health care)"[MeSH Terms]) OR (built environment[tw] AND ("public health"[MeSH Major Topic] OR ("population"[MeSH Terms] OR "population"[All Fields] OR "population groups"[MeSH Terms] OR ("population"[All Fields] AND "groups"[All Fields]) OR "population groups"[All Fields]) AND ("health"[MeSH Terms] OR "health"[All Fields]))) OR ((socioeconomic[tw] OR inequality[tw] OR inequalities[tw] OR disparity[tw] OR disparities[tw] OR equity[tw] OR inequity[tw] OR inequities[tw] OR policy[tw] OR policies[tw] OR determinants[tw]) AND population health[tw] NOT medline[sb]) AND english[la] NOT letter[pt])) OR ("Tetraethyl Lead/toxicity"[mh] OR "Tetraethyl Lead/adverse effects"[mh] OR "Tetraethyl Lead/poisoning"[mh] OR "Tetraethyl Lead/pharmacokinetics"[mh] OR "Tetraethyl Lead/blood"[mh] OR "Tetraethyl Lead/cerebrospinal fluid"[mh] OR "Tetraethyl Lead/urine"[mh] OR "Tetraethyl Lead/antagonists and inhibitors"[mh] OR ("Tetraethyl Lead/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh]))) OR ("Tetraethyl Lead"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "toxicokinetics"[mh:noexp] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh])) OR ("Tetraethyl Lead"[mh] AND ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("Tetraethyl Lead"[majr] AND cancer[sb]) OR ("Tetraethyl Lead/pharmacology"[majr]) OR ("Tetraethyl Lead"[mh] AND ((population health[tw] AND ("public health"[MeSH Major Topic] OR "public health administration"[MeSH Terms] OR "public health/education"[Mesh Terms] OR "public health practice"[MeSH Terms] OR "public policy"[MeSH Terms])) OR (population[tw] AND "health care quality, access, and</p>

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
	<p>evaluation"[MeSH Major Topic] AND "demography"[MeSH Major Topic] AND "health services"[MeSH Major Topic]) OR ("health status indicators"[MeSH Major Topic] AND "population characteristics"[MeSH Major Topic] AND "social environment"[MeSH Major Topic]) OR ("health services accessibility"[MeSH Terms] AND "demography"[MeSH Terms] AND disparities[tw]) OR (population health[ti] AND ("health care quality, access, and evaluation"[MeSH Terms] OR "preventive health services"[MeSH Terms] OR "health planning"[MeSH Terms] OR "health policy"[MeSH Terms] OR "demography"[MeSH Terms] OR "health expenditures"[MeSH Terms] OR "income"[MeSH Terms] OR "population dynamics"[MeSH Terms] OR "social determinants of health"[MeSH Terms] OR "socioeconomic factors"[MeSH Terms] OR "population characteristics"[MeSH Terms] OR "health promotion"[MeSH Terms] OR "public health/education"[MeSH Terms] OR "public health/methods"[MeSH Terms])) OR (population health[tw] AND ("community health services"[MeSH Major Topic] OR "health services"[MeSH Major Topic] OR "health services research"[MeSH Major Topic] OR "delivery of health care"[MeSH Major Topic] OR "health planning"[MeSH Major Topic] OR "health policy"[MeSH Major Topic] OR "preventive health services"[MeSH Major Topic] OR "health care evaluation mechanisms"[MeSH Major Topic] OR "public health administration"[MeSH Major Topic] OR "public health/education"[MAJR] OR "public policy"[MeSH Major Topic] OR "quality of life"[MeSH Major Topic] OR "health surveys"[MeSH Major Topic] OR "public health administration"[MeSH Major Topic] OR "demography"[MeSH Major Topic] OR "socioeconomic factors"[MeSH Major Topic] OR "health behavior"[MeSH Major Topic] OR "attitude to health"[MeSH Major Topic] OR "social environment"[MeSH Major Topic] OR "social welfare"[MeSH Major Topic] OR "population characteristics"[MeSH Major Topic] OR "vulnerable populations"[MeSH Major Topic] OR "residence characteristics"[MeSH Terms] OR "poverty"[MeSH Major Topic] OR "healthcare disparities"[MeSH Major Topic]) OR ("health status indicators"[MeSH Terms] AND "mass screening/methods"[MAJR] AND "morbidity"[MeSH Major Topic]) OR ("health status indicators"[MeSH Major Topic] AND "public health practice"[MeSH Major Topic] AND "outcome assessment (health care)"[MeSH Terms]) OR (built environment[tw] AND ("public health"[MeSH Major Topic] OR ("population"[MeSH Terms] OR "population"[All Fields] OR "population groups"[MeSH Terms] OR ("population"[All Fields] AND "groups"[All Fields]) OR "population groups"[All Fields]) AND ("health"[MeSH Terms] OR "health"[All Fields]))) OR ((socioeconomic[tw] OR inequality[tw] OR inequalities[tw] OR disparity[tw] OR disparities[tw] OR equity[tw] OR inequity[tw] OR inequities[tw] OR policy[tw] OR policies[tw] OR determinants[tw]) AND population health[tw] NOT medline[sb]) AND english[la] NOT letter[pt]) OR ("lead poisoning"[mh]) AND (2013/01/01 : 3000[mhda] OR 2013/01/01 : 3000[crdt] OR 2013/01/01 : 3000[edat] OR 2013/01/01 : 3000[dp]) ("lead acetate"[nm] AND (("Organometallic Compounds/toxicity"[mh] OR "Organometallic Compounds/adverse effects"[mh] OR "Organometallic Compounds/poisoning"[mh] OR "Organometallic Compounds/pharmacokinetics"[mh] OR "Organometallic Compounds/blood"[mh] OR "Organometallic Compounds/cerebrospinal fluid"[mh] OR "Organometallic Compounds/urine"[mh] OR "Organometallic Compounds/antagonists and inhibitors"[mh] OR ("Organometallic Compounds/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh]))) OR ("Organometallic Compounds"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "toxicokinetics"[mh:noexp] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh])) OR ("Organometallic Compounds"[mh] AND ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR</p>

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
	<p>genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("Organometallic Compounds"[majr] AND cancer[sb]) OR ("Organometallic Compounds/pharmacology"[majr]) OR ("Organometallic Compounds"[mh] AND ((population health[tw] AND ("public health"[MeSH Major Topic] OR "public health administration"[MeSH Terms] OR "public health/education"[Mesh Terms] OR "public health practice"[MeSH Terms] OR "public policy"[MeSH Terms])) OR (population[tw] AND "health care quality, access, and evaluation"[MeSH Major Topic] AND "demography"[MeSH Major Topic] AND "health services"[MeSH Major Topic]) OR ("health status indicators"[MeSH Major Topic] AND "population characteristics"[MeSH Major Topic] AND "social environment"[MeSH Major Topic]) OR ("health services accessibility"[MeSH Terms] AND "demography"[MeSH Terms] AND disparities[tw]) OR (population health[ti] AND ("health care quality, access, and evaluation"[MeSH Terms] OR "preventive health services"[MeSH Terms] OR "health planning"[MeSH Terms] OR "health policy"[MeSH Terms] OR "demography"[MeSH Terms] OR "health expenditures"[MeSH Terms] OR "income"[MeSH Terms] OR "population dynamics"[MeSH Terms] OR "social determinants of health"[MeSH Terms] OR "socioeconomic factors"[MeSH Terms] OR "population characteristics"[MeSH Terms] OR "health promotion"[MeSH Terms] OR "public health/education"[Mesh Terms] OR "public health/methods"[Mesh Terms])) OR (population health[tw] AND ("community health services"[MeSH Major Topic] OR "health services"[MeSH Major Topic] OR "health services research"[MeSH Major Topic] OR "delivery of health care"[MeSH Major Topic] OR "health planning"[MeSH Major Topic] OR "health policy"[MeSH Major Topic] OR "preventive health services"[MeSH Major Topic] OR "health care evaluation mechanisms"[MeSH Major Topic] OR "public health administration"[MeSH Major Topic] OR "public health/education"[MAJR] OR "public policy"[MeSH Major Topic] OR "quality of life"[MeSH Major Topic] OR "health surveys"[MeSH Major Topic] OR "public health administration"[MeSH Major Topic] OR "demography"[MeSH Major Topic] OR "socioeconomic factors"[MeSH Major Topic] OR "health behavior"[MeSH Major Topic] OR "attitude to health"[MeSH Major Topic] OR "social environment"[MeSH Major Topic] OR "social welfare"[MeSH Major Topic] OR "population characteristics"[MeSH Major Topic] OR "vulnerable populations"[MeSH Major Topic] OR "residence characteristics"[MeSH Terms] OR "poverty"[MeSH Major Topic] OR "healthcare disparities"[MeSH Major Topic]) OR ("health status indicators"[MeSH Terms] AND "mass screening/methods"[MAJR] AND "morbidity"[MeSH Major Topic]) OR ("health status indicators"[MeSH Major Topic] AND "public health practice"[MeSH Major Topic] AND "outcome assessment (health care)"[MeSH Terms] OR (built environment[tw] AND ("public health"[MeSH Major Topic] OR ("population"[MeSH Terms] OR "population"[All Fields] OR "population groups"[MeSH Terms] OR ("population"[All Fields] AND "groups"[All Fields]) OR "population groups"[All Fields]) AND ("health"[MeSH Terms] OR "health"[All Fields]))) OR ((socioeconomic[tw] OR inequality[tw] OR inequalities[tw] OR disparity[tw] OR disparities[tw] OR equity[tw] OR inequity[tw] OR inequities[tw] OR policy[tw] OR policies[tw] OR determinants[tw]) AND population health[tw] NOT medline[sb]) AND english[la] NOT letter[pt])) OR ("lead azide"[nm] AND ("Azides/toxicity"[mh] OR "Azides/adverse effects"[mh] OR "Azides/poisoning"[mh] OR</p>

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
	"Azides/pharmacokinetics"[mh] OR "Azides/blood"[mh] OR "Azides/cerebrospinal fluid"[mh] OR "Azides/urine"[mh] OR "Azides/antagonists and inhibitors"[mh] OR ("Azides/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh])) OR ("Azides"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "toxicokinetics"[mh:noexp] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh])) OR ("Azides"[mh] AND ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("Azides"[majr] AND cancer[sb]) OR ("Azides/pharmacology"[majr]) OR ("Azides"[mh] AND ((population health[tw] AND ("public health"[MeSH Major Topic] OR "public health administration"[MeSH Terms] OR "public health/education"[Mesh Terms] OR "public health practice"[MeSH Terms] OR "public policy"[MeSH Terms])) OR (population[tw] AND "health care quality, access, and evaluation"[MeSH Major Topic] AND "demography"[MeSH Major Topic] AND "health services"[MeSH Major Topic] OR ("health status indicators"[MeSH Major Topic] AND "population characteristics"[MeSH Major Topic] AND "social environment"[MeSH Major Topic] OR ("health services accessibility"[MeSH Terms] AND "demography"[MeSH Terms] AND disparities[tw]) OR (population health[ti] AND ("health care quality, access, and evaluation"[MeSH Terms] OR "preventive health services"[MeSH Terms] OR "health planning"[MeSH Terms] OR "health policy"[MeSH Terms] OR "demography"[MeSH Terms] OR "health expenditures"[MeSH Terms] OR "income"[MeSH Terms] OR "population dynamics"[MeSH Terms] OR "social determinants of health"[MeSH Terms] OR "socioeconomic factors"[MeSH Terms] OR "population characteristics"[MeSH Terms] OR "health promotion"[MeSH Terms] OR "public health/education"[Mesh Terms] OR "public health/methods"[Mesh Terms])) OR (population health[tw] AND ("community health services"[MeSH Major Topic] OR "health services"[MeSH Major Topic] OR "health services research"[MeSH Major Topic] OR "delivery of health care"[MeSH Major Topic] OR "health planning"[MeSH Major Topic] OR "health policy"[MeSH Major Topic] OR "preventive health services"[MeSH Major Topic] OR "health care evaluation mechanisms"[MeSH Major Topic] OR "public health administration"[MeSH Major Topic] OR "public health/education"[MAJR] OR "public policy"[MeSH Major Topic] OR "quality of life"[MeSH Major Topic] OR "health surveys"[MeSH Major Topic] OR "public health administration"[MeSH Major Topic] OR "demography"[MeSH Major Topic] OR "socioeconomic factors"[MeSH Major Topic] OR "health behavior"[MeSH Major Topic] OR "attitude to health"[MeSH Major Topic] OR "social environment"[MeSH Major Topic] OR "social welfare"[MeSH Major Topic] OR "population characteristics"[MeSH Major Topic] OR "vulnerable populations"[MeSH Major Topic] OR "residence characteristics"[MeSH Terms] OR "poverty"[MeSH Major Topic] OR "healthcare disparities"[MeSH Major Topic])) OR ("health status indicators"[MeSH Terms] AND "mass screening/methods"[MAJR] AND "morbidity"[MeSH Major Topic]) OR ("health status indicators"[MeSH Major Topic] AND "public health practice"[MeSH Major Topic] AND "outcome assessment (health care)"[MeSH Terms]) OR (built environment[tw] AND ("public health"[MeSH Major Topic]

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
	<p>OR (("population"[MeSH Terms] OR "population"[All Fields] OR "population groups"[MeSH Terms] OR ("population"[All Fields] AND "groups"[All Fields]) OR "population groups"[All Fields]) AND ("health"[MeSH Terms] OR "health"[All Fields]))) OR ((socioeconomic[tw] OR inequality[tw] OR inequalities[tw] OR disparity[tw] OR disparities[tw] OR equity[tw] OR inequity[tw] OR inequities[tw] OR policy[tw] OR policies[tw] OR determinants[tw]) AND population health[tw] NOT medline[sb]) AND english[la] NOT letter[pt])) OR ("lead chromate"[nm] AND (("Chromates/toxicity"[mh] OR "Chromates/adverse effects"[mh] OR "Chromates/poisoning"[mh] OR "Chromates/pharmacokinetics"[mh] OR "Chromates/blood"[mh] OR "Chromates/cerebrospinal fluid"[mh] OR "Chromates/urine"[mh] OR "Chromates/antagonists and inhibitors"[mh] OR ("Chromates/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh]))) OR ("Chromates"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "toxicokinetics"[mh:noexp] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh])) OR ("Chromates"[mh] AND ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("Chromates"[majr] AND cancer[sb]) OR ("Chromates/pharmacology"[majr] OR ("Chromates"[mh] AND ((population health[tw] AND ("public health"[MeSH Major Topic] OR "public health administration"[MeSH Terms] OR "public health/education"[Mesh Terms] OR "public health practice"[MeSH Terms] OR "public policy"[MeSH Terms])) OR (population[tw] AND "health care quality, access, and evaluation"[MeSH Major Topic] AND "demography"[MeSH Major Topic] AND "health services"[MeSH Major Topic]) OR ("health status indicators"[MeSH Major Topic] AND "population characteristics"[MeSH Major Topic] AND "social environment"[MeSH Major Topic]) OR ("health services accessibility"[MeSH Terms] AND "demography"[MeSH Terms] AND disparities[tw]) OR (population health[ti] AND ("health care quality, access, and evaluation"[MeSH Terms] OR "preventive health services"[MeSH Terms] OR "health planning"[MeSH Terms] OR "health policy"[MeSH Terms] OR "demography"[MeSH Terms] OR "health expenditures"[MeSH Terms] OR "income"[MeSH Terms] OR "population dynamics"[MeSH Terms] OR "social determinants of health"[MeSH Terms] OR "socioeconomic factors"[MeSH Terms] OR "population characteristics"[MeSH Terms] OR "health promotion"[MeSH Terms] OR "public health/education"[Mesh Terms] OR "public health/methods"[Mesh Terms])) OR (population health[tw] AND ("community health services"[MeSH Major Topic] OR "health services"[MeSH Major Topic] OR "health services research"[MeSH Major Topic] OR "delivery of health care"[MeSH Major Topic] OR "health planning"[MeSH Major Topic] OR "health policy"[MeSH Major Topic] OR "preventive health services"[MeSH Major Topic] OR "health care evaluation mechanisms"[MeSH Major Topic] OR "public health administration"[MeSH Major Topic] OR "public health/education"[MAJR] OR "public policy"[MeSH Major Topic] OR "quality of life"[MeSH Major Topic] OR "health surveys"[MeSH Major Topic] OR "public health administration"[MeSH Major Topic] OR "demography"[MeSH Major Topic] OR</p>

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
	<p>"socioeconomic factors"[MeSH Major Topic] OR "health behavior"[MeSH Major Topic] OR "attitude to health"[MeSH Major Topic] OR "social environment"[MeSH Major Topic] OR "social welfare"[MeSH Major Topic] OR "population characteristics"[MeSH Major Topic] OR "vulnerable populations"[MeSH Major Topic] OR "residence characteristics"[MeSH Terms] OR "poverty"[MeSH Major Topic] OR "healthcare disparities"[MeSH Major Topic]) OR ("health status indicators"[MeSH Terms] AND "mass screening/methods"[MAJR] AND "morbidity"[MeSH Major Topic]) OR ("health status indicators"[MeSH Major Topic] AND "public health practice"[MeSH Major Topic] AND "outcome assessment (health care)"[MeSH Terms]) OR (built environment[tw] AND ("public health"[MeSH Major Topic] OR ("population"[MeSH Terms] OR "population"[All Fields] OR "population groups"[MeSH Terms] OR ("population"[All Fields] AND "groups"[All Fields]) OR "population groups"[All Fields]) AND ("health"[MeSH Terms] OR "health"[All Fields]))) OR ((socioeconomic[tw] OR inequality[tw] OR inequalities[tw] OR disparity[tw] OR disparities[tw] OR equity[tw] OR inequity[tw] OR inequities[tw] OR policy[tw] OR policies[tw] OR determinants[tw]) AND population health[tw] NOT medline[sb]) AND english[la] NOT letter[pt])) OR ("lead nitrate"[nm] AND ("Nitrates/toxicity"[mh] OR "Nitrates/adverse effects"[mh] OR "Nitrates/poisoning"[mh] OR "Nitrates/pharmacokinetics"[mh] OR "Nitrates/blood"[mh] OR "Nitrates/cerebrospinal fluid"[mh] OR "Nitrates/urine"[mh] OR "Nitrates/antagonists and inhibitors"[mh] OR ("Nitrates/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh]))) OR ("Nitrates"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "toxicokinetics"[mh:noexp] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh])) OR ("Nitrates"[mh] AND ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh]) OR "transcription, genetic"[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("Nitrates"[majr] AND cancer[sb]) OR ("Nitrates/pharmacology"[majr]) OR ("Nitrates"[mh] AND ((population health[tw] AND ("public health"[MeSH Major Topic] OR "public health administration"[MeSH Terms] OR "public health/education"[Mesh Terms] OR "public health practice"[MeSH Terms] OR "public policy"[MeSH Terms])) OR (population[tw] AND "health care quality, access, and evaluation"[MeSH Major Topic] AND "demography"[MeSH Major Topic] AND "health services"[MeSH Major Topic]) OR ("health status indicators"[MeSH Major Topic] AND "population characteristics"[MeSH Major Topic] AND "social environment"[MeSH Major Topic]) OR ("health services accessibility"[MeSH Terms] AND "demography"[MeSH Terms] AND disparities[tw]) OR (population health[ti] AND ("health care quality, access, and evaluation"[MeSH Terms] OR "preventive health services"[MeSH Terms] OR "health planning"[MeSH Terms] OR "health policy"[MeSH Terms] OR "demography"[MeSH Terms] OR "health expenditures"[MeSH Terms] OR "income"[MeSH Terms] OR "population dynamics"[MeSH Terms] OR "social determinants of health"[MeSH Terms] OR "socioeconomic factors"[MeSH Terms] OR "population characteristics"[MeSH Terms] OR "health promotion"[MeSH Terms] OR "public health/education"[Mesh Terms] OR "public health/methods"[Mesh Terms])) OR (population health[tw] AND ("community</p>

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
	<p>health services"[MeSH Major Topic] OR "health services research"[MeSH Major Topic] OR "delivery of health care"[MeSH Major Topic] OR "health planning"[MeSH Major Topic] OR "health policy"[MeSH Major Topic] OR "preventive health services"[MeSH Major Topic] OR "health care evaluation mechanisms"[MeSH Major Topic] OR "public health administration"[MeSH Major Topic] OR "public health/education"[MAJR] OR "public policy"[MeSH Major Topic] OR "quality of life"[MeSH Major Topic] OR "health surveys"[MeSH Major Topic] OR "public health administration"[MeSH Major Topic] OR "demography"[MeSH Major Topic] OR "socioeconomic factors"[MeSH Major Topic] OR "health behavior"[MeSH Major Topic] OR "attitude to health"[MeSH Major Topic] OR "social environment"[MeSH Major Topic] OR "social welfare"[MeSH Major Topic] OR "population characteristics"[MeSH Major Topic] OR "vulnerable populations"[MeSH Major Topic] OR "residence characteristics"[MeSH Terms] OR "poverty"[MeSH Major Topic] OR "healthcare disparities"[MeSH Major Topic]) OR ("health status indicators"[MeSH Terms] AND "mass screening/methods"[MAJR] AND "morbidity"[MeSH Major Topic]) OR ("health status indicators"[MeSH Major Topic] AND "public health practice"[MeSH Major Topic] AND "outcome assessment (health care)"[MeSH Terms]) OR (built environment[tw] AND ("public health"[MeSH Major Topic] OR ("population"[MeSH Terms] OR "population"[All Fields] OR "population groups"[MeSH Terms] OR ("population"[All Fields] AND "groups"[All Fields]) OR "population groups"[All Fields]) AND ("health"[MeSH Terms] OR "health"[All Fields]))) OR ((socioeconomic[tw] OR inequality[tw] OR inequalities[tw] OR disparity[tw] OR disparities[tw] OR equity[tw] OR inequity[tw] OR inequities[tw] OR policy[tw] OR policies[tw] OR determinants[tw]) AND population health[tw] NOT medline[sb]) AND english[la] NOT letter[pt])) OR ("lead oxide"[nm] AND ("Oxides/toxicity"[mh] OR "Oxides/adverse effects"[mh] OR "Oxides/poisoning"[mh] OR "Oxides/pharmacokinetics"[mh] OR "Oxides/blood"[mh] OR "Oxides/cerebrospinal fluid"[mh] OR "Oxides/urine"[mh] OR "Oxides/antagonists and inhibitors"[mh] OR ("Oxides/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh]))) OR ("Oxides"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "toxicokinetics"[mh:noexp] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh])) OR ("Oxides"[mh] AND ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic "[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("Oxides"[majr] AND cancer[sb]) OR ("Oxides/pharmacology"[majr] OR ("Oxides"[mh] AND ((population health[tw] AND ("public health"[MeSH Major Topic] OR "public health administration"[MeSH Terms] OR "public health/education"[Mesh Terms] OR "public health practice"[MeSH Terms] OR "public policy"[MeSH Terms])) OR (population[tw] AND "health care quality, access, and evaluation"[MeSH Major Topic] AND "demography"[MeSH Major Topic] AND "health services"[MeSH Major Topic]) OR ("health status indicators"[MeSH Major Topic] AND "population characteristics"[MeSH Major Topic] AND "social environment"[MeSH Major Topic]) OR ("health services accessibility"[MeSH Terms] AND "demography"[MeSH Terms] AND disparities[tw]) OR</p>

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
	<p>(population health[ti] AND ("health care quality, access, and evaluation"[MeSH Terms] OR "preventive health services"[MeSH Terms] OR "health planning"[MeSH Terms] OR "health policy"[MeSH Terms] OR "demography"[MeSH Terms] OR "health expenditures"[MeSH Terms] OR "income"[MeSH Terms] OR "population dynamics"[MeSH Terms] OR "social determinants of health"[MeSH Terms] OR "socioeconomic factors"[MeSH Terms] OR "population characteristics"[MeSH Terms] OR "health promotion"[MeSH Terms] OR "public health/education"[Mesh Terms] OR "public health/methods"[Mesh Terms])) OR (population health[tw] AND ("community health services"[MeSH Major Topic] OR "health services"[MeSH Major Topic] OR "health services research"[MeSH Major Topic] OR "delivery of health care"[MeSH Major Topic] OR "health planning"[MeSH Major Topic] OR "health policy"[MeSH Major Topic] OR "preventive health services"[MeSH Major Topic] OR "health care evaluation mechanisms"[MeSH Major Topic] OR "public health administration"[MeSH Major Topic] OR "public health/education"[MAJR] OR "public policy"[MeSH Major Topic] OR "quality of life"[MeSH Major Topic] OR "health surveys"[MeSH Major Topic] OR "public health administration"[MeSH Major Topic] OR "demography"[MeSH Major Topic] OR "socioeconomic factors"[MeSH Major Topic] OR "health behavior"[MeSH Major Topic] OR "attitude to health"[MeSH Major Topic] OR "social environment"[MeSH Major Topic] OR "social welfare"[MeSH Major Topic] OR "population characteristics"[MeSH Major Topic] OR "vulnerable populations"[MeSH Major Topic] OR "residence characteristics"[MeSH Terms] OR "poverty"[MeSH Major Topic] OR "healthcare disparities"[MeSH Major Topic])) OR ("health status indicators"[MeSH Terms] AND "mass screening/methods"[MAJR] AND "morbidity"[MeSH Major Topic]) OR ("health status indicators"[MeSH Major Topic] AND "public health practice"[MeSH Major Topic] AND "outcome assessment (health care)"[MeSH Terms]) OR (built environment[tw] AND ("public health"[MeSH Major Topic] OR ("population"[MeSH Terms] OR "population"[All Fields] OR "population groups"[MeSH Terms] OR ("population"[All Fields] AND "groups"[All Fields]) OR "population groups"[All Fields]) AND ("health"[MeSH Terms] OR "health"[All Fields]))) OR ((socioeconomic[tw] OR inequality[tw] OR inequalities[tw] OR disparity[tw] OR disparities[tw] OR equity[tw] OR inequity[tw] OR inequities[tw] OR policy[tw] OR policies[tw] OR determinants[tw]) AND population health[tw] NOT medline[sb]) AND english[la] NOT letter[pt])) OR ("lead sulfide"[nm] AND (("Sulfides/toxicity"[mh] OR "Sulfides/adverse effects"[mh] OR "Sulfides/poisoning"[mh] OR "Sulfides/pharmacokinetics"[mh] OR "Sulfides/blood"[mh] OR "Sulfides/cerebrospinal fluid"[mh] OR "Sulfides/urine"[mh] OR "Sulfides/antagonists and inhibitors"[mh] OR ("Sulfides/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh]))) OR ("Sulfides"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "toxicokinetics"[mh:noexp] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh])) OR ("Sulfides"[mh] AND ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene expression"[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh]) OR "transcription, genetic"[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("Sulfides"[majr] AND cancer[sb]) OR</p>

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
	<p>(("Sulfides/pharmacology"[majr]) OR ("Sulfides"[mh] AND ((population health[tw] AND ("public health"[MeSH Major Topic] OR "public health administration"[MeSH Terms] OR "public health/education"[Mesh Terms] OR "public health practice"[MeSH Terms] OR "public policy"[MeSH Terms])) OR (population[tw] AND "health care quality, access, and evaluation"[MeSH Major Topic] AND "demography"[MeSH Major Topic] AND "health services"[MeSH Major Topic]) OR ("health status indicators"[MeSH Major Topic] AND "population characteristics"[MeSH Major Topic] AND "social environment"[MeSH Major Topic]) OR ("health services accessibility"[MeSH Terms] AND "demography"[MeSH Terms] AND disparities[tw]) OR (population health[ti] AND ("health care quality, access, and evaluation"[MeSH Terms] OR "preventive health services"[MeSH Terms] OR "health planning"[MeSH Terms] OR "health policy"[MeSH Terms] OR "demography"[MeSH Terms] OR "health expenditures"[MeSH Terms] OR "income"[MeSH Terms] OR "population dynamics"[MeSH Terms] OR "social determinants of health"[MeSH Terms] OR "socioeconomic factors"[MeSH Terms] OR "population characteristics"[MeSH Terms] OR "health promotion"[MeSH Terms] OR "public health/education"[Mesh Terms] OR "public health/methods"[Mesh Terms])) OR (population health[tw] AND ("community health services"[MeSH Major Topic] OR "health services"[MeSH Major Topic] OR "health services research"[MeSH Major Topic] OR "delivery of health care"[MeSH Major Topic] OR "health planning"[MeSH Major Topic] OR "health policy"[MeSH Major Topic] OR "preventive health services"[MeSH Major Topic] OR "health care evaluation mechanisms"[MeSH Major Topic] OR "public health administration"[MeSH Major Topic] OR "public health/education"[MAJR] OR "public policy"[MeSH Major Topic] OR "quality of life"[MeSH Major Topic] OR "health surveys"[MeSH Major Topic] OR "public health administration"[MeSH Major Topic] OR "demography"[MeSH Major Topic] OR "socioeconomic factors"[MeSH Major Topic] OR "health behavior"[MeSH Major Topic] OR "attitude to health"[MeSH Major Topic] OR "social environment"[MeSH Major Topic] OR "social welfare"[MeSH Major Topic] OR "population characteristics"[MeSH Major Topic] OR "vulnerable populations"[MeSH Major Topic] OR "residence characteristics"[MeSH Terms] OR "poverty"[MeSH Major Topic] OR "healthcare disparities"[MeSH Major Topic])) OR ("health status indicators"[MeSH Terms] AND "mass screening/methods"[MAJR] AND "morbidity"[MeSH Major Topic]) OR ("health status indicators"[MeSH Major Topic] AND "public health practice"[MeSH Major Topic] AND "outcome assessment (health care)"[MeSH Terms]) OR (built environment[tw] AND ("public health"[MeSH Major Topic] OR ("population"[MeSH Terms] OR "population"[All Fields] OR "population groups"[MeSH Terms] OR ("population"[All Fields] AND "groups"[All Fields]) OR "population groups"[All Fields]) AND ("health"[MeSH Terms] OR "health"[All Fields]))) OR ((socioeconomic[tw] OR inequality[tw] OR inequalities[tw] OR disparity[tw] OR disparities[tw] OR equity[tw] OR inequity[tw] OR inequities[tw] OR policy[tw] OR policies[tw] OR determinants[tw]) AND population health[tw] NOT medline[sb]) AND english[la] NOT letter[pt])) OR ("lead carbonate"[nm] AND (("Carbonates/toxicity"[mh] OR "Carbonates/adverse effects"[mh] OR "Carbonates/poisoning"[mh] OR "Carbonates/pharmacokinetics"[mh] OR "Carbonates/blood"[mh] OR "Carbonates/cerebrospinal fluid"[mh] OR "Carbonates/urine"[mh] OR "Carbonates/antagonists and inhibitors"[mh] OR ("Carbonates/metabolism"[mh] AND ("humans"[mh] OR "animals"[mh]))) OR ("Carbonates"[mh] AND ("environmental exposure"[mh] OR ci[sh] OR "toxicokinetics"[mh:noexp] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh])) OR ("Carbonates"[mh] AND ("computational biology"[mh] OR "medical informatics"[mh] OR genomics[mh] OR genome[mh] OR proteomics[mh] OR proteome[mh] OR metabolomics[mh] OR metabolome[mh] OR genes[mh] OR "gene</p>

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
	<p>expression[mh] OR phenotype[mh] OR genetics[mh] OR genotype[mh] OR transcriptome[mh] OR ("systems biology"[mh] AND ("environmental exposure"[mh] OR "epidemiological monitoring"[mh] OR analysis[sh])) OR "transcription, genetic"[mh] OR "reverse transcription"[mh] OR "transcriptional activation"[mh] OR "transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, messenger"[mh] OR "RNA, transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "reverse transcriptase polymerase chain reaction"[mh] OR "base sequence"[mh] OR "trans-activators"[mh] OR "gene expression profiling"[mh])) OR ("Carbonates"[majr] AND cancer[sb]) OR ("Carbonates/pharmacology"[majr] OR ("Carbonates"[mh] AND ((population health[tw] AND ("public health"[MeSH Major Topic] OR "public health administration"[MeSH Terms] OR "public health/education"[Mesh Terms] OR "public health practice"[MeSH Terms] OR "public policy"[MeSH Terms])) OR (population[tw] AND "health care quality, access, and evaluation"[MeSH Major Topic] AND "demography"[MeSH Major Topic] AND "health services"[MeSH Major Topic]) OR ("health status indicators"[MeSH Major Topic] AND "population characteristics"[MeSH Major Topic] AND "social environment"[MeSH Major Topic]) OR ("health services accessibility"[MeSH Terms] AND "demography"[MeSH Terms] AND disparities[tw]) OR (population health[ti] AND ("health care quality, access, and evaluation"[MeSH Terms] OR "preventive health services"[MeSH Terms] OR "health planning"[MeSH Terms] OR "health policy"[MeSH Terms] OR "demography"[MeSH Terms] OR "health expenditures"[MeSH Terms] OR "income"[MeSH Terms] OR "population dynamics"[MeSH Terms] OR "social determinants of health"[MeSH Terms] OR "socioeconomic factors"[MeSH Terms] OR "population characteristics"[MeSH Terms] OR "health promotion"[MeSH Terms] OR "public health/education"[Mesh Terms] OR "public health/methods"[Mesh Terms])) OR (population health[tw] AND ("community health services"[MeSH Major Topic] OR "health services"[MeSH Major Topic] OR "health services research"[MeSH Major Topic] OR "delivery of health care"[MeSH Major Topic] OR "health planning"[MeSH Major Topic] OR "health policy"[MeSH Major Topic] OR "preventive health services"[MeSH Major Topic] OR "health care evaluation mechanisms"[MeSH Major Topic] OR "public health administration"[MeSH Major Topic] OR "public health/education"[MAJR] OR "public policy"[MeSH Major Topic] OR "quality of life"[MeSH Major Topic] OR "health surveys"[MeSH Major Topic] OR "public health administration"[MeSH Major Topic] OR "demography"[MeSH Major Topic] OR "socioeconomic factors"[MeSH Major Topic] OR "health behavior"[MeSH Major Topic] OR "attitude to health"[MeSH Major Topic] OR "social environment"[MeSH Major Topic] OR "social welfare"[MeSH Major Topic] OR "population characteristics"[MeSH Major Topic] OR "vulnerable populations"[MeSH Major Topic] OR "residence characteristics"[MeSH Terms] OR "poverty"[MeSH Major Topic] OR "healthcare disparities"[MeSH Major Topic]) OR ("health status indicators"[MeSH Terms] AND "mass screening/methods"[MAJR] AND "morbidity"[MeSH Major Topic]) OR ("health status indicators"[MeSH Major Topic] AND "public health practice"[MeSH Major Topic] AND "outcome assessment (health care)"[MeSH Terms] OR (built environment[tw] AND ("public health"[MeSH Major Topic] OR ("population"[MeSH Terms] OR "population"[All Fields] OR "population groups"[MeSH Terms] OR ("population"[All Fields] AND "groups"[All Fields]) OR "population groups"[All Fields]) AND ("health"[MeSH Terms] OR "health"[All Fields]))) OR ((socioeconomic[tw] OR inequality[tw] OR inequalities[tw] OR disparity[tw] OR disparities[tw] OR equity[tw] OR inequity[tw] OR inequities[tw] OR policy[tw] OR policies[tw] OR determinants[tw]) AND population health[tw] NOT medline[sb]) AND english[la] NOT letter[pt])) OR (("Lead fluoroborate"[tw] OR "Borate(1-), tetrafluoro-, lead (2+)"[tw] OR "Lead borofluoride"[tw] OR "Lead boron fluoride"[tw] OR "Lead</p>

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
	<p>fluoborate"[tw] OR "Lead tetrafluoroborate"[tw] OR "Lead(II) tetrafluoroborate"[tw] OR "Lead bis(tetrafluoroborate)"[tw] OR "Blei(II)-iodid"[tw] OR "Plumbous iodide"[tw] OR "Plumbum jodatum"[tw] OR "C.I. 77613"[tw] OR "Lead iodide"[tw] OR "Lead diiodide"[tw] OR "Lead(II) iodide"[tw] OR "Chromic acid lead salt with lead molybdate"[tw] OR "Chromic acid, lead and molybdenum salt"[tw] OR "Lead chromate molybdate"[tw] OR "Lead molybdate chromate"[tw] OR "Lead molybdenum chromate"[tw] OR "Molybdenum-lead chromate"[tw] OR "Chromium lead molybdenum oxide"[tw] OR "Lead-molybdenum chromate"[tw] OR "Tricinat"[tw] OR "3,3-didehydro-6,8,9-trinitro-2,4-Dioxa-3-plumbabicyclo[3.3.1]nona-1(9),5,7-triene"[tw] OR "Lead styphnate"[tw] OR "Lead trinitroresorcinate"[tw] OR "Lead tricinate"[tw] OR "Lead(II) styphnate"[tw] OR "1,3-Benzenediol, 2,4,6-trinitro-, lead(2+) salt"[tw] OR "2,4,6-trinitro-1,3-Benzenediol lead(2+) salt"[tw] OR "Lead 2,4,6-trinitro-m-phenylene dioxide"[tw] OR "Lead trinitroresorcinate"[tw] OR "[styphnato(2-)]Lead"[tw] OR "2,4,6-trinitroResorcinol, lead(2+) salt"[tw]) AND (to[sh] OR po[sh] OR ae[sh] OR pk[sh] OR (me[sh] AND ("humans"[mh] OR "animals"[mh])) OR ci[sh] OR bl[sh] OR cf[sh] OR ur[sh] OR "environmental exposure"[mh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("Computational biology"[mh] OR "Medical Informatics"[mh] OR Genomics[mh] OR Genome[mh] OR Proteomics[mh] OR Proteome[mh] OR Metabolomics[mh] OR Metabolome[mh] OR Genes[mh] OR "Gene expression"[mh] OR Phenotype[mh] OR genetics[mh] OR genotype[mh] OR Transcriptome[mh] OR ("Systems Biology"[mh] AND ("Environmental Exposure"[mh] OR "Epidemiological Monitoring"[mh] OR analysis[sh])) OR "Transcription, Genetic "[mh] OR "Reverse transcription"[mh] OR "Transcriptional activation"[mh] OR "Transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, Messenger"[mh] OR "RNA, Transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "Reverse Transcriptase Polymerase Chain Reaction"[mh] OR "Base Sequence"[mh] OR "Trans-activators"[mh] OR "Gene Expression Profiling"[mh])) OR cancer[sb] OR "pharmacology"[sh:noexp] OR lead/ai)) AND (2013/01/01 : 3000[mhda] OR 2013/01/01 : 3000[crdt] OR 2013/01/01 : 3000[edat] OR 2013/01/01 : 3000[dp])</p> <p>("pb"[ti] NOT medline[sb]) AND (2013/01/01 : 3000[crdt] OR 2013/01/01 : 3000[edat] OR 2013/01/01 : 3000[dp]) NOT (((("Lead"[ti] OR "C.I. 77575"[ti] OR "C.I. Pigment Metal 4"[ti] OR "CI 77575"[ti] OR "CI pigment metal 4"[ti] OR "Omaha & grant"[ti] OR "Pb-S 100"[ti] OR "Plumbum"[ti] OR "SSO 1"[ti] OR "Plumbous acetate"[ti] OR "Salt of saturn"[ti] OR "Unichem PBA"[ti] OR "RD 1333"[ti] OR "Plumbous bromide"[ti] OR "Plumbous chloride"[ti] OR "Phoenicochroite"[ti] OR "Plumbous chromate"[ti] OR "Chrome orange"[ti] OR "Blei(II)-iodid"[ti] OR "Plumbous iodide"[ti] OR "Plumbum jodatum"[ti] OR "C.I. 77613"[ti] OR "Plumbous nitrate"[ti] OR "Bleimonoxid"[ti] OR "Bleioxyd"[ti] OR "C.I. 77577"[ti] OR "C.I. Pigment Yellow 46"[ti] OR "CI 77577"[ti] OR "CI Pigment Yellow 46"[ti] OR "Litharge"[ti] OR "Massicot"[ti] OR "Massicotite"[ti] OR "Plumbi monoxidum"[ti] OR "Plumbous oxide"[ti] OR "Plumbum oxydatum"[ti] OR "C.I. 77622"[ti] OR "CI 77622"[ti] OR "Perlex paste 500"[ti] OR "Perlex paste 600A"[ti] OR "Plumbous phosphate"[ti] OR "Trilead bis(orthophosphate)"[ti] OR "Trilead phosphate"[ti] OR "Tricinat"[ti] OR "3,3-didehydro-6,8,9-trinitro-2,4-Dioxa-3-plumbabicyclo[3.3.1]nona-1(9),5,7-triene"[ti] OR "Anglislite"[ti] OR "C.I. 77630"[ti] OR "C.I. Pigment White 3"[ti] OR "CI 77630"[ti] OR "CI pigment white 3"[ti] OR "HB 2000"[ti] OR "Mulhouse White"[ti] OR "Natural anglesite"[ti] OR "Pigment White 3"[ti] OR "TS 100 sulfate"[ti] OR "C.I. 77640"[ti] OR "CI 77640"[ti] OR "Galena"[ti] OR "P 37 filter"[ti] OR "Plumbous sulfide"[ti] OR "Plumbane, tetraethyl-"[ti] OR "Tetra(methylethyl)lead"[ti] OR "Tetraethyllead"[ti] OR "Tetraethylplumbane"[ti] OR "Cerussite"[ti] OR "Cerussite"[ti] OR "Plumbous carbonate"[ti]) NOT medline[sb]) AND</p>

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
	(2013/01/01 : 3000[crdt] OR 2013/01/01 : 3000[edat] OR 2013/01/01 : 3000[dp])) **From the search results of this string, items that included "lead to" in titles were later removed using Endnote: (((("Lead"[ti] OR "C.I. 77575"[ti] OR "C.I. Pigment Metal 4"[ti] OR "CI 77575"[ti] OR "CI pigment metal 4"[ti] OR "Omaha & grant"[ti] OR "Pb-S 100"[ti] OR "Plumbum"[ti] OR "SSO 1"[ti] OR "Plumbous acetate"[ti] OR "Salt of saturn"[ti] OR "Unichem PBA"[ti] OR "RD 1333"[ti] OR "Plumbous bromide"[ti] OR "Plumbous chloride"[ti] OR "Phoenicochroite"[ti] OR "Plumbous chromate"[ti] OR "Chrome orange"[ti] OR "Blei(II)-iodid"[ti] OR "Plumbous iodide"[ti] OR "Plumbum jodatum"[ti] OR "C.I. 77613"[ti] OR "Plumbous nitrate"[ti] OR "Bleimonoxid"[ti] OR "Bleioxyd"[ti] OR "C.I. 77577"[ti] OR "C.I. Pigment Yellow 46"[ti] OR "CI 77577"[ti] OR "CI Pigment Yellow 46"[ti] OR "Litharge"[ti] OR "Massicot"[ti] OR "Massicotite"[ti] OR "Plumbi monoxidum"[ti] OR "Plumbous oxide"[ti] OR "Plumbum oxydatum"[ti] OR "C.I. 77622"[ti] OR "CI 77622"[ti] OR "Perlex paste 500"[ti] OR "Perlex paste 600A"[ti] OR "Plumbous phosphate"[ti] OR "Trilead bis(orthophosphate)"[ti] OR "Trilead phosphate"[ti] OR "Tricinat"[ti] OR "3,3-didehydro-6,8,9-trinitro-2,4-Dioxa-3-plumbabicyclo[3.3.1]nona-1(9),5,7-triene"[ti] OR "Anglislite"[ti] OR "C.I. 77630"[ti] OR "C.I. Pigment White 3"[ti] OR "CI 77630"[ti] OR "CI pigment white 3"[ti] OR "HB 2000"[ti] OR "Mulhouse White"[ti] OR "Natural anglesite"[ti] OR "Pigment White 3"[ti] OR "TS 100 sulfate"[ti] OR "C.I. 77640"[ti] OR "CI 77640"[ti] OR "Galena"[ti] OR "P 37 filter"[ti] OR "Plumbous sulfide"[ti] OR "Plumbane, tetraethyl-"[ti] OR "Tetra(methylethyl)lead"[ti] OR "Tetraethyllead"[ti] OR "Tetraethylplumbane"[ti] OR "Cerussete"[ti] OR "Cerussite"[ti] OR "Plumbous carbonate"[ti]) NOT medline[sb]) AND (2013/01/01 : 3000[crdt] OR 2013/01/01 : 3000[edat] OR 2013/01/01 : 3000[dp]))
4/2016	((("Lead dioxide"[tw] OR "C.I. 77580"[tw] OR "CI 77580"[tw] OR "Lead Brown"[tw] OR "Lead oxide"[tw] OR "Lead peroxide"[tw] OR "Lead superoxide"[tw] OR "Lead(IV) oxide"[tw])) AND (to[sh] OR po[sh] OR ae[sh] OR pk[sh] OR me[sh] AND ("humans"[mh] OR "animals"[mh])) OR ci[sh] OR bl[sh] OR cf[sh] OR ur[sh] OR "environmental exposure"[mh] OR "endocrine system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR "endocrine disruptors"[mh] OR ("Computational biology"[mh] OR "Medical Informatics"[mh] OR Genomics[mh] OR Genome[mh] OR Proteomics[mh] OR Proteome[mh] OR Metabolomics[mh] OR Metabolome[mh] OR Genes[mh] OR "Gene expression"[mh] OR Phenotype[mh] OR genetics[mh] OR genotype[mh] OR Transcriptome[mh] OR ("Systems Biology"[mh] AND ("Environmental Exposure"[mh] OR "Epidemiological Monitoring"[mh] OR analysis[sh])) OR "Transcription, Genetic "[mh] OR "Reverse transcription"[mh] OR "Transcriptional activation"[mh] OR "Transcription factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, Messenger"[mh] OR "RNA, Transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein biosynthesis"[mh] OR "Reverse Transcriptase Polymerase Chain Reaction"[mh] OR "Base Sequence"[mh] OR "Trans-activators"[mh] OR "Gene Expression Profiling"[mh])) OR cancer[sb] OR "pharmacology"[sh:noexp] OR lead/ai)) OR ((("C.I. 77580"[ti] OR "CI 77580"[ti]) NOT medline[sb]) OR ((("C.I. 77578"[ti] OR "C.I. Pigment Red 105"[ti] OR "CI 77578"[ti] OR "CI Pigment Red 105"[ti] OR "Gold satinobre"[ti] OR "Heuconin 5"[ti] OR "Mennige"[ti] OR "Mineral Orange"[ti] OR "Mineral Red"[ti] OR "Minium"[ti] OR "Paris Red"[ti] OR "Pigment Red 105"[ti] OR "Plumboplumbic oxide"[ti] OR "Sandix"[ti] OR "Saturn Red"[ti] OR "Trilead tetraoxide"[ti] OR "Trilead tetroxide"[ti] OR "azarcon"[ti]) NOT medline[sb])) AND (2013/01/01 : 3000[mhda] OR 2013/01/01 : 3000[crdt] OR 2013/01/01 : 3000[edat] OR 2013/01/01 : 3000[dp]))
Toxline	
2/2016	7439-92-1 [rn] AND 2013:2016 [yr] [not] PubMed [org] [not] pubdart [org]

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
	(301-04-2 [rn] OR 13424-46-9 [rn] OR 10031-22-8 [rn] OR 7758-95-4 [rn]) AND 2013:2016 [yr] AND NOT PubMed [org] AND NOT pubdart [org]
	(7758-97-6 [rn] OR 13814-96-5 [rn] OR 10101-63-0 [rn] OR 12709-98-7 [rn] OR 10099-74-8 [rn]) AND 2013:2016 [yr] AND NOT PubMed [org] AND NOT pubdart [org]
	(1317-36-8 [rn] OR 7446-27-7 [rn] OR 15245-44-0 [rn] OR 7446-14-2 [rn] OR 1314-87-0 [rn]) AND 2013:2016 [yr] AND NOT PubMed [org] AND NOT pubdart [org]
	(78-00-2 [rn] OR 598-63-0 [rn]) AND 2013:2016 [yr] AND NOT PubMed [org] AND NOT pubdart [org]
	(39377-56-5 [rn] OR 16040-38-3 [rn] OR 11119-70-3 [rn]) AND 2013:2016 [yr] AND NOT PubMed [org] AND NOT pubdart [org]
	("lead" NOT "nih reporter" [org]) AND 2013:2016 [yr] [not] PubMed [org] [not] pubdart [org]
	("c i 77575" OR "c i pigment metal 4" OR "ci 77575" OR "ci pigment metal 4" OR "omaha & grant" OR "pb s 100" OR "plumbum" OR "sso 1" OR "plumbous acetate" OR "salt of saturn" OR "unichem pba" OR "rd 1333" OR "plumbous bromide" OR "plumbous chloride" OR "phoenicochroite" OR "plumbous chromate" OR "chrome orange" OR "blei (ii) iodid" OR "plumbous iodide") AND 2013:2016 [yr] AND NOT PubMed [org] AND NOT pubdart [org]
	("plumbum jodatum" OR "c i 77613" OR "plumbous nitrate" OR "bleimonoxid" OR "bleioxyd" OR "c i 77577" OR "c i pigment yellow 46" OR "ci 77577" OR "ci pigment yellow 46" OR "litharge" OR "massicot" OR "massicotite" OR "plumbi monoxidum" OR "plumbous oxide" OR "plumbum oxydatum" OR "c i 77622" OR "ci 77622" OR "perlex paste 500" OR "perlex paste 600a" OR "plumbous phosphate") AND 2013:2016 [yr] AND NOT PubMed [org] AND NOT pubdart [org]
	("trilead bis (orthophosphate) " OR "trilead phosphate" OR "tricinat" OR "3 3-didehydro-6 8 9-trinitro-2 4-dioxa-3-plumbabicyclo 3 1] nona-1 (9) 5 7-triene" OR "anglislite" OR "c i 77630" OR "c i pigment white 3" OR "ci 77630" OR "ci pigment white 3" OR "hb 2000" OR "mulhouse white" OR "natural anglesite" OR "pigment white 3" OR "ts 100 sulfate" OR "c i 77640" OR "ci 77640" OR "galena") AND 2013:2016 [yr] AND NOT PubMed [org] AND NOT pubdart [org]
	("p 37 filter" OR "plumbous sulfide" OR "plumbane tetraethyl " OR "tetra (methylethyl) lead" OR "tetraethyllead" OR "tetraethylplumbane" OR "cerussete" OR "cerussite" OR "plumbous carbonate") AND 2013:2016 [yr] AND NOT PubMed [org] AND NOT pubdart [org]
4/2016	("lead tetroxide" OR "lead orthoplumbate" OR "lead oxide" OR "lead tetraoxide" OR "lead tetroxide" OR "orange lead" OR "red lead") AND 2013:2016 [yr] AND NOT PubMed [org] AND NOT pubdart [org]
	("c i 77578" OR "c i pigment red 105" OR "ci 77578" OR "ci pigment red 105" OR "gold satinobre" OR "heuconin 5" OR "mennige" OR "mineral orange" OR "mineral red" OR "minium" OR "paris red" OR "pigment red 105" OR "plumboplumbic oxide" OR "sandix" OR "saturn red" OR "trilead tetraoxide" OR "trilead tetroxide" OR "azarcon") AND 2013:2016 [yr] AND NOT PubMed [org] AND NOT pubdart [org]
	("lead dioxide" OR "c i 77580" OR "ci 77580" OR "lead brown" OR "lead oxide" OR "lead peroxide" OR "lead superoxide" OR "lead (iv) oxide") AND 2013:2016 [yr] AND NOT PubMed [org] AND NOT pubdart [org]
	(1309-60-0 [rn] OR 1314-41-6 [rn]) AND 2013:2016 [yr] AND NOT PubMed [org] AND NOT pubdart [org]

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
Toxcenter	
2/2016	FILE 'TOXCENTER' ENTERED AT 13:10:46 ON 19 FEB 2016
L1	198675 SEA FILE=TOXCENTER 7439-92-1
L2	11485 SEA FILE=TOXCENTER 301-04-2 OR 13424-46-9 OR 10031-22-8 OR 7758-95-4 OR 7758-97-6 OR 13814-96-5 OR 10101-63-0 OR 12709-98-7 OR 10099-74-8 OR 1317-36-8 OR 7446-27-7 OR 15245-44-0 OR 7446-14-2 OR 1314-87-0 OR 78-00-2 OR 598-63-0
L3	382 SEA FILE=TOXCENTER 39377-56-5 OR 16040-38-3 OR 11119-70-3
L4	205804 SEA FILE=TOXCENTER L1 OR L2
L5	111 SEA FILE=TOXCENTER L3 NOT L4
L6	205915 SEA FILE=TOXCENTER L1 OR L2 OR L3
L7	193807 SEA FILE=TOXCENTER L6 NOT PATENT/DT
L8	26193 SEA FILE=TOXCENTER L7 AND ED>=20130101
L9	23356 SEA FILE=TOXCENTER L7 AND PY>2012
L10	26193 SEA FILE=TOXCENTER L8 NOT TSCATS/FS DIS SAVED ACT TOXQUERY/Q -----
L11	QUE (CHRONIC OR IMMUNOTOX? OR NEUROTOX? OR TOXICOKIN? OR BIOMARKER? OR NEUROLOG?)
L12	QUE (PHARMACOKIN? OR SUBCHRONIC OR PBPK OR EPIDEMIOLOGY/ST,CT, IT)
L13	QUE (ACUTE OR SUBACUTE OR LD50# OR LD(W)50 OR LC50# OR LC(W)50)
L14	QUE (TOXICITY OR ADVERSE OR POISONING)/ST,CT,IT
L15	QUE (INHAL? OR PULMON? OR NASAL? OR LUNG? OR RESPIR?)
L16	QUE ((OCCUPATION? OR WORKPLACE? OR WORKER?) AND EXPOS?)
L17	QUE (ORAL OR ORALLY OR INGEST? OR GAVAGE? OR DIET OR DIETS OR DIETARY OR DRINKING(W)WATER?)
L18	QUE (MAXIMUM AND CONCENTRATION? AND (ALLOWABLE OR PERMISSIBLE))
L19	QUE (ABORT? OR ABNORMALIT? OR EMBRYO? OR CLEFT? OR FETUS?)
L20	QUE (FOETUS? OR FETAL? OR FOETAL? OR FERTIL? OR MALFORM? OR OVUM?)
L21	QUE (OVA OR OVARY OR PLACENTA? OR PREGNAN? OR PRENATAL?)
L22	QUE (PERINATAL? OR POSTNATAL? OR REPRODUC? OR STERIL? OR TERATOGEN?)
L23	QUE (SPERM OR SPERMAC? OR SPERMAG? OR SPERMATI? OR SPERMAS? OR SPERMATOB? OR SPERMATOC? OR SPERMATOG?)
L24	QUE (SPERMATOI? OR SPERMATOL? OR SPERMATOR? OR SPERMATOX? OR SPERMATOZ? OR SPERMATU? OR SPERMI? OR SPERMO?)
L25	QUE (NEONAT? OR NEWBORN? OR DEVELOPMENT OR DEVELOPMENTAL?)

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
L26	QUE (ENDOCRIN? AND DISRUPT?)
L27	QUE (ZYGOTE? OR CHILD OR CHILDREN OR ADOLESCEN? OR INFANT?)
L28	QUE (WEAN? OR OFFSPRING OR AGE(W)FACTOR?)
L29	QUE (DERMAL? OR DERMIS OR SKIN OR EPIDERM? OR CUTANEOUS?)
L30	QUE (CARCINO? OR COCARCINO? OR CANCER? OR PRECANCER? OR NEOPLAS?)
L31	QUE (TUMOR? OR TUMOUR? OR ONCOGEN? OR LYMPHOMA? OR CARCINOM?)
L32	QUE (GENETOX? OR GENOTOX? OR MUTAGEN? OR GENETIC(W)TOXIC?)
L33	QUE (NEPHROTOX? OR HEPATOTOX?)
L34	QUE (ENDOCRIN? OR ESTROGEN? OR ANDROGEN? OR HORMON?)
L35	QUE (OCCUPATION? OR WORKER? OR WORKPLACE? OR EPIDEM?)
L36	QUE L11 OR L12 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35
L37	QUE (RAT OR RATS OR MOUSE OR MICE OR GUINEA(W)PIG? OR MURIDAE OR DOG OR DOGS OR RABBIT? OR HAMSTER? OR PIG OR PIGS OR SWINE OR PORCINE OR MONKEY? OR MACAQUE?)
L38	QUE (MARMOSET? OR FERRET? OR GERBIL? OR RODENT? OR LAGOMORPHA OR BABOON? OR CANINE OR CAT OR CATS OR FELINE OR MURINE)
L39	QUE L36 OR L37 OR L38
L40	QUE (HUMAN OR HUMANS OR HOMINIDAE OR MAMMALS OR MAMMAL? OR PRIMATES OR PRIMATE?)
L41	QUE L39 OR L40
L42	26504 SEA FILE=TOXCENTER L8 OR L9
L43	5804 SEA FILE=TOXCENTER L42 AND L40
L44	12460 SEA FILE=TOXCENTER L42 AND L41
L45	10471 SEA FILE=TOXCENTER L42 AND L36
L46	1752 SEA FILE=TOXCENTER L43 NOT L45
L47	12223 SEA FILE=TOXCENTER L45 OR L43
L48	1808 SEA FILE=TOXCENTER L47 AND MEDLINE/FS
L49	3320 SEA FILE=TOXCENTER L47 AND BIOSIS/FS
L50	7088 SEA FILE=TOXCENTER L47 AND CAPLUS/FS
L51	7 SEA FILE=TOXCENTER L47 NOT (L48 OR L49 OR L50)
L52	9699 DUP REM L48 L49 L50 L51 (2524 DUPLICATES REMOVED) ANSWERS '1-9699' FROM FILE TOXCENTER
L*** DEL	1808 S L47 AND MEDLINE/FS
L*** DEL	1808 S L47 AND MEDLINE/FS
L53	1808 SEA FILE=TOXCENTER L52
L*** DEL	3320 S L47 AND BIOSIS/FS
L*** DEL	3320 S L47 AND BIOSIS/FS
L54	2567 SEA FILE=TOXCENTER L52

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
	L*** DEL 7088 S L47 AND CAPLUS/FS
	L*** DEL 7088 S L47 AND CAPLUS/FS
	L55 5318 SEA FILE=TOXCENTER L52
	L*** DEL 7 S L47 NOT (L48 OR L49 OR L50)
	L*** DEL 7 S L47 NOT (L48 OR L49 OR L50)
	L56 6 SEA FILE=TOXCENTER L52
	L57 7891 SEA FILE=TOXCENTER (L53 OR L54 OR L55 OR L56) NOT MEDLINE/FS
	L58 2661 SEA FILE=TOXCENTER L57 AND PY=2013
	L59 2407 SEA FILE=TOXCENTER L57 AND PY=2014
	L60 1634 SEA FILE=TOXCENTER L57 AND PY=2015
	L61 225 SEA FILE=TOXCENTER L57 AND PY=2016
	L62 964 SEA FILE=TOXCENTER L57 NOT (L58 OR L59 OR L60 OR L61)
	D SCAN L58
	D SCAN L59
	D SCAN L60
	D SCAN L61
	D SCAN L62
	FILE 'TOXCENTER' ENTERED AT 10:11:57 ON 24 FEB 2016
L1	198871 SEA FILE=TOXCENTER 7439-92-1
L2	11498 SEA FILE=TOXCENTER 301-04-2 OR 13424-46-9 OR 10031-22-8 OR 7758-95-4 OR 7758-97-6 OR 13814-96-5 OR 10101-63-0 OR 12709-98-7 OR 10099-74-8 OR 1317-36-8 OR 7446-27-7 OR 15245-44-0 OR 7446-14-2 OR 1314-87-0 OR 78-00-2 OR 598-63-0
L3	384 SEA FILE=TOXCENTER 39377-56-5 OR 16040-38-3 OR 11119-70-3
L4	206120 SEA FILE=TOXCENTER L1 OR L2 OR L3
L5	193989 SEA FILE=TOXCENTER L4 NOT PATENT/DT
L6	26375 SEA FILE=TOXCENTER L5 AND ED>=20130101 ACT TOXQUERY/Q

L7	QUE (CHRONIC OR IMMUNOTOX? OR NEUROTOX? OR TOXICOKIN? OR BIOMARKER? OR NEUROLOG?)
L8	QUE (PHARMACOKIN? OR SUBCHRONIC OR PBPK OR EPIDEMIOLOGY/ST,CT, IT)
L9	QUE (ACUTE OR SUBACUTE OR LD50# OR LD(W)50 OR LC50# OR LC(W)50)
L10	QUE (TOXICITY OR ADVERSE OR POISONING)/ST,CT,IT
L11	QUE (INHAL? OR PULMON? OR NASAL? OR LUNG? OR RESPIR?)
L12	QUE ((OCCUPATION? OR WORKPLACE? OR WORKER?) AND EXPOS?)
L13	QUE (ORAL OR ORALLY OR INGEST? OR GAVAGE? OR DIET OR DIETS OR DIETARY OR DRINKING(W)WATER?)
L14	QUE (MAXIMUM AND CONCENTRATION? AND (ALLOWABLE OR PERMISSIBLE))
L15	QUE (ABORT? OR ABNORMALIT? OR EMBRYO? OR CLEFT? OR FETUS?)
L16	QUE (FOETUS? OR FETAL? OR FOETAL? OR FERTIL? OR MALFORM? OR

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
	OVUM?)
L17	QUE (OVA OR OVARY OR PLACENTA? OR PREGNAN? OR PRENATAL?)
L18	QUE (PERINATAL? OR POSTNATAL? OR REPRODUC? OR STERIL? OR TERATOGEN?)
L19	QUE (SPERM OR SPERMAC? OR SPERMAG? OR SPERMATI? OR SPERMAS? OR SPERMATOB? OR SPERMATOC? OR SPERMATOG?)
L20	QUE (SPERMATOI? OR SPERMATOL? OR SPERMATOR? OR SPERMATOX? OR SPERMATOZ? OR SPERMATU? OR SPERMI? OR SPERMO?)
L21	QUE (NEONAT? OR NEWBORN? OR DEVELOPMENT OR DEVELOPMENTAL?)
L22	QUE (ENDOCRIN? AND DISRUPT?)
L23	QUE (ZYGOTE? OR CHILD OR CHILDREN OR ADOLESCEN? OR INFANT?)
L24	QUE (WEAN? OR OFFSPRING OR AGE(W)FACTOR?)
L25	QUE (DERMAL? OR DERMIS OR SKIN OR EPIDERM? OR CUTANEOUS?)
L26	QUE (CARCINO? OR COCARCINO? OR CANCER? OR PRECANCER? OR NEOPLAS?)
L27	QUE (TUMOR? OR TUMOUR? OR ONCOGEN? OR LYMPHOMA? OR CARCINOM?)
L28	QUE (GENETOX? OR GENOTOX? OR MUTAGEN? OR GENETIC(W)TOXIC?)
L29	QUE (NEPHROTOX? OR HEPATOTOX?)
L30	QUE (ENDOCRIN? OR ESTROGEN? OR ANDROGEN? OR HORMON?)
L31	QUE (OCCUPATION? OR WORKER? OR WORKPLACE? OR EPIDEM?)
L32	QUE L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
L33	QUE (RAT OR RATS OR MOUSE OR MICE OR GUINEA(W)PIG? OR MURIDAE OR DOG OR DOGS OR RABBIT? OR HAMSTER? OR PIG OR PIGS OR SWINE OR PORCINE OR MONKEY? OR MACAQUE?)
L34	QUE (MARMOSET? OR FERRET? OR GERBIL? OR RODENT? OR LAGOMORPHA OR BABOON? OR CANINE OR CAT OR CATS OR FELINE OR MURINE)
L35	QUE L32 OR L33 OR L34
L36	QUE (HUMAN OR HUMANS OR HOMINIDAE OR MAMMALS OR MAMMAL? OR PRIMATES OR PRIMATE?)
L37	QUE L35 OR L36
L38	----- 1602 SEA FILE=TOXCENTER L6 AND (L33 OR L34) ACT LEAD1/A -----
L39 (198675)SEA FILE=TOXCENTER 7439-92-1
L40 (11485)SEA FILE=TOXCENTER 301-04-2 OR 13424-46-9 OR 10031-22-8 OR 7758-95-4 OR 7758-97-6 OR 13814-96-5 OR 10101-63-0 OR 12709-98-

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
	7 OR 10099-74-8 OR 1317-36-8 OR 7446-27-7 OR 15245-44-0 OR 7446-14-2 OR 1314-87-0 OR 78-00-2 OR 598-63-0
L41 (382)SEA FILE=TOXCENTER 39377-56-5 OR 16040-38-3 OR 11119-70-3
L42 (205915)SEA FILE=TOXCENTER L39 OR L40 OR L41
L43 (193807)SEA FILE=TOXCENTER L42 NOT PATENT/DT
L44 (26193)SEA FILE=TOXCENTER L43 AND ED>=20130101
L45 (23356)SEA FILE=TOXCENTER L43 AND PY>2012
L46	QUE (CHRONIC OR IMMUNOTOX? OR NEUROTOX? OR TOXICOKIN? OR BIOMARKER? OR NEUROLOG?)
L47	QUE (PHARMACOKIN? OR SUBCHRONIC OR PBPK OR EPIDEMIOLOGY/ST,CT, IT)
L48	QUE (ACUTE OR SUBACUTE OR LD50# OR LD(W)50 OR LC50# OR LC(W)50)
L49	QUE (TOXICITY OR ADVERSE OR POISONING)/ST,CT,IT
L50	QUE (INHAL? OR PULMON? OR NASAL? OR LUNG? OR RESPIR?)
L51	QUE ((OCCUPATION? OR WORKPLACE? OR WORKER?) AND EXPOS?)
L52	QUE (ORAL OR ORALLY OR INGEST? OR GAVAGE? OR DIET OR DIETS OR DIETARY OR DRINKING(W)WATER?)
L53	QUE (MAXIMUM AND CONCENTRATION? AND (ALLOWABLE OR PERMISSIBLE))
L54	QUE (ABORT? OR ABNORMALIT? OR EMBRYO? OR CLEFT? OR FETUS?)
L55	QUE (FOETUS? OR FETAL? OR FOETAL? OR FERTIL? OR MALFORM? OR OVUM?)
L56	QUE (OVA OR OVARY OR PLACENTA? OR PREGNAN? OR PRENATAL?)
L57	QUE (PERINATAL? OR POSTNATAL? OR REPRODUC? OR STERIL? OR TERATOGEN?)
L58	QUE (SPERM OR SPERMAC? OR SPERMAG? OR SPERMATI? OR SPERMAS? OR SPERMATOB? OR SPERMATOC? OR SPERMATOG?)
L59	QUE (SPERMATOI? OR SPERMATOL? OR SPERMATOR? OR SPERMATOX? OR SPERMATOZ? OR SPERMATU? OR SPERMI? OR SPERMO?)
L60	QUE (NEONAT? OR NEWBORN? OR DEVELOPMENT OR DEVELOPMENTAL?)
L61	QUE (ENDOCRIN? AND DISRUPT?)
L62	QUE (ZYGOTE? OR CHILD OR CHILDREN OR ADOLESCEN? OR INFANT?)
L63	QUE (WEAN? OR OFFSPRING OR AGE(W)FACTOR?)
L64	QUE (DERMAL? OR DERMIS OR SKIN OR EPIDERM? OR CUTANEOUS?)
L65	QUE (CARCINO? OR COCARCINO? OR CANCER? OR PRECANCER? OR NEOPLAS?)
L66	QUE (TUMOR? OR TUMOUR? OR ONCOGEN? OR LYMPHOMA? OR CARCINOM?)
L67	QUE (GENETOX? OR GENOTOX? OR MUTAGEN? OR

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
	GENETIC(W)TOXIC?)
	L68 QUE (NEPHROTOX? OR HEPATOTOX?)
	L69 QUE (ENDOCRIN? OR ESTROGEN? OR ANDROGEN? OR HORMON?)
	L70 QUE (OCCUPATION? OR WORKER? OR WORKPLACE? OR EPIDEM?)
	L71 QUE L46 OR L47 OR L48 OR L49 OR L50 OR L51 OR L52 OR L53 OR L54 OR L55 OR L56 OR L57 OR L58 OR L59 OR L60 OR L61 OR L62 OR L63 OR L64 OR L65 OR L66 OR L67 OR L68 OR L69 OR L70
	L72 QUE (HUMAN OR HUMANS OR HOMINIDAE OR MAMMALS OR MAMMAL? OR PRIMATES OR PRIMATE?)
	L73 (26504)SEA FILE=TOXCENTER L44 OR L45
	L74 (5804)SEA FILE=TOXCENTER L73 AND L72
	L75 (10471)SEA FILE=TOXCENTER L73 AND L71
	L76 12223 SEA FILE=TOXCENTER L75 OR L74

	L77 252 SEA FILE=TOXCENTER L38 NOT L76
	L78 8 SEA FILE=TOXCENTER L77 AND MEDLINE/FS
	L79 26 SEA FILE=TOXCENTER L77 AND BIOSIS/FS
	L80 218 SEA FILE=TOXCENTER L77 AND CAPLUS/FS
	L81 0 SEA FILE=TOXCENTER L77 NOT (L78 OR L79 OR L80)
	L82 237 DUP REM L78 L79 L80 (15 DUPLICATES REMOVED) ANSWERS '1-237' FROM FILE TOXCENTER D SCAN L82
4/2016	FILE 'TOXCENTER' ENTERED AT 12:37:35 ON 06 APR 2016
	L1 1212 SEA FILE=TOXCENTER 1309-60-0
	L2 621 SEA FILE=TOXCENTER 1314-41-6
	L3 997 SEA FILE=TOXCENTER (L1 OR L2) NOT PATENT/DT
	L4 174 SEA FILE=TOXCENTER L3 AND ED>=20130101
	L5 156 SEA FILE=TOXCENTER L3 AND PY>2012
	L6 178 SEA FILE=TOXCENTER L4 OR L5 ACT TOXQUERY/Q

	L7 QUE (CHRONIC OR IMMUNOTOX? OR NEUROTOX? OR TOXICOKIN? OR BIOMARKER? OR NEUROLOG?)
	L8 QUE (PHARMACOKIN? OR SUBCHRONIC OR PBPK OR EPIDEMIOLOGY/ST,CT, IT)
	L9 QUE (ACUTE OR SUBACUTE OR LD50# OR LD(W)50 OR LC50# OR LC(W)50)
	L10 QUE (TOXICITY OR ADVERSE OR POISONING)/ST,CT,IT
	L11 QUE (INHAL? OR PULMON? OR NASAL? OR LUNG? OR RESPIR?)
	L12 QUE ((OCCUPATION? OR WORKPLACE? OR WORKER?) AND EXPOS?)
	L13 QUE (ORAL OR ORALLY OR INGEST? OR GAVAGE? OR DIET OR DIETS OR DIETARY OR DRINKING(W)WATER?)
	L14 QUE (MAXIMUM AND CONCENTRATION? AND (ALLOWABLE OR PERMISSIBLE))
	L15 QUE (ABORT? OR ABNORMALIT? OR EMBRYO? OR CLEFT? OR FETUS?)

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database search date	Query string
L16	QUE (FOETUS? OR FETAL? OR FOETAL? OR FERTIL? OR MALFORM?
	OR
	OVUM?)
L17	QUE (OVA OR OVARY OR PLACENTA? OR PREGNAN? OR PRENATAL?)
L18	QUE (PERINATAL? OR POSTNATAL? OR REPRODUC? OR STERIL? OR
	TERATOGEN?)
L19	QUE (SPERM OR SPERMAC? OR SPERMAG? OR SPERMATI? OR
	SPERMAS? OR
	SPERMATOB? OR SPERMATOC? OR SPERMATOG?)
L20	QUE (SPERMATOI? OR SPERMATOL? OR SPERMATOR? OR
	SPERMATOX? OR
	SPERMATOZ? OR SPERMATU? OR SPERMI? OR SPERMO?)
L21	QUE (NEONAT? OR NEWBORN? OR DEVELOPMENT OR
	DEVELOPMENTAL?)
L22	QUE (ENDOCRIN? AND DISRUPT?)
L23	QUE (ZYGOTE? OR CHILD OR CHILDREN OR ADOLESCEN? OR
	INFANT?)
L24	QUE (WEAN? OR OFFSPRING OR AGE(W)FACTOR?)
L25	QUE (DERMAL? OR DERMIS OR SKIN OR EPIDERM? OR CUTANEOUS?)
L26	QUE (CARCINO? OR COCARCINO? OR CANCER? OR PRECANCER?
	OR
	NEOPLAS?)
L27	QUE (TUMOR? OR TUMOUR? OR ONCOGEN? OR LYMPHOMA? OR
	CARCINOM?)
L28	QUE (GENETOX? OR GENOTOX? OR MUTAGEN? OR
	GENETIC(W)TOXIC?)
L29	QUE (NEPHROTOX? OR HEPATOTOX?)
L30	QUE (ENDOCRIN? OR ESTROGEN? OR ANDROGEN? OR HORMON?)
L31	QUE (OCCUPATION? OR WORKER? OR WORKPLACE? OR EPIDEM?)
L32	QUE L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR L14 OR L15
	OR L16 OR L17 OR L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR L24
	OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
L33	QUE (RAT OR RATS OR MOUSE OR MICE OR GUINEA(W)PIG? OR
	MURIDAE
	OR DOG OR DOGS OR RABBIT? OR HAMSTER? OR PIG OR PIGS OR
	SWINE
	OR PORCINE OR MONKEY? OR MACAQUE?)
L34	QUE (MARMOSET? OR FERRET? OR GERBIL? OR RODENT? OR
	LAGOMORPHA
	OR BABOON? OR CANINE OR CAT OR CATS OR FELINE OR MURINE)
L35	QUE L32 OR L33 OR L34
L36	QUE (HUMAN OR HUMANS OR HOMINIDAE OR MAMMALS OR
	MAMMAL? OR
	PRIMATES OR PRIMATE?)
L37	QUE L35 OR L36

L38	24 SEA FILE=TOXCENTER L6 AND L37
L39	0 SEA FILE=TOXCENTER L38 AND MEDLINE/FS
L40	24 DUP REM L38 (0 DUPLICATES REMOVED)
	ANSWERS '1-24' FROM FILE TOXCENTER

APPENDIX B

Table B-2. Database Query Strings Pre-Public Comment Searches

Database	Query string
search date	D SCAN L40

The search was augmented by searching the Toxic Substances Control Act Test Submissions (TSCATS), NTP website, and National Institute of Health Research Portfolio Online Reporting Tools Expenditures and Results (NIH RePORTER) databases using the queries presented in Table B-3. Additional databases were searched in the creation of various tables and figures, such as the TRI Explorer, the Substance priority list (SPL) resource page, and other items as needed. Regulations applicable to Pb were identified by searching international and U.S. agency websites and documents.

Table B-3. Strategies to Augment the Literature Search

Source	Query and number screened when available
TSCATS^a	
2/2016	Compounds searched: 7439-92-1, 301-04-2, 13424-46-9, 10031-22-8, 7758-95-4, 7758-97-6, 11119-70-3, 13814-96-5, 10101-63-0, 12709-98-7, 10099-74-8, 1317-36-8, 7446-27-7, 16040-38-3, 15245-44-0, 7446-14-2, 39377-56-5, 1314-87-0, 78-00-2, 598-63-0, 1309-60-0, 1314-41-6
NTP	
2/2016	"Lead" OR "7439 92 1" OR "301 04 2" OR "13424 46 9" OR "10031 22 8" OR "7758 95 4" OR "7758 97 6" OR "13814 96 5" OR "10101 63 0" OR "12709 98 7" OR "10099 74 8" OR "1317 36 8" OR "7446 27 7" OR "15245 44 0" OR "7446 14 2" OR "1314 87 0" OR "78 00 2" OR "598 63 0" OR "39377 56 5" OR "16040 38 3" OR "11119 70 3" OR "C I 77575" OR "C I Pigment Metal 4" OR "CI 77575" "CI pigment metal 4" OR "Omaha & grant" OR "Pb-S 100" OR "Plumbum" OR "SSO 1" OR "Plumbous acetate" OR "Salt of saturn" OR "Unichem PBA" OR "RD 1333" OR "Plumbous bromide" OR "Plumbous chloride" OR "Phoenicochroite" OR "Plumbous chromate" OR "Chrome orange" OR "Blei(II)-iodid" OR "Plumbous iodide" OR "Plumbum jodatum" OR "C I 77613" OR "Plumbous nitrate" OR "Bleimonoxid" OR "Bleioxyd" OR "C I 77577" OR "C I Pigment Yellow 46" OR "CI 77577" OR "CI Pigment Yellow 46" OR "Litharge" OR "Massicot" OR "Massicotite" OR "Plumbi monoxidum" OR "Plumbous oxide" OR "Plumbum oxydatum" OR "C I 77622" OR "CI 77622" OR "Perlex paste 500" OR "Perlex paste 600A" OR "Plumbous phosphate" OR "Trilead bis(orthophosphate)" OR "Trilead phosphate" OR "Tricinat" OR "3 3-didehydro-6 8 9-trinitro-2 4-Dioxa-3-plumbabicyclo[3 3 1]nona-1(9) 5 7-triene" OR "Anglislite" OR "C I 77630" OR "C I Pigment White 3" OR "CI 77630" OR "CI pigment white 3" OR "HB 2000" OR "Mulhouse White" OR "Natural anglesite" OR "Pigment White 3" OR "TS 100 sulfate" OR "C I 77640" OR "CI 77640" OR "Galena" OR "P 37 filter" OR "Plumbous sulfide" OR "Plumbane tetraethyl-" OR "Tetra(methylethyl)lead" OR "Tetraethyllead" OR "Tetraethylplumbane" OR "Cerussite" OR "Cerussite" OR "Plumbous carbonate"
3/2016	"1309 60 0" OR "1314 41 6" OR "C I 77580" OR "CI 77580" OR "C I 77578" OR "C I Pigment Red 105" OR "CI 77578" OR "CI Pigment Red 105" OR "Gold satinobre" OR "Heuconin 5" OR "Mennige" OR "Mineral Orange" OR "Mineral Red" OR "Minium" OR "Paris Red" OR "Pigment Red 105" OR "Plumboplumbic oxide" OR "Sandix" OR "Saturn Red" OR "Trilead tetraoxide" OR "Trilead tetroxide" OR "azarcon" OR "Lead dioxide" OR "Lead Brown" OR "Lead peroxide" OR "Lead superoxide" OR "Lead(IV) oxide" OR "Lead tetroxide" OR "Lead orthoplumbate" OR "Lead tetraoxide" OR "Orange Lead" OR "Red Lead"

Table B-3. Strategies to Augment the Literature Search

Source	Query and number screened when available
NIH RePORTER	
6/2017	<p>Text Search: "1,3-Benzenediol, 2,4,6-trinitro-, lead(2) salt" OR "2,4,6-trinitro-1,3-Benzenediol lead(2) salt" OR "2,4,6-trinitroResorcinol, lead(2) salt" OR "3,3-didehydro-6,8,9-trinitro-2,4-Dioxa-3-plumbabicyclo[3.3.1]nona-1(9),5,7-triene "[styphnato(2-)]Lead" OR "Acetic acid lead(2) salt" OR "Acetic acid, lead salt" OR "Acetic acid, lead(2) salt" OR "Anglislite" OR "azarcon" OR "Blei(II)-iodid" OR "Bleimonoxid" OR "Bleioxyd" OR "Borate(1-), tetrafluoro-, lead (2)" OR "C.I. 77575" OR "C.I. 77577" OR "C.I. 77578" OR "C.I. 77580" OR "C.I. 77613" OR "C.I. 77622" OR "C.I. 77630" OR "C.I. 77640" OR "C.I. Pigment Metal 4" OR "C.I. Pigment Red 105" OR "C.I. Pigment White 3" OR "C.I. Pigment Yellow 46" OR "Carbonic acid, lead(2) salt)" OR "Cerussete" OR "Cerussite" OR "Chrome orange" OR "Chromic acid (H2CrO4), lead(2) salt" OR "Chromic acid lead salt with lead molybdate" OR "Chromic acid, lead and molybdenum salt" OR "Chromic acid, lead salt" OR "Chromic acid, lead(2) salt" OR "Chromium lead molybdenum oxide" OR "Chromium lead oxide" OR "CI 77575" OR "CI 77577" OR "CI 77578" OR "CI 77580" OR "CI 77622" OR "CI 77630" OR "CI 77640" OR "CI pigment metal 4" OR "CI Pigment Red 105" OR "CI pigment white 3" OR "CI Pigment Yellow 46" OR "Freemans White Lead" OR "Galena" OR "Gold satinobre" OR "HB 2000" OR "Heuconin 5" OR "Lead (II) chloride" OR "Lead 2,4,6-trinitro-m-phenylene dioxide" OR "Lead acetate" OR "Lead azide" OR "Lead bis(tetrafluoroborate)" OR "Lead borofluoride" OR "Lead boron fluoride" OR "Lead Bottoms" OR "Lead bromide" OR "Lead Brown" OR "Lead carbonate" OR "Lead chloride" OR "Lead chromate" OR "Lead chromate molybdate" OR "Lead di(acetate)" OR "Lead diacetate" OR "Lead diazide" OR "Lead dibasic acetate" OR "Lead dibromide" OR "Lead dichloride" OR "Lead diiodide" OR "Lead dinitrate" OR "Lead dioxide" OR "Lead element" OR "Lead flake" OR "Lead fluoborate" OR "Lead fluoroborate" OR "Lead iodide" OR "Lead metal" OR "Lead molybdate chromate" OR "Lead molybdenum chromate" OR "Lead monooxide" OR "Lead monosulfate" OR "Lead monosulfide" OR "Lead monoxide" OR "Lead nitrate" OR "Lead orthophosphate" OR "Lead orthoplumbate" OR "Lead oxide" OR "Lead peroxide" OR "Lead phosphate" OR "Lead protoxide" OR "Lead S 2" OR "Lead S2" OR "Lead styphnate" OR "Lead sulfate" OR "Lead sulfide" OR "Lead sulfide (PbS)" OR "Lead sulphate" OR "Lead sulphide" OR "Lead superoxide" OR "Lead tetraethide" OR "Lead tetraethyl" OR "Lead tetrafluoroborate" OR "Lead tetraoxide (Advanced), Search in: Projects AdminIC: All, Fiscal Year: Active Projects</p> <p>Text Search: "Lead tetroxide" OR "Lead trincate" OR "Lead trinitroresorcinate" OR "Lead(2) sulfate" OR "Lead(2) acetate" OR "Lead(2) azide" OR "Lead(2) bromide" OR "Lead(2) carbonate" OR "Lead(2) chloride" OR "Lead(2) nitrate" OR "Lead(2) oxide" OR "Lead(2) phosphate" OR "Lead(2) sulfide" OR "Lead(II) acetate" OR "Lead(II) azide" OR "Lead(II) bromide" OR "Lead(II) carbonate" OR "Lead(II) chloride" OR "Lead(II) chromate" OR "Lead(II) iodide" OR "Lead(II) nitrate" OR "Lead(II) oxide" OR "Lead(II) phosphate" OR "Lead(II) styphnate" OR "Lead(II) sulfate" OR "Lead(II) sulfide" OR "Lead(II) tetrafluoroborate" OR "Lead(IV) oxide" OR "Lead, tetraethyl-" OR "Lead-molybdenum chromate" OR "Litharge" OR "Massicot" OR "Massicotite" OR "Mennige" OR "Mineral Orange" OR "Mineral Red" OR "Minium" OR "Molybdenum-lead chromate" OR "Mulhouse White" OR "Natural anglesite" OR "Nitric acid, lead(2) salt" OR "Normal lead orthophosphate" OR "Omaha & grant" OR "Orange Lead" OR "P 37 filter" OR "Paris Red" OR "Pb-S 100" OR "Perlex paste 500" OR "Perlex paste 600A" OR "Phoenicochroite" OR "Phosphoric acid, lead salt" OR "Phosphoric acid, lead(2) salt" OR "Pigment Red 105" OR "Pigment White 3" OR "Plumbane, tetraethyl-" OR "Plumbi monoxidum" OR "Plumboplumbic oxide" OR "Plumbous acetate" OR "plumbous bromide" OR "Plumbous carbonate" OR "Plumbous chloride" OR "Plumbous chromate" OR "Plumbous iodide" OR "Plumbous nitrate" OR "Plumbous oxide" OR "Plumbous phosphate" OR "Plumbous sulfide" OR "Plumbum" OR "Plumbum jodatum" OR "Plumbum metallicum" OR "Plumbum oxydatum" OR "RD 1333" OR "Red Lead" OR "Rough lead bullion" OR "Salt of saturn" OR "Sandix" OR "Saturn Red" OR "SSO 1" OR "Sugar of lead" OR "Sulfuric acid,</p>

Table B-3. Strategies to Augment the Literature Search

Source	Query and number screened when available
	<p>lead(2) salt" OR "Tetra(methylethyl)lead" OR "Tetraethyl lead" OR "Tetraethyllead" OR "Tetraethylplumbane" OR "Tricinat" OR "Trilead bis(orthophosphate)" OR "Trilead phosphate" OR "Trilead tetraoxide" OR "Trilead tetroxide" OR "TS 100 sulfate" OR "Unichem PBA" OR "Yellow Lead Ocher" (Advanced), Search in: Projects AdminIC: All, Fiscal Year: Active Projects</p> <p>Text Search: "lead" not ("lead academic" or "lead optimization") (Advanced), Search in: Projects Limit to: Project Title, AdminIC: All, Fiscal Year: Active Projects</p> <p>Text Search: "blood lead" (Advanced), Search in: Projects AdminIC: All, Fiscal Year: Active Projects</p>
Other	Identified throughout the assessment process

^aSeveral versions of the TSCATS database were searched, as needed, by CASRN including TSCATS1 via Toxline (no date limit), TSCATS2 via <https://yosemite.epa.gov/oppts/epatscat8.nsf/ReportSearch?OpenForm> (date restricted by EPA receipt date), and TSCATS via CDAT (date restricted by 'Mail Received Date Range'), as well as google for recent TSCA submissions.

Review articles were identified and used for the purpose of providing background information and identifying additional references. In addition, tree-searching of published literature was conducted to identify other publications. ATSDR also identified reports from the grey literature, which included unpublished research reports, technical reports from government agencies, conference proceedings and abstracts, and theses and dissertations.

The 2016 results were:

- Number of records identified from PubMed, TOXLINE, and TOXCENTER (after duplicate removal): 12,829
- Number of records identified from EPA (2014c) ISA document and other strategies: 1,192
- Total number of records to undergo literature screening: 14,021

B.1.2 Literature Screening

A three-step process was used to screen the literature search to identify relevant studies on Pb:

- Secondary refinement in Endnote
- Title and abstract screen
- Full text screen

Title and Abstract Screen. Within the reference library, an secondary refinement process was used to remove studies with the phrase "lead to" in the title. Following this secondary refinement, titles and abstracts were screened manually for relevance. Studies that were considered relevant (see Table B-1 for inclusion criteria) were moved to the second step of the literature screening process. Studies were excluded when the title and abstract clearly indicated that the study was not relevant to the toxicological profile.

- Number of records excluded by secondary refinement: 502
- Number of studies identified via other strategies: 633
- Number of titles and abstracts screened: 12,960
- Number of studies identified via EPA (2014c) ISA document: 559
- Number of studies considered relevant and moved to the next step: 1,591

APPENDIX B


Full Text Screen. The second step in the literature screening process was a full text review of individual studies considered relevant in the title and abstract screen step. Each study was reviewed to determine whether it was relevant for inclusion in the toxicological profile.

- Number of studies undergoing full text review: 1,591
- Number of studies cited from the pre-public draft of the toxicological profile: 729
- Total number of studies cited in the profile: 1,657

A summary of the results of the literature search and screening is presented in Figure B-1.

APPENDIX B

Figure B-1. September 2016 Literature Search Results and Screen for Pb



APPENDIX C. INGESTION OF LEAD DEBRIS

The main focus of this ATSDR Toxicological Profile for Lead is on health effects of chronic low-level environmental exposures. The profile also provides information on the clinical presentation of acute Pb toxicity, which occurs when large amounts of Pb are ingested. In children, this often occurs through ingestion of paint chips containing Pb, Pb-contaminated soils, or other non-solid forms of Pb. Ingestion of solid forms of Pb (Pb debris) is a unique exposure scenario in which there is accidental or purposeful ingestion of visible debris containing Pb. This exposure may be acute (debris is expelled or removed from the body soon after ingestion) or chronic (Pb debris is retained within the body, leading to continued elevation in PbB). There are several sources of Pb debris, including Pb shot or other debris found at firing or artillery ranges, or Pb shot found in wild game meats. The information presented below reviews toxicokinetics and adverse health effects of ingested Pb debris. Information regarding the chemistry, fate, and transport of Pb debris is reviewed in Chapter 5.

Overview. No controlled studies in humans have evaluated bioavailability or toxicity of ingested Pb debris (e.g., Pb shot and other Pb-containing debris from artillery or shooting ranges). Available information is anecdotal, obtained from case reports. Thus, data are not sufficient to determine the bioavailability of ingested Pb debris or to develop dose-response relationships for toxicity. Case reports of individuals ingesting Pb debris are summarized in Table C-1; these reports demonstrate the following:

- PbB rises rapidly (within hours to a few days) following ingestion of Pb debris.
- The clinical presentation of toxicity following ingestion of Pb debris is the same as that observed for acute Pb poisoning from ingestion of other forms of Pb (see Section 2.2).
- Severity of toxicity of ingested Pb debris will depend upon how much Pb is absorbed (e.g., toxicity is related to PbB; see Section 2.2).
- The onset of toxicity can be rapid (within hours to a few days).
- Following removal of Pb debris from the body, PbBs decrease; however, applying clinical protocols for chelation therapy results in a more rapid decrease in PbB.
- Ingested Pb debris can be retained in the appendix of some individuals and continue to contribute to elevated PbB.

APPENDIX C

Table C-1. Selected Case Studies of Ingestion of Solid Lead (Pb) Debris or Pb Retained in Gunshot Wounds

Reference and exposure	Blood lead concentration (PbB) (µg/dL)	Effects	Treatment
<p>Banner et al. 2012</p> <p>A 15-year-old boy ingested a “handful” of Pb shot. He was admitted to the hospital for treatment 14 days after exposure.</p>	<ul style="list-style-type: none"> • Post-ingestion <ul style="list-style-type: none"> ○ 8 days: 54 ○ 14 days: 41 • Post-treatment (2 weeks): <5 	<ul style="list-style-type: none"> • Most Pb was located in the appendix (14 days post-ingestion) • Abdominal pain • Elevated free erythrocyte protoporphyrin 	<ul style="list-style-type: none"> • Whole bowel irrigation • Appendectomy • Chelation
<p>CDC 2006</p> <p>A 4-year-old boy with previously diagnosed microcephaly and mental delays ingested a metallic charm containing Pb. Time from exposure to first medical visit was not reported.</p>	At death: 180	<ul style="list-style-type: none"> • Charm was retained in the stomach (was not removed) • Intractable vomiting • Cerebral edema • Seizures • Death 	Supportive therapy
<p>Clifton et al. 2002</p> <p>A 21-month-old girl ingested Pb BB pellets. She was taken to the hospital approximately 6 hours post-ingestion.</p>	<ul style="list-style-type: none"> • Pre-ingestion (routine): 12 • Post-ingestion (6 hours): 47 • Post-removal of pellets: 25 • Post-treatment (10 days): 16 	<ul style="list-style-type: none"> • Hyperactivity • No signs of neurological or gastrointestinal toxicity 	<ul style="list-style-type: none"> • Bowel irrigation • Colonoscopy for removal of pellets • Chelation
<p>Cox and Pesola 2005</p> <p>A 73-year-old woman ingested Pb shot in game over decades.</p>	Not reported	<ul style="list-style-type: none"> • Pb shot accumulated in the appendix • No information on adverse health effects was reported 	Not reported
<p>Durlach et al. 1986</p> <p>A 30-year-old man ingested Pb shot in game regularly over an unspecified period of time.</p>	<ul style="list-style-type: none"> • At initial examination: 67.4 • Post-treatment <ul style="list-style-type: none"> ○ 10 days: 52.2 ○ 13 days: 24.5 ○ 1 month: 36.8 ○ 1.5 months: 31.6 	<ul style="list-style-type: none"> • Pb shot accumulated in the appendix • Acute abdominal pain 	<ul style="list-style-type: none"> • Bowel irritation • Chelation • Appendectomy

APPENDIX C

Table C-1. Selected Case Studies of Ingestion of Solid Lead (Pb) Debris or Pb Retained in Gunshot Wounds

Reference and exposure	Blood lead concentration (PbB) (µg/dL)	Effects	Treatment
<p>Fergusson et al. 1997</p> <p>A 4-year-old girl ingested a Pb fishing sinker. She was evaluated in the emergency room within 1 hour of ingestion.</p>	<ul style="list-style-type: none"> Day of ingestion: 4 Day after ingestion: 16 	No signs of toxicity observed	Endoscopy
<p>Gerhardsson et al. 2002</p> <p>A man in his "late 40s" had retained Pb shot following a gunshot wound to the shoulder. Reconstructive surgery occurred 54 days post-accident. Some, but not all, of the Pb shot was removed during surgery.</p>	<p>Approximate (data presented graphically), time after accident:</p> <ul style="list-style-type: none"> 25 days: 28 50 days: 41 54 days (day of surgery): 55 ~60 days: 31 75 days: 48 200 days: 36 375 days: 30 	<ul style="list-style-type: none"> No signs of toxicity observed Not all of the Pb shot could be removed during surgery 	Surgical removal of Pb pellets
<p>Guilaard et al. 2006</p> <p>A 2-year-old boy ingested toy money made from pure metallic Pb.</p>	<p>Time post-ingestion</p> <ul style="list-style-type: none"> 1 day: 31.3 8 days: 61.1 1 month: 30.0 4 months: 24.9 10 months: 9.9 	<ul style="list-style-type: none"> Development of microcytic anemia and increased blood zinc protoporphyrin No signs of toxicity observed 	<ul style="list-style-type: none"> Removal of object Chelation (8 days post-ingestion)
<p>Gustavsson and Gerhardsson 2005</p> <p>A 45-year-old woman with elevated PbB was found to have Pb shot in her intestine from ingestion of game. The Pb shot was spontaneously eliminated. Time from ingestion was estimated to be sometime between 1993 and 2001.</p>	<p>Time of assessment:</p> <ul style="list-style-type: none"> January 2002: 55.0 April 2003 (2 months post-elimination): 34.5 November 2003: 7.2 	<ul style="list-style-type: none"> Malaise and fatigue "Diffuse gastrointestinal symptoms" 	No treatment (object was spontaneously eliminated)

APPENDIX C

Table C-1. Selected Case Studies of Ingestion of Solid Lead (Pb) Debris or Pb Retained in Gunshot Wounds

Reference and exposure	Blood lead concentration (PbB) (µg/dL)	Effects	Treatment
Hatten et al. 2013	Case 1	Case 1	Case 1
<ul style="list-style-type: none"> Case 1: A 15-year-old boy ingested rifle cartridges approximately 1 month prior to evaluation. 	<ul style="list-style-type: none"> Initial assessment: 146 19 days post-treatment: 53 3 months post-treatment: 38 	<ul style="list-style-type: none"> Decreased activity level Vomiting, diarrhea, anorexia Hyperactive patellar and brachioradialis reflexes 	<ul style="list-style-type: none"> Cartridges removed by endoscopy Chelation
<ul style="list-style-type: none"> Case 2: A 65-year-old woman ingested several handfuls of bullets. 	Case 2: Days after ingestion <ul style="list-style-type: none"> Day 1: 9.7 Day 2: 25.7 Day 3: 40.5 Day 60: 17.2 	Case 2 <ul style="list-style-type: none"> No signs of toxicity were observed 	Case 2 <ul style="list-style-type: none"> Endoscopy
Larsen and Blanton 2000	Not reported	<ul style="list-style-type: none"> Abdominal pain and anorexia 	Appendectomy
A 9-year-old boy ingested Pb shot in game; the Pb shot was retained in the appendix.			
Lyons and Filston 1994	<ul style="list-style-type: none"> Peak (time of assessment not reported): 23 Prior to surgery (1.5 months after ingestion): 12 	<ul style="list-style-type: none"> Abdominal discomfort, nausea, vomiting, diarrhea Headache 	Appendectomy
A 4-year-old boy ingested Pb shot, which was lodged in his appendix.			
Madsen et al. 1988	Range: 4.6–18.2	Not reported	Not reported
Seven patients with Pb shot retained in the appendix.			
McKinney and McKinney 2000	Time after ingestion <ul style="list-style-type: none"> 13 hours: 57 36 hours: 79 After treatment: <ul style="list-style-type: none"> 14 days: 14.3 6 months: 25 	<ul style="list-style-type: none"> Vomiting and abdominal pain Decreased blood hemoglobin and hematocrit “Mild” speech and language delays noted post-treatment 	<ul style="list-style-type: none"> Whole bowel irrigation Chelation
A 5.5-year-old girl ingested several Pb pellets.			

APPENDIX C

Table C-1. Selected Case Studies of Ingestion of Solid Lead (Pb) Debris or Pb Retained in Gunshot Wounds

Reference and exposure	Blood lead concentration (PbB) (µg/dL)	Effects	Treatment
<p>McNutt et al. 2001</p> <p>A 45-year-old male ingested 206 Pb bullets. Medical evaluation occurred 5 days after ingestion. Bullets were spontaneously eliminated over 4–47 days after first medical evaluation.</p>	<p>Time after ingestion:</p> <ul style="list-style-type: none"> • 5 days: 391 • 10 days: 171 • 25 days: 41 • 6 weeks: 24 	<ul style="list-style-type: none"> • Abdominal pain and gastrointestinal bleeding • Anemia 	<p>Chelation started at initial medical visit</p>
<p>McQuirter et al. 2004</p> <p>Subjects (n=451) 1-year following gunshot wound with retained bullets.</p>	<ul style="list-style-type: none"> • PbB at time after injury: 1.9 • % with PbB ≥10 (days after injury) <ul style="list-style-type: none"> ○ 0 days: 2.1 ○ 3 days: 7.6 ○ 18 days: 25.1 ○ 3 months: 38.1 ○ 6 months: 28.5 ○ 12 months: 15.8 	<p>Not reported</p>	<p>Not reported</p>
<p>MMWR 2004</p> <p>A 4-year-old boy ingested a Pb medallion.</p>	<ul style="list-style-type: none"> • 2–3 weeks after ingestion: 123 • After treatment: 57 	<ul style="list-style-type: none"> • Abdominal pain, vomiting, diarrhea • Normocytic anemia, elevated protoporphyrin 	<ul style="list-style-type: none"> • Endoscopy • Chelation
<p>Mowad et al. 1998</p> <p>An 8-year-old boy ingested several Pb fishing sinkers. Medical assessment was within 1 days of ingestion.</p>	<p>Time after ingestion:</p> <ul style="list-style-type: none"> • 1 day: 53 • 6 days: 45 (start of chelation) • 1 month: 3 	<p>No signs of toxicity observed</p>	<ul style="list-style-type: none"> • Bowel irrigation • Colonoscopy • Chelation
<p>Treble and Thompson 2002</p> <p>A 2.5-year-old girl ingested Pb pellets.</p>	<p>Time after ingestion</p> <ul style="list-style-type: none"> • 1.5 hours: 56 • 29 hours: 35 • 94 hours: 35 	<p>No signs of toxicity observed</p>	<p>Laxatives</p>

APPENDIX C

Table C-1. Selected Case Studies of Ingestion of Solid Lead (Pb) Debris or Pb Retained in Gunshot Wounds

Reference and exposure	Blood lead concentration (PbB) (µg/dL)	Effects	Treatment
Zardawi and Siriweera 2013 An 8-year-old boy ingested Pb pellets in game over a 2-year period.	Elevated PbB (17.4–27.4) over 2 years Pellets observed in appendix	Hyperactivity	<ul style="list-style-type: none">• Bowel irrigation• Appendectomy

APPENDIX C

Confounding Factors. There are several uncertainties from case reports on ingestion of Pb debris. Therefore, it is not possible to determine dose, bioavailability, or accurate plasma-time concentration curves. Uncertainties include:

- Baseline PbB data are rarely available. Thus, it is difficult to determine the contribution of ingested Pb debris to measured PbB following ingestion.
- Time from ingestion of Pb debris to first clinical evaluation and PbB assessment is often unknown.
- No quantitative data on the dose of Pb ingested in debris are reported.
- No quantitative data on fecal excretion of ingested Pb are reported.
- Information on the chemical composition of Pb debris often is not reported.
- No information on potential differences in the bioavailability of different types of Pb debris is available

Bioavailability of Pb Debris. No quantitative estimates on the bioavailability of Pb debris in humans are available. Several case reports show increased PbB following ingestion of Pb debris, demonstrating that ingested Pb is absorbed (CDC 2006; Clifton et al. 2002; Durlach et al. 1986; Fergusson et al. 1997; Greensher et al. 1974; Guillard et al. 2006; Hatten et al. 2013; McKinney and McKinney 2000; McNutt et al. 2001; MMWR 2004; Mowad et al. 1998; Treble and Thompson 2002); see Table C-1 for details. However, due to lack of information on ingested dose, quantitative estimates of absorption cannot be determined. No information on bioavailability of Pb debris in animals was identified. Lead debris retained within the body will continue to contribute to elevated PbB until it is removed from the body, either spontaneously or by medical intervention (Banner et al. 2012; Clifton et al. 2002; Durlach et al. 1986; Gerhardsson et al. 2002; Guillard et al. 2006; McQuirter et al. 2004).

Lead debris must become bioaccessible (i.e., soluble) in the gastrointestinal tract in order for it to be absorbed. It is likely that processes thought to contribute to rendering ingested soil Pb bioaccessible also are important in rendering ingested Pb debris bioaccessible (see Section 3.1.1). IVBA assays that measure extractable Pb have not been evaluated for predicting bioavailability or RBA of ingested Pb debris, although one study found that IVBA measured at gastric pH predicted the relatively high *in vivo* RBA (100%) of firing range soils (Bannon et al. 2009; see Section 3.1.1).


Although dose-PbB relationships and bioavailability cannot be reliably established from the published case history of Pb debris ingestion, it is possible to use exposure-biokinetics models to reconstruct the time course of PbB expected for a given acute dose of soluble Pb and, from this, estimate the relative

APPENDIX C

bioavailability of Pb from ingested Pb shot that would result in a given peak PbB. This scenario assumes that Pb debris is not retained in the body. The AALM-LG (EPA 2014a) can simulate the internal biokinetics of Pb associated with daily doses of Pb. This model predicts that a child 30 months of age who has a baseline PbB of 1 $\mu\text{g}/\text{dL}$ would experience a 10 $\mu\text{g}/\text{dL}$ increase in PbB in response to ingestion of approximately 1 mg of soluble Pb (Figure C-1). The peak PbB would occur during the day of ingestion and PbB would return to approximately 120% of baseline in approximately 35 days following the dose. If this prediction is extrapolated to the ingestion of Pb shot or other debris, the 1 mg dose of soluble Pb could occur in association with a dose of 100 mg of debris having an RBA of 1%, or 1 g of debris having an RBA of 0.1% (see Section 3.1.5.4 *EPA All Ages Lead Model [AALM]* for more information). Figure C-1 also shows the predicted PbB pattern for six repeated, weekly events in which the child ingested 1 mg of soluble PbB. This would result in periodic increases in PbB, with the maximum following each exposure event increasing until a pseudo-steady-state PbB was reached at approximately 14.5 $\mu\text{g}/\text{dL}$ (13.5 $\mu\text{g}/\text{dL}$ above baseline). The PbB would return to approximately 120% of baseline in approximately 570 days after the last exposure event. This longer time to baseline following multiple exposures reflects the accrual of Pb in bone with multiple dosing and the relatively slow transfer of Pb from bone to blood after exposure ceases (see Section 3.1).

APPENDIX C

Figure C-1. PbB Predicted from AALM-LG for a 0.9 mg Dose of Soluble Pb Ingested by a Child 30 Months of Age



Ingestion of soil from firing ranges may also contribute to PbB. A study in juvenile swine of eight soils (sieved to <250 µm) from small arms firing ranges showed a relative bioavailability range of 77–140%, with a mean of 108 % (SD or SE [not specified]: 18%). Soil from this site largely consisted of highly bioavailable Pb carbonate. However, this study does not provide information on bioavailability of Pb debris.

Retention of Pb Debris in the Appendix. Case reports show that Pb debris can be retained within the appendix (Banner et al. 2012; Cox and Pesola 2005; Durlach et al. 1986; Larsen and Blanton 2000; Lyons and Filston 1994; Madsen et al. 1988; Reddy 1985; Zardawi and Siriweera 2013); see Table C-1 for details. For this to occur, the appendix must be oriented with respect to the cecum in such a way to allow objects to pass through the appendiceal-cecal orifice; approximately 45% of the population have appendices with this orientation. However, approximately 65% of the population have appendices that might hinder foreign body access into the appendiceal lumen due to atypical anatomic position, adhesions, or kinks (Klinger et al. 1998). In addition to orientation of the appendix, the physical size and shape of the debris likely contribute to retention. Although it is not possible to determine the incidence of Pb debris lodged in the gastrointestinal tract or the appendix because not all

APPENDIX C

cases of ingestion of Pb debris are reported in the published literature, approximately 45% of the population is predisposed to retention of Pb debris on orientation of the appendix.

Toxicity of Ingested Pb Debris. Regardless of the source of Pb (e.g., ingested Pb debris, Pb paint, Pb-contaminated soil, occupational exposure), once Pb is absorbed into the body, toxicity will be related to PbB; thus, bioavailability and duration of elevated PbB, rather than the form of Pb ingested, will determine adverse health outcomes. If ingested Pb debris is not retained by the body, toxicity of PbB would be consistent with that described for acute Pb toxicity. A summary of peak PbBs and associated toxicity following exposure of ingested Pb debris is shown in Table C-2. Severity of toxicity increases with PbB. At $\text{PbB} \leq 47 \mu\text{g/dL}$, the only adverse health effect observed was a single report of headache at a PbB of $12 \mu\text{g/dL}$. With increased PbB, effects were observed in several organ systems and severity of effects increased. At a PbB range of $54\text{--}146 \mu\text{g/dL}$, abdominal colic, vomiting, hematological effects, and neurological effects were observed, and at a PbB of $180 \mu\text{g/dL}$, severe effects (seizure and cerebral edema) leading to death were observed. In most cases, the onset of toxicity occurs within hours or days of ingestion. If PbB remains elevated, either due to inadequate medical intervention or Pb that is retained within the body (i.e., appendix, gastrointestinal tract, etc.) adverse health effects associated with chronically elevated PbB would be expected to occur (see Chapter 2, Health Effects). As reviewed in Chapter 2, $\text{PbBs} \leq 10 \mu\text{g/dL}$ are associated with adverse health effects to numerous organ systems, including developmental and neurological effects, with severity exhibiting dose-dependence. Given the many factors that can affect development of Pb-induced toxicity, case reports of individuals cannot provide generalizations of exposure-response relationships. Therefore, epidemiological studies of exposed populations should be consulted to provide general exposure-response data for toxicity associated with prolonged exposure to retained Pb debris.

Table C-2. Peak Blood Lead Concentration (PbB) and Acute Toxicity Associated with Ingestion of Lead (Pb) Debris

Peak PbB ($\mu\text{g/dL}$) ^a	Effects associated with Pb exposure	References
12–16	No effects observed	Fergusson et al. 1997
	Headache	Lyons and Filston 1994
40.5–47	No effects observed	Clifton et al. 2002; Hatten et al. 2013
54–61	No effects observed	Mowad et al. 1998; Treble and Thompson 2002
	Abdominal colic	Banner et al. 2012
	Hematological effects ^b	

APPENDIX C

Table C-2. Peak Blood Lead Concentration (PbB) and Acute Toxicity Associated with Ingestion of Lead (Pb) Debris

Peak PbB ($\mu\text{g}/\text{dL}$) ^a	Effects associated with Pb exposure	References
79	Abdominal colic and vomiting Hematological effects ^c Neurological effects ^d	McKinney and McKinney 2000
123	Abdominal colic, vomiting, diarrhea Hematological effects ^e	MMWR 2004
146	Vomiting Neurological signs ^f	Hatten et al. 2013
180	Vomiting Seizures Cerebral edema Death	CDC 2006
391	Abdominal colic, gastrointestinal bleeding Anemia	McNutt et al. 2001

^aPeak blood Pb reported.

^bElevated free erythrocyte protoporphyrin or microcytic anemia and increased blood zinc protoporphyrin.

^cDecreased blood hemoglobin and hematocrit.

^d"Mild" speech and language delays.

^eNormocytic anemia, elevated protoporphyrin

^fDecreased activity level and hyperactive patellar and brachioradialis reflexes.

REFERENCES

- Banner B, Schaeffer S, Badillo RB, et al. 2012. Multiple lead appendoliths following ingestion of lead shot: Time course and removal by laposcopic appendectomy. *Clin Toxicol* 50(4):266-267. 10.3109/15563650.2012.658473.
- CDC. 2006. Brief report: Death of a child after ingestion of a metallic charm- Minnesota 2006. *MMWR Morb Mortal Wkly Rep* 55(12):340-341. <https://www.cdc.gov/mmwr/pdf/wk/mm5512.pdf>. May 23, 2017.
- Clifton JC, Sigg T, Burda AM, et al. 2002. Acute pediatric lead poisoning: Combined whole bowel irrigation, succimer therapy, and endoscopic removal of ingested lead pellets. *Pediatr Emerg Care* 18(3):200-202. 10.1097/01.pec.0000019226.25165.86.
- Cox WM, Pesola GR. 2005. Buckshot ingestion. *N Engl J Med* 353(26):e23.
- Durlach V, Lisovoski F, Gross A, et al. 1986. Appendicetomy in an unusual case of lead poisoning. *Lancet* 1(8482):687-688.
- EPA. 2014a. Development and evaluation of the all ages lead model (AALM). U.S. Environmental Protection Agency.
- Fergusson J, Malecky G, Simpson E. 1997. Lead foreign body ingestion in children. *J Paediatr Child Health* 33:542-544.
- Gerhardsson L, Dahlin L, Knebel R, et al. 2002. Blood lead concentration after a shotgun accident. *Environ Health Perspect* 110:115-117.

APPENDIX C

- Greensher J, Mofenson HC, Balakrishnan C, et al. 1974. Leading poisoning from ingestion of lead shot. *Pediatrics* 54(5):641-643.
- Guillard O, Flamen P, Fauconneau B, et al. 2006. A case of acute lead poisoning in a 2-year-old child. *Br J Clin Pharmacol* 62(2):247-247. 10.1111/j.1365-2125.2006.02603.x.
- Gustavsson P, Gerhardsson L. 2005. Intoxication from an accidentally ingested lead shot retained in the gastrointestinal tract. *Environ Health Perspect* 113:491-493.
- Hatten BW, Bueso A, Craven P, et al. 2013. Lead toxicity and endoscopic removal of ingested firearm cartridges. *Clin Toxicol (Phila)* 51(5):448-450. 10.3109/15563650.2013.792114.
- Klingler PJ, Seelig MH, DeVault KR, et al. 1998. Ingested foreign bodies within the appendix: A 100-year review of the literature. *Dig Dis* 16(5):308-314.
- Larsen AR, Blanton RH. 2000. Appendicitis due to bird shot ingestion: A case study. *Am Surg* 66(6):589-591.
- Lyons JD, Filston HC. 1994. Lead intoxication from a pellet entrapped in the appendix of a child: Treatment considerations. *J Pediatr Surg* 29(12):1618-1620.
- Madsen HHT, Skjodt T, Jorgensen PJ, et al. 1988. Blood lead levels in patients with lead shot retained in the appendix. *Acta Radiol* 29(6):745-746. 10.1080/02841858809171977.
- McNutt TK, Chambers-Emerson J, Dethlefsen M, et al. 2001. Bite the bullet: Lead poisoning after ingestion of 206 lead bullets. *Vet Hum Toxicol* 43(5):288-289.
- McQuirter JL, Rothenberg SJ, Dinkins GA, et al. 2004. Change in blood lead concentration up to 1 year after a gunshot wound with a retained bullet. *Am J Epidemiol* 159(7):683-692. 10.1093/aje/kwh074.
- MMWR. 2004. Brief report: Lead poisoning from ingestion of a toy necklace- Oregon, 2003. *MMWR Morb Mortal Wkly Rep* 53(26):582-584
- Mowad E, Haddad I, Gemmel DJ. 1998. Management of lead poisoning from ingested fishing sinkers. *Arch Pediatr Adolesc Med* 152(5):485-488.
- Reddy ER. 1985. Retained lead shot in the appendix. *J Can Assoc Radiol* 36(1):47-48.
- Treble RG, Thompson TS. 2002. Elevated blood lead levels resulting from the ingestion of air rifle pellets. *J Anal Toxicol* 26:370-373.
- Zardawi I, Siriweera E. 2013. Pellets in the appendix. *N Engl J Med* 369(6):e7. 10.1056/NEJMicm1214754.

APPENDIX D. QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances may find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Relevance to Public Health: The Relevance to Public Health Section provides an overview of exposure and health effects and evaluates, interprets, and assesses the significance of toxicity data to human health. A table listing minimal risk levels (MRLs) is also included in this chapter.

Chapter 2: Health Effects: Specific health effects identified in both human and animal studies are reported by type of health effect (e.g., death, hepatic, renal, immune, reproductive), route of exposure (e.g., inhalation, oral, dermal), and length of exposure (e.g., acute, intermediate, and chronic).

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting.

Pediatrics:

Section 3.2 **Children and Other Populations that are Unusually Susceptible**
Section 3.3 **Biomarkers of Exposure and Effect**

ATSDR Information Center

Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)

Internet: <http://www.atsdr.cdc.gov>

The following additional materials are available online:

Case Studies in Environmental Medicine are self-instructional publications designed to increase primary health care providers' knowledge of a hazardous substance in the environment and to aid in the evaluation of potentially exposed patients (see <https://www.atsdr.cdc.gov/csem/csem.html>).

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident (see <https://www.atsdr.cdc.gov/MHMI/index.asp>). Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs™) provide answers to frequently asked questions about toxic substances (see <https://www.atsdr.cdc.gov/toxfaqs/Index.asp>).

APPENDIX D

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015 • Web Page: <https://www.cdc.gov/nceh/>.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 395 E Street, S.W., Suite 9200, Patriots Plaza Building, Washington, DC 20201 • Phone: 202-245-0625 or 1-800-CDC-INFO (800-232-4636) • Web Page: <https://www.cdc.gov/niosh/>.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212 • Web Page: <https://www.niehs.nih.gov/>.

Clinical Resources (Publicly Available Information)

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266 • Web Page: <http://www.acoem.org/>.

The American College of Medical Toxicology (ACMT) is a nonprofit association of physicians with recognized expertise in medical toxicology. Contact: ACMT, 10645 North Tatum Boulevard, Suite 200-111, Phoenix AZ 85028 • Phone: 844-226-8333 • FAX: 844-226-8333 • Web Page: <http://www.acmt.net>.

The Pediatric Environmental Health Specialty Units (PEHSUs) is an interconnected system of specialists who respond to questions from public health professionals, clinicians, policy makers, and the public about the impact of environmental factors on the health of children and reproductive-aged adults. Contact information for regional centers can be found at <http://pehsu.net/findhelp.html>.

The American Association of Poison Control Centers (AAPCC) provide support on the prevention and treatment of poison exposures. Contact: AAPCC, 515 King Street, Suite 510, Alexandria VA 22314 • Phone: 701-894-1858 • Poison Help Line: 1-800-222-1222 • Web Page: <http://www.aapcc.org/>.

APPENDIX E. GLOSSARY

Absolute Bioavailability (ABA)—The amount of Pb absorbed expressed as a fraction or percent of ingested.

Absorption—The process by which a substance crosses biological membranes and enters systemic circulation. Absorption can also refer to the taking up of liquids by solids, or of gases by solids or liquids.

Acute Exposure—Exposure to a chemical for a duration of ≤ 14 days, as specified in the Toxicological Profiles.

Action Level (OSHA) – Employee exposure, without regard to the use of respirators, to an airborne concentration averaged over an 8-hour period.

Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the surfaces of solid bodies or liquids with which they are in contact.

Adsorption Coefficient (K_{oc})—The ratio of the amount of a chemical adsorbed per unit weight of organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.

Adsorption Ratio (K_d)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or sediment.

Benchmark Dose (BMD) or Benchmark Concentration (BMC)—is the dose/concentration corresponding to a specific response level estimate using a statistical dose-response model applied to either experimental toxicology or epidemiology data. For example, a BMD_{10} would be the dose corresponding to a 10% benchmark response (BMR). The BMD is determined by modeling the dose-response curve in the region of the dose-response relationship where biologically observable data are feasible. The BMDL or BMCL is the 95% lower confidence limit on the BMD or BMC.

Bioaccessibility (BA)—Fraction or percent of Pb in a medium (e.g., soil) that is released from the medium in the gastrointestinal tract so that it can be available to absorptive transport mechanisms (e.g., transcellular carriers or channels, paracellular diffusion).

Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms at a specific time or during a discrete time period of exposure divided by the concentration in the surrounding water at the same time or during the same period.

Biomarkers—Indicators signaling events in biologic systems or samples, typically classified as markers of exposure, effect, and susceptibility.

Cancer Effect Level (CEL)—The lowest dose of a chemical in a study, or group of studies, that produces significant increases in the incidence of cancer (or tumors) between the exposed population and its appropriate control.

Carcinogen—A chemical capable of inducing cancer.

APPENDIX E

Case-Control Study—A type of epidemiological study that examines the relationship between a particular outcome (disease or condition) and a variety of potential causative agents (such as toxic chemicals). In a case-control study, a group of people with a specified and well-defined outcome is identified and compared to a similar group of people without the outcome.

Case Report—A report that describes a single individual with a particular disease or exposure. These reports may suggest some potential topics for scientific research, but are not actual research studies.

Case Series—Reports that describe the experience of a small number of individuals with the same disease or exposure. These reports may suggest potential topics for scientific research, but are not actual research studies.

Ceiling Value—A concentration that must not be exceeded.

Chronic Exposure—Exposure to a chemical for ≥ 365 days, as specified in the Toxicological Profiles.

Clastogen—A substance that causes breaks in chromosomes resulting in addition, deletion, or rearrangement of parts of the chromosome.

Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are followed forward from exposure to outcome, and who are disease-free at start of follow-up. Often, at least one exposed group is compared to one unexposed group, while in other cohorts, exposure is a continuous variable and analyses are directed towards analyzing an exposure-response coefficient.

Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines the relationship between exposure and outcome to a chemical or to chemicals at a specific point in time.

Data Needs—Substance-specific informational needs that, if met, would reduce the uncertainties of human health risk assessment.

Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result from exposure to a chemical prior to conception (either parent), during prenatal development, or postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any point in the life span of the organism.

Dose-Response Relationship—The quantitative relationship between the amount of exposure to a toxicant and the incidence of the response or amount of the response.

Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to a chemical; the distinguishing feature between the two terms is the stage of development during which the effect occurs. Effects include malformations and variations, altered growth, and *in utero* death.

Epidemiology—The investigation of factors that determine the frequency and distribution of disease or other health-related conditions within a defined human population during a specified period.

Excretion—The process by which metabolic waste products are removed from the body.

Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific alteration of the molecular structure of the genome.

APPENDIX E

Half-life—A measure of rate for the time required to eliminate one-half of a quantity of a chemical from the body or environmental media.

Health Advisory—An estimate of acceptable drinking water levels for a chemical substance derived by EPA and based on health effects information. A health advisory is not a legally enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.

Immediately Dangerous to Life or Health (IDLH)—A condition that poses a threat of life or health, or conditions that pose an immediate threat of severe exposure to contaminants that are likely to have adverse cumulative or delayed effects on health.

Immunotoxicity—Adverse effect on the functioning of the immune system that may result from exposure to chemical substances.

Incidence—The ratio of new cases of individuals in a population who develop a specified condition to the total number of individuals in that population who could have developed that condition in a specified time period.

Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the Toxicological Profiles.

In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.

In vitro bioaccessibility (IVBA)—Bioaccessibility predicted from an *in vitro* extraction assay.

In Vivo—Occurring within the living organism.

Lethal Concentration_(LO) (LC_{LO})—The lowest concentration of a chemical in air that has been reported to have caused death in humans or animals.

Lethal Concentration₍₅₀₎ (LC₅₀)—A calculated concentration of a chemical in air to which exposure for a specific length of time is expected to cause death in 50% of a defined experimental animal population.

Lethal Dose_(LO) (LD_{LO})—The lowest dose of a chemical introduced by a route other than inhalation that has been reported to have caused death in humans or animals.

Lethal Dose₍₅₀₎ (LD₅₀)—The dose of a chemical that has been calculated to cause death in 50% of a defined experimental animal population.

Lethal Time₍₅₀₎ (LT₅₀)—A calculated period of time within which a specific concentration of a chemical is expected to cause death in 50% of a defined experimental animal population.

Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, or group of studies, that produces statistically or biologically significant increases in frequency or severity of adverse effects between the exposed population and its appropriate control.

Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the lymph nodes, spleen, and thymus.

APPENDIX E

Malformations—Permanent structural changes that may adversely affect survival, development, or function.

Metabolism—Process in which chemical substances are biotransformed in the body that could result in less toxic and/or readily excreted compounds or produce a biologically active intermediate.

Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is likely to be without an appreciable risk of adverse noncancer health effects over a specified route and duration of exposure.

Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty factors. The default value for a MF is 1.

Morbidity—The state of being diseased; the morbidity rate is the incidence or prevalence of a disease in a specific population.

Mortality—Death; the mortality rate is a measure of the number of deaths in a population during a specified interval of time.

Mutagen—A substance that causes mutations, which are changes in the DNA sequence of a cell's DNA. Mutations can lead to birth defects, miscarriages, or cancer.

Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of death or pathological conditions.

Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a hazardous substance.

No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no statistically or biologically significant increases in frequency or severity of adverse effects seen between the exposed population and its appropriate control. Although effects may be produced at this dose, they are not considered to be adverse.

Octanol-Water Partition Coefficient (K_{ow})—The equilibrium ratio of the concentrations of a chemical in *n*-octanol and water, in dilute solution.

Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence among subjects exposed to a particular risk factor divided by the incidence among subjects who were not exposed to the risk factor). An odds ratio that is greater than 1 is considered to indicate greater risk of disease in the exposed group compared to the unexposed group.

Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) regulatory limit on the amount or concentration of a substance not to be exceeded in workplace air averaged over any 8-hour work shift of a 40-hour workweek.

Pesticide—General classification of chemicals specifically developed and produced for use in the control of agricultural and public health pests (insects or other organisms harmful to cultivated plants or animals).

APPENDIX E

Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate (disposition) of an exogenous substance in an organism. Utilizing computational techniques, it provides the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.

Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent chemical or metabolite in an animal system. There are two types of pharmacokinetic models: data-based and physiologically-based. A data-based model divides the animal system into a series of compartments, which, in general, do not represent real, identifiable anatomic regions of the body, whereas the physiologically-based model compartments represent real anatomic regions of the body.

Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-response model that quantitatively describes the relationship between target tissue dose and toxic endpoints. These models advance the importance of physiologically based models in that they clearly describe the biological effect (response) produced by the system following exposure to an exogenous substance.

Physiologically Based Pharmacokinetic (PBPK) Model—A type of physiologically based dose-response model that is comprised of a series of compartments representing organs or tissue groups with realistic weights and blood flows. These models require a variety of physiological information, including tissue volumes, blood flow rates to tissues, cardiac output, alveolar ventilation rates, and possibly membrane permeabilities. The models also utilize biochemical information, such as blood:air partition coefficients, and metabolic parameters. PBPK models are also called biologically based tissue dosimetry models.

Prevalence—The number of cases of a disease or condition in a population at one point in time.

Prospective Study—A type of cohort study in which a group is followed over time and the pertinent observations are made on events occurring after the start of the study.

Relative bioavailability (RBA)—Absolute bioavailability (ABA) of Pb in a test material (e.g., soil) expressed as a fraction or percent of the ABA of a reference material (e.g., lead acetate).

Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health (NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour workweek.

Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime. The inhalation RfC is expressed in units of mg/m³ or ppm.

Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the daily oral exposure of the human population to a potential hazard that is likely to be without risk of deleterious noncancer health effects during a lifetime. The oral RfD is expressed in units of mg/kg/day.

Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). RQs are (1) ≥ 1 pound or (2) for selected substances, an amount established by regulation either under CERCLA or under Section 311 of the Clean Water Act. Quantities are measured over a 24-hour period.

APPENDIX E

Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result from exposure to a hazardous substance. The toxicity may be directed to the reproductive organs and/or the related endocrine system. The manifestation of such toxicity may be noted as alterations in sexual behavior, fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of this system.

Retrospective Study—A type of cohort study based on a group of persons known to have been exposed at some time in the past. Data are collected from routinely recorded events, up to the time the study is undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing records and/or examining survivors of the cohort.

Risk—The possibility or chance that some adverse effect will result from a given exposure to a hazardous substance.

Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, existing health condition, or an inborn or inherited characteristic that is associated with an increased occurrence of disease or other health-related event or condition.

Risk Ratio/Relative Risk—The ratio of the risk among persons with specific risk factors compared to the risk among persons without risk factors. A risk ratio that is greater than 1 indicates greater risk of disease in the exposed group compared to the unexposed group.

Short-Term Exposure Limit (STEL)—A STEL is a 15-minute TWA exposure that should not be exceeded at any time during a workday.

Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected number of deaths in a specific standard population.

Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited exposure to those assumed over a lifetime of exposure to a chemical.

Teratogen—A chemical that causes structural defects that affect the development of an organism.

Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists (ACGIH) concentration of a substance to which it is believed that nearly all workers may be repeatedly exposed, day after day, for a working lifetime without adverse effect. The TLV may be expressed as a Time-Weighted Average (TLV-TWA), as a Short-Term Exposure Limit (TLV-STEL), or as a ceiling limit (TLV-C).

Time-Weighted Average (TWA)—An average exposure within a given time period.

Toxicokinetic—The absorption, distribution, metabolism, and elimination of toxic compounds in the living organism.

Toxics Release Inventory (TRI)—TRI tracks the management of certain toxic chemicals that may pose a threat to human health and the environment. U.S. facilities in different industry sectors must report annually how much of each chemical is released to the environment and/or managed through recycling, energy recovery, and treatment. (A "release" of a chemical means that it is emitted to the air or water, or placed in some type of land disposal.)

APPENDIX E

Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL), Reference Dose (RfD), or Reference Concentration (RfC) from experimental data. UFs are intended to account for (1) the variation in sensitivity among the members of the human population, (2) the uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; however, a reduced UF of 3 may be used on a case-by-case basis (3 being the approximate logarithmic average of 10 and 1).

Xenobiotic—Any substance that is foreign to the biological system.

APPENDIX F. ACRONYMS, ABBREVIATIONS, AND SYMBOLS

AAPCC	American Association of Poison Control Centers
ACGIH	American Conference of Governmental Industrial Hygienists
ACOEM	American College of Occupational and Environmental Medicine
ACMT	American College of Medical Toxicology
ADI	acceptable daily intake
ADME	absorption, distribution, metabolism, and excretion
AEGL	Acute Exposure Guideline Level
AIC	Akaike's information criterion
AIHA	American Industrial Hygiene Association
ALT	alanine aminotransferase
AOEC	Association of Occupational and Environmental Clinics
AP	alkaline phosphatase
AST	aspartate aminotransferase
atm	atmosphere
ATSDR	Agency for Toxic Substances and Disease Registry
AWQC	Ambient Water Quality Criteria
BCF	bioconcentration factor
BMD/C	benchmark dose or benchmark concentration
BMD _x	dose that produces a X% change in response rate of an adverse effect
BMDL _x	95% lower confidence limit on the BMD _x
BMDS	Benchmark Dose Software
BMR	benchmark response
BUN	blood urea nitrogen
C	centigrade
CAA	Clean Air Act
CAS	Chemical Abstract Services
CDC	Centers for Disease Control and Prevention
CEL	cancer effect level
CERCLA	Comprehensive Environmental Response, Compensation, and Liability Act
CFR	Code of Federal Regulations
Ci	curie
CI	confidence interval
cm	centimeter
CPSC	Consumer Products Safety Commission
CWA	Clean Water Act
DHHS	Department of Health and Human Services
DNA	deoxyribonucleic acid
DOD	Department of Defense
DOE	Department of Energy
DWEL	drinking water exposure level
EAFUS	Everything Added to Food in the United States
ECG/EKG	electrocardiogram
EEG	electroencephalogram
EPA	Environmental Protection Agency
ERPG	emergency response planning guidelines
F	Fahrenheit
F1	first-filial generation
FDA	Food and Drug Administration
FIFRA	Federal Insecticide, Fungicide, and Rodenticide Act

APPENDIX F

FR	Federal Register
FSH	follicle stimulating hormone
g	gram
GC	gas chromatography
gd	gestational day
GGT	γ -glutamyl transferase
GRAS	generally recognized as safe
HEC	human equivalent concentration
HED	human equivalent dose
HHS	Department of Health and Human Services
HPLC	high-performance liquid chromatography
HSDB	Hazardous Substance Data Bank
IARC	International Agency for Research on Cancer
IDLH	immediately dangerous to life and health
IRIS	Integrated Risk Information System
IVBA	<i>in vitro</i> bioaccessibility
K _d	adsorption ratio
kg	kilogram
kkg	kilokilogram; 1 kilokilogram is equivalent to 1,000 kilograms and 1 metric ton
K _{oc}	organic carbon partition coefficient
K _{ow}	octanol-water partition coefficient
L	liter
LC	liquid chromatography
LC ₅₀	lethal concentration, 50% kill
LC _{Lo}	lethal concentration, low
LD ₅₀	lethal dose, 50% kill
LD _{Lo}	lethal dose, low
LDH	lactic dehydrogenase
LH	luteinizing hormone
LOAEL	lowest-observed-adverse-effect level
LSE	Level of Significant Exposure
LT ₅₀	lethal time, 50% kill
m	meter
mCi	millicurie
MCL	maximum contaminant level
MCLG	maximum contaminant level goal
MF	modifying factor
mg	milligram
mL	milliliter
mm	millimeter
mmHg	millimeters of mercury
mmol	millimole
MRL	Minimal Risk Level
MS	mass spectrometry
MSHA	Mine Safety and Health Administration
Mt	metric ton
NAAQS	National Ambient Air Quality Standard
NAS	National Academy of Science
NCEH	National Center for Environmental Health
ND	not detected
ng	nanogram

APPENDIX F

NHANES	National Health and Nutrition Examination Survey
NIEHS	National Institute of Environmental Health Sciences
NIOSH	National Institute for Occupational Safety and Health
NLM	National Library of Medicine
nm	nanometer
nmol	nanomole
NOAEL	no-observed-adverse-effect level
NPL	National Priorities List
NR	not reported
NRC	National Research Council
NS	not specified
NTP	National Toxicology Program
OR	odds ratio
OSHA	Occupational Safety and Health Administration
PAC	Protective Action Criteria
PAH	polycyclic aromatic hydrocarbon
PBPD	physiologically based pharmacodynamic
PBPK	physiologically based pharmacokinetic
PEHSU	Pediatric Environmental Health Specialty Unit
PEL	permissible exposure limit
PEL-C	permissible exposure limit-ceiling value
pg	picogram
PND	postnatal day
POD	point of departure
ppb	parts per billion
ppbv	parts per billion by volume
ppm	parts per million
ppt	parts per trillion
RBA	relative bioavailability
REL	recommended exposure level/limit
REL-C	recommended exposure level-ceiling value
RfC	reference concentration
RfD	reference dose
RNA	ribonucleic acid
RR	relative risk or risk ratio
SARA	Superfund Amendments and Reauthorization Act
SCE	sister chromatid exchange
SD	standard deviation
SE	standard error
SGOT	serum glutamic oxaloacetic transaminase (same as aspartate aminotransferase or AST)
SGPT	serum glutamic pyruvic transaminase (same as alanine aminotransferase or ALT)
SIC	standard industrial classification
SMR	standardized mortality ratio
sRBC	sheep red blood cell
STEL	short term exposure limit
TLV	threshold limit value
TLV-C	threshold limit value-ceiling value
TRI	Toxics Release Inventory
TSCA	Toxic Substances Control Act
TWA	time-weighted average
UF	uncertainty factor

APPENDIX F

U.S.	United States
USDA	United States Department of Agriculture
USGS	United States Geological Survey
USNRC	U.S. Nuclear Regulatory Commission
VOC	volatile organic compound
WBC	white blood cell
WHO	World Health Organization
>	greater than
≥	greater than or equal to
=	equal to
<	less than
≤	less than or equal to
%	percent
α	alpha
β	beta
γ	gamma
δ	delta
μm	micrometer
μg	microgram
q ₁ [*]	cancer slope factor
-	negative
+	positive
(+)	weakly positive result
(-)	weakly negative result